233-241.pdf
201-208.pdf
	American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Third Edition, Revised. Washington,  DC: the Association, 1987.  	NO_MATCH
	ANTHONY, J.C.; WARNER, L.A.; AND KESSLER, R.C. Comparative  epidemiology of dependence on tobacco, alcohol, controlled  substances, and inhalants: Basic findings from the National  Comorbidity Survey. Experimental and Clinical Psychopharmacology  2:244–268, 1994.  	NO_MATCH
	KESSLER, R.C.; MCGONAGLE, K.A.; ZHAO, S.; ET AL. Lifetime  and 12-month prevalence of DSM–III–R psychiatric disorders in  the United States. Results from the National Comorbidity Survey. Archives in General Psychiatry 51(1):8–19, 1994. 	8279933
	WARNER, L.A.; KESSLER, R.C.; HUGHES, M.; ANTHONY, J.C.;  AND NELSON, C.B. Prevalence and correlates of drug use and  dependence in the United States. Results from the National  Comorbidity Survey. Archives in General Psychiatry 52(3):  219–229, 1995. 	7872850
12249_2008_Article_1310.pdf
	1. Arneodo C, Benoit JP, Thies C. Etude  préliminaire de la microencapsulation d’huiles  essentielles par coacervation complexe. STP  Pharma Sciences. 1986; 2:303-306.  	NO_MATCH
	2. Benoit JP, Thies C. Microencapsulation  methods and industrial applications. In: Benita  S, ed. Drugs and the Pharmaceutical Sciences.  , Vol. 73. New York: Marcel Dekker;1996.  	NO_MATCH
	3. Benita S, Benoit JP, Puisieux F, Thies C.  Characterization of drug-loaded poly(d,l lactide) microspheres. J Pharm Sci.  1984;73:1721-1724.  	6527243
	4. Mathews BR, Nixon JR. Surface characteristics  of gelatin microcapsules by scanning electron  microscopy. J Pharm Pharmacol.  1974;26:383-384.  	4153096
	5. Bodmeier R, McGinity J. Polylactic acid  microspheres containing quinidine base and  quinidine sulphate prepared by the solvent  evaporation technique. I. Methods and  morphology. J Microencapsul. 1987;4:279 288.  	3504509
	6. Cutts LS, Hibberd S, Adler J, Davies MC,  Melia CD. Characterising drug release  processes within controlled release dosage  forms using the confocal laser-scanning  microscope. J Controlled Rel. 1996;42:115 124.  	NO_MATCH
	7. De Smedt SC, Meyvis TKL, Van Oostveldt P,  Demeester J. A new microphotolysis based  approach for mapping the mobility of drugs in  microscopic drug delivery devices. Pharm Res.  1999;16:1639-1642.  	10554110
	8. Bouillot P, Babak V, Dellacherie E. Novel  bioresorbable and bioeliminable surfactants for  microsphere preparation. Pharm Res.  1999;16:148-154.  	9950294
	9. Adler J, Jayan A, Melia CD. A method for  quantifying differential expansion within  hydrating hydrophilic matrixes by tracking  embedded fluorescent microspheres. J Pharm  Sci. 1999;88:371-377.  	10052997
	10. Rojas J, Pinto-Alphandary H, Leo E, Pecquet  S, Couvreur P, Gulik A, Fattal E. A  polysorbate-based non-ionic surfactant can  modulate loading and release of beta lactoglobulin entrapped in multiphase  poly(DL-lactide-co-glycolide) microspheres.  Pharm Res. 1999;16:255-260.  	10100311
	11. Caponetti G, Hrkach JS, Kriwet B, Poh M,  Lotan N, Colombo P, Langer R. Microparticles  of novel branched copolymers of lactic acid  and amino acids: preparation and  characterization. J Pharm. Sci 1999;88:136 141.  	9874715
	12. Lamprecht A, Schäfer UF, Lehr,  CM.  Characterisation of microcapsules by confocal  laser scanning microscopy: analysis of  structure, capsule wall composition and of  encapsulation rate. Eur J Pharm Biopharm.  2000;49:1-9.  	10613921
	13. Alex R, Bodmeier R. Encapsulation of water soluble drugs by a modified solvent  evaporation method. I. Effect of process and  formulation variables on drug entrapment. J  Microencapsul. 1989;7:347-355.  	2384837
	14. Iwata M, McGinity JW. Preparation of multi phase microspheres of poly(lactic acid) and  poly(lactic-co-glycolic acid) containing a W/O  emulsion by a multiple solvent evaporation  technique. J Microencapsul. 1992;9:201-214.  	1593404
	15. Schreiber AB, Haimovich J. Quantitative  fluorometric assay for detection and  characterization of Fc receptors. Meth Enzymol.  1983;93:147-155.  	6865782
	16. Luzzi LA, Gerraughty RJ. Effects of selected  variables on the extractability of oils from  coacervate capsules. J Pharm Sci.  1964;53:429-431.  	14189940
	17. Mussellwhite PR. The surface properties of an  oil-water emulsion stabilized by mixtures of  casein and gelatin. J Colloid and Interface  Science. 1966;21:99-102.  	5906905
	18. Boury F, Ivanova T, Panaiotov I, Proust JE.  Dilatational properties of adsorbed poly(D,L lactide) and bovine serum albumin monolayers  at the dichloromethane/water interface.  Langmuir. 1995;11:1636-1644.  	NO_MATCH
	19. Nihant N, Schugens C, Grandfils C, Jerome R,  Teyssie P. Polylactide microparticles prepared  by double emulsion/evaporation technique. I.  Effect of primary emulsion stability. Pharm  Res. 1994;11:1479-1484.  	7855056
	20. Sezer AD, Akbuga J. Release characteristics of  chitosan treated alginate beads: I. Sustained  release of a macromolecular drug from  chitosan treated alginate beads. J  Microencapsul. 1999;16:195-203.  	10080113
	21. Hari PR, Chandy T, Sharma  CP.  Chitosan/calcium alginate microcapsules for  intestinal delivery of nitrofurantoin. J  Microencapsul. 1996;13:319-329.  	8860687
	22. Murata Y, Toniwa S, Miyamoto E, Kawashima  S. Preparation of alginate gel beads containing  chitosan nicotinic acid salt and the functions.  Eur J Pharm Biopharm. 1999;48:49-52.  	10477328
12249_2008_Article_1255.pdf
	1. Yamashita F, Bando H, Koyama Y, Kitagawa S,  Takakura, Y, Hashida, M. In vivo and in vitro analysis of  skin penetration enhancement based on a two-layer model  with polar and non-polar routes in the stratum corneum.  Pharm Res. 1994;11:185-191.  	8165175
	2. Phillips CA, Michiniak BB. Transdermal delivery of  drugs with differing lipophilicities using azone analogs as  dermal penetration enhances. J Pharm Sci. 1995;84:1427 1437.  	8748324
	3. Flynn GL, Yalkowsky SH, Roseman TJ. Mass  transport phenomena and models: theoretical concepts. J  Pharm Sci. 1974;63:479-510.  	4828694
	4. Ozawa T, Takahashi M. Skin hydration: Recent  Advances. Acta Derm Venereol. Suppl. 1994;185:26-28.  	8091923
	5. Iazzo PA, Olsen RA, Seewald MJ, Powis G, Stier A,  Van Dyke RA. Transient increases of intracellular Ca++  induced by volatile anesthetics in rat hepatocytes. Cell  Calcium. 1990;11:515-524.  	2265428
	6. Reed PW, Lardy HA. A23187: Adivalent  Cationionophore. J Biol Chem. 1972;247:6970.  	4263618
	7. Wallace BA. Gramicidin channels and pores. Ann Rev  Biophysic Chem. 1990; 19:127  	1694667
	8. Araki M, Inaba H, Kon S, Imai M, Mizuguchi T.  Effects of volatile anesthetics on the calcium ionophore  A23187-mediated alterations in hepatic flow and  metabolism in the perfused liver in fasted rats. Acta  Anesthesiol Scan. 1997;41:55-61.  	9061115
	9. Plakas SM, James MO. Bioavailability, metabolism,  and renal excretion of benzoic acid in the channel catfish  (Ictalurus punctatus). Drug Metab Dispos.  1990;18(5):552-556.  	1981701
	10. French DL, Haglund BO, Himmelstein KJ, Mauger  JW: Controlled release of substituted benzoic and  naphthoic acids using Carbopol gels: measurement of  drug concentration profiles and correlation to release rate  kinetics. Pharm Res. 1995;12(10):1513-1520.  	8584491
	11. Miller GR, Smith CA, Stauber WT. Determination of  fibrosis from cryostat sections using high performance  liquid chromatography: skeletal muscle. Histochem J.  1999;31:89-94.  	10416680
	12. Bartlett GR. Phosphorous assay in column  chromatography. J Biol Chem. 1959;234:466-468.  	13641241
	13. Kabadi MB, Chien YW. Intravaginal controlled  administration of flurogestone acetate IV: in-vitro and in vivo correlation for intravaginal drug delivery from rate control vaginal pessary. Drug Develop Ind Pharm. 1985;  11:1313-1361.  	NO_MATCH
	14. Lee CH, Vyavahare N, Zand R, Kruth H, Schoen  FJ,Bianco R,. Levy RJ. Inhibition of aortic wall  calcification in bioprosthetic heart valves by ethanol  pretreatment: Biochemical and biophysical mechanisms. J  Biomed Mater Res. 1998;42(1):30-37.  	9740004
	15. Hu W, Cross TA. Tryptophan hydrogen bonding and  electric dipole moments: functional roles in the gramicidin  channel and implications for membrane proteins.  Biochemistry. 1995;34:14,147-14,155.  	7578012
	16. Heitz F, Gavach C. Ca+2 gramicidin A interactions  and blocking effects on the ionic channel. Biophysical  Chemistry. 1983; 18:153-163.  	6194829
	17. Mitchell DC, Litman BJ. Effect of hydration on  receptor conformation: decreased levels of bound water  promote metarhodopsin II formation.Biochemistry. 1999;  38: 7617-7623.  	10387000
	18. Kuruc M, Krupey J. Application of an insoluble  protein precipitation reagent. Am Biotechnol.  1992;10(3):12-14.  	1368383
	19. Hwang J, Tamm LK, Bohm C, Ramalingam TS,  Betzig E, Edidin M. Nanoscale complexity of  phospholipid monolayers investigated by near-field  scanning optical microscopy. Science. 1995; 270:610-614.  	7570018
	20. Carruthers A, Melchior DL. Human erythrocyte  hexose transporter activity is governed by bilayer  lipid composition in reconstituted vesicles.  Biochemistry. 1984;23(26):6901-6911.  	6543323
JVS001-02-03.pdf
	1. Bredt, D.S and Snyder, S.H. Nitric oxide, a novel neuronal  messenger. Neuron 1992, 8, 3-11.   	1370373
	2. Cooper, J. and Walker, R.D. Listeriosis. Vet. Clin. North.  Am. Food Anim. Pract. 1998, 14, 113-125.   	NO_MATCH
	3. Charlton, K.M. and Garcia, M.M. Spontaneous listeric  encephalitis and neuritis in sheep. Light microscopic studies.  Vet. Pathol. 1997, 14, 297-313.   	560741
	4. Dramsi, S., Levi, S., Triller, A. and Cossart, P. Entry of  Listeria monocytogenes into neurons occurrs by cell-to-cell  spread: an in vitro study. Infect. Immun. 1998, 66, 4461 4468.  	9712801
	5. Greenberg, S.S., Ouyang, J., Zhao, X. and Giles, T.D.  Human and rat neutrophils constitutively express neuronal  nitric oxide synthase mRNA. Nitric Oxide 1998, 2, 203-212.  	9731638
	6. Hooper, D.C., Ohnishi, S.T., Kean, R., Numagami, Y.,  Dietzschold, B. and Koprowski, H. Local nitric oxide  production in viral and autoimmune disease of the central  nervous system. Proc. Natl. Acad. Sci. U.S.A. 1995, 92,  5312-5316.  	7539914
	7. Johnson, G.C., Fales, W.H., Maddox, C.W. and Ramos Vara, J.A. Evaluation of laboratory test for confirming the  diagnosis of encephalitic listeriosis in ruminants. J. Vet.  Diagn. Invest. 1995, 7, 223-228.  	7542480
	8. Jungi, T.W., Pfister, H., Sager, H., Fatzer, R., Vandevelde,  M. and Zurbriggen, A. Comparison of inducible nitric  oxide synthase expression in the brain of Listeria  monocytogenes-infected cattle, sheep and goats and in  macrophages stimulated in vitro. Infect. Immun. 1997, 65,  5279-5288.   	9393827
	9. Krueger, N., Low, C. and Donachie, W. Phenotypic  characterization of the cells of the inflammatory response in  ovine encephalitic listeriosis. J. Comp. Pathol. 1995, 113,  263-275.  	8592052
	10. Kim, S., Moon, C., Wie, M., Kim, H., Tanuma, N.,  Matsumoto, Y. and Shin, T. Enhanced expression of  constitutive and inducible forms of nitric oxide synthase in  autoimmune encephalomyelitis. J. Vet. Sci., 2000, 1, 11-17.  	14612615
	11. Moncada, S., Palmer, R.M.J. and Higgs, E.A. Nitric  oxide: physiology, pathophysiology, and pharmacology.  Pharmacol. Rev., 1991, 43, 109-134.   	1852778
	12. Murphy, S., Simmons, M.L., Agullo, L., Carcia, A.,  Feinstein, D.L., Galea, E., Reis, D.J., Minc-Golomb, D.  and Schwartz, J.P. Synthesis of nitric oxide in CNS glial  cells. T.I.N.S. 1993, 16, 323-328.  	7691008
	13. Nathan, C. and Xie, Q.-W. Nitric oxide synthases: Roles,  tolls and controls. Cell 1994, 78, 915-918.   	7522969
	14. Otter, A. and Blackmore, W.F. Observation on the  presence of Listeria monocytogenes in axons. Acta  Microbiol. Hung. 1989, 36, 125-131.   	2517159
	15. Reiling, N., Ulmer, A.J., Duchrow, M., Ernst, M., Flad,  H.D. and Hauschildt, S. Nitric oxide synthase: mRNA  expression of different isoforms in human monocytes/  macrophages. Eur. J. Immunol. 1994, 24, 1941-1944.  	7520003
	16. Reiling, N., Kroncke, R., Ulmer, A.J., Gerdes, J., Flad,  H.D. and Hauschildt, S. Nitric oxide synthase: expression  of the endothelial, Ca2+/calmodulin-dependent isoform in  human B and T lymphocytes. Eur. J. Immunol. 1996, 26,  511-516.  	8605914
	17. Rouquette, C. and Berche, P. The pathogenesis of infection  by Listeria monocytogenes. Microbiologia 1996, 12, 245 258.  	8767708
	18. Sinz, E.H., Kochanek, P.M., Dixon, C.E., Clark, R.S.,  Carcillo, J.A., Schiding, J.K., Chen, M., Wisniewski,  S.R., Carlos, T.M., William, D., DeKosky, S.T., Watkins,  S.C., Marion, D.W. and Billiar, T.R. Inducible nitric oxide  synthase is an endogenous neuroprotectant after traumatic  brain injury in rats and mice. J. Clin. Invest. 1999, 104, 647 656.   	10487779
	19. Wu, J., Lin, Q., Lu, Y., Willis, W.D. and Westlund, K.N.  Changes in nitric oxide synthase isoforms in the spinal cord  of rat following induction of chronic arthritis. Exp. Brain  Res. 1998, 118, 457-465  	9504841
Nucleic Acids Symp Ser-2000-Inoue-279-80.pdf
	1. Trawick, B. N., Daniher, A. T., and Bashkin, J. K.  (1998) Chem. Rev., 98,939-960.  	NO_MATCH
	2. Inoue, H., Furukawa, T., Shimizu, M., Tamura, T.,  Matsui, M., and Ohtsuka, E. (1999) Chem.  Commun., 45-46.  	NO_MATCH
	3. Tamura, T., Furukawa, T., Komatsu, Y., Ohtsuka,  E., and Inoue, H. (1999) Nucleic Acids Symp. Ser.  No. 42, 109-110.  	10780403
	4. Cuenoud, B., Casset, F., Hiisken, D., Natt, F.,  Wolf, R. M., Altmann, K.-H., Martin, P., and  Moser, H. E. (1998) Angew. Chem. Int. Ed. Engl.,  37, 1288-1291.  	NO_MATCH
20008720.pdf
20008706.pdf
J. Biol. Chem.-2001-Choosakoonkriang-8037-43.pdf
	1. Hyde, S. C., Southern, K. W., Gileadi, U., Fitzjohn, E. M., Mofford, K. A.,  Waddell, B. E., Gooi, H. C., Goddard, C. A., Hannavy, K., Smyth, S. E.,  8043 Egan, J. J., Sorgi, F. L., Huang, L., Cuthbert, A. W., Evans, M. J., Colledge,  W. H., Higgins, C. F., Webb, A. K., and Gill, D. R. (2000) Gene Ther. 7,  1156–1165  	10918483
	2. Welsh, M. J., and Zabner, J. (1999) Hum. Gene Ther. 10, 1559–1572  	10395381
	3. Crook, K., Stevenson, B. J., Dubouchet, M., and Porteous, D. J. (1998) Gene  Ther. 5, 137–143  	9536275
	4. Liu, Y., Mounkes, L. C., Liggitt, H. D., Brown, C. S., Solodin, I., Heath, T. D.,  and Debs, R. J. (1997) Nat. Biotechnol. 15, 167–173  	9035144
	5. Farhood, H., Serbina, N., and Huang, L. (1995) Biochim. Biophys. Acta 1235,  289–295  	7756337
	6. Birchall, J. C., Kellaway, I. W., and Mills, S. N. (1999) Int. J. Pharm. (Amst.)  183, 195–207  	10361170
	7. Ross, P. C., and Hui, S. W. (1999) Gene Ther. 6, 651–659  	10476225
	8. Zuidam, N. J., and Barenholz, Y. (1997) Biochim. Biophys. Acta 1329, 211–222  	9371413
	9. Zuidam, N. J., and Barenholz, Y. (1998) Biochim. Biophys. Acta 1368, 115–128  	9459590
	10. Hirsch-Lerner, D., and Barenholz, Y. (1998) Biochim. Biophys. Acta 1370,  17–30  	9518536
	11. Bhattacharya, S., and Mandal, S. S. (1998) Biochemistry 37, 7764–7777  	9601037
	12. Hirsch-Lerner, D., and Barenholz, Y. (1999) Biochim. Biophys. Acta 1461,  47–57  	10556487
	13. Radler, J. O., Koltover, I., Salditt, T., and Safinya, C. R. (1997) Science 275,  810–814  	9012343
	14. Koltover, I., Salditt, T., Radler, J. O., and Safinya, C. R. (1998) Science 281,  78–81  	9651248
	15. Huebner, S., Battersby, B. J., Grimm, R., and Cevc, G. (1999) Biophys. J. 76,  3158–3166  	10354440
	16. Xu, Y., Hui, S. W., Frederik, P., and Szoka, F. C., Jr. (1999) Biophys. J. 77,  341–353  	10388762
	17. Koltover, I., Salditt, T., and Safinya, C. R. (1999) Biophys. J. 77, 915–924  	10423436
	18. Zuidam, N. J., Barenholz, Y., and Minsky, A. (1999) FEBS Lett. 457, 419–422  	10471821
	19. Zuidam, N. J., and Barenholz, Y. (1999) Int. J. Pharm. (Amst.) 183, 43–46  	10361152
	20. Braun, C. S., Kueltzo, L. A., and Middaugh, C. R. (2001) Methods Mol. Med., in  press  	21318759
	21. Mendelsohn, R., Davies, M. A., Brauner, J. W., Schuster, H. F., and Dluhy,  R. A. (1989) Biochemistry 28, 8934–8939  	NO_MATCH
	22. Davies, M. A., Schuster, H. F., Brauner, J. W., and Mendelsohn, R. (1990)  Biochemistry 29, 4368–4373  	NO_MATCH
	23. Lewis, R. N., Pohle, W., and McElhaney, R. N. (1996) Biophys. J. 70,  2736–2746  	2605234
	24. Smith, S. O., Kustanovich, I., Bhamidipati, S., Salmon, A., and Hamilton, J. A.  (1992) Biochemistry 31, 11660–11664  	1445903
	25. Binder, H., Gutberlet, T., Anikin, A., and Klose, G. (1998) Biophys. J. 74,  1908–1923  	9545052
	26. Neault, J. F., Naoui, M., Manfait, M., and Tajmir-Riahi, H. A. (1996) FEBS  Lett. 382, 26–30  	8612758
	27. Neault, J. F., and Tajmir-Riahi, H. A. (1999) Biophys. J. 76, 2177–2182  	10096911
	28. Alex, S., and Dupuis, P. (1989) Inorg. Chim. Acta 157, 271–281  	NO_MATCH
	29. Koppel, D. E. (1962) J. Chem. Phys. 57, 4814  	NO_MATCH
	30. Taillandier, E., and Liquier, J. (1992) Methods Enzymol. 211, 307–335  	NO_MATCH
	31. Akao, T., Fukumoto, T., Ihara, H., and Ito, A. (1996) FEBS Lett. 391, 215–218  	8706920
	32. Bloomfield, V., Crothers, D. M., and Ignacio, T. J. (2000) in Nucleic Acids, pp.  31, University Science Books, Sausalito, CA  	NO_MATCH
	33. Mohammadi, S., Perree-Fauvet, M., Gresh, N., Hillairet, K., and Taillandier,  E. (1998) Biochemistry 37, 6165–6178  	9558356
	34. Ahmad, R., Naoui, M., Neault, J. F., Diamantoglou, S., and Tajmir-Riahi, H. A.  (1996) J. Biomol. Struct. Dyn. 13, 795–802  	8723774
	35. Tajmir-Riahi, H. A., Naoui, M., and Ahmad, R. (1993) J. Biomol. Struct. Dyn.  11, 83–93  	8216950
	36. Arakawa, H., Ahmad, R., Naoui, M., and Tajmir-Riahi, H. A. (2000) J. Biol.  Chem. 275, 10150–10153  	10744697
	37. Kennedy, M. T., Pozharski, E. V., Rakhmanova, V. A., and MacDonald, R. C.  (2000) Biophys J. 78, 1620–1633  	10692346
	38. Lobo, B. A., Rogers, S., Wiethoff, C. M., Choosakoonkriang, S., Bogdanovich Knipp, S., and Middaugh, C. R. (2001) Methods Mol. Med., in press  	21318761
	39. Cullis, P. R., and de Kruijff, B. (1979) Biochim. Biophys Acta 559, 399–420  	391283
	40. Regelin, A. E., Fankhaenel, S., Gurtesch, L., Prinz, C., von Kiedrowski, G., and  Massing, U. (2000) Biochim. Biophys Acta 1464, 151–164  	10704929
	41. Tilcock, C. P. (1986) Chem. Phys. Lipids 40, 109–125  	3742669
J. Biol. Chem.-2001-Arimura-8550-6.pdf
	1. Banchereau, J., Bazan, F., Blanchard, D., Briere, F., Galizzi, J. P., van Kooten,  C., Liu, Y. J., Rousset, F., and Saeland, S. (1994) Annu. Rev. Immunol. 12,  881–922  	7516669
	2. Foy, T. M., Aruffo, A., Bajorath, J., Buhlman, J. E., and Neolle, R. J. (1994)  Annu. Rev. Immunol. 14, 591–617  	8717526
	3. Clark, L. B., Foy, T. M., and Noelle, R. J. (1994) Adv. Immunol. 63, 43–78  	8787629
	4. van Kooten, C., and Banchereau, J. (1996) Adv. Immunol. 61, 1–77  	8834494
	5. Grewal, I. S., and Flavel, R. A. (1998) Annu. Rev. Immunol. 16, 111–135  	9597126
	6. Liu, Y. J., Joshua, D. E., Williams, G. T., Smith, C. A., Gordon, J., and  MacLennan, I. C. (1989) Nature 342, 929–931  	2594086
	7. Gregory, C. D., Dive, C., Henderson, S., Smith, C. A., Williams, G. T., Gordon,  J., and Rickinson, A. B. (1991) Nature 349, 612–614  	1705663
	8. Banchereau, J., de Paoli, P., Valle, A., Garcia, E., and Rousset, F. (1991)  Science 251, 70–72  	1702555
	9. Tsubata, T., Wu, J., and Honjo, T. (1993) Nature 364, 645–648  	7688865
	10. Inui, S., Kaisho, T., Kikutani, H., Stamenkovic, I., Seed, B., Clark, E. A., and  Kishimoto, T. (1990) Eur. J. Immunol. 20, 1747–1753  	1698631
	11. Heath, A. W., Chang, R., Harada, N., Santos-Argumedo, L., Gordon, J., Han num, C., Campbell, D., Shanafelt, A. B., Clark, E. A., Torres, P., and  Howard, M. (1993) Cell Immunol. 152, 468–480  	7504979
	12. Funakoshi, S., Longo, D. L., Beckwith, M., Conley, D. K., Tsarfaty, G.,  Tsarfaty, I., Armitage, R. J., Fanslow, W. C., Spriggs, M. K., and Murphy,  W. J. (1994) Blood 83, 2787–2794  	7514045
	13. Hess, S., and Engelmann, H. (1996) J. Exp. Med. 183, 159–167  	8551219
	14. Eliopoulos, A. G., Dawson, C. W., Mosialos, G., Floettmann, J. E., Rowe, M.,  Armitage, R. J., Dawson, J., Zapata, J. M., Kerr, D. J., Wakelam, M. J. O.,  Reed, J. C., Kieff, E., and Young, L. S. (1996) Oncogene 13, 2243–2254  	8950992
	15. Peguet-Navarro, J., Dalbiez-Gauthier, C., Moulon, C., Berthier, O., Reano, A.,  Gaucherand, M., Banchereau, J., Rousset, F., and Schmitt, D. (1997) J. Im munol. 158, 144–152  	1008648
	16. Faris, M., Gaskin, F., Parsons, J. T., and Fu, S. M. (1994) J. Exp. Med. 179,  1923–1931  	7515102
	17. Ren, C. L., Morio, T., Fu, S. M., and Geha, R. S. (1994) J. Exp. Med. 179,  673–680  	7507510
	18. Hanissian, S. H., and Geha, R. S. (1997) Immunity 6, 379–387  	9133417
	19. Berberich, I., Shu, G., and Clark, E. A. (1994) J. Immunol. 153, 4357–4366  	7525701
	20. Rothe, M., Sarma, V., Dixit, V. M., and Goeddel, D. V. (1995) Science 269,  1424–1427  	7544915
	21. Schauer, S. L., Wang, Z., Sonenshein, G. E., and Rothstein, T. L. (1996)  J. Immunol. 157, 81–86  	8683159
	22. Grumont, R. J., Rasko, J. E., Strasser, A., and Gerondakis, S. (1996) Mol. Cell.  Biol. 16, 2913–2921  	8649402
	23. Ishida, T., Kobayashi, N., Tojo, T., Ishida, S., Yamamoto, T., and Inoue, J.  (1995) J. Immunol. 155, 5527–5535  	7499834
	24. Lederman, S., Yellin, M. J., Inghirami, G., Lee, J. J., Knowles, D. M., and  Chess, L. (1992) J. Immunol. 149, 3817–3826  	1281189
	25. Barrett, T. B., Shu, G., and Clark, E. A. (1991) J. Immunol. 146, 1722–1729  	1706378
	26. Ranheim, E. A., and Kipps, T. J. (1993) J. Exp. Med. 177, 925–935  	7681471
	27. Liu, Y. J., Barthelemy, C., de Bouteiller, O., Arpin, C., Durand, I., and Banche reau, J. (1995) Immunity 2, 239–248  	7535180
	28. Schattner, E. J., Elkon, K. B., Yoo, D.-H., Tumang, J., Krammer, P. H., Crow,  M. K., and Friedman, S. M. (1995) J. Exp. Med. 182, 1557–1565  	7595225
	29. Klaus, S. J., Berberich, I., Shu, G., and Clark, E. A. (1994) Semin. Immunol. 6,  279–286  	7532458
	30. Berberich, I., Shu, G., Siebelt, F., Woodgett, J. R., Kyriakis, J. M., and Clark,  E. A. (1996) EMBO J. 15, 92–101  	8598210
	31. Sutherland, C. L., Heath, A. W., Pelech, S. L., Young, P. R., and Gold, M. R.  (1996) J. Immunol. 157, 3381–3390  	8871635
	32. Kashiwada, M., Kaneko, Y., Yagita, H., Okumura, K., and Takemori, T. (1996)  Eur. J. Immunol. 26, 1451–1458  	8766546
	33. Purkerson, J. M., and Parker, D. C. (1998) J. Immunol. 160, 2121–2129  	9498749
	34. Craxton, A., Shu, G., Graves, J. D., Saklatvala, J., Krebs, E. G., and Clark,  E. A. (1998) J. Immunol. 161, 3225–3236  	9759836
	35. Ogimoto, M., Katagiri, T., Mashima, K., Hasegawa, K., Mizuno, K., and  Yakura, H. (1994) Int. Immunol. 6, 647–654  	NO_MATCH
	36. Ogimoto, M., Katagiri, T., Mashima, K., Hasegawa, K., Mizuno, K., and  Yakura, H. (1995) Eur. J. Immunol. 25, 2265–2271  	7664790
	37. Yakura, H., Shen, F.-W., Bourcet, E., and Boyse, E. A. (1983) J. Exp. Med. 157,  1077–1088  	6220106
	38. Volarevic, S., Niklinska, B. B., Burns, C. M., June, C. H., Weissman, A. M., and  Ashwell, J. D. (1993) Science 260, 541–544  	8475386
	39. Yan, M., Dai, T., Deak, J. C., Kyriakis, J. M., Zon, L. I., Woodgett, J. R.,  Templeton, D. J. (1994) Nature 372, 798–800  	7997270
	40. Reinhard, C., Shamoon, B., Shyamala, V., and Williams, L. T. (1997) EMBO J.  16, 1080–1092  	9118946
	41. Lee, S. Y., Reichlin, A., Santana, A., Sokol, K. A., Nussenzweig, M. C., and  8556Selective Regulation of CD40 Signaling by CD45  	9390693
	42. Song, H. Y., Regnier, C. H., Kirchning, C. J., Goeddel, D. V., and Rothe, M.  (1997) Proc. Natl. Acad. Sci. U. S. A. 94, 9792–9796  	9275204
	43. Regnier, C. H., Song, H. Y., Gao, X., Goeddel, D. V., Cao, Z., and Rothe, M.  (1997) Cell 90, 373–383  	9244310
	44. Mercurio, F., Zhu, H., Murray, B. W., Shevchenko, A., Bennett, B. L., Li, J. W.,  Young, D. B., Barbosa, M., Mann, M., Manning, A., and Rao, A. (1997)  Science 278, 860–866  	9346484
	45. Lee, F. S., Hagler, J., Chen, Z. J., and Maniatis, T. (1997) Cell 88, 213–222  	9008162
	46. Gruber, M. F., Bjorndahl, J. M., Nakamura, S., and Fu, S. M. (1989) J. Im munol. 142, 4144–4152  	2470814
	47. Byth, K. F., Conroy, L. A., Howlett, S., Smith, A. J. H., May, J., Alexander,  D. R., and Holmes, N. (1996) J. Exp. Med. 183, 1707–1718  	8666928
	48. Miyamoto, S., Chiao, P. J., and Verma, I. M. (1994) Mol. Cell. Biol. 14,  3276–3282  	8164680
J. Biol. Chem.-2001-Deutsch-6967-73.pdf
	1. Devane, W. A., Hanus, L., Breuer, A., Pertwee, R. G., Stevenson, L. A., Griffin,  G., Gibson, D., Mandelbaum, A., Etinger, A., and Mechoulam, R. (1992)  Science 258, 1946–1949  	1470919
	2. Sugiura, T., Kondo, S., Sukagawa, A., Nakane, S., Shinoda, A., Itoh, K.,  Yamashita, A., and Waku, K. (1995) Biochem. Biophys. Res. Commun. 215,  89–97  	11106784
	3. Mechoulam, R., Ben-Shabat, S., Hanus, L., Ligumsky, M., Kaminski, N. E.,  Schatz, A. R., Gopher, A., Almog, S., Martin, B. R., Compton, D. R., Pertwee,  R. G., Griffin, G., Bayewitch, M., Barg, J., and Vogel, Z. (1995) Biochem.  Pharmacol. 50, 83–90  	7605349
	4. Martin, B. R., Mechoulam, R., and Razdan, R. K. (1999) Life Sci. 65, 573–595  	10462059
	5. Deutsch, D. G., and Chin, S. A. (1993) Biochem. Pharmacol. 46, 791–796  	8373432
	6. Koutek, B., Prestwich, G. D., Howlett, A. C., Chin, S. A., Salehani, D., Akha van, N., and Deutsch, D. G. (1994) J. Biol. Chem. 269, 22937–22940  6973  	8083191
	7. Di Marzo, V., Fontana, A., Cadas, H., Schinelli, S., Cimino, G., Schwartz, J. C.,  and Piomelli, D. (1994) Nature 372, 686–691  	7990962
	8. Hillard, C. J., Edgemond, W. S., Jarrahian, A., and Campbell, W. B. (1997)  J. Neurochem. 69, 631–638  	9231721
	9. Di Marzo, V., Bisogno, T., Melck, D., Ross, R., Brockie, H., Stevenson, L.,  Pertwee, R., and De Petrocellis, L. (1998) FEBS Lett. 436, 449–454  	9801167
	10. Maccarrone, M., Bari, M., Menichelli, A., Del Principe, D., and Agro, A. F.  (1999) FEBS Lett. 447, 277–282  	10214961
	11. Hillard, C. J., and Campbell, W. B. (1997) J. Lipid Res. 38, 2383–2398  	9458263
	12. Rakhshan, F., Day, T. A., Blakely, R. D., and Barker, E. L. (2000) J. Pharma col. Exp. Ther. 292, 960–967  	10688610
	13. Piomelli, D., Beltramo, M., Glasnapp, S., Lin, S. Y., Goutopoulos, A., Xie, X. Q.,  and Makriyannis, A. (1999) Proc. Natl. Acad. Sci. U. S. A. 96, 5802–5807  	10318965
	14. Beltramo, M., Stella, N., Calignano, A., Lin, S. Y., Makriyannis, A., and  Piomelli, D. (1997) Science 277, 1094–1097  	9262477
	15. Melck, D., De Petrocellis, L., Orlando, P., Bisogno, T., Laezza, C., Bifulco, M.,  and Di Marzo, V. (2000) Endocrinology 141, 118–126  	10614630
	16. Jarrahian, A., Manna, S., Edgemond, W. S., Campbell, W. B., and Hillard, C. J.  (2000) J. Neurochem. 74, 2597–2606  	10820223
	17. Di Marzo, V., and Deutsch, D. G. (1998) Neurobiol. Cannabinoid Transmission  5, 386–404  	9974173
	18. Omeir, R. L., Arreaza, G., and Deutsch, D. G. (1999) Biochem. Biophys. Res.  Commun. 264, 316–320  	10529361
	19. Patricelli, M. P., Lovato, M. A., and Cravatt, B. F. (1999) Biochemistry 38,  9804–9812  	10433686
	20. Goparaju, S. K., Kurahashi, Y., Suzuki, H., Ueda, N., and Yamamoto, S. (1999)  Biochim. Biophys. Acta 1441, 77–84  	10526230
	21. Deutsch, D. G., Omeir, R., Arreaza, G., Salehani, D., Prestwich, G. D., Huang,  Z., and Howlett, A. (1997) Biochem. Pharmacol. 53, 255–260  	9065728
	22. Deutsch, D. G., Lin, S., Hill, W. A., Morse, K. L., Salehani, D., Arreaza, G.,  Omeir, R. L., and Makriyannis, A. (1997) Biochem. Biophys. Res. Commun.  231, 217–221  	9070252
	23. De Petrocellis, L., Melck, D., Ueda, N., Maurelli, S., Kurahashi, Y., Yamamoto,  S., Marino, G., and Di Marzo, V. (1997) Biochem. Biophys. Res. Commun.  231, 82–88  	9070224
	24. Omeir, R. L., Chin, S., Hong, Y., Ahern, D. G., and Deutsch, D. G. (1995) Life  Sci. 56, 1999–2005  	7776824
	25. Maccarrone, M., van der Stelt, M., Rossi, A., Veldink, G. A., Vliegenthart, J. F.,  and Agro, A. F. (1998) J. Biol. Chem. 273, 32332–32339  	9822713
	26. Abumrad, N., Harmon, C., and Ibrahimi, A. (1998) J. Lipid Res. 39, 2309–2318  	9831619
	27. Giang, D. K., and Cravatt, B. F. (1997) Proc. Natl. Acad. Sci. U. S. A. 94,  2238–2242  	9122178
	28. Arreaza, G., and Deutsch, D. G. (1999) FEBS Lett. 454, 57–60  	10413095
	29. Cravatt, B. F., Prospero-Garcia, O., Siuzdak, G., Gilula, N. B., Henriksen, S. J.,  Boger, D. L., and Lerner, R. A. (1995) Science 268, 1506–1509  	7770779
	30. Arreaza, G., Devane, W. A., Omeir, R. L., Sajnani, G., Kunz, J., Cravatt, B. F.,  and Deutsch, D.G. (1997) Neurosci. Lett. 234, 59–62  	934794
	31. Ueda, N., Yamanaka, K., Terasawa, Y., and Yamamoto, S. (1999) FEBS Lett.  454, 267–270  	10431820
	32. Hillard, C. J., and Jarrahian, A. (2000) Chem. Phys. Lipids 108, 123–134  	11106786
	33. McArthur, M. J., Atshaves, B. P., Frolov, A., Foxworth, W. D., Kier, A. B., and  Schroeder, F. (1999) J. Lipid Res. 40, 1371–1383  	10428973
	34. Bisogno, T., Maurelli, S., Melck, D., Depetrocellis, L., and Di Marzo, V. (1997)  J. Biol. Chem. 272, 3315–3323  	9013571
	35. Gifford, A. N., Bruneus, M., Lin, S., Goutopoulos, A., Makriyannis, A., Volkow,  N. D., and Gatley, S. J. (1999) Eur. J. Pharmacol. 383, 9–14  	10556675
	36. Martin, B. R., Beletskaya, I., Patrick, G., Deutsch, D., Di Marzo, V., and  Razdan, R. K. (2000) J. Pharmacol. Exp. Ther. 294, 1209–1218  	10945879
	37. Chan, P. H., Kerlan, R., and Fishman, R. A. (1982) J. Neurosci. Res. 8, 67–72  	7175979
	38. Madshus, I. H., Tonnessen, T. I., Olsnes, S., and Sandvig, K. (1987) J. Cell.  Physiol. 131, 6–13  	3571337
53_979.pdf
	1) Horinouchi, S.: 7-Butyrolactones that control secondary  metabolism and cell differentiation  in Streptomyces, In  Cell-cell signaling in Bacteria. Ed., G. M. Dunny, et al,  pp. 193-207, American Society for Microbiology, Washington,  D. C, 1999  	NO_MATCH
	2) Yamada, Y.: Autoregulatory factors and regulation of  antibiotic production in Streptomyces, In Microbial signalling  and communication. Ed., R. England, et  al., pp. 177-196, Society for General Microbiology,  Cambridge University Press., Cambridge, 1999  	NO_MATCH
	3) Takano, E.; T. Nihira, Y Hara, I J. Jones, C. J.  Gershater, Y Yamada & M. Bibb: Purification and  structural determination of SCB1 , a 7-butyrolactone that  elicAit3s  (2). antJ.i bBiiool.t ic Chpemro. du2c75t:i on1 1i0n10- 11S01t6,r eptomyc2e00s0 coelicolor  	NO_MATCH
	4) Grafe, U; W. Schade, I. Eritt, W. F. Fleck & L.  Radics: A new inducer of the anthracycline biosynthesis  from Streptomyces viridochromogenes. J. Antibiotics 35 :  1208-1215, 1982  	6962795
	5) Grafe, U; G. Reinhardt, W. Schade, I. Eritt, W.  F. Fleck & L. Radics: Interspecific inducers of  cytodifferntiation and anthracycline  biosynthesis from Streptomyces bikiniensis and S. cyanofuscatus. Biotech nol. Lett. 5: 591-596, 1983  	NO_MATCH
	6) Hara, O. & T. Beppu: Mutants blocked in streptomycin  production in Streptomyces griseus-the role of A factor. J. Antibiotics 35: 349-358, 1982  	6804428
53_954.pdf
	Fuhrmann, U; E. Bause, & P. Hidde: Inhibitiors oligo95s-a1c10h, aride 1985processing. Biochim. Biophys. Acta 825:	3159432
	Truscheit, E.; W. Frommer, B. Junge & W.  Wingender: Chemistry and biochemistry of microbial a-glucosidase inhibitors.  Angew. Chem. Int. Ed. Engl.  20: 744-761,  1981  	NO_MATCH
	Bischoft, H.: Pharmacology of a-glucosidases  inhibition. Eur. J. Clin. Invest. 24 (Suppl. 3): 3-10, 1994  	8001624
	Watanabe, I; J. Kawabata, H. Kurihara & R. Niki:  Isolation and identification of a-glucosidase inhibitors  from Tochu-ch2L(Eucommia ulmoides). Biosci. Biotech.  Biochem. 61:.177-178,"1997  	9028049
	Matsui, T.; C. Yoshimoto, K. Osajima, T. Oki & Y. Osajima: In vitro survey of a-glucosidase inhibitory  food components. Biosci. Biotech. Biochem. 60: 2019 2022, 1996  	8988634
	Nitecki, D. E. & B. Halpern: A simple route to  sterically  pure diketopiperazines.  J. Org. Chem. 33:  864-866, 1968  	21894993
	Lee, S.; T. Kanmera, H. Aoyagi & N. Izumiya: Cyclic  peptides. VI. Asymmetric hydrogenation of dehydro alanine or dehydroaminobutanoic acid residue in cyclic dipeptides. Int. J. Peptide Protein Res. 13: 207-217,  1979  	429097
	Pan, Y T.; J. Ghidoni & A. D. Elbein: The effects of  castanospermine and swainsonine on the activity and  synthesis of intestinal sucrase. Archi. of Biochem. and  Biophys. 303: 134-144, 1993  	8489256
	Bell, R.; S. Carmeli & N. Sar: Vibrindole A,  a metabolite of the marine bacterium, Vibrio  parahaemolyticus, isolated from the toxic mucus of the  box fish Ostracion cubicus. J. Nat. Prod. 57: 1587-1590,  1994	7853008  
	Fenouillet, E.; M. J. Papandreou & L. Jones:  Recombinant HIVenvelope expressed in an a-glucosi dase I-deficient CHOcell line and its parental cell line in the presence of 1-deoxynojirimycin   is functional. Virology 231: 89-95, 1997	9143306
53_903.pdf
	1) Cabib, E.; J. A. Shaw, P. C. Mol, B. Bower & W. J.  Choi: Chitin biosynthesis and morphogenetic process. In  The Mycota. Biochemistry and Molecular Biology. Vol.  III. Ed. R. Brambl & G. A. Marzluf, pp. 243-267, Springer-Verlag,  Berlin,  1 996  	NO_MATCH
	2) Bulawa, C. E.: CSD2, CSD3, and CSD4, genes required  for chitin synthesis in Saccharomyces cerevisiae: the  CSD2gene product is related to chitin synthases and to  developmentally regulated proteins in Rhizobium species  and Xenopus laevis. Mol. Cell. Biol. 12: 1764-1776, 1992	1532231
	3) Takita, M. A. & B. Castilho-Valavicius:  Absence of  cell wall chitin in Saccharomyces cerevisiae leads to  resistance to Kluyveromyces lactis killer toxin. Yeast 9:  589-598, 1993  	8346675
	Bulawa, C. E. & B. C. Osmond: Chitin synthase I and  chitin synthase II are not required for chitin synthesis in  vivo in Saccharomyces cerevisiae. Proc. Natl. Acad. Sci.  U.S.A. 87: 7424-7428, 1990  	2217173
	Shaw, J. A.; P. C. Mol, B. Bowers, S. J. Silverman, M.  M. Valdivieso, A. Duran & E. Cabib: The function of  chitin synthases 2 and 3 in the Saccharomyces cerevisiae cell cycle. J. CellBiol. 114: 111-123,  1991  	2050738
	Cabib, E.; B. Sburlati, B. Bowers & S. J. Silverman:  Chitin synthase I, an auxiliary enzyme for chitin  synthesis in Saccharomyces cerevisiae. X Cell Biol. 108:  1665-1672, 1989  	2523889
	Cabib, E.; S. J. Silverman & J. A. Shaw: Chitinase and  chitin synthase I: counterbalancing activities in cell  separation of Saccharomyces cerevisiae. X Gen.  Microbiol. 138: 97-102,  1992  	1556560
	Silverman, S. X: Similar and different domains of chitin  synthases 1 and 2 of Saccharomyces cerevisiae: two  isozyme with distinct functions. Yeast 5: 459-467, 1989	2533436  
	Silverman, S. X; A. Sburlati, M. Slater & E. Cabib:  Chitin synthase 2 is essential function and cell division  in Saccharomyces cerevisiae. Proc. Natl. Acad. Sci. U.S.A. 85: 4735-4739, 1988 	2968606
	Sburlati, A. & E. Cabib: Chitin synthethase 2, a  presumptive participant in septum formation in  Saccharomyces cerevisiae. X Biol. Chem. 261: 15147 15152, 1986  	2945823
	Gilbertson, R. L. & L. Ryvarden: North American Polypores. Vol. 2. pp. 541-623, Fungi flora, Oslo,  Norway, 1987  	NO_MATCH
	Choi, W. J. & E. Cabib: The use ofdivalent cations and  pH for the determination of specific yeast chitin  synthetases.  Anal. Biochem. 219: 368-372, 1994  	8080094
	Lowry, O. H.; N. I Rosebrough, A. L. Farr & R. X  Randall: Protein measurement with the folin phenol  reagent. X Biol. Chem. 193: 265-275, 1951  	14907713
	Stalpers, X A.: Studies in Mycology. No 16;  Identification of wood-inhibiting fungi in pure culture, p.  248, Centraalbureau voor Schimmelcultures, Baarn,  Netherlands,  1 978  	NO_MATCH
	Ryvarden, L. & R. L. Gilbertson: European Polypores.  Vol. 1-2. p. 743, Fungi flora, Oslo, Norway, 1993  	NO_MATCH
	Larsen, M. X & L. A. Cobb-Poulle: Synopsis  Fungorum 3: Phellinus  (Hymenochaetaecae)-A survey  of the world taxa. p. 206, Fungi flora, Oslo, Norway, 1990  	NO_MATCH
	Gilbertson, R. L. & L. Ryvarden: North American Polypores. Vol. 1-2. p. 885, Fungi flora, Oslo, Norway,  1987  	NO_MATCH
	Dai, Y. C. & M. Q. Xu: Studies on the medicinal  polypore, Phellinus baumil, and its kin, P. linteus.  Mycotaxon 62: 191-200, 1998  	NO_MATCH
	Cabib, E.: Differential inhibition of chitin synthases 1  and 2 from Saccharomyces cerevisiae by polyoxin D and  nikkomycin Z. Antimicrob. Agents Chemother. 35:  170-173, 1991  	2014972
	Georgopapadakou, N. H.: Antifungals targeted to the  cell wall. Exp. Opin. Invest. Drugs. 6: 147-150, 1997  	NO_MATCH
	Denning, D. W.: Echinocandins and pneumocandins- a  newantifungal class with a novel mode of action. X Antimicrob. Chemother. 40: 61 1-614, 1997 	9421307
	Sakurai, T.; N. Cheepthan, T. Mikawa, A. Yokota & F.  Tomita: A novel screen for the detection of chitin acting  antifungal compounds. X Antibiotics 52: 508-51 1, 1999  	10480577
	23) Naowarat, C; T. Higashiyama, N. Phay & F. Tomita:  Rapid and unique screening system for the discovery of  new antifungal antibiotics against chitin  synthesis in  fungal cell walls. Thai J. Biotechnol. 1(1): 31-36, 1999  	NO_MATCH
	24) Naowarat, C; N. Phay, T. Higashiyama, E. Fukushi, H.  Matsuura, T. Mikawa, A. Yokota, A. Ichihara & F.  Tomita: Studies on an antifungi antibiotic from  Ellisiodothis inguinans L1588-A8. Thai J. Biotechnol.  1(1): 37-45, 1999  	NO_MATCH
	25) Pfefferle, W.; H. Anke & M. Bross: Inhibition   solubilized chitin synthase by chlorinated aromatic  compounds isolated from mushroomcultures. Agric.  Biol. Chem. 54(6): 1381-1384, 1990  	NO_MATCH
	26) Hector, R. F. & P. C. Braun: Synergic action of  nikkomycin X and Z with papulacandin B on whole cells  and regenerating protoplasts of Candida albicans.  Antimicrob. Agents Chemother. 29: 389-394, 1986  	3521483
	27) Gaughram, J. P.; M. H. Lai, D. R. Kirsch & S. J.  Silverman: Nikkomycin Z is a specific inhibitor of  Saccharomyces cerevisiae chitin synthase isozyme chs3  in vitro and in vivo. J. Bacteriol. 176: 5857-5860, 1994  	8083179
	Cabib, E.; R. Roberts & B. Bowers: Synthesis of the  yeast cell wall and its regulation.  Ann. Rev. Biochem.  51: 763-793,  1982  	7051965
	Hwang, E. L; B. S. Yun, Y. K. Kim, B. M. Kwon, H. G.  Kim, H. B. Lee, K. S. Bae & S. U. Kim: Chaetoatrosin  A,  a novel ehitin synthase II inhibitor produced by  Chaetomium atrobrunneum F449. J. Antibiotics  53: 248-255, 2000 	10819295
	Kim, S. U; E. I. Hwang, J. Y. Nam, K. H. Son, S. H.  Bok, H. E. Kim & B. M. Kwon: Inhibition  of chitin synthase II by catechins from stem bark of Taxus  cuspidata. Planta Medica 65: 97-98, 1999  	10083852
	Jeong, T. S.; E. I. Hwang, H. B. Lee, E. S. Lee, Y K.  Kim, B. S. Min, K. H. Bae, S. H. Bok & S. U. Kim:  Chitin stnthase II Inhibitory activity of ursolic acid,  isolated from Crataegus pinnatifida. Planta Medica 65: 261-263, 1999  	10232075
262.pdf
241.pdf
207.pdf
196.pdf
J Neurophysiol-2000-Samson-1330-45.pdf
	ADRIA´N HO, LIFSCHITZ WM, TAVITAS RJ, AND GALLI FP. Activity of neural  units in medial geniculate body of cat and rabbit. J Neurophysiol 29:  1046–1060, 1966.  	5971661
	AITKIN LM. Medial geniculate body of the cat: responses to tonal stimuli of  neurons in medial division. J Neurophysiol 36: 275–283, 1973.  	4574714
	AITKIN LM AND DUNLOP CW. Interplay of excitation and inhibition in the cat  medial geniculate body. J Neurophysiol 31: 44–61, 1968.  	5640739
	AITKIN LM AND MARTIN RL. The representation of stimulus azimuth by high  best-frequency azimuth-selective neurons in the central nucleus of the  inferior colliculus of the cat. J Neurophysiol 57: 1185–1200, 1987.  	3585459
	AITKIN LM AND WEBSTER WR. Medial geniculate body of the cat: organization  and responses to tonal stimuli of neurons in ventral division. J Neurophysiol  35: 365–380, 1972.  	5029955
	ALTMAN JA, SYKA J, AND SHMIGIDINA GN. Neuronal activity in the medial  geniculate body of the cat during monaural and binaural stimulation. Exp  Brain Res 10: 81–93, 1970.  	5411976
	ANDERSEN RA, KNIGHT PL, AND MERZENICH MM. The thalamocortical and  corticothalamic connections of AI, AII, and the anterior auditory field  (AAF) in the cat: evidence for two largely segregated systems of connec tions. J Comp Neurol 194: 663–701, 1980.  	7451688
	BARONE P, CLAREY JC, IRONS WA, AND IMIG TJ. Cortical synthesis of azimuth sensitive single-unit responses with nonmonotonic level tuning: a thalamo cortical comparison in the cat. J Neurophysiol 75: 1206–1220, 1996.  	8867129
	CLAREY JC, BARONE P, AND IMIG, T.J. Physiology of thalamus and cortex. In:  The Mammalian Auditory Pathway: Neurophysiology, edited by Fay RR and  Popper A. New York: Springer-Verlag, 1992, chapt. 5, p. 232–334.  	NO_MATCH
	CLAREY JC, BARONE P, IRONS WA, SAMSON FK, AND IMIG TJ. Comparison of  noise and tone azimuth tuning of neurons in cat primary auditory cortex and  medial geniculate body. J Neurophysiol 74: 961–980, 1995.  	7500165
	DELGUTTE B, JORIS PX, LITOVSKY RY, AND YIN TCT. Receptive fields and  binaural interactions for virtual-space stimuli in the cat inferior colliculus.  J Neurophysiol 81: 2833–2851, 1999.  	10368401
	FUZESSERY ZM, WENSTRUP JJ, AND POLLAK GD. Determinants of horizontal  sound location selectivity of binaurally excited neurons in an isofrequency  region of the mustache bat inferior colliculus. J Neurophysiol 63: 1128–  1147, 1990.  	2358867
	HIRSCH JA, CHAN JC, AND YIN TC. Responses of neurons in the cat’s superior  colliculus to acoustic stimuli. I. Monaural and binaural response properties.  J Neurophysiol 53: 726–745, 1985.  	3981235
	IMIG TJ AND ADRIA´N HO. Binaural columns in the primary field (AI) of the cat  auditory cortex. Brain Res 138: 241–257, 1977.  	589474
	IMIG TJ, BIBIKOV NG, POIRIER P, AND SAMSON FK. Directionality derived from  pinna-cue spectral notches in the cat’s dorsal cochlear nucleus. J Neuro physiol 83: 907–925, 2000.  	10669504
	IMIG TJ, IRONS WA, AND SAMSON FR. Single-unit selectivity to azimuthal  direction and sound pressure level of noise bursts in cat high-frequency  primary auditory cortex. J Neurophysiol 63: 1448–1466, 1990.  	2358885
	IMIG TJ AND MOREL A. Tonotopic organization in the ventral nucleus of the  medial geniculate body in the cat. J Neurophysiol 53: 309–340, 1985a.  	3973661
	IMIG TJ AND MOREL A. Tonotopic organization of the lateral part of the  posterior group of thalamic nuclei in the cat. J Neurophysiol 53: 836–851,  1985b.  	3981239
	IMIG TJ, POIRIER P, IRONS WA, AND SAMSON FK. A monaural spectral contrast  mechanism for neural sensitivity to sound direction in the medial geniculate  body of the cat. J Neurophysiol 78: 2754–2771, 1997.  	9356424
	IVARSSON C, DE RIBAUPIERRE Y, AND DE RIBAUPIERRE F. Influence of auditory  localization cues on neuronal activity in the auditory thalamus of the cat.  J Neurophysiol 59: 586–606, 1988.  	3351575
	JORIS PX. Response classes in the dorsal cochlear nucleus and its output tract  in the chloralose-anesthetized cat. J Neurosci 18: 3955–3966, 1998.  	9570822
	KITZES LM, WREGE KS, AND CASSADY JM. Patterns of responses of cortical  cells to binaural stimulation. J Comp Neurol 192: 455–472, 1980.  	7419739
	KITZES LM AND DOHERTY D. Influence of callosal activity on units in the  auditory cortex of the ferret (Mustela putorius). J Neurophysiol 71: 1740–  1751, 1994.  	8064345
	MIDDLEBROOKS JC AND GREEN DM. Sound localization by human listeners.  Annu Rev Psychol 42: 135–159, 1991.  	2018391
	MOREL A AND IMIG TJ. Thalamic projections to fields A, AI, P, and VP in the  cat auditory cortex. J Comp Neurol 265: 119–144, 1987.  	2826552
	MUSICANT AD, CHAN JCK, AND HIND JE. Direction-dependent spectral prop erties of cat external ear: new data and cross-species comparisons. J Acoust  Soc Am 87: 757–781, 1990.  	2307774
	NELKEN I AND YOUNG ED. Two separate inhibitory mechanisms shape the  responses of dorsal cochlear nucleus type IV units to narrowband and  wideband noise. J Neurophysiol 71: 2446–2462, 1994.  	7931527
	POIRIER, P, SAMSON FK, AND IMIG TJ. Directional mechanisms and spatial  preferences of single units in the cat’s inferior colliculus. Soc Neurosci Abstr  22: 889, 1996.  	NO_MATCH
	RAJAN R, AITKIN LM, IRVINE DRF, AND MCKAY J. Azimuthal sensitivity of  neurons in primary auditory cortex of cats. I. Types of sensitivity and effects  of variations in stimulus parameters. J Neurophysiol 64: 872–887, 1990.  	2230931
	RICE JJ, MAY BJ, SPIROU GA, AND YOUNG ED. Pinna-based spectral cues for  sound localization in cat. Hear Res 58: 132–152, 1992.  	1568936
	SAMSON FK, BARONE P, CLAREY JC, AND IMIG TJ. Effects of ear plugging on  single-unit azimuth sensitivity in cat primary auditory cortex. II. Azimuth  tuning dependent upon binaural stimulation. J Neurophysiol 71: 2194–2216,  1994.  	7931511
	SAMSON FK, CLAREY JC, BARONE P, AND IMIG TJ. Effects of ear plugging on  single-unit azimuth sensitivity in cat primary auditory cortex. I. Evidence for  monaural directional cues. J Neurophysiol 70: 492–511, 1993.  	8410151
	SAMSON FK, POIRIER P, IRONS WA, AND IMIG TJ. Effects of ear plugging on  responses of azimuth sensitive neurons in medial geniculate body (MGB)  and primary auditory cortex (AI) of barbiturate anesthetized cats. Soc  Neurosci Abstr 22: 889, 1996.  	NO_MATCH
	SPIROU GA AND YOUNG ED. Organization of dorsal cochlear nucleus type IV  unit response maps and their relationship to activation by band-limited  noise. J Neurophysiol 66: 1750–1766, 1991.  	1765805
	WENSTRUP JJ, FUZESSERY ZM, AND POLLAK GD. Binaural neurons in the  mustache bat’s inferior colliculus. I. Responses of 60-kHz. EI units to  dichotic sound stimulation. J Neurophysiol 60: 1369–1383, 1988a.  	3193162
	WENSTRUP JJ, FUZESSERY ZM, AND POLLAK GD. Binaural neurons in the  mustache bat’s inferior colliculus. II. Determinants of spatial responses  among 60-kHz EI units. J Neurophysiol 60: 1384–1404, 1988b.  	3193163
	WISE LZ AND IRVINE DRF. Topographic organization of interaural intensity  difference sensitivity in deep layers of the cat superior colliculus: implica tions for auditory spatial representation. J Neurophysiol 54: 185–211, 1985.  	4031984
	YOUNG ED, SPIROU GA, AND RICE JJ. Representation of pinna-produced  spectral notches in dorsal cochlear nucleus (DCN). Soc Neurosci Abstr 18:  1037, 1992a.  	NO_MATCH
	YOUNG ED, SPIROU GA, RICE JJ, AND VOIGT HF. Neural organization and  responses to complex stimuli in the dorsal cochlear nucleus. Philos Trans R  Soc Lond B Biol Sci 336: 407–413, 1992b.  	1354382
J Neurophysiol-2000-Keller-1303-13.pdf
	AMADOR N, SCHLAG-REY M, AND SCHLAG J. Primate antisaccades. I. Behav ioral characteristics. J Neurophysiol 80: 1775–1786, 1998.  	9772238
	CHIMOTO S, IWAMOTO Y, SHIMAZU H, AND YOSHIDA K. Monosynaptic activa tion of medium-lead burst neurons from the superior colliculus in the alert  cat. J Neurophysiol 75: 2658–2661, 1996.  	8793771
	EDELMAN JA AND KELLER EL. Activity of visuomotor burst neurons in the  superior colliculus accompanying express saccades. J Neurophysiol 76:  908–926, 1996.  	8871208
	EDELMAN JA AND KELLER EL. Dependence on target configuration of express  saccade-related activity in the primate superior colliculus. J Neurophysiol  80: 1407–1426, 1998.  	9744949
	EVERLING S, DORRIS MC, KLEIN RM, AND MUNOZ DP. Role of primate superior  colliculus in preparation and execution of anti-saccades and pro-saccades.  J Neurosci 19: 2740–2754, 1999.  	10087086
	FRENS MA AND VAN OPSTAL AJ. Monkey superior colliculus activity during  short-term saccadic adaptation. Brain Res Bull 43: 473–483, 1997.  	9250621
	FUCHS AF, KANEKO CRS, AND SCUDDER CA. Brainstem control of saccadic eye  movements. Annu Rev Neurosci 8: 307–337, 1985.  	3920944
	FUCHS AF AND ROBINSON DA. A method for measuring horizontal and vertical  eye movement chronically in the monkey. J Appl Physiol 21: 1068–1070,  1966.  	4958032
	FUNAHASHI S, CHAFEE MV, AND GOLDMAN-RAKIC PS. Prefrontal neuronal  activity in Rhesus monkeys performing a delayed anti-saccade task. Nature  365: 753–756, 1993.  	8413653
	GRANTYN AA AND GRANTYN R. Synaptic actions of tectofugal pathways on  abducens motoneurons in the cat. Brain Res 105: 269–285, 1976.  	1260444
	GRAYBIEL AM. Direct and indirect preoculomotor pathways of the brainstem:  an autoradiographic study of the pontine reticular formation in the cat.  J Comp Neurol 175: 37–78, 1977.  	886026
	GUITTON D AND MUNOZ DP. Control of gaze shifts by the tectoreticulospinal  system in the head-free cat. I. Identification, localization and effects of  behavior on sensory responses. J Neurophysiol 66: 1605–1623, 1991.  	1765797
	HARTING JK. Descending pathways from the superior colliculus: an autoradio graphic analysis in the rhesus monkey (Macaca mulatta). J Comp Neurol  173: 583–612, 1977.  	404340
	HEPP K AND HENN H. Spatio-temporal recording of rapid eye movement  signals in the monkey paramedian pontine reticular formation (PPRF). Exp  Brain Res 52: 105–120, 1983.  	6628590
	HEPP K, HENN V, VILIS T, AND COHEN B. Brainstem regions related to  saccade generation. In: The Neurobiology of Saccadic Eye Movements,  edited by Wurtz RH and Goldberg ME. Amsterdam: Elsevier, 1989, p.  105–212.  	2486322
	JUDGE SJ, RICHMOND BJ, AND CHU FC. Implantation of magnetic search coils  for measurement of eye position: an improved method. Vision Res 20:  535–538, 1980.  	6776685
	KELLER EL. The brainstem. In: Eye Movements, edited by Carpenter RHS.  London: Macmillan, 1991, p. 200–223.  	NO_MATCH
	KELLER EL AND EDELMAN JA. Use of interrupted saccade paradigm to study  spatial and temporal dynamics of saccadic burst cells in superior colliculus  in monkey. J Neurophysiol 72: 2754–2770, 1994.  	7897487
	KELLER EL, GANDHI NJ, AND WEIR PT. Discharge of superior collicular  neurons during saccades made to moving targets. J Neurophysiol 76: 3573–  3577, 1996.  	8930297
	KELLER EL AND MCPEEK RM. State dependent activation of paramedian  pontine reticular formation (PPRF) burst neurons by superior collicular  stimulation in monkey. Soc Neurosci Abstr 25: 6, 1999.  	NO_MATCH
	LEICHNETZ G, SMITH DJ, AND SPENCER RF. Cortical projections to the para median tegmental and basilar pons in the monkey. J Comp Neurol 228:  388–408, 1984.  	6480918
	MIYASHITA N AND HIKOSAKA O. Minimal synaptic delay in the saccadic output  pathway of the superior colliculus studied in awake monkey. Exp Brain Res  112: 187–196, 1996.  	8951387
	MOSCHOVAKIS AK, KITAMA T, DALEZIOS Y, PETIT J, BRANDI AM, AND  GRANTYN A. An anatomical substrate for the spatiotemporal transformation.  J Neurosci 18: 10219–10229, 1998.  	9822775
	MOSCHOVAKIS AK, SCUDDER CA, AND HIGHSTEIN SM. The microscopic anat omy and physiology of the mammalian saccadic system. Prog Neurobiol 50:  133–254, 1996.  	8971981
	OLIVIER E, GRANTYN A, CHAT M, AND BERTHOZ A. The control of slow  orienting eye movements by tectoreticulospinal neurons in the cat—behav ior, discharge patterns and underlying connections. Exp Brain Res 93:  435–449, 1993.  	8519334
	PARE´ M AND GUITTON D. The fixation area of the cat superior colliculus:  effects of electrical stimulation and direct connection with brainstem om nipause neurons. Exp Brain Res 101: 109–122, 1994.  	7843290
	RAYBOURN MS AND KELLER EL. Colliculoreticular organization in primate  oculomotor system. J Neurophysiol 40: 861–878, 1977.  	407334
	SEGRAVES MA. Activity of monkey frontal eye field neurons projecting  to oculomotor regions of the pons. J Neurophysiol 68: 1967–1985,  1992.  	1491252
	STANFORD TR AND SPARKS DL. Systematic errors for saccades to remembered  targets: evidence for a dissociation between saccade metrics and activity in  the superior colliculus. Vision Res 34: 93–106, 1994.  	8116272
	STANTON GB, GOLDBERG ME, AND BRUCE C. Frontal eye field efferents in the  macaque monkey. I. Subcortical pathways and topography of striatal and  thalamic terminal fields. J Comp Neurol 271: 473–492, 1988.  	2454970
	STRASSMAN A, EVINGER C, MCCREA RA, BAKER RG, AND HIGHSTEIN SM.  Anatomy and physiology of intracellularly labelled omnipause neurons in  the cat and squirrel monkey. Exp Brain Res 67: 436–440, 1987.  	3622701
	STRASSMAN A, HIGHSTEIN SM, AND MCCREA RA. Anatomy and physiology of  saccadic burst neurons in the alert squirrel monkey. II. Inhibitory burst  neurons. J Comp Neurol 249: 358–380, 1986.  	3734161
1279.full.pdf
	ABRAHAM WC AND BEAR MF. Metaplasticity: the plasticity of synaptic plas ticity. Trends Neurosci 19: 126–130, 1996.  	8658594
	ANWYL R, WALSHE J, AND ROWAN M. Electroconvulsive treatment reduces  long-term potentiation in rat hippocampus. Brain Res 435: 377–379, 1987.  	3427466
	BARR DS, HOYT KL, MOORE SD, AND WILSON WA. Post-ictal depression  transiently inhibits induction of LTP in area CA1 of the rat hippocampal  slice. Epilepsy Res 27: 111–118, 1997.  	9192185
	BEAR MF. Mechanism for a sliding synaptic modification threshold. Neuron  15: 1–4, 1995.  	7619513
	BIENENSTOCK EL, COOPER LN, AND MUNRO PW. Theory for the development  of neuron selectivity: orientation specificity and binocular interaction in  visual cortex. J Neurosci 2: 32–48, 1982  	7054394
	BLISS TVP AND COLLINGRIDGE GL. A synaptic model of memory: Long-term  potentiation in the hippocampus. Nature 361: 31–39, 1993.  	8421494
	BLITZER RD, WONG T, NOURANIFAR R, IYENGAR R, AND LANDAU EM. Postsyn aptic cAMP pathway gates early LTP in hippocampal CA1 region. Neuron  15: 1403–1414, 1995.  	8845163
	BORTOLOTTO ZA AND COLLINGRIDGE GL. Involvement of calcium/calmodulin dependent protein kinases in the setting of a molecular switch involved in  hippocampal LTP. Neuropharmacology 37: 535–544, 1998.  	9704994
	CHRISTIE BR AND ABRAHAM WC. Priming of associative long-term depression  in the dentate gyrus by u frequency synaptic activity. Neuron 9: 79–84,  1992.  	1321647
	CLARK KA, RANDALL AD, AND COLLINGRIDGE GL. A comparison of paired pulse facilitation of AMPA and NMDA receptor-mediated excitatory  postsynaptic currents in the hippocampus. Exp Brain Res 101: 272–278,  1994.  	7843313
	COAN EJ AND COLLINGRIDGE GL. Magnesium ions block an N-methyl-D aspartate receptor-mediated component of synaptic transmission in rat hip pocampus. Neurosci Lett 53: 21–26, 1985.  	2859558
	COHEN AS AND ABRAHAM WC. Facilitation of long-term potentiation by prior  activation of metabotropic glutamate receptors. J Neurophysiol 76: 953–  962, 1996.  	8871210
	COUSSENS C, KERR DS, AND ABRAHAM WC. Glucocorticoid receptor activation  lowers the threshold for NMDA-receptor–dependent homosynaptic long term depression in the hippocampus through activation of voltage-dependent  calcium channels. J Neurophysiol 78: 1–9, 1997.  	9242254
	FREY U, HUANG YY, AND KANDEL ER. Effects of cAMP stimulates a late stage  of LTP in hippocampal CA1 neurons. Science 260: 1661–1664, 1993.  	8389057
	FUJII S, SAITO K, MIYAKAWA H, ITO K, AND KATO H. Reversal of long-term  potentiation (depotentiation) induced by tetanus stimulation of the input to  CA1 neurons of guinea pig hippocampal slices. Brain Res 555: 112–122,  1991.  	1681992
	GEAN PW. NMDA receptor-independent epileptiform activity induced by  magnesium-free solution in rat amygdala neurons is blocked by CNQX.  Neurosci Lett 119: 53–55, 1990.  	1982960
	GODA Y AND STEVENS CF. Synaptic plasticity: the basis of particular types of  learning. Curr Opin Neurobiol 6: 375–378, 1996.  	8723336
	GOLD JI AND BEAR MF. A model of dendritic spine Ca21 concentration  exploring possible bases for a sliding synaptic modification threshold. Proc  Natl Acad Sci USA 91: 3941–3945, 1994.  	8171016
	HALGREN E AND WILSON CL. Recall deficts produced by afterdischarges in the  human hippocampal formation and amygdala. Clin Neurophysiol 61: 375–  380, 1985.  	2412789
	HEBB DO. Organization of Behavior. New York: Wiley, 1949.  	NO_MATCH
	HERRON CE, WILLIAMSON R, AND COLLINGRIDGE GL. A selective N-methyl D-aspartate antagonist depresses epileptiform activity in rat hippocampal  slices. Neurosci Lett 61: 255–260, 1985.  	2867507
	HESSE GW AND TEYLER TJ. Reversible loss of hippocampal long-term poten tiation following electroconvulsive seizure. Nature 264: 562–564, 1976.  	1004596
	HOLLAND LL AND WAGNER JJ. Primed facilitation of homosynaptic long-term  depression and depotentiation in rat hippocampus. J Neurosci 18: 887–894,  1998.  	9437010
	HSU KS. Characterization of dopamine receptors mediating inhibition of  excitatory synaptic transmission in the rat hippocampal slices. J Neuro physiol 76: 1887–1895, 1996.  	8890301
	HSU KS AND HUANG CC. Characterization of the anoxia-induced long-term  synaptic potentiation in area CA1 of the rat hippocampus. Br J Pharmacol  122: 671–681, 1997.  	9375963
	HSU KS, HUANG CC, HO WC, AND TSAI JJ. Prior short-term synaptic disinhi bition by GABA-antagonist facilitates long-term potentiation and suppresses  long-term depression at CA1 hippocampal synapses. Eur J Neurosci 11:  4059–4069, 1999.  	10583494
	HUANG YY, COLINO A, SELIG DK, AND MALENKA RC. The influence of prior  synaptic activity on the induction of long-term potentiation. Science 255:  730–733, 1992.  	1346729
	HUANG YY AND KANDEL ER. Postsynaptic induction and PKA-dependent  expression of LTP in the lateral amygdala. Neuron 21: 169–178, 1998.  	9697861
	IZUMI Y, CLIFFORD DB, AND ZORUMSKI CF. Low concentrations of N-methyl D-aspartate inhibit the induction of long-term potentiation in rat hippocam pal slices. Neurosci Lett 137: 245–248, 1992.  	1350078
	JENSEN LH AND SHEARDOWN M. Lack of potent antiepileptic effect of specific  non-NMDA EAA receptor antagonist. In: Frontiers in Excitatory Amino Acid Research, edited by Cavalheiro EA, Lehmann L, and Turski L. New  York: Liss, 1988, p. 219–226.  	NO_MATCH
	LINDEN DJ AND CONNOR JA. Participation of postsynaptic PKC in cerebellar  long-term depression in culture. Neuron 15: 1393–1401, 1991.  	1721243
	MALINOW R, SCHULMAN H, AND TSIEN RW. Inhibition of postsynaptic PKC or  CaMKII blocks induction but not expression of LTP. Science 245: 862–866,  1989.  	2549638
	MALINOW R AND TSIEN RW. Presynaptic enhancement shown by whole-cell  recordings of long-term potentiation in hippocampal slices (Abstract). Na ture 346: 177, 1990.  	2164158
	MARTINEZ JLJ AND DERRICK BE. Long-term potentiation and learning. Annu  Rev Psychol 47: 173–203, 1996.  	8624136
	MAYFORD M, WANG J, KANDEL ER, AND O’DELL TJ. CaMKII regulates the  frequency-response function of hippocampal synapses for the production of  both LTD and LTP. Cell 81: 891–904, 1995.  	7781066
	MCNAMARA JO. Cellular and molecular basis of epilepsy. J Neurosci 14:  3413–3425, 1994.  	8207463
	MODY I, LAMBERT JDC, AND HEINEMANN U. Low extracellular magnesium  induces epileptiform activity and spreading depression in rat hippocampal  slices. J Neurophysiol 57: 869–888, 1987.  	3031235
	MOORE SD, BARR DS, AND WILSON WA. Seizure-like activity disrupts LTP in  vitro. Neurosci Lett 163: 117–119, 1993.  	8295725
	MOYER JR, THOMPSON LT, BLACK JP, AND DISTERHOFT JF. Nimodipine in creases excitability of rabbit CA1 pyramidal neurons in an age- and con centration-dependent manner. J Neurophysiol 68: 2100–2109, 1992.  	1491260
	MULLER D AND LYNCH G. Evidence that changes in presynaptic calcium  currents are not responsible for long-term potentiation in hippocampus.  Brain Res 479: 290–299, 1989.  	2924160
	PSARROPOULOU C AND KOSTOPOULOS G. Long-term enhancement of postsyn aptic excitability after brief exposure to Mg21-free medium in normal and  epileptic mice. Brain Res 508: 70–75, 1990.  	2337794
	RAYMOND CR, THOMPSON VL, TATE WP, AND ABRAHAM WC. Metabotropic  glutamate receptors trigger homosynaptic protein synthesis to prolong long term potentiation. J Neurosci 20: 969–976, 2000.  	10648701
	SANES JR AND LICHTMAN W. Can molecules explain long-term potentiation?  Nature Neurosci 2: 597–604, 1999.  	10404178
	SCHULZ PE, COOK EP, AND JOHNSTON D. Changes in paired-pulse facilitation  suggest presynaptic involvement in long-term potentiation. J Neurosci 14:  5327–5337, 1994.  	7916043
	SONENBURG N. mRNA 59 cap-binding protein eIF4E and control of cell  growth. In: Transcriptional Control, edited by Hershey JWB, Mathews MB,  and Sonenburg N. New York: Cold Spring Harbor Laboratory, 1996, p.  245–269.  	NO_MATCH
	SQUIRE LR AND SPANIS CW. Long gradient of retrograde amnesia in mice,  continuity with the findings in humans. Behav Neurosci 98: 345–348, 1984.  	6539119
	STANTON PK. Transient protein kinase C activation primes long-term depres sion and suppresses long-term potentiation of synaptic transmission in  hippocampus. Proc Natl Acad Sci USA 92: 1724–1728, 1995.  	7878048
	SUZUKI T. Messengers from the synapses to the nucleus (MSNs) that establish  late phase of long-term potentiation (LTP) and long-term memory. Neurosci  Res 25: 1–6, 1996.  	8808794
	THOMPSON PJ. Memory function in patients with epilepsy. Adv Neurol 55:  369–384, 1991.  	2003416
	TOMPA P AND FRIEDRICH P. Synaptic metaplasticity and the local charge effect  in postsynaptic dendrites. Trends Neurosci 21: 97–102, 1998.  	9530914
	WEXLER EM AND STANTON PK. Priming of homosynaptic long-term depres sion in hippocampus by previous synaptic activity. Neuroreport 4: 591–594,  1993.  	8390312
Blood-2000-Mudry-1926-32.pdf
	1. Goulden N, Langlands K, Steward C, et al. PCR  assessment of bone marrow status in “isolated”  extramedullary relapse of childhood B-precursor  acute lymphoblastic leukaemia. Br J Haematol. 1994;87:282-285.  	7947268
	2. Miniero R, Saracco P, Pastore G, et al. Relapse  after first cessation of therapy in childhood acute  lymphoblastic leukemia: a 10-year follow-up  study, Italian Association of Pediatric Hematol ogy-Oncology (AIEOP). Med Pediatr Oncol.  1995;24:71-76.  	7990766
	3. Miyake K, Medina K, Ishihara K, Kimoto M, Auer bach R, Kincade PW. A VCAM-like adhesion mol ecule on murine bone marrow stromal cells medi ates binding of lymphocyte precursors in culture.  J Cell Biol. 1991;114:557-565.  	1713592
	4. Ryan DH. Adherence of normal and neoplastic  human B cell precursors to the bone marrow mi croenvironment. Blood Cells. 1993;19:225-241.  	7906154
	5. Kinashi T, Springer TA. Adhesion molecules in  hematopoietic cells. Blood Cells. 1994;20:25-44.  	7527678
	6. Kincade PW. Cell interaction molecules and cyto kines which participate in B lymphopoiesis. Baillieres Clin Haematol. 1992;5:575-598.  	1281019
	7. Makrynikola V, Kabral A, Bradstock KF. Effects of  recombinant human cytokines on precursor-B  acute lymphoblastic leukemia cells. Exp Hematol.  1991;19:674-679.  	1893954
	8. Manabe A, Coustan-Smith E, Behm FG, Rai mondi SC, Campana D. Bone marrow-derived  stromal cells prevent apoptotic cell death in B lineage acute lymphoblastic leukemia. Blood.  1992;79:2370-2377.  	1373973
	9. Gibson LF, Fortney J, Landreth KS, Piktel D, Eric son SG, Lynch JP. Disruption of bone marrow  stromal cell function by etoposide. Biol Blood  Marrow Transplant. 1997;3:122-132.  	9310189
	10. Haskell CM, Berek JS. Cancer Treatment, 4th ed.  Philadelphia: WB Saunders; 1995.  	NO_MATCH
	11. Roberts RA, Spooncer E, Parkinson EK, Lord BI,  Allen TD, Dexter TM. Metabolically inactive 3T3  cells can substitute for marrow stromal cells to  promote the proliferation and development of  multipotent haemopoietic stem cells. J Cell  Physiol. 1987;132:203-214.  	3497927
	12. Hasslen SR, Burns AR, Simon SI, et al. Preservation of spatial organization and antigenicity of leu kocyte surface molecules by aldehyde fixation:  flow cytometry and high-resolution FESEM stud ies of CD62L, CD11b, and Thy-1. J Histochem  Cytochem. 1996;44:1115-1122.  	8813076
	13. Wilmanns C, Fan D, O’Brian CA, Bucana CD,  Fidler IJ. Orthotopic and ectopic organ environ ments differentially influence the sensitivity of mu rine colon carcinoma cells to doxorubicin and  5-fluorouracil. Int J Cancer. 1992;52:98-104.  	1500231
	14. Staroselsky AN, Fan D, O’Brian CA, Bucana CD,  Gupta KP, Fidler IJ. Site-dependent differences in  response of the UV-2237 murine fibrosarcoma to  systemic therapy with adriamycin. Cancer Res. 1990;50:7775-7780	2253220
	15. Murti KG, Brown PS, Kumagai M, Campana D.  Molecular interactions between human B-cell pro genitors and the bone marrow microenvironment.  Exp Cell Res. 1996;226:47-58.  	8660938
	16. Van d V, Smits AJ, Verdaasdonk MA, et al. b1 Integrins dominate cell traffic of leukemic cells in  human bone- marrow stroma. Int J Cancer. 1996;  66:225-233.  	8603816
	17. Bradstock K, Makrynikola V, Bianchi A, Byth K.  Analysis of the mechanism of adhesion of precur sor-B acute lymphoblastic leukemia cells to bone  marrow fibroblasts. Blood. 1993;82:3437-3444.  	7694686
	18. Ryan DH, Nuccie BL, Abboud CN, Winslow JM.  Vascular cell adhesion molecule-1 and the inte grin VLA-4 mediate adhesion of human B cell precursors to cultured bone marrow adherent  cells. J Clin Invest. 1991;88:995-1004.  	1715889
	19. Filshie R, Gottlieb D, Bradstock K. VLA-4 is involved  in the engraftment of the human pre-B acute lympho blastic leukaemia cell line NALM-6 in SCID mice.  Br J Haematol. 1998;102:1292-1300.  	9753059
	20. Brisco MJ, Condon J, Hughes E, et al. Outcome  prediction in childhood acute lymphoblastic leu kaemia by molecular quantification of residual disease at the end of induction [see comments].  Lancet. 1994;343:196-200.  	7904666
	21. Shah N, Oseth L, LeBien TW. Development of a  model for evaluating the interaction between hu man pre-B acute lymphoblastic leukemic cells and the bone marrow stromal cell microenviron ment. Blood. 1998;92:3817-3828.  	9808575
	22. Gibson LF, Piktel D, Narayanan R, Nunez G, Lan dreth KS. Stromal cells regulate bcl-2 and bax  	expression in pro-B cells. Exp Hematol. 1996;24:  628-637.  	8605968
	23. Miyashita T, Reed JC. Bcl-2 oncoprotein blocks  chemotherapy-induced apoptosis in a human leu kemia cell line. Blood. 1993;81:151-157.  	8417786
	24. Thomas A, El Rouby S, Reed JC, et al. Drug-in duced apoptosis in B-cell chronic lymphocytic leukemia: relationship between p53 gene muta tion and bcl-2/bax proteins in drug resistance.  Oncogene. 1996;12:1055-1062.  	8649796
	25. McConkey DJ, Chandra J, Wright S, et al. Apop tosis sensitivity in chronic lymphocytic leukemia is  determined by endogenous endonuclease con tent and relative expression of BCL-2 and BAX.  J Immunol. 1996;156:2624-2630.  	8786328
	26. Taylor ST, Hickman JA, Dive C. Epigenetic deter minants of resistance to etoposide regulation of  Bcl- X(L. and Bax by tumor microenvironmental  factors [see comments]. J Natl Cancer Inst. 2000;  92:18-23.  	10620629
	27. Jiang H, Sugimoto K, Sawada H, et al. Mutual  education between hematopoietic cells and bone  marrow stromal cells through direct cell-to-cell contact: factors that determine the growth of bone  marrow stroma-dependent leukemic (HB-1) cells.  Blood. 1998;92:834-841.  	9680351
	28. Elices MJ, Osborn L, Takada Y, et al. VCAM-1  on activated endothelium interacts with the leu kocyte integrin VLA-4 at a site distinct from the  VLA-4/fibronectin binding site. Cell. 1990;60:577-584.  	1689216
	29. Menard S, Squicciarini P, Luini A, et al. Immuno detection of bone marrow micrometastases in  breast carcinoma patients and its correlation with  primary tumour prognostic features. Br J Cancer.  1994;69:1126-1129.  	7911032
	30. Mansi JL, Berger U, Wilson P, Shearer R,  Coombes RC. Detection of tumor cells in bone  marrow of patients with prostatic carcinoma by  immunocytochemical techniques. J Urol. 1988;  139:545-548.  	2449548
	31. Kamel-Reid S, Letarte M, Doedens M, et al. Bone  marrow from children in relapse with pre-B acute lym phoblastic leukemia proliferates and disseminates  rapidly in scid mice. Blood. 1991;78:2973-2981.  	1835412
1906.full.pdf
	1. Look AT. Oncogenic transcription factors in the  human acute leukemias. Science. 1997;278:  1059-1064.  	9353180
	2. Rauskolb C, Peifer M, Weischaus E. extraden ticle, a regulator of homeotic gene activity, is a  homolog of the homeobox-containing human proto-oncogene PBX1. Cell. 1993;74:1101-1112.  	8104703
	3. Chan SK, Jaffe L, Capovilla M, Botas J, Mann  RS. The DNA binding specificity of Ultrabithorax  is modulated by cooperative interactions with ex tradenticle, another homeoprotein. Cell. 1994;78:  603-615.  	7915199
	4. Chang C-P, Shen W-F, Rozenfeld S, Lawrence  HJ, Largman C, Cleary ML. Pbx proteins display  hexapeptide-dependent cooperative DNA binding  with a subset of Hox proteins. Genes Dev. 1995;  9:663-674.  	7729685
	5. Lu Q, Knoepfler PS, Scheele J, Wright DD,  Kamps MP. Both Pbx1 and E2A-Pbx1 bind the  DNA motif ATCAATCAA cooperatively with the  products of multiple murine Hox genes, some of  which are themselves oncogenes. Mol Cell Biol.  1995;15:3786-3795.  	7791786
	6. Mann RS, Chan S-K. Extra specificity from extra denticle: the partnership between HOX and PBX/  EXD homeodomain proteins. Trends Genet. 1996;12:258-262.  	8763497
	7. Van Dijk MA, Murre C. extradenticle raises the  DNA binding specificity of homeotic selector gene  products. Cell. 1994;78:617-624.  	7915200
	8. Maconochie MK, Nonchev S, Studer M, et al.  Cross-regulation in the mouse HoxB complex: the  expression of Hoxb2 in rhombomere 4 is regulated by Hoxb1. Genes Dev. 1997;11:1885-1895.  	9242495
	9. Po¨pperl H, Bienz M, Studer M, et al. Segmental  expression of Hoxb-1 is controlled by a highly  conserved autoregulatory loop dependent upon  exd/pbx. Cell. 1995;81:1031-1042.  	7600572
	10. Rauskolb C, Weischaus E. Coordinate regulation  of downstream genes by extradenticle and the  homeotic selector proteins. EMBO J. 1994;13:  3561-3569.  	7914871
	11. Kamps MP, Murre CM, Sun X-H, Baltimore D. A  new homeobox gene contributes the DNA binding  domain of the t(1;19) translocation protein in  pre-B ALL. Cell. 1990;60:547-555.  	1967983
	12. Nourse J, Mellentin JD, Galili N, et al. Chromo somal translocation t(1;19) results in synthesis of  a homeobox fusion mRNA that codes for a poten tial chimeric transcription factor. Cell. 1990;60:  535-545.  	1967982
	13. Bain G, Murre C. The role of E-proteins in B- and  T-lymphocyte development. Semin Immunol.  1998;10:143-153.  	9618760
	14. LeBrun DP, Cleary ML. Fusion with E2A alters the  transcriptional properties of the homeodomain  protein PBX1 in t(1;19) leukemias. Oncogene.  1994;9:1641-1647.  	8183558
	15. Lu Q, Wright DD, Kamps MP. Fusion with E2A  converts the Pbx1 homeodomain protein into a  constitutive transcriptional activator in human leu kemias carrying the t(1;19) translocation. Mol Cell  Biol. 1994;14:3938-3948.  	7910944
	16. Van Dijk MA, Voorhoeve PM, Murre C. Pbx1 is  converted into a transcriptional activator upon  acquiring the N-terminal region of E2A in pre-B  cell acute lymphoblastic leukemia. Proc Natl Acad  Sci U S A. 1993;90:6061-6065.  	8327485
	17. Chang C-P, De Vivo I, Cleary ML. The Hox coop erativity motif of chimeric oncoprotein E2a-Pbx1  is necessary and sufficient for oncogenesis. Mol  Cell Biol. 1997;17:81-88.  	8972188
	18. Kamps MP, Wright DD, Lu Q. DNA-binding by  oncoprotein E2A-Pbx1 is important for blocking  differentiation but dispensible for fibroblast trans formation. Oncogene. 1996;12:19-30.  	8552391
	19. Artavanis-Tsakonas S, Matsuro K, Fortini ME.  Notch signaling. Science. 1995;268:225-232.  	7716513
	20. Greenwald I. Structure/function studies of lin-12/  Notch proteins. Curr Opin Genet Dev. 1994;4:  556-562.  	7950324
	21. Weinmaster G. The ins and outs of Notch signal ing. Mol Cell Neurosci. 1997;9:91-102.  	9245493
	22. Kopan R, Schroeter E, Weintraub H, Nye JS. Sig nal transduction by activated mNotch: importance  of proteolytic processing and its regulation by the  extracellular domain. Proc Natl Acad Sci U S A.  	1996;93:1683-1688.	8643690
	23. Schroeter EH, Kisslinger JA, Kopan R. Notch-1  signalling requires ligand-induced proteolytic re lease of intracellular domain. Nature. 1998;393:  382-386.  	9620803
	24. Struhl G, Adachi A. Nuclear access and action of  notch in vivo. Cell. 1998;93:649-660.  	9604939
	25. Chitnis AB. The role of Notch in lateral inhibition  and cell fate specification. Mol Cell Neurosci.  1995;6:311-321.  	8846001
	26. Kopan R, Nye JS, Weintraub H. The intracellular  domain of mouse Notch: a constitutively activated  repressor of myogenesis directed at the basic  helix-loop-helix region of MyoD. Development.  1994;120:2385-2396.  	7956819
	27. Lieber T, Kidd S, Alcamo E, Corbin V, Young MW.  Antineurogenic phenotypes induced by truncated  Notch proteins indicate a role in signal transduc tion and may point to a novel function for Notch in  nuclei. Genes Dev. 1993;7:1949-1965.  	8406001
	28. Robey E, Chang D, Itano A, et al. An activated  form of Notch influences the choice between CD4  and CD8 T cell lineages. Cell. 1996;87:483-492.  	8898201
	29. Ellisen LW, Bird J, West DC, et al. TAN-1, the hu man homologue of the Drosophila Notch gene, is  broken by chromosomal translocations in T lymphoblastic neoplasms. Cell. 1991;66:649-661.  	1831692
	30. Aster J, Pear W, Hasserjian R, et al. Functional  analysis of the TAN-1 gene, a human homolog of  Drosophila notch. Cold Spring Harbor Symp  Quant Biol. 1994;59:125-136.  	7587062
	31. Capobianco AJ, Zagouras P, Blaumueller CM,  Artavanis-Tsakonas S, Bishop JM. Neoplastic  transformation by truncated alleles of human  NOTCH1/TAN1 and NOTCH2. Mol Cell Biol.  1997;17:6265-6273.  	9343387
	32. Pear WS, Aster JC, Scott ML, et al. Exclusive de velopment of T cell neoplasms in mice trans planted with bone marrow expressing activated  Notch alleles. J Exp Med. 1996;183:2283-2291.  	8642337
	33. Dedera DA, Waller EK, LeBrun DP, et al. Chi meric homeobox gene E2A-PBX1 induces prolif eration, apoptosis, and malignant lymphomas in  transgenic mice. Cell. 1993;74:833-843.  	8104101
	34. Hogan B, Constantini F, Lacy E. Manipulating the  Mouse Embryo: A Laboratory Manual. Cold  Spring Harbor, NY: Cold Spring Harbor Labora tory Press; 1986.  	NO_MATCH
	35. Abraham KM, Levin SD, Martin JD, Forbush KA,  Perlmutter RM. Thymic tumorigenesis induced by  overexpression of p56lck. Proc Natl Acad Sci  U S A. 1991;88:3977-3981.  	1708890
	36. Sambrook J, Fritsch EF, Maniatis T. Molecular  Cloning: A Laboratory Manual, 2nd ed. Cold  Spring Harbor, NY: Cold Spring Harbor Labora tory Press; 1989:18.53-18.73.  	NO_MATCH
	37. Natarajan D, BoultenA. Isolation of genomic se quences flanking a retroviral insertion site using a  novel PCR-based method. Gene. 1995;161:195-196.  	7665078
	38. Haupt Y, Alexander WS, Barri G, Klinken SP,  Adams JM. Novel zinc finger gene implicated as  myc collaborator by retrovirally accelerated lym phomagenesis in Em-myc transgenic mice. Cell.  1991;65:753-763.  	1904009
	39. Van Lohuizen M, Verbeek S, Scheijen B,  Wientjens E, van der Gulden H, Berns A. Identifi cation of cooperating oncogenes in Em-myc  transgenic mice by provirus tagging. Cell. 1991;  65:737-752.  	1904008
	40. Cuypers HT, Selten G, Quint W, et al. Murine leu kemia virus-induced T-cell lymphomagenesis:  integration of proviruses in a distinct chromo somal region. Cell. 1984;37:141-150.  	6327049
	41. Girard L, Hanna Z, Beaulieu N, et al. Frequent  provirus insertional mutagenesis of Notch1 in thy momas of MMTVD/myc transgenic mice suggests  collaboration of c-myc and Notch1 for oncogenesis. Genes Dev. 1996;10:1930-1944.  	8756350
	42. Kurooka H, Kuroda K, Honjo T. Roles of the  ankyrin repeats and C-terminal region of the  mouse notch1 intracellular region. Nucl Acids  Res. 1998;26:5448-5455.  	9826771
	43. Feldman BJ, Reid TR, Cleary ML. Pim1 cooper ates with E2a-Pbx1 to facilitate the progression of  thymic lymphomas in transgenic mice. Onco gene. 1997;15:2735-2742.  	9401000
	44. Fortini ME, Artavanis-Tsakonas S. The suppres sor of hairless protein participates in notch recep tor signaling. Cell. 1994;79:273-282.  	7954795
	45. Nofziger D, Miyamoto A, Lyons KM, Weinmaster  G. Notch signaling imposes two distinct blocks in  the differentiation of C2C12 myoblasts. Develop ment. 1999;126:1689-1702.  	10079231
	46. Shawber C, Nofziger D, Hsieh JJ, et al. Notch  signaling inhibits muscle cell differentiation  through a CBF1-independent pathway. Develop ment. 1996;122:3765-3773.  	9012498
	47. Ordentlich P, Lin A, Shen C-P, et al. Notch inhibition  of E47 supports the existence of a novel signaling  pathway. Mol Cell Biol. 1998;18:2230-2239.  	9528794
	48. Aplan PD, Lombardi DP, Ginsberg AM, Cossman  J, Bertness VI, Kirsch IR. Disruption of the human  SCL locus by “illegitimate” V-(D)-J recombinase activity. Science. 1991;250:1426-1429.  	2255914
	49. Begley CG, Aplan PD, Davey MP, et al. Chromo somal translocation in a human leukemic stem cell line disrupts the T-cell antigen receptor delta chain diversity region and results in a previously  unreported fusion transcript. Proc Natl Acad Sci  U S A. 1989;86:2031-2035.  	2467296
	50. Brown L, Cheng JT, Chen Q, et al. Site-specific  recombination of the tal-1 gene is a common oc currence in human T cell leuekmia. EMBO J.  1990;9:3343-3351.  	2209547
	51. Chen Q, Cheng JT, Tasi LH, et al. The tal gene  undergoes chromosome translocation in T cell  leukemia and potentially encodes a helix-loop helix protein. EMBO J. 1990;9:415-424.  	2303035
	52. Finger LR, Kagan J, Christopher G, et al. Involve ment of the TCL5 gene on human chromosome 1  in T-cell leukemia and melanoma. Proc Natl Acad  Sci U S A. 1989;86:5039-5043.  	2740341
	53. Hsu HL, Wadman I, Baer R. Formation of in vivo  complexes between the TAL1 and E2A polypep tides of leukemic T cells. Proc Natl Acad Sci U S A. 1994;91:3181-3185.  	8159721
	54. Park ST, Sun XH. The Tal1 oncoprotein inhibits  E47-mediated transcription: mechanisms of inhi bition. J Biol Chem. 1998;273:7030-7037.  	9507011
	55. Bain G, Engel I, Robanus Maandag EC, et al.  E2A deficiency leads to abnormalities in a/b T-cell  development and to rapid development of T-cell  lymphomas. Mol Cell Biol. 1997;17:4782-4791.  	9234734
	56. Yan W, Young AZ, Soares VC, Kelley R, Benezra  R, Zhuang Y. High incidence of T-cell tumors in  E2A-null mice and E2A/Id1 double knockout  mice. Mol Cell Biol. 1997;17:7317-7327.  	9372963
	57. Sawada S, Littman DR. A heterodimer of Heb and  an E12-related protein interacts with the CD4 en hancer and regulates its activity in T-cell lines. Cell Biol. 1993;13:5620-5628.  	8355705
	58. Hasserjian RP, Aster JC, Davi F, Weinberg DS,  Sklar J. Modulated expression of Notch1 during  thymocyte development. Blood. 1996;88:970 976.  	8704256
	59. Washington T, Schweighoffer E, Gridley T, et al.  Notch activity influences the ab versus gD T cell  lineage decision. Cell. 1997;88:833-843.  	NO_MATCH
	60. Jehn BM, Bielke W, Pear WS, Osborne BA. Cut ting edge: protective effects of Notch-1 on TCR induced apoptosis. J Immunol. 1999;162:635 	9916679
	61. Smith KS, Jacobs Y, Chang C-P, Cleary ML. Chi meric oncoprotein E2a-Pbx1 induces apoptosis  of hematopoietic cells by a p53-independent mechanism that is suppressed by Bcl-2. Onco gene. 1997;14:2917-2926.  	9205098
	62. Nazarov V, Wolff L. Novel integration site at the  distal 39 end of the c-myb locus in retrovirus-in duced promonocytic leukemias. J Virol. 1995;69:  3885-3888.  	7745739
	63. Ceci JD, Patriotis CP, Tsatsanis C, et al. Tpl-2 is  an oncogenic kinase that is activated by carboxy terminal truncation. Genes Dev. 1997;11:688 700.  	9087424
	64. Sakura H, Kanei-Ishii C, Nagase T, Nakagoshi H,  Gonda TJ, Ishii S. Delineation of three functional  domains of the transcriptional activator encoded  by the c-myc proto-oncogene. Proc Natl Acad Sci  U S A. 1989;86:5758-5762.  	2668947
	65. Rogers S, Wells R, Rechsteiner M. Amino acids  common to rapidly degraded proteins: the PEST  hypothesis. Science. 1986;234:364-368.  	2876518
	66. Mango SE, Maine EM, Kimble J. Carboxyl-termi nal truncation activates glp-1 protein to specify  vulval fates in Caenorhabditis elegans. Nature.  1991;352:811-815.  	1881436
	67. Rebay I, Fehon RG, Artavanis-Tsakonas S. Spe cific truncations of Drosophila Notch define domi nant activated and dominant negative forms of  the receptor. Cell. 1993;74:319-329.  	8343959
	68. Axelrod JD, Matsuno K, Artavanis-Tsakonas S,  Perrimon N. Interaction between Wingless and  Notch signaling pathways mediated by Dishev elled. Science. 1996;271:1826-1832.  	8596950
	69. Guo M, Jan LY, Jan YN. Control of daughter cell  fates during asymmetric division: Interaction of  Numb and Notch. Neuron. 1996;17:27-41.  	8755476
	70. Zhong W, Feder JN, Jiang MM, Jan LY, Jan YN.  Asymmetric localization of a mammalian numb  homolog during mouse cortical neurogenesis.  Neuron. 1996;17:43-53.  	8755477
	71. Lyman D, Young MW. Further evidence for func tion of the Drosophila Notch protein as a trans membrane receptor. Proc Natl Acad Sci U S A.  1993;90:10395-10399.  	8234305
	72. Luo B, Aster JC, Hasserjian RP, Kuo F, Sklar J.  Isolation and functional analysis of a cDNA for  human Jagged2, a gene encoding a ligand for the  Notch1 receptor. Mol Cell Biol. 1997;17:6057 6067.  	9315665
	73. Varnum-Finney B, Purton LE, Yu M, et al. The  Notch ligand, Jagged-1, influences the develop ment of primitive hematopoietic precursor cells.  Blood. 1998;91:4084-4091.  	9596653
	74. Bash J, Zong W-X, Banga S, et al. Rel/NF-kB can  trigger the Notch signaling pathway by inducing the expression of Jagged1, a ligand for Notch re ceptors. EMBO J. 1999;18:2803-2811.  	10329626
Blood-2000-Anagnostopoulos-1889-99.pdf
	1. Lukes RJ, Craver LF, Hall TC, Rappaport H,  Ruben P. Report of the nomenclature committee.  Cancer Res. 1966;26:1311.  	NO_MATCH
	2. Jackson H. Classification and prognosis of  Hodgkin’s disease and allied disorders. Surg Gy necol Obstet. 1937;64:465.  	NO_MATCH
	3. Jackson H, Parker F. Hodgkin’s disease. I. Gen eral considerations. N Engl J Med. 1944;230:1.  	NO_MATCH
	4. Rappaport H, Winter WJ, Hicks EB. Follicular  lymphoma: a re-evaluation of its position in the  scheme of malignant lymphoma, based on a sur vey of 253 cases. Cancer. 1956;4:792.  	13356265
	5. Lukes RJ, Butler JJ. The pathology and nomen clature of Hodgkin’s disease. Cancer Res. 1966;  26:1063.  	NO_MATCH
	6. Lukes RJ, Butler JJ, Hicks EB. Natural history of  Hodgkin’s disease as related to its pathologic pic ture. Cancer. 1966;19:317.  	NO_MATCH
	7. Hansmann M-L, Wacker HH, Radzun HJ. Para granuloma is a variant of Hodgkin’s disease with  predominance of B cells. Virchows Arch (Pathol  Anat). 1986;409:171.  	3087053
	8. Hansmann M-L, Zwingers T, Bo¨ske A, Lo¨ffler H,  Lennert K. Clinical features of nodular paragranu loma (Hodgkin’s disease, lymphocyte predomi nance type, nodular). J Cancer Res Clin Oncol.  1984;108:321.  	6511805
	9. Pinkus GS, Said JW. Hodgkin’s disease, lympho cyte predominance type, nodular—a distinct en tity? Unique staining profile for L&H variants of  Reed -Sternberg cells defined by monoclonal an tibodies to leucocyte common antigen, granulo cyte specific antigen, and B cell specific antigen.  Am J Pathol. 1985;118:1-6.  	3155594
	10. Poppema S, Kaiserling E, Lennert K. Epidemiol ogy of nodular paragranuloma (Hodgkin’s disease with lymphocyte predominance, nodular). J  Cancer Res Clin Oncol. 1979;95:57.  	500769
	11. Poppema S, Kaiserling E, Lennert K. Nodular  paragranuloma and progressively transformed  germinal centers: ultrastructural and immunohis tological findings. Virchows Arch (Cell Pathol).  1979;31:211.  	43015
	12. Stein H, Hansmann M-L, Lennert K, Brandtzaeg  P, Gatter KC, Mason DY. Reed-Sternberg and  Hodgkin cells in lymphocyte-predominant  Hodgkin’s disease of nodular subtype contain J  chain. Am J Clin Pathol. 1986;86:292.  	3529924
	13. Timens W, Visser L, Poppema S. Nodular lym phocyte predominance type of Hodgkin’s disease  is a germinal center lymphoma. Lab Invest. 1986;  54:457.  	3083157
	14. Coles FB, Cartun RW, Pastuszak WT. Hodgkin’s  disease, lymphocyte predominant type: immuno reactivity with B cell antibodies. Mod Pathol. 	3266337
	15. Chittal SM, Caveriviere P, Schwarting R, et al.  Monoclonal antibodies in the diagnosis of  Hodgkin’s disease: the search for a rational  panel. Am J Surg Pathol. 1988;12:9.  	2827535
	16. Pinkus GS, Said JW. Hodgkin’s disease, lympho cyte predominance type, nodular-further evi dence for a B cell derivation: L&H variants of  Reed-Sternberg cells express L26, a pan B cell  marker. Am J Pathol. 1988;133:211.  	3263805
	17. Nicholas DS, Harris S, Wright DH. Lymphocyte  predominance Hodgkin’s disease—an immuno histochemical study. Histopathol. 1990;16:157.  	2323737
	18. Chittal SM, Alard C, Rossi J-F, et al. Further phe notypic evidence that nodular, lymphocyte-pre dominant Hodgkin’s disease is a large B-cell lym phoma in evolution. Am J Surg Pathol. 1990;14:  1024.  	2240355
	19. Pileri S, Sabattini E, Tazzari PL, et al. Hodgkin’s  disease: update of findings. Haematologica.  1991;76:175.  	1660436
	20. Harris NL, Jaffe ES, Stein H, et al. A revised Eu ropean-American classification of lymphoid neo plasms: a proposal from the International Lym phoma Study Group. Blood. 1994;84:1361.	8068936
	21. Mason DY, Banks PM, Chan J, et al. Nodular lym phocyte predominance Hodgkin’s disease: a dis tinct clinicopathological entity. Am J Surg Pathol.  1994;18:526.  	8172327
	22. Regula DP, Hoppe RT, Weiss LM. Nodular and  diffuse types of lymphocyte predominance  Hodgkin’s disease. N Engl J Med. 1988;318:214.  	3336412
	23. Borg-Grech A, Radford JA, Crowther D, Swindell  R, Harris M. A comparative study of the nodular  and diffuse variants of lymphocyte-predominant  Hodgkin’s disease. J Clin Oncol. 1989;7:1303.  	2769329
	24. Tefferi A, Zellers RA, Banks PM, Therneau TM,  Colgan JP. Clinical correlates of distinct immuno phenotypic and histologic subcategories of lymphocyte-predominance Hodgkin’s disease. J Clin  Oncol. 1990;8:1959.  	2230888
	25. Hansmann M-L, Stein H, Dallenbach F, Fellbaum  C. Diffuse lymphocyte-predominant Hodgkin’s  disease (diffuse paragranuloma): a variant of the  B-cell derived nodular type. Am J Pathol. 1991;  138:29.  	1987769
	26. Jaffe ES, Longo DL, Cossman J, Hsu S-M, Arnold  A, Kosrmeyer SJ. Diffuse B-cell lymphomas with  T-cell predominance in patients with follicular lym phoma or “pseudo T-cell lymphoma” [abstract].  Lab Invest. 1984;50:27a.  	NO_MATCH
	27. Chittal SM, Brousset P, Voigt JJ, Delsol G. Large  B-cell lymphoma rich in T-cells and simulating Hodgkin’s disease. Histopathology. 1991;19:211.  	1655614
	28. Macon WR, Williams NE, Greer JP, Stein RS,  Collins RD, Cousar JB. T-cell rich B-cell lympho mas: a clinicopathologic study of 19 cases. Am J  Surg Pathol. 1992;16:351.  	NO_MATCH
	29. Ng CS, Chan JKC, Hui PK, Lau WH. Large B-cell  lymphomas with high content of reactive T cells.  Hum Pathol. 1989;20:1145.  	2591944
	30. Osborne BM, Butler JJ, Pugh WC. The value of  immunophenotyping on paraffin sections in the  identification of T-cell rich B-cell large-cell lym phomas: lineage confirmed by JH rearrangement.  Am J Surg Pathol. 1990;14:933.  	2169708
	31. Ramsay AD, Smith WJ, Isaacson PG. T-cell rich  B-cell lymphoma. Am J Surg Pathol. 1988;12:  433.  	NO_MATCH
	32. Krishnan J, Wallberg K, Frizzera G. T-cell rich  large B-cell lymphoma. Am J Surg Pathol. 1994;  18:455.  	NO_MATCH
	33. Rodriguez J, Pugh WC, Cabanillas F. T-cell rich  B-cell lymphoma. Blood. 1993;82:1586.  	NO_MATCH
	34. de Wolf Peeters C, Pittaluga S. T-cell rich B-cell  lymphoma: a morphological variant of non  Hodgkin’s lymphomas or a clinico-pathological  entity? Histopathology. 1995;26:383.  	7541773
	35. de Jong D, van Gorp J, Sie-Go D, van Heerde P.  T-cell rich B-cell non Hodgkin’s lymphoma: a pro gressed form of follicle centre cell lymphoma and  lymphocyte predominance Hodgkin’s disease. Histopathology. 1996;28:15. 	8838116
	36. Ashton-Key M, Thorpe PA, Allen JP, Isaacson  PG. Follicular Hodgkin’s disease. Am J Surg  Pathol. 1995;19:1294.  	7573692
	37. Diehl V, Sextro M, Franklin J, et al. Clinical pre sentation, course and prognostic factors in lym phocyte predominant Hodgkin’s disease and lym phocyte-rich classical Hodgkin’s disease: report  from the European Task Force on Lymphoma  Project on lymphocyte-predominant Hodgkin’s  disease. J Clin Oncol. 1999;117:776.  	10071266
	38. Norton AJ, Jordan S, Yeomans P. Brief, high-tem perature heat denaturation (pressure cooking): a  simple and effective method of antigen retrieval for routinely processed tissues. J Pathol. 1994;  173:371. 	7965396
	39. Hummel M, Anagnostopoulos I, Dallenbach F,  Korbjuhn P, Dimmler C, Stein H. EBV infection  patterns in Hodgkin’s disease and normal lym phoid tissue: expression and cellular localization  of EBV gene products. Br J Haematol. 1992;83:  689.  	1336392
	40. Georgii A, Fischer R, Hu¨bner K, Schwarze EW,  Bernhards J. Classification of Hodgkin’s disease  biopsies by a panel of four histopathologists: re port of 1140 patients from the German national  trial. Leuk Lymphoma. 1993;9:365.	8348072
	41. von Wasielewski R, Werner M, Fischer R, et al.  Lymphocyte-predominant Hodgkin’s disease: an  immunohistochemical analysis of 208 reviewed  Hodgkin’s disease cases from the German Hodgkin Study Group. Am J Pathol. 1997;150:  793. 	9060817
	42. Kadin ME, Glatstein E, Dorfman RF. Clinico pathological studies of 117 untreated patients  subjected to laparotomy for the staging of  Hodgkin’s disease. Cancer. 1971;27:1277.  	5088206
	43. Lukes RJ. Criteria for involvement of lymph node,  bone marrow, spleen and liver in Hodgkin’s dis ease. Cancer Res. 1971;31:1755.  	4941351
	44. Poppema S, Kaiserling E, Lennert K. Hodgkin’s  disease with lymphocytic predominance, nodular  type (nodular paragranuloma) and progressively  transformed germinal centers: a cytohistological  study. Histopathology. 1979;3:295.  	468131
	45. Korkolopoulou P, Cordell J, Jones M, et al. The  expression of the B-cell marker mb-1 (CD79a) in  Hodgkin’s disease. Histopathology. 1994;24:511.  	NO_MATCH
	46. Hall PA, D’ Ardenne AJ. Value of CD15 immuno staining in diagnosing Hodgkin’s disease: a review of published literature. J Clin Pathol. 1987;  40:1298.  	3320093
	47. Angel CA, Warford A, Campbell AC, Pringle JH,  Lauder I. The immunohistology of Hodgkin’s dis ease: Reed-Sternberg cells and their variants. J Pathol. 1987;153:21. 	3499498
	48. Algara P, Martinez P, Sachez L, et al. Lymphocyte  predominance Hodgkin’s disease (nodular para granuloma)-a bcl-2 negative germinal centre lym phoma. Histopathology. 1991;19:69.  	1916688
	49. Fellbaum C, Hansmann M-L, Niedermeyer H, et  al. Influence of Epstein-Barr virus genomes on  patient survival in Hodgkin’s disease. Am J Clin  Pathol. 1992;98:319.  	1326892
	50. Pallesen G, Hamilton-Dutoit SJ, Rowe M, Young  LS. Expression of Epstein-Barr virus latent gene  products in tumor cells of Hodgkin’s disease. Lan cet. 1991;337:320.  	1671232
	51. Delsol G, Brousset P, Chittal S, Rigal Huguet F.  Correlation of the expression of Epstein-Barr vi rus latent membrane protein and in situ hybridiza tion with biotinylated BamHI-W probes in  Hodgkin’s disease. Am J Pathol. 1992;140:247.  	1310829
	52. Murray PG, Young LS, Rowe M, Crocker J. Im munohistochemical demonstration of the Epstein Barr virus encoded latent membrane protein in  paraffin sections of Hodgkin’s disease. J Pathol.  1992;166:1.  	1311374
	53. Weiss LM, Chen YY, Liu XF, Shibata D. Epstein Barr virus and Hodgkin’s disease: a correlation in  situ hybridization and polymerase chain reaction  study. Am J Pathol. 1991;139:1259.  	1661073
	54. Coates PJ, Slavin G, d’Ardenne AJ. Persistence  of Epstein-Barr virus in Reed-Sternberg cells  throughout the course of Hodgkin’s disease.  J Pathol. 1991;164:291.  	1656004
	55. Alkan S, Ross CW, Hanson CA, Schnitzer B. Ep stein-Barr virus and bcl-2 protein overexpression  are not detected in neoplastic cells of nodular lymphocyte predominance Hodgkin’s disease.  Mod Pathol. 1995;8:544.  	7675775
Blood-2000-Merad-1865-72.pdf
	1. Banchereau J, Steinman RM. Dendritic cells and  the control of immunity. Nature. 1998;392:245 252.  	9521319
	2. Larsen CP, Steinman RM, Witmer-Pack M,  Hankins DF, Morris PJ, Austyn JM. Migration and  maturation of Langerhans cells in skin transplants  and explants. J Exp Med. 1990;172:1483-1493.  	2230654
	3. Bujdoso R, Hopkins J, Dutia BM, Young P, Mc Connell I. Characterization of sheep afferent  lymph dendritic cells and their role in antigen car riage. J Exp Med. 1989;170:1285-1301.  	2794860
	4. Macatonia SE, Knight SC, Edwards AJ, Griffiths  S, Fryer P. Localization of antigen on lymph node  dendritic cells after exposure to the contact sensi tizer fluorescein isothiocyanate: functional and  morphological studies. J Exp Med. 1987;166:  1654-1667.  	3119761
	5. Vremec D, Zorbas M, Scollay R, et al. The sur face phenotype of dendritic cells purified from  mouse thymus and spleen: investigation of the  CD8 expression by a subpopulation of dendritic  cells. J Exp Med. 1992;176:47-58.  	1613465
	6. Maurer D, Stingl G. Dendritic cells in the context  of skin immunity. In: Lotze MT, Thomson AW, eds.  Dendritic Cells: Biology and Clinical Implications.  San Diego: Academic Press; 1999.  	NO_MATCH
	7. Geissmann F, Prost C, Monnet JP, Dy M, Brousse  N, Hermine O. Transforming growth factor beta1,  in the presence of granulocyte/macrophage  colony-stimulating factor and interleukin 4, in duces differentiation of human peripheral blood  monocytes into dendritic Langerhans cells. J Exp  Med. 1998;187:961-966.  	9500798
	8. Zhang Y, Zhang YY, Ogata M, et al. Transforming growth factor-b1 polarizes murine hematopoietic  progenitor cells to generate Langherans cell-like  dendritic cells through a monocyte/macrophage  differentiation pathway. Blood. 1999;93:1208 1220.  	9949163
	9. Sprent J, Webb SR. Intrathymic and extrathymic  clonal deletion of T cells. Curr Opin Immunol.  1995;7:196-205.  	7546379
	10. Ardavin C, Wu L, Li CL, Shortman K. Thymic den dritic cells and T cells develop simultaneously in  the thymus from a common precursor population.  Nature. 1993;362:761-763.  	8469288
	11. Vestweber D, Kemler R. Rabbit antiserum against  a purified surface glycoprotein decompacts  mouse preimplantation embryos and reacts with  specific adult tissues. Exp Cell Res. 1984;152:  169-178.  	6370707
	12. Schuler G, Steinman RM. Murine epidermal  Langerhans cells mature into potent immuno stimulatory dendritic cells in vitro. J Exp Med.  1985;161:526-546.  	3871837
	13. Metlay JP, Witmer-Pack MD, Agger R, Crowley  MT, Lawless D, Steinman RM. The distinct leuko cyte integrins of mouse spleen dendritic cells as  identified with new hamster monoclonal antibod ies. J Exp Med. 1990;171:1753-1771.  	2185332
	14. Kraal G, Breel M, Janse M, Bruin G. Langerhans’  cells, veiled cells, and interdigitating cells in the  mouse recognized by a monoclonal antibody. J  Exp Med. 1986;163:981-997.  	3950549
	15. Borkowski TA, Van Dyke BJ, Schwarzenberger K,  McFarland VW, Farr A, Udey MC. Expression of  E-cadherin by murine dendritic cells: E-cadherin  as a dendritic cell differentiation antigen charac teristic of epidermal Langerhans cells and related  cells. Eur J Immunol. 1994;24:2767-2774.  	7957569
	16. Wu L, Li C, Shortman K. Thymic dendritic cell  precursors: relationship to the T lymphocyte lin eage and phenotype of the dendritic cell progeny.  J Exp Med. 1996;184:903-911.  	9064350
	17. Wu L, Vremec D, Ardavin C, et al. Mouse thymus  dendritic cells: kinetics of development and  changes in surface markers during maturation.  Eur J Immunol. 1995;25:418-425.  	7875203
	18. Brocker T, Riedinger M, Karjalainen K. Targeted  expression of major histocompatibility complex  (MHC) class II molecules demonstrates that den dritic cells can induce negative but not positive selection of thymocytes in vivo. J Exp Med. 1997;  185:541-550. 	9053454
	19. Pulendran B, Smith JL, Caspary G, et al. Distinct  dendritic cell subsets differentially regulate the  class of immune response in vivo. Proc Natl Acad  Sci U S A. 1999;96:1036-1041.  	9927689
	20. Maldonado-Lopez R, De Smedt T, Michel P, et al.  CD8a1 and CD8a- subclasses of dendritic cells  direct the development of distinct T helper cells in  vivo. J Exp Med. 1999;189:587-592.  	9927520
	21. Fung-Leung WP, Schilham MW, Rahemtulla A, et  al. CD8 is needed for development of cytotoxic T  cells but not helper T cells. Cell. 1991;65:443 	1673361
	22. Power CA, Church DJ, Meyer A, et al. Cloning  and characterization of a specific receptor for the  novel CC chemokine MIP-3alpha from lung den dritic cells. J Exp Med. 1997;186:825-835.  	9294137
	23. Greaves DR, Wang W, Dairaghi DJ, et al. CCR6, a CC chemokine receptor that interacts with mac rophage inflammatory protein 3alpha and is  highly expressed in human dendritic cells. J Exp  Med. 1997;186:837-844.  	9294138
	24. Rossi DL, Vicari AP, Franz-Bacon K, McClanahan  TK, Zlotnik A. Identification through bioinformatics  of two new macrophage proinflammatory human chemokines: MIP-3alpha and MIP-3beta. J Im munol. 1997;158:1033-1036.  	9013939
	25. Dieu MC, Vanbervliet B, Vicari A, et al. Selective  recruitment of immature and mature dendritic cells by distinct chemokines expressed in differ ent anatomic sites. J Exp Med. 1998;188:373 386.  	9670049
	26. Yang D, Chertov O, Bykovskaia SN, et al. beta Defensins: linking innate and adaptive immunity  through dendritic and T cell CCR6. Science. 1999;286:525-528. 	10521347
	27. Schweickart VL, Raport CJ, Godiska R, et al.  Cloning of human and mouse EBI1, a lymphoid specific G-protein-coupled receptor encoded on  human chromosome 17q12–q21.2. Genomics. 1994;23:643-650.	7851893
	28. Hedrick JA, Zlotnik A. Identification and charac terization of a novel beta chemokine containing  six conserved cysteines. J Immunol. 1997;159:  1589-1593.  	9257816
	29. Gunn MD, Tangemann K, Tam C, Cyster JG, Rosen SD, Williams LT. A chemokine expressed  in lymphoid high endothelial venules promotes the adhesion and chemotaxis of naive T lympho cytes. Proc Natl Acad Sci U S A. 1998;95:258 263.  	9419363
	30. Chan VW, Kothakota S, Rohan MC, et al. Sec ondary lymphoid-tissue chemokine (SLC) is che motactic for mature dendritic cells. Blood. 1999;  93:3610-3616.  	10339465
	31. Gunn MD, Kyuwa S, Tam C, et al. Mice lacking  expression of secondary lymphoid organ chemo kine have defects in lymphocyte homing and den dritic cell localization [see comments]. J Exp Med.  1999;189:451-460.  	9927507
	32. Saeki H, Moore AM, Brown MJ, Hwang ST. Cut ting edge: secondary lymphoid-tissue chemokine  (SLC) and CC chemokine receptor 7 (CCR7) par ticipate in the emigration pathway of mature den dritic cells from the skin to regional lymph nodes.  J Immunol. 1999;162:2472-2475.  	10072485
	33. Godiska R, Chantry D, Raport CJ, et al. Human  macrophage-derived chemokine (MDC), a novel  chemoattractant for monocytes, monocyte derived dendritic cells, and natural killer cells. J  Exp Med. 1997;185:1595-1604.  	9151897
	34. Tang HL, Cyster JG. Chemokine up-regulation  and activated T cell attraction by maturing den dritic cells. Science. 1996;284:819-822.  	NO_MATCH
	35. Imai T, Yoshida T, Baba M, Nishimura M, Kakizaki  M, Yoshie O. Molecular cloning of a novel T cell directed CC chemokine expressed in thymus by  signal sequence trap using Epstein-Barr virus vector. J Biol Chem. 1996;271:21514-21521.	8702936
	36. De St Groth B. The evolution of self-tolerance: a  new cell arises to meet the challenge of self-reac tivity. Immunol Today. 1998;19:448-454.  	9785668
	37. Reis e Sousa C, Germain R. Analysis of adjuvant  function by direct visualization of accumulation of  antigen-bearing dendritic cells in the T cell area of  lymphoid tissue. J Immunol. 1999;162:6552 	10352271
	38. Inaba K, Pack M, Inaba M, Sakuta H, Isdell F,  Steinman RM. High levels of a major histocom patibility complex II–self-peptide complex on den dritic cells from the T cell areas of lymph nodes. J  Exp Med. 1997;186:665-672.  	9271582
	39. Reis e Sousa C, Hieny S, Scharton-Kersten T, et  al. In vivo microbial stimulation induces rapid CD40 ligand-independent production of interleu kin 12 by dendritic cells and their redistribution to  T cell areas [see comments]. J Exp Med. 1997; 186:1819-1829.  	9382881
	40. Ohteki T, Fukao T, Suzue K, et al. Interleukin 12 dependent interferon gamma production by  CD8alpha1 lymphoid dendritic cells. J Exp Med.  1999;189:1981-1986.  	10377194
v017p00286.pdf
Am J Clin Nutr-2000-Borchers-339-47.pdf
	1. Scimone A, Scimone A. US sees the green in herbal supplements.  Chem Market Rep 1998;254:FR3–4.  	NO_MATCH
	2. Thomson WAR. Medicines from the earth: a guide to healing plants.  New York: Harper & Row, 1983.  	NO_MATCH
	3. Foster S, Duke JA. A field guide to medicinal plants: eastern and  central North America. Boston: Houghton Mifflin Company, 1990.  	NO_MATCH
	4. Tierra M. The way of herbs. New York: Pocket Books, 1990.  	NO_MATCH
	5. Duke JA. The green pharmacy. Emmaus, PA: Rodale Press, 1997.  	NO_MATCH
	6. Blumenthal M. New world plants; new world drugs. Allergy Proc  1992;13:345–52.  	1283381
	7. Schacter L. Etoposide phosphate: what, why, where, and how?  Semin Oncol 1996;23:1–7.  	8996569
	8. Moerman DE. An analysis of the food plants and drug plants of  native North America. J Ethnopharmacol 1996;52:1–22.  	8733114
	9. Moerman DE. Medicinal plants of North America. Ann Arbor, MI:  Museum of Anthropology, University of Michigan, 1986.  	NO_MATCH
	10. Johnson Gottesfeld LM, Anderson B. Gitksan traditional medicine:  herbs and healing. J Ethnobiol 1988;8:13–33.  	NO_MATCH
	11. Turner NJ, Hebda RJ. Contemporary use of bark for medicine by  two Salishan native elders of Southeast Vancouver Island, Canada.  J Ethnopharmacol 1990;29:59–72.  	2345461
	12. Johnson Gottesfeld LM. Wet’suwet’en ethnobotany: traditional  plant uses. J Ethnobiol 1994;14:185–200.  	NO_MATCH
	13. Ritch-Krc EM, Thomas S, Turner NJ, Towers GHN. Carrier herbal  medicine: traditional and contemporary plant use. J Ethnopharma col 1996;52:85–94.  	8735452
	14. Moerman DE. The medicinal flora of native North America: an  analysis. J Ethnopharmacol 1991;31:1–42.  	2030588
	15. Reichard GA. Navaho religion: a study of symbolism. Princeton,  NJ: Princeton University Press, 1990.  	NO_MATCH
	16. Vogel VJ. American Indian medicine: University of Oklahoma  Press, 1970.  	NO_MATCH
	17. Arnason T. Use of plants for food and medicine by native peoples of  eastern Canada. Can J Bot 1981;59:2189–325.  	NO_MATCH
	18. Herrick JW. Iroquois medical botany. Syracuse, NY: Syracuse Uni versity Press, 1995.  	NO_MATCH
	19. Hobbs C. Echinacea: a literature review. Botany, history, chemistry,  pharmacology, toxicology, and clinical uses. Herbalgram 1994;33:  35–48.  	NO_MATCH
	20. Schwarz H-D. 100 Jahre Lobelin. Z Phytother 1990;11:159–60.  	NO_MATCH
	21. Orvis KS, Goldman IL. Relationship between antiplatelet activity  and sulfur fertility in hydroponic and field-grown onions (Allium  cepa). Hort Sci 1997;32:523 (abstr).  	NO_MATCH
	22. Weber ND, Andersen DO, North JA, Murray BK, Lawson LD,  Hughes BG. In vitro virucidal effects of Allium sativum (garlic)  extract and compounds. Planta Med 1992;58:417–23.  	1470664
	23. Goldman IL. Strength of onion-induced human antiplatelet activity  is associated with plant development. Hort Sci 1997;32:523 (abstr).  	NO_MATCH
	24. McCutcheon AR, Ellis SM, Hancock REW, Towers GHN. Antibi otic screening of medicinal plants of the British Columbian native  peoples. J Ethnopharmacol 1992;37:213–23.  	1453710
	25. McCutcheon AR, Roberts TE, Gibbons E, et al. Antiviral screening  of British Columbian medicinal plants. J Ethnopharmacol 1995;49:  101–10.  	8847882
	26. Tunón H, Olavsdotter C, Bohlin L. Evaluation of anti-inflammatory  activity of some Swedish medicinal plants. Inhibition of prostaglandin  biosynthesis and PAF-induced exocytosis. J Ethnopharmacol 1995;  48:61–76.  	8583796
	27. Yesilada E, Sezik E. Screening of some Turkish medicinal plants used  in the treatment of rheumatoid arthritis and inflammatory diseases for  their anti-inflammatory activities. Planta Med 1990;56:659.  	NO_MATCH
	28. Wagner H. Search for new plant constituents with potential  antiphlogistic and antiallergic activity. Planta Med 1989;55:235–41.  	2662231
	29. Müller-Jakic B, Breu W, Pröbstle A, Redl K, Greger H, Bauer R. In  vitro inhibition of cyclooxygenase and 5-lipoxygenase by alkamides  from Echinacea and Achillea species. Planta Med 1994;60:37–40.  	8134414
	30. Wagner H, Breu W, Willer F, Wierer M, Remiger P, Schwenker G.  In vitro inhibition of arachidonate metabolism by some alkamides  and prenylated phenols. Planta Med 1989;55:566–7.  	NO_MATCH
	31. Hartisch C, Kolodziej H, von Bruchhausen F. Dual inhibitory activ ities of tannins from Hamamelis virginiana and related polyphenols  on 5-lipoxygenase and lyso-PAF:acetyl-CoA acetyltransferase.  Planta Med 1997;63:106–10.  	9140221
	32. Vavrecková C, Gawlik I, Müller K. Benzophenanthridine alkaloids  of Chelidonium majus; I. Inhibition of 5- and 12-lipoxygenase by a  non-redox mechanism. Planta Med 1996;62:397–401.   	9005450
	33. Sumner H, Salan U, Knight DW, Hoult JRS. Inhibition of 5-lipoxy genase and cyclo-oxygenase in leukocytes by feverfew. Involvement  of sesquiterpene lactones and other components. Biochem Pharma col 1992;43:2313–20.  	1319159
	34. Obertreis B, Giller K, Teucher T, Behnke B, Schmitz H. Antiphlo gistische Effekte von Extractum Urticae dioicae foliorum im Ver gleich zu kaffeoyläpfelsäure. (Antiphlogistic effects of Urtica  dioica leaf extract compared to caffeic malic acid.) Arzneimit telforschung 1996;46:52–6.  	NO_MATCH
	35. Agarwal S, Reynolds MA, Pou S, Peterson DE, Charon JA, Suzuki  JB. The effect of sanguinarine on human peripheral blood neutrophil  viability and functions. Oral Microbiol Immunol 1991;6:51–61.  	1945482
	36. Chaturvedi MM, Kumar A, Darnay BG, Chainy GBN, Agarwal S,  Aggarwal BB. Sanguinarine (pseudochelerythrine) is a potent  inhibitor of NF-B activation, IB phosphorylation, and degrada tion. J Biol Chem 1997;272:30129–34.  	9374492
	37. Erdelmeier CAJ, Cinatl J Jr, Rabenau H, Doerr HW, Biber A, Koch  E. Antiviral and antiphlogistic activities of Hamamelis virginiana  bark. Planta Med 1996;62:241–5.  	8693037
	38. Duwiejua M, Zeitlin IJ, Waterman PG, Gray AI. Anti-inflammatory  activity of Polygonum bistorta, Guaiacum officinale and Hamamelis  virginiana in rats. J Pharm Pharmacol 1994;46:286–90.  	8051612
	39. Hughes-Formella BJ, Bohnsack K, Rippke F, et al. Anti-inflamma tory effect of hamamelis lotion in a UVB erythema test. Dermatol ogy 1998;196:316–22.  	9621139
	40. Korting HC, Schafer-Korting M, Hart H, Laux P, Schmid M. Anti inflammatory activity of hamamelis distillate applied topically to  the skin. Influence of vehicle and dose. Eur J Clin Pharmacol  1993;44:315–8.  	8513841
	41. Korting HC, Schafer-Korting M, Klovekorn W, Klovekorn G, Martin  C, Laux P. Comparative efficacy of hamamelis distillate and hydrocor tisone cream in atopic eczema. Eur J Clin Pharmacol 1995;48:461–5.  	8582464
	42. Yesilada E, Üstün O, Sezik E, Takaishi Y, Ono Y, Honda G.  Inhibitory effects of Turkish folk remedies on inflammatory  cytokines: interleukin-1, interleukin-1 and tumor necrosis factor  . J Ethnopharmacol 1997;58:59–73.  	9324006
	43. Zakay-Rones Z, Varsano N, Zlotnik M, et al. Inhibition of several  strains of influenza virus in vitro and reduction of symptoms by an  elderberry extract (Sambucus nigra L.) during an outbreak of  influenza B Panama. J Altern Complement Med 1995;1:361–9.  	NO_MATCH
	44. Bauer R, Remiger P, Jurcic K, Wagner H. Beeinflussung der Phagozy tose-aktivität durch Echinacea-Extrakte. (Effects of Echinacea  extracts on phagocytic activity.) Z Phytotherapie 1989;10:43–8 (in  German).  	NO_MATCH
	45. Bauer R, Remiger P. TLC and HPLC analysis of alkamides in Echi nacea drugs. Planta Med 1989;55:367–71.  	NO_MATCH
	46. Perry NB, van Klink JW, Burgess EJ, Parmenter GA. Alkamide lev els in Echinacea purpurea: a rapid analytical method revealing dif ferences among roots, rhizomes, stems, leaves and flowers. Planta  Med 1997;63:58–62.  	NO_MATCH
	47. Bauer R, Jurcic K, Puhlmann J, Wagner H. Immunologische In-vivo und In-vitro-Untersuchungen mit Echinacea-Extrakten. (Immuno logical in vivo and in vitro examinations of Echinacea extracts.)  Arzneimittelforschung 1988;38:276–81 (in German).  	3370076
	48. O’Hara MA, Kiefer D, Farrell K, Kemper K. A review of 12 com monly used medicinal herbs. Arch Fam Med 1998;7:523–36.  	9821826
	49. Tympner K-D. Der immunbiologische Wirkungsnachweis von  Pflanzenextrakten. (The demonstration of immunobiological effec tiveness of plant extracts.). Z Angewandte Phytother 1981;5:181–4  (in German).  	NO_MATCH
	50. Gaisbauer M, Schleich T, Stickl HA, Wilczek I. Untersuchungen  zum Einfluß von Echinacea purpurea Moench auf die Phagozytose  von Granulozyten mittels Messung der Chemilumineszenz. (The  effect of Echinacea purpurea Moench on the phagocytosis in gran ulocytes measured by chemiluminescence.) Arzneim-Forsch/Drug  Res 1990;40:594–8 (in German).  	2383303
	51. Jurcic K, Melchart D, Holzmann M, et al. Zwei Probandenstudien  zur Stimulierung der Granulozyten-Phagozytose durch Echinacea extrakt-haltige präparate. (Two clinical studies on the stimulation of  granulocyte phagocytosis by preparations containing Echinacea.)  Z Phytother 1989;10:67–70.  	NO_MATCH
	52. Burger RA, Torres AR, Warren RP, Caldwell VD, Hughes BG. Echi nacea-induced cytokine production by human macrophages. Int J  Immunopharmacol 1997;19:371–9.  	9568541
	53. Wagner H, Proksch A, Vollmar A, Kreutzkamp B, Bauer J. In-vitro Phagozytose-Stimulierung durch isolierte Pflanzenstoffe gemessen  im Phagozytose-Chemilumineszenz-(CL)-Modell. (In vitro phagocy tosis stimulation by isolated plant materials in a chemoluminescence phagocytosis model.) Planta Med 1985;2:139–44 (in German).  	4034729
	54. Roesler J, Emmendörffer A, Steinmüller C, Luettig B, Wagner H,  Lohmann-Matthes M-L. Application of purified polysaccharides  from cell cultures of the plant Echinacea purpurea to test subjects  mediates activation of the phagocytic system. Int J Immunopharma col 1991;13:931–41.  	1761359
	55. See DM, Broumand N, Sahl L, Tilles JG. In vitro effects of echi nacea and ginseng on natural killer and antibody-dependent cell  cytotoxicity in healthy subjects and chronic fatigue syndrome or  acquired immunodeficiency syndrome patients. Immunopharmacol ogy 1997;35:229–35.  	9043936
	56. Steinmüller C, Roesler J, Gröttrup E, Franke G, Wagner H, Lohmann Matthes M-L. Polysaccharides isolated from plant cell cultures of  Echinacea purpurea enhance the resistance of immunosuppressed  mice against systemic infections with Candida albicans and Listeria  monocytogenes. Int J Immunopharmacol 1993;15:605–14.  	8375943
	57. Roesler J, Steinmüller C, Kinderlein A, Emmendörffer A, Wagner  H, Lohmann-Matthes M-L. Application of purified polysaccharides  from cell cultures of the plant Echinacea purpurea to mice mediates  protection against systemic infections with Listeria monocytogenes  and Candida albicans. Int J Immunopharmacol 1991;13:27–37.  	2026472
	58. Möse JR. Zur Wirkung von Echinacin auf Phagozytoseaktivität und  natural killer cells. (On the effect of Echinacin on phagocytic activity  and natural killer cells.) Medwelt 1983;51/52:1463–7 (in German).  	6366434
	59. Melchart D, Linde K, Worku F, et al. Results of five randomized  studies on the immunomodulatory activity of preparations of Echi nacea. J Altern Complement Med 1995;1:145–60.  	NO_MATCH
	60. Elsässer-Beile U, Willenbacher W, Bartsch HH, Gallati H, Schulte  Mönting J, von Kleist S. Cytokine production in leukocyte cultures  during therapy with Echinacea extract. J Clin Lab Anal 1996;10:  441–5.  	8951617
	61. Bräunig B, Dorn M, Knick E. Echinaceae purpureae radix: zur  Stärkung der körpereigenen Abwehr bei grippalen Infekten.  (Echinacea purpurea radix: for strengthening host immunity in res piratory infections.) Z Phytother 1992;13:7–13 (in German).  	NO_MATCH
	62. Schmidt U, Albrecht M, Schenk N. Pflanzliches Immunstimulans  senkt Häufigkeit grippaler Infekte. (A plant-derived immunostimu lant reduces the frequency of upper respiratory infections.) Natur  Ganzheits Medizin 1990;3:277–81 (in German).  	NO_MATCH
	63. Melchart D, Walther E, Linde K, Brandmaier R, Lersch C. Echi nacea root extracts for the prevention of upper respiratory tract  infections. Arch Fam Med 1998;7:541–5.  	NO_MATCH
	64. Mengs U, Clare CB, Poiley JA. Toxicity of Echinacea purpurea.  Arzneimittelforschung 1991;41:1076–81.  	NO_MATCH
	65. Schimmer O, Abel G, Behninger C. Untersuchungen zur Gentoxi schen Potenz eines neutralen Polysaccharids aus Echinacea-Gewe bekulturen in menschlichen Lymphozytenkulturen. (Investigations  of the genotoxic potential of a neutral polysaccharide from Echi nacea tissue cultures in cultures of human lymphocytes.) Z Phy tother 1989;10:39–42.  	NO_MATCH
	66. Mullins RJ. Echinacea-associated anaphylaxis. Med J Aust 1998;  168:170–1.  	9507713
	67. Myers SP, Wohlmuth H. Echinacea-associated anaphylaxis. Med J  Aust 1998;168:583–4.  	9640313
	68. Bauer R, Khan IA, Wagner H. Neue Möglichkeiten zur Standar disierung von Echinacea-Extrakten. (New possibilities for stan dardization of Echinacea extracts.) Sci Pharm 1986;54:145 (abstr)  (in German).  	NO_MATCH
	69. Obertreis B, Ruttkowski T, Teucher T, Behnke B, Schmitz H. Ex vivo in-vitro inhibition of lipopolysaccharide stimulated tumor  necrosis factor- and interleukin-1 secretion in human whole blood  by extractum Urticae dioicae foliorum. Arzneimittelforschung  1996;46:389–94.  	8740085
	70. Riehemann K, Behnke B, Schulze-Osthoff K. Plant extracts from  stinging nettle (Urtica dioica), an antirheumatic remedy, inhibit the  proinflammatory transcription factor NF-B. FEBS Lett 1999;442:  89–94.  	9923611
	71. Feldmann M, Brennan FM, Maini RN. Rheumatoid arthritis. Cell  1996;85:307–10.  	NO_MATCH
	72. Feldmann M, Brennan FM, Maini RN. Role of cytokines in rheuma toid arthritis. Annu Rev Immunol 1996;14:397–440.  	8717520
	73. Marok R, Winyard PG, Coumbe A, et al. Activation of the tran scription factor nuclear factor-B in human inflamed synovial tis sue. Arthritis Rheum 1996;39:583–91.  	8630106
	74. Shiozawa S, Shimizu K, Tanaka K, Hino K. Studies on the contri bution of c-fos/AP-1 to arthritic joint destruction. J Clin Invest  1997;99:1210–6.  	9077528
	75. Miyazawa K, Mori A, Yamamoto K, Okudaira H. Constitutive tran scription of the human interleukin-6 gene by rheumatoid synovio cytes. Spontaneous activation of NF-B and CBF1. Am J Pathol  1998;152:793–803.  	9502421
	76. Teucher T, Obertreis B, Ruttkowski T, Schmitz H. Zytokin-Sekre tion im Vollblut gesunder Probanden nach oraler Einnahme eines  Urtica dioica L.-Blattextraktes. (Cytokine secretion in whole blood  of healthy volunteers after oral ingestion of an Urtica dioica L. leaf  extract.) Arzneimittelforschung 1996;46:906–10.  	NO_MATCH
	77. Le Moal MA, Truffa-Bachi P. Urtica dioica agglutinin, a new mito gen for murine T lymphocytes: unaltered interleukin-1 production  but late interleukin 2-mediated proliferation. Cell Immunol 1988;  115:24–35.  	3261205
	78. Le Moal MA, Colle J-H, Galelli A, Truffa-Bachi P. Mouse T-lym phocyte activation by Urtica dioica agglutinin. II. Original pattern  of cell activation and cytokine production induced by UDA. Res  Immunol 1992;143:701–9.  	1439142
	79. Galelli A, Truffa-Bachi P. Urtica dioica agglutinin. A superanti genic lectin from stinging nettle rhizome. J Immunol 1993;151:  1821–31.  	8345184
	80. Musette P, Galelli A, Truffa-Bachi P, Peumans W, Kourilsky P,  Gachelin G. The J segment of the T cell receptor contributes to the  V-specific T cell expansion caused by staphylococcal enterotoxin  B and Urtica dioica superantigens. Eur J Immunol 1996;26:618–22.  	8605929
	81. Galelli A, Delcourt M, Wagner M-C, Peumans W, Truffa-Bachi P.  Selective expansion followed by profound deletion of mature  V8.3+ T cells in vivo after exposure to the superantigenic lectin  Urtica dioica agglutinin. J Immunol 1995;154:2600–11.  	7876535
	82. Delcourt M, Peumans WJ, Wagner M-C, Truffa-Bachi P. V-spe cific deletion of mature thymocytes induced by plant superantigen  Urtica dioica agglutinin. Cell Immunol 1996;168:158–64.  	8640861
	83. Thompson SD, Murray KJ, Grom AA, Passo MH, Choi E, Glass  DN. Comparative sequence analysis of the human T cell receptor   chain in juvenile rheumatoid arthritis and juvenile spondy larthropathies. Arthritis Rheum 1998;41:482–97.  	NO_MATCH
	84. Robinson CP, Cornelius J, Bounous DE, Yamamoto H, Humphreys Beher MG, Peck AB. Characterization of the changing lymphocyte  populations and cytokine expression in the exocrine tissues of  autoimmune NOD mice. Autoimmunity 1998;27:29–44.  	9482205
	85. Suzuki M, Cheng KC, Krug MS, Yoo TJ. Successful prevention of  retrocochlear hearing loss in murine experimental allergic encephalo myelitis with T cell receptor V8-specific antibody. Ann Otol Rhi nol Laryngol 1998;107:917–27.  	9823840
	86. Goldman-Brezinski S, Brezinski K, Zhang X-M, et al. Effects of  oral tolerance induction by myelin basic protein on V8+ Lewis rat  T cells. J Neurosci Res 1998;51:67–75.  	9452310
	87. Musette P, Pannetier C, Gachelin G, Kourilsky P. The expansion of  a CD4+ T cell population bearing a distinctive  chain in MRL  lpr/lpr mice suggests a role for the fas protein in peripheral T cell  selection. Eur J Immunol 1994;24:2761–6.  	7525303
	88. Musette P, Galelli A, Chabre H, et al. Urtica dioica agglutinin, a  V8.3-specific superantigen, prevents the development of the sys temic lupus erythematosus-like pathology of MRL lpr/lpr mice. Eur  J Immunol 1996;26:1707–11.  	8765010
Am J Clin Nutr-2000-Scott-333-4.pdf
	1. McCully KS. Vascular pathology of homocysteinemia: implications  for the pathogenesis of arteriosclerosis. Am J Pathol 1969;56:  111–28.  	5792556
	2. Brattström L, Wilcken DEL. Homocysteine and cardiovascular dis ease: cause or effect? Am J Clin Nutr 2000;72:315–23.  	10919920
	3. Mudd SH, Skovby F, Levy HL, et al. The natural history of homo cystinuria due to cystathionine beta-synthase deficiency. Am J Hum  Genet 1985;37:1–31.  	3872065
	4. Nygard O, Vollset SE, Refsum H, et al. Total plasma homocysteine  and cardiovascular risk profile. The Hordaland Homosycteine  Study. JAMA 1995;274:1526–33.  	7474221
	5. Bostom A, Brosnan JT, Hall B, Nadeau MR, Selhub J. Net uptake of  plasma homocysteine by the rat kidney in vivo. Atherosclerosis  1995;116:59–62.  	7488333
	6. Guttormsen AB, Ueland PM, Svarstad E, Refsum H. Kinetic basis  of hyperhomocysteinemia in patients with chronic renal failure.  Kidney Int 1997;52:495–502.  	9264008
	7. Ueland PM, Refsum H, Beresford SAA, Vollset SE. The contro versy over homocysteine and cardiovascular risk. Am J Clin Nutr  2000;72:324–32.  	10919921
1203626a.pdf
	Aguirre KM, McCormick RJ and Schwarzbauer JE. (1994).  J. Biol. Chem., 269, 27863 – 29868.  	NO_MATCH
	Bar-Sagi D and Feramisco JR. (1986). Science, 233, 1061 –  1068.  	NO_MATCH
	Barbacid M. (1987). Annu. Rev. Biochem., 56, 779 – 827.  	NO_MATCH
	Boudreau N and Bissell MJ. (1998). Curr. Opin. Cell. Biol.,  10, 640 – 646.  	NO_MATCH
	Bourdoulous S, Orend G, MacKenna DA, Pasqualini R and  Ruoslahti E. (1998). J. Cell Biol., 143, 267 – 276.  	NO_MATCH
	Damsky CH, Fitzgerald ML and Fisher SJ. (1992). J. Clin.  Invest., 89, 210 – 222.  	NO_MATCH
	Dudley DT, Pang L, Decker SJ, Bridges AJ and Saltiel AR.  (1995). Proc. Natl. Acad. Sci. USA, 92, 7686 – 7689.  	NO_MATCH
	Efimova T, LaCelle P, Welter JF and Eckert RL. (1998). J.  Biol. Chem., 273, 24387 – 24395.  	NO_MATCH
	Esparza J, Vilardell C, Calvo J, Juan M, Vives J, Urbano Marquez A, Yague J and Cid MC. (1999). Blood, 94,  2754 – 2766.  	NO_MATCH
	Furcht LT, Mosher DF, Wendelschafer-Crabb G and  Foidart JM. (1979). Cancer Res., 39, 2077 – 2083.  	NO_MATCH
	Gailit J and Ruoslahti E. (1988). J. Biol. Chem., 263, 12927 –  12932.  	NO_MATCH
	Giancotti FG and Ruoslahti E. (1990). Cell, 60, 849 – 859.  	NO_MATCH
	Grenz H, Carbonetto S and Goodman SL. (1993). J. Cell  Sci., 105, 739 – 751.  	NO_MATCH
	Hall A, Marshall CJ, Spurr NK and Weiss RA. (1983).  Nature, 303, 396 – 400.  	NO_MATCH
	Hemler ME, Sanchez-Madrid F, Flotte TJ, Krensky AM,  Burako SJ, Bhan AK, Springer TA and Strominger JL.  (1984). J. Immunol., 132, 3011 – 3018.  	NO_MATCH
	Hughes PE, Renshaw MW, Pfa M, Forsyth J, Keivens VM,  Schwartz MA and Ginsberg MH. (1997). Cell., 88, 521 –  530.  	NO_MATCH
	Hulley PA, Gordon F and Hough FS. (1998). Endocrinology,  139, 2423 – 2431.  	NO_MATCH
	Hynes RO. (1990). Fibronectins. Springer-Verlag, New York.  	NO_MATCH
	Hynes RO, Destree AT, Mautner VM and Ali IU. (1977). J.  Supramol. Struct., 7, 397 – 408.  	NO_MATCH
	Hynes RO and Wyke JA. (1975). Virology, 64, 492 – 504.  	NO_MATCH
	Kapron-Bras C, Fitz-Gibbon L, Jeevaratnam P, Wilkins J  and Dedhar S. (1993). J. Biol. Chem., 268, 20701 – 20704.  	NO_MATCH
	Kazlauskas A and Cooper JA. (1988). J. Cell. Biol., 106,  1395 – 1402.  	NO_MATCH
	Keely P, Parise L and Juliano R. (1998). Trends. Cell. Biol.,  8, 101 – 106.  	NO_MATCH
	Kohno M. (1985). J. Biol. Chem., 260, 1771 – 1779.  	NO_MATCH
	Mader S and White JH. (1993). Proc. Natl. Acad. Sci. USA.,  90, 5603 – 5607.  	NO_MATCH
	Malumbres M and Pellicer A. (1998). Front Biosci., 3, d887 –  d912.  	NO_MATCH
	Marcantonio EE and Hynes RO. (1988). J. Cell. Biol., 106,  1765 – 1772.  	NO_MATCH
	Matsumoto T, Yokote K, Tamura K, Takemoto M, Ueno H,  Saito Y and Mori S. (1999). J. Biol. Chem., 274, 13954 –  13960.  	NO_MATCH
	McKeown-Longo PJ and Etzler CA. (1987). J. Cell. Biol.,  104, 601 – 610.  	NO_MATCH
	McKeown-Longo PJ and Mosher DF. (1983). J. Cell. Biol.,  97, 466 – 472.  	NO_MATCH
	Meyer M, Maly K, Uberall F, Hoflacher J and Grunicke H.  (1991). J. Biol. Chem., 266, 8230 – 8235.  	NO_MATCH
	Morino N, Mimura T, Hamasaki K, Tobe K, Ueki K,  Kikuchi K, Takehara K, Kadowaki T, Yazaki Y and  Nojima Y. (1995). J. Biol. Chem., 270, 269 – 273.  	NO_MATCH
	Mosher DF. (1993). Curr. Opin. Struct. Biol., 3, 214 – 222.  	NO_MATCH
	Mould AP, Akiyama SK and Humphries MJ. (1995). J. Biol.  Chem., 270, 26270 – 26277.  	NO_MATCH
	Moustakas A and Stournaras C. (1999). J. Cell. Sci., 112,  1169 – 1179.  	NO_MATCH
	Olden K and Yamada KM. (1977). Cell., 11, 957 – 969.  	NO_MATCH
	Oliver N, Newby RF, Furcht LT and Bourgeois S. (1983).  Cell., 33, 287 – 296.  	NO_MATCH
	Plantefaber LC and Hynes RO. (1989). Cell., 56, 281 – 290.  	NO_MATCH
	Rasheed S, Nelson-Rees WA, Toth EM, Arnstein P and  Gardner MB. (1974). Cancer, 33, 1027 – 1033.  	NO_MATCH
	Schlaepfer DD, Hanks SK, Hunter T and van der Geer P.  (1994). Nature, 372, 786 – 791.  	NO_MATCH
	Schwarzbauer JE and Sechler JL. (1999). Curr. Opin. Cell.  Biol., 11, 622 – 627.  	NO_MATCH
	Schwarzbauer JE, Spencer CS and Wilson CL. (1989). J.  Cell. Biol., 109, 3445 – 3453.  	NO_MATCH
	Sechler JL, Corbett SA and Schwarzbauer JE. (1997). Mol.  Biol. Cell., 8, 2563 – 2573.  	NO_MATCH
	Sechler JL and Schwarzbauer JE. (1997). Cell. Adhes.  Commun., 4, 413 – 424.  	NO_MATCH
	Sechler JL and Schwarzbauer JE. (1998). J. Biol. Chem., 273,  25533 – 25536.  	NO_MATCH
	Sechler JL, Takada Y and Schwarzbauer JE. (1996). J. Cell.  Biol., 134, 573 – 583.  	NO_MATCH
	Seuerlein T, Withers DJ, Mann D and Rozengurt E. (1996).  Mol. Biol. Cell., 7, 1865 – 1875.  	NO_MATCH
	Singh RP, Dhawan P, Golden C, Kapoor GS and Mehta  KD. (1999). J. Biol. Chem., 274, 19593 – 19600.  	NO_MATCH
	Sottile J, Hocking DC and Swiatek PJ. (1998). J. Cell. Sci.,  111, 2933 – 2943.  	NO_MATCH
	Stice LL, Vaziri C and Faller DV. (1999). Front. Biosci., 4,  D72 –D86.  Control of fibronectin matrix assembly by activated Ras  KA Brenner et al  	NO_MATCH
	Stone KR, Smith RE and Joklik WK. (1974). Virology, 58,  86 – 100.  	NO_MATCH
	Uht RM, Anderson CM, Webb P and Kushner PJ. (1997).  Endocrinology, 138, 2900 – 2908.  	NO_MATCH
	Varner JA and Cheresh DA. (1996). Curr. Opin. Cell. Biol., 8,  724 – 730.  	NO_MATCH
	Wahrman MZ, Gagnier SE, Kobrin DR, Higgins PJ and  Augenlicht LH. (1985). Tumour. Biol., 6, 41 – 56.  	NO_MATCH
	Werb Z, Tremble PM, Behrendtsen O, Crowley E and  Damsky CH. (1989). J. Cell. Biol., 109, 877 – 889.  	NO_MATCH
	Wu C. (1997). Histol. Histopathol., 12, 233 – 240.  	NO_MATCH
	Yamada KM, Kennedy DW, Yamada SS, Gralnick H, Chen  WT and Akiyama SK. (1990). Cancer. Res., 50, 4485 –  4496.  	NO_MATCH
	Yamada KM, Yamada SS and Pastan I. (1976). Proc. Natl.  Acad. Sci. USA., 73, 1217 – 1221.  	NO_MATCH
	Young PR, McLaughlin MM, Kumar S, Kassis S, Doyle  ML, McNulty D, Gallagher TF, Fisher S, McDonnell PC,  	NO_MATCH
	Carr SA, Huddleston MJ, Seibel G, Porter TG, Livi GP,  	NO_MATCH
	Adams JL and Lee JC. (1997). J. Biol. Chem., 272, 12116 –  12121.  	NO_MATCH
	Zhang Q, Checovich WJ, Peters DM, Albrecht RM and  Mosher DF. (1994). J. Cell. Biol., 127, 1447 – 1459.  	NO_MATCH
	Zhang Q, Magnusson MK and Mosher DF. (1997). Mol.  Biol. Cell., 8, 1415 – 1425.  	NO_MATCH
	Zhong C, Chrzanowska-Wodnicka M, Brown J, Shaub A,  Belkin AM and Burridge K. (1998). J. Cell. Biol., 141,  539 – 551.  	NO_MATCH
	Zhu X, Ohtsubo M, Bohmer RM, Roberts JM and Assoian  RK. (1996). J. Cell. Biol., 133, 391 – 403.  	NO_MATCH
j.1432-1327.2000.01418.x.pdf
	1. Wolff, I.A. (1966) Seed lipids. Seed triglyceride oils are chemically  diverse, scientifically interesting, and versatile in utility. Science 154,  1140±1149.  	NO_MATCH
	2. Shanklin, J. & Cahoon, E.B. (1998) Desaturation and related modifi cations of fatty acids. Annu. Rev. Plant Physiol. Plant Mol. Biol.  49, 611±641.  	NO_MATCH
	3. Girke, T., Sperling, P. & Heinz, E. (1998) Cloning of desaturases with  new specificities. In Advances in Plant Lipid Research (SaÂnchez, J.,  CerdaÂ-Olmedo, E. & MartÂõnez-Force, E., eds), pp. 103±109.  Secretariado de Publicaciones de la Universidad de Sevilla, Seville,  Spain.  	NO_MATCH
	4. van de Loo, F.J., Broun, P., Turner, S. & Somerville, C. (1995) An  oleate 12-hydroxylase from Ricinus communis L. is a fatty acyl  desaturase homologue. Proc. Natl Acad. Sci. USA 92, 6743±6747.  	7624314
	5. Broun, P., Boddupalli, S. & Somerville, C. (1998) A bifunctional oleate  12-hydroxylase: desaturase from Lesquerella fendleri. Plant J. 13,  201±210.  	9680976
	6. Broun, P., Shanklin, J., Whittle, E. & Somerville, C. (1998) Catalytic  plasticity of fatty acid modification enzymes underlying chemical  diversity of plant lipids. Science 282, 1315±1317.  	9812895
	7. Haigh, W.G., Morris, L.J. & James, A.T. (1968) Acetylenic acid  biosynthesis in Crepis rubra. Lipids 3, 307±312.  	NO_MATCH
	8. Lee, M., Lenman, M., Banaú, A., Bafor, M., Singh, S., Schweizer, M.,  Nilsson, R., Liljenberg, C., Dahlqvist, A., Gummeson, P.-O., SjoÈdahl, S., Green, A. & Stymne, S. (1998) Identification of non-heme diiron  proteins that catalyze triple bond and epoxy group formation. Science  280, 915±918.  	9572738
	9. Kohn, G., Hartman, E., Stymne, S. & Beutelmannn, J. (1994) Biosyn thesis of acetylenic fatty acids in the moss Ceratodon purpureus  (Hedw.) Brid.*. J. Plant Physiol. 144, 265±271.  	NO_MATCH
	10. Cahoon, E.B., Carlson, T.J., Ripp, K.G., Schweiger, B.J., Cook, G.A.,  Hall, S.E. & Kinney, A.J. (1999) Biosynthetic origin of conjugated  double bonds: Production of fatty acid components of high-value  drying oils in transgenic soybean embryos. Proc. Natl Acad. Sci. USA  96, 12935±12940.  	10536026
	11. Fritsche, K., Hornung, E., Peitzsch, N., Renz, A. & Feussner, I. (1999)  Isolation and characterization of a calendic producing (8,11) linoleoyl desaturase. FEBS Lett 462, 249±253.  	10622705
	12. Wallis, J.G. & Browse, J. (1999) The D8-desaturase of Euglena  gracilis: an alternative pathway for synthesis of 20-carbon poly unsaturated fatty acids. Arch. Biochem. Biophys. 365, 307±316.  	10328826
	13. Napier, J., Sayanova, O., Sperling, P. & Heinz, E. (1999) A growing  family of cytochrome b5-domain fusion proteins. Trends Plant Sci. 4,  2±4.  	NO_MATCH
	14. Pasentsis, K., Paulo, N., Algarra, P., Dittrich, P. & ThuÈmmler, F. (1998)  Characterization and expression of the phytochrome gene family in  the moss Ceratodon purpureus. Plant J. 13, 51±61.  	9680964
	15. Riggs, M.G. & McLachlan, A. (1986) A simplified screening procedure  for large numbers of plasmid minipreparations. Biotechniques 4,  310±313.  	NO_MATCH
	16. Dohmen, R.J., Strasser, A.W.M., HoÈner, C.B. & Hollenberg, C.P.  (1991) An efficient transformation procedure enabling long-term  storage of competent cells of various yeast genera. Yeast 7, 691±692.  	1776359
	17. Ausubel, F.M., Brent, R., Kingston, R.E., Moore, D.D., Seidman, J.G.,  Smith, J.A., Struhl, K., Albright, L.M., Coen, D.M. & Varki, A.  (1995). Current Protocols in Molecular Biology. John Wiley & Sons.  New York, USA.  	NO_MATCH
	18. Avery, S.V., Howlett, N.G. & Radice, S. (1996) Copper toxicity towards  S. cerevisiae: dependence on plasma membrane fatty acid composi tion. Appl. Environ. Microbiol. 62, 3960±3966.  	8899983
	19. Girke, T., Schmidt, H., ZaÈhringer, U., Reski, R. & Heinz, E. (1998)  Identification of a novel D6-acyl-group desaturase by targeted gene  disruption in Physcomitrella patens. Plant J. 15, 39±48.  	9744093
	20. Christie, W.W. (1998) Mass spectrometry of fatty acids with methylene interrupted ene-yne systems. Chem. Phys. Lipids 94, 35±41.  	NO_MATCH
	21. Huang, Y.S., Chaudhary, S., Thurmond, J.M., Bobik, E.G. Jr, Yuan, L.,  Chan, G.M., Kirchner, S.J., Mukerji, P. & Knutzon, D.S. (1999)  Cloning of D12- and D6-desaturases from Mortierella alpina and  recombinant production of g-linolenic acid in S. cerevisiae. Lipids  34, 649±659.  	NO_MATCH
	22. Sayanova, O., Smith, M.A., Lapinskas, P., Stobart, A.K., Dobson, G.,  Christie, W.W., Shewry, P.R. & Napier, J.A. (1997) Expression of a  borage desaturase cDNA containing an N-terminal cytochrome b5  domain results in the accumulation of high levels of D6-desaturated  fatty acids in transgenic tobacco. Proc. Natl Acad. Sci. USA 94,  4211±4216.  	9108131
	23. Napier, J.A., Hey, S.J., Lacey, D.J. & Shewry, P.R. (1998) Identification  of a Caenorhabditis elegans D6-fatty-acid-desaturase by heterlogous  expression in S. cerevisiae. Biochem. J. 330, 611±614.  	9480865
	24. Cho, H.P., Nakamura, M.T. & Clarke, S.D. (1999) Cloning, expression,  and nutritional regulation of the mammalian D-6-desaturase. J. Biol.  Chem. 274, 471±477.  	9867867
	25. Reddy, A.S., Nuccio, M.L., Gross, L.M. & Thomas, T.L. (1993)  Isolation of a D6-desaturase gene from the cyanobacterium  Synechocystis sp. strain PCC 6803 by gain-of-function expression  in Anabaena sp. strain PCC 7120. Plant Mol. Biol. 27, 293±300.  	8389613
	26. Murata, N., Deshnium, P. & Tasaka, Y. (1996) Biosynthesis of  g-linolenic acid in the cyanobacterium Spirulina platensis. In  g-Linolenic Acid, Metabolism and its Roles in Nutrition and  Medicine (Huang, Y. & Milles, D.E., eds), pp. 22±32. AOC Press,  Champaign, IL, USA.  	NO_MATCH
	27. Lederer, F. (1994) The cytochrome b5-fold: an adaptable module.  Biochimie 76, 674±692.  	7893819
	28. Sperling, P., Schmidt, H. & Heinz, E. (1995) A cytochrome b5 containing fusion protein similar to acyl lipid desaturases. Eur. J.  Biochem. 232, 798±805.  	7588718
	29. Kohn, G., Vierengel, A., Vandekerkhove, O. & Hartmann, E. (1987)  9-Octadecen-6-ynoic acid from Riccia fluitans. Phytochemistry 26,  2101±2102.  	NO_MATCH
	30. Fay, L. & Richli, U. (1991) Location of double bonds in polyunsatu rated fatty acids by gas chromatography-mass spectrometry after  4,4-dimethyloxazoline derivatization. J. Chromatogr. 541, 89±98.  	NO_MATCH
	31. AÊ ndersson, B., Anderson, W.H., Chipault, J.R., Ellison, E.C., Fenton,  S.W., Gellerman, J.L., Hawkins, J.M. & Schlenk, H. (1974) 9,12,15 Octadecatrien-6-ynoic acid, a new acetylenic acid from mosses.  Lipids 9, 506±511.  	1160525
	32. Mitchell, A.G. & Martin, C.E. (1995) A novel cytochrome b5-like  domain is linked to the carboxyl terminus of the S. cerevisiae D9 fatty  acid desaturase. J. Biol. Chem. 270, 29766±29772.  	8530368
	33. Sayanova, O., Shewry, P.R. & Napier, J.A. (1999) Histidine-41 of the  cytochrome b5 domain of the borage D 6 fatty acid desaturase is  essential for enzyme activity. Plant Physiol. 121, 641±646.  	10517856
	34. Heinz, E. (1993) Biosynthesis of polyunsaturated fatty acids. In Lipid  Metabolism in Plants (Moore, T.S. Jr, ed.), pp. 33±89. CRC Press,  Boca Raton, FL.  	NO_MATCH
	35. Sperling, P., ZaÈhringer, U. & Heinz, E. (1998) A sphingolipid  desaturase from higher plants. Identification of a new cytochrome  b5 fusion protein. J. Biol. Chem. 273, 28590±28596.  	9786850
	36. Meckenstock, R.U., Krieger, R., Ensign, S., Kroneck, P.M.H. & Schink,  B. (1999) Acetylene hydratase of Pelobacter acetylenicus. Molecular  and spectroscopic properties of the tungsten iron-sulfur enzyme.  Eur. J. Biochem. 264, 176±182.  	10447686
j.1432-1327.2000.01408.x.pdf
	1. Mauro, A. (1961) Satellite cell of skeletal muscle fibers. J. Biophys.  Biochem. Cytol. 9, 493±498.  	13768451
	2. Plaghki, L. (1985) Regeneration and myogenesis of striated muscle.  J. Physiol. (Paris) 80, 51±110.  	2933512
	3. Zomzely-Neurath, C.E. (1983) Enolase. Enzymes in the Nervous  System. Handbook Neurochem. 4, 403±433.  	NO_MATCH
	4. Lucas, M., Goblet, C., Keller, A., LamandeÂ, N., Gros, F., Whalen, R.G.  & Lazar, M. (1992) Modulation of embryonic and muscle-specific  enolase gene products in the developing mouse hindlimb.  Differentiation 51, 1±7.  	1280607
	5. Keller, A., Ott, M.O., LamandeÂ, N., Lucas, M., Gros, F., Buckingham,  M. & Lazar, M. (1992) Activation of the gene encoding the glycolytic  enzyme beta-enolase during early myogenesis precedes an  increased expression during fetal muscle development. Mech.  Dev. 38, 41±54.  	1525038
	6. Kato, K., Shimizu, A., Semba, R. & Satoh, T. (1985) Tissue  distribution, developmental profiles and effect of denervation on  enolase isozymes in rat muscles. Biochim. Biophys. Acta 841, 50±58.  	3893549
	7. Merkulova, T., Thornell, L.E., Butler-Browne, G., Oberlin, C., Lucas,  M., LamandeÂ, N., Lazar, M. & Keller, A. (1999) The beta enolase  subunit displays three different patterns of microheterogeneity in  human striated muscle. J. Muscle Res. Cell. Motil. 20, 55±63.  	10360234
	8. Keller, A., Rouzeau, J.D., Farhadian, F., Wisnewsky, C., Marotte, F.,  LamandeÂ, N., Samuel, J.L., Schwartz, K., Lazar, M. & Lucas, M.  (1995) Differential expression of alpha and beta-enolase genes during  rat heart development and hypertrophy. Am. J. Physiol. Heart Circ.  Physiol. 38, H1843±H1851.  	8594891
	9. Nozais, M., Merkulova, T., Keller, A., Janmot, C., LompreÂ, A.M.,  d'Albis, A. & Lucas, M. (1999) Denervation of rabbit gastrocnemius  and soleus muscles ± effect on muscle-specific enolase. Eur. J.  Biochem. 263, 195±201.  	10429204
	10. Merkulova, T., Keller, A., Oliviero, P., Marotte, F., Samuel, J.-L.,  Rappaport, L., LamandeÂ, N. & Lucas, M. (2000) Thyroid hormones  modulate differentially isozymic enolase gene expressions during  rat skeletal and cardiac muscle development. Am. J. Physiol. 278,  E330±E339.  	NO_MATCH
	11. Discher, D., Bishopric, N., Wu, X., Peterson, C. & Webster, K. (1998)  Hypoxia regulates b-enolase and pyruvate kinase-M promoters by  modulating Sp1/Sp3 binding to a conserved GC element. J. Biol.  Chem. 273, 26087±26093.  	9748288
	12. Semenza, G., Jiang, B.-H., Leung, S., Passantino, R., Concordet, J.-P.,  Maire, P. & Giallongo, A. (1996) Hypoxia response elements in the  aldolase A, enolase 1, and lactate dehydrogenase A gene promoters  contain essential binding sites for hypoxia-inducible factor 1. J. Biol.  Chem. 271, 32529±32537.  	8955077
	13. Merkulova, T., Lucas, M., Jabet, C., LamandeÂ, N., Rouzeau, J.D.,  Gros, F., Lazar, M. & Keller, A. (1997) Biochemical characterization  of the mouse muscle-specific enolase: Developmental changes in  electrophoretic variants and selective binding to other proteins.  Biochem. J. 323, 791±800.  	9169614
	14. Knull, H. & Minton, A. (1996) Structure within eukaryotic cytoplasm  and its relationship to glycolytic metabolism. Cell Biochem. Funct.  14, 237±248.  	8952042
	15. Wojtas, K., Slepecky, N., von Kalm, L. & Sullivan, D. (1997) Flight  muscle function in Drosophila requires colocalization of glycolytic  enzymes. Mol. Biol. Cell 8, 1665±1675.  	9307964
	16. Foucault, G., Vacher, M., Cribier, S. & Arrio-Dupont, M. (2000)  Interactions between b-enolase and creatine kinase in the cytosol of  skeletal muscle cells. Biochem. J. 346, 127±131.  	10657248
	17. Foucault, G., Vacher, M., Merkulova, T., Keller, A. & Arrio-Dupont, M.  (1999) Presence of enolase in the M-band of skeletal muscle and  possible indirect interaction with the cytosolic muscle isoform of  creatine kinase. Biochem. J. 338, 115±121.  	9931306
	18. Angelov, D.N., Neiss, W.F., Gunkel, A., Guntinaslichius, O. &  Stennert, E. (1994) Axotomy induces intranuclear immuno localization of neuron-specific enolase in facial and hypoglossal  neurons of the rat. J. Neurocytol. 23, 218±233.  	8035205
	19. Kherif, S., Lafuma, C., Dehaupas, M., Lachkar, S., Fournier, J.,  VerdieÁre-Sahuque, M., Fardeau, M. & Alameddine, H. (1999)  Expression of matrix metalloproteinases 2 and 9 in regenerating  skeletal muscle: a study in experimentally injured and mdx muscles.  Dev. Biol. 205, 158±170.  	9882504
	20. Bradford, M.M. (1976) A rapid and sensitive method for the  quantitation of microgram quantities of proteins utilizing the  principle of protein-dye binding. Anal. Biochem. 72, 248±254.  	942051
	21. Keller, A., Scarna, H., Mermet, A. & Pujol, J.F. (1981) Biochemical  and immunological properties of the mouse brain enolases purified by  a simple method. J. Neurochem. 36, 1389±1397.  	7264635
	22. CreÂminon, C., Pilard, F., Grassi, J., Perly, B. & Pradelles, P. (1994) A  sensitive and specific enzyme immunoassay for cyclomaltoheptaose  and some derivatives. Carbohydr. Res. 258, 179±186.  	8039174
	23. McLaughlin, L., Wei, V., Stockman, P., Leahy, K., Needleman, P.,  Grassi, J. & Pradelles, P. (1987) Development, validation and  application of an enzyme immunoassay (EIA) of atriopeptin.  Biochem. Biophys. Res. Commun. 144, 469±476.  	2953338
	24. Pradelles, P., Grassi, J., Chabardes, D. & Guiso, N. (1989) Enzyme  immunoassays of adenosine cyclic 3 0,5 0-monophosphate and guano sine cyclic 3 0,5 0-monophosphate using acetylcholinesterase. Anal.  Chem. 61, 447±453.  	2541635
	25. Ellman, G., Courtney, K., Andres, V. & Featherstone, R. (1961) A new  and rapid colorimetric determination of acetylcholine esterase  activity. Biochem. Pharmacol. 7, 88±95.  	13726518
	26. d'Albis, A., Couteaux, R., Janmot, C., Roulet, A. & Mira, J.-C. (1988)  Regeneration after cardiotoxin injury of innervated and denervated  slow and fast muscles of mammals. Myosin isoform analysis. Eur.  J. Biochem. 174, 103±110.  	3371354
	27. Ovadi, J. & Srere, P. (1996) Metabolic consequences of enzyme  interactions. Cell Biochem. Funct. 14, 249±258.  	8952043
	28. DoÈlken, G., Leisner, E. & Pette, D. (1975) Immunofluorescent  localization of glycogenolytic and glycolytic enzyme proteins and  of malate dehydrogenase isozymes in cross-striated skeletal muscle  and heart of the rabbit. Histochemistry 43, 113±121.  	124716
	29. Dechesne, C. & Keller, A. (1996) Differential a enolase immuno reactivity in the two neuron types of the rat spiral ganglion during  postnatal development. Comparison with neurofilament protein  immunoreactivity. Auditory Neurosci. 2, 33±46.  	NO_MATCH
	30. Popanda, O., Fox, G. & Thielmann, H. (1998) Modulation of DNA  polymerase a, d and : by lactate dehydrogenase and 3-phos phoglycerate kinase. Biochim. Byophys. Acta 1397, 102±117.  	9545551
	31. Green, G., Girardot, R., Baldacini, O., Ledig, M. & Monteil, H. (1993)  Characterization of enolase from Clostridium difficile. Curr.  Microbiol. 26, 53±56.  	NO_MATCH
	32. al Giery, A. & Brewer, J.M. (1992) Characterization of the interaction  of yeast enolase with polynucleotides. Biochim. Biophys. Acta 1159,  134±140.  	1382613
	33. Babbitt, P.C., Hasson, M.S., Wedekind, J.E., Palmer, D.R., Barrett,  W.C., Reed, G.H., Rayment, I., Ringe, D., Kenyon, G.L. & Gerlt, J.A.  (1996) The enolase superfamily: a general strategy for enzyme catalyzed abstraction of the alpha-protons of carboxylic acids.  Biochemistry 35, 16489±16501.  	8987982
	34. Gorsich, S.W., Barrows, V., Halbert, J. & Farrar, W.W. (1999)  Purification and properties of gg-enolase from pig brain. J. Protein  Chem. 18, 103±115.  	10071935
	35. Hattori, T., Takei, N., Mizuno, Y., Kato, K. & Kohsaka, S. (1995)  Neurotrophic and neuroprotective effects of neuron-specific enolase  on cultured neurons from embryonic rat brain. Neurosci. Res. 21,  191±198.  	7753500
	36. Piatigorsky, J. & Wistow, G. (1989) Enzyme/crystallins: gene sharing  as an evolutionary strategy. Cell 57, 197±199.  	2649248
	37. Redlitz, A., Fowler, B., Plow, E. & Miles, L. (1995) The role of an  enolase-related molecule in plasminogen binding to cells. Eur. J.  Biochem. 227, 407±415.  	7851415
	38. Haimoto, H., Takahashi, Y., Koshikawa, T., Nagura, H. & Kato, K.  (1985) Immunohistochemical localization of gamma-enolase in  normal human tissues other than nervous and neuroendocrine tissues.  Lab. Invest. 52, 257±263.  	3974199
	39. Couteaux, R., Mira, J.C. & d'Albis, A. (1988) Regeneration of  muscles after cardiotoxin injury. I. Cytological aspects. Biol. Cell  62, 171±182.  	3390626
j.1432-1327.2000.01405.x.pdf
	1. Matthews, D.M. (1991) Protein Absorption. Development and Present  State of the Subject. Wiley-Liss, New York.  	NO_MATCH
	2. Ganapathy, V., Brandsch, M. & Leibach, F.H. (1994) Physiology of the  Gastro-Intestinal Tract (Johnson, L.R., ed.), 3rd edn, pp. 1773±1794.  Raven Press, New York.  	NO_MATCH
	3. Temple, C.S., Stewart, A.K., Meredith, D., Lister, N.A., Morgan, K.M.,  Collier, I.D., Vaughan-Jones, R.D., Boyd, C.A.R., Bailey, P.D. &  Bronk, J.R. (1998) Peptide mimics as substrates for the intestinal  peptide transporter. J. Biol. Chem. 273, 20±22.  	9417040
	4. Borner, V., Fei, Y.J., Hartrodt, B., Ganapathy, V., Leibach, F.H.,  Neubert, K. & Brandsch, M. (1998) Transport of amino acid aryl  amides by the intestinal H1/peptide cotransport system, PEPT1.  Eur. J. Biochem. 255, 698±702.  	9738910
	5. Doring, F., Will, J., Amasheh, S., Clauss, W., Ahlbrecht, H. & Daniel,  H. (1998) Minimal molecular determinants of substrates for  recognition by the intestinal peptide transporter. J. Biol. Chem. 273,  23211±23218.  	9722551
	6. Lister, N.A., Sykes, A.P., Bailey, P.D., Boyd, C.A.R. & Bronk,  J.R. (1994) Dipeptide transport and hydrolysis in isolated loops  of rat small intestine. Effects of stereospecificity. J. Physiol. 484,  173±182.  	7602518
	7. Guha, N., Boyd, C.A.R. & Meredith, D. (1999) Modified amino  acids and peptides as inhibitors of the rabbit peptide transporter  PepT1 expressed in Xenopus laevis oocytes. J. Physiol. 517P,  27P.  	NO_MATCH
	8. Fei, Y.J., Kanai, Y., Nussberger, S., Ganapathy, V., Leibach, F.H.,  Romero, M.F., Singh, S.M., Boron, M.F. & Hediger, M.A. (1994)  Expression cloning of a mammalian proton-coupled oligopeptide  transporter. Nature 368, 563±566.  	8139693
	9. Meredith, D. & Boyd, C.A.R. (1996) His57 is an essential  residue for the transport of the anionic dipeptide d-Phe-l-Glu  by PepT1 expressed in Xenopus laevis oocytes. J. Physiol.  497, 89P±90P.  	NO_MATCH
	10. Deves, R., Chavez, P. & Boyd, C.A.R. (1992) Identification of a new  transport system (y1L) in human erythrocytes that recognises lysine  and leucine with high affinity. J. Physiol. 454, 491±501.  	1474499
	11. Daniel, H., Morse, E.L. & Adibi, S.A. (1992) Determinants of substrate  affinity for the oligopeptide/H1 symporter in the renal brush border  membrane. J. Biol. Chem. 267, 9565±9573.  	1577796
	12. Ganapathy, M.E., Huang, W., Wang, H., Ganapathy, V. & Leibach, F.H.  (1998) Valacyclovir: a substrate for the intestinal and renal peptide  transporters PEPT1 and PEPT2. Biochem. Biophys. Res. Commun.  246, 470±475.  	9610386
	13. Miyamoto, Y., Ganapathy, V. & Leibach, F.H. (1986) Identification of  histidyl and thiol groups at the active site of rabbit renal dipeptide  transporter. J. Biol. Chem. 261, 16133±16140.  	3023343
	14. Temple, C.S., Bronk, J.R., Bailey, P.D. & Boyd, C.A.R. (1995)  Substrate-charge dependence of stoichiometry shows membrane  potential is the driving force for proton±peptide cotransport in rat  renal cortex. Eur. J. Physiol. 430, 825±829.  	7478939
	15. Terada, T., Saito, H., Mukai, M. & Inui, K.I. (1996) Identification  of the histidine residues involved in substrate recognition by a rat  H1/peptide cotransporter, PEPT1. FEBS Lett. 394, 196±200.  	8843163
	16. Fei, Y.J., Lui, W., Prasad, P.D., Kekuda, R., Oblak, T.G., Ganapathy, V.  & Leibach, F.H. (1997) Identification of the histidyl residue  obligatory for the catalytic activity of the human H1/peptide  cotransporters PEPT1 and PEPT2. Biochemistry 36, 452±460.  	9003198
	17. Meredith, D. & Boyd, C.A.R. (1995) Oligopeptide transport by  epithelial cells. J. Memb. Biol. 145, 1±12.  	7636881
	18. Terada, T., Saito, H. & Inui, K.I. (1998) Interaction of beta-lactam  antibiotics with histidine residue of rat H1/peptide cotransporters,  PEPT1 and PEPT2. J. Biol. Chem. 273, 5582±5585.  	9488685
	19. Bolger, M.B., Haworth, I.S., Yeung, A.K., Ann., D., von Grafenstein,  H., Hamm-Alvarez, S., Okamoto, C.T., Kim, K.J., Basu, S.K., Wu, S. & Lee, V.H. (1998) Structure, function, and molecular modeling  approaches to the study of the intestinal dipeptide transporter PepT1.  J. Pharmac. Sci. 87, 1286±1291.  	9811478
	20. Temple, C.S., Collier, I.D., Bronk, J.R., Bailey, P.D. & Boyd, C.A.R.  (1998) Structural requirements for non-peptide substrate binding to  the epithelial proton-coupled oligopeptide transporter. J. Physiol.  511P, 26P±27P.  	NO_MATCH
	21. Doring, F., Walter, J., Will, J., Focking, M., Boll, M., Amasheh, S.,  Clauss, W. & Daniel, H. (1998) Delta-aminolevulinic acid transport  by intestinal and renal peptide transporters and its physiological and  clinical implications. J. Clin. Invest. 101, 2761±2767.  	9637710
j.1432-1327.2000.01399.x.pdf
	1. Peck, H.D. & Gest, H. (1957) Formic dehydrogenase and the hydro genlyase enzyme complex in coli-aerogenes bacteria. J. Bacteriol. 73,  706±721.  	13449036
	2. BoÈhm, R., Sauter, M. & BoÈck, A. (1990) Nucleotide sequence and  expression of an operon in Escherichia coli coding for formate  hydrogenlyase components. Mol. Microbiol. 4, 231±243.  	2187144
	3. Lutz, S., Jacobi, A., Schlensog, V., BoÈhm, R., Sawers, G. & BoÈck, A.  (1991) Molecular characterization of an operon (hyp) necessary for  the activity of the three hydrogenase isoenzymes in Escherichia coli.  Mol. Microbiol. 5, 123±135.  	1849603
	4. Pecher, A., Zinoni, F. & BoÈck, A. (1985) The seleno-polypeptide of  formic dehydrogenase (formate hydrogen-lyase linked) from  Escherichia coli: genetic analysis. Arch. Microbiol. 141, 359±363.  	3160320
	5. Maier, T., Binder, U. & BoÈck, A. (1996) Analysis of the hydA locus of  Escherichia coli: two genes (hydN and hypF ) involved in formate and  hydrogen metabolism. Arch. Microbiol. 165, 333±341.  	8661925
	6. Sankar, P., Lee, J.H. & Shanmugam, K.T. (1988) Gene-product  relationships of fhlA and fdv genes of Escherichia coli. J. Bacteriol.  170, 5440±5445.  	3056900
	7. Schlensog, V. & BoÈck, A. (1990) Identification and sequence analysis  of the gene encoding the transcriptional activator of the formate  hydrogenlyase system of Escherichia coli. Mol. Microbiol. 4,  1319±1327.  	2280686
	8. Sauter, M., BoÈhm, R. & BoÈck, A. (1992) Mutational analysis of the  operon (hyc) determining hydrogenase 3 formation in Escherichia  coli. Mol. Microbiol. 6, 1523±1532.  	1625581
	9. Birkmann, A. & BoÈck, A. (1989) Characterization of a cis regulatory  DNA element necessary for formate induction of the formate  dehydrogenase gene ( fdhF ) of Escherichia coli. Mol. Microbiol. 3,  187±195.  	2668685
	10. Birkmann, A., Sawers, R.G. & BoÈck, A. (1987) Involvement of the  ntrA gene product in the anaerobic metabolism of Escherichia coli.  Mol. Gen. Genet. 210, 535±542.  	3323848
	11. Lutz, S., BoÈhm, A., Beier, A. & BoÈck, A. (1990) Characterisation of  divergent NtrA-dependend promotors in the anaerobically expressed  gene cluster coding for hydrogenase 3 components of Escherichia  coli. Mol. Microbiol. 4, 13±20.  	2181234
	12. Schlensog, V., Lutz, S. & BoÈck, A. (1994) Purification and DNA binding properties of FHLA, the transcriptional activator of the  formate hydrogenlyase system from Escherichia coli. J. Biol. Chem.  269, 19590±19596.  	8034727
	13. Hopper, S. & BoÈck, A. (1995) Effector-mediated stimulation of ATPase  activity by the s54-dependent transcriptional activator FHLA from  Escherichia coli. J. Bacteriol. 177, 2798±2803.  	7751289
	14. Hopper, S., Korsa, I. & BoÈck, A. (1996) The nucleotide concentration  determines the specificity of in vitro transcription activation by the  s54-dependent activator FhlA. J. Bacteriol. 178, 199±203.  	8550417
	15. Morett, E. & Segovia, L. (1993) The s54 bacterial enhancer-binding  protein family: mechanism of action and phylogenetic relationship of  their funcional domains. J. Bacteriol. 175, 6067±6074.  	8407777
	16. Shingler, V. (1996) Signal sensing by s54-dependent regulators:  derepression as a control mechanism. Mol. Microbiology 19,  409±416.  	8830233
	17. Weiss, V. & Magasanik, B. (1988) Phosphorylation of nitrogen  regulator I (NRI) of Escherichia coli. Proc. Natl Acad. Sci. USA  85, 8919±8923.  	2848245
	18. Henderson, N., Austin, S.A. & Dixon, R.A. (1989) Role of metal ions  in negative regulation of nitrogen fixation by the nifL gene product  from Klebsiella pneumoniae. Mol. Gen. Genet. 216, 484±491.  	NO_MATCH
	19. Pavel, H., Forsman, M. & Shingler, V. (1994) An aromatic effector  specificity mutant of the transcriptional regulator DmpR overcomes  the growth constraints of Pseudomonas sp. strain CF600 on para substituted methylphenols. J. Bacteriol. 176, 7550±7557.  	8002579
	20. Abril, M.A., Michan, C., Timmis, K.N. & Ramos, J.L. (1989)  Regulator and enzyme specificities of the TOL plasmid-encoded  upper pathway for degradation of aromatic hydrocarbons and  expansion of the substrate range of the pathway. J. Bacteriol. 171,  6782±6790.  	2687253
	21. Shingler, V. & Moore, T. (1994) Sensing of aromatic compounds by the  DmpR transcriptional activator of phenol-catabolizing Pseudomonas  sp. strain CF600. J. Bacteriol. 176, 1555±1560.  	8132448
	22. Weiss, D.S., Batut, J., Klose, K.E., Keener, J. & Kustu, S. (1991) The  phosphorylated form of the enhancer-binding protein NTRC has an  ATPase acivity that is essential for activation of transcription. Cell 67,  155±167.  	1833069
	23. Cornish, E.C., Argyropoulos, V.P., Pittard, J. & Davidson, B.E. (1986)  Structure of the Escherichia coli K12 regulatory gene tyrR.  Nucleotide sequence and sites of initiation of transcription and  translation. J. Biol. Chem. 261, 403±410.  	3001057
	24. North, A.K., Klose, K.E., Stedman, K.M. & Kustu, S. (1993)  Prokaryotic enhancer-binding proteins reflect eukaryote-like mod ularity: the puzzle of nitrogen regulatory protein C. J. Bacteriol. 175,  4267±4273.  	8331061
	25. Pelton, J.G., Kustu, S. & Wemmer, D.E. (1999) Solution structure  of the DNA-binding domain of NtrC with three alanine  substitutions. J. Mol. Biol. 292, 1095±1110.  	10512705
	26. PeÂrez-MartÂõn, J. & Lorenzo, V. (1996) In vitro activities of an  N-terminal truncated form of XylR, a s54-dependent transcriptional  activator of Pseudomonas putida. J. Mol. Biol. 258, 575±587.  	8636993
	27. Shingler, V. & Pavel, H. (1995) Direct regulation of the ATPase activity  of the transcriptional activator DmpR by aromatic compounds. Mol.  Microbiol. 17, 505±513.  	8559069
	28. FernaÂndez, S., Lorenzo, V. & PeÂrez-MartÂõn, J. (1995) Activation of the  transcriptional regulator XylR of Pseudomonas putida by  release of repression between functional domains. Mol. Microbiol.  16, 205±213.  	7565083
	29. Lee, J.H., Scholl, D., Nixon, B.T. & Hoover, T.R. (1994) Constitutive  ATP hydrolysis and transcription activation by a stable, truncated  form of Rhizobium meliloti DctD, a sigma 54-dependent transcrip tional activator. J. Biol. Chem. 269, 20401±20409.  	8051135
	30. Delgado, A., Salto, R., MarqueÂs, S. & Ramos, J.L. (1995) Single amino  acid changes in the signal reception domain of XylR result in  mutations that stimulate transcription in the absence of effectors.  J. Biol. Chem. 270, 5144±5150.  	7890623
	31. PeÂrez-MartÂõn, J. & Lorenzo, V. (1995) The amino-terminal  domain of the procaryotic enhancer-binding protein XylR is a  specific intramolecular repressor. Proc. Natl Acad. Sci. USA  92, 9392±9396.  	7568139
	32. Korsa, I. & BoÈck, A. (1997) Characterization of fhlA mutations  resulting in ligand ± independent transcriptional activation and ATP  hydrolysis. J. Bacteriol. 179, 41±45.  	8981978
	33. Begg, Y.A., Whyte, J.A. & Haddock, B.Y. (1977) The identifica tion of mutants of Escherichia coli deficient in formate  dehydrogenase and nitrate reductase activities using dye indicator  plates. FEMS Microbiol. Lett. 2, 47±50.  	NO_MATCH
	34. Balch, W.E. & Wolfe, R.S. (1976) New approach to the  cultivation of methanogenic bacteria: 2-mercaptoethanesulfonic  acid (HS-CoM)-dependent growth of Methanobacterium ruminan tium in a pressurized atmosphere. Appl. Environ. Microbiol. 32,  781±791.  	827241
	35. Miller, J.H. (1972) Experiments in Molecular Genetics. Cold Spring  Harbor Laboratory Press, Cold Spring Harbor, New York.  	NO_MATCH
	36. Sambrook, J., Fritsch, E.F. & Maniatis, T. (1989) Molecular Cloning: a  Laboratory Manual. Cold Spring Harbor Laboratory Press, Cold  Spring Harbor, New York.  	NO_MATCH
	37. Fiedler, S. & Wirth, R. (1988) Transformation of bacteria with plasmid  DNA by electroporation. Anal. Biochem. 170, 38±44.  	3133958
	38. Dixon, W.J., Hayes, J.J., Levin, J.R., Weidner, M.F., Dombroski, B.A.  & Tullius, T.D. (1991) Hydroxyl radical footprinting. Methods  Enzymol. 208, 380±413.  	1664026
	39. Schickor, P. & Heumann, H. (1994) Hydroxyl radical footprinting. In  DNA±Protein Interactions: Principles and Protocols (Kneanle, G.G.,  ed.), pp. 21±32. Humana Press Inc, Totowa.  	8004196
	40. Maxam, A.M. & Gilbert, W. (1977) A new method for sequencing  DNA. Proc. Natl Acad. Sci. USA 74, 560±564.  	265521
	41. Whitaker, J.R. & Granum, P.E. (1980) An absolute method for protein  determination based on difference in absorbance at 235 and 280 nm.  Anal. Biochem. 109, 156±159.  	7469012
	42. Laemmli, U.K. (1970) Cleavage of structural proteins during  the assembly of the head of bacteriophage T4. Nature 227,  680±685.  	5432063
	43. Fiedler, G., Pajatsch, M. & BoÈck, A. (1996) Genetics of a novel starch  utilisation pathway present in Klebsiella oxytoca. J. Mol. Biol. 256,  279±291.  	8594196
	44. Mills, D.M., Bajaj, V. & Lee, C.A. (1995) A 40 kb chromosomal  fragment encoding Salmonella typhimurium invasion genes is absent  from the corresponding region of the Escherichia coli K-12  chromosome. Mol. Microbiol. 15, 749±759.  	7783645
	45. Hopper, S. (1995) Das Formiat-Regulon von Escherichia coli: Unter suchungen zur FhlA-abhaÈngigen Regulation. PhD Thesis, Ludwig Maximilians-UniversitaÈt, MuÈnchen.  	NO_MATCH
	46. Bantscheff, M., Weiss, V. & Glocker, M.O. (1999) Identification  of linker regions and domain borders of the transcription  activator protein NtrC from Escherichia coli by limited  proteolysis, in-gel digestion, and mass spectrometry. Biochemistry  38, 11012±11020.  	10460156
	47. Flashner, Y., Weiss, D.S., Keener, J. & Kustu, S. (1995) Constitutive  forms of the enhancer-binding protein NtrC: evidence that  essential oligomerization determinants lie in the central activation  domain. J. Mol. Biol. 249, 700±713.  	7602583
	48. PeÂrez-MartÂõn, J. & Lorenzo, V. (1996) Physical and functional analysis  of the prokaryotic enhancer of the s54-promotors of the TOL plasmid  of Pseudomonas putida. J. Mol. Biol. 258, 562±574.  	8636992
	49. Csonka, L.N. (1981) Proline over-production results in enhanced  osmotolerance in Salmonella typhimurium. Mol. Gen. Genet. 182,  82±86.  	7022140
	50. Bender, H. (1977) Cyclodextrin glucanotransferase from Klebsiella  pneumoniae. 2. Significance of the enzyme for the metabolism of  cyclodextrins by Klebsiella pneumoniae M 5 al. Arch. Microbiol. 113,  49±56.  	329783
	51. Casadaban, M.J. & Cohen, S.N. (1979) Lactose genes fused to  exogenous promoters in one step using a Mu-lac bacteriophage: in  vivo probe for transcriptional control sequences. Proc. Natl Acad.  Sci. USA 76, 4530±4533.  	159458
	52. Hopper, S., Babst, M., Schlensog, V., Fischer, H.M., Hennecke, H. &  BoÈck, A. (1994) Regulated expression in vitro of genes coding for  formate hydrogenlyase components of Escherichia coli. J. Biol.  Chem. 269, 19597±19604.  	8034728
	53. Schlensog, V. (1993) Genetische Analyse, Struktur und Funktion des  Formiat-Hydrogen-Lyase-Aktivatorproteins (FhlA) von Escherichia  coli. PhD Thesis, Ludwig-Maximilians-UniversitaÈt, MuÈnchen.  	NO_MATCH
	54. Sawers, G. & Suppmann, B. (1992) Anaerobic induction of pyruvate  formate-lyase gene expression is mediated by the ArcA and FNR  proteins. J. Bacteriol. 174, 3474±3478.  	1592804
	55. Yanisch-Perron, C., Vieira, J. & Messing, J. (1985) Improved M13  phage cloning vectors and host strains: nucleotide sequences of the  M13mp18 and pUC19 vectors. Gene 33, 103±109.  	2985470
	56. Studier, F.W. & Moffatt, B.A. (1986) Use of bacteriophage T7 RNA  polymerase to direct selective high-level expression of cloned genes.  J. Mol. Biol. 189, 113±130.  	3537305
	57. Bolivar, F., Rodriguez, R.L., Greene, P.J., Betlach, M.C., Heynecker,  H.L. & Boyer, H.W. (1977) Construction and characterization of  new cloning vehicles. II. A multipurpose cloning system. Gene 2,  95±113.  	344137
	58. Tabor, S. & Richardson, C.C. (1985) A bacteriophage T7 RNA  polymerase/promoter system for controlled exclusive expression of  specific genes. Proc. Natl Acad. Sci. USA 82, 1074±1078.  	3156376
	59. Martinez, E., Bartolome, B. & de la Cruz, F. (1988) pACYC184 derived cloning vectors containing the multiple cloning site and lacZ  alpha reporter gene of pUC8/9 and pUC18/19 plasmids. Gene (Amst.)  68, 159±162.  	2851489
2_ftp.pdf
J Immunol-2000-Baurain-6057-66.pdf
	1. Van den Eynde, B., and P. van der Bruggen. 1997. T cell-defined tumor antigens.  Curr. Opin. Immunol. 9:684.  	9368778
	2. van der Bruggen, P., C. Traversari, P. Chomez, C. Lurquin, E. De Plaen,  B. Van den Eynde, A. Knuth, and T. Boon. 1991. A gene encoding an antigen  recognized by cytolytic T lymphocytes on a human melanoma. Science 254:1643.  	1840703
	3. De Plaen, E., K. Arden, C. Traversari, J. J. Gaforio, J.-P. Szikora, C. De Smet,  F. Brasseur, P. van der Bruggen, B. Lethe´, C. Lurquin, et al. 1994. Structure,  chromosomal localization and expression of twelve genes of the MAGE family.  Immunogenetics 40:360.  	7927540
	4. Boe¨l, P., C. Wildmann, M.-L. Sensi, R. Brasseur, J.-C. Renauld, P. Coulie,  T. Boon, and P. van der Bruggen. 1995. BAGE, a new gene encoding an antigen  recognized on human melanomas by cytolytic T lymphocytes. Immunity 2:167.  	7895173
	5. Van den Eynde, B., O. Peeters, O. De Backer, B. Gaugler, S. Lucas, and T. Boon.  1995. A new family of genes coding for an antigen recognized by autologous  cytolytic T lymphocytes on a human melanoma. J. Exp. Med. 182:689.  	7544395
	6. Wo¨lfel, T., M. Hauer, J. Schneider, M. Serrano, C. Wo¨lfel, E. Klehmann-Hieb,  E. De Plaen, T. Hankeln, K.-H. Meyer zum Bu¨schenfelde, and D. Beach. 1995.  A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a  human melanoma. Science 269:1281.  	7652577
	7. Mandruzzato, S., F. Brasseur, G. Andry, T. Boon, and P. van der Bruggen. 1997.  A CASP-8 mutation recognized by cytolytic T lymphocytes on a human head and  neck carcinoma. J. Exp. Med. 186:785.  	9271594
	8. Robbins, P. F., M. El-Gamil, Y. F. Li, Y. Kawakami, D. Loftus, E. Appella, and  S. A. Rosenberg. 1996. A mutated b-catenin gene encodes a melanoma-specific  antigen recognized by tumor infiltrating lymphocytes. J. Exp. Med. 183:1185.  	8642260
	9. Rubinfeld, B., P. Robbins, M. El-Gamil, I. Albert, E. Porfiri, and P. Polakis. 1997.  Stabilization of b-catenin by genetic defects in melanoma cell lines. Science  275:1790.  	9065403
	10. Coulie, P. G., H. Ikeda, J.-F. Baurain, and R. Chiari. 1999. Anti-tumor immunity  at work in a melanoma patient. Adv. Cancer Res. 76:213.  	10218103
	11. Lehmann, F., M. Marchand, P. Hainaut, P. Pouillart, X. Sastre, H. Ikeda, T. Boon,  and P. G. Coulie. 1995. Differences in the antigens recognized by cytolytic T cells  on two successive metastases of a melanoma patient are consistent with immune  selection. Eur. J. Immunol. 25:340.  	7875194
	12. Chiari, R., F. Foury, E. De Plaen, J.-F. Baurain, J. Thonnard, and P. G. Coulie.  1999. Two antigens recognized by autologous CTL on a melanoma result from a  single point mutation in an essential housekeeping gene. Cancer Res. 59:5785.  	10582700
	13. Coulie, P. G., F. Lehmann, B. Lethe´, J. Herman, C. Lurquin, M. Andrawiss, and  T. Boon. 1995. A mutated intron sequence codes for an antigenic peptide rec ognized by cytolytic T lymphocytes on a human melanoma. Proc. Natl. Acad.  Sci. USA 92:7976.  	7644523
	14. Espevik, T., and J. Nissen-Meyer. 1986. A highly sensitive cell line, WEHI 164  clone 13, for measuring cytotoxic factor/tumor necrosis factor from human  monocytes. J. Immunol. Methods 95:99.  	3782828
	15. Davis, L. G., M. D. Dibner, and J. F. Battey. 1986. Guanidine isothiocyanate  preparation of total RNA. In Basic Methods in Molecular Biology. L. G. Davis et  al., eds. Elsevier, New York, p. 130.  	NO_MATCH
	16. Hansen, M. B., S. E. Nielsen, and K. Berg. 1989. Re-examination and further  development of a precise and rapid dye method for measuring cell growth/cell  kill. J. Immunol. Methods 119:203.  	2470825
	17. Atherton, E., C. J. Logan, and R. C. Sheppard. 1981. Peptide synthesis. II. Pro cedures for solid phase synthesis using Na-fluorenylmethysoxycarbamylamino acid on polymide supports: synthesis of substance P and of acyl carrier protein  65–74 decapeptide. J. Chem. Soc. London Perkin Trans. 1:538.  	NO_MATCH
	18. Schutze, K., and G. Lahr. 1998. Identification of expressed genes by laser-me diated manipulation of single cells. Nat. Biotechnol. 16:737.  	9702771
	19. Altman, J. D., P. A. H. Moss, P. J. R. Goulder, D. H. Barouch,  M. G. McHeyzer-Williams, J. I. Bell, A. J. McMichael, and M. M. Davis. 1996.  Phenotypic analysis of antigen-specific T lymphocytes. Science 274:94.  	8810254
	20. Van Snick, J., A. Vink, S. Cayphas, and C. Uyttenhove. 1987. Interleukin-HP1,  a T cell-derived hybridoma growth factor that supports the in vitro growth of  murine plasmocytomas. J. Exp. Med. 165:641.  	3493321
	21. Geneve´e, C., A. Diu, J. Nierat, A. Caignard, P. Y. Dietrich, L. Ferradini,  S. Roman-Roman, F. Triebel, and T. Hercend. 1992. An experimentally validated  panel of subfamily-specific oligonucleotide primers (Va1-w29/Vb1-w24) for the  study of human T cell receptor variable V gene segment usage by polymerase  chain reaction. Eur. J. Immunol. 22:1261.  	1533591
	22. Manfras, B. J., W. A. Rudert, M. Trucco, and B. O. Boehm. 1997. Analysis of the  a/b T-cell receptor repertoire by competitive and quantitative family-specific  PCR with exogenous standards and high resolution fluorescence based CDR3 size  imaging. J. Immunol. Methods 210:235.  	9520306
	23. Lauber, J., P. Fabrizio, S. Teigelkamp, W. S. Lane, E. Hartmann, and  R. Luhrmann. 1996. The HeLa 200 kDa U5 snRNP-specific protein and its ho mologue in Saccharomyces cerevisiae are members of the DEXH-box protein  family of putative RNA helicases. EMBO J. 15:4001.  	8670905
	24. Parker, K. C., M. A. Bednarek, and J. E. Coligan. 1994. Scheme for ranking  potential HLA-A2 binding peptides based on independent binding of individual  peptide side-chains. J. Immunol. 152:163.  	8254189
	25. Rammensee, H.-G., T. Friede, and S. Stevanovic. 1995. MHC ligands and peptide  motifs: first listing. Immunogenetics 41:178.  	7890324
	26. Brash, D. E., J. A. Rudolph, J. A. Simon, A. Lin, G. J. McKenna, H. P. Baden,  A. J. Halperin, and J. Ponten. 1991. A role for sunlight in skin cancer: UV induced p53 mutations in squamous cell carcinoma. Proc. Natl. Acad. Sci. USA  88:10124.  	1946433
	27. Goldstein, A. M., N. C. Dracopoli, M. Engelstein, M. C. Fraser, W. H. J. Clark,  and M. A. Tucker. 1994. Linkage of cutaneous malignant melanoma/dysplastic  nevi to chromosome 9p, and evidence for genetic heterogeneity. Am. J. Hum.  Genet. 54:489.  	8116618
	28. Puig, S., A. Ruiz, C. Lazaro, T. Castel, M. Lynch, J. Palou, A. Vilalta,  J. Weissenbach, J. M. Mascaro, and X. Estivill. 1995. Chromosome 9p deletions  in cutaneous malignant melanoma tumors: the minimal deleted region involves  markers outside the p16 (CDKN2) gene. Am. J. Hum. Genet. 57:395.  	7668266
	29. Healy, E., C. E. Belgaid, M. Takata, A. Vahlquist, I. Rehman, H. Rigby, and  J. L. Rees. 1996. Allelotypes of primary cutaneous melanoma and benign mela nocytic nevi. Cancer Res. 56:589.  	8564976
	30. McMichael, A. J., and C. A. O’Callaghan. 1998. A new look at T cells. J. Exp.  Med. 187:1367.  	NO_MATCH
	31. Murali-Krishna, K., J. D. Altman, M. Suresh, D. J. D. Sourdive, A. J. Zajac,  J. D. Miller, J. Slansky, and R. Ahmed. 1998. Counting antigen-specific CD8 T  cells: a reevaluation of bystander activation during viral infection. Immunity  8:177.  	9491999
	32. Bieganowska, K., P. Ho¨llsberg, G. J. Buckle, D.-G. Lim, T. F. Greten, J. Schneck,  J. D. Altman, S. Jacobson, S. L. Ledis, B. Hanchard, et al. 1999. Direct analysis  of viral-specific CD81 T cells with soluble HLA-A2/Tax11–19 tetramer com plexes in patients with human T cell lymphotropic virus-associated myelopathy.  J. Immunol. 162:1765.  	9973440
	33. Nagata, S., and P. Goldstein. 1995. The Fas death factor. Science 267:1449.  	7533326
	34. Subramanya, H. S., L. E. Bird, J. A. Brannigan, and D. B. Wigley. 1996. Crystal  structure of a DExx box DNA helicase. Nature 384:379.  	8934527
	35. Linder, P., P. F. Lasko, M. Ashburner, P. Leroy, P. J. Nielsen, K. Nishi,  J. Schnier, and P. P. Slonimski. 1989. Birth of the D-E-A-D box. Nature 337:121.  	NO_MATCH
	36. Gorbalenya, A. E., and E. V. Koonin. 1993. Helicases: amino acid sequence  comparisons and structure-function relationships. Curr. Opin. Strut. Biol. 3:419.  	NO_MATCH
	37. Dubey, P., R. C. Hendrickson, S. C. Meredith, C. T. Siegel, J. Shabanowitz,  J. C. A. Skipper, V. H. Engelhard, D. F. Hunt, and H. Schreiber. 1997. The  immunodominant antigen of an ultraviolet-induced regressor tumor is generated  by a somatic point mutation in the DEAD box helicase p68. J. Exp. Med. 185:  695.  	9034148
	38. Friedberg, E. C. 1992. Xeroderma pigmentosum, Cockayne’s syndrome, heli cases, and DNA repair: what’s the relationship? Cell 71:887.  	1458537
	39. Coin, F., E. Bergmann, A. Tremeau-Bravard, and J. M. Egly. 1999. Mutations in  XPB and XPD helicases found in xeroderma pigmentosum patients impair the  transcription function of TFIIH. EMBO J. 18:1357.  	10064601
	40. Ellis, N. A., J. Groden, T. Z. Ye, J. Straughen, D. J. Lennon, S. Ciocci,  M. Proytcheva, and J. German. 1995. The Bloom’s syndrome gene product is  homologous to RecQ helicases. Cell 83:655.  	7585968
	41. Yu, C. E., J. Oshima, Y. H. Fu, E. M. Wijsman, F. Hisama, R. Alisch,  S. Matthews, J. Nakura, T. Miki, S. Ouais, et al. 1996. Positional cloning of the  Werner’s syndrome gene. Science 272:258.  	8602509
	42. Oshima, J., C. E. Yu, C. Piussan, G. Klein, J. Jabkowski, S. Balci, T. Miki,  J. Nakura, T. Ogihara, J. Ells, et al. 1996. Homozygous and compound heterozy gous mutations at the Werner syndrome locus. Hum. Mol. Genet. 5:1909.  	8968742
	43. Gibbons, R., D. J. Picketts, L. Villard, and D. R. Higgs. 1995. Mutations in a  putative global transcriptional regulator cause X-linked mental retardation with  alpha-thalassemia (ATR-X syndrome). Cell 80:837.  	7697714
	44. Troelstra, C., A. van Gool, J. de Wit, W. Vermeulen, D. Bootsma, and  J. H. Hoeijmakers. 1992. ERCC6, a member of a subfamily of putative helicases,  is involved in Cockayne’s syndrome and preferential repair of active genes. Cell  71:939.  	1339317
	45. Trepel, F. 1974. Number and distribution of lymphocytes in man: a critical anal ysis. Klin. Wochenschr. 52:511.  	4853392
	46. Tan, L. C., N. Gudgeon, N. E. Annels, P. Hansasuta, C. A. O’Callaghan,  S. Rowland-Jones, A. J. McMichael, A. B. Rickinson, and M. F. C. Callan. 1999.  A re-evaluation of the frequency of CD81 T cells specific for EBV in healthy  virus carriers. J. Immunol. 162:1827.  	9973448
	47. Gray, C. M., J. Lawrence, J. M. Schapiro, J. D. Altman, M. A. Winters,  M. Crompton, M. Loi, S. K. Kundu, M. M. Davis, and T. C. Merigan. 1999.  Frequency of class I HLA-restricted anti-HV CD81 T cells in individuals receiv ing highly active antiretroviral therapy (HAART). J. Immunol. 162:1780.  	9973442
	48. Lee, P. P., C. Yee, P. A. Savage, L. Fong, D. Brockstedt, J. S. Weber, D. Johnson,  S. Swetter, J. Thompson, P. D. Greenberg, et al. 1999. Characterization of cir culating T cells specific for tumor-associated antigens in melanoma patients. Nat.  Med. 5:677.  	10371507
	49. Ogg, G. S., P. R. Dunbar, P. Romero, J.-L. Chen, and V. Cerundolo. 1998. High  frequency of skin-homing melanocyte-specific cytotoxic T lymphocytes in auto immune vitiligo. J. Exp. Med. 188:1203.  	9743539
	50. Pittet, M. J., D. Valmori, P. R. Dunbar, D. E. Speiser, D. Lie´nard, F. Lejeune,  K. Fleischhauer, V. Cerunodolo, J.-C. Cerottini, and P. Romero. 1999. High  frequencies of naive Melan-A/MART-1-specific CD81 T cells in a large propor tion of human histocompatibility leukocyte antigen (HLA)-A2 individuals.  J. Exp. Med. 190:705.  	10477554
	51. Dunbar, P. R., J.-L. Chen, D. Chao, N. Rust, H. Teisserenc, G. S. Ogg,  P. Romero, P. Weynants, and V. Cerundolo. 1999. Cutting edge: rapid cloning of  tumor-specific CTL suitable for adoptive immunotherapy of melanoma. J. Im munol. 162:6959.  	10358133
	52. Brichard, V. G., G. Warnier, A. Van Pel, G. Morlighem, S. Lucas, and T. Boon.  1995. Individual differences in the orientation of the cytolytic T cell response  against mouse tumor P815. Eur. J. Immunol. 25:664.  	7705394
	53. Marchand, M., N. van Baren, P. Weynants, V. Brichard, B. Dre´no, M.-H. Tessier,  E. Rankin, G. Parmiani, F. Arienti, Y. Humblet, et al. 1999. Tumor regressions  observed in patients with metastatic melanoma treated with an antigenic peptide  encoded by gene MAGE-3 and presented by HLA-A1. Int. J. Cancer 80:219.  	9935203
	54. Rosenberg, S. A., J. C. Yang, D. J. Schwartzentruber, P. Hwu, F. M. Marincola,  S. L. Topalian, N. P. Restifo, M. E. Dudley, S. L. Schwarz, P. J. Spiess, et al.  1998. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for  the treatment of patients with metastatic melanoma. Nat. Med. 4:321.  	9500606
	55. Nestle, F. O., S. Alijagic, M. Gilliet, Y. Sun, S. Grabbe, R. Dummer, G. Burg, and  D. Schadendorf. 1998. Vaccination of melanoma patients with peptide- or tumor  lysate-pulsed dendritic cells. Nat. Med. 4:328.  	9500607
J Immunol-2000-Watarai-6027-33.pdf
	1. Isobe, M., H. Yagita, K. Okumura, and A. Ihara. 1992. Specific acceptance of  cardiac allograft after treatment with antibodies to ICAM-1 and LFA-1. Science  255:1125.  	1347662
	2. Isobe, M., J. Suzuki, H. Yagita, K. Okumura, S. Yamazaki, R. Nagai, Y. Yazaki,  and M. Sekiguchi. 1994. Immunosuppression to cardiac allografts and soluble  antigens by anti-vascular cell adhesion moleucle-1 and anti-very late antigen-4  monoclonal antibodies. J. Immunol. 153:5810.  	7527450
	3. Bergese, S. D., E. H. Huang, R. P. Pelletier, M. B. Widmer, R. M. Ferguson, and  C. G. Orosz. 1995. Regulation of endothelial VCAM-1 expression in murine  cardiac grafts. Am. J. Pathol. 147:166.  	7536398
	4. Schowengerdt, K. O., J. Y. Zhu, S. M. Stepkowski, Y. Tu, M. L. Entman, and  C. M. Ballantyne. 1995. Cardiac allograft survival in mice deficient in intercel lular adhesion molecule-1. Circulation 92:82.  	7788921
	5. Taub, D. D., and J. J. Oppenheim. 1994. Chemokines, inflammation, and immu nity. Ther. Immunol. 1:229.  	NO_MATCH
	6. Rollins, B. J. 1997. Chemokines. Blood 90:909.  	9242519
	7. Baggiolini, M., A. Walz, and S. L. Kunkel. 1989. Neutrophil-activating peptide 1/interleukin-8, a novel cytokine that activates neutrophils. J. Clin. Invest. 84:  1045.  	2677047
	8. Watanabe, K., K. Konishi, M. Fugioka, S. Kinoshita, and H. Nakagawa. 1989.  The neutrophil chemoattractant produced by the rat kidney epitheliod cell line  NRK-52E is a protein related to the KC/gro protein. J. Biol. Chem. 264:19559.  	2684956
	9. Luster, A. D., and J. V. Ravetch. 1987. Biochemical characterization of a g  interferon-inducible cytokine (IP-10). J. Exp. Med. 166:1084.  	2443596
	10. Liao, F., R. L. Rabin, J. R. Yannelli, L. G. Koniaris, P. Vanguri, and J. M. Farber.  1995. Human Mig chemokine: biochemical and functional characterization.  J. Exp. Med. 182:1301.  	7595201
	11. Schall, T. J., M. Lewis, K. J. Koller, A. Lee, G. C. Rice, G. H. Wong,  T. Gatanaga, G. A. Granger, R. Lentz, H. Raab, et al. 1990. Molecular cloning  and expression of a receptor for human tumor necrosis factor. Cell 61:361.  	2158863
	12. Sherry, B., P. Tekamp-Olson, C. Gallegos, D. Bauer, G. Davatelis, S. D. Wolpe,  F. Masiarz, D. Coit, and A. Cerami. 1988. Resolution of the two components of  macrophage inflammatory protein 1, and cloning and characterization of one of  those components, macrophage inflammatory protein-1b. J. Exp. Med. 168:2251.  	3058856
	13. Matsushima, K., C. G. Larsen, G. C. DuBois, and J. J. Oppenheim. 1989. Puri fication and characterization of a novel monocyte chemotactic and activating  factor produced by a human myelomonocytic cell line. J. Exp. Med. 169:1485.  	2926331
	14. Rollins, B. J., E. D. Morrison, and C. D. Stiles. 1988. Cloning and expression of  JE, a gene inducible by platelet-derived growth factor and whose product has  cytokine like properties. Proc. Natl. Acad. Sci. USA 85:3738.  	3287374
	15. Vaddi, K., and R. C. Newton. 1994. Regulation of monocyte integrin expression  by b-family chemokines. J. Immunol. 153:4721.  	7525713
	16. Tanaka, Y., D. H. Adams, S. Hubscher, H. Hirano, U. Siebenlist, and S. Shaw.  1993. T-cell adhesion induced by proteoglycan-immobilized cytokine MIP-1b.  Nature 361:79.  	7678446
	17. Djeu, J. Y., K. Matsushima, J. J. Oppenheim, K. Shiotsuki, and D. K. Blanchard.  1990. Functional activation of human neutrophils by recombinant monocyte-de rived neutrophil chemotactic factor/IL-8. J. Immunol. 144:2205.  	2155963
	18. Taub, D. D., M. Anver, J. J. Oppenheim, D. L. Longo, and W. J. Murphy. 1996.  T lymphocyte recruitment by interleukin-8 (IL-8): IL-8-induced degranulation of  neutrophils releases potent chemoattractants for human T lymphocytes both in  vitro and in vivo. J. Clin. Invest. 97:1931.  	8621778
	19. Fahey, T. J. I., K. J. Tracey, P. Tekamp-Olson, L. S. Cousens, W. G. Jones,  G. T. Shires, A. Cerami, and B. Sherry. 1992. Macrophage inflammatory protein  1 modulates macrophage function. J. Immunol. 148:2764.  	1573267
	20. Russell, M. E., D. H. Adams, L. R. Wyner, Y. Yamashita, N. J. Halnon, and  M. J. Karnovsky. 1993. Early and persistent induction of monocyte chemoattrac tant protein 1 in rat cardiac allografts. Proc. Natl. Acad. Sci. USA 90:6086.  	8327487
	21. Wieder, K. J., W. W. Hancock, G. Schmidbauer, C. L. Corpier, I. Wieder,  L. Kobzik, T. B. Strom, and J. W. Kupiec-Weglinski. 1993. Rapamycin treatment  depresses intragraft expression of KC/MIP-2, granzyme B, and IFN-g in rat re cipients of cardiac allografts. J. Immunol. 151:1158.  	8335897
	22. Schmouder, R. L., R. M. Strieter, A. Walz, and S. L. Kunkel. 1995. Epithelial derived neutrophil-activating factor-78 production in human renal tubule epithe lial cells and in renal allograft rejection. Transplantation 59:118.  	7839412
	23. Pattison, J., P. J. Nelson, P. Huie, I. von Leuttichau, G. Farshid, R. K. Sibley, and  A. M. Krensky. 1994. RANTES chemokine expression in cell-mediated trans plant rejection of the kidney. Lancet 343:209.  	7507196
	24. Nadeau, K. C., H. Azuma, and N. L. Tilney. 1995. Sequential cytokine dynamics  in chronic rejection of rat renal allografts: roles for cytokines RANTES and  MCP-1. Proc. Natl. Acad. Sci. USA 92:8729.  	7568006
	25. Nagano, H., K. C. Nadeau, M. Takada, M. Kusaka, and N. L. Tilney. 1997.  Sequential cellular and molecular kinetics in acutely rejecting renal allografts in  rats. Transplantation 63:1101.  	9133471
	26. Kondo, T., A. C. Novick, H. Toma, and R. L. Fairchild. 1996. Induction of  chemokine gene expression during allogeneic skin graft rejection. Transplanta tion 61:1750.  	8685955
	27. Ichikawa, T., M. Kawai, A. Uenaka, H. Yamamoto, M. Gotoh, M. Monden,  T. Mori, H. Shiku, and E. Nakayama. 1989. The role of CD81 and CD41 cells  in rejection of multiple minor H-disparate skin grafts. Transplantation 47:909.  	2497573
	28. Qin, S., M. Wise, S. P. Cobbold, L. Leong, Y.-C. M. Kong, J. R. Parnes, and  H. Waldmann. 1990. Induction of tolerance in peripheral T cells with monoclonal  antibodies. Eur. J. Immunol. 20:2737.  	1702726
	29. Cobbold, S. P., A. Jayasuriya, A. Nash, T. D. Prospero, and H. Waldmann. 1984.  Therapy with monoclonal antibodies by elimination of T-cell subsets in vivo.  Nature 312:548.  	6150440
	30. Tannenbaum, C. S., R. Tubbs, D. Armstrong, J. H. Finke, R. M. Bukowski, and  T. A. Hamilton. 1998. The CXC chemokines IP-10 and Mig are necessary for  IL-12 mediated regression of the mouse RENCA tumor. J. Immunol. 161:927.  	9670971
	31. Billingham, R. E., and P. B. Medawar. 1951. The technique of free skin grafting  in mammals. J. Exp. Biol. 28:385.  	NO_MATCH
	32. Chirgwin, J. M., A. E. Przybyla, R. J. MacDonald, and W. J. Rutter. 1979.  Isolation of biologically active ribonucleic acid from sources enriched in ribo nucleases. Biochemistry 18:5294.  	518835
	33. Fort, P., L. Marty, M. Piechaczyk, S. El Sabrouty, C. Dani, P. Jeanteur, and  J. M. Blanchard. 1985. Various rat adult tissues express only one major mRNA  species from the glyceraldehyde-3-phosphate-dehydrogenase multigenic family.  Nucleic Acids Res. 13:1431.  	2987824
	34. DiPietro, L. A., M. D. Burdick, Q. E. Low, S. L. Kunkel, and R. M. Strieter. 1998.  MIP-1a as a critical macrophage chemoattractant in murine wound repair.  J. Clin. Invest. 101:1693.  	9541500
	35. Englehardt, E., A. Toksoy, M. Goebeler, S. Debus, E.-B. Brocker, and  R. Gillitzer. 1998. Chemokines IL-8, GROa, MCP-1, IP-10, and Mig are sequen tially and differentially expressed during phase-specific infiltration of leukocyte  subsets in human wound healing. Am. J. Pathol. 153:1849.  	9846975
	36. Kondo, T., K. Morita, Y. Watarai, M. B. Auerbach, D. D. Taub, A. C. Novick,  H. Toma, and R. L. Fairchild. 2000. Early increased chemokine expression and  production in murine allogeneic skin grafts is mediated by natural killer cells.  Transplantation 69:969.  	10755559
	37. Hoglund, P., J. Sundback, M. Y. Olsson-Alheim, M. Johansson, M. Salcedo,  C. Ohlen, H.-G. Ljunggren, C. L. Sentman, and K. Karre. 1997. Host MHC class  I gene control of NK-cell specificity in the mouse. Immunol. Rev. 155:11.  	9059879
	38. Koga, S., H. Toma, A. C. Novick, and R. L. Fairchild. 1999. CD81 T cells  produce RANTES during acute rejection of murine allogeneic skin grafts. Trans plantation 67:854.  	10199734
	39. Farber, J. M. 1997. Mig and IP-10: CXC chemokines that target lymphocytes.  J. Leukocyte Biol. 61:246.  	9060447
	40. Borson, N. D., M. A. Strausbauch, R. B. Kennedy, R. P. Oda, J. P. Landers, and  P. J. Wettstein. 1999. Temporal sequence of transcription of perforin, Fas ligand,  and tumor necrosis factor-a genes in rejecting skin allografts. Transplantation  67:672.  	10096521
	41. Koga, S., M. D. Auerbach, T. M. Engeman, A. C. Novick, H. Toma, and  R. L. Fairchild. 1999. T cell infiltration into class II MHC-disparate allografts and  acute rejection is dependent on the IFN-g-induced chemokine Mig. J. Immunol.  163:4878.  	10528189
	42. Kapoor, A., K. Morita, T. M. Engeman, S. Koga, E. M. Vapnek, M. G. Hobart,  and R. L. Fairchild. 2000. Early expression of interferon-g inducible protein 10  and monokine induced by interferon-g in cardiac allografts is mediated by CD81  T cells. Transplantation 69:1147.  	10762220
	43. Shanley, T. P., H. Schmal, H. P. Friedl, M. L. Jones, and P. A. Ward. 1995. Role  of macrophage inflammatory protein-1a (MIP-1a) in acute lung injury in rats.  J. Immunol. 154:4793.  	7722328
	44. Smith, R. E., R. M. Strieter, S. H. Phan, N. W. Lukacs, G. B. Huffnagle,  C. A. Wilke, M. D. Burdick, P. Lincoln, H. Evanhoff, and S. L. Kunkel. 1994.  Production and function of murine macrophage inflammatory protein-1a in bleo mycin-induced lung injury. J. Immunol. 153:4704.  	7525712
	45. Karpus, W. J., N. W. Lukas, B. L. McRae, R. M. Strieter, S. L. Kunkel, and  S. D. Miller. 1995. An important role for the chemokine macrophage inflamma tory protein-1a in the pathogenesis of the T cell-mediated autoimmune disease,  experimental autoimmune encephalomyelitis. J. Immunol. 155:5003.  	7594507
	46. Huffnagle, G. B., R. M. Strieter, T. J. Standiford, R. A. McDonald,  M. D. Burdick, S. L. Kunkel, and G. B. Toews. 1995. The role of monocyte  chemotactic protein-1 (MCP-1) in the recruitment of monocytes and CD41 T  cells during a pulmonary Cryptococcus neoformans infection. J. Immunol. 155:  4790.  	7594481
	47. Gong, J.-H., L. G. Ratkay, J. D. Waterfield, and I. Clark-Lewis. 1997. An an tagonist of monocyte chemoattractant protein 1 (MCP-1) inhibits arthritis in the  MRL-lpr mouse model. J. Exp. Med. 186:131.  	9207007
	48. Lloyd, C. M., A. W. Minto, M. E. Dorf, A. Proudfoot, T. N. C. Wells,  D. J. Salant, and J.-C. Gutierrez-Ramos. 1997. RANTES and monocyte chemoat tractant protein-1 (MCP-1) play an important role in the inflammatory phase of  crescentic nephritis, but only MCP-1 is involved in crescent formation and in terstitial fibrosis. J. Exp. Med. 185:1371.  	9104823
	49. Sechler, J. M. G., J. C. Yip, and A. S. Rosenberg. 1997. Genetic variation among  129 substrains: practical consequences. J. Immunol. 159:5766.  	9550369
	50. Konieczny, B. T., Z. Dai, E. T. Elwood, S. Saleem, P. S. Linsley, F. K. Baddoura,  C. P. Larsen, T. C. Pearson, and F. G. Lakkis. 1998. IFN-g is critical for long term allograft survival induced by blocking the CD28 and CD40 ligand T cell  costimulation pathways. J. Immunol. 160:2059.  	9498741
1049.pdf
	1. Kalender WA, Sissler W, Klotz E, Vock P. Spiral  volumetric CT with single-breath-hold technique,  continuous transport, and continuous scanner ro tation.  Radiology 1990 ;176:181–183  	2353088
	2. Crawford CR, King K. Computed tomography  scanning with simultaneous patient translation.  Med Phys  1990 ;17:967–982  	2280740
	3. Remy-Jardin M, Remy J, Giraud F, Marquette  CH. Pulmonary nodules: detection with thick section spiral CT versus conventional CT.  Radiol ogy 1993 ;187:513–520  	8475300
	4. Buckley JA, Scott WW, Siegelman SS, et al. Pul monary nodules: effect of increased data sam pling on detection with spiral CT and confidence  in diagnosis.  Radiology 1995 ;196:395–400  	7617851
	5. Costello P. Thoracic helical CT.  RadioGraphics  1994 ;14:913–918   	7938778
	6. Costello P, Dupuy DE, Ecker CP, Tello R. Spiral CT  of the thorax with reduced volume of contrast  material: a comparative study.  Radiology 1992 ;183:  663–666  	1584915
	7. Cascade PN, Gross BH, Kazerooni EA, et al.  Variability in the detection of enlarged mediasti nal lymph nodes in staging lung cancer: a com parison of contrast-enhanced and unenhanced CT.  AJR 1998 ;170:927–931  	9530036
	8. Hopper KD. With helical CT, is nonionic contrast  a better choice than ionic contrast for rapid and  large IV bolus injections (answer to question)?  AJR 1996 ;166:715  	8623657
	9. Debatin J, Cohan RH, Leder RA, Zakrzewski CB,  Dunnick NR. Selective use of low-osmolar con trast media.  Invest Radiol  1991 ;26:17–21  	2022448
	10. Cohan RH, Dunnick NR, Leder RA, et al. Extrava sation of nonionic contrast media: efficacy of con servative treatment.  Radiology 1990 ;176:65–67  	2353113
	11. Hopper KD, Mosher TJ, Kasales CJ, TenHave TR,  Tully DA, Weaver JS. Thoracic spiral CT: delivery  of contrast material pushed with injectable saline so lution in a power injector.  Radiology 1997 ;205:  269–271  	9314997
	12. Rubin GD, Lane MJ, Bloch DA, Leung AN, Stark  P. Optimization of thoracic spiral CT: effects of  iodinated contrast medium concentration.  Radiol ogy 1996 ;201:785–791  	8939232
1033.pdf
	1. Shuman WP, Moss AA. The adrenal glands. In:  Moss AA, Gamsu G, Genant HK, eds.  Computed  tomography of the body , 2nd ed. Philadelphia:  Saunders,  1992 :1045–1056  	NO_MATCH
	2. Oliver TW Jr, Bernardino ME, Miller JI, Mansour  K, Greene D, Davis WA. Isolated adrenal masses  in nonsmall-cell bronchogenic carcinoma.  Radiol ogy 1984 ;153:217–218  	6473783
	3. Welch TJ, Sheedy PF II, Stephens DH, Johnson  CM, Swenson SJ. Percutaneous adrenal biopsy: re view of 10-year experience.  Radiology 1994 ;193:  341–344  	7972740
	4. Mody MK, Kazerooni EA, Korobkin M. Percuta neous CT-guided biopsy of adrenal masses: imme diate and delayed complications.  J Comput Assist  Tomogr  1995 ;19:434–439  	7790554
	5. Lee MJ, Hahn PF, Papanicolaou N, et al. Benign  and malignant adrenal masses: CT distinction with  attenuation coefficients, size, and observer analy sis.  Radiology 1991 ;179:415–418   	2014283
	6. van Erkel AR, van Gils APG, Lequin M, Kruit wagen C, Bloem JL, Falke THM. CT and MR dis tinction of adenomas and nonadenomas of the  adrenal glands.  J Comput Assist Tomogr  	8188912
	7. Singer AA, Obuchowski NA, Einstein DM, Paush ter DM. Metastasis or adenoma? Computed tomo graphic evaluation of the adrenal mass. J Med 1994 ;61:200–205 	8026063
	8. Korobkin M, Brodeur FJ, Yutzy GG, et al. Differen tiation of adrenal adenomas from nonadenomas us ing CT attenuation values.  AJR 1996 ;166:531–536   	8623622
	9. Mitchell DG, Crovello M, Matteucci T, Petersen  RO, Miettinen MM. Benign adrenocortical  masses: diagnosis with chemical shift MR imag ing.  Radiology 1992 ;185:345–351  	1410337
	10. Tsushima Y, Ishizaka H, Matsumoto M. Adrenal  masses: differentiation with chemical shift, fast  low-angle shot MR imaging.  Radiology  	8430178
	11. Mayo-Smith WW, Lee MJ, McNicholas MM,  Hahn PF, Boland GW, Saini S. Characterization of  adrenal masses (<5 cm) by use of chemical shift  MR imaging: observer performance versus quanti tative measures.  AJR 1995 ;165:91–95  	7785642
	12. Korobkin M, Lombardi TJ, Aisen AM, et al. Char acterization of adrenal masses with chemical shift  and gadolinium-enhanced MR imaging. 1995 ;197:411–418 	7480685
	13. McNicholas MMJ, Lee MJ, Mayo-Smith WW,  Hahn PF, Boland GW, Mueller PR. An imaging al gorithm for the differential diagnosis of adrenal ad enomas and metastases.  AJR 1995 ;165:1453–1459  	7484585
	14. Schwartz LH, Panicek DM, Doyle MV, et al. Com parison of two algorithms and their associated  charges when evaluating adrenal masses in patients  with malignancies.  AJR 1997 ;168:1575–1578  	9168729
	15. Dwamena BA, Kloos RT, Fendrick AM, et al. Di agnostic evaluation of the adrenal incidentaloma:  decision and cost-effectiveness analyses. 1998 ;39:707–712  	9544685
	16. Smith TJ, Hillner BE, Neighbors DM, McSorley  PA, Le Chevalier T. Economic evaluation of a ran domized clinical trial comparing vinorelbine, vi norelbine plus cisplatin, and vindesine plus  cisplatin for non-small-cell lung cancer. col 1995 ;13:2166–2173  	7666075
	17. Sandler MA, Pearlberg JL, Madrazo BL, Gitschlag  KF, Gross SC. Computed tomographic evaluation  of the adrenal gland in the preoperative assessment  of bronchogenic carcinoma.  Radiology  	7146405
	18. Pagani JJ. Non-small cell lung carcinoma adrenal  metastases: computed tomography and percutane ous needle biopsy in their diagnosis.  Cancer 53:1058–60  	6692299
	19. Salvatierra A, Baamonde C, Llamas JM, Cruz F,  Lopez-Pujol J. Extrathoracic staging of bron chogenic carcinoma.  Chest 1990 ;97:1052–1058  	2184992
	20. Silverman SG, Mueller PR, Pinkney LP, Koenker  RM, Seltzer SE. Predictive value of image-guided  adrenal biopsy: analysis of results of 101 biopsies.  Radiology 1993 ;187:715–718  	8497619
	21. Malenka DJ, Colice GL, Jacobs C, Beck JR. Medi astinal staging in non-small-cell lung cancer.  Med  Decis Making 1989 ;9:231–242  	NO_MATCH
	22. Damhuis RA, Schutte PR. Resection rates and  postoperative mortality in 7,899 patients with lung  cancer.  Euro Respir J  1996 ;9:7–10  	8834326
	23. Vrdoljak E, Mise K, Sapunar D, Rozga A, Marusic  M. Survival analysis of untreated patients with non small-cell lung cancer.  Chest 1994 ;106:1797–1800  	7988203
	24. Bunn PA Jr. The treatment of non-small cell lung can cer: current perspectives and controversies, future di rections.  Semin Oncol 1994 ;21[suppl 6]:49–59  	8052874
	25. Ginsberg RJ, Kris MG, Armstrong JG. Cancer of the  Lung. In: DeVita VT, Hellman S, Rosenberg SA,  eds.  Cancer: principles & practice of oncology , 4th  ed. Philadelphia: Lippincott,  1993 :673–712  	NO_MATCH
	26. Eisenberg JM. Clinical economics: a guide to the  economic analysis of clinical practices.  JAMA  1989 ;262:2879–2886  	2509745
	27. Smith TJ, Hillner BE, Desch CE. Efficacy and  cost-effectiveness in oncology: rational allocation  of cancer care resources.  J Natl Cancer Inst 1993  85:1460–1474  	NO_MATCH
	28. Outwater EK, Siegelman ES, Huang AB, Birn baum BA. Adrenal masses: correlation between  CT attenuation value and chemical shift ratio at  MR imaging with in-phase and opposed-phase se quences.  Radiology 1996 ;200:749–752  	8756926
	29. Korobkin M, Giordano TJ, Brodeur FJ, et al. Adre nal adenomas: relationship between histologic  lipid and CT and MR findings.  Radiology 1996  200:743–747  	8756925
	30. Ries LA. Influence of extent of disease, histology,  and demographic factors on lung cancer survival in  the SEER population-based data.  Semin Surg On col 1994 ;10:21–30  	8115783
	31. Jaakkimainen L, Goodwin PJ, Pater J, Warde P,  Murray N, Rapp E. Counting the costs of chemo therapy in a National Cancer Institute of Canada  randomized trial in nonsmall-cell lung cancer.  J  Clin Oncol 1990 ;8:1301–1309  	2166142
	32. Korobkin M, Brodeur FJ, Francis IR, Quint LE,  Dunnick NR, Goodsitt M. Delayed enhanced CT  for differentiation of benign from malignant adre nal masses.  Radiology 1996 ;200:737–742   	8756924
	33. Boland GW, Hahn PF, Pena C, Mueller PR. Adre nal masses: characterization with delayed contrast enhanced CT.  Radiology 1997 ;202:693–696  	9051018
	34. Boland GW, Goldberg MA, Lee MJ, et al. Indeter minate adrenal mass in patients with cancer:  evaluation at PET with 2-[F-18]-fluoro-2-deoxy D-glucose.  Radiology 1995 ;194:131–134  	7997539
	35. Erasmus JJ, Patz EF Jr, McAdams HP, et al. Evalua tion of adrenal masses in patients with bronchogenic  carcinoma using 18F-fluorodeoxyglucose positron  emission tomography.  AJR 1997 ;168:1357–1360  	9129444
	36. Tengs TO, Adams ME, Pliskin JS, et al. Five-hun dred life-saving interventions and their cost-effec tiveness.  Risk Anal 1995 ;15:369–390  	7604170
1009.pdf
	1. Puri P, Blake N, O’Donnell B, Guiney EJ. De layed primary anastomosis following spontane ous growth of esophageal segments in esophageal  atresia.  J Pediatr Surg 1981 ;16:180–183  	7241321
	2. Tam PKH, Chan FL, Saing H. Diagnosis and  evaluation of esophageal atresia by direct sagittal  CT.  Pediatr Radiol 1987 ;17:68–70  	3822585
	3. Tam PKH, Chan FL, Saing H. Direct sagittal CT  scan: a new diagnostic approach for surgical neo nates.  J Pediatr Surg 1987 ;22:397–400  	3585662
	4. Higgins WE, Ramaswamy K, Swift RD, McLen nan G, Hoffman EA. Virtual bronchoscopy for  three-dimensional pulmonary image assessment:  state of the art and future needs.  RadioGraphics  1998 ;18:761–778  	9599397
	5. Ferretti GR, Vining DJ, Knoplioch J, Coulomb  M. Tracheobronchial tree: three-dimensional spi ral CT with bronchoscopic perspective.  J Comput  Assist Tomogr 1996 ;20:777–781  	8797912
	6. Summers RM, Shaw DJ, Shelhamer JH. CT virtual  bronchoscopy of simulated endobronchial lesions:  effect of scanning, reconstruction, and display set tings and potential pitfalls.  AJR 1998 ;170:947–950  	9530041
	7. Konen E, Katz M, Rozenman J, Ben-Shlush A,  Itzchak Y, Szeinberg A. Virtual bronchoscopy in  children: early clinical experience.  AJR 1998  171:1699–1702  	9843316
Cancer Res-2000-Paige-1690-7.pdf
	1. Lisitsyn, N., Lisitsyn, N., and Wigler, M. Cloning the differences between two  complex genomes. Science (Washington DC), 259: 946–951, 1993.  	8438152
	2. Friend, S., Bernards, R., Roggel, J., Weinberg, R., Rapaport, J., Albert, D., and Dryja,  T. A human DNA segment with properties of the gene that predisposes to retino blastoma and osteosarcoma. Nature (Lond.), 323: 643–646, 1986.  	2877398
	3. Call, K. M., Glaser, T., Ito, C. Y., Buckler, A. J., Pelletier, J., Haber, D. A., Rose,  E. A., Kral, A., Yeger, H., and Lewis, W. H. Isolation and characterization of a zinc  finger polypeptide gene at the human chromosome 11 Wilms’ tumor locus. Cell, 60:  509–520, 1990.  	2154335
	4. Schutte, M., da-Costa, L. T., Hahn, S. A., Moskaluk, C., Hoque, A. T., Rozenblum,  E., Weinstein, C. L., Bittner, M., Meltzer, P. S., Trent, J. M., Yeo, C. J., Hruban,  R. H., and Kern, S. E. Identification by representational difference analysis of a  homozygous deletion in pancreatic carcinoma that lies within the BRCA2 region.  Proc. Natl. Acad. Sci. USA, 92: 5950–5954, 1995.  	7597059
	5. Kamb, A., Gruis, N. A., Weaver-Feldhaus, J., Liu, Q., Harshman, K., Tavtigian, S. V.,  Stockert, E., Day, R. R., Johnson, B. E., and Skolnick, M. H. A cell cycle regulator  potentially involved in genesis of many tumor types. Science (Washington DC), 264:  436–440, 1994.  	8153634
	6. Ohta, M., Inoue, H., Cotticelli, M. G., Kastury, K., Baffa, R., Palazzo, J., Siprashvili,  Z., Mori, M., McCue, P., Druck, T., Croce, C. M., and Huebner, K. The FHIT gene,  spanning the chromosome 3p14.2 fragile site and renal carcinoma-associated t(3;8)  breakpoint, is abnormal in digestive tract cancers. Cell, 84: 587–597, 1996.  	8598045
	7. Hannon, G. J., and Beach, D. p15INK4B is a potential effector of TGF-b-induced cell  cycle arrest. Nature (Lond.), 371: 257–261, 1994.  	8078588
	8. Quelle, D. E., Zindy, F., Ashmun, R. A., and Sherr, C. J. Alternative reading frames  of the INK4a tumor suppressor gene encode two unrelated proteins capable of  inducing cell cycle arrest. Cell, 83: 993–1000, 1995.  	8521522
	9. Watson, J. E. V., Gabra, H., Taylor, K. J., Rabiasz, G. J., Morrison, H., Perry, P.,  Smyth, J. F., and Porteous, D. J. Identification and characterization of a homozygous  deletion found in ovarian ascites by representational difference analysis. Genome  Res., 9: 226–233, 1999.  	10077528
	10. Li, C., Berx, G., Larsson, C., Auer, G., Aspenblad, U., Pan, Y., Sundelin, B., Ekman,  P., Nordenskjold, M., van Roy, F., and Bergerheim, U. S. R. Distinct deleted regions  on chromosome segment 16q23–24 associated with metastases in prostate cancer.  Genes Chromosomes Cancer, 24: 175–182, 1999.  	10451696
	11. Latil, A., Cussenot, O., Fournier, G., Driouch, K., and Lidereau, R. Loss of heterozy gosity at chromosome 16q in prostate adenocarcinoma: identification of three inde pendent regions. Cancer Res., 57: 1058–1062, 1997.  	9067271
	12. Driouch, K., Dorion-Bonnet, F., Briffod, M., Champeme, M. H., Longy, M., and  Lidereau, R. Loss of heterozygosity on chromosome arm 16q in breast cancer  metastases. Genes Chromosomes Cancer, 19: 185–191, 1997.  	9219000
	13. Iida, A., Isobe, R., Yoshimoto, M., Kasumi, F., Nakamura, Y., and Emi, M. Local ization of a breast cancer tumour-suppressor gene to a 3-cM interval within chromo somal region 16q22. Br. J. Cancer, 75: 264–267, 1997.  	9010036
	14. Chen, T., Sahin, A., and Aldaz, C. M. Deletion map of chromosome 16q in ductal  carcinoma in situ of the breast: refining a putative tumor suppressor gene region.  Cancer Res., 56: 5605–5609, 1996.  	8971163
	15. Roylance, R., Gorman, P., Harris, W., Liebmann, R., Barnes, D., Hanby, A., and  Sheer, D. Comparative genomic hybridization of breast tumors stratified by histo logical grade reveals new insights into the biological progression of breast cancer.  Cancer Res., 59: 1433–1436, 1999.  	10197608
	16. Chou, Y-H., Chung, K-C., Jeng, L-B., Chen, T-C, and Liaw, Y-F. Frequent allelic  loss on chromosomes 4q and 16q associated with human hepatocellular carcinoma in  Taiwan. Cancer Lett., 123: 1–6, 1998.  	9461010
	17. Iwabuchi, H., Sakamoto, M., Sakunaga, H., Ma, Y. Y., Carcangiu, M. L., Pinkel, D.,  Yang-Feng, T. L., and Gray, J. W. Genetic analysis of benign, low-grade, and  high-grade ovarian tumors. Cancer Res., 55: 6172–6180, 1995.  	8521410
	18. Doggett, N. A., Breuning, M. H., and Callen, D. F. Report of the fourth international  workshop on human chromosome 16 mapping 1995. Cytogenet. Cell Genet., 72:  271–293, 1996.  	8641131
	19. Smith, D. I., Huang, H., and Wang, L. Common fragile sites and cancer. Int. J. Oncol.,  12: 187–196, 1998.  	NO_MATCH
	20. Lisitsyn, N. A., Lisitsina, N. M., Dalbagni, G., Barker, P., Sanchez, C. A., Gnarra, J.,  Linehan, W. M., Reid, B. J., and Wigler, M. H. Comparative genomic analysis of  tumors: detection of DNA losses and amplification. Proc. Natl. Acad. Sci. USA, 92:  151–155, 1995.  	7816807
	21. Wolf, C., Hayward, I., Lawrie, S., Buckton, K., McIntyre, M., Adams, D., Lewis, A.,  Scott, A., and Smyth, J. Cellular heterogeneity and drug resistance in two ovarian  adenocarcinoma cell lines derived from a single patient. Int. J. Cancer, 39: 695–702,  1987.  	3583449
	22. Hay, F. G., Duncan, L. W., and Leonard, R. C. F. Establishment and characterisation  of two new small cell lung cancer cell lines–one from a patient with previous familial  retinoblastoma. Br. J. Cancer, 63: 43–45, 1991.  	1645570
	23. Brattain, M. G., Fine, W. D., Khaled, F. M., Thompson, J., and Brattain, D. E.  Heterogeneity of malignant cells from a human colonic carcinoma. Cancer Res., 41:  1751–1756, 1981.  	7214343
	24. Boyd, A. C. Turbo cloning: a fast, efficient method for cloning PCR products and  other blunt-ended DNA fragments into plasmids. Nucleic Acids Res., 21: 817–821,  1993.  	8451184
	25. Doggett, N. A., Goodwin, L. A., Tesmer, J. G., Meincke, L. J., Bruce, D. C., Clark,  L. M., Altherr, M. R., Ford, A. A., Chi, H. C., Marrone, B. L., Longmire, J. L., Lane,  S. A., Whitmore, S. A., Lowenstein, M. G., Sutherland, R. D., Mundt, M. O., Knill,  E. H., Bruno, W. J., Macken, C. A., Torney, D. C., Wu, J-R., Griffith, J., Sutherland,  G. R., Deaven, L. L., Callen, D. F., and Moyzis, R. K. An integrated physical map of  human chromosome 16. Nature (Lond.), 377: 335–365, 1995.  	7566100
	26. Chumakov, I., Rigault, P., Guillou, S., Ougen, P., Billaut, A., Guasconi, G., Gervy, P.,  LeGall, I., Soularue, P., and Grinas, L. Continuum of overlapping clones spanning the  entire human chromosome 21q. Nature (Lond.), 359: 380–387, 1992.  	1406950
	27. Wu, C., Zhu, S., Simpson, S., and de Jong, P. J. DOP-vector PCR: a method for rapid  isolation and sequencing of insert termini from PAC clones. Nucleic Acids Res., 24:  2614–2615, 1996.  	8692704
	28. Church, D. M., Stotler, C. J., Rutter, J. L., Murrell, J. R., Trofatter, J. A., and Buckler,  A. J. Isolation of genes from complex sources of mammalian genomic DNA using  exon amplification. Nat. Genet., 6: 98–105, 1994.  	8136842
	29. Nelson, D. L., Ledbetter, S. A., Corbo, L., Victoria, M. F., Ramirez-Solis, R.,  Webster, T. D., Ledbetter, D. H., and Caskey, C. T. Alu polymerase chain reaction:  a method for rapid isolation of human-specific sequences from complex DNA  sources. Proc. Natl. Acad. Sci. USA, 86: 6686–6690, 1989.  	2771952
	30. Staden, R. The Staden sequence analysis package. Mol. Biotechnol., 5: 233–241,  1996.  	8837029
	31. Glover, T. W., Berger, C., Coyle, J., and Echo, B. DNA polymerase a inhibition by  aphidicolin induces gaps and breaks at common fragile sites in human chromosomes.  Hum. Genet., 67: 136–142, 1984.  	6430783
	32. Lichter, P., and Cremer, T. Chromosome analysis by non-isotopic in situ hybridiza tion. In: D. E. Rooney and B. H. Czepulkowski (eds.), Human Cytogenetics: A  Practical Approach, Ed. 1, Vol. 1, pp. 157–192. Oxford, United Kingdom: Oxford  University Press, 1992.  	NO_MATCH
	33. Suzuki, S., Sano, K., and Tanihara, H. Diversity of the cadherin family: evidence for  eight new cadherins in nervous tissue. Cell Regul., 2: 261–270, 1991.  	2059658
	34. Bussemakers, M. J., van Bokhoven, A., Mees, S. G., Kemler, R., and Schalken, J. A.  Molecular cloning and characterization of the human E-cadherin cDNA. Mol. Biol.  Rep., 17: 123–128, 1993.  	8459805
	35. Kastury, K., Baffa, R., Druck, T., Ohta, M., Cotticelli, M. G., Inoue, H., Negrini, M.,  Rugge, M., Huang, D., Croce, C. M., Palazzo, J., and Huebner, K. Potential gastro intestinal tumor suppressor locus at the 3p14.2 FRA3B site identified by homozygous  deletions in tumor cell lines. Cancer Res., 56: 978–983, 1996.  	8640789
	36. Mangelsdorf, M., Ried, K., Woollatt, E., Dayan, S., Eyre, H., Finnis, M., Hobson, L.,  Nancarrow, J., Venter, D., Baker, E., and Richards, R. I. Chromosomal fragile site  FRA16D and DNA instability in cancer. Cancer Res., 60: 1683–1689, 2000.  	10749140
	37. Bednarek, A. K., and Aldaz, C. M. Characterization of transcripts from a commonly  deleted area of chromosome 16 (q23.3–q24.1). Proc. Am. Assoc. Cancer Res., 39:  128, 1998.  	NO_MATCH
	38. Becker-Follmann, J., Gaa, A., Bausch, E., Natt, E., Scherer, G., and von Deimling, O.  High-resolution mapping of a linkage group on mouse chromosome 8 conserved on  human chromosome 16Q. Mamm. Genome, 8: 172–177, 1997.  	9069116
	39. Yoshida, M. C., Nishizawa, M., Kataoka, K., Goto, N., Fujiwara, K. T., and Kawai,  S. Localization of the human MAF protooncogene on chromosome 16 to bands  q22–q23. Cytogenet. Cell Genet., 58: 2003, 1991.  	NO_MATCH
	40. Mourelatos, Z., Gonatas, J. O., Cinato, E., and Gonatas, N. K. Cloning and sequence  analysis of the human MG160, a fibroblast growth factor and E-selectin binding  membrane sialoglycoprotein of the Golgi apparatus. DNA Cell Biol., 15: 1121–1128,  1996.  	8985126
	41. Peyrard, M., Parveneh, S., Lagercrantz, S., Ekman, M., Fransson, I., Sahlen, S., and  Dumanski, J. P. Cloning, expression pattern, and chromosomal assignment to 16q23  of the human g-adaptin gene (ADTG). Genomics, 50: 275–280, 1998.  	9653655
	42. Nomura, N., Nagase, T., Miyajima, N., Sazuka, T., Tanaka, A., Sato, S., Seki, N.,  Kawarabayasi, Y., Ishikawa, K., and Tabata, S. Prediction of the coding sequences of  unidentified human genes. II. The coding sequences of 40 new genes (KIAA0041–  KIAA0080) deduced by analysis of cDNA clones from human cell line KG-1. DNA  Res., 1: 223–229, 1994.  	7584044
	43. Pan, M. G., Xiong, J., Copeland, N. G., Gilbert, D. J., Jenkins, N. A., and Goeddel,  D. V. Sequence, genomic organization, and chromosome localization of the mouse  TRADD gene. J. Inflamm., 46: 168–175, 1995.  	NO_MATCH
	44. Kremmidiotis, G., Baker, E., Crawford, J., Eyre, H. J., Nahmias, J., and Callen, D. F.  Localization of human cadherin genes to chromosome regions exhibiting cancer related loss of heterozygosity. Genomics, 49: 467–471, 1998.  	9615235
	45. Berx, G., Cleton-Jansen, A. M., Nollet, F., de Leeuw, W. J., van de Vijver, M.,  Cornelisse, C., and van Roy, F. E-cadherin is a tumour/invasion suppressor gene  mutated in human lobular breast cancers. EMBO J., 14: 6107–6115, 1995.  	8557030
	46. Yunis, J. J., Soreng, A. L., and Bowe, A. E. Fragile sites are targets of diverse  mutagens and carcinogens. Oncogene, 1: 59–69, 1987.  	3438083
	47. Chesi, M., Bergsagel, P. L., Shonukan, O. O., Martelli, M. L., Brents, L. A., Chen, T.,  Schrock, E., Ried, T., and Kuehl, W. M. Frequent dysregulation of the c-maf  proto-oncogene at 16q23 by translocation to an Ig locus in multiple myeloma. Blood,  91: 4457–4463, 1998.  	9616139
	48. Boldog, F., Gemmill, R. M., West, J., Robinson, M., Robinson, L., Li, E., Roche, J.,  Todd, S., Waggoner, B., Lundstrom, R., Jacobson, J., Mullokandov, M. R., Klinger,  H., and Drabkin, H. A. Chromosome 3p14 homozygous deletions and sequence  analysis of FRA3B. Hum. Mol. Genet., 6: 193–203, 1997.  	9063739
	49. Mimori, K., Druck, T., Inoue, H., Alder, H., Berk, L., Mori, M., Huebner, K., and  Croce, C. M. Cancer-specific chromosome alterations in the constitutive fragile  region FRA3B. Proc. Natl. Acad. Sci. USA, 96: 7456–7461, 1999.  	10377436
	50. Huang, H., Qian, J., Proffit, J., Wilber, K., Jenkins, R., and Smith, D. I. FRA7G  extends over a broad region: coincidence of human endogenous retroviral sequences  (HERV-H) and small polydispersed circular DNAs (spcDNA) and fragile sites.  Oncogene, 16: 2311–2319, 1998.  	9620548
	51. Mishmar, D., Rahat, A., Scherer, S. W., Nyakatura, G., Hinzmann, B., Kohwi, Y.,  Mandel-Gutfroind, Y., Lee, J. R., Drescher, B., Sas, D. E., Margalit, H., Platzer, M.,  Weiss, A., Tsui, L. C., Rosenthal, A., and Kerem, B. Molecular characterization of a  common fragile site (FRA7H) on human chromosome 7 by the cloning of a simian  virus 40 integration site. Proc. Natl. Acad. Sci. USA, 95: 8141–8146, 1998.  	9653154
	52. Wang, L., Darling, J., Zhang, J. S., Huang, H., Liu, W., and Smith, D. I. Allele specific late replication and fragility of the most active common fragile site, FRA3B.  Hum. Mol. Genet., 8: 431–437, 1999.  	9949202
	53. Le Beau, M. M., Rassool, F. V., Neilly, M. E., Espinosa, R., III, Glover, T. W., Smith,  D. I., and McKeithan, T. W. Replication of a common fragile site, FRA3B, occurs late  in S phase and is delayed further upon induction: implications for the mechanism of  fragile site induction. Hum. Mol. Genet., 7: 755–761, 1998.  	9499431
	54. Lengauer, C., Kinzler, K. W., and Vogelstein, B. Genetic instabilities in human  cancers. Nature (Lond.), 396: 643–649, 1998.  	9872311
	55. Lengauer, C., Kinzler, K. W., and Vogelstein, B. Genetic instability in colorectal  cancers. Nature (Lond.), 386: 623–627, 1997.  	9121588
Cancer Res-2000-Boucher-1631-6.pdf
	1. Moolten, F. L. Drug sensitivity (“suicide”) genes for selective cancer chemotherapy.  Cancer Gene Ther., 1: 279–287, 1994.  	7543006
	2. Bridgewater, J. A., Springer, C. J., Knox, R. J., Minton, N. P., Michael, N. P., and  Collins, M. K. Expression of the bacterial nitroreductase enzyme in mammalian cells  renders them selectively sensitive to killing by the prodrug CB1954. Eur. J. Cancer,  31A: 2362–2370, 1995.  	NO_MATCH
	3. Mullen, C. A., Kilstrup, M., and Blaese, R. M. Transfer of the bacterial gene for  cytosine deaminase to mammalian cells confers lethal sensitivity to 5-fluorocytosine:  a negative selection system. Proc. Natl. Acad. Sci. USA, 89: 33–37, 1992.  	1729703
	4. Moolten, F. L. Tumor chemosensitivity conferred by inserted herpes thymidine kinase  genes: paradigm for a prospective cancer control strategy. Cancer Res., 46: 5276–  5281, 1986.  	3019523
	5. Balzarini, J., Bohman, C., and DeClercq, E. Differential metabolism of cytostatic of  (E)-5-(2-bromovinyl)-29-deoxyuridine, 9-(1,3-dihydroxy-2-propoxymethyl)guanine,  and other antiherpetic drugs on tumor cells transfected by the thymidine kinase gene  of herpes simplex virus type 1 or type 2. J. Biol. Chem., 269: 6332–6337, 1993.  	8384209
	6. Ilsley, D. D., Lee, S-H., Miller, W. H., and Kuchta, R. D. Acyclic guanosine analogs  inhibit DNA polymerases a, d, and Iˆ with very different potencies and have unique  mechanisms of action. Biochemistry, 34: 2504–2510, 1995.  	7873530
	7. Freeman, S. M., Abboud, C. N., Whartenby, K. A., Packman, C. H., Koeplin, D. S.,  Moolten, F. L., and Abraham, G. N. The “bystander effect”: tumor regression when  a fraction of the tumor mass is genetically modified. Cancer Res., 53: 5274–5283,  1993.  	8221662
	8. DiMaio, J. M., Clary, B. M., Via, D. F., Coveney, E., Pappas, T. N., and Lyerly, H. K.  Directed enzyme pro-drug gene therapy for pancreatic cancer in vivo. Surgery, 116:  205–213, 1994.  	8047987
	9. Ezzeddine, Z. D., Martuza, R. L., Platika, D., Short, M. P., Malick, A., Choi, B., and  Breakefield, X. O. Selective killing of glioma cells in culture and in vivo by retrovirus  transfer of the herpes simplex virus thymidine kinase gene. New Biol., 3: 608–614,  1991.  	1655012
	10. Caruso, M., Panis, Y., Gagandeep, S., Houssin, D., Salzmann, J-L., and Klatzmann,  D. Regression of established macroscopic liver metastases after in situ transduction of  a suicide gene. Proc. Natl. Acad. Sci. USA, 90: 7024–7028, 1993.  	8346212
	11. Ram, Z., Culver, K. W., Walbridge, S., Blaese, R. M., and Oldfield, E. H. In situ  retroviral-mediated gene transfer for the treatment of brain tumors in rats. Cancer  Res., 53: 83–88, 1993.  	8380127
	12. Vile, R. G., and Hart, I. R. Use of tissue-specific expression of the herpes simplex  virus thymidine kinase gene to inhibit growth of established murine melanomas  following direct intratumoral injection of DNA. Cancer Res., 53: 3860–3864, 1993.  	8395331
	13. Ido, A., Nakata, K., Kato, Y., Nakao, K., Murata, K., Fujita, M., Ishii, N., Tamaoki,  T., Shiku, H., and Nagataki, S. Gene therapy for hepatoma cells using a retrovirus  vector carrying herpes simplex virus thymidine kinase gene under the control of  human a-fetoprotein gene promoter. Cancer Res., 55: 3105–3109, 1995.  	7541712
	14. O’Malley, B. W., Jr., Chen, S-H., Schwartz, M. R., and Woo, S. L. C. Adenovirus mediated gene therapy for human head and neck squamous cell cancer in a nude  mouse model. Cancer Res., 55: 1080–1085, 1995.  	7866992
	15. Yoshida, K., Kawami, H., Yamaguchi, Y., Kuniyasu, H., Nishiyama, M., Hirai, T.,  Yanagihara, K., Tahara, E., and Toge, T. Retrovirally transmitted gene therapy for  gastric carcinoma using herpes simplex virus thymidine kinase gene. Cancer (Phila.),  75: 1467–1471, 1995.  	7889476
	16. Roth, J. A., and Cristiano, R. J. Gene therapy for cancer: what have we done and  where are we going? J. Natl. Cancer Inst., 89: 21–39, 1997.  	NO_MATCH
	17. Denning, C., and Pitts, J. D. Bystander effects of different enzyme-prodrug systems  for cancer gene therapy depend on different pathways for intercellular transfer of  toxic metabolites, a factor that will govern clinical choice of appropriate regimes.  Hum. Gene Ther., 8: 1825–1835, 1997.  	9358032
	18. Rubsam, L. Z., Boucher, P. D., Murphy, P. J., KuKuruga, M., and Shewach, D. S.  Cytotoxicity and accumulation of ganciclovir triphosphate in bystander cells cocul tured with herpes simplex virus type 1 thymidine kinase-expressing human glioblas toma cells. Cancer Res., 59: 669–675, 1999.  	9973216
	19. Bi, W. L., Parysek, L. M., Warnick, R., and Stambrook, P. J. In vitro evidence that  metabolic cooperation is responsible for the bystander effect observed with HSVtk  retroviral gene therapy. Hum. Gene Ther., 4: 725–731, 1993.  	8186287
	20. Boucher, P. D., Ruch, R. J., and Shewach, D. S. Differential ganciclovir-mediated  cytotoxicity and bystander killing in human colon carcinoma cell lines expressing  herpes simplex virus thymidine kinase. Hum. Gene Ther., 9: 801–814, 1998.  	9581903
	21. Machado, S. G., and Robinson, G. A. A direct, general approach based on isobolo grams for assessing the joint action of drugs in pre-clinical experiments. Stat. Med.,  13: 2289–2309, 1994.  	7855464
	22. Griffiths, G. M., Berek, C., Kaartinen, M., and Milstein, C. Somatic mutation and  maturation of immune response to 2-phenyl-oxazolone. Nature (Lond.), 312: 271–  275, 1984.  	6504141
	23. Hoogenboom, H. R., Griffiths, A. D., Johnson, K. S., Chriswell, D. J., Hudson, P., and  Winter, G. Multi-subunit proteins on the surface of filamentous phage: methodologies  for displaying antibody (Fab) heavy and light chains. Nucleic Acids Res., 19:  4133–4137, 1991.  	1908075
	24. Coloma, M. J., Hastings, A., Wims, L. A., and Morrison, S. L. Novel vectors for the  expression of antibody molecules using variable regions generated by polymerase  chain reaction. J. Immunol. Methods, 152: 89–104, 1992.  	1640112
	25. Samejima, Y., and Meruelo, D. ‘Bystander killing’ induces apoptosis and is inhibited  by forskolin. Gene Ther., 2: 50–58, 1995.  	7712332
	26. Mesnil, M., Piccoli, C., Tiraby, G., Willecke, K., and Yamasaki, H. Bystander killing  of cancer cells by herpes simplex virus thymidine kinase gene is mediated by  connexins. Proc. Natl. Acad. Sci. USA, 93: 1831–1835, 1996.  	8700844
	27. Elshami, A. A., Saavedra, A., Zhang, H., Kucharczuk, J. C., Spray, D. C., Fishman,  G. I., Amin, K. M., Kaiser, L. R., and Albelda, S. M. Gap junctions play a role in the  “bystander effect” of the herpes simplex virus thymidine kinase/ganciclovir system in  vitro. Gene Ther., 3: 85–92, 1996.  	8929915
	28. Yeager, M., and Nicholson, B. J. Structure of gap junction intercellular channels.  Curr. Opin. Struct. Biol., 6: 183–192, 1996.  	8728651
	29. Fick, J., Barker, F. G. I., Dazin, P., Westphale, E. M., Beyer, E. C., and Israel, M. A.  The extent of heterocellular communication mediated by gap junctions is predictive  of bystander tumor cytotoxicity in vitro. Proc. Natl. Acad. Sci. USA, 92: 11071–  11075, 1995.  	7479939
	30. Yang, L., Chiang, Y., Lenz, H., Danenberg, K. D., Spears, C. P., Gordon, E. M.,  Anderson, W. F., and Parekh, D. Intercellular communication mediates the bystander  effect during herpes simplex thymidine kinase/ganciclovir-based gene therapy of  human gastrointestinal tumor cells. Hum. Gene Ther., 9: 719–728, 1998.  	9551619
	31. Rogulski, K. R., Kim, J. H., Kim, S. H., and Freytag, S. O. Glioma cells transduced  with an Escherichia coli CD/HSV-1 TK fusion gene exhibit enhanced metabolic  suicide and radiosensitivity. Hum. Gene Ther., 8: 73–85, 1997.  	8989997
	32. Aghi, M., Kramm, C. M., Chou, T., Breakefield, X. O., and Chiocca, E. A. Syner gistic anticancer effects of ganciclovir/thymidine kinase and 5-fluorocytosine/cyto sine deaminase gene therapies. J. Natl. Cancer Inst., 90: 370–380, 1998.  	9498487
	33. Gwilt, P. R., and Tracewell, W. G. Pharmacokinetics and pharmacodynamics of  hydroxyurea. Clin. Pharmacokinet., 34: 347–358, 1998.  	9592619
	34. Donehower, R. C. Hydroxyurea. In: B. A. Chabner, and D. L. Longo (eds.), Cancer  Chemotherapy and Biotherapy, pp. 253–261. Philadelphia: Lippincott-Raven Pub lishers, 1996.  	NO_MATCH
	35. Bianchi, V., Pontis, E., and Reichard, P. Changes of deoxyribonucleoside triphos phate pools induced by hydroxyurea and their relation to DNA synthesis. J. Biol.  Chem., 261: 16037–16042, 1986.  	3536919
	36. Rubsam, L. Z., Davidson, B. L., and Shewach, D. S. Superior cytotoxicity with  ganciclovir compared with acyclovir and 1-b-D-arabinofuranosylthymine in herpes  simplex virus-thymidine kinase-expressing cells: a novel paradigm for cell killing.  Cancer Res., 58: 3873–3882, 1998.  	9731497
	37. Yoshioka, A., Tanaka, S., Osamu, H., Koyama, Y., Hirota, Y., Ayusawa, D., Seno, T.,  Garrett, C., and Wataya, Y. Deoxyribonucleoside triphosphate imbalance. J. Biol.  Chem., 262: 8235–8241, 1987.  	NO_MATCH
	38. Wadler, S., Horowitz, R., Zhang, H., and Schwartz, E. L. Effects of perturbations of  pools of deoxyribonucleoside triphosphates on expression of ribonucleotide reduc tase, a G1/S transition state enzyme, in p53-mutated cells. Biochem. Pharmacol., 55:  1353–1360, 1998.  	10076525
	39. Collins, A., and Oates, D. J. Hydroxyurea: effects on deoxyribonucleotide pool sizes  correlated with effects on DNA repair in mammalian cells. Eur. J. Biochem., 169:  299–305, 1987.  	3691495
992266.pdf
	1. Cotran, R.S. 1999. Inflammation: historical perspectives. In  Inflammation: Basic Principles and Clinical Correlates, 3rd  ed. J.I. Gallin, R. Snyderman, D.T. Fearon, B.F. Haynes,  and C. Nathan, editors. Lippincott Williams & Wilkins, Phil adelphia. 5–10.  	NO_MATCH
	2. Weissmann, G., J.E. Smolen, and H.M. Korchak. 1980. Re lease of inflammatory mediators from stimulated neutrophils.  N. Engl. J. Med. 303:27–34.  	6246431
	3. Samuelsson, B. 1982. From studies of biochemical mecha nisms to novel biological mediators: prostaglandin endoper oxides, thromboxanes and leukotrienes. In Les Prix Nobel:  Nobel Prizes, Presentations, Biographies and Lectures. T.  Frängsmyr, editor. Almqvist & Wiksell, Stockholm. 153–174.  	NO_MATCH
	4. Yokomizo, T., T. Izumi, K. Chang, Y. Takuwa, and T.  Shimizu. 1997. A G-protein-coupled receptor for leuko triene B4 that mediates chemotaxis. Nature. 387:620–624.  	9177352
	5. Perez, H.D. 1994. Chemoattractant receptors. Curr. Opin.  Hematol. 1:40–44.  	NO_MATCH
	6. Pillinger, M.H., and S.B. Abramson. 1995. The neutrophil  in rheumatoid arthritis. Rheum. Dis. Clin. North Am. 21:691–  714.  	8619095
	7. Serhan, C.N., J.Z. Haeggstrom, and C.C. Leslie. 1996. Lipid  mediator networks in cell signaling: update and impact of cy tokines. FASEB J. 10:1147–1158.  	8751717
	8. Diamond, P., A. McGinty, D. Sugrue, H.R. Brady, and C.  Godson. 1999. Regulation of leukocyte trafficking by li poxins. Clin. Chem. Lab. Med. 37:293–297.  	10353475
	9. Node, K., Y. Huo, X. Ruan, B. Yang, M. Spiecker, K. Ley,  D.C. Zeldin, and J.K. Liao. 1999. Anti-inflammatory prop erties of cytochrome P450 epoxygenase-derived eicosanoids.  Science. 285:1276–1279.  	10455056
	10. Munger, K.A., A. Montero, M. Fukunaga, S. Uda, T. Yura,  E. Imai, Y. Kaneda, J.M. Valdivielso, and K.F. Badr. 1999.  Transfection of rat kidney with human 15-lipoxygenase sup presses inflammation and preserves function in experimental  glomerulonephritis. Proc. Natl. Acad. Sci. USA. 96:13375–  13380.  	10557328
	11. Weissmann, G. 1991. Aspirin. Sci. Am. 264:84–90.  	NO_MATCH
	12. Marcus, A.J. 1995. Aspirin as prophylaxis against colorectal  cancer. N. Eng. J. Med. 333:656–658.  	7637730
	13. Takano, T., S. Fiore, J.F. Maddox, H.R. Brady, N.A. Peta sis, and C.N. Serhan. 1997. Aspirin-triggered 15-epi-lipoxin  A4 (LXA4) and LXA4 stable analogs are potent inhibitors of  acute inflammation: evidence for anti-inflammatory recep tors. J. Exp. Med. 185:1693–1704.  	9151906
	14. Clish, C.B., J.A. O’Brien, K. Gronert, G.L. Stahl, N.A. Peta sis, and C.N. Serhan. 1999. Local and systemic delivery of a  stable aspirin-triggered lipoxin prevents neutrophil recruit ment in vivo. Proc. Natl. Acad. Sci. USA. 96:8247–8252.  	10393980
	15. Chiang, N., K. Gronert, C.B. Clish, J.A. O’Brien, M.W.  Freeman, and C.N. Serhan. 1999. Leukotriene B4 receptor  transgenic mice reveal novel protective roles for lipoxins and  aspirin-triggered lipoxins in reperfusion. J. Clin. Invest. 104:  309–316.  	10430612
	16. Hachicha, M., M. Pouliot, N.A. Petasis, and C.N. Serhan.  1999. Lipoxin (LX) A4 and aspirin-triggered 15-epi-LXA4  inhibit tumor necrosis factor a–initiated neutrophil responses  and trafficking: regulators of a cytokine–chemokine axis. J.  Exp. Med. 189:1923–1929.  	10377187
	17. Fiore, S., J.F. Maddox, H.D. Perez, and C.N. Serhan. 1994.  Identification of a human cDNA encoding a functional high  affinity lipoxin A4 receptor. J. Exp. Med. 180:253–260.  	8006586
	18. Fiore, S., and C.N. Serhan. 1995. Lipoxin A4 receptor acti vation is distinct from that of the formyl peptide receptor in  myeloid cells: inhibition of CD11/18 expression by lipoxin  A4-lipoxin A4 receptor interaction. Biochemistry. 34:16678–  16686.  	8527441
	19. Quehenberger, O., E.R. Prossnitz, S.L. Cavanagh, C.G. Coch rane, and R.D. Ye. 1993. Multiple domains of the N-formyl  peptide receptor are required for high-affinity ligand binding.  Construction and analysis of chimeric N-formyl peptide re ceptors. J. Biol. Chem. 268:18167–18175.  	8349692
	20. Castano, A.R., S. Tangri, J.E. Miller, H.R. Holcombe,  M.R. Jackson, W.D. Huse, M. Kronenberg, and P.A. Peter son. 1995. Peptide binding and presentation by mouse CD1.  Science. 269:223–226.  	7542403
	21. Beckman, E.M., S.A. Porcelli, C.T. Morita, S.M. Behar,  S.T. Furlong, and M.B. Brenner. 1994. Recognition of a  lipid antigen by CD1-restricted ab1 T cells. Nature. 372:  691–694.  	7527500
	22. Brezinski, D.A., and C.N. Serhan. 1991. Characterization of  lipoxins by combined gas chromatography and electron-cap ture negative ion chemical ionization mass spectrometry: for mation of lipoxin A4 by stimulated human whole blood. Biol.  Mass Spectrom. 20:45–52.  	1883860
	23. Falk, W., R.H. Goodwin, and E. Leonard. 1980. A 48-well  microchemotaxis assembly for rapid and accurate measure ment of leukocyte migration. J. Immunol. Methods. 33:239–  247.  	6989919
	24. Gronert, K., S.P. Colgan, and C.N. Serhan. 1998. Charac terization of human neutrophil and endothelial cell ligand operated extracellular acidification rate by microphysiometry:  impact of reoxygenation. J. Pharmacol. Exp. Ther. 285:252–  261.  	9536019
	25. Wang, C.R., A.R. Castano, P.A. Peterson, C. Slaughter,  K.F. Lindahl, and J. Deisenhofer. 1995. Nonclassical binding  of formylated peptide in crystal structure of the MHC class Ib  molecule H2-M3. Cell. 82:655–664.  	7664344
	26. Shawar, S.M., R.R. Rich, and E.L. Becker. 1995. Peptides  from the amino-terminus of mouse mitochondrially encoded  NADH dehydrogenase subunit 1 are potent chemoattracta nts. Biochem. Biophys. Res. Commun. 211:812–818.  	7598710
	27. Serhan, C.N., J.F. Maddox, N.A. Petasis, I. Akritopoulou Zanze, A. Papayianni, H.R. Brady, S.P. Colgan, and J.L.  Madara. 1995. Design of lipoxin A4 stable analogs that block  transmigration and adhesion of human neutrophils. Biochem istry. 34:14609–14615.  	7578068
	28. Klein, C., J.I. Paul, K. Sauve, M.M. Schmidt, L. Arcangeli, J.  Ransom, J. Trueheart, J.P. Manfredi, J.R. Broach, and A.J.  Murphy. 1998. Identification of surrogate agonists for the  human FPRL-1 receptor by autocrine selection in yeast. Nat.  Biotechnol. 16:1334–1337.  	9853614
	29. Tessier, P.A., P.H. Naccache, I. Clark-Lewis, R.P. Gladue,  K.S. Neote, and S.R. McColl. 1997. Chemokine networks  in vivo: involvement of C-X-C and C-C chemokines in  neutrophil extravasation in vivo in response to TNF-a. J.  Immunology. 159:3595–3602.  	9317159
	30. Gabay, C., and I. Kushner. 1999. Acute-phase proteins and  other systemic responses to inflammation. N. Engl. J. Med.  340:448–454.  	9971870
	31. Su, S.B., W. Gong, J.L. Gao, W. Shen, P.M. Murphy, J.J.  Oppenheim, and J.M. Wang. 1999. A seven-transmembrane,  G protein–coupled receptor, FPRL1, mediates the chemo tactic activity of serum amyloid A for human phagocytic  cells. J. Exp. Med. 189:395–402.  	9892621
	32. Miettinen, H.M., J.M. Gripentrog, and A.J. Jesaitis. 1998.  Chemotaxis of chinese hamster ovary cells expressing the hu man neutrophil formyl peptide receptor: role of signal trans duction molecules and a5b1 integrin. J. Cell Sci. 111:1921–  1928.  	9645940
	33. Maddox, J.F., M. Hachicha, T. Takano, N.A. Petasis, V.V.  Fokin, and C.N. Serhan. 1997. Lipoxin A4 stable analogs are  potent mimetics that stimulate human monocytes and THP-1  cells via a G-protein-linked lipoxin A4 receptor. J. Biol.  Chem. 272:6972–6978.  	9054386
	34. Villanueva, M.S., C.J. Becker, and E.G. Pamer. 1994. Infec tion with Listeria monocytogenes impairs sialic acid addition to  host cell glycoproteins. J. Exp. Med. 180:2137–2145.  	7964488
	35. Olofsson, S., B. Khanna, and E. Lycke. 1980. Altered kinetic  properties of sialyl and galactosyl transferases associated with  herpes simplex virus infection of GMK and BHK cells. J.  Gen. Virol. 47:1–9.  	6154121
	36. Kim, J.W., and J.M. Cunningham. 1993. N-linked glycosyl ation of the receptor for murine ecotropic retroviruses is al tered in virus-infected cells. J. Biol. Chem. 268:16316–16320.  	8393858
	37. Miettinen, H.M., J.S. Mills, J.M. Gripentrog, E.A. Dratz,  B.L. Granger, and A.J. Jesaitis. 1997. The ligand binding site  of the formyl peptide receptor maps in the transmembrane  region. J. Immunol. 159:4045–4054.  	9378994
	38. Quehenberger, O., Z.K. Pan, E.R. Prossnitz, S.L. Cavanagh,  C.G. Cochrane, and R.D. Ye. 1997. Identification of an  N-formyl peptide receptor ligand binding domain by a gain of-function approach. Biochem. Biophys. Res. Commun. 238:  377–381.  	9299516
	39. Tai, H.H., C. Huang, and N. Chiang. 1997. Structure and  function of prostanoid receptors as revealed by site-directed  mutagenesis. In Eicosanoids and Other Bioactive Lipids in  Cancer, Inflammation and Radiation Injury. K.V. Honn, L.J.  Marnett, R. Jones, and P.Y.-K. Wong, editors. Plenum  Press, New York. 205–209.  	9321954
	40. Fiore, S., S.W. Ryeom, P.F. Weller, and C.N. Serhan. 1992.  Lipoxin recognition sites. Specific binding of labeled lipoxin  A4 with human neutrophils. J. Biol. Chem. 267:16168–  16176.  	1322894
	41. Liang, J.S., and J.D. Sipe. 1995. Recombinant human serum  amyloid A (apoSAAp) binds cholesterol and modulates cho lesterol flux. J. Lipid Res. 36:37–46.  	7706946
	42. Linke, R.P., V. Bock, G. Valet, and G. Rothe. 1991. Inhibi tion of the oxidative burst response of N-formyl peptide stimulated neutrophils by serum amyloid-A protein. Biochem.  Biophys. Res. Commun. 176:1100–1105.  	2039494
	43. Deng, X., H. Ueda, S.B. Su, W. Gong, N.M. Dunlop, J.-L.  Gao, P.M. Murphy, and J.M. Wang. 1999. A synthetic pep tide derived from human immunodeficiency virus type 1  gp120 downregulates the expression and function of  chemokine receptors CCR5 and CXCR4 in monocytes by  activating the 7-transmembrane G-protein-coupled receptor  FPRL1/LXA4R. Blood. 94:1165–1173.  	10438703
	44. Pettit, E.J., and F.S. Fay. 1998. Cytosolic free calcium and  the cytoskeleton in the control of leukocyte chemotaxis.  Physiol. Rev. 28:949–960.  	9790567
	45. Serhan, C.N. 1994. Lipoxin biosynthesis and its impact in in flammatory and vascular events. Biochim. Biophys. Acta. 1212:  1–25.  	8155718
	46. Levy, B.D., V.V. Fokin, J.M. Clark, M.J.O. Wakelam, N.A.  Petasis, and C.N. Serhan. 1999. Polyisoprenyl phosphate  (PIPP) signaling regulates phospholipase D activity: a “stop”  signaling switch for aspirin-triggered lipoxin A4. FASEB J.  13:903–911.  	10224233
	47. Schaldach, C.M., J. Riby, and L.F. Bjeldanes. 1999. Lipoxin  A4: a new class of ligand for the Ah receptor. Biochemistry. 38:  7594–7600.  	10360957
	48. Fernandez-Salguero, P., T. Pineau, D.M. Hilbert, T.  McPhail, S.S.T. Lee, S. Kimura, D.W. Nebert, S. Rudikoff,  J.M. Ward, and F.J. Gonzalez. 1995. Immune system impair ment and hepatic fibrosis in mice lacking the dioxin-binding  Ah receptor. Science. 268:722–726.  	7732381
992200.pdf
	1. Janeway, C.A., Jr. 1992. The immune system evolved to dis tinguish infectious nonself from non-infectious self. Immunol.  Today. 13:11–16.  	1739426
	2. Takahashi, K., M.J. Donovan, R.A. Rogers, and R.A.B.  Ezekowitz. 1998. Distribution of murine mannose receptor  expression from early embryogenesis through to adulthood.  Cell Tissue Res. 292:311–323.  	9560474
	3. Linehan, S.A., L. Martínez-Pomares, P.D. Stahl, and S. Gor don. 1999. Mannose receptor and its putative ligands in nor mal murine lymphoid and nonlymphoid organs: in situ ex pression of mannose receptor by selected macrophages,  endothelial cell, perivascular microglia, and mesangial cells,  but not dendritic cells. J. Exp. Med. 189:1961–1972.  	10377192
	4. Stahl, P.D., and R.A.B. Ezekowitz. 1998. The mannose re ceptor is a pattern recognition receptor involved in host de fense. Curr. Opin. Immunol. 10:50–55.  	9523111
	5. Sallusto, F., M.I. Cella, C. Danieli, and A. Lanzavecchia.  1995. Dendritic cells use macropinocytosis and the mannose  receptor to concentrate macromolecules in the major histo compatibility complex class II compartment: downregulation  by cytokines and bacterial products. J. Exp. Med. 182:389–  400.  	7629501
	6. Prigozy, T.I., P.A. Sieling, D. Clemens, P.L. Stewart, S.M.  Behar, S.A. Porcelli, M.B. Brenner, R.L. Modlin, and M.  Kronenberg. 1997. The mannose receptor delivers lipoglycan  antigens to endosomes for presentation to T cells by CD1b  molecules. Immunity. 6:187–197.  	9047240
	7. Ishizaki, J., K. Hanasaki, K. Higashino, J. Kishimo, N. Kiku chi, O. Ohara, and H. Arita. 1994. Molecular cloning of pan creatic group I phospholipase A2 receptor. J. Biol. Chem.  269:12156–12162.  	7509792
	8. Lambeau, G., P. Ancian, J. Barhanin, and M. Lazdunski.  1994. Cloning and expression of a membrane receptor for  secretory phospholipases A2. J. Biol. Chem. 269:1575–1578.  	8294398
	9. Ancian, P., G. Lambeau, M.-G. Madei, and M. Lazdunski.  1995. The human 180 kDa receptor for secretory phospholi pases A2. J. Biol. Chem. 270:8963–8970.  	NO_MATCH
	10. Jiang, W.P., W.J. Swiggard, C. Heufler, M. Peng, A. Mirza,  R.M. Steinman, and M.C. Nussenzweig. 1995. The receptor  DEC-205 expressed by dendritic cells and thymic epithelial  cells is involved in antigen processing. Nature. 375:151–155.  	7753172
	11. Wu, K., J. Yuan, and L.A. Lasky. 1996. Characterization of a  novel member of the macrophage mannose receptor type C  lectin family. J. Biol. Chem. 271:21323–21330.  	8702911
	12. Taylor, M.E., K. Bezouska, and K. Drickamer. 1992. Contri bution to ligand binding by multiple carbohydrate recogni tion domains in the macrophage mannose receptor. J. Biol.  Chem. 267:1719–1726.  	1730714
	13. Taylor, M.E., and K. Drickamer. 1993. Structural require ments for high affinity binding of complex ligands by the  mannose receptor. J. Biol. Chem. 268:399–404.  	8416946
	14. Weis, W.I., M.E. Taylor, and K. Drickamer. 1998. The  C-type lectin superfamily in the immune system. Immunol.  Rev. 163:19–34.  	9700499
	15. Mullin, N.P., P.G. Hitchen, and M.E. Taylor. 1997. Mecha nism of Ca21 and monosaccharide binding to a C-type car bohydrate-recognition domain of the macrophage mannose  receptor. J. Biol. Chem. 272:5668–5681.  	9038177
	16. Fiete, D., and J.U. Baenziger. 1997. Isolation of the SO4 4-GalNAcb1, 4GlcNAcb1, 2Mana-specific receptor from  rat liver. J. Biol. Chem. 272:14629–14637.  	9169424
	17. Fiete, D., M.C. Beranek, and J.U. Baenziger. 1997. The  macrophage endothelial cell mannose receptor cDNA en codes a protein that binds oligosaccharides terminating with  SO4-4-GalNAcb1,4GlcNAcb or Man at independent sites.  Proc. Natl. Acad. Sci. USA. 94:11256–11261.  	9326596
	18. Fiete, D.J., M.C. Beranek, and J.U. Baenziger. 1998. A cys teine-rich domain of the “mannose” receptor mediates Gal NAc-4-SO4 binding. Proc. Natl. Acad. Sci. USA. 95:2089–  2093.  	9482843
	19. Leteux, C., W. Chai, R.W. Loveless, C.-T. Yuen, L. Uhlin Hansen, Y. Combarnous, M. Jankovic, S.C. Maric, Z. Misu lovin, M.C. Nussenzweig, and T. Feizi. 2000. The cysteine-rich  domain of the macrophage mannose receptor is a multispe cific lectin which recognizes chondroitin sulfates A and B and  sulfated oligosaccharides of blood-group Lewisa and Lewisx  types in addition to the sulfated N-glycans of luteinizing hor mone. J. Exp. Med. 191:1117–1126.  	10748230
	20. Baenziger, J.U., S. Kumar, R.M. Brodbeck, P.L. Smith, and  M.C. Beranek. 1992. Circulatory half-life but not interaction  with the lutropin chorionic-gonadotropin receptor is modu lated by sulfation of bovine lutropin oligosaccharides. Proc.  Natl. Acad. Sci. USA. 89:334–338.  	1729704
	21. Smith, P.L., G.R. Bousfield, S. Kuman, D. Fiete, and J.U.  Baenziger. 1993. Equine lutropin and chorionic gonadotro pin bear oligosaccharides terminating with SO4-4-GalNAc  and Sia-a-2,3Gal, respectively. J. Biol. Chem. 268:795–802.  	8419356
	22. Martínez-Pomares, L., M. Kosco-Vilbois, E. Darley, P. Tree,  S. Herren, J.-Y. Bonnefoy, and S. Gordon. 1996. Fc chi meric protein containing the cysteine-rich domain of the  murine mannose receptor binds to macrophages from splenic  marginal zone and lymph node subcapsular sinus and to ger minal centers. J. Exp. Med. 184:1927–1937.  	8920880
	23. Taylor, M.E., J.T. Conary, M.R. Lennartz, P.D. Stahl, and  K. Drickmer. 1990. Primary structure of the mannose recep tor contains multiple motifs resembling carbohydrate-recog nition domains. J. Biol. Chem. 265:12156–12162.  	2373685
	24. Otwinowski, Z., and W. Minor. 1997. Processing of X-ray  diffraction data collected in oscillation mode. Methods Enzy mol. 276:307–326.  	NO_MATCH
	25. De La Fortelle, E., and G. Bricogne. 1997. Maximum-likeli hood heavy-atom parameter refinement for multiple isomor phous replacement and multiwavelength anomalous diffrac tion methods. Methods Enzymol. 276:472–494.  	NO_MATCH
	26. Abrahams, J.P., and A.G.W. Leslie. 1996. Methods used in  the structure determination of bovine mitochondrial F1 ATP ase. Acta Crystallogr. D. 52:30–42.  	NO_MATCH
	27. Kleywegt, G.J., and T.A. Jones. 1997. Template convolution  to enhance or detect structural features in macromolecular  electron density maps. Acta Crystallogr. D. 53:179–185.  	NO_MATCH
	28. Jones, T.A., and M. Kjeldgaard. 1997. Electron density map  interpretation. Methods Enzymol. 277:173–208.  	NO_MATCH
	29. Brünger, A.T., P.D. Adams, G.M. Clore, P. Gros, R.W.  Grosse-Kunstleve, J.-S. Jiang, J. Kuszewski, M. Nilges, N.S.  Pannu, R.J. Read, et al. 1998. Crystallography and NMR  system: a new software system for macromolecular structure  determination. Acta Crystallogr. D. 54:905–921.  	9757107
	30. Brünger, A.T. 1992. Free R value: a novel statistical quantity  for assessing the accuracy of crystal structures. Nature. 355:  472–475.  	NO_MATCH
	31. Kraulis, P.J. 1991. MOLSCRIPT: a program to produce  both detailed and schematic plots of protein structures. J.  Appl. Crystallogr. 24:946–950.  	NO_MATCH
	32. Merritt, E.A., and M.E.P. Murphy. 1994. Raster3D version  2.0, a program for photorealistic molecular graphics. Acta  Crystallogr. D. 50:869-873.  	NO_MATCH
	33. Nicholls, A., R. Bharadwaj, and B. Honig. 1993. GRASP:  graphical representation and analysis of surface properties.  Biophys. J. 64:A166.  	NO_MATCH
	34. Murzin, A.G., A.M. Lesk, and C. Chothia. 1992. Beta-trefoil  fold patterns of structure and sequence in the Kunitz inhibi tors, interleukins-1b and 1a and fibroblast growth factors. J.  Mol. Biol. 223:531–543.  	1738162
	35. McLachlan, A.D. 1979. Three-fold structural pattern in the  soybean trypsin inhibitory (Kunitz). J. Mol. Biol. 133:557–  563.  	537058
	36. Rutenber, E., and J.D. Robertus. 1991. Structure of ricin  B-chain at 2.5 Å resolution. Proteins. 10:260–269.  	1881882
	37. Zhu, X., H. Komiya, A. Chirino, S. Faham, G.M. Fox, T.  Arakawa, B.T. Hsu, and D.C. Rees. 1991. Three-dimen sional structures of acidic and basic fibroblast growth factors.  Science. 251:90–93.  	1702556
	38. Finzel, B.C., L.L. Clancy, D.R. Holland, S.W. Muchmore,  K.D. Watenpaugh, and H.M. Einspahr. 1989. Crystal struc ture of recombinant human interleukin-1b at 2.0 Å resolu tion. J. Mol. Biol. 209:779–791.  	NO_MATCH
	39. Graves, B.J., M.H. Hatada, W.A. Hendrickson, J.K. Miller,  V.S. Madison, and Y. Satow. 1990. Structure of interleukin 1a at 2.7 Å resolution. Biochemistry. 29:2679–2684.  	2346741
	40. Habazetti, J., D. Gondol, R. Wiltscheck, J. Otlewski, M.  Schleicher, and T.A. Holak. 1992. Structure of hisactophilin  is similar to interleukin-1b and fibroblast growth factor. Na ture. 359:855–858.  	1436061
	41. Harris, N., L.L. Peters, E.M. Eicher, M. Rits, D. Raspberry,  Q.G. Eichbaum, M. Super, and R.A. Ezekowitz. 1994. The  exon-intron structure and chromosomal localization of the  mouse macrophage mannose receptor gene Mrc1: identifica tion of a ricin-like domain at the N-terminus of the receptor.  Biochem. Biophys. Res. Commun. 198:682–692.  	8297379
	42. Weis, W.I., and K. Drickamer. 1996. Structural basis of lec tin-carbohydrate recognition. Annu. Rev. Biochem. 65:441–  473.  	8811186
	43. Pflugrath, J.W., and F.A. Quiocho. 1988. The 2 Å resolution  structure of the sulfate-binding protein involved in active  transport in Salmonella typhimurium. J. Mol. Biol. 200:163–  180.  	3288756
	44. Quiocho, F.A., J.S. Sack, and N.K. Vyas. 1987. Stabilization  of charges on isolated ionic groups sequestered in proteins by  polarized peptide units. Nature. 329:561–564.  	3657977
	45. DiGabriele, A.D., I. Lax, D.I. Chen, C.M. Svahn, M. Jaye, J.  Schlessinger, and W.A. Hendrickson. 1998. Structure of a  heparin-linked biologically active dimer of fibroblast growth  factor. Nature. 393:812–817.  	9655399
	46. Perez, S., N. Mouhous-Riou, N.E. Nifant’ev, Y.E. Tsvet kov, B. Bachet, and A. Imberty. 1996. Crystal and molecular  structure of a histo-blood group antigen involved in cell ad hesion: the Lewisx trisaccharide. Glycobiology. 6:537–542.  	8877374
	47. Ng, K.K.-S., and W.I. Weis. 1997. Structure of a selectin like mutant of mannose binding protein complexed with sial ylated and sulfated Lewisx oligosaccharides. Biochemistry. 36:  979–988.  	9033386
	48. Kogelberg, H., T.A. Frenkiel, S.W. Homans, A. Lubineau,  and T. Feizi. 1996. Conformational studies on the selectin  and natural killer cell receptor ligands sulfo- and sialyl-lacto N-fucopentaoses (SuLNFPII and SLNFPII) using NMR  spectroscopy and molecular dynamics simulations. Compari sons with the nonacidic parent molecule LNFPII. Biochemis try. 35:1954–1964.  	8639679
	49. Simpson, D.Z., P.G. Hitchen, E.L. Elmhirst, and M.E. Tay lor. 1999. Multiple interactions between pituitary hormones  and the mannose receptor. Biochem. J. 343:403–411.  	10510307
	50. Martínez-Pomares, L., J.A. Mahoney, R. Káposzta, S.A.  Linehan, P.D. Stahl, and S. Gordon. 1998. A functional solu ble form of the murine mannose receptor is produced by  macrophages in vitro and is present in mouse serum. J. Biol.  Chem. 273:23376–23380.  	9722572
	51. Hodel, A., S.-H. Kim, and A.T. Brünger. 1992. Model bias  in macromolecular crystal structures. Acta Crystallogr. A. 48:  851–858.  	NO_MATCH
	52. Kolatkar, A.R., and W.I. Weis. 1996. Structural basis of ga lactose recognition by C-type animal lectins. J. Biol. Chem.  271:6679–6685.  	8636086
J. Biol. Chem.-2000-Askarian-Amiri-17241-8.pdf
	1. Tate, W. P., and Mannering, S. A. (1996) Mol. Microbiol. 21, 213–219  	NO_MATCH
	2. Freistroffer, D. V., Pavlov, M. Y., MacDougall, J., Buckingham, R. H., and  Ehrenberg, M. (1997) EMBO J. 16, 4126–4133  	NO_MATCH
	3. Craigen, W. J., Cook, R. G., Tate, W. P., and Caskey, C. T. (1985) Proc. Natl.  Acad. Sci. U. S. A. 82, 3616–3620  	NO_MATCH
	4. Mikuni, O., Ito, K., Moffat, J., Matsumura, K., McCaughan, K., Nobukuni, T.,  Tate, W. P., and Nakamura, Y. (1994) Proc. Natl. Acad. Sci. U. S. A. 91,  5798–5802  	NO_MATCH
	5. Tate, W. P., Beaudet, A. L., and Caskey, C. T. (1973) Proc. Natl. Acad. Sci.  U. S. A. 70, 2350–2355  	NO_MATCH
	6. Zhouravleva, G., Frolova, L., Le Goff, X., Le Guellec, R., Inge-Vechtomov, S.,  Kisselev, L., and Philippe, M. (1995) EMBO J. 14, 4065–4072  	NO_MATCH
	7. Ito, K., Ebihara, K., Uno, M., and Nakamura, Y. (1996) Proc. Natl. Acad. Sci.  U. S. A. 93, 5443–5448  	NO_MATCH
	8. Lee, C. C., Timms, K. M., Trotman, C. N., and Tate, W. P. (1987) J. Biol. Chem.  262, 3548–3552  	NO_MATCH
	9. Pel, H. J., Maat, C., Rep, M., and Grivell, L. A. (1992) Nucleic Acids Res. 20,  6339–6346  	NO_MATCH
	10. Pel, H. J., Rozenfeld, S., and Bolotin-Fukuhara, M. (1996) Curr. Genetics 30,  19–28  	NO_MATCH
	11. Zhang, Y. L., and Spremulli, L. L. (1998) Biochim. Biophys. Acta 1443,  245–250  	NO_MATCH
	12. Tate, W. P., Poole, E. S., and Mannering, S. A. (1996) Prog. Nucleic Acids Res.  Mol. Biol. 52, 293–335  	NO_MATCH
	13. Jukes, T. H., and Osawa, S. (1993) Comp. Biochem. Physiol. 106B, 489–494  	NO_MATCH
	14. Weiss-Brummer, B., Huttenhofer, A., and Kaudewitz, F. (1984) Mol. Gen.  Genet. 198, 62–68  	NO_MATCH
	15. John, U. P., Willson, T. A., Linnane, A. W., and Nagley, P. (1986) Nucleic Acids  Res. 14, 7437–7451  	NO_MATCH
	16. Pel, H. J., Rep, M., Dubbink, H. J., and Grivell, L. A. (1993) Nucleic Acids Res.  21, 5308–5315  	NO_MATCH
	17. Papadopoulou, B., Dekker, P., Blom, J., and Grivell, L. A. (1990) EMBO J. 9,  4135–4143  	NO_MATCH
	18. Matthews, D. E., Hessler, R. A., Denslow, N. D., Edwards, J. E., and O’Brien,  T. W. (1982) J. Biol. Chem. 257, 8788–8794  	NO_MATCH
	19. Daum, G., Bo¨hni, P. C., and Schatz, G. (1982) J. Biol. Chem. 257, 13028–13033 17248Functional Characterization of Yeast mRF1  	NO_MATCH
	20. Lowry, O. H., Rosebrough, N. J., Farr, A. L., and Randall, R. J. (1951) J. Biol.  Chem. 193, 265–275  	NO_MATCH
	21. Caskey, C. T., Beaudet, A. L., Scolnick, E. M., and Rosman, M. (1971) Proc.  Natl. Acad. Sci. U. S. A. 68, 3163–3167  	NO_MATCH
	22. Poole, E. S., Brimacombe, R., and Tate, W. P. (1997) RNA 3, 974–982  	NO_MATCH
	23. Claros, M. G., and Vincens, P. (1996) Eur. J. Biochem. 241, 779–786  	NO_MATCH
	24. Brown, C. M., and Tate, W. P. (1994) J. Biol. Chem. 269, 33164–33170  	NO_MATCH
	25. Pel, H. J., Rep, M., and Grivell, L. A. (1992) Nucleic Acids Res. 20, 4423–4428  	NO_MATCH
	26. Devereux, J., Haeberili, P., and Snithies, O. (1984) Nucleic Acids Res. 14,  387–395  	NO_MATCH
	27. Nakamura, Y., and Ito, K. (1998) Genes Cells 3, 265–278  	NO_MATCH
	28. Wilson, D. N., Dalphin, M. E., Pel, H. J., Major, L. L., Manson, J. B., and Tate,  W. P. (2000) in The Ribosome: Structure, Function, Antibiotics, and Cellular  Interactions (Garrett, R. A., Douthwaite, S. R., Liljas, A., Matheson, A. T.,  Moore, P. B., and Noller, H. F., eds.), pp. 495–507, ASM Press, Washington,  D. C.  	NO_MATCH
	29. Moffat, J. G., and Tate, W. P. (1994) J. Biol. Chem. 269, 18899–18903  	NO_MATCH
	30. Yoshimura, K., Ito, K., and Nakamura, Y. (1999) Genes Cells 4, 253–266  	NO_MATCH
	31. Clemons, W. M., Jr., May, J. L. C., Wimberly, B. T., McCutcheon, J. P., Capel,  M. S., and Ramakrishnan, V. (1999) Nature 400, 833–840  	NO_MATCH
	32. Cate, J. H., Yusupov, M. S., Yusupova, G. Zh., Earnest, T. N., and Noller, H. F.  (1999) Science 285, 2095–2104  	NO_MATCH
	33. Moazed, D., and Noller, H. F. (1986) Cell 47, 985–994  	NO_MATCH
	34. Moazed, D., and Noller, H. F. (1990) J. Mol. Biol. 211, 135–145  	NO_MATCH
	35. Mueller, F., and Brimacombe, R. (1997) J. Mol. Biol. 271, 524–544  	NO_MATCH
	36. Ito, K., Uno, M., and Nakamura, Y. (2000) Nature 403, 680–684  	NO_MATCH
	37. Moazed, D., Samaha, R. R., Gualerzi, C., and Noller, H. F. (1995) J. Mol. Biol.  248, 207–210  	NO_MATCH
	38. Dahlquist, K., and Puglisi, J. D. (1995) Nucleic Acids Symp. Ser. 33, 170–171  	NO_MATCH
	39. Spurio, R., Paci, M., Pawlik, R. T., Lateana, A., Digiacco, B. V., Pon, C. L., and  Gualerzi, C. O. (1991) Biochimie 73, 1001–1006  	NO_MATCH
	40. McCaughan, K. K., Poole, E. S., Pel, H. J., Mansell, J. B., Mannering, S. A., and  Tate, W. P. (1998) Biol. Chem. 379, 857–866  	NO_MATCH
	41. Yoshizawa, S., Fourmy, D., and Puglisi, J. D. (1999) Science 285, 1722–1725  	NO_MATCH
J. Biol. Chem.-2000-Newton-15128-34.pdf
	1. Chrivia, J. C., Kwok, R. P., Lamb, N., Hagiwara, M., Montminy, M. R., and  Goodman, R. H. (1993) Nature 365, 855–859  	NO_MATCH
	2. Eckner, R., Ewen, M. E., Newsome, D., Gerdes, M., DeCaprio, J. A., Lawrence,  J. B., and Livingston, D. M. (1994) Genes Dev. 8, 869–884  	NO_MATCH
	3. Shikama, N., Lyon, J., and La Thangue, N. B. (1997) Trends Cell Biol. 7,  230–236  	NO_MATCH
	4. Horvai, A. E., Xu, L., Korzus, E., Brard, G., Kalafus, D., Mullen, T. M., Rose,  D. W., Rosenfeld, M. G., and Glass, C. K. (1997) Proc. Natl. Acad. Sci.  U. S. A. 94, 1074–1079  	NO_MATCH
	5. Xu. L., Lavinsky, R. M., Dasen, J. S., Flynn, S. E., McInerney, E. M., Mullen,  T. M., Heinzel, T., Szeto, D., Korzus, E., Kurokawa, R., Aggarwal, A. K.,  Rose, D. W., Glass, C. K., and Rosenfeld, M. G. (1997) Nature 395, 301–306  	NO_MATCH
	6. Boyes, J., Byfield, P., Nakatani, Y., and Ogryzko, V. (1998) Nature 396,  594–598  	NO_MATCH
	7. Zhang, W., and Bieker, J. J. (1998) Proc. Natl. Acad. Sci. U. S. A. 95,  9855–9860  	NO_MATCH
	8. Gingras, S., Simard, J., Groner, B., and Pfitzner, E. (1999) Nucleic Acids Res.  27, 2722–2729  	NO_MATCH
	9. Hung, H. L., Lau, J., Kim, A. Y., Weiss, M. J., and Blobel, G. A. (1999) Mol.  Cell. Biol. 19, 3496–3505  	NO_MATCH
	10. Yang, X. J., Ogryzko, V. V., Nishikawa, J., Howard, B. H., and Nakatani, Y.  (1996) Nature 382, 319–324  	NO_MATCH
	11. Bannister, A. J., and Kouzarides, T. (1996) Nature 384, 641–643  	NO_MATCH
	12. Wolffe, A. P., and Hayes, J. J. (1999) Nucleic Acids Res. 27, 711–720  	NO_MATCH
	13. Nakajima, T., Uchida, C., Anderson, S. F., Lee, C. G., Hurwitz, J., Parvin, J. D.,  and Montminy, M. (1997) Cell 90, 1107–1112  	NO_MATCH
	14. Cho, H., Orphanides, G., Sun, X., Yang, X. J., Ogryzko, V., Lees, E., Nakatani,  Y., and Reinberg, D. (1998) Mol. Cell. Biol. 18, 5355–5363  	NO_MATCH
	15. Kamei, Y., Xu, L., Heinzel, T., Torchia, J., Kurokawa, R., Gloss, B., Lin, S. C.,  Heyman, R. A., Rose, D. W., Glass, C. K., and Rosenfeld, M. G. (1996) Cell  85, 403–414  	NO_MATCH
	16. Kwok, R. P., Lundblad, J. R., Chrivia, J. C., Richards, J. P., Bachinger, H. P.,  Brennan, R. G., Roberts, S. G., Green, M. R., and Goodman, R. H. (1994)  Nature 370, 223–226  	NO_MATCH
	17. Parker, D., Ferreri, K., Nakajima, T., LaMorte, V. J., Evans, R., Koerber, S. C.,  Hoeger, C., and Montminy, M. R. (1996) Mol. Cell. Biol. 16, 694–703  	NO_MATCH
	18. Radhakrishnan, I., Perez-Alvarado, G. C., Parker, D., Dyson, H. J., Montminy,  M. R., and Wright, P. E. (1997) Cell 91, 741–752  	NO_MATCH
	19. Schwabe, J. W., and Klug, A. (1994) Nat. Struct. Biol. 1, 345–349  	NO_MATCH
	20. Mackay, J. P., and Crossley, M. (1998) Trends Biochem. Sci. 23, 1–4  	NO_MATCH
	21. Johnson, M. L., Correia, J. J., Yphantis, D. A., and Halvorson, H. R. (1981)  Biophys. J. 36, 575–588  	NO_MATCH
	22. Hayes, D. B., Laue, T., and Philo, J. (1995) SEDNTERP, University of New  Hampshire, Durham, NH  	NO_MATCH
	23. Bax, A., and Davis, D. G. (1985) J. Magn. Reson. 65, 355–360  	NO_MATCH
	24. Kumar, A., Ernst, R. R., and Wu¨thrich, K. (1980) Biochem. Biophys. Res.  Commun. 95, 1–6  	NO_MATCH
	25. Piantini, U., Sørensen, O. W., and Ernst, R. R. (1982) J. Am. Chem. Soc. 104,  6800–6801  	NO_MATCH
	26. Kowalski, K., Czolij, R., King, G. F., Crossley, M., and Mackay, J. P. (1999)  J. Biomol. NMR 13, 249–262 15134Zinc Bundles within CBP  	NO_MATCH
	27. Ausubel, F., Brent, R., Kingston, R. E., Moore, D. D., Seidman, J. G., Smith,  J. A., and Struhl, K. (1997) Short Protocols in Molecular Biology, 3rd Ed.,  John Wiley & Sons, Inc., New York  	8889332
	28. Sambrook, J., Fritsch, E. F., and Maniatis, T. (1989) Molecular Cloning: A  Laboratory Manual, 2nd Ed., Cold Spring Harbor Laboratory, Cold Spring  Harbor, NY  	NO_MATCH
	29. Wu¨thrich, K. (1986) NMR of Proteins and Nucleic Acids, John Wiley & Sons,  Inc., New York  	NO_MATCH
	30. Wishart, D. S., Sykes, B. D., and Richards, F. M. (1992) Biochemistry 31,  1647–1651  	NO_MATCH
	31. Bisotto, S., Minorgan, S., and Rehfuss, R. P. (1996) J. Biol. Chem. 271,  17746–17750  	NO_MATCH
	32. Swope, D. L., Mueller, C. L., and Chrivia, J. C. (1996) J. Biol. Chem. 271,  28138–28145  	NO_MATCH
	33. Yoshida, E., Nakajima, T., Murakami, K., and Fukamizu, A. (1998) Gene  (Amst.) 208, 307–314  	NO_MATCH
	34. Arany, Z., Huang, L. E., Eckner, R., Bhattacharya, S., Jiang, C., Goldberg,  M. A., Bunn, H. F., and Livingston, D. M. (1996) Proc. Natl. Acad. Sci.  U. S. A. 93, 12969–12973  	NO_MATCH
	35. Gerritsen, M. E., Williams, A. J., Neish, A. S., Moore, S., Shi, Y., and Collins,  T. (1997) Proc. Natl. Acad. Sci. U. S. A. 94, 2927–2932  	NO_MATCH
	36. Bhattacharya, S., Michels, C. L., Leung, M. K., Arany, Z. P., Kung, A. L., and  Livingston, D. M. (1999) Genes Dev. 13, 64–75  	NO_MATCH
	37. Wang, G. L., and Semenza, G. L. (1995) J. Biol. Chem. 270, 1230–1237  	NO_MATCH
	38. Thanos, D., and Maniatis, T. (1995) Cell 80, 529–532  	NO_MATCH
	39. Glenn, D. J., and Maurer, R. A. (1999) J. Biol. Chem. 274, 36159–36167  	NO_MATCH
	40. Schmeichel, K. L., and Beckerle, M. C. (1994) Cell 79, 211–219  	NO_MATCH
	41. Saurin, A. J., Borden, K. L., Boddy, M. N., and Freemont, P. S. (1996) Trends  Biochem. Sci. 21, 208–214  	NO_MATCH
	42. Fox, A. H., Liew, C., Holmes, M., Kowalski, K., Mackay, J., and Crossley, M.  (1999) EMBO J. 18, 2812–2822  	NO_MATCH
	43. Shioda, T., Lechleider, R. J., Dunwoodie, S. L., Li, H., Yahata, T., de Cae stecker, M. P., Fenner, M. H., Roberts, A. B., and Isselbacher, K. J. (1998)  Proc. Natl. Acad. Sci. U. S. A. 95 9785–9790  	NO_MATCH
	44. Saha, V., Chaplin, T., Gregorini, A., Ayton, P., and Young, B. D. (1995) Proc.  Natl. Acad. Sci. U. S. A. 92, 9737–9741  	NO_MATCH
	45. Aasland, R., Gibson, T. J., and Stewart, A. F. (1995) Trends Biochem. Sci. 20,  56–59  	NO_MATCH
J. Biol. Chem.-2000-Shanmugavelu-1802-6.pdf
	1. Hammock, B. D. (1985) in Comprehensive Insect Physiology, Biochemistry, and  Pharmacology (Kerkut, G. A., and Gilbert, L. I., eds) pp. 431–72, Pergamon  Press, New York  	NO_MATCH
	2. Abdel-Aal, Y. A. I., and Hammock, B. D. (1986) Science 233, 1073–1076  	NO_MATCH
	3. Wroblewski, V. J., Harshman, L. G., Hanzlik, T. N., and Hammock, B. D.  (1990) Arch. Biochem. Biophys. 278, 461–466  	NO_MATCH
	4. Crossley, A. C. (1985) in Comprehensive Insect Physiology, Biochemistry, and  Pharmacology (Kerkut, G. A., and Gilbert, L. I., eds) pp. 487–515,  Pergamon Press, New York  	NO_MATCH
	5. Locke, M., and Russell, V. W. (1998) in Microscopic Anatomy of Invertebrates.  (Harrison, F. W., and Locke, M., eds) Vol. 11B, pp. 687–709, Wiley-Liss Inc.,  New York  	NO_MATCH
	6. Booth, T. F., Bonning, B. C., and Hammock, B. D. (1992) Tissue & Cell 24,  267–282  	NO_MATCH
	7. Ichinose, R., Nakamura, A., Yamoto, T., Booth, T. F., Maeda, S., and  Hammock, B. D. (1992) Insect Biochem. Mol. Biol. 22, 893–904  	NO_MATCH
	8. Ichinose, R., Kamita, S. G., Maeda, S., and Hammock, B. D. (1992) Pestic.  Biochem. Physiol. 42, 13–23  	NO_MATCH
	9. Bonning, B. C., Booth, T. F., and Hammock, B. D. (1997) Arch. Insect Biochem.  Physiol. 34, 275–286  	NO_MATCH
	10. Bonning, B. C., Ward, V. K., van Meer, M., Booth, T. F., and Hammock, B. D.  (1997) Proc. Natl. Acad. Sci. U. S. A. 94(12), 6007–6012  	NO_MATCH
	11. Chomczynski, P., and Sacchi, N. (1987) Anal. Biochem. 162, 156–159  	NO_MATCH
	12. Vaughn, J. L., Goodwin, R. H., Tompkins, G. J., and McCawley, P. (1977) In  Vitro 13, 213–217  	NO_MATCH
	13. Bonning, B. C., Hirst, M., Possee, R. D., and Hammock, B. D. (1992) Insect  Biochem. Mol. Biol. 22, 453–458  	NO_MATCH
	14. O’Reilly, D. R., Miller, L. K., and Luckow, V. A. (1992) Baculovirus Expression  Vectors a Laboratory Manual, W. H. Freeman and Company, New York  	NO_MATCH
	15. Hammock, B. D., and Roe, R. M. (1985) Methods in Enzymol. 111, 487–495  	NO_MATCH
	16. Hammock, B. D., Bonning, B., Possee, R. D., Hanzlik, T. N., and Maeda, S.  (1990) Nature 344, 458–461  	NO_MATCH
	17. Crameri, R., and Suter, M. (1993) Gene 137, 69–75  	NO_MATCH
	18. Crameri, R., Jaussi, R., Menz, G., and Blaser, K. (1994) Eur. J. Biochem. 226,  53–58  	NO_MATCH
	19. Altschul, S. F., Gish, W., Miller, W. M., Eyers, E. W., and Lipman, D. J. (1990)  J. Mol. Biol. 215, 403–410  	NO_MATCH
	20. Luo, W., and Lin, S. (1997) BioTechniques 23, 631–632  	NO_MATCH
	21. Sambrook, J., Fritsch, E. F., and Maniatis, T. (1989) Molecular Cloning, A  Laboratory Manual, Cold Spring Harbor Laboratory, New York  	NO_MATCH
	22. Snyder, M. J., Walding, J. K., and Feyereisen, F. (1995) Insect Biochem. Mol.  Biol. 25, 455–465  	NO_MATCH
	23. Snyder, M. J., Stevens, J. L., Anderson, J. F., and Feyereisen, R. (1995) Arch.  Insect Biochem. Biophys. 321, 13–20  	NO_MATCH
	24. Bonning, B. C., Possee, R. D., and Hammock, B. D. (1999) J. Invertebr. Pathol.  73, 234–236  	NO_MATCH
	25. Haunerland, N. H. (1996) Insect Biochem. Molec. Biol. 26, 755–765  	NO_MATCH
	26. Hanzlik, T. N., Abdel-Aal, Y. A. I., Harshman, L. G., and Hammock, B. D.  (1989) J. Biol. Chem. 264, 12419–12425  	NO_MATCH
	27. Carcamo, J., Ravera, M. W., Brissette, R., Dedova, O., Beasley, J. R., Alam Moghe, A., Wan, C., Blume, A., and Mandecki, W. (1998) Proc. Natl. Acad.  Sci. U. S. A. 95, 11146–11151  	NO_MATCH
J. Biol. Chem.-2000-Choi-1723-30.pdf
	1. Zeevaart, J. A. D., and Creelman, R. A. (1988) Annu. Rev. Plant Physiol. Plant  Mol. Biol. 39, 439–473  	NO_MATCH
	2. Leung, J., and Giraudat, J. (1998) Annu. Rev. Plant Physiol. Plant Mol. Biol.  49, 199–222  1730Abscisic Acid-responsive Element Binding Factors  	NO_MATCH
	3. Shinozaki, K., and Yamaguchi-Shinozaki, K. (1996) Curr. Opin. Biotechnol. 7,  161–167  	NO_MATCH
	4. Thomashow, M. F. (1998) Plant Physiol. 118, 1–7  	NO_MATCH
	5. Ingram, J., and Bartels, D. (1996) Annu. Rev. Plant Physiol. Plant Mol. Biol.  47, 377–403  	NO_MATCH
	6. Busk, P. K., and Pages, M. (1998) Plant Mol. Biol. 37, 425–435  	NO_MATCH
	7. Guiltinan, M. J., Marcotte, W. R., and Quatrano, R. S. (1990) Science 250,  267–271  	NO_MATCH
	8. Giuliano, G, Pichersky, E., Malik, V. S., Timko, M. P., Scolnik, P. A., and  Cashmore, A. R. (1988) Proc. Natl. Acad. Sci. U. S. A. 85, 7089–7093  	NO_MATCH
	9. Menkens, A. E., Schindler, U., and Cashmore, A. R. (1995) Trend Biochem Sci.  20, 506–510  	NO_MATCH
	10. Izawa, T., Foster, R., and Chua, N.-H. (1993) J. Mol. Biol. 230, 1131–1144  	NO_MATCH
	11. Oeda, K., Salinas, J., and Chua, N.-H. (1991) EMBO J. 10, 1793–1802  	NO_MATCH
	12. Schindler, U., Menkens, A. E., Beckmann, H., Ecker, J. R., and Cashmore,  A. R. (1992) EMBO J. 4, 1261–1273  	NO_MATCH
	13. Lu, G., Paul, A.-L., McCarty D. R., and Ferl, R. J. (1996) Plant Cell 8, 847–857  	NO_MATCH
	14. Kim, S. Y., and Thomas, T. L. (1998) J. Plant Physiol. 152, 607–613  	NO_MATCH
	15. Kim, S. Y., Chung, H.-J., and Thomas, T. L. (1997) Plant J. 11, 1237–1251  	NO_MATCH
	16. Foster, R., Izawa, T., and Chua, N.-H. (1994) FASEB J. 8, 192–200  	NO_MATCH
	17. Meshi, T., and Iwabuchi, M. (1995) Plant Cell Physiol. 36, 1405–1420  	NO_MATCH
	18. Kusano, T., Berberich, T., Harada, M., Suzuki, N., and Sugawara, K. (1995)  Mol. Gen. Genet. 248, 507–517  	NO_MATCH
	19. Nakagawa, H., Ohmiya, K., and Hattori, T. (1996) Plant J. 9, 217–227  	NO_MATCH
	20. Yamaguchi-Shinozaki, K., and Shinozaki, K. (1994) Plant Cell 6, 251–264  	NO_MATCH
	21. Busk, P. K., Jensen, A. B., and Pages, M. (1997) Plant J. 11, 1285–1295  	NO_MATCH
	22. Ono, A., Izawa, T., Chua, N.-H., and Shimamoto, K. (1996) Plant Physiol. 112,  483–491  	NO_MATCH
	23. Chung, H.-J. (1996) Analysis of the 59 Upstream Region of the Carrot Dc3 Gene:  Bipartite Structure of the Dc3 Promoter for Embryo-specific and ABA inducible Expression. Doctoral Dissertation, Texas A & M University  	NO_MATCH
	24. Pla, M., Vilardell, J., Guiltinan, M. J., Marcotte, W. R., Niogret, M. F.,  Quatrano, R. S., and Pages, M. (1993) Plant Mol. Biol. 21, 259–266  	NO_MATCH
	25. Ausubel, F. M., Brent, R., Kingston, R. E., Moore, D. D., Seidman, J. G., Smith,  J. A., and Struhl, K. (1994) Current Protocols in Molecular Biology, Green  Publishing Associates/Wiley Interscience, New York  	NO_MATCH
	26. Sambrook, J., Fritsch, E. F., and Maniatis, T. (1989) Molecular Cloning: A  Laboratory Manual, 2nd Ed., Cold Spring Harbor Laboratory, Cold Spring  Harbor, NY  	NO_MATCH
	27. Guthrie, C., and Fink, G. R. (eds) (1991) Guide to Yeast Genetics and Molecular  Biology, Methods in Enzymology, Vol. 194, Academic Press, San Diego  	NO_MATCH
	28. Altschul, S. F., Gish, W., Miller, W., Myers, E. W., and Lipman, D. J. (1990) J.  Mol. Biol. 215, 403–410  	NO_MATCH
	29. Thompson, J. D., Higgins, D. G., and Gibson, T. J. (1994) Nucleic Acids Res. 22,  4673–4680  	NO_MATCH
	30. Chomczynski, P., and Mackey, K. (1995) Biotechniques 19, 942–945  	NO_MATCH
	31. Ma, J., and Ptashne, M. (1987) Cell 51, 113–119  	NO_MATCH
	32. Landschulz, W. H., Johnson, P. F., and McKnight, S. L. (1988) Science 240,  1759–1764  	NO_MATCH
	33. Kemp, B. E., and Pearson, R. B. (1990) Trends Biochem. Sci. 15, 342–346  	NO_MATCH
	34. Lam, E., and Chua, N.-H. (1991) J. Biol. Chem. 266, 17131–17135  	NO_MATCH
	35. Pollock, R., and Treisman. R. (1990) Nucleic Acids Res. 18, 6197–6204  	NO_MATCH
	36. Thomas, T. L., Chung, H.-J., and Nunberg, A. N. (1997) in Signal Transduction  in Plants (Aducci, P. ed.) pp. 23–43, Birkhaeuser Verlag, Basel, Switzerland  	NO_MATCH
	37. de Bruxelles G. L., Peacock, W. J., Dennis, E. S., and Dolferus, R. (1996) Plant  Physiol. 111, 381–391  	NO_MATCH
	38. Jaglo-Ottosen, K. R., Gilmour S. J., Zarka, D. G., Schabenberger, and  Thomashow, M. F. (1998) Science 280, 104–106  	NO_MATCH
	39. Liu, Q, Kasuga, M., Sakuma, Y., Abe, H., Miura, S., Yamaguchi-Shinozaki, K.,  and Shinozaki, K. (1998) Plant Cell 10, 1391–1406  	NO_MATCH
	40. Hollung, K., Espelund, M., Schou, K., and Jakobsen, K. S. (1997) Plant Mol.  Biol. 35, 561–571  	NO_MATCH
	41. Ishitani, M., Xiong, L., Stevenson, B., and Zhu, J.-K. (1997) Plant Cell 9,  1935–1949  	NO_MATCH
J Pharmacol Exp Ther-2000-Cousins-104-13.pdf
	Anderson IM and Cowen PJ (1992) Effect of pindolol on endocrine and temperature  responses to buspirone in healthy volunteers. Psychopharmacol Ser (Berl) 106:  428–432.  	1570392
	Anderson IM, Cowen PJ and Grahame-Smith DG (1990) The effects of gepirone on  neuroendocrine function and temperature in humans. Psychopharmacol Ser (Berl)  100:498–503.  	2157231
	Azmitia EC (1981) Bilateral serotonergic projections to the dorsal hippocampus of  the rat: Simultaneous localization of 3H–5HT and HRP after retrograde transport.  J Comp Neurol 203:737–743.  	6173402
	Balcells-Olivero M, Cousins MS and Seiden LS (1998) Holtzman and Harlan  Sprague-Dawley rats: Differences in 72-sec performance and 8-hydroxy-di propylamino-tetralin-induced hypothermia. J Pharmacol Exp Ther 286:742–752.  	9694929
	Chen NH and Reith ME (1994) Effects of locally applied cocaine, lidocaine, and  various uptake blockers on monoamine transmission in the ventral tegmental area  of freely moving rats: A microdialysis study on monoamine interrelationships.  J Neurochem 63:1701–1713.  	7931325
	Cousins MS and Salamone JD (1996) Involvement of ventrolateral striatal dopamine  in movement initiation and execution: A microdialysis and behavioral investiga tion. Neuroscience 70:849–859.  	8848171
	Cowen PJ, Power AC, Ware CJ and Anderson IM (1994) 5-HT1A receptor sensitivity  in major depression. A neuroendocrine study with buspirone. Br J Psychiatry  164:372–379.  	8199791
	De Vry J (1995) 5-HT1A receptor agonists: Recent developments and controversial  issues. Psychopharmacol Ser (Berl) 121:1–26.  	8539333
	Fletcher PJ (1994) Effects of 8-OH-DPAT, 5-CT and muscimol on behaviour main tained by a DRL 20 schedule of reinforcement, following microinjection into the  dorsal or median raphe nuclei. Behav Pharmacol 5:326–336.  	NO_MATCH
	Fletcher PJ (1995) Effects of combined or separate 5,7-dihydroxytryptamine lesions  of the dorsal and median raphe nuclei on responding maintained by a DRL 20s  schedule of food reinforcement. Brain Res 675:45–54.  	7540930
	Forster EA, Cliffe IA, Bill DJ, Dover GM, Jones D, Reilly Y and Fletcher A (1995) A  pharmacological profile of the selective silent 5-HT1A receptor antagonist, WAY 100635. Eur J Pharmacol 281:81–88.  	8566121
	Fowler SC and Liou JR (1994) Microcatalepsy and disruption of forelimb usage  during operant behavior: Differences between dopamine D1 (SCH-23390) and D2  (raclopride) antagonists. Psychopharmacology 115:24–30.  	7862901
	Gershon ES, Badner JA, Goldin LR, Sanders AR, Cravchik A and Detera-Wadleigh  SD (1998) Closing in on genes for manic-depressive illness and schizophrenia.  Neuropsychopharmacology 18:233–242.  	9509491
	Gonzalez LE, File SE and Overstreet DH (1998) Selectively bred lines of rats differ  in social interaction and hippocampal 5-HT1A receptor function: A link between  anxiety and depression? Pharmacol Biochem Behav 59:787–792.  	9586832
	Gudelsky GA, Koenig JI and Meltzer HY (1986) Thermoregulatory responses to  serotonin (5-HT) receptor stimulation in the rat: Evidence for opposing roles of  5-HT2 and 5-HT1A receptors. Neuropharmacology 25:1307–1313.  	2951611
	Gupta ML, Gupta TK and Bhargava KP (1967) Central anticholinergic activity of  imipramine and allied drugs. Can J Physiol Pharmacol 45:353–355.  	6040438
	Heffner TG, Hartman JA and Seiden LS (1980) A rapid method for the regional  dissection of the rat brain. Pharmacol Biochem Behav 13:453–456.  	7422701
	Jolly DC, Richards JB and Seiden LS (1999) Serotonergic mediation of DRL 72-s  behavior: Receptor subtype involvement in a behavioral screen for antidepressant  drugs. Biol Psychiatry 45:1151–1162.  	10331107
	Jordan S, Kramer GL, Zukas PK, Moeller M and Petty F (1994) In vivo biogenic  amine efflux in medial prefrontal cortex with imipramine, fluoxetine, and fluvox amine. Synapse (NY) 18:294–297.  	7886621
	Keppel G (1991) Design and Analysis: A Researcher’s Handbook, Prentice-Hall, Inc.,  Upper Saddle River, NJ.  	NO_MATCH
	Knapp DJ, Overstreet DH and Crews FT (1998) Brain 5-HT1A receptor autoradiog raphy and hypothermic responses in rats bred for differences in 8-OH-DPAT  sensitivity. Brain Res 782:1–10.  	9519243
	Koenig JI, Meltzer HY and Gudelsky GA (1988) 5-Hydroxytryptamine1A receptor mediated effects of buspirone, gepirone and ipsapirone. Pharmacol Biochem Behav  29:711–715.  	2901112
	Kostowski W, Dyr W, Krzascik P, Jarbe T and Archer T (1992) 5-Hydroxytrypt amine1A receptor agonists in animal models of depression and anxiety. Pharmacol  Toxicol 71:24–30.  	1387935
	Lesch KP, Mayer S, Disselkamp-Tietze J, Hoh A, Schoellnhammer G and Schulte  HM (1990) Subsensitivity of the 5-hydroxytryptamine1A (5-HT1A) receptor mediated hypothermic response to ipsapirone in unipolar depression. Life Sci  46:1271–1277.  	1971701
	Lin MT, Wu JJ and Tsay BL (1983) Serotonergic mechanisms in the hypothalamus  mediate thermoregulatory responses in rats. Naunyn-Schmiedeberg’s Arch Phar macol 322:271–278.  	6866135
	Lucki I (1998) The spectrum of behaviors influenced by serotonin. Biol Psychiatry  44:151–162.  	9693387
	Marek GJ, Li AA and Seiden LS (1989) Evidence for involvement of 5-hydroxy tryptamine1 receptors in antidepressant-like drug effects on differential reinforcement-of-low-rate 72-second behavior. J Pharmacol Exp Ther 250:60 –  71.  	2746511
	McGuire PS and Seiden LS (1980) The effects of tricyclic antidepressants on perfor mance under a differential-reinforcement-of-low-rates schedule in rats. J Phar macol Exp Ther 214:635–641.  	7400965
	Meltzer HY and Maes M (1995) Effects of ipsapirone on plasma cortisol and body  temperature in major depression. Biol Psychiatry 38:450–457.  	8672605
	Overstreet DH, Daws LC, Schiller GD, Orbach J and Janowsky DS (1998) Cholin ergic/serotonergic interactions in hypothermia: Implications for rat models of  depression. Pharmacol Biochem Behav 59:777–785.  	9586831
	Overstreet DH, Rezvani AH, Knapp DJ, Crews FT and Janowsky DS (1996) Further  selection of rat lines differing in 5-HT1A receptor sensitivity: Behavioral and  functional correlates. Psychiatr Genet 6:107–117.  	8902886
	Overstreet DH, Rezvani AH, Pucilowski O, Gause L and Janowsky DS (1994) Rapid  selection for serotonin-1A sensitivity in rats. Psychiatr Genet 4:57–62.  	8049904
	Pollard GT and Howard JL (1986) Similar effects of antidepressant and non antidepressant drugs on behavior under an interresponse-time greater than 72-s  schedule. Psychopharmacol Ser (Berl) 89:253–258.  	3088646
	Porsolt RD, Anton G, Blavet N and Jalfre M (1978) Behavioural despair in rats: A  new model sensitive to antidepressant treatments. Eur J Pharmacol 47:379–391.  	204499
	Richards JB, Sabol KE and Seiden LS (1993a) DRL interresponse-time distributions:  Quantification by peak deviation analysis. J Exp Anal Behav 60:361–385.  	8409824
	Richards JB, Sabol KE and Seiden LS (1993b) Fluoxetine prevents the disruptive  effects of fenfluramine on differential-reinforcement-of-low-rate 72-second sched ule performance. J Pharmacol Exp Ther 267:1256–1263.  	8263788
	Richards JB and Seiden LS (1991) A quantitative interresponse-time analysis of  DRL performance differentiates similar effects of the antidepressant desipramine  and the novel anxiolytic gepirone. J Exp Anal Behav 56:173–192.  	1683359
	Schreiber R and De Vry J (1993) Neuroanatomical basis for the antidepressant-like  effects of the 5-HT1A receptor agonists 8-OH-DPAT and ipsapirone in the rat  forced swimming test. Behav Pharmacol 4:625–636.  	NO_MATCH
	Tatarczynska E and Chojnacka-Wojcik E (1989) Effects of 8-OH-DPAT and ipsapi rone in the tests used for evaluation of the antidepressant action. Pol J Pharmacol  Pharm 41:321–330.  	2534521
	Wogar MA, Bradshaw CM and Szabadi E (1993) Does the effect of central 5-hydroxy tryptamine depletion on timing depend on motivational change? Psychopharma cology 112:86–92.  	NO_MATCH
76.full.pdf
	Aghajanian GK and Marek GJ (1997) Serotonin induces excitatory postsynaptic  potentials in apical dendrites of neocortical pyramidal cells. Neuropharmacology  36:589–599.  	9225284
	Aghajanian GK and Marek GJ (1999a) Serotonin, via 5-HT2A receptors, increases  EPSCs in layer V pyramidal cells of prefrontal cortex by an asynchronous mode of  glutamate release. Brain Res 825:161–171.  	10216183
	Aghajanian GK and Marek GJ (1999b) Serotonin-glutamate interactions: A new  target for antipsychotic drugs. Neuropsychopharmacology, in press.  	NO_MATCH
	Aghajanian GK and Rasmussen K (1989) Intracellular studies in the facial nucleus  illustrating a simple new method for obtaining viable motoneurons in adult rat  brain slices. Synapse 3:331–338.  	2740992
	Arunlakshana O and Schild HO (1959) Some quantitative uses of drug antagonists.  Br J Pharmacol 14:48–58.  	13651579
	Berendse HW and Groenewegen HJ (1991) Restricted cortical termination fields of  the midline and intralaminar thalamic nuclei in the rat. Neuroscience 42:73–102.  	1713657
	Blue ME, Yagaloff KA, Mamounas LA, Hartig PR and Molliver ME (1988) Corre spondence between 5-HT2 receptors and serotonergic axons in rat neocortex. Brain  Res 453:315–328.  	3401769
	Conn PJ and Pin J-P (1997) Pharmacology and functions of metabotropic glutamate  receptors. Annu Rev Pharmacol Toxicol 37:205–237.  	9131252
	Connors BW and Gutnick MJ (1990) Intrinsic firing patterns of diverse neocortical  neurons. Trends Neurosci 13:99–104.  	1691879
	de Boer T (1996) The pharmacologic profile of mirtazepine. J Clin Psychiatry 57:19–  25.  	8636062
	Eison AS, Eison MS, Torrente JR, Wright RN and Yocca FD (1990) Nefazodone:  Preclinical pharmacology of a new antidepressant. Psychopharmacol Bull 26:311–  315.  	2274630
	Fitzjohn SM, Bortolotto ZA, Palmer MJ, Doherty AJ, Ornstein PL, Schoepp DD,  Kingston AE, Lodge D and Collingridge GL (1998) The potent mGlu receptor  antagonist LY341495 identifies roles for both cloned and novel mGlu receptors in  hippocampal synaptic plasticity. Neuropharmacology 37:1445–1458.  	9886667
	Goda Y and Stevens CF (1994) Two components of transmitter release at a central  synapse. Proc Natl Acad Sci USA 91:12942–12946.  	7809151
	Helton DR, Tizzano JP, Monn JA, Schoepp DD and Kallman MJ (1997) LY354740: A  metabotropic glutamate receptor agonist which ameliorates symptoms of nicotine  withdrawal in rats. Neuropharmacology 36:1511–1516.  	9517421
	Helton DR, Tizzano JP, Monn JA, Schoepp DD and Kallman MJ (1998) Anxiolytic  and side-effect profile of LY354740: A potent, highly selective, orally active agonist  for Group II metabotropic glutamate receptors. J Pharmacol Exp Ther 284:651–  660.  	9454811
	Johnson BG, Wright RA, Arnold MB, Wheeler WJ, Ornstein PL and Schoepp DD  (1999) [3H]-LY341495 as a novel antagonist radioligand for group II metabotropic  glutamate (mGlu) receptors: Characterization of binding to membranes of mGlu  receptor subtype expressing cells. Neuropharmacology, 38:1519–1529.  	10530814
	Kingston AE, Ornstein PL, Wright RA, Johnson BG, Mayne NG, Burnett JP, Bel agaje R, Wu S and Schoepp DD (1998) LY341495 is a nanomolar potent and  selective antagonist of group II metabotropic glutamate receptors. Neuropharma cology 37:1–12.  	9680254
	Kroeze WK and Roth BL (1998) The molecular biology of serotonin receptors: Ther apeutic implications for the interface of mood and psychosis. Biol Psychiatry  44:1128–1142.  	9836016
	Li H, Weiss SRB, Chuang D-M, Post RM and Rogawski MA (1998) Bidirectional  synaptic plasticity in the rat basolateral amygdala: Characterization of an activ ity-dependent switch sensitive to the presynaptic metabotropic glutamate receptor  antagonist 2S-a-ethylglutamic acid. J Neurosci 18:1662–1670.  	9464991
	Lovinger DM and McCool BA (1995) Metabotropic glutamate receptor-mediated  presynaptic depression at corticostriatal synapses involves mGlu2 or 3. J Neuro physiol 73:1076–1083.  	7608756
	Marek GJ and Aghajanian GK (1998a) 5-HT-induced EPSCs in neocortical layer V  pyramidal cells: Suppression by m-opiate receptor activation. Neuroscience 86:485–  497.  	NO_MATCH
	Marek GJ and Aghajanian GK (1998b) The electrophysiology of prefrontal 5-HT  systems: Therapeutic implications for mood and psychosis. Biol Psychiatry 44:  1118–1127.  	9836015
	Marek GJ and Aghajanian GK (1999) 5-HT2A receptor or a1-adrenoceptor activation  induces excitatory postsynaptic currents in layer V pyramidal cells of the medial  prefrontal cortex. Eur J Pharmacol 367:197–206.  	10078993
	Marek GJ and Gewirtz JC (1999) Serotonin2A receptor-induced EPSCs in layer V  pyramidal cells of prefrontal cortex: Block by lesions of medial thalamus. Soc  Neurosci Abstr 25:449.  	NO_MATCH
	Marek GJ, McDougle CJ, Price LH and Seiden LS (1992) A comparison of trazodone  and fluoxetine: Implications for a serotonergic mechanism of antidepressant ac tion. Psychopharmacology 109:2–11.  	NO_MATCH
	McCormick DA, Connors BW, Lighthall JW and Prince DA (1985) Comparative  electrophysiology of pyramidal and sparsely spiny neurons of the neocortex. J Neu rophysiol 54:782–806.  	2999347
	Moghaddam B and Adams BW (1998) Reversal of phencyclidine effects by a group II  metabotropic glutamate receptor agonists in rats. Science (Wash DC) 281:1349–  1352.  	9721099
	Monn JA, Valli MJ, Massey SM, Hansen MM, Kress TJ, Wepsiec JP, Harkness AR,  Grutsch JL, Wright RA, Johnson BG, Andis SL, Kingston A, Tomlinson R, Lewis  R, Griffey KR, Tizzano JP and Schoepp DD (1999) Synthesis, pharmacological  characterization, and molecular modeling of heterobicyclic amino acids related to  (1)-2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylic acid (LY354740): Identification  of two new potent, selective and systemically active agonists for group II metabo tropic glutamate receptors. J Med Chem 42:1027–1040.  	10090786
	Monn JA, Valli MJ, Massey SM, Wright RA, Salhoff CR, Johnson BG, Howe T, Alt  CA, Rhodes GA, Robey RL, Griffey KR, Tizzano JP, Kallman MJ, Helton DR and  Schoepp DD (1997) Design, synthesis, and pharmacological characterization of  (1)-2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylic acid (LY354740): A potent, selec tive, and orally active group 2 metabotropic glutamate receptor agonist possessing  anticonvulsant and anxiolytic properties. J Med Chem 40:528–537.  	9046344
	Ohishi H, Akazawa C, Shigemoto R, Nakanishi S and Mizuno N (1995) Distributions  of the mRNAs for L-2-amino-4-phosphonobutyrate-sensitive metabotropic gluta mate receptors, mGluR4 and mGluR7, in the rat brain. J Comp Neurol 360:555–  570.  	8801249
	Ohishi H, Neki A and Mizuno N (1997) Distribution of a metabotropic glutamate  receptor, mGluR2, in the central nervous system of the rat and mouse: An immu nohistochemical study with a monoclonal antibody. Neurosci Res 30:65–82.  	9572581
	Ohishi H, Shigemoto R, Nakanishi S and Mizuno N (1993a) Distribution of the  messenger RNA for a metabotropic glutamate receptor, mGluR2, in the central  nervous system of the rat. Neuroscience 53:1009–1018.  	8389425
	Ohishi H, Shigemoto R, Nakanishi S and Mizuno N (1993b) Distribution of the  mRNA for a metabotropic glutamate receptor (mGluR3) in the rat brain: An in situ  hybridization study. J Comp Neurol 335:252–266.  	8227517
	Paxinos G and Watson C (1986) The Rat Brain in Stereotaxic Coordinates, 2nd ed.,  plates 9 and 10, Academic Press, New York.  	NO_MATCH
	Petralia RS, Wang Y-X, Niedzielski AS and Wenthold RJ (1996) The metabotropic  glutamate receptors, mGluR2 and mGluR3, show unique postsynaptic, presynap tic and glial localizations. Neuroscience 71:949–976.  	8684625
	Richelson E and Nelson A (1984) Antagonism by antidepressants of neurotransmit ter receptors of normal human brain in vitro. J Pharmacol Exp Ther 230:94–102.  	6086881
	Saugstad JA, Kinzie JM, Shinohara MM, Segerson TP and Westbrook GL (1997)  Cloning and expression of rat metabotropic glutamate receptor 8 reveals a distinct  pharmacological profile. J Pharmacol Exp Ther 51:119–125.  	9016353
	Scanziani M, Salin PA, Vogt KE, Malenka RC and Nicoll RA (1997) Use-dependent  increases in glutamate concentration activate presynaptic metabotropic glutamate  receptors. Nature (Lond) 385:630–634.  	9024660
	Schiller J, Schiller Y, Stuart G and Sakman B (1997) Calcium action potentials  restricted to distal apical dendrites of rat neocortical pyramidal cells. J Physiol  505:605–616.  	9457639
	Schoepp DD, Jane DE and Monn JA (1999) Pharmacological agents acting at sub types of metabotropic glutamate receptors. Neuropharmacology 38:1431–1476.  	10530808
	Schoepp DD, Johnson BG, Wright RA, Salhoff CR, Mayne NG, Wu S, Cockerham SL,  Burnett JP, Belagaje R, Bleakman D and Monn JA (1997) LY354740 is a potent  and highly selective group II metabotropic glutamate receptor agonist in cells  expressing human glutamate receptors. Neuropharmacology 36:1–11.  	9144636
	Schoepp DD, Johnson BG, Wright RA, Salhoff CR and Monn JA (1998) Potent,  stereoselective, and brain region selective modulation of second messengers in the  rat brain by (1)LY354740, a novel group II metabotropic glutamate receptor  agonist. Naunyn-Schmiedeberg’s Arch Pharmacol 358:175–180.  	9750002
	Schwindt PC and Crill WE (1997) Local and propagated dendritic action potentials  evoked by glutamate iontophoresis on rat neocortical pyramidal neurons. J Neu rophysiol 77:2466–2483.  	9163370
	Van der Kloot W (1991) The regulation of quantal size. Prog Neurobiol (NY) 36:93–  130.  	1847748
	Vollenweider FX, Vollenweider-Scherpenhuyzen MFI, Babler A, Vogel H and Hell D  (1998) Psilocybin induces schizophrenia-like psychosis in humans via a seroto nin-2 agonist action. Neuroreport 9:3897–3902.  	9875725
	Wander TJ, Nelson A, Okazaki H and Richelson E (1986) Antagonism by antide pressants of serotonin S1 and S2 receptors of normal human brain in vitro. Eur  J Pharmacol 132:115–121.  	3816971
	Wright RA, McDonald JW and Schoepp DD (1994) Distribution and ontogeny of  1S,3R-1-aminocyclopentane-1,3-dicarboxylic acid sensitive and quisqualate insen sitive [3H]glutamate binding sites in the rat brain. J Neurochem 63:938–945.  	7914226
J Pharmacol Exp Ther-2000-Bauer-31-7.pdf
	Berlin J, Tutsch KD, Hutson P, Cleary J, Rago RP, Arzoomanian RZ, Alberti D,  Feierabend C and Wilding G (1997) Phase I clinical and pharmacokinetic study of  oral carboxyamidotriazole, a signal transduction inhibitor. J Clin Oncol 15:781–  789.  	9053505
	Berridge MJ and Irvine RF (1989) Inositol phosphates and cell signaling. Nature  (Lond) 341:197–205.  	2550825
	Figg WD, Cole KA, Reed E, Steinberg SM, Piscitelli SC, Davis PA, Soltis MJ, Jacob  J, Boudoilas S, Goldspiel B, Sarosy G, Liotta LA and Kohn EC (1995) Pharmaco kinetics of orally administered carboxyamido-triazole, an inhibitor of calcium  mediated signal transduction. Clin Cancer Res 1:797–803.  	NO_MATCH
	Folkman J (1966) Tumor behavior in isolated perfuse organs: In vitro growth and  metastases of biopsy material in rabbit thyroid and canine intestinal segments.  Ann Surg 164:493–502.  	5951515
	Folkman J (1971) Tumor angiogenesis: Therapeutic implications. N Engl J Med  285:1182–1186.  	4938153
	Frank S, Kolb N, Werner ER and Pfeilschifter J (1998) Coordinated induction of  inducible nitric oxide synthase and GTP-cyclohydrolase I is dependent on inflam matory cytokines and interferon-gamma in HaCaT keratinocytes: Implications for  the model of cutaneous wound repair. J Invest Dermatol 111:1065–1071.  	9856818
	Gimrone MA Jr, Aster RH and Cotran RS (1969) Preservation of vascular integrity  in organs perfused in vitro with a platelet-rich medium. Nature (Lond) 221:33–36.  	5775827
	Gusovsky F, Lueders JE, Kohn EC and Felder CC (1993) Muscarinic receptor mediated tyrosine phosphorylation of phospholipase C-gamma. J Biol Chem 268:  7768–7772.  	NO_MATCH
	Horti J, Dixon SC, Logothetis CJ, Guo Y, Reed E and Figg WD (1999) Increased  transcriptional activity of prostate-specific antigen in the presence of TNP-470, an  angiogenesis inhibitor. Br J Cancer 79:1588–1593.  	10188911
	Hupe DJ, Behrens ND and Boltz R (1990) Anti-proliferative activity of L-651,582  correlates with calcium-mediated regulation of nucleotide metabolism at phospho ribosyl pyrophosphate synthetase. J Cell Physiol 144:457–466.  	2167901
	Hupe DJ, Boltz R, Cohen CJ, Felix J, Ham E, Miller D, Soderman D and Van Skiver  D (1991) The inhibition of receptor-mediated and voltage-dependent calcium entry  by the antiproliferative L-651,582. J Biol Chem 266:10136–10142.  	1645340
	Jacobs W, Mikkelsen T, Smith R, Nelson K, Rosenblum ML and Kohn EC (1997)  Inhibitory effects of CAI in glioblastoma growth and invasion. J Neuro-Oncol  32:93–101.  	9120549
	Kobayashi S, Somlyo AP and Somlyo AV (1988) Guanine nucleotide- and inositol  1,4,5-trisphosphate-induced calcium release in rabbit main pulmonary artery.  J Physiol 403:601–619.  	3150985
	Kohn EC, Alessandro R, Spoonster J, Wersto RP and Liotta LA (1995) Angiogenesis:  Role of calcium-mediated signal transduction. Proc Natl Acad Sci USA 92:1307–1311.  	7533291
	Kohn EC, Figg WD, Sarosy GA, Bauer KS, Davis PA, Soltis MJ, Thompkins A, Liotta  LA and Reed E (1997). Phase I trial of micronized formulation carboxyamidotria zole in patients with refractory solid tumors: Pharmacokinetics, clinical outcome,  and comparison of formulations. J Clin Oncol 15:1985–1993.  	9164210
	Kohn EC, Jacobs W, Kim YS, Alessandro R, Stetler-Stevenson WG and Liotta LA  (1994) Calcium influx modulates expression of matrix metalloproteinase-2 (72 kDa type IV collagenase, gelatinase A). J Biol Chem 269:21505–21511.  	8063786
	Kohn EC and Liotta LA (1990) L651582: A novel antiproliferative and antimetasta sis agent. J Natl Cancer Inst 82:54–60.  	2152805
	Kroll J and Waltenberger J (1998) VEGF-A induces expression of eNOS and iNOS in  endothelial cells via VEGF receptor-2 (KDR). 252:716–743.  	9837777
	Lambert PA, Somers KD, Kohn EC and Perry RR (1997) Antiproliferative and  anti-invasive effects of carboxyamido-triazole on breast cancer cell lines. Surgery  122:372–379.  	9288143
	Miyazaki S (1988). Inositol 1,4,5-trisphosphate-induced calcium release and guanine  nucleotide-binding protein-mediated periodic calcium rises in golden hamster  eggs. J Cell Biol 106:345–353.  	3123497
	Morbidelli L, Chang C-H, Douglas JG, Granger HJ, Ledda F and Ziche M (1996)  Nitric oxide mediates mitogenic effect of VEGF on coronary endothelium. Am  Physiol Soc 363:H411–H415.  	8769777
	Park YC, Jun CD, Kang HS, Kim HD, Kim HM and Chung HT (1996) Role of  intracellular calcium as a priming signal for the induction of nitric oxide synthesis  in murine peritoneal macrophages. Immunology 87:296–302.  	8698394
	Pinkus GS, Etheridge CL and O’Connor EM (1986) Are keratin proteins a better  tumor marker than epithelial membrane antigen? A comparative immunohisto chemical study of various paraffin-embedded neoplasms using monoclonal and  polyclonal antibodies. Am J Clin Pathol 85:269–277.  	2428237
	Sunyer T, Rothe L, Kirsch D, Jiang X, Anderson F, Osdoby P and Collin-Osdoby P  (1997) Ca21 or phorbol ester but not inflammatory stimuli elevate inducible nitric  oxide synthase messenger ribonucleic acid and nitric oxide (NO) release in avian  osteoclasts: Autocrine NO mediates Ca21-inhibited bone resorption. Endocrinol ogy 138:2148–2162.  	9112415
	Trachtman H, Futterweit S, Franki N and Singhal PC (1998) Effect of vascular  endothelial growth factor on nitric oxide production by cultured rat mesangial  cells. Biochem Biophys Res Commun 245:443–446.  	9571172
	Wasilenko WJ, Palad AJ, Somers KD, Blackmore PF, Kohn EC, Rhim JS, Wright GL  and Schellhammer PF (1996) Effects of the calcium influx inhibitor carboxyamido triazole on the proliferation and invasiveness of human prostate tumor cell lines.  Intl J Cancer 68:259–264.  	8900438
	Weidner N, Carroll PR, Flax J, Blumenfeld W and Folkman J (1993) Tumor angio genesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol  143:401–409.  	7688183
	Weidner N, Semple JP, Welch WR and Folkman J (1991) Tumor angiogenesis and  metastasis correlation in invasive breast carcinoma. N Engl J Med 324:1–8.  	1701519
	Weikert S, Freyer D, Weih M, Isaev N, Busch C, Schultze J, Megow D and Dirnagl  U (1997) Rapid Ca21-dependent NO-production from central nervous system cells  in culture measured by NO-nitrite/ozone chemoluminescence. Brain Res 748:1–11.  	9067439
	Send reprint requests to: Dr. William D. Figg, Medicine Branch, Division of  Clinical Sciences, National Cancer Institute, NIH, Bldg. 10, Room 5A01, 10  Center Dr., Bethesda, MD 20892. E-mail: wdfigg@helix.nih.gov  	NO_MATCH
spp-01-1-38.pdf
spp-01-1-21.pdf
nihms226142.pdf
nihms59621.pdf
nihms38938.pdf
	1. Bairey Merz C, Dwyer J, Nordstrom C, Walton K, Salerno J, Schneider R. Psychosocial stress and  cardiovascular disease: Pathophysiological links. Behav Med 2002;27:141–146. [PubMed: 12165968]  	12165968
	2. Tennant CC. Life stress and hypertension. J Cardiovasc Risk 2001;8:51–56. [PubMed: 11234726]  	11234726
	3. Penninx BW, Beekman AT, Honig A, et al. Depression and cardiac mortality: Results from a  community based longitudinal study. Arch Gen Psychiatry 2001;58:221–227. [PubMed: 11231827]  	11231827
	4. Tennant CC, Mclean L. Mood disturbances and coronary heart disease: Progress in the past decade.  Med J Aust 2000;172:151–152. [PubMed: 10772583]  	10772583
	5. Rozanski A, Blumenthal JA, Kaplan J. Impact of psychological factors on the pathogenesis of  cardiovascular disease and implications for therapy. Circulation 1999;99:2192–2217. [PubMed:  10217662]  	10217662
	6. Bairey Merz C, Subramanian R. Efficacy of psychosocial interventions and stress management for  reduction of coronary artery disease events. Preventive Cardiology 1999;1:1–6.  	NO_MATCH
	7. Linden W, Stossel C, Maurice J. Psychosocial interventions for patients with coronary artery disease.  Arch Intern Med 1996;156:745–752. [PubMed: 8615707]  	8615707
	8. Nunes E, Frank K, Kornfeld D. Psychologic treatment for Type A behavior pattern and for coronary  artery disease: A meta-analysis of the literature. Psychosom Med 1987;49:159–173. [PubMed:  3554294]  	3554294
	9. Polk, DM.; Nordstrom, CK.; Dwyer, J.; Kop, WJ.; Krantz, DS.; Bairey Merz, CN. Novel psychosocial  factors and cardiovascular disease. In: Shah, PK., editor. Risk Factors in Coronary Disease. New York:  Marcel Dekker; 2003.  	NO_MATCH
	10. Frasure-Smith N, Lesperance F, Prince RH, et al. Randomized trial of home-based psychosocial  nursing intervention for patients recovering from myocardial infarction. Lancet 1997;350:473–479.  [PubMed: 9274583]  	9274583
	11. Jones DA, West RR. Psychological rehabilitation after myocardial infarction: Multicentre randomised  controlled trial. BMJ 1996;313:1517–1521. [PubMed: 8978226]  	8978226
	12. Orme-Johnson DW, Walton KG. All approaches to preventing or reversing effects of stress are not  the same. American Journal of Health Promotion 1998;12:297–299. [PubMed: 10181138]  	10181138
	13. Murphy LR. Stress management in work settings: A critical review of the health effects. American  Journal of Health Promotion 1996;11:112–135. [PubMed: 10163598]  	10163598
	14. Murphy, M.; Donovan, S.; Taylor, E. The Physical and Psychological Effects of Meditation: A Review  of Contemporary Research with a Comprehensive Bibliography. Sausalito, California: Institute of  Noetic Sciences; 1997. p. 1931-1996.  	NO_MATCH
	15. Alexander, CN.; Davies, JL.; Dixon, CA., et al. Growth of higher stages of consciousness: Maharishi’s  Vedic psychology of human development. In: Alexander, CN.; Langer, EJ., editors. Higher Stages  of Human Development: Perspectives on Adult Growth. New York: Oxford University Press; 1990.  p. 286-341.  	NO_MATCH
	16. Schneider RH, Alexander CN, Salerno J, Robinson D, Fields J, Nidich S. Disease prevention and  health promotion in the aging with a traditional system of natural medicine: Maharishi Vedic  Medicine (MVM). The Journal of Aging and Health 2002;14:57–78.  	11892761
	17. Nader T, Rothenberg S, Averbach R, Charles B, Fields J, Schneider R. Improvements in chronic  diseases with a comprehensive natural medicine approach: A review and case studies. Behav Med  2000;26:34–46. [PubMed: 10971882]  	10971882
	18. Walton K, Pugh N. Stress, steroids, and “ojas”: Neuroendocrine mechanisms and current promise of  ancient approaches to disease prevention. Indian J Physiol Pharmacol 1995;39:3–36. [PubMed:  7705867]  	7705867
	19. Orme-Johnson, DW.; Farrow, J. Scientific Research on the Transcendental Meditation Program:  Collected Papers. Vol. 1. Rheinweiler, West Germany: MERU Press; 1977. p. 722  	776380
	20. Chalmers, R.; Clements, G.; Schenkluhn, H.; Weinless, M. Scientific Research on the Transcendental  Meditation Program: Collected Papers. Vol. 2–4. Vlodrop, The Netherlands: MVU Press; 1990.  	NO_MATCH
	21. Wallace, RK.; Orme-Johnson, DW.; Dillbeck, MC. Scientific Research on the Transcendental  Meditation Program: Collected Papers. Vol. 5. Fairfield, Iowa: MIU Press; 1990.  	NO_MATCH
	22. Jevning R, Wallace RK, Biedebach M. The physiology of meditation: A review. A wakeful  hypometabolic integrated response. Neurosci Biobehav Rev 1992;16:415–424. [PubMed: 1528528]  	1528528
	23. Hawkins MA. Effectiveness of the Transcendental Meditation program in criminal rehabilitation and  substance abuse recovery: A review of the research. Journal of Offender Rehabilitation 2002;36:47–  65.  	11681142
	24. Roth, R. Maharishi Mahesh Yogi’s Transcendental Meditation. Washington, DC: Primus; 1994. p.  90-102.  	NO_MATCH
	25. Williams R, Barefoot J, Califf R. Prognostic importance of social and economic resources among  medically treated patients with angiographically documented coronary artery disease. JAMA  1992:267.  	1729574
	26. Julkunen J, Salonen R, Kaplan G, Chesney M, Salonen J. Hostility and the progression of carotid  atherosclerosis. Psychosom Med 1994;56:519–525. [PubMed: 7871107]  	7871107
	27. Reed DM, LaCroix AZ, Karasek RA, Miller D, MacLean CA. Occupational strain and the incidence  of coronary heart disease. Am J Epidemiol 1989;129:495–502. [PubMed: 2916542]  	2916542
	28. Hlatky MA, Lam LC, Lee KL, et al. Job strain and the prevalence and outcome of coronary artery  disease. Circulation 1995;92:327–333. [PubMed: 7634445]  	7634445
	29. Grundy SM, Pasternak R, Greenland P, Smith SJ, Fuster V. AHA/ACC scientific statement:  Assessment of cardiovascular risk by use of multiple-risk-factor assessment equations: A statement  for healthcare professionals from the American Heart Association and the American College of  Cardiology. J Am Coll Cardiol 1999;34:1348–1359. [PubMed: 10520820]  	10520820
	30. Schneider RH, Staggers F, Alexander C, et al. A randomized controlled trial of stress reduction for  hypertension in older African Americans. Hypertension 1995;26:820–827. [PubMed: 7591024]  	7591024
	31. Alexander C, Schneider R, Staggers F, et al. A trial of stress reduction for hypertension in older  African Americans (Part II): Sex and risk factor subgroup analysis. Hypertension 1996;28:228–237.  [PubMed: 8707387]  	8707387
	32. Alexander CN, Langer EJ, Newman RI, Chandler HM, Davies JL. Transcendental Meditation,  mindfulness, and longevity: an experimental study with the elderly. J Person Soc Psychol  1989;57:950–964.  	2693686
	33. Wenneberg S, Schneider R, Walton K, et al. A controlled study of the effects of the Transcendental  Meditation program on cardiovascular reactivity and ambulatory blood pressure. Int J Neurosci  1997;89:15–28. [PubMed: 9134445]  	9134445
	34. Barnes VA, Treiber FA, Davis H. Impact of Transcendental Meditation on cardiovascular function  at rest and during acute stress in adolescents with high normal blood pressure. J Psychosom Res  2001;51:597–605. [PubMed: 11595248]  	11595248
	35. De Armond, DL. Effects of the Transcendental Meditation program on psychological, physiological,  behavioral and organizational consequences of stress in managers and executives in management.  Fairfield, Iowa: Maharishi University of Management; 1996. p. 161  	NO_MATCH
	36. Schneider R, Nidich S, Salerno J, et al. Lower lipid peroxide levels in practitioners of the  Transcendental Meditation program. Psychosom Med 1998;60:38–41. [PubMed: 9492237]  	9492237
	37. Calderon, R. Effects of Nonpharmacological Approaches on Cholesterol Levels in Mild Hypertensive  African Americans: A Pilot Study of the Transcendental Meditation Program and a Health Education  Program dissertation. Fairfield, Iowa: Maharishi University of Management; 2000. p. 122  	NO_MATCH
	38. Alexander, CN.; Robinson, P.; Rainforth, M. Treating and preventing alcohol, nicotine and drug abuse  through Transcendental Meditation Technique: A review and statistical analysis. In: O’Connell, DF.;  Alexander, CN., editors. Self Recovery—Treating Addictions Using Transcendental Meditation and  Maharishi Ayur-Veda. New York: Haworth Press; 1994. p. 13-88.  	NO_MATCH
	39. Collins R, Petro R, MacMahone S, et al. Blood pressure, stroke, and coronary heart disease, part 2,  Short-term reductions in blood pressure: Overview of randomized drug trials in their epidemiological  context. Lancet 1990;335:827–838. [PubMed: 1969567]  	1969567
	40. Collins P, Fox K. Pathophysiology of angina. Lancet 1990;335:94–96. [PubMed: 1967428]  	1967428
	41. Cooper MJ, Aygen MM. Transcendental Meditation in the management of hypercholesterolemia.  Journal of Human Stress 1979;5:24–27. [PubMed: 392003]  	420081
	42. Salonen JT, Yla-Herttuala S, Yamamoto R, et al. Autoantibody against oxidized LDL and progression  of carotid atherosclerosis. Lancet 1992;339:883–887. [PubMed: 1348295]  	1348295
	43. Naito C, Kawamura M, Yamamoto Y. Lipid peroxides as the initiating factor of atherosclerosis. Ann  N Y Academ Sci 1990:27–45.  	NO_MATCH
	44. Berliner J, Navab M, Fogelman A, et al. Atherosclerosis: Basic mechanisms. Oxidation, inflammation  and genetics. Circulation 1995;91:2488–2496. [PubMed: 7729036]  	7729036
	45. Matthews KA, Woodall KL, Allen MT. Cardiovascular reactivity to stress predicts future blood  pressure status. Hypertension 1993;22:479–485. [PubMed: 8406652]  	8406652
	46. Kamarck TW, Jennings JR, Pogue-Geile M, Manuck SB. A multidimensional measurement model  for cardiovascular reactivity: Stability and cross-validation in two adult samples. Health Psychol  1994;13:471–478. [PubMed: 7889901]  	7889901
	47. Eppley K, Abrams AI, Shear J. Differential effects of relaxation techniques on trait anxiety: A meta analysis. J Clin Psychol 1989;45:957–974. [PubMed: 2693491]  	2693491
	48. Gaylord C, Orme-Johnson D, Travis F. The effects of the Transcendental Meditation technique and  progressive muscle relaxation on EEG coherence, stress reactivity, and mental health in black adults.  Intern J Neurosci 1989;46:77–86.  	2670798
	49. Alexander CN, Rainforth MV, Gelderloos P. Transcendental Meditation, self actualization, and  psychological health: A conceptual overview and statistical meta-analysis. Journal of Social Behavior  and Personality 1991;6:189–247.  	NO_MATCH
	50. Ferguson, PC. An integrative meta-analysis of psychological studies investigating the treatment  outcomes of meditation techniques. In: Chalmers, R.; Clements, G.; Schenkluhn, H.; Weinless, M.,  editors. Scientific Research on Maharishi’s Transcendental Meditation and TM-Sidhi Programme:  Collected Papers. Vol. 4. Vlodrop, Holland: Maharishi European Research University, MVU Press;  1991. p. 2039-2048.  	NO_MATCH
	51. Jevning R, Wilson AF, Smith WR. Adrenocortical activity during meditation. Hormones and Behavior  1978;10:54–60. [PubMed: 350747]  	350747
	52. Dillbeck MC, Orme-Johnson DW. Physiological differences between Transcendental Meditation and  rest. American Psychologist 1987;42:879–881.  	NO_MATCH
	53. Michaels RR, Huber MJ, McCann DS. Evaluation of Transcendental Meditation as a method of  reducing stress. Science 1976;192:1242–1244. [PubMed: 775639]  	775639
	54. Mills PJ, Schneider RH, Hill D, Walton KG, Wallace RK. Beta-adrenergic receptor sensitivity in  subjects practicing transcendental meditation. J Psychosom Res 1990;34:29–33. [PubMed: 2156071]  	2156071
	55. Alexander CN, Swanson GC, Rainforth MV, Carlisle TW, Todd CC, Oates RM. Effects of the  Transcendental Meditation program on stress reduction, health, and employee development: A  prospective study in two occupational settings. Anxiety, Stress and Coping: An International Journal  1993;6:245–262.  	NO_MATCH
	56. Walton KG, Pugh N, Gelderloos P, Macrae P. Stress reduction and preventing hypertension:  Preliminary support for a psychoneuroendocrine mechanism. Journal of Alternative and  Complementary Medicine 1995;1:263–283.  	NO_MATCH
	57. Levitsky, DK. Effects of the Transcendental Meditation program on neuroendocrine indicators of  chronic stress dissertation. Fairfield, Iowa: Maharishi University of Management; 1997. p. 298  	NO_MATCH
	58. MacLean C, Walton K, Wenneberg S, et al. Effects of the Transcendental Meditation program on  adaptive mechanisms: Changes in hormone levels and responses to stress after 4 months of practice.  Psychoneuroendocrinology 1997;22:277–295. [PubMed: 9226731]  	9226731
	59. Infante JR, Peran F, Martinez M, et al. ACTH and beta-endorphin in Transcendental Meditation.  Physiol Behav 1998;64:311–315. [PubMed: 9748098]  	9748098
	60. Infante JR, Torres-Avisbal M, Pinel P, et al. Catecholamines in practitioners of the Transcendental  Meditation technique. Physio Behav 2001;72:141–146.  	11239991
	61. Barnes VA, Treiber FA, Turner JR, Davis H, Strong WB. Acute effects of Transcendental Meditation  on hemodynamic functioning in middle-aged adults. Psychosom Med 1999;61:525–531. [PubMed:  10443761]  	10443761
	62. Alexander C, Walton K, Goodman R. Walpole study of the TM program in maximum security  prisoners I: Cross-sectional differences in development and psychopathology. Journal of Offender  Rehabilitation 2002;36:97–125.  	NO_MATCH
	63. Castillo-Richmond A, Schneider R, Alexander C, et al. Effects of stress reduction on carotid  atherosclerosis in hypertensive African Americans. Stroke 2000;31:568–573. [PubMed: 10700487]  	10700487
	64. Fields JZ, Walton KG, Schneider RH, et al. Effect of a multimodality natural medicine program on  carotid atherosclerosis in older subjects: A pilot trial of Maharishi Vedic Medicine. Am J Cardiol  	2002;89:952–958. [PubMed: 11950434]	11950434
	65. Blankenhorn DH, Hodis HN. Arterial imaging and atherosclerosis reversal. George Lyman Duff  Memorial Lecture. Arteriosclerosis & Thrombosis 1994;14:177–192. [PubMed: 8305407]  	NO_MATCH
	66. Kondwani, KA. Psychology. Fairfield, Iowa: Maharishi University of Management; 1998.  Nonpharmacologic treatment of hypertension and hypertensive heart disease in African Americans:  A trial of the Transcendental Meditation program and a health education program; p. 130  	NO_MATCH
	67. Zamarra JW, Schneider RH, Besseghini I, Robinson DK, Salerno JW. Usefulness of the  Transcendental Meditation program in the treatment of patients with coronary artery disease. Am J  Cardio 1996;78:77–80.  	8623742
	68. Salonen JT, Salonen R. Ultrasound B-mode imaging in observational studies of atherosclerotic  progression. Circulation 1993;87(Suppl 2):56–65.  	8443925
	69. Koren MJ, Devereux RB, Casale PN, Savage DD, Laragh JH. Relation of left ventricular mass and  geometry to morbidity and mortality in uncomplicated essential hypertension. Ann Intern Med  1991;114:345–352. [PubMed: 1825164]  	1825164
	70. Kondwani K, Schneider RH, Alexander CN, et al. Left ventricular mass regression with the  Transcendental Meditation technique and a health education program in hypertensive African  Americans. Journal of Social Behavior and Personality. In press  	NO_MATCH
	71. Devereux RB, Okin PM, Roman MJ. Pre-clinical cardiovascular disease and surrogate end-points in  hypertension: Does race influence target organ damage independent of blood pressure? Ethnicity and  Disease 1998;8:138–148. [PubMed: 9681280]  	9681280
	72. Devereux RB, Roman MJ, Ganau A, de Simone G, Okin PM, Kligfield P. Cardiac and arterial  hypertrophy and atherosclerosis in hypertension. Hypertension 1994;23:802–809. [PubMed:  8206580]  	8206580
	73. Devereux R, Roman M. Hypertensive left ventricular hypertrophy: Pathogenesis, prognostic  importance and treatment. CVR & R 1992 August;:24–33.  	NO_MATCH
	74. Alexander CN, Barnes VA, Schneider RH, et al. A randomized controlled trial of stress reduction on  cardiovascular and all-cause mortality in the elderly: Results of 8 and 15 year follow-ups. Circulation  1996;93:629.[abstract]  	NO_MATCH
Mol Cancer Ther-2002-Yokoi-275-86.pdf
	1. Schreiber, S. L. Target-oriented and diversity-oriented organic synthe sis in drug discovery. Science (Wash. DC), 287: 1964–1969, 2000.  	NO_MATCH
	2. Drews, J. Drug discovery: a historical perspective. Science (Wash. DC),  287: 1960–1964, 2000.  	NO_MATCH
	3. Maren, T. H. Relations between structure and biological activity of  sulfonamides. Ann. Rev. Pharmacol. Toxicol., 16: 309–327, 1976.  	59572
	4. Supuran, C. T., and Scozzafava, A. Carbonic anhydrase inhibitors  and their therapeutic potential. Exp. Opin. Ther. Patents, 10: 575– 600,  2000.  	NO_MATCH
	5. Yoshino, H., Ueda, N., Niijima, J., Sugumi, H., Kotake, Y., Koyanagi, N.,  Yoshimatsu, K., Asada, M., Watanabe, T., Nagasu, T., Tsukahara, K.,  Iijima, A., and Kitoh, K. Novel sulfonamides as potential, systemically  active antitumor agents. J. Med. Chem., 35: 2496–2497, 1992.  	1619621
	6. Owa, T., Yoshino, H., Okauchi, T., Yoshimatsu, K., Ozawa, Y., Sugi,  N. H., Nagasu, T., Koyanagi, N., and Kitoh, K. Discovery of novel antitumor  sulfonamides targeting G1 phase of the cell cycle. J. Med. Chem., 42:  3789–3799, 1999.  	10508428
	7. Owa, T., Okauchi, T., Yoshimatsu, K., Sugi, N. H., Ozawa, Y., Nagasu,  T., Koyanagi, N., Okabe, T., Kitoh, K., and Yoshino, H. A focused com pound library of novel N-(7-indolyl)benzenesulfonamides for the discovery  of potent cell cycle inhibitors. Bioorg. Med. Chem. Lett., 10: 1223–1226,  2000.  	10866386
	8. Owa, T., and Nagasu, T. Novel sulphonamide derivatives for the treat ment of cancer. Exp. Opin. Ther. Patents, 10: 1725–1740, 2000.  	NO_MATCH
	9. Yoshimatsu, K., Yamaguchi, A., Yoshino, H., Koyanagi, N., and Kitoh,  K. Mechanism of action of E7010: inhibition of mitosis by binding to the  colchicine site of tubulin. Cancer Res., 57: 3208–3213, 1997.  	NO_MATCH
	10. Koyanagi, N., Nagasu, T., Fujita, F., Watanabe, T., Tsukahara, K.,  Funahashi, Y., Fujita, M., Taguchi, T., Yoshino, H., and Kitoh, K. In vivo  tumor growth inhibition produced by a novel sulfonamide, E7010, against  rodent and human tumors. Cancer Res., 54: 1702–1706, 1994.  	8137285
	11. Yamamoto, K., Noda, K., Yoshimura, A., Fukuoka, M., Furuse, K., and  Niitani, H. Phase I study of E7010. Cancer Chemother. Pharmacol., 42:  127–134, 1998.  	NO_MATCH
	12. Ozawa, Y., Sugi, N. H., Nagasu, T., Owa, T., Watanabe, T., Koyanagi,  N., Yoshino, H., Kitoh, K., and Yoshimatsu, K. E7070, a novel sulfonamide  agent with potent antitumor activity in vitro and in vivo. Eur. J. Cancer, 37:  2275–2282, 2001.  	11677118
	13. Punt, C. J., Fumoleau, P., van de Walle, B., Faber, M. N., Ravic, M.,  and Campone, M. Phase I and pharmacokinetic study of E7070, a novel  sulfonamide, given at a daily times five schedule in patients with solid  tumors. A study by the EORTC-early clinical studies group (ECSG). Ann.  Oncol., 12: 1289–1293, 2001.  	11697842
	14. Punt, C. J. A., Fumoleau, P., Walle, B. V. D., Deporte-Fety, R.,  Bourcier, C., Faber, M., Ravic, M., and T. Wagener, D. J. Proc. Am. Assoc.  Cancer Res., 41: 609, 2000.  	NO_MATCH
	15. Raymond, E., ten Bokkel-Huinink, W. W., Taieb, J., Beijnen, J. H.,  Mekhaldi, S., Kroon, K., Wanders, J., Ravic, M., Fumoleau, P., Ducreux,  M., Escudier, B., and Armand, J. P. Proc. Am. Assoc. Cancer Res., 41:  611, 2000.  	NO_MATCH
	16. Schena, M., Shalon, D., Davis, R. W., and Brown, P. O. Quantitative  monitoring of gene expression patterns with a complementary DNA mi croarray. Science (Wash. DC), 270: 467–470, 1995.  	7569999
	17. Lockhart, D. J., Dong, H., Byrne, M. C., Follettie, M. T., Gallo, M. V.,  Chee, M. S., Mittmann, M., Wang, C., Kobayashi, M., Horton, H., and  Brown, E. L. Expression monitoring by hybridization to high-density oli gonucleotide arrays. Nat. Biotechnol., 14: 1675–1680, 1996.  	NO_MATCH
	18. Stockwell, B. R., Hardwick, J. S., Tong, J. K., and Schreiber, S. L.  Chemical genetic and genomic approaches reveal a role for copper in  specific gene activation. J. Am. Chem. Soc., 121: 10662–10663, 1999.  	NO_MATCH
	19. Marton, M. J., DeRisi, J. L., Bennett, H. A., Iyer, V. R., Meyer, M. R.,  Roberts, C. J., Stoughton, R., Burchard, J., Slade, D., Dai, H., Bassett,  D. E., Jr., Hartwell, L. H., Brown, P. O., and Friend, S. H. Drug target  validation and identification of secondary drug target effects using DNA  microarrays. Nat. Med., 4: 1293–1301, 1998.  	9809554
	20. Hardwick, J. S., Kuruvilla, F. G., Tong, J. K., Shamji, A. F., and  Schreiber, S. L. Rapamycin-modulated transcription defines the subset of  nutrient-sensitive signaling pathways directly controlled by the Tor pro teins. Proc. Natl. Acad. Sci. USA, 96: 14866–14870, 1999.  	10611304
	21. Scherf, U., Ross, D. T., Waltham, M., Smith, L. H., Lee, J. K., Tanabe,  L., Kohn, K. W., Reinhold, W. C., Myers, T. G., Andrews, D. T., Scudiero,  D. A., Eisen, M. B., Sausville, E. A., Pommier, Y., Botstein, D., Brown,  P. O., and Weinstein, J. N. A gene expression database for the molecular  pharmacology of cancer. Nat. Genet., 24: 236–244, 2000.  	10700175
	22. Dittrich, C., Dumez, H., Calvert, H., Hanauske, A. R., Ravic, M., Faber,  M., van Houten, T., Wanders, J., and Fumoleau, P. Proc. Am. Assoc.  Cancer Res., 41: 609, 2000.  	NO_MATCH
	23. Mosmann, T. Rapid colorimetric assay for cellular growth and sur vival: application to proliferation and cytotoxicity assays. J. Immunol.  Methods, 65: 55–63, 1983.  	6606682
	24. Ro¨dicker, F., Stiewe, T., Zimmermann, S., and Pu¨tzer, B. M. Thera peutic efficacy of E2F1 in pancreatic cancer correlates with TP73 induc tion. Cancer Res., 61: 7052–7055, 2001.  	11585734
	25. Liu, X. M., Wang, L. G., Kreis, W., Budman, D. R., and Adams, L. M.  Differential effect of vinorelbine versus paclitaxel on ERK2 kinase  activity during apoptosis in MCF-7 cells. Br. J. Cancer, 85: 1403–1411,  2001.  	11720482
	26. Kumar, R., and Korutla, L. Induction of expression of interferon stimulated gene factor-3 (ISGF-3) proteins by interferons. Exp. Cell Res.,  216: 143–148, 1995.  	7529187
	27. Hwang, L. H., and Murray, A. W. A novel yeast screen for mitotic  arrest mutants identifies DOC1, a new gene involved in cyclin proteolysis.  Mol. Biol. Cell, 8: 1877–1887, 1997.  	9348530
	28. Rosania, G. R., Chang, Y-T., Perez, O., Sutherlin, D., Dong, H., Lock hart, D. J., and Schultz, P. G. Myoseverin, a microtubule-binding molecule  with novel cellular effects. Nat. Biotechnol., 18: 304–308, 2000.  	10700146
	29. Ben-Ze’ev, A., Farmer, S. R., and Penman, S. Mechanisms of regu lating tubulin synthesis in cultured mammalian cells. Cell, 17: 319–325,  1979.  	455467
	30. Chen, Y., McPhie, D. L., Hirschberg, J., and Neve, R. L. The amyloid  precursor protein-binding protein APP-BP1 drives the cell cycle through  the S-M checkpoint and causes apoptosis in neurons. J. Biol. Chem., 275:  8929–8935, 2000.  	10722740
	31. Nigg, E. A. Cyclin-dependent kinase 7: at the cross-roads of tran scription, DNA repair and cell cycle control? Curr. Opin. Cell Biol., 8:  312–317, 1996.  	8743880
	32. Rossignol, M., Kolb-Cheynel, I., and Egly, J. M. Substrate specificity  of the cdk-activating kinase (CAK) is altered upon association with TFIIH.  EMBO J., 16: 1628–1637, 1997.  	9130708
	33. Yankulov, K. Y., and Bentley, D. L. Regulation of CDK7 substrate  specificity by MAT1 and TFIIH. EMBO J., 16: 1638–1646, 1997.  	9130709
	34. Araujo, S. J., Tirode, F., Coin, F., Pospiech, H., Syvaoja, J. E., Stucki,  M., Hubscher, U., Egly, J. M., and Wood, R. D. Nucleotide excision repair  of DNA with recombinant human proteins: definition of the minimal set of  factors, active forms of TFIIH, and modulation by CAK. Genes Dev., 14:  349–359, 2000.  	10673506
	35. Korn, E. L., Arbuck, S. G., Pluda, J. M., Simon, R., Kaplan, R. S., and  Christian, M. C. Clinical trial designs for cytostatic agents: are new ap proaches needed? J. Clin. Oncol., 19: 265–272. 2001.  	11134222
	36. McKendrick, L., Thompson, E., Ferreira, J., Morley, S. J., and Lewis,  J. D. Interaction of eukaryotic translation initiation factor 4G with the nuclear cap-binding complex provides a link between nuclear and cyto plasmic functions of the m(7) guanosine cap. Mol. Cell. Biol., 21: 3632–  3641, 2001.  	NO_MATCH
	37. Basse, F., Stout, J. G., Sims, P. J., and Wiedmer, T. Isolation of an  erythrocyte membrane protein that mediates Ca2-dependent trans bilayer movement of phospholipid. J. Biol. Chem., 271: 17205–17210,  1996.  	8663431
	38. Kawakami, T., Furukawa, Y., Sudo, K., Saito, H., Takami, S., Taka hashi, E., and Nakamura, Y. Isolation and mapping of a human gene  (PDCD2) that is highly homologous to Rp8, a rat gene associated with  programmed cell death. Cytogenet. Cell Genet., 71: 41–43, 1995.  	7606924
Mol Cancer Ther-2002-Raymond-227-35.pdf
	1. Cvitkovic, E. A historical perspective on oxaliplatin: rethinking the role  of platinum compounds and learning from near misses. Semin. Oncol., 25:  1–3, 1998.  	9609102
	2. Raymond, E., Chaney, S. G., Taamma, A., and Cvitkovic, E. Oxaliplatin:  a review of preclinical and clinical studies. Ann. Oncol., 9: 1053–1071,  1998.  	9834817
	3. Raymond, E., Faivre, S., Woynarowski, J. M., and Chaney, S. G.  Oxaliplatin: mechanism of action and antineoplastic activity. Semin. On col., 25: 4–12, 1998.  	9609103
	4. Soulie´, P., Raymond, E., Brienza, S., and Cvitkovic, E. Oxaliplatin: the  first DACH platinum in clinical practice. Bull. Cancer, 84: 665–673, 1997.  	9295871
	5. Cvitkovic, E. Ongoing and unsaid on oxaliplatin: the hope. Br. J. Can cer, 77 (Suppl. 4): 8–11, 1998.  	9647613
	6. Llory, J. F., Soulie´, P., Cvitkovic, E., and Misset, J. L. Feasibility of  high-dose platinum delivery with combined carboplatin and oxaliplatin.  J. Natl. Cancer Inst. (Bethesda), 86: 1098–1099, 1994.  	8043147
	7. Soulie´, P., Bensmaine, A., Garrino, C., Chollet, P., Brain, E., Fereres,  M., Jasmin, C., Musset, M., Misset, J. L., and Cvitkovic, E. Oxaliplatin/  cisplatin (L-OHP/CDDP) combination in heavily pretreated ovarian cancer.  Eur. J. Cancer, 33: 1400–1406, 1997.  	9337681
	8. Kidani, Y., Iigo, M., Inagaki, K., Hoshi, A., and Kuretani, K. Antitumor  activity of 1,2-diaminocyclohexane–platinum complexes against sarco ma-180 ascites form. J. Med. Chem., 21: 1315–1318, 1978.  	722741
	9. Loehrer, P. J., Turner, S., Kubilis, P., Hui, S., Correa, J., Ansari, R.,  Stephens, D., Woodburn, R., and Meyer, S. A prospective randomized trial  of fluorouracil versus fluorouracil plus cisplatin in the treatment of meta static colorectal cancer: a Hoosier Oncology Group trial. J. Clin. Oncol., 6:  642–648, 1988.  	3282033
	10. Kemeny, N., Israel, K., Niedzwiecki, D., Chapman, D., Botet, J., Min sky, B., Vinciguerra, V., Rosenbluth, R., Bosselli, B., and Cochran, C.  Randomized study of continuous infusion fluorouracil versus fluorouracil  plus cisplatin in patients with metastatic colorectal cancer. J. Clin. Oncol.,  8: 313–318, 1990.  	2405107
	11. Sasaki, K., Yamamitsu, S., Hirata, K., Koide, S., Takasaka, H., Hiraike,  N., Katsuramaki, T., Denno, R., and Shirasaka, T. Combination chemo therapy of intermittent infusion 5-FU and CDDP for advanced colorectal  adenocarcinoma: a Sapporo Cancer Study Trial. Proc. Am. Soc. Clin.  Oncol., 17: 302a, 1998.  	NO_MATCH
	12. Rixe, O., Ortuzar, W., Alvarez, M., Parker, R., Reed, E., Paull, K., and  Fojo, T. Oxaliplatin, tetraplatin, cisplatin, and carboplatin: spectrum of  activity in drug-resistant cell lines and in the cell lines of the National  Cancer Institute’s Anticancer Drug Screen panel. Biochem. Pharmacol.,  52: 1855–1865, 1996.  	8951344
	13. Pendyala, L., Kidani, Y., Perez, R., Wilkes, J., Bernacki, R. J., and  Creaven, P. J. Cytotoxicity, cellular accumulation and DNA binding of  oxaliplatin isomers. Cancer Lett., 97: 177–184, 1995.  	7497460
	14. Pendyala, L., and Creaven, P. J. In vitro cytotoxicity, protein binding,  red blood cell partitioning, and biotransformation of oxaliplatin. Cancer  Res., 53: 5970–5976, 1993.  	8261411
	15. Holmes, J., Stanko, J., Varchenko, M., Ding, H., Madden, V. J.,  Bagnell, C. R., Wyrick, S. D., and Chaney, S. G. Comparative neurotoxicity  of oxaliplatin, cisplatin, and ormaplatin in a Wistar rat model. J. Toxicol.  Sci., 46: 342–351, 1998.  	10048138
	16. Raymond, E., Lawrence, R., Izbicka, E., Faivre, S., and Von Hoff, D. D.  Activity of oxaliplatin against human tumor colony-forming units. Clin.  Cancer Res., 4: 1021–1029, 1998.  	9563898
	17. Kraker, A., Steinkampf, R. W., and Moore, C. W. Transport of Cis-Pt  and Cis-Pt analogs in sensitive and resistant murine leukemia cell lines.  Proc. Am. Assoc. Cancer Res., 27: 286, 1986.  	NO_MATCH
	18. Fukuda, M., Ohe, Y., Kanzawa, F., Oka, M., Hara, K., and Saijo, N.  Evaluation of novel platinum complexes, inhibitors of topoisomerase I and  II in non-small cell lung cancer (NSCLC) sublines resistant to cisplatin.  Anticancer Res., 15: 393–398, 1995.  	7763011
	19. Raymond, E., Buquet-Fagot, C., Djelloul, S., Mester, J., Cvitkovic, E.,  Allain, P., Louvet, C., and Gespach, C. Antitumor activity of oxaliplatin in  combination with 5-fluorouracil and the thymidylate synthase inhibitor  AG337 in human colon, breast and ovarian cancers. Anticancer Drugs, 8:  876–885, 1997.  	9402315
	20. Saris, C. P., van de Vaart, P. J. M., Rietbroek, R. C., and Blommaert,  F. A. In vitro formation of DNA adducts by cisplatin, lobaplatin and oxali platin in calf thymus DNA in solution and in cultured human cells. Carci nogenesis (Lond.), 17: 2763–2769, 1996.  	9006117
	21. Woynarowski, J. M., Faivre, S., Herzig, M. C., Arnett, B., Chapman,  W. G., Trevino, A. V., Raymond, E., Chaney, S. G., Vaisman, A., Varch enko, M., et al. Oxaliplatin-induced damage of cellular DNA. Mol. Phar macol., 58: 920–927, 2000.  	11040038
	22. Woynarowski, J. M., Chapman, W. G., Napier, C., Herzig, M. C., and  Juniewicz, P. Sequence- and region-specificity of oxaliplatin adducts in  naked and cellular DNA. Mol. Pharmacol., 54: 770–777, 1998.  	9804612
	23. Luo, F. R., Wyrick, S. D., and Chaney, S. G. Cytotoxicity, cellular  uptake, and cellular biotransformations of oxaliplatin in human colon  carcinoma cells. Oncol. Res., 10: 595–603, 1998.  	10367941
	24. Luo, F. R., Yen, T. Y., Wyrick, S. D., and Chaney, S. G. High-perfor mance liquid chromatographic separation of the biotransformation prod ucts of oxaliplatin. J. Chromatogr. B Biomed. Sci. Appl., 724: 345–356,  1999.  	10219677
	25. Luo, F. R., Wyrick, S. D., and Chaney, S. G. Biotransformations of  oxaliplatin in rat blood in vitro. J. Biochem. Mol. Toxicol., 13: 159–169,  1999.  	10098901
	26. Faivre, S., and Woynarowski, J. M. Oxaliplatin effects on DNA integrity  and apoptosis induction in human tumor cells. Proc. Am. Assoc. Cancer  Res., 39: 158, 1998.  	NO_MATCH
	27. Vaisman, A., Varchenko, M., Umar, A., Kunkel, T. A., Risinger, J. I.,  Barrett, J. C., Hamilton, T. C., and Chaney, S. G. The role of hMLH1,  hMSH3, and hMSH6 defects in cisplatin and oxaliplatin resistance: cor relation with replicative bypass of platinum-DNA adducts. Cancer Res.,  58: 3579–3585, 1998.  	9721864
	28. Reardon, J. T., Vaisman, A., Chaney, S. G., and Sancar, A. Efficient  nucleotide excision repair of cisplatin, oxaliplatin, and Bis-aceto-ammine dichloro-cyclohexylamine-platinum(IV) (JM216) platinum intrastrand DNA  diadducts. Cancer Res., 59: 3968–3971, 1999.  	10463593
	29. Vaisman, A., Lim, S. E., Patrick, S. M., Copeland, W. C., Hinkle, D. C.,  Turchi, J. J., and Chaney, S. G. Effect of DNA polymerases and high  mobility group protein 1 on the carrier ligand specificity for translesion  synthesis past platinum-DNA adducts. Biochemistry, 38: 11026–11039,  1999.  	10460158
	30. Scheeff, E. D., Briggs, J. M., and Howell, S. B. Molecular modeling of  the intrastrand guanine-guanine DNA adducts produced by cisplatin and  oxaliplatin. Mol. Pharmacol., 56: 633–643, 1999.  	10462551
	31. Sharp, S. Y., O’Neill, C. F., Boxall, F., Rogers, P., Stephens, T., and  Kelland, L. R. Non-cross resistance between oxaliplatin and ZD0473 in  acquired oxaliplatin-resistant colon and ovarian carcinoma cell lines. Clin.  Cancer Res. (suppl.), 6: 4537s, 2000.  	NO_MATCH
	32. Damia, G., Guidi, G., and D’Incalci, M. Expression of genes involved  in nucleotide excision repair and sensitivity to cisplatin and melphalan in  human cancer cell lines. Eur. J. Cancer, 34: 1783–1788, 1998.  	9893669
	33. Hibino, Y., Hiraoka, Y., Kamiuchi, S., Kusashio, E., and Sugano, N.  Enhancement of excision repair of cisplatin-DNA adducts by cell-free  extract from a cisplatin-resistant rat cell line. Biochem. Pharmacol., 57:  1415–1422, 1999.  	10353263
	34. Petersen, L. N., Mamenta, E. L., Stevnsner, T., Chaney, S. G., and  Bohr, V. A. Increased gene specific repair of cisplatin induced interstrand  crosslinks in cisplatin resistant cell lines and studies on carrier ligand  specificity. Carcinogenesis (Lond.), 17: 2597–2602, 1996.  	9006094
	35. Issa, J. P. The epigenetics of colorectal cancer. Ann. N. Y. Acad. Sci.,  910: 140–153, 2000.  	10911911
	36. Thibodeau, S. N., French, A., Roche, P., Cunningham, J., Tester, D.,  Lindor, N., Moslein, G., Baker, S., Liskay, R., Burgart, L., et al. Altered  expression of hMSH2 and hMSH1 in tumors with microsatellite instability  and genetic alterations in mismatch repair genes. Cancer Res., 56: 4836–  4840, 1996.  	8895729
	37. Wheeler, J. M., Beck, N. E., Kim, H. C., Tomlinson, I. P., Mortensen,  N. J., and Bodmer, W. F. Mechanisms of inactivation of mismatch repair  genes in human colorectal cancer cell lines: the predominant role of  hMLH1. Proc. Natl. Acad. Sci. USA, 96: 10296–10301, 1999.  	10468602
	38. Kuismanen, S. A., Holmberg, M. T., Salovaara, R., Schweizer, P.,  Aaltonen, L. A., de la, C. A., Nystrom-Lahti, M., and Peltomaki, P. Epige netic phenotypes distinguish microsatellite-stable and -unstable colorec tal cancers. Proc. Natl. Acad. Sci. USA, 96: 12661–12666, 1999.  	10535979
	39. Herman, J., Umar, A., Polyak, K., Graff, J., Ahuja, N., Issa, J., Markow itz, S., Willson, J., Hamilton, S. R., and Kinzler, K. W., et al. Incidence and  functional consequences of hMLH1 promoter hypermethylation in colo rectal carcinoma. Proc. Natl. Acad. Sci. USA, 95: 6870–6875, 1998.  	9618505
	40. Thibodeau, S. N., French, A., Cunningham, J., Tester, D., Burgart, L.,  Roche, P., McDonnel, S., Schaid, D., Vockely, C., Michels, V., et al.  Microsatellite instability in colorectal cancer: different mutator phenotypes  and the principal involvement of hMLH1. Cancer Res., 58: 1713–1718,  1998.  	9563488
	41. Strathdee, G., Mackean, M., Illand, M., and Brown, R. A role for  methylation of the hMLH1 promoter in loss of hMLH1 expression and drug  resistance in ovarian cancer. Oncogene, 18: 2335–2341, 1999.  	10327053
	42. Kuismanen, S. A., Holmberg, M. T., Salovaara, R., de la, C. A., and  Peltomaki, P. Genetic and epigenetic modification of MLH1 accounts for  a major share of microsatellite-unstable colorectal cancers. Am. J.  Pathol., 156: 1773–1779, 2000.  	10793088
	43. King, B. L., Carcangiu, M. L., Carter, D., Kiechle, M., Pfisterer, J.,  Pfleiderer, A., and Kacinski, B. M. Microsatellite instability in ovarian  neoplasms. Br. J. Cancer, 72: 376–382, 1995.  	7640221
	44. Kolodner, R. D. Mismatch repair: mechanisms and relationship to  cancer susceptibility. Trends Biochem. Sci., 20: 397–401, 1995.  234   Cellular and Molecular Pharmacology of Oxaliplatin  	8533151
	45. Paulson, T. G., Wright, F. A., Parker, B. A., Russack, V., and Wahl, G.  M. Microsatellite instability correlates with reduced survival and poor  disease prognosis in breast cancer. Cancer Res., 56: 4021–4026, 1996.  	8752173
	46. Herfarth, K. K., Kodner, I. J., Whelan, A. J., Ivanovich, J. L., Bra camontes, J. R., Wells, S. A., Jr., and Goodfellow, P. J. Mutations in MLH1  are more frequent than in MSH2 in sporadic colorectal cancers with  microsatellite instability. Genes Chromosomes Cancer, 18: 42–49, 1997.  	8993979
	47. Brown, R., Hirst, G. L., Gallagher, W., Mcllwrath, A., Margison, G. P.,  van der Zee, A., and Anthoney, D. A. hMLH1 expression and cellular  responses of ovarian tumour cells to treatment with cytotoxic anticancer  agents. Oncogene, 15: 45–52, 1997.  	9233776
	48. Mackay, H. J., Cameron, D., Rahilly, M., Mackean, M. J., Paul, J.,  Kaye, S. B., and Brown, R. Reduced MLH1 expression in breast tumors  after primary chemotherapy predicts disease-free survival. J. Clin. Oncol.,  18: 87–93, 2000.  	10623697
	49. Herman, J., Umar, A., Polyak, K., Graff, J., Ahuja, N., Issa, J. P.,  Markowitz, S., Willson, J., Hamilton, S. R., Kinzler, K. W., et al. Incidence  and functional consequences of hMLH1 promoter hypermethylation in  colorectal carcinoma. Proc. Natl. Acad. Sci. USA, 95: 6870–6875, 1998.  	9618505
	50. Brown, R., Hirst, G. L., Gallagher, W., Mcllwrath, A., Margison, G. P.,  van der Zee, A., and Anthoney, D. A. hMLH1 expression and cellular  responses of ovarian tumour cells to treatment with cytotoxic anticancer  agents. Oncogene, 15: 45–52, 1997.  	9233776
	51. Plumb, J. A., Strathdee, G., Sludden, J., Kaye, S., and Brown, R.  Reversal of drug resistance in human tumor xenografts by 2-deoxy-5 azacytidine-induced demethylation of the hMLH1 gene promoter. Cancer  Res., 60: 6039–6044, 2000.  	11085525
	52. Aebi, S., Kurdi-Haidar, B., Gordon, R., Cenni, B., Zheng, H., Fink, D.,  Christen, R. D., Boland, C. R., Koi, M., Fishel, R., et al. Loss of DNA  mismatch repair in acquired resistance to cisplatin. Cancer Res., 56:  3087–3090, 1996.  	8674066
	53. Ferry, K. V., Fink, D., Johnson, S. W., Nebel, S., Hamilton, T. C., and  Howell, S. B. Decreased cisplatin damage-dependent DNA synthesis in  cellular extracts of mismatch repair deficient cells. Biochem. Pharmacol.,  57: 861–867, 1999.  	10086318
	54. Fink, D., Nebel, S., Aebi, S., Zheng, H., Cenni, B., Nehme, A., Chris ten, R. D., and Howell, S. B. The role of DNA mismatch repair in platinum  drug resistance. Cancer Res., 56: 4881–4886, 1996.  	8895738
	55. Strathdee, G., Mackean, M. J., Illand, M., and Brown, R. A role for  methylation of the hMLH1 promoter in loss of hMLH1 expression and drug  resistance in ovarian cancer. Oncogene, 18: 2335–2341, 1999.  	10327053
	56. Strathdee, G., Appleton, K., Illand, M., Millan, D. W., Sargent, J., Paul,  J., and Brown, R. Primary ovarian carcinomas display multiple methylator  phenotypes involving known tumor suppressor genes. Am. J. Pathol.,  158: 1121–1127, 2001.  	11238060
	57. de Gramont, A., Vignoud, J., Tournigand, C., Louvet, C., Andre, T.,  Varette, C., Raymond, E., Moreau, S., Le Bail, N., and Krulik, M. Oxaliplatin  with high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion  in pretreated metastatic colorectal cancer. Eur. J. Cancer, 33: 214–219,  1997.  	9135491
	58. Fink, D., Zheng, H., Nebel, S., Norris, P. S., Aebi, S., Lin, T. P., Nehme,  A., Christen, R. D., Haas, M., MacLeod, C. L., et al. In vitro and in vivo  resistance to cisplatin in cells that have lost DNA mismatch repair. Cancer  Res., 57: 1841–1845, 1997.  	9157971
	59. Nebel, S., Fink, D., Nehme, A., Aebi, S., Christen, R. D., and Howell,  S. B. Role of the DNA mismatch repair proteins in the recognition of  platinum DNA adducts. Proc. Am. Assoc. Cancer Res., 38: 359, 1997.  	NO_MATCH
	60. Nehme, A., Baskaran, R., Nebel, S., Fink, D., Howell, S. B., Wang,  J. Y., and Christen, R. D. Induction of JNK and c-Abl signalling by cisplatin  and oxaliplatin in mismatch repair-proficient and -deficient cells. Br. J.  Cancer, 79: 1104–1110, 1999.  	10098743
	61. Moreland, N. J., Illand, M., Kim, Y. T., Paul, J., and Brown, R. Mod ulation of drug resistance mediated by loss of mismatch repair by the DNA  polymerase inhibitor aphidicolin. Cancer Res., 59: 2102–2106, 1999.  	10232595
	62. Durant, S. T., Morris, M. M., Illand, M., McKay, H. J., McCormick, C.,  Hirst, G. L., Borts, R. H., and Brown, R. Dependence on RAD52 and RAD1  for anticancer drug resistance mediated by inactivation of mismatch repair  genes. Curr. Biol., 9: 51–54, 1999.  	9889125
	63. Akaboshi, M., Kawai, K., Ujeno, Y., Takada, S., and Miyahara, T.  Binding characteristics of (-)-(R)-2-aminomethylpyrrolidine(1,1-cyclobu tanedicarboxylato)-2-platinum(II) to DNA, RNA and protein molecules in  HeLa cells and its lethal effect: comparison with cis- and trans-diam minedichloroplatinums(II). Jpn. J. Cancer Res., 85: 106–111, 1994.  	7508903
	64. Akaboshi, M., Kawai, K., Maki, H., Akuta, K., Ujeno, Y., and Miyahara,  T. The number of platinum atoms binding to DNA, RNA and protein  molecules of HeLa cells treated with cisplatin at its mean lethal concen tration. Jpn. J. Cancer Res., 83: 522–526, 1992.  	1618702
	65. Woynarowski, J. M., Koester, S., Woynarowska, B., Arnett, B.,  Trevino, A. V., Chan, D., Higdon, A., Munoz, R., Herzig, M. C., and Faivre,  S. Is drug-induced damage sufficient for apoptosis induction? Proc. Am.  Assoc. Cancer Res., 40: 736, 1999.  	NO_MATCH
	66. Chaney, S., and Sancar, A. DNA repair: enzymatic mechanisms and  relevance to drug response. J. Natl. Cancer Inst. (Bethesda), 88: 1346–  1360, 1996.  	8827012
	67. Graham, M., Lockwood, G., Greenslade, D., Brienza, S., Bayssas, M.,  and Gamelin, E. Clinical pharmacokinetics of oxaliplatin: a critical review.  Clin. Cancer Res., 6: 1205–1218, 2000.  	10778943
	68. Misset, J. L., Bleiberg, H., Sutherland, W., Bekradda, M., and Cvitk ovic, E. Oxaliplatin clinical activity: a review. Crit. Rev. Oncol. Hematol.,  35: 75–93, 2000.  	10936465
	69. Mavroudis, D., Kourousis, C., Kakolyris, S., Agelaki, S., Kalbakis, K.,  Androulakis, N., Souglakos, J., Vardakis, N., Samonis, G., and Geor goulias, V. Phase I study of gemcitabine/oxaliplatin combination in pa tients with advanced solid tumors: a preliminary report. Semin. Oncol., 27:  25–30, 2000.  	10697033
	70. Carethers, J. M., Chauhan, D. P., Fink, D., Nebel, S., Bresalier, R. S.,  Howell, S. B., and Boland, C. R. Mismatch repair proficiency and in vitro  response to 5-fluorouracil. Gastroenterology, 117: 123–131, 1999.  	10381918
	71. Meyers, M., Wagner, M. W., Hwang, H. S., Kinsella, T. J., and Booth man, D. A. Role of the hMLH1 DNA mismatch repair protein in fluoropy rimidine-mediated cell death and cell cycle responses. Cancer Res., 61:  5193–5201, 2001.  	11431359
	72. Plasencia, C., Taron, M., Martinez, E., Rossell, R., and Abad, A.  Down-regulation of thymidylate synthase gene expression after oxaliplatin  administration: implications for the synergistic activity of sequential ox aliplatin/5FU in sensitive and 5FU-resistant cell lines. Proc. Am. Assoc.  Cancer Res., 42: 508, 2001.  	NO_MATCH
	73. Fischel, J. L., Etienne, M. C., Formento, P., and Milano, G. Search for  the optimal schedule for the oxaliplatin/5-fluorouracil association modu lated or not by folinic acid: preclinical data. Clin. Cancer Res., 4: 2529–  2535, 1998.  	9796987
	74. Metzger, G., Massari, C., Etienne, M. C., Comisso, M., Brienza, S.,  Touitou, Y., Milano, G., Bastian, G., Misset, J. L., and Levi, F. Spontane ous or imposed circadian changes in plasma concentrations of 5 fluorouracil coadministered with folinic acid and oxaliplatin: relationship  with mucosal toxicity in patients with cancer. Clin. Pharmacol. Ther., 56:  190–201, 1994.  	8062496
	75. Gale, G. R., Loretta, M., Atkins, L. M., Schwartz, P., and Meischen,  S. J. Potentiating action of 5-fluorouracil when used in combination with  platinum compounds and cyclophosphamide in treatment of advanced  L1210 leukemia. Bioinorg. Chem., 8: 445–451, 1978.  	687671
	76. Ducreux, M., Louvet, C., Bekradda, M., and Cvitkovic, E. Oxaliplatin  for the treatment of advanced colorectal cancer: future directions. Semin.  Oncol., 25: 47–53, 1998.  	9609108
	77. Louvet, C., Raymond, E., Coudray, A. M., Chazard, M., and Gespach,  C. Antitumor activity of UFT  folinic acid (FA) in combination with  oxaliplatin (Ox) against human HT29 colon cancer xenografts in athymic  nude mice. Proc. Am. Assoc. Cancer Res., 40: 292, 1999.  	NO_MATCH
	78. Raymond, E., Djelloul, S., Buquet-Fagot, C., Goldwasser, F., Mester,  J., Cvitkovic, E., Louvet, C., and Gespach, C. Oxaliplatin (LOHP), and  cisplatin (CDDP) in combination with 5FU, specific thymidylate synthase  (TS) inhibitors (AG337, ZD1694), and topoisomerase I (TOPO-I) inhibitors SN38, CPT-11), in human colonic, ovarian and breast cancers (meeting  abstract). Proc. Am. Assoc. Cancer Res., 37: 291, 1996.  	NO_MATCH
	79. Faivre, S., Raymond, E., Woynarowski, J. M., and Cvitkovic, E. Su praadditive effect of 2,2-difluorodeoxycytidine (gemcitabine) in combi nation with oxaliplatin in human cancer cell lines. Cancer Chemother.  Pharmacol., 44: 117–123, 1999.  	10412945
	80. Lin, X., Ramamurthi, K., Mishima, M., Kondo, A., Christen, R. D., and  Howell, S. B. P53 modulates the effects of loss of DNA mismatch repair  on sensitivity of human colon cancer cells to the cytotoxic and mutagenic  effects of cisplatin. Cancer Res., 61: 1508–1516, 2001.  	11245458
	81. Mathe, G., Chenu, E., Bourut, C., and Florentin, I. Experimental study  of three platinum complexes: CDDP, CBDCA and L-OHP on L1210 leu kemia. Proc. Am. Assoc. Cancer Res., 30: 471, 1989.  	NO_MATCH
	82. Mathe, G., Kidani, Y., Segiguchi, M., Eriguchi, M., Fredj, G., Peytavin,  G., Misset, J. L., Brienza, S., de Vassals, F., and Chenu, E. Oxalato platinum or 1-OHP, a third-generation platinum complex: an experimental  and clinical appraisal and preliminary comparison with cis-platinum and  carboplatinum. Biomed. Pharmacother., 43: 237–250, 1989.  	2675999
	83. Goldwasser, F., Bozec, L., Zeghari-Squalli, N., and Misset, J. L.  Cellular pharmacology of the combination of oxaliplatin with topotecan in  the IGROV-1 human ovarian cancer cell line. Anticancer Drugs, 10: 195–  201, 1999.  	10211550
	84. Zeghari-Squalli, N., Raymond, E., Cvitkovic, E., and Goldwasser, F.  Cellular pharmacology of the combination of the DNA topoisomerase I  inhibitor SN-38 and the diaminocyclohexane platinum derivative oxalipla tin. Clin. Cancer Res., 5: 1189–1196, 1999.  	10353756
	85. Bissery, M. C., Vrignaud, P., and Lavelle, F. In vivo evaluation of the  irinotecan-oxaliplatin combination. Proc. Am. Assoc. Cancer Res., 39:  526, 1998.  	NO_MATCH
	86. Mailliet, P., Segal-Bendirdjian, E., Kozelka, J., Barreau, M., Baudoin,  B., Bissery, M. C., Gontier, S., Laoui, A., Lavelle, F., and Le Pecq, J. B.  Asymmetrically substituted ethylenediamine platinum(II) complexes as  antitumor agents: synthesis and structure-activity relationships. Antican cer Drug Des., 10: 51–73, 1995.  	7695813
	87. Skou, G., Mangold, G., Dexter, D., and Von Hoff, D. D. Comparison of  an oxaliplatin-taxol versus carboplatin-taxol regimen in the treatment of  the MV-522 human lung tumor xenograft. Proc. Am. Assoc. Cancer Res.,  37: 375, 1996.  	NO_MATCH
	88. Debner, J., Dexter, D., Mangold, G., Juniewicz, P., Rake, J., and Von  Hoff, D. D. Evaluation of oxaliplatin-tirapazamine-taxol combinations in  the MV-522 human lung carcinoma xenograft model. Proc. Am. Assoc.  Cancer Res., 38: 312, 1997.  	NO_MATCH
	89. Faivre, S., Kalla, S., Cvitkovic, E., Bourdon, O., Hauteville, D., Dourte,  L. M., Bensmaine, A., Itzhaki, M., Marty, M., and Extra, J. M. Oxaliplatin  and paclitaxel combination in patients with platinum-pretreated ovarian  carcinoma: an investigator-originated compassionate use experience.  Ann. Oncol., 10: 1125–1128, 1999.  	10572615
	90. Giacchetti, S., Perpoint, B., Zidani, R., Le Bail, N., Faggiuolo, R.,  Focan, C., Chollet, P., Llory, J. F., Letourneau, Y., Coudert, B., Bertheaut Cvitkovic, F., Larregain-Fournier, D., Le Rol, A., Walter, S., Adam, R.,  Misset, J. L., and Levi, F. Phase III multicenter randomized trial of oxali platin added to chronomodulated fluorouracil-leucovorin as first-line treat ment of metastatic colorectal cancer. J. Clin. Oncol., 18: 136–147, 2000.  	10623704
	91. De Gramont, A., Figer, A., Seymour, M., Homerin, M., Hmissi, A.,  Cassidy, J., Boni, C., Cortes-Funes, H., Cervantes, A., Freyer, G., et al.  Leucovorin and fluorouracil with or without oxaliplatin as first-line treat ment in advanced colorectal cancer. J. Clin. Oncol., 18: 2938–2947, 2000.  	10944126
	92. Fizazi, K., Ducreux, M., Ruffie, P., Bonnay, M., Daniel, C., Soria, J. C.,  Hill, C., Fandi, A., Poterre, M., Smith, M., et al. Phase I, dose-finding, and  pharmacokinetic study of raltitrexed combined with oxaliplatin in patients  with advanced cancer. J. Clin. Oncol., 18: 2293–2300, 2000.  	10829050
	93. Wasserman, E., Cuvier, C., Lokiec, F., Goldwasser, F., Kalla, S.,  Me´ry-Mignard, D., Ould Kaci, M., Bensmaine, A., Dupont-Andre´, G., Mah joubi, M., et al. Combination of oxaliplatin plus irinotecan in patients with  gastrointestinal tumors: results of two independent phase I studies with  pharmacokinetics. J. Clin. Oncol., 17: 1751–1759, 1999.  	10561212
	94. Scheithauer, W., Kornek, G. V., Raderer, M., Valencak, J., Weinlander,  G., Hejna, M., Haider, K., Kwasny, W., and Depisch, D. Combined irino tecan and oxaliplatin plus granulocyte colony-stimulating factor in pa tients with advanced fluoropyrimidine/leucovorin-pretreated colorectal  cancer. J. Clin. Oncol., 17: 902–906, 1999.  	10071282
	95. Kemeny, N., Tong, W., Stockman, J., Blanchette, J., and Saltz, L.  Phase I trial of weekly oxaliplatin and irinotecan in previously treated  patients with metastatic colorectal cancer. Proc. Am. Soc. Clin. Oncol.,  19: 245a, 2000.  	NO_MATCH
	96. Goldwasser, F., Gross-Goupil, M., Tigaud, J. M., Di Palma, M.,  Marceau-Suissa, J., Wasserman, E., Yovine, A., Misset, J. L., and Cvit kovic, E. Dose escalation of CPT-11 in combination with oxaliplatin using  an every two weeks schedule: a phase I study in advanced gastrointes tinal cancer patients. Ann. Oncol., 11: 1463–1470, 2000.  	11142487
	97. Misset, J. L., Goldwasser, F., Riofrio, M., Gross, M., Romain, D., and  Lokiec, F. Topotecan-oxaliplatin every three weeks: a phase I and phar macological study. Proc. Am. Soc. Clin. Oncol., 18: 220a, 1999.  	NO_MATCH
	98. Delaloge, S., Laadem, A., Chouaki, N., Pautier, P., Taamma, A.,  Misset, J. L., Cvitkovic, E., and Lhomme, C. Feasibility study of the  paclitaxel (PXL), oxaliplatin (LOHP) and ciplatin (CDDP) combination in  advanced ovarian cancer (AOC). Proc. Am. Soc. Clin. Oncol., 18: 365a,  1999.  	NO_MATCH
	99. Buechele, T., Schmoll, H., Grothey, A., and Voigt, W. Biweekly Do cetaxel (Doc), Gemcitabine (Gem), Oxaliplatin (LOHP) in heavily pretreated  patients with solid tumors–a pilot study. Proc. Am. Soc. Clin. Oncol., 18:  205a, 1999.  	NO_MATCH
	100. el-akawi, Z., Abu-hadid, M., Perez, R., Glavy, J., Zdanowicz, J.,  Creaven, P. J., and Pendyala, L. Altered glutathione metabolism in oxali platin resistant ovarian carcinoma cells. Cancer Lett., 105: 5–14, 1996.  	8689632
J Infect Dis.-2002-Greene-1790-6.pdf
	1. Pinner RW, Teutsch SM, Simonsen L, Klug LA, Clarke MJ, Berkelman RL.  Infectious disease in the United States. JAMA 1996;275:189–93.  	NO_MATCH
	2. Center for Disease Control and Prevention. Premature deaths, monthly mor tality and monthly physician contacts: United States. MMWR Morb Mor tal Wkly Rep 1997;46:556–61.  	NO_MATCH
	3. Arston BJ, Plouffe JF, File TM Jr, et al. Incidence of community-acquired  pneumonia requiring hospitalisation: results of a population-based active  surveillance study in Ohio. The Community-Based Incidence Study  Group. Arch Intern Med 1997;157:1709–22.  	9250232
	4. Niederman MS, McCombs JS, Unger AN, Kumar A, Popovian R. The cost  of treating community-acquired pneumonia. Clin Ther 1998;20:820–37.  	9737840
	5. Fine MJ, Smith MA, Carson CA, et al. Prognosis and outcomes of patients  with community-acquired pneumonia: a meta-analysis. JAMA 1996;275:  134–41.  	8531309
	6. Monton C, Torres A, El-Ebiary M, Filella X, Xaubet A, de la Bellacasa JP.  Cytokine expression in severe pneumonia: a bronchoalveolar lavage study.  Crit Care Med 1999;27:1745–53.  	10507593
	7. Kosmas EN, Baxevanis CN, Papamichail M, Kordossis T. Daily variation  in circulating cytokines and acute-phase proteins correlates with clinical  and laboratory indices in community-acquired pneumonia. Eur J Clin  Invest 1997;27:308–15.  	9134379
	8. Puren AJ, Feldman C, Savage N, Becker PJ, Smith C. Patterns of cytokine  expression in community-acquired pneumonia. Chest 1995;107:1342–9.  	7750329
	9. Dehoux MS, Boutten A, Ostinelli J, et al. Compartmentalized cytokine  production within the human lung in unilateral pneumonia. Am J Res pir Crit Care Med 1994; 150:710–6.  	8087341
	10. Glynn P, Coakley R, Kilgallen I, Murphy N, O’Neill SJ. Circulating inter leukin 6 and interleukin 10 in community acquired pneumonia. Thorax  1999;54:51–5.  	10343632
	11. Black RA, Rauch CT, Kozlosky CJ, et al. A metalloproteinase disintegrin  that releases TNF-a from cells. Nature 1997;385:729–33.  	NO_MATCH
	12. Nelson S, Bagby GJ, Bainton BG, Wilson LA, Thompson JJ, Summer WR.  Compartmentalization of intraalveolar and systemic lipopolysaccharide induced tumor necrosis factor and the pulmonary inflammatory response.  J Infect Dis 1989;159:189–94.  	2644368
	13. Boutten A, Dehoux MS, Seta N, et al. Compartmentalised IL-8 and elastase  release within the human lung in unilateral pneumonia. Am J Respir Crit  Care Med 1996;153:336–42.  	8542140
	14. Munford RS, Pugin J. Normal responses to injury prevent systemic inflam mation and can be immunosuppressive. Am J Respir Crit Care Med 2001;  163:316–21.  	11179099
	15. Peschon JJ, Slack JL, Reddy P, et al. An essential role for ectodomain shed ding in mammalian development. Science 1998;282:1281–4.  	9812885
	16. Hansen HP, Dietrich S, Kisseleva T, et al. CD30 shedding from Karpas 299  lymphoma cells is mediated by TNF-alpha–converting enzyme. J Immu nol 2000;165:6703–9.  	11120787
	17. Lum L, Wong BR, Josien R, et al. Evidence for a role of a tumor necrosis  factor–alpha (TNF-alpha)–converting enzyme–like protease in shedding  of TRANCE, a TNF family member involved in osteoclastogenesis and  dendritic cell survival. J Biol Chem 1999;274:13613–8.  	10224132
	18. Zhang Y, Jiang J, Black RA, Baumann G, Frank SJ. Tumor necrosis fac tor–alpha converting enzyme (TACE) is a growth hormone binding pro tein (GHBP) sheddase: the metalloprotease TACE/ADAM-17 is critical  for (PMA-induced) GH receptor proteolysis and GHBP generation. En docrinology 2000;141:4342–8.  	11108241
	19. Rovida E, Paccagnini A, Del Rosso M, Peschon J, Dello Sbarba P. TNF alpha–converting enzyme cleaves the macrophage colony-stimulating fac tor receptor in macrophages undergoing activation. J Immunol 2001;166:  1583–9.  	11160199
	20. Garton KJ, Gough PJ, Blobel CP, et al. TACE (ADAM17) mediates the  cleavage and shedding of Fractalkine (CX3CL1). J Biol Chem 2001;276:  37993–8001.  	NO_MATCH
	21. Montero JC, Yuste L, Diaz-Rodriguez E, Esparis-Ogando A, Pandiella A. Dif ferential shedding of transmembrane neuregulin isoforms by the tumor ne crosis factor–alpha–converting enzyme. Mol Cell Neurosci 2000;16:631–48.  	11083924
	22. Rio C, Buxbaum JD, Peschon JJ, Corfas G. Tumor necrosis factor–alpha–  converting enzyme is required for cleavage of erbB4/HER4. J Biol Chem  2000;275:10379–87.  	10744726
	23. Buxbaum JD, Liu KN, Luo Y, et al. Evidence that tumor necrosis factor alpha  converting enzyme is involved in regulated alpha-secretase cleavage of the  Alzheimer amyloid protein precursor. J Biol Chem 1998;273:27765–7.  	9774383
	24. Reddy P, Slack JL, Davis R, et al. Functional analysis of the domain structure  of tumor necrosis factor–alpha converting enzyme. J Biol Chem 2000;275:  14608–14.  	10799547
	25. Althoff K, Reddy P, Voltz N, Rose-John S, Mullberg J. Shedding of inter leukin-6 receptor and tumor necrosis factor alpha: contribution of the  stalk sequence to the cleavage pattern of transmembrane proteins. Eur J  Biochem 2000;267:2624–31.  	10785383
	26. Montero-Julian FA. The soluble IL-6 receptors: serum levels and biological  function. Cell Mol Biol (Noisy-le-grand) 2001;4:583–97.  	11502067
	27. Hurst SM, Wilkinson TS, McLoughlin RM, et al. IL-6 and its soluble receptor  orchestrate a temporal switch in the pattern of leukocyte recruitment seen  during acute inflammation. Immunity 2001;14:705–14.  	11420041
	28. Fine MJ, Auble TE, Yealy DM, et al. A prediction rule to identify low-risk  patients with community-acquired pneumonia. N Engl J Med 1997;336:  243–50.  	8995086
	29. American College of Chest Physicians/Society of Critical Care Medicine Con sensus Conference. Definitions for sepsis and organ failure and guidelines  for the use of innovative therapies in sepsis. Crit Care Med 1992;20:864–74.  	NO_MATCH
	30. Klech H, Pohl W. Technical recommendations and guidelines for bronchoal veolar lavage (BAL). Report of the European Society of Pneumology  Task Group. Eur Respir J 1989;2:561–84.  	NO_MATCH
	31. Bartlett JG, Dowell SF, Mandell LA, File TM Jr, Musher DM, Fine MJ.  Guidelines from the Infectious Diseases Society of America: practical  guidelines for the management of community-acquired pneumonia in  adults. Clin Infect Dis 2000;31:347–82.  	NO_MATCH
	32. Niederman MS, Bass JB Jr, Campbell GD, et al. Guidelines for the initial  management of adults with community-acquired pneumonia: diagnosis,  assessment of severity, and initial antimicrobial therapy. American Tho racic Society. Medical Section of the American Lung Association. Am  Rev Respir Dis 1993;148:1418–26.  	8239186
	33. Rennard SI, Basset G, Lecossier D, et al. Estimation of volume of epithelial  lining fluid recovered by lavage using urea as a marker of dilution. J Appl  Physiol 1986;60:532–8.  	3512509
	34. Flick DA, Gifford GE. Comparison of in vitro cell cytotoxic assays for  tumour necrosis factor. J Immunol Methods 1984;68:167–75.  	6707477
	35. Kamentsky LA, Burger DE, Gershman RJ, Kamentsky LD, Luther E. Slide based laser scanning cytometry. Acta Cytol 1997;41:123–43.  	9022736
	36. Woltmann G, Ward R, Symon F, Rew D, Pavord I, Wardlaw A. Objective  quantitative analysis of eosinophils and bronchial epithelial cells in in duced sputum by laser scanning cytometry. Thorax 1999;54:124–30.  	10325916
	37. Luettig B, Decker T, Lohmann-Matthes ML. Evidence for the existence of  two forms of membrane tumour necrosis factor: an integral protein and  a molecule attached to its receptor. J Immunol 1989;143:4034–8.  	2556474
	38. Dinerallo C. A. Biologic basis for interleukin-1 in disease. Blood 1996;87:  2095–47.  	8630372
	39. Doedens JR, Black RA. Stimulation-induced down-regulation of tumour  necrosis factor–a–converting enzyme. J Biol Chem 2000;275:14598–607.  	10799546
	40. Arend WP, Welgus HG, Thompson RC, Eisenberg SP. Biological properties  of recombinant human monocyte-derived interleukin-1 receptor antago nist. J Clin Invest 1990;85:1694–97.  	2139669
	41. Arend WP, Malyak M, Smith MF, et al. Binding of IL-1a, IL-1b and IL-1  receptor antagonist by soluble IL-1 receptors and levels of soluble IL-1  receptors in synovial fluid. J Immunol 1994;153:4766–74.  	7963543
	42. Rooney M, Varsani H, Martin K, Lombard PR, Dayer JM, Woo P. Tumour  necrosis factor–a and its receptors in juvenile chronic arthritis. Rheu matology 2000;39:432–8.  	10817778
	43. O’Grady NP, Preas HL, Pugin J, et al. Local inflammatory responses fol lowing bronchial endotoxin instillation in humans. Am J Respir Crit Care  Med 2001;163:1591–8.  	11401879
	44. Re F, Muzio M, De Rossi M et al. The type II “receptor” as a decoy target  for interleukin 1 in polymorphonuclear leukocytes: characterisation of  induction by dexamethasone and ligand binding properties of the released  decoy receptor. J Exp Med 1994;179:739–43.  	8294881
	45. Thabard W, Collette M, Mellerin MP, et al. IL-6 upregulates its own receptor  on some human myeloma cell lines. Cytokine 2001;14:352–6.  	11497497
	46. Remick DG, Call DR, Ebong SJ, et al. Combination immunotherapy with  soluble tumor necrosis factor receptors plus interleukin 1 receptor antag onist decreases sepsis mortality. Crit Care Med 2001;29:473–81.  	11373406
	47. Cox G. IL-10 enhances resolution of pulmonary inflammation in vivo by  promoting apoptosis of neutrophils. Am J Physiol 1996;271:L566–71.  	8897903
	48. Fiorentino DF, Zlotnik A, Mosmann TR, Howard M, O’Garra A. IL-10 inhibits  cytokine production by activated macrophages. J Immunol 1991;147:  3815–22.  	1940369
	49. van der Poll T, Marchant A, Keogh CV, Goldman M, Lowry SFl. Interleukin 10 impairs host defense in murine pneumococcal pneumonia. J Infect Dis  1996;174:994–1000.  	8896500
	50. Coeshott C, Ohnemus C, Pilyavskaya A, et al. Converting enzyme–  independent release of tumor necrosis factor alpha and IL-1beta from a  stimulated human monocytic cell line in the presence of activated neu trophils or purified proteinase 3. Proc Natl Acad Sci USA 1999;96:6261–6.  	10339575
4536.full.pdf
	1. Ben-Jonathan N, Hnasko R 2001 Dopamine as a prolactin (PRL) inhibitor.  Endocr Rev 22:724–763  	11739329
	2. Autelitano DJ, Snyder L, Sealfon SC, Roberts JL 1989 Dopamine D2 receptor messenger RNA is differentially regulated by dopaminergic agents  in rat anterior and neurointermediate pituitary. Mol Cell Endocrinol 67:  101–105  	2575547
	3. Mansour A, Meador-Woodruff JH, Bunzow JR, Civelli O, Akil H, Watson SJ  1990 Localization of dopamine D2 receptor mRNA and D1 and D2 receptor  binding in the rat brain and pituitary: an in situ hybridization-receptor auto radiographic analysis. J Neurosci 10:2587–2600  	2143777
	4. Kelly MA, Rubinstein M, Asa SL, Zhang G, Saez C, Bunzow JR, Allen RG,  Hnasko R, Ben-Jonathan N, Grandy DK, Low MJ 1997 Pituitary lactotroph  hyperplasia and chronic hyperprolactinemia in dopamine D2 receptor-defi cient mice. Neuron 19:103–113  	9247267
	5. Saiardi A, Bozzi Y, Baik JH, Borrelli E 1997 Antiproliferative role of dopa mine: loss of D2 receptors causes hormonal dysfunction and pituitary hyper plasia. Neuron 19:115–126  	9247268
	6. Asa SL, Kelly MA, Grandy DK, Low MJ 1999 Pituitary lactotroph adenomas  develop after prolonged lactotroph hyperplasia in dopamine D2 receptor deficient mice. Endocrinology 140:5348–5355  	10537166
	7. Freeman ME, Kanyicska B, Lerant A, Nagy G 2000 Prolactin: structure, func tion, and regulation of secretion. Physiol Rev 80:1523–1631  	11015620
	8. De Paul AL, Pons P, Aoki A, Torres AI 1997 Heterogeneity of pituitary  lactotrophs: immunocytochemical identification of functional subtypes. Acta  Histochem 99:277–289  	9381911
	9. Chen CL, Meites J 1970 Effects of estrogen and progesterone on serum  and pituitary prolactin levels in ovariectomized rats. Endocrinology 86:  503–505  	5410438
	10. Neill JD, Freeman ME, Tillson SA 1971 Control of the proestrus surge of  prolactin and luteinizing hormone secretion by estrogens in the rat. Endocri nology 89:1448–1453  	5166047
	11. Sarkar DK, Gottschall PE, Xie QW, Meites J 1984 Reduced tuberoinfundibular  dopaminergic neuronal function in rats with in situ prolactin-secreting pitu itary tumors. Neuroendocrinology 38:498–503  	6738813
	12. Perez RL, Machiavelli GA, Romano MI, Burdman JA 1986 Prolactin release,  oestrogens and proliferation of prolactin-secreting cells in the anterior pitu itary gland of adult male rats. J Endocrinol 108:399–403  	3701233
	13. Raymond V, Beaulieu M, Labrie F, Boissier J 1978 Potent antidopaminergic  activity of estradiol at the pituitary level on prolactin release. Science 200:  1173–1175  	418505
	14. West B, Dannies PS 1980 Effects of estradiol on prolactin production and  dihydroergocryptine-induced inhibition of prolactin production in primary  cultures of rat pituitary cells. Endocrinology 106:1108–1113  	6766855
	15. Gudelsky GA, Porter JC 1981 Sex-related difference in the release of dopamine  into hypophysial portal blood. Endocrinology 109:1394–1398  	6795025
	16. Diaz-Torga G, Feierstein C, Libertun C, Gelman D, Kelly MA, Low MJ,  Rubinstein M, Becu-Villalobos D 2002 Disruption of the D2 dopamine re ceptor alters GH and IGF-I secretion and causes dwarfism in male mice.  Endocrinology 143:1270–1279  	11897683
	17. Wynick D, Small CJ, Bacon A, Holmes FE, Norman M, Ormandy CJ, Kilic  E, Kerr NC, Ghatei M, Talamantes F, Bloom SR, Pachnis V 1998 Galanin  regulates prolactin release and lactotroph proliferation. Proc Natl Acad Sci  USA 95:12671–12676  	9770544
	18. Barton AC, Demarest KT, Lookingland KJ, Moore KE 1989 A sex difference  in the stimulatory afferent regulation of tuberoinfundibular dopaminergic  neuronal activity. Neuroendocrinology 49:361–366  	2497397
	19. Gunnet JW, Lookingland KJ, Moore KE 1986 Comparison of the effects of  castration and steroid replacement on incertohypothalamic dopaminergic neu rons in male and female rats. Neuroendocrinology 44:269–275  	3027597
	20. Arbogast LA, Hyde JF 2000 Estradiol attenuates the forskolin-induced increase  in hypothalamic tyrosine hydroxylase activity. Neuroendocrinology 71:  219–227  	10773741
	20a.Schuff KG, Hentges ST, Kelly MA, Binart N, Kelly PA, Iuovone PM, Asa SL,  Low MJ, Lack of prolactin receptor signaling in mice results in lactotroph  proliferation and prolactinomas by dopamine-dependent and independent  mechanisms. J Clin Invest, in press  	12370275
	21. Sinha YN, Gilligan TA 1982 Estrogen in high doses inhibits perphenazine induced prolactin release. Endocrinology 110:126–130  	7053978
	22. Chun TY, Gregg D, Sarkar DK, Gorski J 1998 Differential regulation by  estrogens of growth and prolactin synthesis in pituitary cells suggests that only  a small pool of estrogen receptors is required for growth. Proc Natl Acad Sci  USA 95:2325–2330  	9482884
	23. Sarkar DK, Hentges ST, De A, Reddy RHR 1998 Hormonal control of pitu itary prolactin-secreting tumors. Front Biosci 3:d934–d943  	NO_MATCH
	24. Holtzman S, Stone JP, Shellabarger CJ 1979 Influence of diethylstilbestrol  treatment on prolactin cells of female ACI and Sprague-Dawley rats. Cancer  Res 39:779–784  	427765
	25. Lloyd RV, Coleman K, Fields K, Nath V 1987 Analysis of prolactin and growth  hormone production in hyperplastic and neoplastic rat pituitary tissues by the  hemolytic plaque assay. Cancer Res 47:1087–1092  	3542200
	26. Shull JD, Spady TJ, Snyder MC, Johansson SL, Pennington KL 1997 Ovary intact, but not ovariectomized female ACI rats treated with 17-estradiol  rapidly develop mammary carcinoma. Carcinogenesis 18:1595–1601  	9276635
	27. Spady TJ, Harvell DM, Snyder MC, Pennington KL, McComb RD, Shull JD  1998 Estrogen-induced tumorigenesis in the Copenhagen rat: disparate sus ceptibilities to development of prolactin-producing pituitary tumors and  mammary carcinomas. Cancer Lett 124:95–103  	9500197
	28. Stone JP, Holtzman S, Shellabarger CJ 1979 Neoplastic responses and cor related plasma prolactin levels in diethylstilbestrol-treated ACI and Sprague Dawley rats. Cancer Res 39:773–778  	427764
	29. Wendell DL, Herman A, Gorski J 1996 Genetic separation of tumor growth  and hemorrhagic phenotypes in an estrogen-induced tumor. Proc Natl Acad  Sci USA 93:8112–8116  	8755612
	30. Wiklund J, Wertz N, Gorski J 1981 A comparison of estrogen effects on uterine  and pituitary growth and prolactin synthesis in F344 and Holtzman rats.  Endocrinology 109:1700–1707  	7297500
	31. Gardner W, Strong L 1940 The strain-limited development of tumors of the  pituitary gland in mice receiving estrogens. Yale J Biol Med 12:543–548  	NO_MATCH
	32. Shida N, Ikeda H, Yoshimoto T, Oshima M, Taketo MM, Miyoshi I 1998  Estrogen-induced tumorigenesis in the pituitary gland of TGF-beta(/)  knockout mice. Biochim Biophys Acta 1407:79–83  	9639680
	33. Griffith JS, Jensen SM, Lunceford JK, Kahn MW, Zheng Y, Falase EA, Lyttle  CR, Teuscher C 1997 Evidence for the genetic control of estradiol-regulated  responses. Implications for variation in normal and pathological hormone dependent phenotypes. Am J Pathol 150:2223–2230  	9176411
	34. Spearow JL, Barkley M 1999 Genetic control of hormone-induced ovulation  rate in mice. Biol Reprod 61:851–856  In the article by S. Filippi et al. (Endocrinology 143:4271–4280, 2002), the affiliation for Saverio Bettuzzi  appeared incorrectly. The correct affiliation for Prof. Bettuzzi is Department of Experimental Medicine,  University of Parma, 43100 Parma, Italy. The authors regret the error.  	10491616
	35. Spearow JL, Doemeny P, Sera R, Leffler R, Barkley M 1999 Genetic variation in  susceptibility to endocrine disruption by estrogen in mice. Science 285:1259–1261  	10455051
	36. Shen ES, Hardenburg JL, Meade EH, Arey BJ, Merchenthaler I, Lopez FJ 1999  Estradiol induces galanin gene expression in the pituitary of the mouse in an  estrogen receptor -dependent manner. Endocrinology 140:2628–2631  	10342850
	37. Brown AE, Mani S, Tobet SA 1999 The preoptic area/anterior hypothalamus  of different strains of mice: sex differences and development. Brain Res Dev  Brain Res 115:171–182  	10407134
	38. Mathieson WB, Taylor SW, Marshall M, Neumann PE 2000 Strain and sex  differences in the morphology of the medial preoptic nucleus of mice. J Comp  Neurol 428:254–265  	11064365
	39. Cai A, Hayes JD, Patel N, Hyde JF 1999 Targeted overexpression of galanin  in lactotrophs of transgenic mice induces hyperprolactinemia and pituitary  hyperplasia. Endocrinology 140:4955–4964  	10537119
4505.full.pdf
	1. Boisclair YR, Rhoads RP, Ueki I, Wang J, Ooi GT 2001 The acid-labile subunit  (ALS) of the 150 kDa IGF-binding protein complex: an important but forgotten  component of the circulating IGF system. J Endocrinol 170:63–70  	11431138
	2. Delhanty PJD 1998 The regulation and actions of ALS. In: Takano K, Hizuka  N, Takahashi S-I, eds. Molecular mechanisms to regulate the activities of  insulin-like growth factors. Amsterdam: Elsevier; 135–143  	NO_MATCH
	3. Twigg SM, Baxter RC 1998 Insulin-like growth factor (IGF)-binding protein  5 forms an alternative ternary complex with IGFs and the acid-labile subunit.  J Biol Chem 273:6074–6079  	9497324
	4. Baxter RC, Meka S, Firth SM 2002 Molecular distribution of IGF binding  protein-5 in human serum. J Clin Endocrinol Metab 87:271–276  	11788658
	5. Dai J, Scott CD, Baxter RC 1994 Regulation of the acid-labile subunit of the  insulin-like growth factor complex in cultured rat hepatocytes. Endocrinology  135:1066–1072  	8070348
	6. Ooi GT, Cohen FJ, Tseng LYH, Rechler MM, Boisclair YR 1997 Growth  hormone stimulates transcription of the gene encoding the acid-labile subunit  (ALS) of the circulating insulin-like growth factor-binding protein complex  and ALS promoter activity in rat liver. Mol Endocrinol 11:997–1007  	9178759
	7. Ueki I, Ooi GT, Tremblay ML, Hurst KR, Bach LA, Boisclair YR 2000 In activation of the acid labile subunit gene in mice results in mild retardation of  postnatal growth despite profound disruptions in the circulating insulin-like  growth factor system. Proc Natl Acad Sci USA 97:6868–6873  	10823924
	8. Yakar S, Rosen CJ, Beamer WG, Ackert-Bicknell CL, Wu Y, Liu JL, Ooi GT,  Setser J, Frystyk J, Boisclair YR, LeRoith D 2002 Circulating levels of IGF-1  directly regulate bone growth and density. J Clin Invest 110:771–781  	12235108
	9. Thissen JP, Ketelslegers JM, Underwood LE 1994 Nutritional regulation of the  insulin-like growth factors. Endocr Rev 15:80–101  	8156941
	10. Hayden JM, Marten NW, Burke EJ, Straus DS 1994 The effect of fasting on  insulin-like growth factor-I nuclear transcript abundance in rat liver. Endo crinology 134:760–768  	8299571
	11. Straus DS, Takemoto CD 1990 Effect of fasting on insulin-like growth factor-I  (IGF-I) and growth hormone receptor mRNA levels and IGF-I gene transcrip tion in rat liver. Mol Endocrinol 4:91–100  	2325671
	12. Dai J, Baxter RC 1994 Regulation in vivo of the acid-labile subunit of the rat  serum insulin-like growth factor-binding protein complex. Endocrinology 135:  2335–2341  	7527331
	13. Frystyk J, Delhanty PJ, Skjaerbaek C, Baxter RC 1999 Changes in the circu lating IGF system during short-term fasting and refeeding in rats. Am J Physiol  277:E245–E252  	10444419
	14. Oster MH, Levin N, Fielder PJ, Robinson IC, Baxter RC, Cronin MJ 1996  Developmental differences in the IGF-I system response to severe and chronic  calorie malnutrition. Am J Physiol 270:E646–E653  	8928772
	15. Clemmons DR, Thissen JP, Maes M, Ketelslegers JM, Underwood LE 1989  Insulin-like growth factor-I (IGF-I) infusion into hypophysectomized or pro tein-deprived rats induces specific IGF-binding proteins in serum. Endocri nology 125:2967–2972  	2479531
	16. Tannenbaum GS, Epelbaum J, Colle E, Brazeau P, Martin JB 1978 Antiserum  to somatostatin reverses starvation-induced inhibition of growth hormone but  not insulin secretion. Endocrinology 102:1909–1914  	744057
	17. Beauloye V, Willems B, de Coninck V, Frank SJ, Edery M, Thissen J-P 2002  Impairment of liver GH receptor signaling by fasting. Endocrinology 143:  792–800  	11861499
	18. Delhanty PJD, Baxter RC 1998 The regulation of acid-labile subunit gene  expression and secretion by cyclic adenosine 3, 5-monophosphate. Endocri nology 139:260–265  	9421423
	19. Thissen JP, Triest S, Moats-Staats BM, Underwood LE, Mauerhoff T, Maiter  D, Ketelslegers JM 1991 Evidence that pretranslational and translational de fects decrease serum insulin-like growth factor-I concentrations during dietary  protein restriction. Endocrinology 129:429–435  	2055198
	20. Fliesen T, Maiter D, Gerard G, Underwood LE, Maes M, Ketelslegers JM 1989  Reduction of serum insulin-like growth factor-I by dietary protein restriction  is age dependent. Pediatr Res 26:415–419  	2812891
	21. Smith WJ, Underwood LE, Clemmons DR 1995 Effects of caloric or protein  restriction on insulin-like growth factor-I (IGF-I) and IGF-binding proteins in  children and adults. J Clin Endocrinol Metab 80:443–449  	7531712
	22. Baxter RC, Dai J 1994 Purification and characterization of the acid-labile  subunit of rat serum insulin-like growth factor binding protein complex. En docrinology 134:848–852  	7507839
	23. Frystyk J, Baxter RC 1998 Competitive binding assay for determination of rat  insulin-like growth factor binding protein-3. Endocrinology 139:1454–1457  	9492083
	24. Crawford BA, Martin JL, Howe CJ, Handelsman DJ, Baxter RC 1992 Com parison of extraction methods for insulin-like growth factor-I in rat serum. J  Endocrinol 134:169–176  	1383373
	25. Lewitt MS, Saunders H, Phyual JL, Baxter RC 1994 Regulation of insulin-like  growth factor-binding protein-1 in rat serum. Diabetes 43:232–239  	7507068
	26. Delhanty PJ, Han VK 1993 The expression of insulin-like growth factor (IGF) binding protein-2 and IGF-II genes in the tissues of the developing ovine fetus.  Endocrinology 132:41–52  	7678219
	27. Baxter RC, Turtle JR 1978 Regulation of hepatic growth hormone receptors by  insulin. Biochem Biophys Res Commun 84:350–357  	214071
	28. Rhoads RP, Greenwood PL, Bell AW, Boisclair YR 2000 Nutritional regula tion of the genes encoding the acid-labile subunit and other components of the  circulating insulin-like growth factor system in the sheep. J Anim Sci 78:2681–  2689  	11048934
	29. Baxter RC 1997 Editorial: the binding protein’s binding protein—clinical ap plications of acid-labile subunit (ALS) measurement. J Clin Endocrinol Metab  82:3941–3943  	NO_MATCH
	30. Shimatsu A, Rotwein P 1987 Mosaic evolution of the insulin-like growth  factors. Organization, sequence, and expression of the rat insulin-like growth  factor I gene. J Biol Chem 262:7894–7900  	3034909
	31. VandeHaar MJ, Moats-Staats BM, Davenport ML, Walker JL, Ketelslegers  JM, Sharma BK, Underwood LE 1991 Reduced serum concentrations of in sulin-like growth factor-I (IGF-I) in protein-restricted growing rats are accom panied by reduced IGF-I mRNA levels in liver and skeletal muscle. J Endo crinol 130:305–312  	1919400
	32. Zhang J, Chrysis D, Underwood LE 1998 Reduction of hepatic insulin-like  growth factor I (IGF-I) messenger ribonucleic acid (mRNA) during fasting is  associated with diminished splicing of IGF-I pre-mRNA and decreased sta bility of cytoplasmic IGF-I mRNA. Endocrinology 139:4523–4530  	9794461
	33. Zimmermann EM, Li L, Hoyt EC, Pucilowska JB, Lichtman S, Lund PK 2000  Cell-specific localization of insulin-like growth factor binding protein mRNAs  in rat liver. Am J Physiol 278:G447–G457  	10712265
	34. Davis TA, Fiorotto ML, Nguyen HV, Reeds PJ 1993 Enhanced response of  muscle protein synthesis and plasma insulin to food intake in suckled rats.  Am J Physiol 265:R334–R340  	8368387
	35. Lee PD, Giudice LC, Conover CA, Powell DR 1997 Insulin-like growth factor  binding protein-1: recent findings and new directions. Proc Soc Exp Biol Med  216:319–357  	9402139
	36. Rajaram S, Baylink DJ, Mohan S 1997 Insulin-like growth factor-binding  proteins in serum and other biological fluids—regulation and functions. En docr Rev 18:801–831  	9408744
	37. Oldham JM, Martyn JA, Hua KM, MacDonald NA, Hodgkinson SC, Bass JJ  1999 Nutritional regulation of IGF-II, but not IGF-I, is age dependent in sheep.  J Endocrinol 163:395–402  	10588812
	38. Yoshizawa F, Kimball SR, Jefferson LS 1997 Modulation of translation ini tiation in rat skeletal muscle and liver in response to food intake. Biochem  Biophys Res Commun 240:825–831  	9398653
	39. Davis TA, Burrin DG, Fiorotto ML, Nguyen HV 1996 Protein synthesis in  skeletal muscle and jejunum is more responsive to feeding in 7- than in  26-day-old pigs. Am J Physiol 270:E802–E809  	8967468
	40. Haystead TA, Haystead CM, Hu C, Lin TA, Lawrence Jr JC 1994 Phosphor ylation of PHAS-I by mitogen-activated protein (MAP) kinase. Identification  of a site phosphorylated by MAP kinase in vitro and in response to insulin in  rat adipocytes. J Biol Chem 269:23185–23191  	8083223
	41. Davis TA, Nguyen HV, Suryawan A, Bush JA, Jefferson LS, Kimball SR 2000  Developmental changes in the feeding-induced stimulation of translation ini tiation in muscle of neonatal pigs. Am J Physiol 279:E1226–E1234  	11093908
	42. Davis TA, Burrin DG, Fiorotto ML, Reeds PJ, Jahoor F 1998 Roles of insulin  and amino acids in the regulation of protein synthesis in the neonate. J Nutr  128:347S–350S  	9478022
	43. Davis TA, Fiorotto ML, Burrin DG, Reeds PJ, Nguyen HV, Beckett PR, Vann  RC, O’Connor PM 2002 Stimulation of protein synthesis by both insulin and  amino acids is unique to skeletal muscle in neonatal pigs. Am J Physiol  282:E880–E890  	11882508
	44. Suryawan A, Nguyen HV, Bush JA, Davis TA 2001 Developmental changes  in the feeding-induced activation of the insulin-signaling pathway in neonatal  pigs. Am J Physiol 281:E908–E915  	11595645
Chest-2002-Light-1506-8.pdf
	1 Rinaldo JE, Owens GR, Rogers RM. Adult respiratory dis tress syndrome following intrapleural instillation of talc.  J Thorac Cardiovasc Surg 1983; 85:523–526  	6834872
	2 Bouchama A, Chastre JC, Gaudichet A, et al. Acute pneumo nitis with bilateral pleural effusion after talc pleurodesis.  Chest 1984; 86:795–797  	6488927
	3 Kennedy L, Rusch VW, Strange C, et al. Pleurodesis using  talc slurry. Chest 1994; 106:342–346  	7774299
	4 Marel M, Ska´cel Z, Bedna´r M, et al. Corynebacterium  parvum, bleomycin and talc in the treatment of malignant  pleural effusions. J Balkan Union Oncol 1998; 1:165–170  	NO_MATCH
	5 Rehse DH, Aye RW, Florence MG. Respiratory failure  following talc pleurodesis. Am J Surg 1999; 177:437–440  	10365887
	6 Todd TR, Delarue NC, Ilves R, et al. Talc poudrage for  malignant pleural effusion. Chest 1980; 78:542–543  	NO_MATCH
	7 Nandy P. Recurrent spontaneous pneumothorax: an effective  method of talc poudrage. Chest 1980; 77:493–495  	7357969
	8 Migueres J, Jover A. Indications du talcage de ple´vre sous  pleursocopie au cours des pleure´sies malignes re´cidivantes: a  au cours des pleure´sies malignes re´cidivantes; a propos de 26  observations. Poumon Coeur 1981; 37:295–297  	NO_MATCH
	9 de Campos JRM, Vargas FS, Werebe EC, et al. Thoracoscopy  talc poudrage: a 15-year experience. Chest 2001; 119:801–806  	11243960
	10 Brant A, Eaton T. Serious complications with talc slurry  pleurodesis. Respirology 2001; 6:181–185  	11555375
	11 Scalzetti EM. Unilateral pulmonary edema after talc pleu rodesis. J Thorac Imaging 2001; 16:99–102  	11292212
	12 Zazenski R, Ashton WH, Briggs D, et al. Talc: occurrence,  characterization, and consumer applications. Regul Toxicol  Pharmacol 1995; 21:218–229  	7644709
	13 Cardillo G, Facciolo F, Carbone L, et al. Long-term fol low-up of video-assisted talc pleurodesis in malignant recur rent pleural effusions. Eur J Cardiothorac Surg 2002; 21:  302–306  	11825740
	14 Weissberg D, Ben-Zeev I. Talc pleurodesis: experience with  360 patients. J Thorac Cardiovasc Surg 1993; 106:689–695  	8412264
	15 Rodriguez-Panadero F, Antony VB. Pleurodesis: state of the  art. Eur Respir J 1997; 10:1648–1654  	9230261
	16 Kennedy L, Harley RA, Sahn SA, et al. Talc slurry pleurode sis: pleural fluid and histologic analysis. Chest 1995; 107:  707–712  	7781372
	17 Werebe EC, Pazetti R, De Campos JRM, et al. Systemic  distribution of talc after intrapleural administration in rats.  Chest 1999; 115:190–193  	9925083
	18 Ferrer J, Villarino MA, Tura JM, et al. Talc preparations used  for pleurodesis vary markedly from one preparation to an other. Chest 2001; 119:1901–1905  	11399721
	19 Broaddus VC, Light RW. Disorders of the pleura; general  principles and diagnostic approach. In: Murray JF, Nadel JA,  eds. Textbook of respiratory medicine. 3rd ed. Philadelphia,  PA: WB Saunders Company, 2000; 995–2012  	NO_MATCH
	20 Light RW, Cheng D-S, Lee YC, et al. A single intrapleural  injection of transforming growth factor-	2 produces excellent  pleurodesis in rabbits. Am J Respir Crit Care Med 2000;  162:98–104  	10903227
	21 Lee YC, Lane KB, Parker RB, et al. Transforming growth  factor-	2 (TGF-	2) produces effective pleurodesis in sheep  with no systemic complications. Thorax 2000; 55:1058–1062  	11083893
	22 Lee YCG, Teixeira LR, Devin CJ, et al. Transforming growth  factor-beta(2) induces pleurodesis significantly faster than  talc. Am J Respir Crit Care Med 2001; 163:640–644  	11254517
	23 Vargas FS, Teixeira LR, Vaz MAC, et al. Silver nitrate is  superior to talc slurry in producing pleurodesis in rabbits.  Chest 2000; 118:808–813  	10988206
	24 Vargas FS, Teixeira LR, Antonangelo L, et al. Experimental  pleurodesis in rabbits induced by silver nitrate or talc: 1-year  follow-up. Chest 2001; 119:1516–1520  	11348962
	25 Vargas FS, Carmo AO, Teixeira LR. A new look at old agents  for pleurodesis: nitrogen mustard, sodium hydroxide and  silver nitrate. Curr Opin Pulm Med 2000; 6:281–286  	10912633
Am J Physiol Renal Physiol-2002-Devuyst-F1176-91.pdf
	1. Abdulnour-Nakhoul S and Boulpaep EL. Transcellular  chloride pathways in ambystoma proximal tubule. J Membr  Biol 166: 15–35, 1998.  	9784583
	2. Adachi S, Uchida S, Ito H, Hata M, Hiroe M, Marumo F,  and Sasaki S. Two isoforms of a chloride channel predomi nantly expressed in thick ascending limb of Henle’s loop and  collecting ducts of rat kidney. J Biol Chem 269: 17677–17683,  1994.  	8021279
	3. Akizuki N, Uchida S, Sasaki S, and Marumo F. Impaired  solute accumulation in inner medulla of Clcnk1/ mice kidney.  Am J Physiol Renal Physiol 280: F79–F87, 2001.  	11133517
	4. Aladjem M, Lotan D, Boichis H, Orda S, and Katznelson  D. Renal function in patients with cystic fibrosis. Nephron 34:  84–86, 1983.  	6866178
	5. Alper SL. The band 3-related anion exchanger (AE) gene fam ily. Annu Rev Physiol 53: 549–564, 1991.  	2042971
	6. Anderson MP, Sheppard DN, Berger HA, and Welsh MJ.  Chloride channels in the apical membrane of normal and cystic  fibrosis airway and intestinal epithelia. Am J Physiol Lung Cell  Mol Physiol 263: L1–L14, 1992.  	1322048
	7. Aniento F, Gu F, Parton RG, and Gruenberg J. An endo somal beta COP is involved in the pH-dependent formation of  transport vesicles destined for late endosomes. J Cell Biol 133:  29–41, 1996.  	8601610
	8. Assael BM, Marra G, Tirelli AS, Cavanna G, Claris Ap piani A, Giunta A, Amoretti M, and Milani S. Renal func tion in cystic fibrosis. Int J Pediatr Nephrol 7: 213–216, 1986.  	3818181
	9. Bae HR and Verkman AS. Protein kinase A regulates chlo ride conductance in endocytic vesicles from proximal tubule.  Nature 348: 637–639, 1990.  	1701220
	10. Bailey MA and Walter SJ. Renal effects of glibenclamide: a  micropuncture study. J Pharmacol Exp Ther 285: 464–467,  1998.  	9580584
	11. Bailly C. Transducing pathways involved in the control of  NaCl reabsorption in the thickascending limb of Henle’s loop.  Kidney Int 65: S29–S35, 1998.  	9551429
	12. Barasch J, Kiss B, Prince A, Saiman L, Gruenert D, and  al-Awqati Q. Defective acidification of intracellular organelles  in cystic fibrosis. Nature 352: 70–73, 1991.  	1712081
	13. Barg S, Huang P, Eliasson L, Nelson DJ, Obermuller S,  Rorsman P, Thevenod F, and Renstrom E. Priming of  insulin granules for exocytosis by granular Cl uptake and  acidification. J Cell Sci 114: 2145–2154, 2001.  	11493650
	14. Beck L, Karaplis AC, Amizuka N, Hewson AS, Ozawa H,  and Tenenhouse HS. Targeted inactivation of Npt2 in mice  leads to severe renal phosphate wasting, hypercalciuria, and  skeletal abnormalities. Proc Natl Acad Sci USA 95: 5372–5377,  1998.  	9560283
	15. Benharouga M, Fritsch J, Banting G, and Edelman A.  Properties of chloride-conductive pathways in rat kidney corti cal and outer-medulla brush-border membranes—inhibition by  anti-(cystic fibrosis transmembrane regulator) mAbs. Eur  J Biochem 246: 367–372, 1997.  	9208926
	16. Bentur L, Kerem E, Couper R, Baumal R, Canny G, Durie  P, and Levison H. Renal calcium handling in cystic fibrosis:  lack of evidence for a primary renal defect. J Pediatr 116:  556–560, 1990.  	1690795
	17. Berg U, Kusoffsky E, and Strandvik B. Renal function in  cystic fibrosis with special reference to the renal sodium han dling. Acta Paediatr Scand 71: 833–838, 1982.  	7180453
	18. Birkenhager R, Otto E, Schurmann MJ, Vollmer M, Ruf  EM, Maier-Lutz I, Beekmann F, Fekete A, Omran H,  Feldmann D, Milford DV, Jeck N, Konrad M, Landau D,  Knoers NV, Antignac C, Sudbrak R, Kispert A, and Hilde brandt F. Mutation of BSND causes Bartter syndrome with  sensorineural deafness and kidney failure. Nat Genet 29: 310–  314, 2001.  	11687798
	19. Blaisdell CJ and Guggino WB. Anion channels. In: The  Kidney: Physiology and Pathophysiology, edited by Seldin DW  and Giebisch G. Philadelphia, PA: Lippincott Williams &  Wilkins, 2000, p. 277–291.  	NO_MATCH
	20. Boat TF. Cystic fibrosis. In: Nelson Textbook of Pediatrics (16th  ed.), edited by Behrman RE, Kliegman RM, and Jenson HB.  Philadelphia, PA: Saunders, 2000, p. 1315–1327.  	NO_MATCH
	21. Bo¨sl MR, Stein V, Hubner C, Zdebik AA, Jordt SE, Muk hopadhyay AK, Davidoff MS, Holstein AF, and Jentsch  TJ. Male germ cells and photoreceptors, both dependent on  close cell-cell interactions, degenerate upon ClC-2 Cl channel  disruption. EMBO J 20: 1289–1299, 2001.  	11250895
	22. Bradbury NA. Intracellular CFTR: localization and function.  Physiol Rev 79: S175–S191, 1999.  	9922381
	23. Bradbury NA, Jilling T, Berta G, Sorscher EJ, Bridges  RJ, and Kirk KL. Regulation of plasma membrane recycling  by CFTR. Science 256: 530–532, 1992.  	1373908
	24. Bradbury NA, Jilling T, Kirk KL, and Bridges RJ. Regu lated endocytosis in a chloride secretory epithelial cell line.  Am J Physiol Cell Physiol 262: C752–C759, 1992.  	1312784
	25. Brill SR, Ross KE, Davidow CJ, Ye M, Grantham JJ, and  Caplan MJ. Immunolocalization of ion transport proteins in  human autosomal dominant polycystic kidney epithelial cells.  Proc Natl Acad Sci USA 93: 10206–10211, 1996.  	8816777
	26. Bushinsky DA, Parker WR, and Asplin JR. Calcium phos phate supersaturation regulates stone formation in genetic  hypercalciuric stone-forming rats. Kidney Int 57: 550–560,  2000.  	10652032
	27. Calvet JP and Grantham JJ. The genetics and physiology of  polycystic kidney disease. Semin Nephrol 21: 107–123, 2001.  	11245774
	28. Choi JY, Muallem D, Kiselyov K, Lee MG, Thomas PJ,  and Muallem S. Aberrant CFTR-dependent HCO3  transport  in mutations associated with cystic fibrosis. Nature 410 : 94–97,  2001.  	11242048
	29. Christensen EI and Birn H. Megalin and cubilin: synergistic  endocytic receptors in renal proximal tubule. Am J Physiol  Renal Physiol 280: F562–F573, 2001.  	11249847
	30. Christensen EI, Birn H, Verroust P, and Moestrup SK.  Membrane receptors for endocytosis in the renal proximal tu bule. Int Rev Cytol 180: 237–284, 1998.  	9496636
	31. Clarke LL, Grubb BR, Yankaskas JR, Cotton CU, Mc Kenzie A, and Boucher RC. Relationship of a non-cystic  fibrosis transmembrane conductance regulator-mediated chlo ride conductance to organ-level disease in Cftr(/) mice. Proc  Natl Acad Sci USA 91: 479–483, 1994.  	7507247
	32. Clarke LL and Harline MC. Dual role of CFTR in cAMP stimulated HCO3  secretion across murine duodenum. Am J  Physiol Gastrointest Liver Physiol 274: G718–G726, 1998.  	9575854
	33. Cleiren E, Benichou O, Van Hul E, Gram J, Bollerslev J,  Singer FR, Beaverson K, Aledo A, Whyte MP, Yoneyama  T, deVernejoul MC, and Van Hul W. Albers-Schonberg dis ease (autosomal dominant osteopetrosis, type II) results from  mutations in the ClCN7 chloride channel gene. Hum Mol Genet  10: 2861–2867, 2001.  	11741829
	34. Colledge WH, Abella BS, Southern KW, Ratcliff R, Jiang  C, Cheng SH, MacVinish LJ, Anderson JR, Cuthbert AW,  and Evans MJ. Generation and characterization of a delta  F508 cystic fibrosis mouse model. Nat Genet 10: 445–452, 1995.  	7545494
	35. Crawford IT and Maloney PC. Identification of cystic fibrosis  transmembrane conductance regulator in renal endosomes.  Methods Enzymol 292: 652–663, 1998.  	9711589
	36. Crawford I, Maloney PC, Zeitlin PL, Guggino WB, Hyde  SC, Turley H, Gatter KC, Harris A, and Higgins CF.  Immunocytochemical localization of the cystic fibrosis gene  product CFTR. Proc Natl Acad Sci USA 88: 9262–9266, 1991.  	1718002
	37. Cutting GR. Cystic fibrosis. In: Emory and Rimoin’s Principle  and Practice of Medical Genetics (4th ed.), edited by Rimoin DL,  Connor JM, Pyeritz RE, and Korf BR. London: Churchill Liv ingstone, 2002, p. 1561–1606.  	NO_MATCH
	38. Davidow CJ, Maser RL, Rome LA, Calvet JP, and  Grantham JJ. The cystic fibrosis transmembrane conductance  regulator mediates transepithelial fluid secretion by human  autosomal dominant polycystic kidney disease epithelium in  vitro. Kidney Int 50: 208–218, 1996.  	8807590
	39. Delaney SJ, Alton EW, Smith SN, Lunn DP, Farley R,  Lovelock PK, Thomson SA, Hume DA, Lamb D, Porteous  DJ, Dorin JR, and Wainwright BJ. Cystic fibrosis mice  carrying the missense mutation G551D replicate human geno type-phenotype correlations. EMBO J 15: 955–963, 1996.  	8605891
	40. Devuyst O. Dietary salt and renal stone disease. Lancet 349:  507, 1997.  	9040605
	41. Devuyst O, Burrow CR, Schwiebert EM, Guggino WB,  and Wilson PD. Developmental regulation of CFTR expres sion during human nephrogenesis. Am J Physiol Renal Fluid  Electrolyte Physiol 271: F723–F735, 1996.  	8853436
	42. Devuyst O, Christie PT, Courtoy PJ, Beauwens R, and  Thakker RV. Intra-renal and subcellular distribution of the  human chloride channel, CLC-5, reveals a pathophysiological  basis for Dent’s disease. Hum Mol Genet 8: 247–257, 1999.  	9931332
	43. DiGiovanni SR, Nielsen S, Christensen EI, and Knepper  MA. Regulation of collecting duct water channel expression by  vasopressin in Brattleboro rat. Proc Natl Acad Sci USA 91:  8984–8988, 1994.  	7522327
	44. Donckerwolcke RA, van Diemen-Steenvoorde R, van der  Laag J, Koomans HA, and Boer WH. Impaired diluting  segment chloride reabsorption in patients with cystic fibrosis.  Child Nephrol Urol 12: 186–191, 1992.  	1473090
	45. Dorin JR, Dickinson P, Alton EW, Smith SN, Geddes DM,  Stevenson BJ, Kimber WL, Fleming S, Clarke AR, Hooper  ML, Anderson L, Beddington RSP, and Portgeous DJ.  Cystic fibrosis in the mouse by targeted insertional mutagene sis. Nature 359: 211–215, 1992.  	1382232
	46. Dutzler R, Campbell EB, Cadene M, Chait BT, and Mac Kinnon R. X-ray structure of a ClC chloride channel at 3.0 Å  reveals the molecular basis of anion selectivity. Nature 415:  287–294, 2002.  	11796999
	47. Edmonds RD, Silva IV, Guggino WB, Butler RB, Zeitlin  PL, and Blaisdell CJ. ClC-5: ontogeny of an alternative chlo ride channel in respiratory epithelia. Am J Physiol Lung Cell  Mol Physiol 282: L501–L507, 2002.  	11839544
	48. Estevez R, Boettger T, Stein V, Birkenhager R, Otto E,  Hildebrandt F, and Jentsch TJ. Barttin is a Cl channel  beta-subunit crucial for renal Cl reabsorption and inner ear  K secretion. Nature 414: 558–561, 2001.  	11734858
	49. Fahlke C, Rhodes TH, Desai RR, and George AL Jr. Pore  stoichiometry of a voltage-gated chloride channel. Nature 394:  687–690, 1998.  	9716133
	50. Fahlke C, Yu HT, Beck CL, Rhodes TH, and George AL Jr.  Pore-forming segments in voltage-gated chloride channels. Na ture 390: 529–532, 1997.  	9394005
	51. Fisher SE, Black GC, Lloyd SE, Hatchwell E, Wrong O,  Thakker RV, and Craig IW. Isolation and partial character ization of a chloride channel gene which is expressed in kidney  and is a candidate for Dent’s disease (an X-linked hereditary  nephrolithiasis). Hum Mol Genet 3: 2053–2059, 1994.  	NO_MATCH
	52. Friedrich T, Breiderhoff T, and Jentsch TJ. Mutational  analysis demonstrates that ClC-4 and ClC-5 directly mediate  plasma membrane currents. J Biol Chem 274: 896–902, 1999.  	9873029
	53. Fuller CM, Ji HL, Tousson A, Elble RC, Pauli BU, and  Benos DJ. Ca2-activated Cl channels: a newly emerging  anion transport family. Pflu¨gers Arch 443, Suppl 1: S107–S110,  2001.  	11845314
	54. Gabriel SE, Clarke LL, Boucher RC, and Stutts MJ. CFTR  and outward rectifying chloride channels are distinct proteins  with a regulatory relationship. Nature 363: 263–268, 1993.  	7683773
	55. Gibson GA, Hill WG, and Weisz OA. Evidence against the  acidification hypothesis in cystic fibrosis. Am J Physiol Cell  Physiol 279: C1088–C1099, 2000.  	11003589
	56. Greger R. Ion transport mechanisms in thick ascending limb  of Henle’s loop of mammalian nephron. Physiol Rev 65: 760–  797, 1985.  	2409564
	57. Grubb BR. Ion transport across the jejunum in normal and  cystic fibrosis mice. Am J Physiol Gastrointest Liver Physiol  268: G505–G513, 1995.  	7534995
	58. Grubb BR and Boucher RC. Enhanced colonic Na absorp tion in cystic fibrosis mice versus normal mice. Am J Physiol  Gastrointest Liver Physiol 272: G393–G400, 1997.  	9124365
	59. Grubb BR and Boucher RC. Pathophysiology of gene-tar geted mouse models for cystic fibrosis. Physiol Rev 79: S193–  S214, 1999.  	9922382
	60. Grubb BR, Vick RN, and Boucher RC. Hyperabsorption of  Na and raised Ca2-mediated Cl secretion in nasal epithelia  of CF mice. Am J Physiol Cell Physiol 266: C1478–C1483, 1994.  	7515571
	61. Guinamard R, Chraibi A, and Teulon J. A small-conduc tance Cl channel in the mouse thick ascending limb that is  activated by ATP and protein kinase A. J Physiol 485: 97–112,  1995.  	7658386
	62. Gu¨nther W, Luchow A, Cluzeaud F, Vandewalle A, and  Jentsch TJ. ClC-5, the chloride channel mutated in Dent’s  disease, colocalizes with the proton pump in endocytotically  active kidney cells. Proc Natl Acad Sci USA 95: 8075–8080,  1998.  	9653142
	63. Gutknecht DR. Kidney stones and cystic fibrosis (Abstract).  Am J Med 111: 83, 2001.  	11460857
	64. Hanaoka K, Devuyst O, Schwiebert EM, Wilson PD, and  Guggino WB. A role for CFTR in human autosomal dominant  polycystic kidney disease. Am J Physiol Cell Physiol 270: C389–  C399, 1996.  	8772467
	65. Harris PC. Molecular basis of polycystic kidney disease:  PKD1, PKD2 and PKHD1. Curr Opin Nephrol Hypertens 11:  309–314, 2002.  	11981261
	66. Hasty P, O’Neal WK, Liu KQ, Morris AP, Bebok Z,  Shumyatsky GB, Jilling T, Sorscher EJ, Bradley A, and  Beaudet AL. Severe phenotype in mice with termination mu tation in exon 2 of cystic fibrosis gene. Somat Cell Mol Genet 21:  177–187, 1995.  	7482032
	67. Higgins JT Jr, Gebler B, and Fromter E. Electrical proper ties of amphibian urinary bladder epithelia. II. The cell poten tial profile in Necturus maculosus. Pflu¨gers Arch 371: 87–97,  1977.  	563576
	68. Hilpert J, Nykjaer A, Jacobsen C, Wallukat G, Nielsen R,  Moestrup SK, Haller H, Luft FC, Christensen EI, and  Willnow TE. Megalin antagonizes activation of the parathy roid hormone receptor. J Biol Chem 274: 5620–5625, 1999.  	10026179
	69. Hoenderop JG, Willems PH, and Bindels RJ. Toward a  comprehensive molecular model of active calcium reabsorption.  Am J Physiol Renal Physiol 278: F352–F360, 2000.  	10710538
	70. Hoopes RR Jr, Hueber PA, Reid RJ Jr, Braden GL,  Goodyer PR, Melnyk AR, Midgley JP, Moel DI, Neu AM,  VanWhy SK, and Scheinman SJ. CLCN5 chloride-channel  mutations in six new North American families with X-linked  nephrolithiasis. Kidney Int 54: 698–705, 1998.  	9734595
	71. Horster M. Embryonic epithelial membrane transporters.  Am J Physiol Renal Physiol 279: F982–F996, 2000.  	11097616
	72. Huber S, Braun G, Burger-Kentischer A, Reinhart B,  Luckow B, and Horster M. CFTR mRNA and its truncated  splice variant (TRN-CFTR) are differentially expressed during  collecting duct ontogeny. FEBS Lett 423: 362–366, 1998.  	9515740
	73. Huber S, Schroppel B, Kretzler M, Schlondorff D, and  Horster M. Single cell RT-PCR analysis of ClC-2 mRNA ex pression in ureteric bud tip. Am J Physiol Renal Physiol 274:  F951–F957, 1998.  	9612334
	74. Husted RF, Volk KA, Sigmund RD, and Stokes JB. Anion  secretion by the inner medullary collecting duct. Evidence for  involvement of the cystic fibrosis transmembrane conductance  regulator. J Clin Invest 95: 644–650, 1995.  	7532187
	75. Igarashi T, Gunther W, Sekine T, Inatomi J, Shiraga H,  Takahashi S, Suzuki J, Tsuru N, Yanagihara T, Shimazu  M, Jentsch TJ, and Thakker RV. Functional characteriza tion of renal chloride channel, CLCN5, mutations associated  with Dent’s Japan disease. Kidney Int 54: 1850–1856, 1998.  	9853249
	76. Illek B, Yankaskas JR, and Machen TE. cAMP and  genistein stimulate HCO3  conductance through CFTR in hu man airway epithelia. Am J Physiol Lung Cell Mol Physiol 272:  L752–L761, 1997.  	9142951
	77. Imai M and Kokko JP. Sodium chloride, urea, and water  transport in the thin ascending limb of Henle. Generation of  osmotic gradients by passive diffusion of solutes. J Clin Invest  53: 393–402, 1974.  	NO_MATCH
	78. Imai M, Taniguchi J, and Tabei K. Function of thin loops of  Henle. Kidney Int 31: 565–579, 1987.  	3550226
	79. Jentsch TJ, Stein V, Weinreich F, and Zdebik AA. Molec ular structure and physiological function of chloride channels.  Physiol Rev 82: 503–568, 2002.  	11917096
	80. Jentsch TJ, Steinmeyer K, and Schwarz G. Primary struc ture of Torpedo marmorata chloride channel isolated by expres sion cloning in Xenopus oocytes. Nature 348: 510–514, 1990.  	2174129
	81. Kalin N, Claass A, Sommer M, Puchelle E, and Tummler  B. DeltaF508 CFTR protein expression in tissues from patients  with cystic fibrosis. J Clin Invest 103: 1379–1389, 1999.  	10330420
	82. Katz SM, Krueger LJ, and Falkner B. Microscopic nephro calcinosis in cystic fibrosis. N Engl J Med 319: 263–266, 1988.  	3393180
	83. Kawasaki M, Uchida S, Monkawa T, Miyawaki A, Miko shiba K, Marumo F, and Sasaki S. Cloning and expression of  a protein kinase C-regulated chloride channel abundantly ex pressed in rat brain neuronal cells. Neuron 12: 597–604, 1994.  	8155321
	84. Kearns GL, Berry PL, Bocchini JA Jr, Hilman BC, and  Wilson JT. Renal handling of beta 2-microglobulin in patients  with cystic fibrosis. DICP 23: 1013–1017, 1989.  	2690470
	85. Kibble JD, Balloch KJ, Neal AM, Hill C, White S, Robson  L, Green R, and Taylor CJ. Renal proximal tubule function is  preserved in Cftr(tm2cam) deltaF508 cystic fibrosis mice.  J Physiol 532: 449–457, 2001.  	11306663
	86. Kibble JD, Neal AM, Colledge WH, Green R, and Taylor  CJ. Evidence for cystic fibrosis transmembrane conductance  regulator-dependent sodium reabsorption in kidney, using  Cftr(tm2cam) mice. J Physiol 526: 27–34, 2000.  	10878096
	87. Kibble J, Neal A, White S, Green R, Evans S, and Taylor  C. Renal effects of glibenclamide in cystic fibrosis mice. J Am  Soc Nephrol 12: 2507–2510, 2001.  	11675429
	88. Kieferle S, Fong P, Bens M, Vandewalle A, and Jentsch  TJ. Two highly homologous members of the ClC chloride chan nel family in both rat and human kidney. Proc Natl Acad Sci  USA 91: 6943–6947, 1994.  	8041726
	89. Kishore BK, Fuming L, Maldague P, Tulkens PM, and  Courtoy PJ. Mechanism of the thesaurismosis and altered  lysosomal dynamics induced by poly-D-glutamic acid in kidney  proximal tubular cells. Lab Invest 74: 1025–1037, 1996.  	8667607
	90. Knepper MA and Inoue T. Regulation of aquaporin-2 water  channel trafficking by vasopressin. Curr Opin Cell Biol 9:  560–564, 1997.  	9261056
	91. Kobayashi K, Uchida S, Mizutani S, Sasaki S, and Ma rumo F. Intrarenal and cellular localization of CLC-K2 protein  in the mouse kidney. J Am Soc Nephrol 12: 1327–1334, 2001.  	11423561
	92. Kokko JP and Rector FC Jr. Countercurrent multiplication  system without active transport in inner medulla. Kidney Int 2:  214–223, 1972.  	4657922
	93. Kondo Y, Yoshitomi K, and Imai M. Effects of anion trans port inhibitors and ion substitution on Cl transport in TAL of  Henle’s loop. Am J Physiol Renal Fluid Electrolyte Physiol 253:  F1206–F1215, 1987.  	3425728
	94. Kornak U, Kasper D, Bosl MR, Kaiser E, Schweizer M,  Schulz A, Friedrich W, Delling G, and Jentsch TJ. Loss of  the ClC-7 chloride channel leads to osteopetrosis in mice and  man. Cell 104: 205–215, 2001.  	11207362
	95. Krivan HC, Ginsburg V, and Roberts DD. Pseudomonas  aeruginosa and Pseudomonas cepacia isolated from cystic fibro sis patients bind specifically to gangliotetraosylceramide (asialo  GM1) and gangliotriaosylceramide (asialo GM2). Arch Biochem  Biophys 260: 493–496, 1988.  	3124753
	96. Lang F, Busch GL, Ritter M, Volkl H, Waldegger S, Gul bins E, and Haussinger D. Functional significance of cell  volume regulatory mechanisms. Physiol Rev 78: 247–306, 1998.  	9457175
	97. Lee MG, Choi JY, Luo X, Strickland E, Thomas PJ, and  Muallem S. Cystic fibrosis transmembrane conductance regu lator regulates luminal Cl/HCO3  exchange in mouse subman dibular and pancreatic ducts. J Biol Chem 274: 14670–14677,  1999.  	10329661
	98. Letz B and Korbmacher C. cAMP stimulates CFTR-like Cl  channels and inhibits amiloride-sensitive Na channels in  mouse CCD cells. Am J Physiol Cell Physiol 272: C657–C666,  1997.  	9124310
	99. Levy J, Smith AL, Koup JR, Williams-Warren J, and  Ramsey B. Disposition of tobramycin in patients with cystic  fibrosis: a prospective controlled study. J Pediatr 105: 117–124,  1984.  	6376743
	100. Liu W, Morimoto T, Kondo Y, Iinuma K, Uchida S, Sasaki  S, Marumo F, and Imai M. Analysis of NaCl transport in thin  ascending limb of Henle’s loop in CLC-K1 null mice. Am J  Physiol Renal Physiol 282: F451–F457, 2002.  	11832425
	101. Lloyd SE, Gunther W, Pearce SH, Thomson A, Bianchi  ML, Bosio M, Craig IW, Fisher SE, Scheinman SJ, Wrong  O, Jentsch TJ, and Thakker RV. Characterisation of renal  chloride channel, CLCN5, mutations in hypercalciuric nephro lithiasis (kidney stones) disorders. Hum Mol Genet 6: 1233–  1239, 1997.  	9259268
	102. Lloyd SE, Pearce SH, Fisher SE, Steinmeyer K, Schwap pach B, Scheinman SJ, Harding B, Bolino A, Devoto M,  Goodyer P, Rigden SP, Wrong O, Jentsch TJ, Craig IW,  and Thakker RV. A common molecular basis for three inher ited kidney stone diseases. Nature 379: 445–449, 1996.  	8559248
	103. Lloyd SE, Pearce SH, Gunther W, Kawaguchi H, Igarashi  T, Jentsch TJ, and Thakker RV. Idiopathic low molecular  weight proteinuria associated with hypercalciuric nephrocalci nosis in Japanese children is due to mutations of the renal  chloride channel (CLCN5). J Clin Invest 99: 967–974, 1997.  	9062355
	104. Lu W, Peissel B, Babakhanlou H, Pavlova A, Geng L, Fan  X, Larson C, Brent G, and Zhou J. Perinatal lethality with  kidney and pancreas defects in mice with a targetted Pkd1  mutation. Nat Genet 17: 179–181, 1997.  	9326937
	105. Ludewig U, Pusch M, and Jentsch TJ. Two physically  distinct pores in the dimeric ClC-0 chloride channel. Nature  383: 340–343, 1996.  	8848047
	106. Lukacs GL, Chang XB, Kartner N, Rotstein OD, Riordan  JR, and Grinstein S. The cystic fibrosis transmembrane reg ulator is present and functional in endosomes. Role as a deter minant of endosomal pH. J Biol Chem 267: 14568–14572, 1992.  	1378835
	107. Luyckx VA, Goda FO, Mount DB, Nishio T, Hall A, Hebert  SC, Hammond TG, and Yu AS. Intrarenal and subcellular  localization of rat CLC5. Am J Physiol Renal Physiol 275:  F761–F769, 1998.  	9815133
	108. Luyckx VA, Leclercq B, Dowland LK, and Yu AS. Diet dependent hypercalciuria in transgenic mice with reduced  CLC5 chloride channel expression. Proc Natl Acad Sci USA 96:  12174–12179, 1999.  	10518595
	109. Marvao P, De Jesus Ferreira MC, Bailly C, Paulais M,  Bens M, Guinamard R, Moreau R, Vandewalle A, and  Teulon J. Cl absorption across the thick ascending limb is not  altered in cystic fibrosis mice. A role for a pseudo-CFTR Cl  channel. J Clin Invest 102: 1986–1993, 1998.  	NO_MATCH
	110. Masilamani S, Knepper MA, and Burg MB. Urine concen tration and dilution. In: The Kidney (6th ed.), edited by Brenner  BM. Philadelphia, PA: Saunders, 2000, p. 595–635.  	NO_MATCH
	111. Matsumura Y, Uchida S, Kondo Y, Miyazaki H, Ko SB,  Hayama A, Morimoto T, Liu W, Arisawa M, Sasaki S, and  Marumo F. Overt nephrogenic diabetes insipidus in mice lack ing the CLC-K1 chloride channel. Nat Genet 21: 95–98, 1999.  	9916798
	112. McNicholas CM, Guggino WB, Schwiebert EM, Hebert  SC, Giebisch G, and Egan ME. Sensitivity of a renal K  channel (ROMK2) to the inhibitory sulfonylurea compound  glibenclamide is enhanced by coexpression with the ATP-bind ing cassette transporter cystic fibrosis transmembrane regula tor. Proc Natl Acad Sci USA 93: 8083–8088, 1996.  	8755607
	113. Mellman I, Fuchs R, and Helenius A. Acidification of the  endocytic and exocytic pathways. Annu Rev Biochem 55: 663–  700, 1986.  	2874766
	114. Moestrup SK, Cui S, Vorum H, Bregengard C, Bjorn SE,  Norris K, Gliemann J, and Christensen EI. Evidence that  epithelial glycoprotein 330/megalin mediates uptake of polyba sic drugs. J Clin Invest 96: 1404–1413, 1995.  	7544804
	115. Mohammad-Panah R, Ackerley C, Rommens J,  Choudhury M, Wang Y, and Bear CE. The chloride channel  ClC-4 co-localizes with cystic fibrosis transmembrane conduc tance regulator and may mediate chloride flux across the apical  membrane of intestinal epithelia. J Biol Chem 277: 566–574,  2002.  	11675385
	116. Morales MM, Carroll TP, Morita T, Schwiebert EM,  Devuyst O, Wilson PD, Lopes AG, Stanton BA, Dietz HC,  Cutting GR, and Guggino WB. Both the wild-type and a  functional isoform of CFTR are expressed in kidney. Am J  Physiol Renal Fluid Electrolyte Physiol 270: F1038–F1048,  1996.  	8764323
	117. Morales MM, Nascimento DS, Capella MA, Lopes AG, and  Guggino WB. Arginine vasopressin regulates CFTR and ClC-2  mRNA expression in rat kidney cortex and medulla. Pflu¨gers  Arch 443: 202–211, 2001.  	11713645
	118. Morello JP and Bichet DG. Nephrogenic diabetes insipidus.  Annu Rev Physiol 63: 607–630, 2001.  	11181969
	119. Murray CB, Chu S, and Zeitlin PL. Gestational and tissue specific regulation of C1C-2 chloride channel expression. Am J  Physiol Lung Cell Mol Physiol 271: L829–L837, 1996.  	8944727
	120. Murray CB, Morales MM, Flotte TR, McGrath-Morrow  SA, Guggino WB, and Zeitlin PL. ClC-2: a developmentally  dependent chloride channel expressed in the fetal lung and  downregulated after birth. Am J Respir Cell Mol Biol 12:  597–604, 1995.  	7766424
	121. Nadeau JH. Modifier genes in mice and humans. Nat Rev  Genet 2: 165–174, 2001.  	11256068
	122. Obermuller N, Gretz N, Kriz W, Reilly RF, and Witzgall R.  The swelling-activated chloride channel ClC-2, the chloride  channel ClC-3, and ClC-5, a chloride channel mutated in kid ney stone disease, are expressed in distinct subpopulations of  renal epithelial cells. J Clin Invest 101: 635–642, 1998.  	9449697
	123. O’Neal WK, Hasty P, McCray PB Jr, Casey B, Rivera Perez J, Welsh MJ, Beaudet AL, and Bradley A. A severe  phenotype in mice with a duplication of exon 3 in the cystic  fibrosis locus. Hum Mol Genet 2: 1561–1569, 1993.  	7505691
	124. Ornellas DS, Nascimento DS, Christoph DH, Guggino  WB, and Morales MM. Aldosterone and high-NaCl diet mod ulate ClC-2 chloride channel gene expression in rat kidney.  Pflu¨gers Arch 444: 193–201, 2002.  	11976932
	125. Pearson H. Surviving a knockout blow. Nature 415: 8–9, 2002.  	11780081
	126. Perez-Brayfield MR, Caplan D, Gatti JM, Smith EA, and  Kirsch AJ. Metabolic risk factors for stone formation in pa tients with cystic fibrosis. J Urol 167: 480–484, 2002.  	11792901
	127. Persu A and Devuyst O. Transepithelial chloride secretion  and cystogenesis in autosomal dominant polycystic kidney dis ease. Nephrol Dial Transplant 15: 747–750, 2000.  	10831619
	128. Persu A, Devuyst O, Lannoy N, Materne R, Brosnahan G,  Gabow PA, Pirson Y, and Verellen-Dumoulin C. CF gene  and cystic fibrosis transmembrane conductance regulator ex pression in autosomal dominant polycystic kidney disease.  J Am Soc Nephrol 11: 2285–2296, 2000.  	11095651
	129. Piwon N, Gunther W, Schwake M, Bosl MR, and Jentsch  TJ. ClC-5 Cl channel disruption impairs endocytosis in a  mouse model for Dent’s disease. Nature 408: 369–373, 2000.  	11099045
	130. Poschet JF, Skidmore J, Boucher JC, Firoved AM, Van  Dyke RW, and Deretic V. Hyperacidification of cellubrevin  endocytic compartments and defective endosomal recycling in  cystic fibrosis respiratory epithelial cells. J Biol Chem 277:  13959–13965, 2002.  	11809765
	131. Quinton PM. The neglected ion: HCO3 . Nat Med 7: 292–293,  2001.  	NO_MATCH
	132. Rao S and Verkman AS. Analysis of organ physiology in  transgenic mice. Am J Physiol Cell Physiol 279: C1–C18, 2000.  	10898711
	133. Ratcliff R, Evans MJ, Cuthbert AW, MacVinish LJ, Fos ter D, Anderson JR, and Colledge WH. Production of a  severe cystic fibrosis mutation in mice by gene targeting. Nat  Genet 4: 35–41, 1993.  	7685652
	134. Reenstra WW, Sabolic I, Bae HR, and Verkman AS. Pro tein kinase A dependent membrane protein phosphorylation  and chloride conductance in endosomal vesicles from kidney  cortex. Biochemistry 31: 175–181, 1992.  	1310027
	135. Reinhart SC, Norden AG, Lapsley M, Thakker RV, Pang  J, Moses AM, Frymoyer PA, Favus MJ, Hoepner JA, and  Scheinman SJ. Characterization of carrier females and af fected males with X-linked recessive nephrolithiasis. J Am Soc  Nephrol 5: 1451–1461, 1995.  	7703383
	136. Rosenstein BJ and Zeitlin PL. Cystic fibrosis. Lancet 351:  277–282, 1998.  	NO_MATCH
	137. Rozmahel R, Wilschanski M, Matin A, Plyte S, Oliver M,  Auerbach W, Moore A, Forstner J, Durie P, Nadeau J,  Bear C, and Tsui LC. Modulation of disease severity in cystic  fibrosis transmembrane conductance regulator deficient mice  by a secondary genetic factor. Nat Genet 12: 280–287, 1996.  	8589719
	138. Sakamoto H, Sado Y, Naito I, Kwon TH, Inoue S, Endo K,  Kawasaki M, Uchida S, Nielsen S, Sasaki S, and Marumo  F. Cellular and subcellular immunolocalization of ClC-5 chan nel in mouse kidney: colocalization with H-ATPase. Am J  Physiol Renal Physiol 277: F957–F965, 1999.  	10600943
	139. Samaniego-Picota MD and Whelton A. Aminoglycoside-in duced nephrotoxicity in cystic fibrosis: a case presentation and  review of the literature. Am J Ther 3: 248–257, 1996.  	NO_MATCH
	140. Sasaki S and Yoshiyama N. Interaction of chloride and  bicarbonate transport across the basolateral membrane of rab bit proximal straight tubule. J Clin Invest 81: 1004–1011, 1988.  	3335635
	141. Scheinman SJ. X-linked hypercalciuric nephrolithiasis: clini cal syndromes and chloride channel mutations. Kidney Int 53:  3–17, 1998.  	9452994
	142. Scheinman SJ, Guay-Woodford LM, Thakker RV, and  Warnock DG. Genetic disorders of renal electrolyte transport.  N Engl J Med 340: 1177–1187, 1999.  	10202170
	143. Schmid A, Burckhardt G, and Gogelein H. Single chloride  channels in endosomal vesicle preparations from rat kidney  cortex. J Membr Biol 111: 265–275, 1989.  	2481041
	144. Schmidt-Rose T and Jentsch TJ. Transmembrane topology  of a CLC chloride channel. Proc Natl Acad Sci USA 94: 7633–  7638, 1997.  	9207144
	145. Schwake M, Friedrich T, and Jentsch TJ. An internaliza tion signal in ClC-5, an endosomal Cl channel mutated in  Dent’s disease. J Biol Chem 276: 12049–12054, 2001.  	NO_MATCH
	146. Schwiebert EM, Benos DJ, Egan ME, Stutts MJ, and  Guggino WB. CFTR is a conductance regulator as well as a  chloride channel. Physiol Rev 79: S145–S166, 1999.  	9922379
	147. Schwiebert EM, Cid-Soto LP, Stafford D, Carter M, Blais dell CJ, Zeitlin PL, Guggino WB, and Cutting GR. Analy sis of ClC-2 channels as an alternative pathway for chloride  conduction in cystic fibrosis airway cells. Proc Natl Acad Sci  USA 95: 3879–3884, 1998.  	9520461
	148. Schwiebert EM, Egan ME, Hwang TH, Fulmer SB, Allen  SS, Cutting GR, and Guggino WB. CFTR regulates out wardly rectifying chloride channels through an autocrine mech anism involving ATP. Cell 81: 1063–1073, 1995.  	7541313
	149. Seki G, Taniguchi S, Uwatoko S, Suzuki K, and Kuro kawa K. Activation of the basolateral Cl conductance by  cAMP in rabbit renal proximal tubule S3 segments. Pflu¨gers  Arch 430: 88–95, 1995.  	7667081
	150. Seksek O, Biwersi J, and Verkman AS. Evidence against  defective trans-Golgi acidification in cystic fibrosis. J Biol Chem  271: 15542–15548, 1996.  	8663158
	151. Sheppard DN and Welsh MJ. Structure and function of the  CFTR chloride channel. Physiol Rev 79: S23–S45, 1999.  	9922375
	152. Shi LB, Fushimi K, Bae HR, and Verkman AS. Heteroge neity in ATP-dependent acidification in endocytic vesicles from  kidney proximal tubule. Measurement of pH in individual en docytic vesicles in a cell-free system. Biophys J 59: 1208–1217,  1991.  	1714779
	153. Shimkets RA, Lifton RP, and Canessa CM. The activity of  the epithelial sodium channel is regulated by clathrin-mediated  endocytosis. J Biol Chem 272: 25537–25541, 1997.  	9325269
	154. Silva IV, Blaisdell CJ, Guggino SE, and Guggino WB. PTH  regulates expression of ClC-5 chloride channel in the kidney.  Am J Physiol Renal Physiol 278: F238–F245, 2000.  	10662728
	155. Simon DB, Bindra RS, Mansfield TA, Nelson-Williams C,  Mendonca E, Stone R, Schurman S, Nayir A, Alpay H,  Bakkaloglu A, Rodriguez-Soriano J, Morales JM, Sanjad  SA, Taylor CM, Pilz D, Brem A, Trachtman H, Griswold  W, Richard GA, John E, and Lifton RP. Mutations in the  chloride channel gene, CLCNKB, cause Bartter’s syndrome  type III. Nat Genet 17: 171–178, 1997.  	9326936
	156. Simon DB, Karet FE, Hamdan JM, DiPietro A, Sanjad SA,  and Lifton RP. Bartter’s syndrome, hypokalaemic alkalosis  with hypercalciuria, is caused by mutations in the Na-K-2Cl  cotransporter NKCC2. Nat Genet 13: 183–188, 1996.  	8640224
	157. Simon DB, Karet FE, Rodriguez-Soriano J, Hamdan JH,  DiPietro A, Trachtman H, Sanjad SA, and Lifton RP.  Genetic heterogeneity of Bartter’s syndrome revealed by muta tions in the K channel, ROMK. Nat Genet 14: 152–156, 1996.  	8841184
	158. Snouwaert JN, Brigman KK, Latour AM, Malouf NN,  Boucher RC, Smithies O, and Koller BH. An animal model  for cystic fibrosis made by gene targeting. Science 257: 1083–  1088, 1992.  	1380723
	159. Stanton BA. Cystic fibrosis transmembrane conductance reg ulator (CFTR) and renal function. Wien Klin Wochenschr 109:  457–464, 1997.  	9261986
	160. Steinmeyer K, Schwappach B, Bens M, Vandewalle A,  and Jentsch TJ. Cloning and functional expression of rat  CLC-5, a chloride channel related to kidney disease. J Biol  Chem 270: 31172–31177, 1995.  	8537381
	161. Stenvinkel P, Hjelte L, Alvan G, Hedman A, Hultman E,  and Strandvik B. Decreased renal clearance of sodium in  cystic fibrosis. Acta Paediatr Scand 80: 194–198, 1991.  	2035310
	162. Stobrawa SM, Breiderhoff T, Takamori S, Engel D,  Schweizer M, Zdebik AA, Bosl MR, Ruether K, Jahn H,  Draguhn A, Jahn R, and Jentsch TJ. Disruption of ClC-3, a  chloride channel expressed on synaptic vesicles, leads to a loss  of the hippocampus. Neuron 29: 185–196, 2001.  	11182090
	163. Strange K, Emma F, and Jackson PS. Cellular and molec ular physiology of volume-sensitive anion channels. Am J  Physiol Cell Physiol 270: C711–C730, 1996.  	8638650
	164. Stutts MJ, Canessa CM, Olsen JC, Hamrick M, Cohn JA,  Rossier BC, and Boucher RC. CFTR as a cAMP-dependent  regulator of sodium channels. Science 269: 847–850, 1995.  	7543698
	165. Sullivan LP, Wallace DP, and Grantham JJ. Epithelial  transport in polycystic kidney disease. Physiol Rev 78: 1165–  1191, 1998.  	9790573
	166. Takahashi N, Chernavvsky DR, Gomez RA, Igarashi P,  Gitelman HJ, and Smithies O. Uncompensated polyuria in a  mouse model of Bartter’s syndrome. Proc Natl Acad Sci USA  97: 5434–5439, 2000.  	10779555
	167. Tauc M, Bidet M, and Poujeol P. Chloride currents activated  by calcitonin and cAMP in primary cultures of rabbit distal  convoluted tubule. J Membr Biol 150: 255–273, 1996.  	8661992
	168. Thiemann A, Grunder S, Pusch M, and Jentsch TJ. A  chloride channel widely expressed in epithelial and non-epithe lial cells. Nature 356: 57–60, 1992.  	1311421
	169. Traebert M, Roth J, Biber J, Murer H, and Kaissling B.  Internalization of proximal tubular type II Na-Pi cotransporter  by PTH: immunogold electron microscopy. Am J Physiol Renal  Physiol 278: F148–F154, 2000.  	10644666
	170. Traebert M, Volkl H, Biber J, Murer H, and Kaissling B.  Luminal and contraluminal action of 1–34 and 3–34 PTH  peptides on renal type IIa Na-Pi cotransporter. Am J Physiol  Renal Physiol 278: F792–F798, 2000.  	10807591
	171. Trezise AE, Chambers JA, Wardle CJ, Gould S, and Har ris A. Expression of the cystic fibrosis gene in human foetal  tissues. Hum Mol Genet 2: 213–218, 1993.  	7684639
	172. Uchida S. In vivo role of CLC chloride channels in the kidney.  Am J Physiol Renal Physiol 279: F802–F808, 2000.  	11053039
	173. Uchida S, Sasaki S, Furukawa T, Hiraoka M, Imai T,  Hirata Y, and Marumo F. Molecular cloning of a chloride  channel that is regulated by dehydration and expressed pre dominantly in kidney medulla. J Biol Chem 268: 3821–3824,  1993.  	8034678
	174. Uchida S, Sasaki S, Fushimi K, and Marumo F. Isolation of  human aquaporin-CD gene. J Biol Chem 269: 23451–2355,  1994.  	7522228
	175. Uchida S, Sasaki S, Nitta K, Uchida K, Horita S, Nihei H,  and Marumo F. Localization and functional characterization  of rat kidney-specific chloride channel, ClC-K1. J Clin Invest  95: 104–113, 1995.  	7814604
	176. Vandewalle A, Cluzeaud F, Bens M, Kieferle S, Stein meyer K, and Jentsch TJ. Localization and induction by  dehydration of ClC-K chloride channels in the rat kidney. Am J  Physiol Renal Physiol 272: F678–F688, 1997.  	9176380
	177. Vandewalle A, Cluzeaud F, Peng KC, Bens M, Luchow A,  Gunther W, and Jentsch TJ. Tissue distribution and subcel lular localization of the ClC-5 chloride channel in rat intestinal  cells. Am J Physiol Cell Physiol 280: C373–C381, 2001.  	11208533
	178. Van Doorninck JH, French PJ, Verbeek E, Peters RH,  Morreau H, Bijman J, and Scholte BJ. A mouse model for  the cystic fibrosis delta F508 mutation. EMBO J 14: 4403–  4411, 1995.  	7556083
	179. Vandorpe D, Kizer N, Ciampollilo F, Moyer B, Karlson K,  Guggino WB, and Stanton BA. CFTR mediates electrogenic  chloride secretion in mouse inner medullary collecting duct  (mIMCD-K2) cells. Am J Physiol Cell Physiol 269: C683–C689,  1995.  	7573398
	180. Van Kuijck MA, van Aubel RA, Busch AE, Lang F, Russel  FG, Bindels RJ, van Os CH, and Deen PM. Molecular  cloning and expression of a cyclic AMP-activated chloride con ductance regulator: a novel ATP-binding cassette transporter.  Proc Natl Acad Sci USA 93: 5401–5406, 1996.  	8643587
	181. Van Slegtenhorst MA, Bassi MT, Borsani G, Wapenaar  MC, Ferrero GB, de Conciliis L, Rugarli EI, Grillo A,  Franco B, Zoghbi HY, and Ballabio A. A gene from the  Xp22.3 region shares homology with voltage-gated chloride  channels. Hum Mol Genet 3: 547–552, 1994.  	8069296
	182. Van Weert AW, Dunn KW, Gueze HJ, Maxfield FR, and  Stoorvogel W. Transport from late endosomes to lysosomes,  but not sorting of integral membrane proteins in endosomes,  depends on the vacuolar proton pump. J Cell Biol 130: 821–  834, 1995.  	7642700
	183. Waldegger S and Jentsch TJ. From tonus to tonicity: phys iology of CLC chloride channels. J Am Soc Nephrol 11: 1331–  1339, 2000.  	10864591
	184. Wang SS, Devuyst O, Courtoy PJ, Wang XT, Wang H,  Wang Y, Thakker RV, Guggino S, and Guggino WB. Mice  lacking renal chloride channel, ClC-5, are a model for Dent’s  disease, a nephrolithiasis disorder associated with defective  receptor-mediated endocytosis. Hum Mol Genet 9: 2937–2945,  2000.  	11115837
	185. Wang T, Segal AS, Giebisch G, and Aronson PS. Stimula tion of chloride transport by cAMP in rat proximal tubules.  Am J Physiol Renal Fluid Electrolyte Physiol 268: F204–F210,  1995.  	7864157
	186. Welsh MJ, Ramsey BW, Accurso F, and Cutting GR. Cystic  fibrosis. In: The Metabolic and Molecular Bases of Inherited  Disease, edited by Scriver CR, Beaudet AL, Sly WS, and Valle  D. New York: McGraw-Hill, 2001, p. 5121–5188.  	NO_MATCH
	187. Welsh MJ and Smith AE. Molecular mechanisms of CFTR  chloride channel dysfunction in cystic fibrosis. Cell 73: 1251–  1254, 1993.  	7686820
	188. Wrong OM, Norden AG, and Feest TG. Dent’s disease; a  familial proximal renal tubular syndrome with low-molecular weight proteinuria, hypercalciuria, nephrocalcinosis, metabolic  bone disease, progressive renal failure and a marked male  predominance. Q J Med 87: 473–493, 1994.  	7922301
	189. Wu G, D’Agati V, Cai Y, Markowitz G, Park JH, Reynolds  DM, Maeda Y, Le TC, Hou H Jr, Kucherlapati R, Edel mann W, and Somlo S. Somatic inactivation of Pkd2 results  in polycystic kidney disease. Cell 93: 177–188, 1998.  	9568711
	190. Yasui M, Hazama A, Kwon TH, Nielsen S, Guggino WB,  and Agre P. Rapid gating and anion permeability of an intra cellular aquaporin. Nature 402: 184–187, 1999.  	10647010
	191. Yasui M, Kwon TH, Knepper MA, Nielsen S, and Agre P.  Aquaporin-6: an intracellular vesicle water channel protein in  renal epithelia. Proc Natl Acad Sci USA 96: 5808–5813, 1999.  	10318966
	192. Yoshikawa M, Uchida S, Yamauchi A, Miyai A, Tanaka Y,  Sasaki S, and Marumo F. Localization of rat CLC-K2 chloride  channel mRNA in the kidney. Am J Physiol Renal Physiol 276:  F552–F558, 1999.  	10198414
	193. Yoshitomi K, Kondo Y, and Imai M. Evidence for conductive  Cl pathways across the cell membranes of the thin ascending  limb of Henle’s loop. J Clin Invest 82: 866–871, 1988.  	2458388
	194. Yu AS. Role of ClC-5 in the pathogenesis of hypercalciuria:  recent insights from transgenic mouse models. Curr Opin  Nephrol Hypertens 10: 415–420, 2001.  	11342807
	195. Zeiher BG, Eichwald E, Zabner J, Smith JJ, Puga AP,  McCray PB Jr, Capecchi MR, Welsh MJ, and Thomas KR.  A mouse model for the delta F508 allele of cystic fibrosis. J Clin  Invest 96: 2051–2064, 1995.  	NO_MATCH
	196. Zimniak L, Winters CJ, Reeves WB, and Andreoli TE. Cl  channels in basolateral renal medullary vesicles. X. Cloning of  a Cl channel from rabbit outer medulla. Kidney Int 48: 1828–  1836, 1995.  	8587242
1745.pdf
	1. Maron DJ, Fazio S, Linton MF. Current perspectives on statins. Circu lation. 2000;101:207–223.  	10637210
	2. Faggiotto A, Paoletti R. State-of-the-Art lecture: statins and blockers of  the renin-angiotensin system—vascular protection beyond their primary  mode of action. Hypertension. 1999;34:987–996.  	10523396
	3. Laufs U, Liao JK. Direct vascular effects of HMG-CoA reductase inhib itors. Trends Cardiovasc Med. 2000;10:143–148.  	11239793
	4. Napoli C, de Nigris F, Palinski W. Multiple role of reactive oxygen  species in the arterial wall. J Cell Biochem. 2001;82:674–682.  Downloaded from atvb.ahajournals.org at NEUROZENTRUM BIBLIOTHEK on July 6, 2011   	11500945
	5. Rosenson RS, Tangney CC. Antiatherothrombotic properties of statins:  Implications for cardiovascular event reduction. JAMA. 1998;279:  1643–1650.  	9613915
	6. LaRosa JC. Pleiotropic effects of statins and their clinical significance.  Am J Cardiol. 2001;88:291–293.  	11472710
	7. Palinski W, Tsimikas S. Immunomodulatory effects of statins: Mech anisms and potential impact on arteriosclerosis. J Am Soc Nephrol.  2002;13:1673–1681.  	12039998
	8. Weitz-Schmidt G, Welzenbach K, Brinkmann V, Kamata T, Kallen J,  Bruns C, Cottens S, Takada Y, Hommel U. Statins selectively inhibit  leukocyte function antigen-1 by binding to a novel regulatory integrin  site. Nature Med. 2001;7:687–692.  	11385505
	9. Ignarro LJ, Napoli C, Loscalzo J. Nitric oxide donors and cardiovascular  agents modulating the bioactivity of nitric oxide: an overview. Circ Res.  2002;90:21–28.  	11786514
	10. Bea F, Blessing E, Bennet B, Levitz M, Wallace EP, Rosenfeld ME.  Simvastatin promotes atherosclerotic plaque stability in apolipoprotein E  deficient mice independently of lipid-lowering. Arterioscler Thromb Vasc  Biol. 2002;22:1832–1837.  	12426212
	11. Sparrow CP, Burton CA, Hernandez M, Mundt S, Hassing H, Patel S,  Rosa R, Hermanowski-Vosatka A, Wang P-R, Zhang D, Peterson L,  Detmers PA, Chao Y-S, Wright SD. Simvastatin has anti-inflammatory  and anti-atherosclerotic activities independent of plasma cholesterol lowering. Arterioscler Thromb Vasc Biol. 2001;21:115–121.  	11145942
	12. Rekhter MD. How to evaluate plaque vulnerability in animal models of  atherosclerosis? Cardiovasc Res. 2002;54:36–41.  	12062359
	13. Reddick RL, Zhang SH, Maeda N. Atherosclerosis in mice lacking apo E:  evaluation of lesional development and progression. Arterioscler Thromb.  1994;14:141–147.  	8274470
	14. Nakashima Y, Plump AS, Raines EW, Breslow JL, Ross R. ApoE deficient mice develop lesions of all phases of atherosclerosis throughout  the aortic tree. Arterioscler Thromb. 1994;14:133–140.  	8274468
	15. Palinski W, Ord V, Plump AS, Breslow JL, Steinberg D, Witztum JL.  ApoE-deficient mice are a model of lipoprotein oxidation in athero genesis: demonstration of oxidation-specific epitopes in lesions and high  titers of autoantibodies to malondialdehyde-lysine in serum. Arterioscler  Thromb. 1994;14:605–616.  	7511933
	16. Calara F, Silvestre M, Casanada F, Yuan N, Napoli C, Palinski W.  Spontaneous plaque rupture and secondary thrombosis in apolipoprotein  E-deficient and LDL receptor-deficient mice. J Pathol. 2001;195:  257–263.  	11592107
	17. Carmeliet P, Moons L, Collen D. Mouse models of angiogenesis, arterial  stenosis, atherosclerosis and hemostasis. Cardiovasc Res. 1998;39:8–33.  	9764187
	18. Palinski W, Napoli C, Reaven PD. Mouse models of atherosclerosis. In:  Simons DI, Rogers C, eds. Contemporary Cardiology: Vascular Disease  and Injury: Preclinical Research. Totowa, NJ: Humana Press; 2000:  149–174.  	11264988
	19. Bennet MR. Breaking the plaque: evidence for plaque rupture in animal  models of atherosclerosis. Arterioscler Thromb Vasc Biol. 2002;1:  713–714.  	12006380
	20. Seo HS, Lombardi DM, Polinsky P, Powell-Braxton L, Bunting S,  Schwartz SM, Rosenfeld ME. Peripheral vascular stenosis in apoli poprotein E-deficient mice: potential roles of lipid deposition, medial  atrophy, and adventitial inflammation. Arterioscler Thromb Vasc Biol.  1997;17:3593–3601.  	9437210
	21. Johnson JL, Jackson CL. Atherosclerotic plaque rupture in the apoli poprotein E knockout mouse. Atherosclerosis. 2001;154:399–406.  	11166772
	22. Williams H, Johnson JL, Carson KGS, Jackson CL. Characteristics of  intact and ruptured atherosclerotic plaques in brachiocephalic arteries of  apolipoprotein E knockout mice. Arterioscler Thromb Vasc Biol. 2002;  22:788–792.  	12006391
	23. Napoli C, de Nigris F, Welch J, Calara FB, Stuart RO, Glass CK, Palinski  W. Maternal hypercholesterolemia during pregnancy promotes early  atherogenesis in LDL receptor-deficient mice and alters aortic gene  expression determined by microarray. Circulation. 2002;105:1360–1367.  	11901049
	24. von der Thusen JH, van Vlijmen BJ, Hoeben RC, Kockx MM, Havekes  LM, van Berkel TJ, Biessen EA. Induction of atherosclerotic plaque  rupture in apolipoprotein E-/- mice after adenovirus-mediated transfer of  p53. Circulation. 2002;105:2064–2070.  	11980686
	25. Nakata Y, Maeda N. Vulnerable atherosclerotic plaque morphology in  apolipoprotein E–deficient mice unable to make ascorbic acid. Circu lation. 2002;105:1485–1490.  	11914259
	26. Caligiuri G, Levy B, Pernow J, Thorén P, Hansson GK. Myocardial  infarction mediated by endothelin receptor signaling in hypercholesterol emic mice. Proc Natl Acad Sci U S A. 1999;96:6920–6924.  	10359814
	27. Libby P. Molecular bases of the acute coronary syndromes. Circulation.  1995;91:2844–2850.  	7758192
	28. Braun A, Trigatti BL, Post MJ, Sato K, Simons M, Edelberg JM,  Rosenberg RD, Schrenzel M, Krieger M. Loss of SR-BI expression leads  to the early onset of occlusive atherosclerotic coronary artery disease,  spontaneous myocardial infarctions, severe cardiac dysfunction, and pre mature death in apolipoprotein E–deficient mice. Circ Res. 2002;90:  270–276.  	11861414
	29. Williams JK, Sukhova GK, Herrington DM, Libby P. Pravastatin has  cholesterol-lowering independent effects on the artery wall of athero sclerotic monkeys. J Am Coll Cardiol. 1998;31:684–691.  	9502654
	30. Shah PK, Falk E, Badimon JJ, Fernandez-Ortiz A, Mailhac A,  Villareal-Levy G, Fallon JT, Regnstrom J, Fuster V. Human monocyte derived macrophages induce collagen breakdown in fibrous caps of ath erosclerotic plaques: potential role of matrix-degrading metallopro teinases and implications for plaque rupture. Circulation. 1995;92:  1565–1569.  	7664441
	31. Lemaître V, O’Byrne TK, Borczuk AC, Okada Y, Tall AR, D’Armiento  J. ApoE knockout mice expressing human matrix metalloproteinase-1 in  macrophages have less advanced atherosclerosis. J Clin Invest. 2001;107:  1227–1234.  	11375412
	32. Silence J, Collen D, Lijnen HR. Reduced atherosclerotic plaque but  enhanced aneurysm formation in mice with inactivation of the tissue  inhibitor of metalloproteinase-1 (TIMP-1) gene. Circ Res. 2002;90:  897–903.  	11988491
	33. Silence J, Lupu F, Collen D, Lijnen HR. Persistence of atherosclerotic  plaque but reduced aneurysm formation in mice with stromelysin-1  (MMP-3) gene inactivation. Arterioscler Thromb Vasc Biol. 2001;21:  1440–1445.  	11557669
	34. Crisby M, Nordin-Fredriksson G, Shah PK, Yano J, Zhu J, Nilsson J.  Pravastatin treatment increases collagen content and decreases lipid  content, inflammation, metalloproteinases, and cell death in human  carotid plaques: implications for plaque stabilization. Circulation. 2001;  103:926–933.  	11181465
	35. Hansson GK. Immune mechanisms in atherosclerosis. Arterioscler  Thromb Vasc Biol. 2001;21:1876–1890.  	11742859
	36. Hernandez-Perera O, Perez-Sala D, Navarro-Antolin J, Sanchez-Pascuala  R, Hernandez G, Diaz C, Lamas S. Effects of the 3-hydroxy-3 methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on  the expression of endothelin-1 and endothelial nitric oxide synthase in  vascular endothelial cells. J Clin Invest. 1998;101:2711–2719.  	9637705
	37. Laufs U, La Fata V, Plutzky J, Liao JK. Upregulation of endothelial nitric  oxide synthase by HMG-CoA reductase inhibitors. Circulation. 1998;97:  1129–1135.  	9537338
	38. Laufs U, Liao JK. Post-transcriptional regulation of endothelial nitric  oxide synthase mRNA stability by Rho GTPase. J Biol Chem. 1998;273:  24266–24271.  	9727051
	39. Endres M, Laufs U, Huang Z, Nakamura T, Huang P, Moskowitz MA,  Liao JK. Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA  reductase inhibitors mediated by endothelial nitric oxide synthase. Proc  Natl Acad Sci U S A. 1998;95:8880–8885.  	9671773
	40. Wilson SH, Simari RD, Best PJM, Peterson TE, Lerman LO, Aviram M,  Nath KA, Holmes DR Jr, Lerman A. Simvastatin preserves coronary  endothelial function in hypercholesterolemia in the absence of lipid  lowering. Arterioscler Thromb Vasc Biol. 2001;21:122–128.  	11145943
	41. Wilson SH, Herrmann J, Lerman LO, Holmes DR Jr, Napoli C, Ritman  EL, Lerman A. Simvastatin preserves the structure of coronary adventitial  vasa vasorum in experimental hypercholesterolemia independent of lipid  lowering. Circulation. 2002;105:415–418.  	11815421
	42. Bonetti PO, Wilson SH, Rodriguez-Porcel M, Holmes DR Jr, Lerman LO,  Lerman A. Simvastatin preserves myocardial perfusion and coronary  microvascular permeability in experimental hypercholesterolemia inde pendent of lipid lowering. J Am Coll Cardiol. 2002;40:546–554.  	12142124
	43. Kimura M, Kurose I, Russell J, Granger DN. Effects of fluvastatin on  leukocyte-endothelial cell adhesion in hypercholesterolemic rats. Arte rioscler Thromb Vasc Biol. 1997;17:1521–1526.  	9301630
	44. Weber C, Erl W, Weber KS, Weber PC. HMG-CoA reductase inhibitors  decrease CD11b expression and CD11b-dependent adhesion of  monocytes to endothelium and reduce increased adhesiveness of  monocytes isolated from patients with hypercholesterolemia. J Am Coll  Cardiol. 1997;30:1212–1217.  	9350917
	45. Romano M, Diomede L, Sironi M, Massimiliano L, Sottocorno M,  Polentarutti N, Guglielmotti A, Albani D, Bruno A, Fruscella P, Salmona  M, Vecchi A, Pinza M, Mantovani A. Inhibition of monocyte chemotactic  protein-1 synthesis by statins. Lab Invest. 2000;80:1095–1100.  	10908155
	46. Liu L, Moesner P, Kovach NL, Bailey R, Hamilton AD, Sebti SM, Harlan  JM. Integrin-dependent leukocyte adhesion involves geranylgeranylated  protein(s). J Biol Chem. 1999;274:33334–33340.  	10559211
	47. Kwak B, Mulhaupt F, Myit S, Mach F. Statins as a newly recognized type  of immunosuppressor. Nature Med. 2000;6:1399–1402.  	11100127
	48. Weitz-Schmidt G, Welzenbach K, Brinkmann V, Kamata T, Kallen J,  Bruns C, Cottens S, Takada Y, Hommel U. Statins selectively inhibit  leukocyte function antigen-1 by binding to a novel regulatory integrin  site. Nature Med. 2001;7:687–692.  	11385505
	49. Cutts JL, Scallen TJ, Watson J, Bankhurst AD. Role of mevalonic acid in  the regulation of natural killer cell cytotoxicity. J Cell Physiol. 1989;139:  550–557.  	2738100
	50. Pahan K, Sheikh FG, Namboodiri AM, Singh I. Lovastatin and phenyl acetate inhibit the induction of nitric oxide synthase and cytokines in rat  primary astrocytes, microglia, and macrophages. J Clin Invest. 1997;100:  2671–2679.  	9389730
	51. Rudich SM, Mongini PK, Perez RV, Katznelson S. HMG-CoA reductase  inhibitors pravastatin and simvastatin inhibit human B-lymphocyte acti vation. Transplant Proc. 1998;30:992–995.  	9636401
	52. Bustos C, Hernández-Presa MA, Ortego M, Tuñón J, Ortega L, Pérez F,  Díaz C, Hernández G, Egido J. HMG-CoA reductase inhibition by ator vastatin reduces neointimal inflammation in a rabbit model of atheroscle rosis. J Am Coll Cardiol. 1998;32:2057–2064.  	9857893
	53. Inoue I, Goto S, Mizotani K, Awata T, Mastunaga T, Kawai S, Nakajima  T, Hokari S, Komoda T, Katayama S. Lipophilic HMG-CoA reductase  inhibitor has an anti-inflammatory effect: reduction of MRNA levels for  interleukin-1beta, interleukin-6, cyclooxygenase-2, and p22phox by reg ulation of peroxisome proliferator-activated receptor alpha (PPAR alpha)  in primary endothelial cells. Life Sci. 2000;67:863–876.  	10946846
	54. Ito T, Ikeda U, Shimpo M, Ohki R, Takahashi M, Yamamoto K, Shimada  K. HMG-CoA reductase inhibitors reduce interleukin-6 synthesis in  human vascular smooth muscle cells. Cardiovasc Drugs Ther. 2002;16:  121–126.  	12090904
	55. Bellosta S, Via D, Canavesi M, Pfister P, Fumagalli R, Paoletti R, Bernini  F. HMG-CoA reductase inhibitors reduce MMP-9 secretion by macro phages. Arterioscler Thromb Vasc Biol. 1998;18:1671–1678.  	9812903
	56. Aikawa M, Rabkin E, Sugiyama S, Voglic SJ, Fukumoto Y, Furukawa Y,  Shiomi M, Schoen FJ, Libby P. An HMG-CoA reductase inhibitor,  cerivastatin, suppresses growth of macrophages expressing matrix met alloproteinases and tissue factor in vivo and in vitro. Circulation.;2001;  103:276–283.  	NO_MATCH
	57. Laufs U, Marra D, Node K, Liao JK. 3-Hydroxy-3-methylglutaryl-CoA  reductase inhibitors attenuate vascular smooth muscle proliferation by  preventing rho GTPase-induced down-regulation of p27(Kip1). J Biol  Chem. 1999;274:21926–21931.  	10419514
	58. Guijarro C, Blanco-Colio LM, Ortego M, Alonso C, Ortiz A, Plaza JJ,  Diaz C, Hernandez G, Edigo J. 3-hydroxy-3-methylglutaryl coenzyme A  reductase and isoprenylation inhibitors induce apoptosis of vascular  smooth muscle cells in culture. Circ Res. 1998;83:490–500.  	9734471
	59. Fukumoto Y, Libby P, Rabkin E, Hill CC, Enomoto M, Hirouchi Y,  Shiomi M, Aikawa M. Statins alter smooth muscle cell accumulation and  collagen content in established atheroma of watanabe heritable hyperlip idemic rabbits. Circulation. 2001;103:993–999.  	11181475
	60. Kureishi Y, Luo Z, Shiojima I, Bialik A, Fulton D, Lefer DJ, Sessa WC,  Walsh K. The HMG-CoA reductase inhibitor simvastatin activates the  protein kinase Akt and promotes angiogenesis in normocholesterolemic  animals. Nature Med. 2000;6:1004–1010.  	10973320
	61. Vincent L, Chen W, Hong L, Mirshahi F, Mishal Z, Mirshahi-Khorassani  T, Vannier JP, Soria J, Soria C. Inhibition of endothelial cell migration by  cerivastatin, an HMG-CoA reductase inhibitor: contribution to its anti angiogenic effect. FEBS Lett. 2001;495:159–166.  	11334884
	62. Crisby M, Nordin-Fredriksson G, Shah PK, Yano J, Zhu J, Nilsson J.  Pravastatin treatment increases collagen content and decreases lipid  content, inflammation, metalloproteinases, and cell death in human  carotid plaques: implications for plaque stabilization. Circulation. 2001;  103:926–933.  	11181465
	63. Wong B, Lumma WC, Smith AM, Sisko JT, Wright SD, Cai TQ. Statins  suppress THP-1 cell migration and secretion of matrix metalloproteinase  9 by inhibiting geranylgeranylation. J Leukoc Biol. 2001;69:959–962.  	11404382
	64. Giroux LM, Davignon J, Naruszewicz M. Simvastatin inhibits the oxi dation of low-density lipoproteins by activated human monocyte-derived  macrophages. Biochim Biophys Acta. 1993;1165:335–338.  	8380338
	65. Takemoto M, Node K, Nakagami H, Liao Y, Grimm M, Takemoto Y,  Kitakaze M, Liao JK. Statins as antioxidant therapy for preventing  cardiac myocyte hypertrophy. J Clin Invest. 2001;108:1429–1437.  	11714734
	66. Wassmann S, Laufs U, Baumer AT, Muller K, Ahlbory K, Linz W, Itter  G, Rosen R, Bohm M, Nickenig G. HMG-CoA reductase inhibitors  improve endothelial dysfunction in normocholesterolemic hypertension  via reduced production of reactive oxygen species. Hypertension. 2001;  37:1450–1457.  	11408394
	67. Essig M, Nguyen G, Prie D, Escoubet B, Sraer JD, Friedlander G.  3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors increase  fibrinolytic activity in rat aortic endothelial cells: role of geranylgerany lation and Rho proteins. Circ Res. 1998;83:683–690.  	9758637
	68. Laufs U, Gertz K, Huang P, Nickenig G, Bohm M, Dirnagl U, Endres M.  Atorvastatin upregulates type III nitric oxide synthase in thrombocytes,  decreases platelet activation, and protects from cerebral ischemia in  normocholesterolemic mice. Stroke. 2000;31:2442–2449.  	11022078
	69. Colli S, Eligini S, Lalli M, Camera M, Paoletti R, Tremoli E. Vastatins  inhibit tissue factor in cultured human macrophages: a novel mechanism  of protection against atherothrombosis. Arterioscler Thromb Vasc Biol.  17:265–272.  	9081680
	70. Baetta R, Camera M, Comparato C, Altana C, Ezekowitz MD, Tremoli E.  Fluvastatin reduces tissue factor expression and macrophage accumu lation in carotid lesions of cholesterol-fed rabbits in the absence of lipid  lowering. Arterioscler Thromb Vasc Biol. 2001;22:692–698.  	11950712
	71. Hernandez-Presa MA, Martin-Ventura JL, Ortego M, Gomez-Hernandez  A, Tunon J, Hernandez-Vargas P, Blanco-Colio LM, Mas S, Aparicio C,  Ortega L, Vivanco F, Gerique JG, Diaz C, Hernandez G, Egido J.  Atorvastatin reduces the expression of cyclooxygenase-2 in a rabbit  model of atherosclerosis and in cultured vascular smooth muscle cells.  Atherosclerosis. 2002;160:49–58.  	11755922
	72. Rosenson RS, Tangney CC. Antiatherothrombotic properties of statins:  implications for cardiovascular event reduction. JAMA. 1998;279:  1643–1650.  	9613915
	73. Scandinavian Simvastatin Survival Study Group. Randomised trial of  cholesterol lowering in 4444 patients with coronary heart disease: the  Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:  1383–1389.  	7740647
	74. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW,  McKillop JH, Packard CJ. Prevention of coronary heart disease with  pravastatin in men with hypercholesterolemia:. West of Scotland Coro nary Prevention Study Group. N Engl J Med. 1995;333:1301–1307.  	7566020
	75. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG,  Brown L, Warnica JW, Arnold JM, Wun CC, Davis BR, Braunwald E.  The effect of pravastatin on coronary events after myocardial infarction in  patients with average cholesterol levels: Cholesterol and Recurrent  Events Trial investigators. N Engl J Med. 1996;335:1001–1009.  	8801446
	76. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection  Study of cholesterol lowering with simvastatin in 20,536 high-risk indi viduals: a randomised placebo-controlled trial. Lancet. 2002;360:7–22.  	12480448
	77. Schwartz GG, Olsson AG, Ezekowitz MD, Ganz P, Oliver MF, Waters D,  Zeiher A, Chaitman BR, Leslie S, Stern T. Effects of atorvastatin on early  recurrent ischemic events in acute coronary syndromes: the MIRACL  study—a randomized controlled trial. JAMA. 2001;285:1711–1718.  	11277825
	78. Chan AW, Bhatt DL, Chew DP, Quinn MJ, Moliterno DJ, Topol EJ, Ellis  SG. Early and sustained survival benefit associated with statin therapy at  the time of percutaneous coronary intervention. Circulation. 2002;105:  691–696.  	11839623
	79. Kobashigawa JA, Katznelson S, Laks H, Johnson JA, Yeatman L, Wang  XM, Chia D, Terasaki PI, Sabad A, Cogert GA, Trosian K, Hamilton MA,  Koriguchi JD, Kawata N, Hage A, Drinkwater DC, Stevenson LW. Effect  of pravastatin on outcomes after cardiac transplantation. N Engl J Med.  1995;333:621–627.  	7637722
	80. Wenke K, Meiser B, Thiery J, Nagel D, von Scheidt W, Steinbeck G,  Seidel D, Reichart B. Simvastatin reduces graft vessel disease and mor tality after heart transplantation: a four-year randomized trial. Circu lation. 1997;96:1398–1402.  	9315523
	81. Ellis SG, Chew D, Chan A, Whitlow PL, Schneider JP, Topol EJ. Death  following creatine kinase-MB elevation after coronary intervention: iden tification of an early risk period: importance of creatine kinase-MB level,  completeness of revascularization, ventricular function, and probable  benefit of statin therapy. Circulation. 2002;106:1205–1210.  	12208794
ehp110s-000851.pdf
2301.full.pdf
	1. Wolcott CD, Rallison ML: Infancy-onset diabetes mellitus and multiple  epiphyseal dysplasia. J Pediatr 80:292–297, 1972  	5008828
	2. Delepine M, Nicolino M, Barrett T, Golamaully M, Lathrop GM, Julier C:  EIF2AK3, encoding translation initiation factor 2-alpha kinase 3, is mu tated in patients with Wolcott-Rallison syndrome. Nat Genet 25:406–409,  2000  	10932183
	3. Harding HP, Zhang Y, Ron D: Translation and protein folding are coupled  by the endoplasmic reticulum resident kinase. Nature 397:271–274, 1992  	NO_MATCH
	4. Shi Y, Vattem KA, Sood R, An J, Liang J, Stramm L, Wek R: Identification and  characterization of pancreatic eukaryotic initiation factor 2-subunit kinase,  PEK, involved in translational control. Mol Cell Biol 18:7499–7509, 1998  	9819435
	5. Bertolotti A, Zhang Y, Hendershot LM, Harding HP, Ron D: Dynamic  interaction of BiP and ER stress transducers in the unfolded-protein  response. Nature Cell Biol 2:326–332, 2000  	10854322
	6. Liu CY, Schroder M, Kaufman RJ: Ligand-independent dimerization acti vates the stress response kinases IRE1 and PERK in the lumen of the  endoplasmic reticulum. J Biol Chem 275:24881–24885, 2000  	10835430
	7. Harding HP, Zeng H, Zhang Y, Jungries R, Chung P, Plesken H, Sabatini DD,  Ron D: Diabetes mellitus and exocrine pancreas dysfunction in Perk –/–  mice reveals a role for translational control in secretory cell survival. Mol  	11430819
	8. Thorton CM, Carson DJ, Stewart FJ: Autopsy findings in the Wolcott Rallison syndrome. Pediatr Pathol Lab Med 17:487–496, 1997  	9185226
	9. Von Mu¨hlendahl KE, Herkenhoff H: Long-term course of neonatal diabetes.  N Engl J Med 333:704–708, 1995  	7637748
	10. Scheuner D, Song B, McEwen E, Liu C, Laybutt R, Gillespie P, Saunders T,  Bonner-Weir S, Kaufman RJ: Translational control is required for the  unfolded protein response and in vivo glucose homeostasis. Mol Cell  	11430820
2264.full.pdf
	1. Wakisaka M, He Q, Spiro MJ, Spiro RG: Glucose entry into rat mesangial  cells is mediated by both Na-coupled and facilitative transporters.  Diabetologia 38:291–297, 1995  	7758875
	2. Heilig CW, Liu Y, England RL, Freytag SO, Gilbert JD, Heilig KO, Zhu M,  Concepcion LA, Brosius FC III: D-glucose stimulates mesangial cell GLUT1  expression and basal and IGF-1–sensitive glucose uptake in rat mesangial  cells: implications for diabetic nephropathy. Diabetes 46:1030–1039, 1997  	9166676
	3. Larkins RG, Dunlop ME: The link between hyperglycemia and diabetic  nephropathy. Diabetologia 35:499–504, 1992  	1612221
	4. Vlassara H: Recent progress in advanced glycation end products and  diabetic complications. Diabetes 46 (Suppl. 2):S19–S25, 1997  	9285494
	5. Koya D, King GL: Protein kinase C activation and the development of  diabetic complications (Review). Diabetes 47:859–866, 1998  	9604860
	6. Heilig CW, Concepcion LA, Riser BL, Freytag SO, Zhu M, Cortes P:  Overexpression of glucose transporters in rat mesangial cells cultured in a  normal glucose milieu mimics the diabetic phenotype. J Clin Invest  96:1802–1814, 1995  	7560072
	7. Heilig CW, Brosius FC III, Henry DN: Glucose transporters of the glomer ulus and the implications for diabetic nephropathy. Kidney Int 60:S91–  S99, 1997  	9285909
	8. Mogyorosi A, Ziyadeh FN: GLUT1 and TGF-: the link between hypergly caemia and diabetic nephropathy. Nephrol Dial Transplant 14:2827–2829,  1999  	10570081
	9. Gutierrez C, Vendrell J, Pastor R, Broch M, Aguilar C, Llor C, Simon I,  Richart C: GLUT1 gene polymorphism in non-insulin-dependent diabetes  mellitus: genetic susceptibility relationship with cardiovascular risk fac tors and microangiopathic complications in a Mediterranean population.  Diabetes Res Clin Pract 41:113–120, 1998  	9789717
	10. Liu ZH, Guan TJ, Chen ZH, Li LS: Glucose transporter (GLUT1) allele  (XbaI-) associated with nephropathy in non-insulin-dependent diabetes  mellitus. Kidney Int 55:1843–1848, 1999  	10231446
	11. Grzeszczak W, Moczulski DK, Zychma M, Zukowska-Szczechowska E,  Trautsolt W, Szydlowska I: Role of GLUT1 gene in susceptibility to diabetic  nephropathy in type 2 diabetes. Kidney Int 59:631–636, 2001  	11168944
	12. Hodgkinson AD, Millward BA, Demaine AG: Polymorphisms of the glucose  transporter (GLUT1) gene are associated with diabetic nephropathy.  Kidney Int 59:985–989, 2001  	11231353
	13. Tarnow L, Grarup N, Hansen T, Parving HH, Pedersen O: Diabetic  microvascular complications are not associated with two polymorphisms  in the GLUT-1 and PC-1 genes regulating glucose metabolism in Caucasian  type 1 diabetic patients. Nephrol Dial Transplant 16:1653–1656, 2001  	11477169
	14. Murakami T, Nishiyama T, Shirotani T, Shinohara Y, Kan M, Ishii K, Kanai  F, Nakazuru S, Ebina Y: Identification of two enhancer elements in the  gene encoding the type 1 glucose transporter from the mouse which are  responsive to serum, growth factor and oncogenes. J Biol Chem 267:9300–  9306, 1992  	1339457
	15. Behrooz A, Ismail-Beigi F: Dual control of Glut1 glucose transporter gene  expression by hypoxia and by inhibition of oxidative phosphorylation.  J Biol Chem 272:5555–5562, 1997  	9038162
	16. Tao T, Tanizawa Y, Matsutani A, Matsubara A, Kaneko T, Kaku K:  HepG2/erythrocyte glucose transporter (GLUT1) gene in NIDDM: a popu lation association study and molecular scanning in Japanese subjects.  Diabetologia 38:942–947, 1995  	7589880
	17. Warram JH, Gearin G, Laffel L, Krolewski AS: Effect of duration of type 1  diabetes on the prevalence of stages of diabetic nephropathy defined by  urinary albumin/creatinine ratio. J Am Soc Nephrol 7:930–937, 1996  	8793803
	18. Fukumoto H, Seino S, Imura H, Seino Y, Bell GI: Characterization and  expression of human HepG2/erythrocyte glucose-transporter gene. Diabe tes 37:657–661, 1988  	2834252
	19. Shows TB, Eddy RL, Byers MG, Fukushima Y, Dehaven CR, Murray JC,  Bell GI: Polymorphic human glucose transporter gene (GLUT) is on  chromosome 1p31.33p35. Diabetes 36:546–549, 1987  	3028891
	20. Araki S, Moczulski DK, Hanna L, Scott LJ, Warram JH, Krolewski AS:  APOE polymorphisms and the development of diabetic nephropathy in  Type 1 diabetes: results of case-control and family based studies. Diabetes  49:2190–2195, 2000  	11118024
	21. Terwillinger J, Ott J: Handbook of Human Genetic Linkage. Baltimore,  MD, John Hopkins University, 1994, p. 188–198  	NO_MATCH
	22. Hennekens CH, Buring JE: Epidemiology in Medicine. Mayrent SL, Ed.  Boston, Little, Brown and Company, p. 54–98  	16016475
	23. Baroni MG, D’Andrea MP, Capici F, Buzzetti R, Cavallo MG, Fallucca F,  Giovannini C, Pozzilli P: High frequency of polymorphism but no mutations  found in the GLUT1 glucose transporter gene in NIDDM and familial  obesity by SSCP analysis. Hum Genet 102:479–482, 1998  	9600248
	24. Todaka M, Nishiyama T, Murakami T, Saito S, Ito K, Kanai F, Kan M, Ishii  K, Hayashi H, Shichiri M, Ebina Y: The role of insulin in activation of two  enhancers in the mouse GLUT1 gene. J Biol Chem 269:29265–29270, 1994  	7961896
	25. LeFrancois-Martinez AM, Martinez A, Antoine B, Raymondjean M, Kahn A:  Upstream stimulatory factor proteins are major components of the glucose  response complex of the L-type pyruvate kinase gene promoter. J Biol  Chem 270:2640–2643, 1995  	7852331
	26. Travers MT, Vallance AJ, Gourlay HT, Gill CA, Klein I, Bottema CB, Barber  MC: Promoter I of the ovine acteyl-CoA carboxylase-a´ gene: an E-box motif  at 	114 in the proximal promoter binds upstream stimulatory factor  (USF)-1 and USF-2 and acts as an insulin-response sequence in differen tiating adipocytes. Biochem J 359:273–284, 2001  	11583573
	27. Arnqvist HJ, Ballermann BJ, King GL: Receptors for and effects of insulin  and IGF-I in rat glomerular mesangial cells. Am J Physiol 254:C411–C416,  1988  	3279808
	28. Henry DN, Busik JV, Brosius FC III, Heilig CW: Glucose transporters  control gene expression of aldose reductase, PKC, and GLUT1 in  mesangial cells in vitro. Am J Physiol 277: F97–F104, 1999  	10409302
	29. Du XL, Edelstein D, Rossetti L, Fantus IG, Goldberg H, Ziyadeh F, Wu J,  Brownlee M: Hyperglycemia-induced mitochondrial superoxide overpro duction activates the hexosamine pathway and induces plasminogen  activator inhibitor-1 expression by increasing Sp1 glycosylation. Proc Natl  Acad Sci U S A 97:12222–12226, 2000  	11050244
1562.pdf
	1. Bedard, D. L., R. Unterman, L. H. Bopp, M. J. Brennan, M. L. Haberl, and  C. Johnson. 1986. Rapid assay for screening and characterizing microorgan isms for the ability to degrade polychlorinated biphenyls. Appl. Environ.  Microbiol. 51:761–768.  	3085588
	2. Bedard, D. L., R. E. Wagner, M. J. Brennan, M. L. Haberl, and J. F. Brown,  Jr. 1987. Extensive degradation of Aroclors and environmentally trans formed polychlorinated biphenyls by Alcaligenes eutrophus H850. Appl. En viron. Microbiol. 53:1094–1102.  	3111365
	3. Bedard, D. L., and M. L. Haberl. 1990. Influence of chlorine substitution  pattern on the degradation of polychlorinated biphenyls by eight bacterial  strains. Microb. Ecol. 20:87–102.  	NO_MATCH
	4. Beil, S., J. R. Mason, K. N. Timmis, and D. H. Pieper. 1998. Identification of  chlorobenzene dioxygenase sequence elements involved in dechlorination of  1,2,4,5-tetrachlorobenzene. J. Bacteriol. 180:5520–5528.  	9791099
	5. Brühlmann, F., and W. Chen. 1999. Tuning biphenyl dioxygenase for ex tended substrate specificity. Biotechnol. Bioeng. 63:544–551.  	10397810
	6. Butler, C. S., and J. R. Mason. 1997. Structure-function analysis of the  bacterial aromatic ring-hydroxylating dioxygenases. Adv. Microb. Physiol.  38:47–84.  	8922118
	7. Carredano, E., A. Karlsson, B. Kauppi, D. Choudhury, R. E. Parales, J. V.  Parales, K. Lee, D. T. Gibson, H. Eklund, and S. Ramaswamy. 2000. Sub strate binding site of naphthalene 1,2-dioxygenase: functional implications of  indole binding. J. Mol. Biol. 296:701–712.  	10669618
	8. Erickson, B. D., and F. J. Mondello. 1993. Enhanced biodegradation of  polychlorinated biphenyls after site-directed mutagenesis of a biphenyl di oxygenase gene. Appl. Environ. Microbiol. 59:3858–3862.  	8285689
	9. Furukawa, K., N. Tomizuka, and A. Kamibayashi. 1979. Effect of chlorine  substitution on the bacterial metabolism of various polychlorinated biphe nyls. Appl. Environ. Microbiol. 38:301–310.  	117752
	10. Furukawa, K. 1982. Microbial degradation of polychlorinated biphenyls, p.  33–57. In A. M. Chakrabarty (ed.), Biodegradation and detoxification of  environmental pollutants. CRC Press, Boca Raton, Fla.  	NO_MATCH
	11. Furukawa, K., and T. Miyazaki. 1986. Cloning of gene cluster encoding  biphenyl degradation in Pseudomonas pseudoalcaligenes. J. Bacteriol. 166:  392–398.  	NO_MATCH
	12. Furukawa, K. 1994. Molecular genetics and evolutionary relationship of  PCB-degrading bacteria. Biodegradation 5:289–300.  	7765839
	13. Gibson, D. T., D. L. Cruden, J. D. Haddock, G. J. Zlstra, and J. M. Brand.  1993. Oxidation of polychlorinated biphenyls by Pseudomonas sp. strain  LB400 and Pseudomonas pseudoalcaligenes KF707. J. Bacteriol. 175:4561–  4564.  	8331086
	14. Graham-Lorence, S., M. W. Khalil, M. C. Lorence, C. R. Mendelson, and  E. R. Simpson. 1991. Structure-function relationships of human aromatase  cytochrome P-450 by using molecular modeling and site-directed mutagen esis. J. Biol. Chem. 266:11939–11946.  	2050688
	15. Haddock, J. D., J. R. Horton, and D. T. Gibson. 1995. Dihydroxylation and  dechlorination of chlorinated biphenyls by purified biphenyl 2,3-dioxygenase  from Pseudomonas sp. strain LB400. J. Bacteriol. 177:20–26.  	8002618
	16. Hegg, E. L., and L. Que, Jr. 1997. The 2-His-1-carboxylate facial triad—an  emerging structural motif in mononuclear nonheme iron(II) enzymes. Eur.  J. Biochem. 250:625–629.  	9461283
	17. Hirose, J., A. Suyama, S. Hayashida, and K. Furukawa. 1994. Construction  of hybrid biphenyl (bph) and toluene (tod) genes for functional analysis of  aromatic ring dioxygenases. Gene 138:27–33.  	8125315
	18. Hurtubise, Y., D. Barriault, and M. Sylvestre. 1998. Involvement of the  terminal oxygenase  subunit in the biphenyl dioxygenase reactivity pattern  for chlorobiphenyls. J. Bacteriol. 180:5828–5835.  	9811638
	19. Iwasaki, M., T. A. Darden, L. G. Pedersen, D. G. Davis, R. O. Juvonen, T.  Sueyoshi, and M. Negishi. 1993. Engineering mouse P450coh to a novel  corticosterone 15 alpha-hydroxylase and modeling steroid-binding orienta tion in the substrate pocket. J. Biol. Chem. 268:759–762.  	8419350
	20. Iwasaki, M., T. A. Darden, C. E. Perker, K. B. Tomer, L. G. Pedersen, and  M. Negishi. 1994. Inherent versatility of P450 oxygenase. Conferring dehy droepiandrosterone hydroxylase activity to P450 2a-4 by a single amino acid  mutation at position 117. J. Biol. Chem. 269:9079–9083.  	8132645
	21. Jiang, H., R. E. Parales, N. A. Lynch, and D. T. Gibson. 1996. Site-directed  mutagenesis of conserved amino acids in the  subunit of toluene dioxyge nase: potential mononuclear nonheme iron coordination sites. J. Bacteriol.  178:3133–3139.  	8655491
	22. Kauppi, B., K. Lee, E. Carredano, R. E. Parales, D. T. Gibson, H. Eklund,  and S. Ramaswamy. 1998. Structure of an aromatic ring-hydroxylating di oxygenase-naphthalene 1,2-dioxygenase. Structure 6:571–586.  	9634695
	23. Kimura, N., A. Nishi, M. Goto, and K. Furukawa. 1997. Functional analyses  of a variety of chimeric dioxygenases constructed from two biphenyl dioxy genases that are similar structurally but different functionally. J. Bacteriol.  179:3936–3943.  	9190809
	24. Kumamaru, T., H. Suenaga, M. Mitsuoka, T. Watanabe, and K. Furukawa.  1998. Enhanced degradation of polychlorinated biphenyls by directed evo lution of biphenyl dioxygenase. Nat. Biotechnol. 16:663–666.  	9661201
	25. Maeda, T., Y. Takahashi, H. Suenaga, A. Suyama, M. Goto, and K. Fu rukawa. 2001. Functional analyses of Bph-Tod hybrid dioxygenase, which  exhibits high degradation activity for trichloroethylene. J. Biol. Chem. 276:  29833–29838.  	11390387
	26. Mason, J. R., and R. Cammack. 1992. The electron-transport proteins of  hydroxylating bacterial dioxygenases. Annu. Rev. Microbiol. 46:277–305.  	1444257
	27. Masse, R., F. Messier, L. Peloquin, C. Ayotte, and M. Sylvestre. 1984.  Microbial biodegradation of 4-chlorobiphenyl, a model compound of chlo rinated biphenyls. Appl. Environ. Microbiol. 47:947–951.  	6742836
	28. Mondello, F. J. 1989. Cloning and expression in Escherichia coli of Pseudo monas strain LB400 genes encoding polychlorinated biphenyl degradation. J.  Bacteriol. 171:1725–1732.  	2493454
	29. Mondello, F. J., M. P. Turcich, J. H. Lobos, and B. D. Erickson. 1997.  Identification and modification of biphenyl dioxygenase sequence that de termine the specificity of polychlorinated biphenyl degradation. Appl. Envi ron. Microbiol. 63:3096–3103.  	9251195
	30. Parales, R. E., J. V. Parales, and D. T. Gibson. 1999. Aspartate 205 in the  catalytic domain of naphthalene dioxygenase is essential for activity. J. Bac teriol. 181:1831–1837.  	10074076
	31. Parales, R. E., S. M. Resnick, C.-L. Yu, D. R. Boyd, N. D. Sharma, and D. T.  Gibson. 2000. Regioselectivity and enantioselectivity of naphthalene dioxy genase during arene cis-dihydroxylation: control by phenylalanine 352 in the   subunit. J. Bacteriol. 182:5495–5504.  	10986254
	32. Parales, R. E., K. Lee, S. M. Resnick, H. Jiang, D. J. Lessner, and D. T.  Gibson. 2000. Substrate specificity of naphthalene dioxygenase: effect of  specific amino acids at the active site of the enzyme. J. Bacteriol. 182:1641–  1649.  	10692370
	33. Pikus, J. D., J. M. Studts, K. McClay, R. J. Steffan, and B. G. Fox. 1997.  Changes in the regiospecificity of aromatic hydroxylation produced by active  site engineering in the diiron enzyme toluene 4-monooxygenase. Biochem istry 36:9283–9289.  	9280437
	34. Poulos, T. L., B. C. Finzel, I. C. Gunsalus, G. C. Wagner, and J. Kraut. 1985.  The 2.6-A crystal structure of Pseudomonas putida cytochrome P-450. J. Biol.  Chem. 260:16122–16130.  	4066706
	35. Poulos, T. L., B. C. Finzel, and A. Howard. 1987. High-resolution crystal  structure of cytochrome P450. J. Mol. Biol. 195:687–700.  	3656428
	36. Seeger, M., M. Zielinski, K. N. Timmis, and B. Hofer. 1999. Regiospecificity  of dioxygenation of di- to pentachlorobiphenyls and their degradation to  chlorobenzoates by bph-encoded catabolic pathway of Burkholderia sp. strain  LB400. Appl. Environ. Microbiol. 65:3614–3621.  	10427057
	37. Suenaga, H., A. Nishi, T. Watanabe, M. Sakai, and K. Furukawa. 1999.  Engineering a hybrid Pseudomonad to acquire 3,4-dioxygenase activity for  polychlorinated biphenyls. J. Biosci. Bioeng. 87:430–435.  	NO_MATCH
	38. Suenaga, H., M. Goto, and K. Furukawa. 2001. Emergence of multifunc tional oxygenase activities by random priming recombination. J. Biol. Chem.  276:22500–22506.  	11312272
	39. Suenaga, H., M. Mitsuoka, Y. Ura, T. Watanabe, and K. Furukawa. 2001.  Directed evolution of biphenyl dioxygenase: emergence of enhanced degra dation capacity for benzene, toluene, and alkylbenzenes. J. Bacteriol. 183:  5441–5444.  	11514531
	40. Sylvestre, M., and M. Sondossi. 1994. Selection of enhanced polychlorinated  biphenyl-degrading bacterial strains for bioremediation: consideration of  branching pathways, p. 47–73. In G. R. Chaudhry (ed.), Biological degrada tion and bioremediation of toxic chemicals. Dioscorides Press, Portland,  Oreg.  	NO_MATCH
	41. Szklarz, G. D., Y. A. He, and J. R. Halpert. 1995. Site-directed mutagenesis  as a tool for molecular modeling of cytochrome P450 2B1. Biochemistry  34:14312–14322.  	7578035
	42. Taira, K., J. Hirose, S. Hayashida, and K. Furukawa. 1992. Analysis of bph  operon from the polychlorinated biphenyl-degrading strain of Pseudomonas  pseudoalcaligenes KF707. J. Biol. Chem. 267:4844–4853.  	1537863
1459.pdf
	1. Akiyama, Y., A. Kihara, H. Tokuda, and K. Ito. 1996. FtsH (HflB) is an  ATP-dependent protease selectively acting on SecY and some other mem brane proteins. J. Biol. Chem. 271:31196–31201.  	8940120
	2. Amerik, A., V. K. Antonov, A. E. Gorbalenya, S. A. Kotova, T. V. Rotanova,  and E. V. Shimbarevich. 1991. Site-directed mutagenesis of La protease. A  catalytically active serine residue. FEBS Lett. 287:211–214.  	1652461
	3. Black, M. J., and M. E. Jones. 1983. Inorganic phosphate determination in  the presence of a labile organic phosphate: assay for carbamyl phosphate  phosphatase activity. Anal. Biochem. 135:233–238.  	6322612
	4. Bochtler, M., C. Hartmann, H. K. Song, G. P. Bourenkov, H. D. Bartunik,  and R. Huber. 2000. The structures of HsIU and the ATP-dependent pro tease HsIU-HsIV. Nature 403:800–805.  	10693812
	4a.Bradford, M. M. 1976. A rapid and sensitive method for the quantitation of  microgram quantities of protein utilizing the principle of protein-dye bind ing. Anal. Biochem. 72:248–254.  	942051
	5. Chin, D. T., S. A. Goff, T. Webster, T. Smith, and A. L. Goldberg. 1988.  Sequence of the lon gene in Escherichia coli. A heat-shock gene which  encodes the ATP-dependent protease La. J. Biol. Chem. 263:11718–11728.  	3042779
	6. Chung, C. H., and A. L. Goldberg. 1981. The product of the lon (capR) gene  in Escherichia coli is the ATP-dependent protease, protease La. Proc. Natl.  Acad. Sci. USA 78:4931–4935.  	6458037
	7. Ebel, W., M. M. Skinner, K. P. Dierksen, J. M. Scott, and J. E. Trempy. 1999.  A conserved domain in Escherichia coli Lon protease is involved in substrate  discriminator activity. J. Bacteriol. 181:2236–2243.  	10094703
	8. Ezaki, S., N. Maeda, T. Kishimoto, H. Atomi, and T. Imanaka. 1999. Pres ence of a structurally novel type ribulose-bisphosphate carboxylase/oxygen ase in the hyperthermophilic archaeon, Pyrococcus kodakaraensis KOD1.  J. Biol. Chem. 274:5078–5082.  	9988755
	9. Fischer, H., and R. Glockshuber. 1993. ATP hydrolysis is not stoichiomet rically linked with proteolysis in the ATP-dependent protease La from Esch erichia coli. J. Biol. Chem. 268:22502–22507.  	8226758
	10. Frank, E. G., D. G. Ennis, M. Gonzalez, A. S. Levine, and R. Woodgate. 1996.  Regulation of SOS mutagenesis by proteolysis. Proc. Natl. Acad. Sci. USA  93:10291–10296.  	8816793
	11. Goldberg, A. L., R. P. Moerschell, C. H. Chung, and M. R. Maurizi. 1994.  ATP-dependent protease La (Lon) from Escherichia coli. Methods Enzymol.  244:350–375.  	7845219
	12. Goldberg, A. L., and L. Waxman. 1985. The role of ATP hydrolysis in the  breakdown of proteins and peptides by protease La from Escherichia coli.  J. Biol. Chem. 260:12029–12034.  	2931432
	13. Gottesman, S. 1999. Regulation by proteolysis: developmental switches.  Curr. Opin. Microbiol. 2:142–147.  	10322171
	14. Gottesman, S., and M. R. Maurizi. 1992. Regulation by proteolysis: energy dependent proteases and their targets. Microbiol. Rev. 56:592–621.  	1480111
	15. Gottesman, S., M. R. Maurizi, and S. Wickner. 1997. Regulatory subunits of  energy-dependent proteases. Cell 91:435–438.  	9390551
	16. Gottesman, S., and D. Zipser. 1978. Deg phenotype of Escherichia coli lon  mutants. J. Bacteriol. 133:844–851.  	146704
	17. Grossman, A. D., R. R. Burgess, W. Walter, and C. A. Gross. 1983. Mutations  in the Lon gene of E. coli K12 phenotypically suppress a mutation in the  sigma subunit of RNA polymerase. Cell 32:151–159.  	6337720
	18. Hashimoto, H., M. Nishioka, S. Fujiwara, M. Takagi, T. Imanaka, T. Inoue,  and Y. Kai. 2001. Crystal structure of DNA polymerase from hyperthermo philic archaeon Pyrococcus kodakaraensis KOD1. J. Mol. Biol. 306:469–477.  	11178906
	19. Hoskins, J. R., M. Pak, M. R. Maurizi, and S. Wickner. 1998. The role of the  ClpA chaperone in proteolysis by ClpAP. Proc. Natl. Acad. Sci. USA 95:  12135–12140.  	9770452
	20. Hoskins, J. R., S. K. Singh, M. R. Maurizi, and S. Wickner. 2000. Protein  binding and unfolding by the chaperone ClpA and degradation by the pro tease ClpAP. Proc. Natl. Acad. Sci. USA 97:8892–8897.  	10922051
	21. Jubete, Y., M. R. Maurizi, and S. Gottesman. 1996. Role of the heat shock  protein DnaJ in the lon-dependent degradation of naturally unstable pro teins. J. Biol. Chem. 271:30798–30803.  	8940060
	22. Kessel, M., M. R. Maurizi, B. Kim, E. Kocsis, B. L. Trus, S. K. Singh, and  A. C. Steven. 1995. Homology in structural organization between E. coli  ClpAP protease and the eukaryotic 26 S proteasome. J. Mol. Biol. 250:587–  594.  	7623377
	23. Kihara, A., Y. Akiyama, and K. Ito. 1998. Different pathways for protein  degradation by the FtsH/HflKC membrane-embedded protease complex: an  implication from the interference by a mutant form of a new substrate  protein, YccA. J. Mol. Biol. 279:175–188.  	9636708
	24. Kitano, K., N. Maeda, T. Fukui, H. Atomi, T. Imanaka, and K. Miki. 2001.  Crystal structure of a novel-type archaeal Rubisco with pentagonal symme try. Structure 9:473–481.  	11435112
	25. Larimore, F. S., L. Waxman, and A. L. Goldberg. 1982. Studies of the  ATP-dependent proteolytic enzyme, protease La, from Escherichia coli.  J. Biol. Chem. 257:4187–4195.  	7040380
	26. Maeda, N., K. Kitano, T. Fukui, S. Ezaki, H. Atomi, K. Miki, and T.  Imanaka. 1999. Ribulose bisphosphate carboxylase/oxygenase from the hy perthermophilic archaeon Pyrococcus kodakaraensis KOD1 is composed  solely of large subunits and forms a pentagonal structure. J. Mol. Biol.  293:57–66.  	10512715
	27. Maupin-Furlow, J. A., H. C. Aldrich, and J. G. Ferry. 1998. Biochemical  characterization of the 20S proteasome from the methanoarchaeon Meth anosarcina thermophila. J. Bacteriol. 180:1480–1487.  	9515917
	28. Maurizi, M. R. 1987. Degradation in vitro of bacteriophage lambda N pro tein by Lon protease from Escherichia coli. J. Biol. Chem. 262:2696–2703.  	2950089
	29. Menon, A. S., and A. L. Goldberg. 1987. Binding of nucleotides to the  ATP-dependent protease La from Escherichia coli. J. Biol. Chem.  262:14921–14928.  	3312196
	30. Menon, A. S., and A. L. Goldberg. 1987. Protein substrates activate the  ATP-dependent protease La by promoting nucleotide binding and release of  bound ADP. J. Biol. Chem. 262:14929–14934.  	3312197
	31. Mizusawa, S., and S. Gottesman. 1983. Protein degradation in Escherichia  coli: the lon gene controls the stability of sulA protein. Proc. Natl. Acad. Sci.  USA 80:358–362.  	6300834
	32. Morikawa, M., Y. Izawa, N. Rashid, T. Hoaki, and T. Imanaka. 1994. Puri fication and characterization of a thermostable thiol protease from a newly  isolated hyperthermophilic Pyrococcus sp. Appl. Environ. Microbiol. 60:  4559–4566.  	7811092
	33. Nakatani, M., S. Ezaki, H. Atomi, and T. Imanaka. 2000. A DNA ligase from  a hyperthermophilic archaeon with unique cofactor specificity. J. Bacteriol.  182:6424–6433.  	11053387
	34. Neuwald, A. F., L. Aravind, J. L. Spouge, and E. V. Koonin. 1999. AAA: a  class of chaperone-like ATPases associated with the assembly, operation,  and disassembly of protein complexes. Genome Res. 9:27–43.  	9927482
	35. Rep, M., J. M. van Dijl, K. Suda, G. Schatz, L. A. Grivell, and C. K. Suzuki.  1996. Promotion of mitochondrial membrane complex assembly by a pro teolytically inactive yeast Lon. Science 274:103–106.  	8810243
	36. Sambrook, J., and D. W. Russell. 2001. Molecular cloning: a laboratory  manual, 3rd ed. Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y.  	NO_MATCH
	37. Schumann, W. 1999. FtsH—a single-chain charonin? FEMS Microbiol. Rev.  23:1–11.  	10077851
	38. Seemuller, E., A. Lupas, D. Stock, J. Lowe, R. Huber, and W. Baumeister.  1995. Proteasome from Thermoplasma acidophilum: a threonine protease.  Science 268:579–582.  	7725107
	39. Singh, S. K., R. Grimaud, J. R. Hoskins, S. Wickner, and M. R. Maurizi.  2000. Unfolding and internalization of proteins by the ATP-dependent pro teases ClpXP and ClpAP. Proc. Natl. Acad. Sci. USA 97:8898–8903.  	10922052
	40. Smith, C. K., T. A. Baker, and R. T. Sauer. 1999. Lon and Clp family  proteases and chaperones share homologous substrate-recognition domains.  Proc. Natl. Acad. Sci. USA 96:6678–6682.  	10359771
	41. Sousa, M. C., C. B. Trame, H. Tsuruta, S. M. Wilbanks, V. S. Reddy, and  D. B. McKay. 2000. Crystal and solution structures of an HslUV protease chaperone complex. Cell 103:633–643.  	11106733
	42. Starkova, N. N., E. P. Koroleva, L. D. Rumsh, L. M. Ginodman, and T. V.  Rotanova. 1998. Mutations in the proteolytic domain of Escherichia coli  protease Lon impair the ATPase activity of the enzyme. FEBS Lett. 422:  218–220.  	9490010
	43. Straus, D. B., W. A. Walter, and C. A. Gross. 1988. Escherichia coli heat  shock gene mutants are defective in proteolysis. Genes Dev. 2:1851–1858.  	3149251
	44. Swamy, K. H., and A. L. Goldberg. 1981. E. coli contains eight soluble  proteolytic activities, one being ATP dependent. Nature 292:652–654.  	7019728
	45. Takagi, M., M. Nishioka, H. Kakihara, M. Kitabayashi, H. Inoue, B.  Kawakami, M. Oka, and T. Imanaka. 1997. Characterization of DNA poly merase from Pyrococcus sp. strain KOD1 and its application to PCR. Appl.  Environ. Microbiol. 63:4504–4510.  	9361436
	46. Tomoyasu, T., K. Yamanaka, K. Murata, T. Suzaki, P. Bouloc, A. Kato, H.  Niki, S. Hiraga, and T. Ogura. 1993. Topology and subcellular localization of  FtsH protein in Escherichia coli. J. Bacteriol. 175:1352–1357.  	8444797
	47. Torres-Cabassa, A. S., and S. Gottesman. 1987. Capsule synthesis in Esch erichia coli K-12 is regulated by proteolysis. J. Bacteriol. 169:981–989.  	3029041
	48. van Melderen, L., M. H. D. Thi, P. Lecchi, S. Gottesman, M. Couturier, and  M. R. Maurizi. 1996. ATP-dependent degradation of CcdA by Lon protease.  Effects of secondary structure and heterologous subunit interactions. J. Biol.  Chem. 271:27730–27738.  	8910366
	49. Wang, J., J. A. Hartling, and J. M. Flanagan. 1997. The structure of ClpP at  2.3 Å resolution suggests a model for ATP-dependent proteolysis. Cell 91:  447–456.  	9390554
	50. Wang, J., J. J. Song, M. C. Franklin, S. Kamtekar, Y. J. Im, S. H. Rho, I. S.  Seong, C. S. Lee, C. H. Chung, and S. H. Eom. 2001. Crystal structures of the  HslVU peptidase-ATPase complex reveal an ATP-dependent proteolysis  mechanism. Structure 9:177–184.  	11250202
	51. Watanabe, S., T. Muramatsu, H. Ao, Y. Hirayama, K. Takahashi, M. Tano kura, and Y. Kuchino. 1999. Molecular cloning of the Lon protease gene  from Thermus thermophilus HB8 and characterization of its gene product.  Eur. J. Biochem. 266:811–819.  	10583374
	52. Waxman, L., and A. L. Goldberg. 1985. Protease La, the lon gene product,  cleaves specific fluorogenic peptides in an ATP-dependent reaction. J. Biol.  Chem. 260:12022–12028.  	3900067
	53. Waxman, L., and A. L. Goldberg. 1986. Selectivity of intracellular proteoly sis: protein substrates activate the ATP-dependent protease (La). Science  232:500–503.  	2938257
	54. Wickner, S., and M. R. Maurizi. 1999. Here’s the hook: similar substrate  binding sites in the chaperone domains of Clp and Lon. Proc. Natl. Acad. Sci.  USA 96:8318–8320.  	10411867
	55. Wickner, S., M. R. Maurizi, and S. Gottesman. 1999. Posttranslational qual ity control: folding, refolding, and degrading proteins. Science 286:1888–  1893.  	10583944
	56. Zwickl, P., D. Ng, K. M. Woo, H. P. Klenk, and A. L. Goldberg. 1999. An  archaebacterial ATPase, homologous to ATPases in the eukaryotic 26S  proteasome, activates protein breakdown by 20S proteasomes. J. Biol. Chem.  274:26008–26014.  	10473546
12051215.pdf
	1. National Audit Office. The performance of the NHS cervical  screening programme in England: report by the comptroller and  auditor general. London: Stationery Office, 1998.  	NO_MATCH
	2. Quinn MJ, Babb PJ, Jones J, Allen E. Effect of screening on inci dence and mortality from cancer of the cervix: evaluation based  on routinely collected statistics. BMJ 1999; 318: 904-908.  	10102852
	3. Parkin DM, Nguyen-Dinh X, Day N. The impact of screening on  the incidence of cervical cancer in England and Wales. Br J  Obstet Gynaecol 1985; 92: 150-157.  	3970894
	4. Sasieni PD, Cuzick J, Lynch-Farmery E, NCN Working Group.  Estimating the efficacy of screening by auditing smear histories of  women with and without cervical cancer. Br J Cancer 1996; 73:  1001-1005.  	NO_MATCH
	5. Cervical Screening Programme, England: 1999-2000. Department  of Health Statistical Bulletin 2000/30 London, 2000.  	NO_MATCH
	6. Cockburn J, Redman S, Mill D, Henry E. Public understanding of  medical screening. J Med Screening 1995; 2: 224-227.  	8719153
	7. NHS Executive South Thames. Review of cervical screening ser vices at Kent and Canterbury Hospitals NHS Trust. London: NHS  Executive South Thames, 1995.  	NO_MATCH
	8. Leicester Health Authority. An audit of cervical screening in  Leicestershire. Leicester: Leicester Health Authority, 2001.  	12171231
	9. Wilson S. Cervical cancer screening. In: Marshall MN, Campbell  S, Hacker J, Roland M (eds). Quality indicators for general prac tice; a practical guide to clinical quality indicators for primary care  health professionals and managers. London: Royal Society of  Medicine Press Ltd, 2001.  	NO_MATCH
	10. Sawaya GF, Brown AD, Washington AE, Garber AM. Current  approaches to cervical screening. N Engl J Med 2001; 34(21):  1603-1607.  	NO_MATCH
	11. McMeekin DS, McGonigle KF, Vasilev SA. Cervical cancer preven tion: towards cost-effective screening. Medscape Womens Health  1997; 2(12): 1. http://www.medscape.com  	NO_MATCH
	12. Strabanek P, McCormick J. Follies and fallacies in medicine.  Whithorn, Dumfries: Tarragon Press, 1998; 102-117.  	NO_MATCH
	13. Lea R. Healthcare in the UK: the need for reform. Institute of  Directors policy paper. London: Institute of Directors, 2000.  	NO_MATCH
	14. Bryant J, Stevens A. Cervical screening interval. R&D Directorate,  South and West Regional Health Authority, 1995.  	7748639
	15. Cancer Research Campaign. Cancer of the cervix uteri. Factsheet  12.2 1994.  	NO_MATCH
	16. Wilson JMG, Junger G. Principles and practice of screening for  disease. [Public Health Papers, No 34.] Geneva: WHO, 1968.  	4234760
	17. Cadman D, Chambers L, Feldman W, Sackett D. Assessing the  effectiveness of community screening programmes. JAMA 1984;  251: 1580-1585.  	6700057
	18. Sasieni PD. Use of routine data to monitor and evaluate cervical  screening. In: Duffy SW, Hill C, Esteve J (eds). Quantitative  Methods for the Evaluation of Cancer Screening. London: Arnold,  2001; 93-105.  	NO_MATCH
	19. Ostor AG. Natural history of cervical intra-epithelial neoplasia: a  critical review. Int J Gynecol Pathol 1993; 12: 186-192.  	8463044
	20. Campion MJ, McCance DJ, Cuzick J, Singer A. Progressive  potential of mild cervical atypia: prospective cytological, colpo scopic and virological study. Lancet 1986; 2: 237-240.  	2874275
	21. Holowaty P, Miller AB, Rohan T, To T. The natural history of dyspla sia of the uterine cervix. J Natl Cancer Inst 1999; 91: 252-258.  	10037103
	22. Richart RM, Barron BA. A follow-up study of patients with cervical  dysplasia. Am J Obstet Gynecol 1969; 105: 386-393.  	5810787
	23. Richart RM, Barron BA. Screening strategies for cervical cancer  and cervical intraepithelial neoplasia. Cancer 1981; 47(suppl 5):  1176-1181.  	7237375
	24. Woodman C, Collins S, Winter H, et al. Natural history of cervical  human papillomavirus infection in young women: a longitudinal  cohort study. Lancet 2001; 357: 1831-1836.  	11410191
	25. Kinney W, Sung HY, Kearney KA, et al. Missed opportunities for  cervical cancer screening of HMO members developing invasive  cervical cancer. Gynecol Oncol 1998; 71: 428-430.  	9887244
	26. Womack C, Warren AY. Achievable laboratory standards: a review  of cytology of 99 women with cervical cancer. Cytopathology  1998; 9: 171-177.  	9638378
	27. Department of Health and Social Security. Health services man agement: cervical cancer screening. [Health circular HC(88)1.]  Heywood: DHSS, 1988.  	NO_MATCH
	28. Wilson S, Woodman C. Costs and benefits of cervical screening.  In: Luesley D, Jordan J, Richart RM (eds). Intraepithelial neoplasia  of the lower genital tract. New York: Churchill Livingstone, 1995:  61-70.  	NO_MATCH
	29. Lauver D, Rubin M. Women’s concerns about abnormal  Papanicolaou results. J Obstet Gynecol Neonatal Nurs 1990; 20:  154-159.  	2030453
	30. Campion MJ, Brown JR, McCance DJ, et al. Psychosexual trauma  of an abnormal cervical smear. Br J Obstet Gynaecol 1988; 95(2):  175-181.  	2831933
	31. Office for National Statistics. Cancer Statistics: registrations 1994.  ONS Series MBI, No 27, 2000.  	NO_MATCH
	32. Office for National Statistics. Mortality statistics: cause 1999. ONS  Series DH2, No 26, 2000.  	NO_MATCH
	33. Shingleton HM, Patrick RL, Johnston WW, Smith RA. The current  status of the Papanicolaou smear. CA Cancer J Clin 1995; 45:  305-320.  	7656133
	34. Nanda K, McCrory DC, Myers ER, et al. Accuracy of the  Papanicolaou test in screening for and follow-up of cervical cyto logical abnormalities: a systematic review. Ann Intern Med 2000;  132: 810-819.  	10819705
	35. Fahey MT, Irwig L, Macaskill P. Meta-analysis of Pap test accuracy.  Am J Epidemiol 1995; 141(7): 680-689.  	NO_MATCH
	36. Frame PS, Frame JS. Determinants of cancer screening frequen cy: the example of screening for cervical cancer. J Am Board Fam  Pract 1998; 11: 87-95.  	9542700
	37. Frable WJ. Does a zero error standard exist for the Papanicolaou  smear? A pathologists perspective. Arch Pathol Lab Med 1997;  121: 301-310.  	9111124
	38. Petticrew MP, Sowden AJ, Lester-Sharp D, Wright K. False-nega tive results in screening programmes: systematic review of impact  and implications. Health Technol Assess 2000; 5(4): 15.  	10859208
	39. Hogg C. Patients, power and politics. London: Sage, 1999.  	NO_MATCH
	40. Duncan ID. Guidelines for Clinical Practice and Programme  Management NHSCSP Publication No.8. December 1997. NHS  cervical screening programme, Sheffield.  	NO_MATCH
	41. Miller AB, Chamberlain J, Day NE, et al. Report on a Workshop of  the UICC Project on Evaluation of Screening for Cancer. Int J  Cancer 1990; 46: 761-769.  	2228303
	42. Flannelly G. A national screening programme: the answer to can cer of the cervix. Irish Medical Times 1999; 33: 49.   	NO_MATCH
	43. Walter SD. Optimal use of Pap Smear screening for cervical can cer. In: Duffy SW, Hill C, Esteve J (eds). Quantitative Methods for  the Evaluation of Cancer Screening. London: Arnold, 2001: 115 126.  	NO_MATCH
	44. Cancer screening. In: Miller AB, Chamberlain J, Day NE, et al  (eds). International Union Against Cancer. Cambridge: Cambridge  University Press, 1991.   	NO_MATCH
	45. Sawaya GF, Grady D, Kerlikowske K, et al. The positive predictive  value of cervical smears in previously screened postmenopausal  women: the heart and estrogen/progestin replacement study (HERS). Ann Intern Med 2000; 133: 942-950.  	11119395
	46. van Wijngaarden WJ, Duncan ID. Rationale for stopping cervical  screening in women over 50. BMJ 1993; 306: 967-971.  	8490472
	47. Sherlaw-Johnson C, Galllivan S, Jenkins D. Withdrawing low risk  women from cervical screening programmes: mathematical mod elling study. BMJ 1999; 318: 356-361.  	9933195
	48. Follen-Mitchell M, Schottenfeld D. The natural history of cervical  intraepithelial neoplasia and management of abnormal  Papanicolaou smears in cervical cancer and pre-invasive neopla sia. Philadelphia: Lippincott Raven, 1996; 103-113.  	NO_MATCH
	49. Herbert A, Stein K, Bryant TN, et al. Relation between the inci dence of invasive cervical cancer and the screening interval: is a  five year interval too long? J Med Screen 1996; 3: 140-145.  	8946309
	50. Waugh N, Robertson A. Costs and benefits of cervical screening  II. Is it worth reducing the screening interval from five to three  years? Cytopathology 1996; 7: 241-248.  	8853970
	51. Koopmanschap MA, Lubbe KT, van Ortmarssen GJ, et al.  Economic aspects of cervical screening. Soc Sci Med 1990; 30:  1081-1087.  	2114040
	52. Parkin DM, Moss SM. An evaluation of screening policies for cervi cal cancer in England and Wales using a computer simulation  model. J Epidemiol Community Health 1986; 40: 143-153.  	3746177
	53. Wilkinson C. Peters TJ, Harvey IM, Stott NCH. Risk targeting in  cervical screening: a new look at an old problem. Br J Gen Pract  1992; 42: 435-438.  	1466924
	54. Knox EG. Ages and frequencies for cervical cancer screening. Br  J Cancer 1976; 34: 444-452  	823954
	55. Wolfendale M. Cervical samplers: most important variable is prob ably the operator’s skill. BMJ 1991; 302: 1554-1555.  	1741819
	56. Duguid HLD. Does mild atypia on a cervical smear warrant further  investigation? Lancet 1986; ii: 1225.   	2877367
	57. Buntinx F, Knottnerus J, Crebolder H, et al. Does feedback  improve the quality of cervical smears? A randomised controlled  trial. Br J Gen Pract 1993; 43: 194-198.  	8347386
	58. Wilkinson C, Jones JM, McBride J. Anxiety caused by abnormal  results of cervical smear test: a controlled trial. BMJ 1990; 300:  440.  	2107898
	59. Lester H, Wilson S. Is default from colposcopy a problem, and if  so, what can we do? A systematic review of the literature. Br J  Gen Pract 1999; 49: 223-229.  	10343430
	60. Martin-Hirsch P, Lilford R, Jarvis G, Kitchener HC. Efficacy of cervi cal smear collection devices: a systematic review and meta-analy sis. Lancet 1999; 354: 1763-1770.  	10577637
	61. Buntix, F, Brouwers M. Relation between sampling device and  detection of abnormality in cervical smears: a meta-analysis of  randomised and quasi-randomised studies. BMJ 1996; 313: 1285 1290.  	8942687
	62. Klinkhamer P, Vooijs G, de Haan A. Intra-observer variability in the  quality assessment of cervical smears. Acta Cytol 1989; 33: 215 218.  	2929223
	63. Vet de H, Knipschild P, Schouten H, et al. Interobserver variation in  histo-pathological grading of cervical dysplasia. J Clin Epidemiol  1990; 43: 1395-1398.  	2254777
	64. Spurgeon P, Barwell F, Kerr D. Waiting times for cancer patients in  England after general practitioner referrals: retrospective national  study. BMJ 2000; 320: 838-839.  	10731176
	65. Pill R, French J, Harding K, Stoff N. Invitation to attend a health  check in a general practice setting: comparison of attenders and  non-attenders. J R Coll Gen Pract 1988, 38: 53-56.  	3204565
	66. Townsend P, Davidson N, Whitehead M. Inequalities in health.  London: Penguin, 1988.  	NO_MATCH
	67. Torgerson DJ, Donaldson C. An economic view of high compli ance as a screening object. BMJ 1994; 308: 117-119.  	8298385
	68. Jenkins D, Gallivan S, Sherlaw-Johnson C, et al. Compliance in  screening programme: high compliance essential in cervical  screening programme. BMJ 1994; 308: 652-653.  	8148720
	69. Cohen MM. Why is there no progress against cervical cancer.  CMAJ 1996; 154(12): 1867-1869.   	8653646
	70. Marshall MN, Campbell S, Hacker J, Roland M (eds). Quality indi cators for general practice; a practical guide to clinical quality indi cators for primary care health professionals and managers.  London: The Royal Society of Medicine Press Ltd, 2001.  	NO_MATCH
e171.pdf
0600.pdf
	1. Baquero, F., J. A. Garcı´a-Rodrı´guez, J. Garcı´a de Lomas, L. Aguilar, and the  Spanish Surveillance Group for Respiratory Pathogens. 1999. Antimicrobial  resistance of 1,113 Streptococcus pneumoniae isolates from patients with  respiratory tract infections in Spain: results of a 1-year (1996–1997) multi center surveillance study. Antimicrob. Agents Chemother. 43:357–359.  	9925532
	2. Craig, W. A. 1998. Pharmacokinetic/pharmacodynamic parameters: rationale  for antibacterial dosing of mice and men. Clin. Infect. Dis. 26:1–10.  	9455502
	3. De Hennezel, L., F. Ramisse, P. Binder, G. Marchal, and J. Alonso. 2001.  Effective combination therapy for invasive pneumococcal pneumonia with  ampicillin and intravenous immunoglobulins in a mouse model. Antimicrob.  Agents Chemother. 45:316–318.  	11120987
	4. Densen, P. 2000. Complement, p. 67–89. In G. L. Mandell, J. E. Bennett, and  R. Dolin (ed.), Principles and practice of infectious diseases, 5th ed.  Churchill Livingstone, Philadelphia, Pa.  	NO_MATCH
	5. Fenoll, A., I. Jado, D. Vicioso, A. Pérez, and J. Casal. 1998. Evolution of  Streptococcus pneumoniae serotypes and antibiotic resistance in Spain: up date (1990 to 1996). J. Clin. Microbiol. 36:3447–3454.  	9817852
	6. Fenoll, A., I. Jado, D. Vicioso, S. Berrón, J. E. Yuste, and, J. Casal. 2000.  Streptococcus pneumoniae in children in Spain: 1990–1999. Acta Paediatr.  Suppl. 435:44–50.  	11194798
	7. Gemmel, C. G., and V. Lorian. 1996. Effects of low concentrations of anti biotics on bacterial ultrastructure, virulence, and susceptibility to immuno defenses: clinical significance, p. 397–452. In V. Lorian (ed.), Antibiotics in  laboratory medicine, 4th ed. The Williams & Wilkins Co., Baltimore, Md.  	NO_MATCH
	8. Gómez-Lus, M. L., L. Aguilar, M. Martı´n, M. J. Giménez, P. Martı´nez, and  J. Prieto. 1997. Intracellular and extracellular killing of a penicillin-resistant,  serotype-9 strain of Streptococcus pneumoniae by polymorphonuclear leuco cytes in the presence of sub-inhibitory concentrations of clavulanic acid. J.  Antimicrob. Chemother. 40:142–144.  	9249222
	9. Gómez-Lus, M. L., M. J. Giménez, J. Prieto, M. Martı´n, J. Frı´as, and L.  Aguilar. 1998. Effect of polymorphonuclear neutrophils on serum bacteri cidal activity against Streptococcus pneumoniae after amoxicillin administra tion. Eur. J. Clin. Microbiol. Infect. Dis. 17:40–43.  	9512181
	10. Heinzel, F. P. 2000. Antibodies, p. 45–67. In G. L. Mandell, J. E. Bennett,  and R. Dolin (ed.), Principles and Practice of infectious diseases, 5th ed.  Churchill Livingstone, Philadelphia, Pa.  	NO_MATCH
	11. Hostetter, M. K. 2000. Opsonic and nonopsonic interactions of C3 with  Streptococcus pneumoniae, p. 309–313. In A. Tomasz (ed.), Streptococcus  pneumoniae. Mary Ann Liebert, Inc., Larchmont, N.Y.  	10432269
	12. Keller, M. A., and E. R. Stiehm. 2000. Passive immunity in prevention and  treatment of infectious diseases. Clin. Microbiol. Rev. 13:602–614.  	11023960
	13. Marco, F., E. Bouza, J. Garcı´a de Lomas, L. Aguilar, and the Spanish  Surveillance Group for Respiratory Pathogens. 2000. Streptococcus pneu moniae in community-acquired respiratory tract infections in Spain: the  impact of serotype and geographical, seasonal and clinical factors on its  susceptibility to the most commonly prescribed antibiotics. J. Antimicrob.  Chemother. 46:557–564.  	11020252
	14. Martı´n, M., M. L. Gómez-Lus, L. Aguilar, P. Martı´nez, M. J. Giménez, and  J. Prieto. 1997. Effect of clavulanic acid and/or polymorphonuclear neutro phils on amoxicillin bactericidal activity against Streptococcus pneumoniae.  Eur. J. Clin. Microbiol. Infect. Dis. 16:512–516.  	9272386
	15. Musher, D. M. 2000. Streptococcus pneumoniae, p. 2128–2147 . In G. L.  Mandell, J. E. Bennett, and R. Dolin (ed.), Principles and practice of infec tious diseases, 5th ed. Churchill Livingstone, Philadelphia, Pa.  	NO_MATCH
	16. National Committee for Clinical Laboratory Standards. 2001. Perfomance  standards for antimicrobial susceptibility testing; 11th informational supple ment. NCCLS document M100-S11. National Committee for Clinical Lab oratory Standards, Wayne, Pa.  	NO_MATCH
	17. Pallarés, R., J. Liñares, M. Vadillo, C. Cabellos, F. Manresa, P. F. Viladrich,  R. Martı´n, and F. Gudiol. 1995. Resistance to penicillin and cephalosporin  and mortality from severe pneumococcal pneumonia in Barcelona, Spain.  N. Engl. J. Med. 333:474–480.  	7623879
	18. Pérez-Trallero, E., M. Alkorta, J. M. Garcı´a-Arenzana, A. Iturzaeta, and M.  Gomariz. 1998. In-vitro, in-vivo and ex-vivo studies with oral beta-lactams  against Streptococcus pneumoniae. J. Antimicrob. Chemother. 41:629–634.  	9687101
	19. Severin, A., E. Severina, and A. Tomasz. 1997. Abnormal physiological  properties and altered cell wall composition in Streptococcus pneumoniae  grown in the presence of clavulanic acid. Antimicrob. Agents Chemother.  41:504–510.  	9055983
0963.pdf
	1. Andrews, J. M., T. M. Weller, J. P. Ashby, R. M. Walker, and R. Wise. 2000.  The in vitro activity of ABT773, a new ketolide antimicrobial agent. J.  Antimicrob. Chemother. 46:1017–1022.  	11102425
	2. Arason, V. A. 1996. Do antimicrobials increase the carriage rate of penicillin  resistant pneumococci in children? Cross sectional prevalence study. Brit.  Med. J. 313:387–391.  	8761224
	3. Austin, D. J., K. G. Kristinsson, and R. M. Anderson. 1999. The relationship  between the volume of antimicrobial consumption in human communities  and the frequency of resistance. Proc. Natl. Acad. Sci. USA 96:1152–1156.  	9927709
	4. Ban, N., P. Nissen, J. Hansen, P. B. Moore, and T. A. Steitz. 2000. The  complete atomic structure of the large ribosomal subunit at 2.4 A resolution.  Science 289:905–920.  	10937989
	5. Barry, A. L., P. C. Fuchs, and S. D. Brown. 1998. Antipneumococcal activ ities of a ketolide (HMR 3647), a streptogramin (quinupristin-dalfopristin),  a macrolide (erythromycin), and a lincosamide (clindamycin). Antimicrob.  Agents Chemother. 42:945–946.  	9559816
	6. Bartlett, J. G., S. F. Dowell, L. A. Mandell, T. M. File, Jr., D. M. Musher, and  A. Fine. 2000. Practice guidelines for the management of community-ac quired pneumonia in adults. Clin. Infect. Dis. 31:347–382.  	NO_MATCH
	7. Bonnefoy, A., A. M. Girard, C. Agouridas, and J. F. Chantot. 1997. Ketolides  lack inducibility properties of MLS(B) resistance phenotype. J. Antimicrob.  Chemother. 40:85–90.  	9249208
	8. Bryskier, A. 2000. Ketolides-telithromycin, an example of a new class of  antibacterial agents. Clin. Microbiol. Infect. 6:661–669.  	11284926
	9. Capobianco, J. O., Z. Cao, V. D. Shortridge, Z. Ma, R. K. Flamm, and P.  Zhong. 2000. Studies of the novel ketolide ABT-773: transport, binding to  ribosomes, and inhibition of protein synthesis in Streptococcus pneumoniae.  Antimicrob. Agents Chemother. 44:1562–1567.  	10817709
	10. Centers for Disease Control and Prevention. 2001. Resistance of Streptococ cus pneumoniae to fluoroquinolones—United States, 1995–1999. Morbid.  Mortal. Wkly. Rep. 50:800–804.  	NO_MATCH
	11. Chen, D., A. McGeer, J. C. de Azavedo, D. E. Low, and The Canadian  Bacterial Surveillance Network. 1999. Decreased susceptibility of Strepto coccus pneumoniae to fluoroquinolones in Canada. N. Engl. J. Med. 341:  233–239.  	NO_MATCH
	12. Davidson, R., R. Cavalcanti, J. L. Brunton, D. J. Bast, J. C. de Azavedo, P.  Kibsey, C. Fleming, and D. E. Low. 2002. Resistance to levofloxacin and  failure of treatment of pneumococcal pneumonia. N. Engl. J. Med. 346:747–  750.  	11882730
	13. Davies, T. A., L. M. Ednie, D. M. Hoellman, G. A. Pankuch, M. R. Jacobs,  and P. C. Appelbaum. 2000. Antipneumococcal activity of ABT-773 com pared to those of 10 other agents. Antimicrob. Agents Chemother. 44:1894–  1899.  	10858350
	14. Doern, G. V., K. P. Heilmann, H. K. Huynh, P. R. Rhomberg, S. L. Coffman,  and A. B. Brueggemann. 2001. Antimicrobial resistance among clinical iso lates of Streptococcus pneumoniae in the United States during 1999–2000,  including a comparison of resistance rates since 1994–1995. Antimicrob.  Agents Chemother. 45:1721–1729.  	11353617
	15. Doit, C., C. Loukil, F. Fitoussi, P. Geslin, and E. Bingen. 1999. Emergence  in France of multiple clones of clinical Streptococcus pneumoniae isolates  with high-level resistance to amoxicillin. Antimicrob. Agents Chemother.  43:1480–1483.  	10348775
	16. Douthwaite, S., and W. S. Champney. 2001. Structures of ketolides and  macrolides determine their mode of interaction with the ribosomal target  site. J. Antimicrob. Chemother. 48(Suppl. T1):1–8.  	11566971
	17. Fasola, E. L., S. Bajaksouzian, P. C. Appelbaum, and M. R. Jacobs. 1997.  Variation in erythromycin and clindamycin susceptibilities of Streptococcus  pneumoniae by four test methods. Antimicrob. Agents Chemother. 41:129–  134.  	8980768
	18. Felmingham, D. 2001. Microbiological profile of telithromycin, the first ke tolide antimicrobial. Clin. Microbiol. Infect. 7(Suppl. 3):2–10.  	11523558
	19. File, T. M., Jr., J. Segreti, L. Dunbar, R. Player, R. Kohler, R. R. Williams,  C. Kojak, and A. Rubin. 1997. A multicenter, radomized study comparing  the efficacy and safety of intravenous and/or oral levofloxacin versus ceftri axone and/or cefuroxime axetil in treatment of adults with community acquired pneumonia. Antimicrob. Agents Chemother. 41:1965–1972.  	9303395
	20. Gemmell, C. G. 2001. Susceptibility of a variety of clinical isolates to lin ezolid: a European inter-country comparison. J. Antimicrob. Chemother.  48:47–52.  	11474632
	21. Giovanetti, E., M. P. Montanari, F. Marchetti, and P. E. Varaldo. 2000. In  vitro activity of ketolides telithromycin and HMR 3004 against Italian iso lates of Streptococcus pyogenes and Streptococcus pneumoniae with different  erythromycin susceptibility. J. Antimicrob. Chemother. 46:905–908.  	11102408
	22. Heffelfinger, J. D., S. F. Dowell, J. H. Jorgensen, K. P. Klugman, L. R.  Mabry, D. M. Musher, J. F. Plouffe, A. Rakowsky, A. Schuchat, and C. G.  Whitney. 2000. Management of community-acquired pneumonia in the era  of pneumococcal resistance: a report from the Drug-Resistant Streptococcus  pneumoniae Therapeutic Working Group. Arch. Intern. Med. 160:1399–  1408.  	10826451
	23. Ho, P. L., T. K. Ng, R. W. Yung, T. L. Que, E. K. Yip, C. W. Tse, and K. Y.  Yuen. 2001. Activity of linezolid against levofloxacin-resistant Streptococcus  pneumoniae, methicillin-resistant Staphylococcus aureus and vancomycin-re sistant enterococci in Hong Kong. J. Antimicrob. Chemother. 48:590–592.  	11581246
	24. Ho, P. L., T. L. Que, D. N. Tsang, T. K. Ng, K. H. Chow, and W. H. Seto.  1999. Emergence of fluoroquinolone resistance among multiply resistant  strains of Streptococcus pneumoniae in Hong Kong. Antimicrob. Agents  Chemother. 43:1310–1313.  	10223962
	25. Hoban, D. J., A. K. Wierzbowski, K. Nichol, and G. G. Zhanel. 2001. Mac rolide-resistant Streptococcus pneumoniae in Canada during 1998–1999:  prevalence of mef(A) and erm(B) and susceptibilities to ketolides. Antimi crob. Agents Chemother. 45:2147–2150.  	11408241
	26. Hyde, T. B., K. Gay, D. S. Stephens, D. J. Vugia, M. Pass, S. Johnson, N. L.  Barrett, W. Schaffner, P. R. Cieslak, P. S. Maupin, E. R. Zell, J. H. Jor gensen, R. R. Facklam, and C. G. Whitney. 2001. Macrolide resistance  among invasive Streptococcus pneumoniae isolates. JAMA 286:1857–1862.  	11597287
	27. Ip, M., D. J. Lyon, R. W. Yung, C. Chan, and A. F. Cheng. 2001. Macrolide  resistance in Streptococcus pneumoniae in Hong Kong. Antimicrob. Agents  Chemother. 45:1578–1580.  	11302833
	28. Janoir, C., V. Zeller, M. D. Kitzis, N. J. Moreau, and L. Gutmann. 1996.  High-level fluoroquinolone resistance in Streptococcus pneumoniae requires  mutations in parC and gyrA. Antimicrob. Agents Chemother. 40:2760–2764.  	9124836
	29. Johnston, N. J., J. C. de Azavedo, J. D. Kellner, and D. E. Low. 1998.  Prevalence and characterization of the mechanisms of macrolide, lincos amide, and streptogramin resistance in isolates of Streptococcus pneumoniae.  Antimicrob. Agents Chemother. 42:2425–2426.  	9736575
	30. Klugman, K. P. 2001. Antibiotic selection of multiply resistant pneumococci.  Clin. Infect. Dis. 33:489–491.  	11462185
	31. Leclercq, R. 2001. Overcoming antimicrobial resistance: profile of a new  ketolide antibacterial, telithromycin. J. Antimicrob. Chemother. 48(Suppl.  B):9–23.  	11566972
	32. Leclercq, R., and P. Courvalin. 1991. Bacterial resistance to macrolide,  lincosamide, and streptogramin antibiotics by target modification. Antimi crob. Agents Chemother. 35:1267–1272.  	1929280
	33. Mandell, L. A., T. J. Marrie, R. F. Grossman, A. W. Chow, and R. H. Hyland.  2000. Canadian guidelines for the initial management of community-ac quired pneumonia: an evidence-based update by the Canadian Infectious  Diseases Society and the Canadian Thoracic Society. Clin. Infect. Dis. 31:  383–421.  	11058205
	34. McGee, L., K. P. Klugman, A. Wasas, T. Capper, and A. Brink. 2001.  Serotype 19f multiresistant pneumococcal clone harboring two erythromycin  resistance determinants [erm (B) and mef(A)] in South Africa. Antimicrob.  Agents Chemother. 45:1595–1598.  	11302838
	35. Melander, E., S. Molstad, K. Persson, H. B. Hansson, M. Soderstrom, and  K. Ekdahl. 1998. Previous antibiotic consumption and other risk factors for  carriage of penicillin-resistant Streptococcus pneumoniae in children. Eur.  J. Clin. Microbiol. Infect. Dis. 17:834–838.  	10052545
	36. Montanari, M. P., M. Mingoia, E. Giovanetti, and P. E. Varaldo. 2001.  Differentiation of resistance phenotypes among erythromycin-resistant  pneumococci. J. Clin. Microbiol. 39:1311–1315.  	11283047
	37. Morosini, M. I., R. Canton, E. Loza, M. C. Negri, J. C. Galan, F. Almaraz,  and F. Baquero. 2001. In vitro activity of telithromycin against Spanish  Streptococcus pneumoniae isolates with characterized macrolide resistance  mechanisms. Antimicrob. Agents Chemother. 45:2427–2431.  	11502509
	38. National Committee for Clinical Laboratory Standards. 2000. Methods for  dilution antimicrobial susceptibility tests for bacteria that grow aerobically,  5th ed. Approved standard M7-A5. National Committee for Clinical Labo ratory Standards, Wayne, Pa.  	NO_MATCH
	39. National Committee for Clinical Laboratory Standards. 2000. Performance  standards for antimicrobial disk susceptibility tests, 7th ed. Approved stan dard M2-A7. National Committee for Clinical Laboratory Standards,  Wayne, Pa.  	NO_MATCH
	40. National Committee for Clinical Laboratory Standards. 2002. Performance  standards for antimicrobial susceptibility testing. Twelfth informational sup plement, M100-S12. National Committee for Clinical Laboratory Standards,  Wayne, Pa.  	NO_MATCH
	41. Niederman, M. S., L. A. Mandell, A. Anzueto, J. B. Bass, W. A. Broughton,  G. D. Campbell, N. Dean, T. File, M. J. Fine, P. A. Gross, F. Martinez, T. J.  Marrie, J. F. Plouffe, J. Ramirez, G. A. Sarosi, A. Torres, R. Wilson, and  V. L. Yu. 2001. Guidelines for the management of adults with community acquired pneumonia. Diagnosis, assessment of severity, antimicrobial ther apy, and prevention. Am. J. Respir. Crit. Care Med. 163:1730–1754.  	11401897
	42. Pankuch, G. A., M. A. Visalli, M. R. Jacobs, and P. C. Appelbaum. 1998.  Susceptibilities of penicillin- and erythromycin-susceptible and -resistant  pneumococci to HMR 3647 (RU 66647), a new ketolide, compared with  susceptibilities to 17 other agents. Antimicrob. Agents Chemother. 42:624–  630.  	9517943
	43. Perez-Trallero, E., C. Fernandez-Mazarrasa, C. Garcia-Rey, E. Bouza, L.  Aguilar, J. Garcia-de-Lomas, and F. Baquero. 2001. Antimicrobial suscep tibilities of 1,684 Streptococcus pneumoniae and 2,039 Streptococcus pyogenes  isolates and their ecological relationships: results of a 1-year (1998–1999)  multicenter surveillance study in Spain. Antimicrob. Agents Chemother.  45:3334–3340.  	11709305
	44. Petitpretz, P., P. Arvis, M. Marel, J. Moita, and J. Urueta. 2001. Oral  moxifloxacin vs. high-dosage amoxicillin in the treatment of mild-to-moder ate, community-acquired, suspected pneumococcal pneumonia in adults.  Chest 119:185–195.  	11157603
	45. Pihlajamaki, M., P. Kotilainen, T. Kaurila, T. Klaukka, E. Palva, and P.  Huovinen. 2001. Macrolide-resistant Streptococcus pneumoniae and use of  antimicrobial agents. Clin. Infect. Dis. 33:483–488.  	11462184
	46. Richardson, D. C., D. Bast, A. McGeer, and D. E. Low. 2001. Evaluation of  susceptibility testing to detect fluoroquinolone resistance mechanisms in  Streptococcus pneumoniae. Antimicrob. Agents Chemother. 45:1911–1914.  	11353652
	47. Roberts, M. C., J. Sutcliffe, P. Courvalin, L. B. Jensen, J. Rood, and H.  Seppala. 1999. Nomenclature for macrolide and macrolide-lincosamide streptogramin B resistance determinants. Antimicrob. Agents Chemother.  43:2823–2830.  	10582867
	48. Seppala, H., A. Nissinen, Q. Yu, and P. Huovinen. 1993. Three different  phenotypes of erythromycin-resistant Streptococcus pyogenes in Finland. J.  Antimicrob. Chemother. 32:885–891.  	8144429
	49. Shinabarger, D. L., K. R. Marotti, R. W. Murray, A. H. Lin, E. P. Melchior,  S. M. Swaney, D. S. Dunyak, W. F. Demyan, and J. M. Buysse. 1997.  Mechanism of action of oxazolidinones: effects of linezolid and eperezolid on  translation reactions. Antimicrob. Agents Chemother. 41:2132–2136.  	9333037
	50. Simor, A. E., M. Louie, The Canadian Bacterial Surveillance Network, and  D. E. Low. 1996. Canadian national survey of prevalence of antimicrobial  resistance among clinical isolates of Streptococcus pneumoniae. Antimicrob.  Agents Chemother. 40:2190–2193.  	8878605
	51. Slee, A. M., M. A. Wuonola, R. J. McRipley, I. Zajac, M. J. Zawada, P. T.  Bartholomew, W. A. Gregory, and M. Forbes. 1987. Oxazolidinones, a new  class of synthetic antibacterial agents: in vitro and in vivo activities of DuP  105 and DuP 721. Antimicrob. Agents Chemother. 31:1791–1797.  	3435127
	52. Sutcliffe, J., A. Tait-Kamradt, and L. Wondrack. 1996. Streptococcus pneu moniae and Streptococcus pyogenes resistant to macrolides but sensitive to  clindamycin: a common resistance pattern mediated by an efflux system.  Antimicrob. Agents Chemother. 40:1817–1824.  	8843287
	53. Tait-Kamradt, A., T. Davies, P. C. Appelbaum, F. Depardieu, P. Courvalin,  J. Petitpas, L. Wondrack, A. Walker, M. R. Jacobs, and J. Sutcliffe. 2000.  Two new mechanisms of macrolide resistance in clinical strains of Strepto coccus pneumoniae from Eastern Europe and North America. Antimicrob.  Agents Chemother. 44:3395–3401.  	11083646
	54. Tait-Kamradt, A., T. Davies, M. Cronan, M. R. Jacobs, P. C. Appelbaum,  and J. Sutcliffe. 2000. Mutations in 23S rRNA and ribosomal protein L4  account for resistance in pneumococcal strains selected in vitro by macrolide  passage. Antimicrob. Agents Chemother. 44:2118–2125.  	10898684
	55. Tankovic, J., B. Perichon, J. Duval, and P. Courvalin. 1996. Contribution of  mutations in gyrA and parC genes to fluoroquinolone resistance of mutants  of Streptococcus pneumoniae obtained in vivo and in vitro. Antimicrob.  Agents Chemother. 40:2505–2510.  	8913454
	56. Tsiodras, S., H. S. Gold, G. Sakoulas, G. M. Eliopoulos, C. Wennersten, L.  Venkataraman, R. C. Moellering, and M. J. Ferraro. 2001. Linezolid resis tance in a clinical isolate of Staphylococcus aureus. Lancet 358:207–208.  	11476839
	57. Whitney, C. G., M. M. Farley, J. Hadler, L. H. Harrison, C. Lexau, A.  Reingold, L. Lefkowitz, P. R. Cieslak, M. Cetron, E. R. Zell, J. H. Jorgensen,  and A. Schuchat. 2000. Increasing prevalence of multidrug-resistant Strep tococcus pneumoniae in the United States. N. Engl. J. Med. 343:1917–1924.  	11136262
	58. Yusupova, G. Z., M. M. Yusupov, J. H. Cate, and H. F. Noller. 2001. The  path of messenger RNA through the ribosome. Cell 106:233–241.  	11511350
	59. Zurenko, G. E., B. H. Yagi, R. D. Schaadt, J. W. Allison, J. O. Kilburn, S. E.  Glickman, D. K. Hutchinson, M. R. Barbachyn, and S. J. Brickner. 1996. In  vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial  agents. Antimicrob. Agents Chemother. 40:839–845.  	8849237
11788790.pdf
	1. Balbin EG, Ironson GH, Solomon GF. (1999) Stress and cop ing: the psychoneuroimmunology of HIV/AIDS. Baillieres Best  Pract. Res. Clin. Ednocrinol. Metab. 13: 615–633.  	10903818
	2. Chrousos GP. (2000) Stress, chronic inflammation, and emo tional and physical well-being: concurrent effects and chronic  sequelae. J. Allergy Clin. Immunol. 106: 275–291.  	11080744
	3. Yang EV, Glaser R. (2000) Stress-induced immunomodula tion: impact on immune defenses against infectious disease.  Biomed. Pharmacother. 54: 245–250.  	10917461
	4. Swain MG, Patchev V, Vergalla J, et al. (1993) Suppression of  hypothalamic-pituitary-adrenal axis responsiveness to stress  in a rat model of acute cholestasis. J. Clin. Invest. 91: 1903–1908.  	8387536
	5. Malan FS, Horak IG, de Vos V, van Wyk JA. (1997) Wildlife  parasites: lessons for parasite control in livestock. Vet. Para sitol. 71: 137–153.  	9261975
	6. Kraabel BJ, Miller MW. (1997) Effect of simulated stress on  susceptibility of bighorn sheep neutrophils to Pasteurella  haemolytica leukotoxin. J. Wildl. Dis. 33: 558–566.  	9249702
	7. McEwen BS, Seeman T. (1999) Protective and damaging effects  of mediators of stress. Elaborating and testing the concepts of  allostasis and allostatic load. Ann. N.Y. Acad. Sci. USA 896: 30–47.  	10681886
	8. Birmaher B, Rabin BS, Garcia MR, et al. (1994) Cellular im munity in depressed, conduct disorder, and normal adoles cents: role of adverse life events. J. Am. Acad. Child Adolesc.  Psychiatry 33: 671–678.  	8056730
	9. Strange KS, Kerr LR, Andrews HN, et al. (2000) Psychosocial  stressors and mammary tumor growth: an animal model.  Neurotoxicol. Teratol. 22: 89–102.  	10642118
	10. Elenkov IJ, Chrousos GP. (1999) Stress, cytokine patterns  and susceptibility to disease. Baillieres Best Pract. Res. Clin.  Endocrinol. Metab. 13: 583–595.  	10903816
	11. Kiecolt-Glaser JK, Glaser R. (1999) Psychoneuroimmunology  and cancer: fact or fiction? Eur. J. Cancer 35: 1603–1607.  	10673969
	12. Bauer ME, Vedhara K, Perks P, et al. (2000) Chronic stress in  caregivers of dementia patients is associated with reduced  lymphocyte sensitivity to glucocorticoids. J. Neuroimmunol.  103: 84–92.  	10674993
	13. Lacey K, Zaharia MD, Griffiths J, et al. (2000) A prospective  study of neuroendocrine and immune alterations associated  with the stress of an oral academic examination among grad uate students. Psychoneuroendocrinol. 25: 339–356.   	10725611
	14. Cohen S, Miller GE, Rabin BS. (2001) Psychological stress  and antibody response to immunization: a critical review of  the human literature. Psychosom. Med. 63: 7–18.  	11211068
	15. Cacioppo JT, Poehlmann KM, Kiecolt-Glaser JK, et al. (1998)  Cellular immune responses to acute stress in female care givers of dementia patients and matched controls. Health  Psychol. 17: 182–189.  	9548709
	16. Weicker H, Werle E. (1991) Interaction between hormones  and the immune system. Int. J. Sports Med. 12: S30–S37.  	1894395
	17. Ashwell JD, Lu FW, Vacchio MS. (2000) Glucocorticoids in T  cell development and function. Ann. Rev. Immunol. 18: 309–345.  	10837061
	18. Rook GA. (1999) Glucocorticoids and immune function. Bail lieres Best Pract. Res. Clin. Endocrinol. Metab. 13: 567–581.  	10903815
	19. Nosseri C, Coppola S, Ghibelli L. (1994) Possible involve ment of Poly(ADP-Ribosyl) polymerase in triggering stress induced apoptosis. Exp. Cell Res. 212: 367–373.  	8187831
	20. Pieper AA, Verma A, Zhang J, Snyder S. (1999) Poly (ADP ribose) polymerase, nitric oxide, and cell death. Trends Phar macol. Sci. 20: 171–181.  	10322503
	21. Eliasson MJL, Sampei K, Mandir AS, et al. (1997) Poly  (ADP-ribose) polymerase gene Disruption renders mice re sistant to cerebral ischemia. Nature Med. 3: 1089–1095.  	9334719
	22. Mandir AS, Przedborski S, Jackson-Lewis V, et al. (1999) Poly  (ADP-ribose) polymerase activation mediates 1-methyl-4 phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced parkin sonism. Proc. Natl. Acad. Sci. USA 96: 5774–5779.  	10318960
	23. Pieper AA, Walles T, Wei G, et al. (2000) Myocardial postis chemic injury is reduced by poly ADP ribose polymerase-1  gene disruption. Mol. Med. 6: 271–282.  	10949908
	24. Pieper AA, Brat DJ, Krug DK, et al. (1999) Poly (ADP-ribose)  polymerase-deficient mice are protected from streptozotocin induced diabetes. Proc. Natl. Acad. Sci. 96: 3059–3064.  	10077636
	25. Cossette S, Frasure-Smith N, Lesperance F. (2001) Clinical  implications of a reduction in psychological distress on car diac prognosis in patients participating in a psychosocial in tervention program. Psychosom. Med. 63: 257–266.  	11292273
	26. Haines A, Cooper J, Meade TW. (2001) Psychological char acteristics and fatal ischaemic heart disease. Heart 85: 385–  389.  	11250959
	27. Naliboff BD, Goldstein IB, Shapiro D, Frank HJ. (1988) Men tal and physical stress as moderators of the postural response  in insulin-dependent diabetic patients. Health. Psychol. 7:  499–514.  	3215159
	28. Wang ZQ, Stingl L, Morrison C, et al. (1997) PARP is impor tant for genomic stability but dispensable in apoptosis. Genes  Dev. 11: 2347–2358.  	9308963
	29. Dixon F, Jacot-Guillarmod H, McConahey PJ. (1966) The  antibody responses of rabbits and rats to hemocyanin. J.  Immunol. 97: 350–355.  	5925706
	30. Drazen DL, Kriegsfeld LJ, Schneider JE, Nelson RJ. (2000)  Leptin, but not immune function, is linked to reproductive  responsiveness. Am. J. Physiol. 278: 1401–1407.  	10848504
	31. Tsutsui N, Kamiyama T. (1998) Suppression of in vitro IFN gamma production by spleen cells of Plasmodium chabaudi infected C57BL/10 mice exposed to dexamethasone at a low  dose. Int. J. Immunopharmacol. 20: 141–152.  	9730250
	32. DeVries AC, Gerber JM, Richardson HN, et al. (1997) Stress  affects corticosteroid and immunoglobulin concentrations  in male house mice (Mus musculus) and prairie voles (Micro tus ochrogaster). Comp. Biochem. Physiol. A Physiol. 118: 655–  663.  	9406441
	33. Shu J, Stevenson JR, Zhou X. (1993) Modulation of cellular  immune responses by cold water swim stress in the rat. Dev  Comp Immunol 17: 357–371.  	8375569
	34. Song C, Kelly JP, Leonard BE. (1994) The effect of stressful  behavioral exposure on endocrine and immune parameters in  the rat. Stress Med. 10: 239–245.  	NO_MATCH
	35. Nelson RJ. (1997) The use of genetic “knockout” mice in  behavioral endocrinology research. Horm. Behav. 31: 188–  196.  	9213133
	36. Kickhoefer VA, Siva AC, Kedersha NL, et al. (1999) The 193 kD vault protein, VPARP is a novel poly (ADP-ribose) poly merase. J. Cell Biol. 146: 917–928.  	10477748
	37. Ame JC, Rolli V, Schreiber V, et al. (1999) PARP-2, a novel  mammalian DNA damage-dependent Poly (ADP-ribose)  polymerase. J. Biol. Chem. 274: 17860–17868.  	10364231
11788789.pdf
	1. Minden A, Lin A, McMahon M, et al. (1994) Differential ac tivation of ERK and JNK mitogen-activated protein kinases  by Raf-1 and MEKK. Science 266: 1719–1723.  	7992057
	2. Lee JC, Laydon JT, McDonnell PC, et al. (1994) A protein ki nase involved in the regulation of inflammatory cytokine  biosynthesis. Nature 372: 739–746.  	7997261
	3. Coso OA, Chiariello M, Yu JC, et al. (1995) The small GTP binding proteins Rac1 and Cdc42 regulate the activity of the  JNK/SAPK signaling pathway. Cell 81: 1137–1146.  	7600581
	4. Liu MK, Herrera-Velit P, Brownsey RW, Reiner NE. (1994)  CD14-dependent activation of protein kinase C and mitogen activated protein kinases (p42 and p44) in human monocytes  treated with bacterial lipopolysaccharide. J. Immunol. 153:  2642–2652.  	7521366
	5. Gupta S, Barrett T, Whitmarsh AJ, et al. (1996) Selective in teraction of JNK protein kinase isoforms with transcription  factors. EMBO. J. 15: 2760–2770.  	8654373
	6. Hambleton J, Weinstein SL, Lem L, DeFranco AL. (1996) Ac tivation of c-Jun N-terminal kinase in bacterial lipopolysac charide-stimulated macrophages. Proc. Natl. Acad. Sci. USA 93:  2774–2778.  	8610116
	7. van den Blink B, Juffermans NP, ten Hove T, et al. (2001) p38  mitogen-activated protein kinase inhibition increases cy tokine release by macrophages in vitro and during infection  in vivo. J. Immunol. 166: 582–587.  	11123340
	8. Beyaert R, Cuenda A, Vanden Berghe W, et al. (1996) The  p38/RK mitogen-activated protein kinase pathway regulates  interleukin-6 synthesis response to tumor necrosis factor.  EMBO. J. 15: 1914–1923.  	8617238
	9. Scherle PA, Jones EA, Favata MF, et al. (1998) Inhibition of  MAP kinase kinase prevents cytokine and prostaglandin E2  production in lipopolysaccharide-stimulated monocytes. J.  Immunol. 161: 5681–5686.  	9820549
	10. van der Poll T, van Deventer SJH. (1999) Endotoxemia in  healthy subjects as a human model of inflammation. In:  Cohen J, Marshall J (eds.) The Immune Response in the Crit ically Ill, Springer–Verlag, USA/Germany, pg. 335–357.  	NO_MATCH
	11. Carter AB, Monick MM, Hunninghake GW. (1999) Both Erk  and p38 kinases are necessary for cytokine gene transcription.  Am. J. Respir. Cell. Mol. Biol. 20: 751–758.  	10101008
	12. Zhu W, Downey JS, Gu J, et al. (2000) Regulation of TNF ex pression by multiple mitogen-activated protein kinase path ways. J. Immunol. 164: 6349–6358.  	10843689
	13. van der Poll T, Calvano SE, Kumar A, et al. (1995) Endotoxin  induces downregulation of tumor necrosis factor receptors on  circulating monocytes and granulocytes in humans. Blood 86:  2754–2759.  	7670115
	14. van der Poll T, Coyle SM, Barbosa K, et al. (1996) Epineph rine inhibits tumor necrosis factor-alpha and potentiates in terleukin 10 production during human endotoxemia. J. Clin.  Invest. 97: 713–719.  	8609227
	15. Versteeg HH, Nijhuis E, van den Brink GR, et al. (2000) A  new phosphospecific cell-based ELISA for p42/p44 mitogen activated protein kinase (MAPK), p38 MAPK, protein kinase  B and cAMP-response—element-binding protein. Biochem. J.  350 Pt 3: 717–722.  	10970784
	16. Yokoi T, Ohmichi M, Tasaka K, et al. (2000) Activation of the  luteinizing hormone beta promoter by gonadotropin releasing hormone requires c-Jun NH2-terminal protein ki nase. J. Biol. Chem. 275: 21639–21647.  	10787426
	17. Medvedev AE, Kopydlowski KM, Vogel SN. (2000) Inhibi tion of lipopolysaccharide-induced signal transduction in  endotoxin-tolerized mouse macrophages: dysregulation of  cytokine, chemokine, and toll-like receptor 2 and 4 gene  expression. J. Immunol. 164: 5564–5574.  	10820230
	18. Mendez C, Kramer AA, Salhab KF, et al. (1999) Tolerance to  shock: an exploration of mechanism. Ann Surg 229: 843–849;  discussion 849–850.  	10363898
	19. Jin H, Yang R, Marsters S, et al. (1995) Protection against en dotoxic shock by bactericidal/permeability—increasing pro tein in rats. J. Clin. Invest. 95: 1947–1952.  	7706502
	20. De Cesaris P, Starace D, Riccioli A, et al. (1998) Tumor necro sis factor-alpha induces interleukin-6 production and inte grin ligand expression by distinct transduction pathways. J.  Biol. Chem. 273: 7566–7571.  	9516459
	21. Chan ED, Winston BW, Uh ST, et al. (1999) Evaluation of the  role of mitogen-activated protein kinases in the expression of  inducible nitric oxide synthase by IFN-gamma and TNF alpha in mouse macrophages. J. Immunol. 162: 415–422.  	9886415
	22. Nick JA, Avdi NJ, Gerwins P, et al. (1996) Activation of a p38  mitogen-activated protein kinase in human neutrophils by  lipopolysaccharide. J. Immunol. 156: 4867–4875.  	8648136
	23. Hambleton J, Weinstein SL, Lem L, DeFranco AL. (1996) Ac tivation of c-Jun N-terminal kinase in bacterial lipopolysac charide—stimulated macrophages. Proc. Natl. Acad. Sci. USA  93: 2774–2778.  	8610116
	24. Avdi NJ, Nick JA, Whitlock BB, et al. (2001) Tumor necrosis  factor-alpha activation of the c-Jun N-terminal kinase path way in human neutrophils. Integrin involvement in a path way leading from cytoplasmic tyrosine kinases apoptosis. J.  Biol. Chem. 276: 2189–2199.  	11053415
63.pdf
4765.full.pdf
	1. Clark PA, Rogol AD 1996 Growth hormones and sex steroid interactions at  puberty. Endocrinol Metab Clin North Am 25:665–681  	8879992
	2. Theintz G, Buchs B, Rizzoli R, et al. 1992 Longitudinal monitoring of bone  mass accumulation in healthy adolescents: evidence for a marked reduction  after 16 years of age at the levels of lumbar spine and femoral neck in female  subjects. J Clin Endocrinol Metab 75:1060–1065  	1400871
	3. Beunen G, Malina RM 1988 Growth and physical performance relative to the  timing of the adolescent spurt. Exer Sport Sci Rev 16:502–540  	3292266
	4. Recker RR, Davies KM, Hinders SM, Heaney RP, Stegman MR, Kimmel DB  1992 Bone gain in young adult women. JAMA 268:2403–2408  	1404797
	5. Matkovic V, Jelic T, Wardlaw GM, et al. 1994. Timing of peak bone mass in  Caucasian females and its implication for the prevention of osteoporosis.  Inference from a cross-sectional model. J Clin Invest 93:799–808  	8113412
	6. Kaufman JM, Taelman P, Vermeulen A, Vandeweghe M 1992 Bone mineral  status in growth hormone-deficient males with isolated and multiple pituitary  deficiencies of childhood onset. J Clin Endocrinol Metab 74:118–123  	1727808
	7. Larsson L, Grimby G, Karlsson J 1979 Muscle strength and speed of move ment in relation to age and muscle morphology. J Appl Physiol 46:451–456  	438011
	8. Borges O 1989 Isometric and isokinetic knee extension and flexion torque in  men and women aged 20–70. Scand J Rehab Med 21:45–53  	2711137
	9. Jørgensen JOL, Pedersen SA, Thuesen L, et al. 1989 Beneficial effect of growth  hormone treatment in GH-deficient adults. Lancet i:1221–1225  	2566779
	10. Nelson DA, Simpson PM, Johnson CC, Barondess DA, Kleerekoper M 1997  The accumulation of whole body skeletal mass in third- and fourth-grade  children: effects of age, gender, ethnicity, and body composition. Bone 20:73–78  	8988351
	11. Johannsson G, Albertsson-Wikland K, Bengtsson B-Å 1999 Discontinuation  of growth hormone (GH) treatment: metabolic effects in GH-deficient and  GH-sufficient adolescent patients compared with control subjects. Swedish  Study Group for Growth Hormone Treatment in Children. J Clin Endocrinol  Metab 84:4516–4524  	10599711
	12. Tulldahl J, Pettersson K, Andersson SW, Huthe´n L 1999 Mode of infant  feeding and achieved growth in adolescence: early feeding patterns in relation  to growth and body composition in adolescence. Obes Res 7:431–437  	10509599
	13. Johannsson G, Grimby G, Stibrant Sunnerhagen K, Bengtsson B-Å 1997 Two  years of growth hormone (GH) treatment increases isometric and isokinetic  muscle strength in GH-deficient adults. J Clin Endocrinol Metab 82:2877–2884  	9284713
	14. Thorstensson A, Grimby G, Karlsson J 1976 Force-velocity relations and fiber  composition in human knee extensor muscle. J Appl Physiol 40:12–16  	1248977
	15. Nordenskjo¨ld UM, Grimby G 1993 Grip force in patients with rheumatoid  arthritis and fibromyalgia and in healthy subjects. A study with Grippit in strument. Scand J Rheumatol 22:14–19  	8434241
	16. Lagersto¨m C, Nordgren B 1998 On the reliability and usefulness of methods  for grip strength measurement. Scand J Rehabil Med 30:112–119  	9606774
	17. Diggle PJ, Liang K-Y, Zeger SL 1994 Analysis of longitudinal data. Oxford:  Oxford University Press  	NO_MATCH
	18. Giustina A, Veldhuis JD 1998 Pathophysiology of the neuroregulation of  growth hormone secretion in experimental animals and the human. Endocr  Rev 19:717–797  	9861545
	19. Rudman D, Kutner MH, Rogers CM, Lubin MF, Flemming GA, Bain RP 1981  Impaired growth hormone secretion in the adult population. Relation to age  and adiposity. J Clin Invest 67:1361–1369  	7194884
	20. Taaffe DR, Pruitt L, J R, et al. 1994 Effect of recombinant human growth  hormone on the muscle strength response to resistance exercise in elderly men.  J Clin Endocrinol Metab 79:1361–1366  	7525633
	21. Lamberts SWJ, Van ben Beld AW, Van der Lely A-J 1997 The endocrinology  of aging. Science 278:419–424  	9334293
	22. Armstong N, Welsman J 1997 Young people and physical activity. Oxford:  Oxford University Press  	NO_MATCH
	23. Ogle GD, Allen JR, Humphries IR, et al. 1995 Body-composition assessment  by dual-energy x-ray absorptiometry in subjects aged 4–26 y. Am J Clin Nutr  61:746–753  	7702015
	24. Narici MV, Roi GS, Landoni L, Minetti AE, Cerretelli P 1989 Changes in force,  cross-sectional area and neural activation during strength training and de training of the human quadriceps. Eur J Appl Physiol 59:310–319  	2583179
	25. Seger JY, Thorstensson A 2000 Muscle strength and electromyogram in boys  and girls followed through puberty. Eur J Appl Physiol 81:54–61  	10552267
	26. Vahl N, Juul A, Jørgensen JOL, Ørskov H, Skakkebæk NE, Christiansen JS  2000 Continuation of growth hormone (GH) replacement in GH-deficient  patients during transition from childhood and adulthood: a two-year placebo controlled study. J Clin Endocrinol Metab 85:1874–1881  	10843168
	27. Rutherford OM, Jones DA, Round JM, Buchanan CR, Preece MA 1991  Changes in skeletal muscle and body composition after discontinuing of  growth hormone treatment in growth hormone deficient adults. Clin Endo crinol (Oxf) 34:469–475  	1889131
	28. Schoenau E, Neu CM, Mokov E, Wassmer G, Manz F 2000 Influence of  puberty on muscle area and cortical bone area of the forearm in boys and girls.  J Clin Endocrinol Metab 85:1095–1098  	10720045
	29. Bengtsson B-Å, Ede´n S, Lo¨nn L, et al. 1993 Treatment of adults with growth  hormone (GH) deficiency with recombinant human GH. J Clin Endocrinol  Metab 76:309–317  	8432773
	30. Bjo¨rk S, Jo¨nsson B, Westphal O, Levin J-E 1989 Quality of life of adults with  growth hormone deficiency: a controlled study. Acta Paediatr Scand  356(Suppl):55–59  	2816358
4717.full.pdf
	1. Consensus Development Conference 1993 Diagnosis, prophylaxis, and treat ment of osteoporosis. Am J Med 94:646–650  	NO_MATCH
	2. Salamone LM, Pressman AR, Seeley DG, et al. 1996 Estrogen replacement  therapy: a survey of older women’s attitudes. Arch Intern Med 156:1293–1297  	8651837
	3. Beauchesne M-F, Miller P 1999 Etidronate and alendronate in the treatment  of postmenopausal osteoporosis. Ann Pharmacother 33:587–599  	10369624
	4. Kaplan NM, Palmer BF, Rubin CD 1999 Treatment considerations in the  management of age-related osteoporosis. Am J Med Sci 318:158–170  	10487406
	5. Kloosterboer HJ 1997 Tibolone and its metabolites: pharmacology, tissue  specificity and effects in animal models of tumors. Gynecol Endocrinol  11(Suppl 1):63–68  	NO_MATCH
	6. Moore RA 1999 Livial: a review of clinical studies. Br J Obstet Gynaecol  106(Suppl 19):1–21  	10890791
	7. Klearchou N, Kanallaki-Kyparissi M, Deligeorgi F, Koliakou M, Karagian nis V, Mamopoulos M, The effect of Livial at the mammary gland. Mammo graphic and hypermicroscopic findings. The 9th International Menopause  Society World Congress on the Menopause, Yokohama, Japan, 1999; Abstract  P351  	NO_MATCH
	8. Kloosterboer HJ, Sands R 2000 Intracrinology: the secret of the tissue-spec ificity of tibolone. J Brit Menopause Soc 6(Suppl 2):23–27  	NO_MATCH
	9. Ederveen AGH, Kloosterboer HJ, The protective effect of tibolone on ovari ectomy-induced bone loss is blocked by an anti-estrogen. The First Amsterdam  Menopause Symposium, Amsterdam, The Netherlands, 1998; Abstract OST-04  	NO_MATCH
	10. Markiewicz L, Gurpide E 1990 In vitro evaluation of estrogenic, estrogen  antagonistic and progestagenic effects of a steroidal drug (Org OD-14) and its  metabolites on human endometrium. J Steroid Biochem 35:535–541  	2355729
	11. Tang B, Markiewicz L, Kloosterboer HJ, Gurpide E 1993 Human endometrial  3-hydroxysteroid dehydrogenase/isomerase can locally reduce intrinsic es trogenic/progestagenic activity ratios of a steroidal drug (Org OD 14). J Steroid  Biochem Mol Biol 45:345–351  	8499344
	12. Hammar M, Christau S, Nathorst-Boeoes J, Rud T, Garre K 1998 A double blind, randomised trial comparing the effects of tibolone and continuous  combined hormone replacement therapy in postmenopausal women with  menopausal symptoms. Br J Obstet Gynaecol 105:904–911  	9746385
	13. Valdivia I, Ortega D 2000 Mammographic density in postmenopausal women  treated with tibolone, estriol or conventional hormone replacement therapy.  Clin Drug Invest 20:101–107  	NO_MATCH
	14. Pasqualini JR, Chetrite GS 1999 Estrone sulfatase versus estrone sulfotrans ferase in human breast cancer: potential clinical applications. J Steroid Biochem  Mol Biol 69:287–292  	10419004
	15. Gompel A, Kandouz M, Siromachkova M, et al. 1997 The effect of tibolone  on proliferation, differentiation and apoptosis in normal breast cells. Gynecol  Endocrinol 11(Suppl 1):77–79  	NO_MATCH
	16. Lindsay R, Mackhart D, Krazewski A, Coupe J 1980 Prospective double-blind  trial of synthetic steroid (ORG OD 14) for preventing postmenopausal osteo porosis. Br Med J 281:456–457  	6992927
	17. Rymer J, Chapman M, Fogelman I 1990 OD14: a novel steroid for treatment  of menopausal symptoms. J Obstet Gynaecol 10:454–455  	NO_MATCH
	18. Geusens P, Dequeker J, Gielen J, Schot LPC 1991 Non-linear increase in  vertebral density induced by a synthetic steroid (ORG OD14) in women with  established osteoporosis. Maturitas 13:155–162  	1921738
	19. Berning B, Kuijk CV, Kuiper JW, Coelingh Bennink HJT, Kicovic PM,  Fauser BCJM 1996 Effects of two doses of tibolone on trabecular and cortical  bone loss in early postmenopausal women: a two-year randomized, placebo controlled study. Bone 19:395–399  	8894146
	20. Bjarnason NH, Bjarnason K, Jaarbo J, Rosenquist C, Christiansen C 1996  Tibolone: prevention of bone loss in late post-menopausal women. J Clin  Endocrinol Metab 81:2419–2422  	8675554
	21. Lippuner K, Haenggi W, Birkhaeuser MH, Casez JP, Jaeger P 1997 Prevention  of postmenopausal bone loss using tibolone or conventional peroral or trans dermal hormone replacement therapy with 17-estradiol and dydrogesterone.  J Bone Miner Res 12:806–812  	9144347
	22. Prelevic GM, Bartram C, Wood J, Okolo S, Ginsburg J 1996 Comparative  effects on bone mineral density of tibolone, transdermal estrogen and oral  estrogen/progestogen therapy in postmenopausal women. Gynecol Endocri nol 10:413–420  	9032569
	23. Riggs BL 1996 Editorial: tibolone as an alternative to estrogen for the pre vention of postmenopausal osteoporosis in selected postmenopausal women.  J Clin Endocrinol Metab 81:2417–2418  	8675553
	24. Rymer JM 1998 The effects of tibolone. Gynecol Endocrinol 12:213–220  	9675570
	25. Studd J, Arnala I, Kicovic PM, Zamblera D, Kroger H, Holland N 1998 A  randomized study of tibolone on bone mineral density in osteoporotic post menopausal women with previous fractures. Obstet Gynecol 92:574–579  	9764631
	26. Ross PD, Davis JW, Epstein RS, Wasnich RD 1991 Pre-existing fractures and  bone mass predict vertebral fracture incidence in women. Ann Intern Med  114:919–923  	2024857
	27. Melton III LJ, Atkinson EJ, O’Fallon WM, Wahner HW, Riggs BL 1993  Long-term fracture prediction by bone mineral assessed at different skeletal  sites. J Bone Miner Res 8:1227–1233  	8256660
	28. The Writing Group for the PEPI 1996 Effects of hormone therapy on bone  mineral density: results from the postmenopausal estrogen/progestin inter ventions (PEPI) trial. JAMA 276:1389–1396  	NO_MATCH
	29. McClung M, Clemmeson B, Daifotis A, et al. for the Alendronate Osteo porosis Prevention Study Group 1998 Alendronate prevents postmenopausal  bone loss in women without osteoporosis. A double-blind, randomized, con trolled trial. Ann Intern Med 128:253–261  	NO_MATCH
	30. Delmas PD, Bjarnason JH, Mitlak BH, et al. 1997 Effects of raloxifene on bone  mineral density, serum cholesterol concentrations, and uterine endometrium  in postmenopausal women. N Engl J Med 337:1641–1647  	9385122
	31. Mortenson L, Charles P, Bekker PJ, Digennaro J, Johnston Jr CC 1998 Risedr onate increases bone mass in an early postmenopausal population: two years  of treatment plus one year of follow-up. J Clin Endocrinol Metab 83:396–402  	9467547
	32. Doren M, Rubig A, Coelingh Bennink HJT, Holzgreve W 1999 Impact on  uterine bleeding and endometrial thickness: tibolone compared with contin uous combined estradiol and norethisterone acetate replacement therapy.  Menopause 6:299–306  	10614676
	33. Bjarnason NH, Bjarnason K, Haarbo J, Bennink HJTC, Christiansen C 1997  Tibolone: influence on markers of cardiovascular disease. J Clin Endocrinol  Metab 82:1752–1756  	9177376
	34. Farish E, Barnes JF, Rolton HA, Spowart K, Fletcher CD, Hart DM 1995  Effects of tibolone on lipoprotein (a) and HDL subfractions. Maturitas 20:  215–219  	7715475
	35. Hanggi W, Lippuner K, Riesen W, Jaeger P, Birkhauser MH 1997 Long term  influence of different postmenopausal hormone replacement regimens on  serum lipids and lipoprotein (a): a randomised study. Br J Obstet Gynaecol  104:708–717  	9197875
	36. Milner MH, Sinnott MM, Cooke TM, Kelly A, McGill T, Harrison RF 1996  A 2-year study of lipid and lipoprotein changes in postmenopausal women  with tibolone and estrogen-progestin. Obstet Gynecol 87:593–595  	8602314
	37. Cummings SR, Palermo L, Browner W, et al. 2000 Monitoring osteoporosis  therapy with bone densitometry. Misleading changes and regression to the  mean. JAMA 283:1318–1321  	NO_MATCH
1204460a.pdf
	Alcorta DA, Xiong Y, Phelps D, Hannon G, Beach D and  Barrett JC. (1996). Proc. Natl. Acad. Sci. USA, 93,  13742 – 13747.  	NO_MATCH
	Allsopp RC, Vaziri H, Patterson C, Goldstein S, Younglai  EV, Futcher AB, Greider CW and Harley CB. (1992).  Proc. Natl. Acad. Sci. USA, 89, 10114 – 10118.  	NO_MATCH
	Allsopp RC, Chang E, Kashefi-Aazam M, Rogaev EI,  Piatyszak MA, Shay JW and Harley CB. (1995). Exp.  Cell Res., 220, 194 – 200.  	NO_MATCH
	Bodnar AG, Ouellette M, Frolkis M, Holt SE, Chiu C-P,  Morin GB, Harley CB, Shay JW, Lichsteiner S and Wright  WE. (1998). Science, 279, 349 – 352.  	NO_MATCH
	Burns JE, Baird MC, Clark LJ, Burns P, Edington K,  Chapman C, Mitchell R, Robertson G, Soutar D and  Parkinson EK. (1993). Br. J. Cancer, 67, 1274 – 1284.  	NO_MATCH
	Collardo M, Medema RH, Garcia-Cao I, Dubuisson MLN,  Barradas M, Glassford J, Rivas C, Burgering BMT,  Serrano M and Lam EW-F. (2000). J. Biol. Chem., 275,  21960 – 21968.  	NO_MATCH
	Cristofolo VJ and Pignolo RJ. (1993). Physiol. Rev., 73,  617 – 638.  	NO_MATCH
	Dietrich C, Wallenfang K, Oesch F and Wieser R. (1997).  Exp. Cell Res., 232, 72 – 78.  	NO_MATCH
	Accumulation of p16INK4A can be cell division-independent  J Munro et al  	NO_MATCH
	Dimri GP, Lee X, Basile G, Acosta M, Scott G, Roskelley C,  Medrano EE, Linskens M, Rubelj I, Pereira-Smith O,  Peacocke M and Campisi J. (1995). Proc. Natl. Acad. Sci.  USA, 92, 9363 – 9367.  	NO_MATCH
	Durand B, Gao F-B and Ra M. (1997). EMBO J., 16, 306 –  317.  	NO_MATCH
	Durand B, FeroML, Roberts JM and RaMC. (1998). Curr.  Biol., 8, 431 – 440.  	NO_MATCH
	Goldstein S and Singal GP. (1974). Exp. Cell Res., 88, 359 –  364.  	NO_MATCH
	Hara E, Smith R, Parry D, Tahara H, Stone S and Peters G.  (1996). Mol. Cell Biol., 16, 859 – 867.  	NO_MATCH
	Harley CB. (1991). Mutat. Res., 256, 271 – 282.  	NO_MATCH
	Hayflick L. (1965). Exp. Cell Res., 37, 614 – 636.  	NO_MATCH
	Holliday R. (1996). BioEssays, 18, 3 – 5.  	NO_MATCH
	Jiang X-R, Jimenez G, Chang E, Frolkis M, Kusler B, Sage  M, Beeche M, Bodnar AG, Wahl GM, Tlsty TD and Chiu  C-P. (1999). Nature Genet., 21, 111 – 114.  	NO_MATCH
	Jones CJ, Kipling D, Morris M, Hepburn P, Skinner J,  Bounacer A, Wyllie FS, Ivan M, Bartek J, Wynford Thomas and Bond JA. (2000). Mol. Cell Biol., 20, 5690 –  5699.  	NO_MATCH
	Kamijo T, van de Kamp E, Chong MJ, Zindy F, Diehl JA,  Sherr CJ and McKinnon PJ. (1999). Cancer Res., 59,  2464 – 2469.  	NO_MATCH
	Karlseder J, Broccoli D, Dal Y, Hardy S and de Lange T.  (1999). Science, 283, 1321 – 1324.  	NO_MATCH
	Kipling D and Cooke HJ. (1990). Nature, 347, 400 – 402.  	NO_MATCH
	Kiyono T, Foster SA, Koop JI, McDougal JK, Galloway  DA and Klingelhutz AJ. (1998). Nature, 396, 84 – 88.  	NO_MATCH
	Lee HW, Blasco MA, Gottlieb GJ, Horner II JW, Greider  CW and DePinho RA. (1998). Nature, 392, 569 – 574.  	NO_MATCH
	Makarov VL, Hirose Y and Langmore JP. (1997). Cell, 88,  657 – 666.  	NO_MATCH
	Mazars GR and Jat PS. (1997). Proc. Natl. Acad. Sci. USA,  94, 151 – 156.  	NO_MATCH
	McConnell BB, Starborg M, Brookes S and Peters G. (1998).  Curr. Biol., 8, 351 – 354.  	NO_MATCH
	Morales CP, Holt SE, Ouellette M, Kaur KJ, Yan Y, Wilson  KS, White MA, Wright WE and Shay JW. (1999). Nature  Genet., 21, 115 – 118.  	NO_MATCH
	Olovnikov AM. (1973). J. Theor. Biol., 41, 181 – 190.  	NO_MATCH
	Palmero I, Pantoja C and Serrano M. (1998). Nature, 395,  125 – 126.  	NO_MATCH
	Polyak K, Kato J-Y, Solomon MJ, Sherr CJ, Massague J,  Roberts JM and Ko A. (1994). Genes Dev., 8, 9 – 22.  	NO_MATCH
	Robles SJ and Adami GR. (1998). Oncogene, 16, 1113 – 1123.  	NO_MATCH
	Rubelj I and Vondracek Z. (1999). J. Theor. Biol., 197, 425 –  438.  	NO_MATCH
	Serrano M, Lee HW, Chin L, Cordon-Cardo C, Beach D and  DePinho RA. (1996). Cell, 85, 27 – 37.  	NO_MATCH
	Serrano M, Lin AW, McCurrach ME, Beach D and Lowe  SW. (1997). Cell, 88, 593 – 602.  	NO_MATCH
	Schor SL and Schor AM. (1987). BioEssays, 7, 200 – 204.  	NO_MATCH
	Shelton D, Chang E, Whittier PS, Choi D and Funk WD.  (1999). Curr. Biol., 9, 939 – 945.  	NO_MATCH
	Sitte N, Saretzki G and von Zglinicki T. (1998). Free Rad.  Biol. Med., 24, 885 – 893.  	NO_MATCH
	Smith JR and Whitney RG. (1980). Science, 207, 82 – 84.  van Steensel B, Smogorzewska A and de Lange T. (1998).  Cell, 92, 401 – 413.  	NO_MATCH
	Stein GH and Dulic V. (1995). BioEssays, 17, 537 – 543.  	NO_MATCH
	Stott FJ, Bates S, James MJ, McConnell BB, Starborg M,  Brookes S, Palmero I, Ryan K, Hara E, Vousden K and  Peters G. (1998). EMBO J., 17, 5001 – 5014.  	NO_MATCH
	Takuwa N and Takuwa Y. (1997). Mol. Cell Biol., 17, 5348 –  5358.  	NO_MATCH
	Tresini M, Mawal-Dewan M, Cristofolo VJ and Sell C.  (1998). Cancer Res., 58, 1 – 4.  	NO_MATCH
	Vaziri H and Benchimol S. (1998). Curr. Biol., 8, 279 – 282.  	NO_MATCH
	Vaziri H, West MD, Allsopp RC, Davison TS, Wu Y-S,  Arrowsmith CH, Poirier GG and Benchimol S. (1997).  EMBO J., 16, 6018 – 6033.  	NO_MATCH
	Wong H and Riabowol K. (1996). Exp. Geront., 31, 311 –  325.  	NO_MATCH
	Wright WE, Brasiskyte D, Piatyszek MA and Shay JW.  (1996). EMBO J., 15, 1734 – 1741.  	NO_MATCH
	von Zglinicki T, Saretzki G, Docke W and Lotze C. (1995).  Exp. Cell Res., 220, 186 – 193.  	NO_MATCH
	Zindy F, Quelle DE, Roussel MF and Sherr CJ. (1997).  Oncogene, 15, 203 – 211.  	NO_MATCH
1204445a.pdf
	Ahmed FE and Setlow RB. (1977). Cancer Res., 37, 3414 –  3419.  	NO_MATCH
	Balajee AS, May A and Bohr VA. (1998). Mutation Res., 404,  3 – 11.  	NO_MATCH
	Barratt RA, Kao G, McKenna WG, Juang J and Muschel  RJ. (1998). Cancer Res., 58, 2639 – 2645.  	NO_MATCH
	Beetham KL and Tolmach LJ. (1982). J. Cell. Physiol., 113,  385 – 397.  	NO_MATCH
	Beisker W, Hittelman WN. (1988). Exp. Cell. Res., 174,  156 – 167.  	NO_MATCH
	Biade S, Stobbe CC and Chapman JD. (1997). Radiat. Res.,  147, 416 – 421.  	NO_MATCH
	Cohn SM and Lieberman MW. (1984). J. Biol. Chem., 259,  12463 – 12469.  	NO_MATCH
	Dolbeare F, Gratzner H, Pallavicini MG and Gray JW.  (1983). PNAS, 80, 5573 – 5577.  	NO_MATCH
	Featherstone C and Jackson SP. (1999). Curr. Biol., 9,  R759 –R761.  	NO_MATCH
	Fox MH, Arndt-Jovin DJ, Jovin TM, Baumann PH, Robert Nicould M. (1991). J. Cell. Sci., 99, 247 – 253.  	NO_MATCH
	Gowen LC, Avrutskaya AV, Latour AM, Koller BH,  Leadon SA. (1998). Science, 281, 1009 – 1012.  	NO_MATCH
	Haaf T, Raderschall E, Reddy G, Ward DC, Radding CM  and Golub EI. (1999). J. Cell. Biol., 144, 11 – 20.  	NO_MATCH
	Hartwell LH and Kastan MB. (1994). Science, 266, 1821 –  1828.  	NO_MATCH
	Hoy CA, Carswell C and Schimke RT. (1993). Mutat. Res.,  290, 217 – 230.  	NO_MATCH
	Jacquet P, de Saint-Georges L, Barrio S, Baugnet-Mahieu L.  (1995). Int. J. Radiat. Biol., 67, 347.  	NO_MATCH
	Jin P, Hardy S and Morgan D. (1998). J. Cell. Biol., 141,  875 – 885.  	NO_MATCH
	Juan G, Li X and Darzynkiewicz Z. (1997). Cancer Res., 57,  803 – 807.  	NO_MATCH
	Jung T and Streer C. (1992). Int. J. Radiat. Biol., 62, 161 –  168.  	NO_MATCH
	Kalle WHJ, Haekamp-van Dokkum AM, Lohman PHM,  Nataranjan AT, van Zeeland AA and Mullenders LHF.  (1993). Anal. Biochem., 208, 228 – 236.  	NO_MATCH
	Kao G, McKenna WG, Maity A, Blank K, Muschel RJ.  (1997). Cancer Res., 57, 753 – 758.  	NO_MATCH
	Kao GD, McKenna WG and Muschel RJ. (1999). J. Biol.  Chem., 274, 34779 – 34784.  	NO_MATCH
	Kaufmann WK, Kies PE. (1998). Mutat. Res., 400, 153 – 167.	NO_MATCH
	Kill IR, Bridgger JM, Campbell KHS, Maldonado-Codina  G and Hutchinson CJ. (1991). J. Cell Sci., 100, 869 – 876.  	NO_MATCH
	Lau CC and Pardee AB. (1982). PNAS USA, 79, 2942 – 2946.  	NO_MATCH
	Li J, Meyer A and Donoghue D. (1997). PNAS USA, 94,  502 – 507.  	NO_MATCH
	Liao H, Winkfein RJ, Mack G, Rattner JB and Yen TJ.  (1995). J. Cell Biol., 130, 507 – 518.  	NO_MATCH
	Lock RB. (1992). Cancer Res., 52, 1817 – 1822.  	NO_MATCH
	Maity A, McKenna WG and Muschel RJ. (1995). EMBO J.,  14, 603 – 609.  	NO_MATCH
	Murnane JP. (1995). Cancer and Metastasis Reviews, 14, 17 –  29.  	NO_MATCH
	Nagasawa H, Keng P, Harley R, Dahlberg W and Little JB.  (1994). Int. J. Radiat. Biol., 66, 373 – 379.  	NO_MATCH
	Nakayasu H and Berezney R. (1989). J. Cell. Biol., 108, 1 –  11.  	NO_MATCH
	Nishii K, Kabarowski JH, Gibbons DL, Griths SD, Titley  I, Wiedemann LM and Greaves MF. (1996). Oncogene, 13,  2225 – 2234.  	NO_MATCH
	O’Connor PM, Ferris DK, Pagano M, Draetta G, Pines J,  Hunter T, Longo DL and Kohn KW. (1993). J. Biol.  Chem., 268, 8298 – 8308.  	NO_MATCH
	Ohtsubo M, Theodoras AM, Schumacher J, Roberts JM and  Pagano M. (1995). Mol. Cell. Biol., 15, 2612 – 2624.  	NO_MATCH
	O’Keefe RT, Henderson SC and Spector DL. (1992). J. Cell.  Biol., 116, 1095 – 1110.  	NO_MATCH
	Paull TT, Rogakou EP, Yamazaki V, Kirchgessner CU,  Gellert M and Bonner WM. (2000). Curr. Biol., 10, 886 –  895.  	NO_MATCH
	Pines J and Hunter T. (1994). EMBO J., 13, 3772 – 3781.  	NO_MATCH
	Richold M and Arlett CF. (1972). Int. J. Radiat. Biol. Relat.  Stud. Phys. Chem. Med., 21, 127 – 136.  	NO_MATCH
	Rieber MS and Rieber M. (1997). DNA Cell Biol., 16, 121 –  125.  	NO_MATCH
	Scully R, Chen J, Ochs RL, Keegan K, Hoekstra M and  Feunteun J. (1997). Cell., 90, 425 – 435.  	NO_MATCH
	Selden JR, Dolbeare F, Clair JH, Nichols WW, Miller JE,  Kleemeyer KM, Hyland RJ and DeLuca JG. (1993).  Cytometry, 14, 154 – 167.  	NO_MATCH
	Sherwood S, Rush D, Kung A and Schimke R. (1994). Exp.  Cell Res., 211, 275 – 281.  	NO_MATCH
	Stefanini M, Reuser A and Bootsma D. (1982). Somatic Cell  Genet., 8, 635 – 642.  	NO_MATCH
	Detection of repair during G2 DNA damage checkpoint  GD Kao et al  	NO_MATCH
	Takata M, Sasaki MS, Sonoda E, Morrison C, Hashimoto  M, Utsumi H, Yamaguchi-Iwai Y, Shinohara A and  Takeda S. (1998). EMBO J., 17, 5497 – 5508.  	NO_MATCH
	Tsao Y-P, D’Arpa P and Liu L. (1992). Cancer Res., 52,  1823 – 1829.  	NO_MATCH
	Van Dierendonck JH, Keyzer R, van de Velde CJH and  Cornelissse CJ. (1989). Cytometry, 10, 143 – 150.  	NO_MATCH
	Vijg J, Mullaart E, van der Schans GP, Lohman PH and  Knook DL. (1984). Mutat. Res., 132, 129 – 138.  	NO_MATCH
	Wang XQ and Ellem KA. (1994). Exp. Cell. Res., 212, 176 –  189.  	NO_MATCH
	Wang Y, Cortez D, Yazdi P, Ne N, Elledge SJ and Qin J.  (2000). Genes Dev., 14, 927 – 939.  	NO_MATCH
	Zelle B, Berends F and Lohman PH. (1980). Mutat. Res., 73,  157 – 169.  	NO_MATCH
	Zhong Q, Chen CENP-F, Li S, Chen Y, Wang CC, Xiao J,  Chen PL, Sharp ZD and Lee WH. (1999). Science, 285,  747 – 750.  	NO_MATCH
1204462a.pdf
	Alberti L, Borrello MG, Ghizzoni S, Torriti F, Rizzetti MG  and Pierotti MA. (1998). Oncogene, 17, 1079 – 1087.  	NO_MATCH
	Arighi E, Alberti L, Torriti F, Ghizzoni S, Rizzetti MG,  Pelicci G, Pasini B, Bongarzone I, Piutti C, Pierotti MA  and Borrello MG. (1997). Oncogene, 14, 773 – 782.	NO_MATCH
	Asai N, Murakami H, Iwashita T and Takahashi M. (1996).  J. Biol. Chem., 271, 17644 – 17649.  	NO_MATCH
	Besset V, Scott RP and Ibanez CF. (2000). J. Biol. Chem.,  275, 39159-39166.  	NO_MATCH
	Bongarzone I, Monzini N, Borrello MG, Carcano C,  Ferraresi G, Arighi E, Mondellini P, Della Porta G and  Pierotti MA. (1993). Mol. Cell. Biol., 13, 358 – 366.  	NO_MATCH
	Bongarzone I, Pierotti MA, Monzini N, Mondellini P,  Manenti G, Donghi R, Pilotti S, Grieco M, Santoro M,  Fusco A, Vecchio G and Della Porta G. (1989). Oncogene,  4, 1457 – 1462.  	NO_MATCH
	Bordeaux MC, Forcet C, Granger L, Corset V, Bidaud C,  Billaud M, Bredesen DE, Edery P and Mehlen P. (2000).  EMBO J., 19, 4056 – 4063.  	NO_MATCH
	Borrello MG, Pelicci G, Arighi E, De Filippis L, Greco A,  Bongarzone I, Rizzetti MG, Pelicci PG and Pierotti MA.  (1994). Oncogene, 9, 1661 – 1668.  	NO_MATCH
	Borrello MG, Alberti L, Arighi E, Bongarzone I, Battistini  C, Bardelli A, Pasini B, Piutti C, Rizzetti MG, Mondellini  P, Radice MT and Pierotti MA. (1996). Mol. Cell. Biol.,  16, 2151 – 2163.  	NO_MATCH
	Creedon DJ, Tansey MG, Baloh RH, Osborne PA, Lampe  PA, Fahrner TJ, Heuckeroth RO, Milbrandt J and  Johnson Jr EM. (1997). Proc. Natl. Acad. Sci. USA, 94,  7018 – 7023.  	NO_MATCH
	Durbec P, Marcos-Gutierrez CV, KilKenny C, Grigoriou M,  Wartiowaara K, Suvanto P, Smith D, Ponder B,  Costantini F, Saarma M, Sariola H and Pachnis V.  (1996). Nature, 381, 789 – 793.  	NO_MATCH
	Durick K, Yao VJ, Borrello MG, Bongarzone I, Pierotti MA  and Taylor SS. (1995). J. Biol. Chem., 270, 24642 – 24645.  	NO_MATCH
	Durick K, Wu RY, Gill GN and Taylor SS. (1996). J. Biol.  Chem., 271, 12691 – 12694.  	NO_MATCH
	Durick K, Gill GN and Taylor SS. (1998). Mol. Cell. Biol.,  18, 2298 – 2308.  	NO_MATCH
	Fambrough D, McClure K, Kazlauskas A and Lander ES.  (1999). Cell, 97, 727 – 741.  	NO_MATCH
	Fischer AH, Bond JA, Taysavang P, Battles OE and  Wynford-Thomas D. (1998). Am. J. Pathol., 153, 1443 –  1450.  	NO_MATCH
	Fixman ED, Naujokas MA, Rodrigues GA, Moran MF and  Park M. (1995). Oncogene, 10, 237 – 249.  	NO_MATCH
	Gotoh N, Toyoda M and Shibuya M. (1997). Mol. Cell.  Biol., 17, 1824 – 1831.  	NO_MATCH
	Guo M and Hay BA. (1999). Curr. Opin. Cell. Biol., 11, 745 –  752.  	NO_MATCH
	Hayashi H, Ichihara M, Iwashita T, Murakami H, Shimono  Y, Kawai K, Kurokawa K, Murakumo Y and Imai T.  (2000). Oncogene, 14, 4469 – 4475.  	NO_MATCH
	Hennige AM, Lammers R, Arlt D, Hoppner W, Strack V,  Niederfellner G, Seif FJ, Haring H and Kellerer M. (2000).  Mol. Cell. Endocrinol., 167, 69 – 76.  	NO_MATCH
	Hill RJ, Zozulya S, Lu YL, Hollenbach PW, Joyce-Shaikh B,  Bogenberger J and Gishizky ML. (1996). Cell Growth  Di., 7, 1125 – 1134.  	NO_MATCH
	Ishizaka Y, Ochiai M, Tahira T, Sugimura T and Nagao M.  (1989). Oncogene, 4, 789 – 794.  	NO_MATCH
	Kavanaugh WM and Williams LJ. (1994). Science, 266,  1862 – 1865.  	NO_MATCH
	Liu X, Vega QC, Decker RA, Pandey A, Worby CA and  Dixon JE. (1996). J. Biol. Chem., 271, 5309 – 5312.  	NO_MATCH
	Lorenzo MJ, Gish GD, Houghton C, Stonehouse TJ,  Pawson T, Ponder BAJ and Smith DP. (1997). Oncogene,  14, 763 – 771.  	NO_MATCH
	Lowenstein EJ, Daly RJ, Batzer AG, Li W, Margolis B,  Lammers R, Ullrich A, Skolnik EY, Bar-Sagi D and  Schlessinger J. (1992). Cell, 70, 431 – 442.  	NO_MATCH
	Migliaccio E, Giorgio M, Mele S, Pelicci G, Reboldi P,  Pandolfi PP, Lanfrancone L and Pelicci PG. (1999).  Nature, 402, 309 – 313.  	NO_MATCH
	Milbrandt J, de Sauvage FJ, Fahrner TJ, Baloh RH, Leitner  ML, Tansey MG, Lampe PA, Heuckeroth RO, Kotzbauer  PT, Simburger KS, Golden JP, Davies JA, Vejsada R,  Kato AC, Hynes M, Sherman D, Nishimura M, Wang LC,  	NO_MATCH
	Vandlen R, Moat B, Klein RD, Poulsen K, Gray C,  Garces A, Henderson CE, Phillips HS and Johnson Jr EM.  (1998). Neuron, 20, 245 – 253.  	NO_MATCH
	Pandey A, Duan H, Di Fiore PP and Dixit VM. (1995). J.  Biol. Chem., 270, 21461 – 21463.  	NO_MATCH
	Pandey A, Liu X, Dixon JE, Di Fiore PP and Dixit VM.  (1996). J. Biol. Chem., 271, 10607 – 10610.  	NO_MATCH
	Pasini B, Borrello MG, Greco A, Bongarzone I, Luo Y,  Mondellini P, Alberti L, Miranda C, Arighi E, Bocciardi  R, Seri M, Barone V, Romeo G and Pierotti MA. (1995).  Nature Genet., 10, 35 – 40.  	NO_MATCH
	Pasini B, Ceccherini I and Romeo G. (1996). Trends Genet.,  12, 138 – 144.  	NO_MATCH
	Pelicci G, Lanfrancone L, Grignani F, McGlade J, Cavallo  F, Forni G, Nicoletti I, Pawson T and Pelicci PG. (1992).  Cell, 70, 93 – 104.  	NO_MATCH
	Pelicci G, Lanfrancone L, Salcini AE, Romano A, Mele S,  Borrello MG, Segatto O, Di Fiore PP and Pelicci PG.  (1995). Oncogene, 11, 899 – 907.  	NO_MATCH
	Pierotti MA, Bongarzone I, Borrello MG, Greco A, Pilotti S  and Sozzi G. (1996). Genes Chrom. Cancer, 16, 1 – 14.  	NO_MATCH
	Porter AC and Vaillancourt RR. (1998). Oncogene, 17,  1343 – 1352.  	NO_MATCH
	Santoro M, Wong WT, Aroca P, Santos E, Matoskova B,  Grieco M, Fusco A and Di Fiore PP. (1994). Mol. Cell.  Biol., 14, 663 – 675.  	NO_MATCH
	Schlessinger J. (1993). Trends Biochem. Sci., 18, 273 – 275.  	NO_MATCH
	Segoun-Cariou C and Billaud M. (2000). J. Biol. Chem.,  275, 356 – 3576.  	NO_MATCH
	Songyang Z, Carraway III KL, Eck MJ, Harrison SC,  Feldman RA, Mohammadi M, Schlessinger J, Hubbard  SR, Smith DP, Eng C, Lorenzo MJ, Ponder BAJ, Mayer  BJ and Cantley LC. (1995). Nature, 373, 536 – 539.  	NO_MATCH
	Songyang Z, Shoelson SE, McGlade J, Olivier P, Pawson T,  Bustelo XR, Barbacid M, Sabe H, Hanafusa H and Yi T.  (1994). Mol. Cell. Biol., 14, 2777 – 2785.  	NO_MATCH
	Takahashi M, Buma Y, Iwamoto T, Inaguma Y, Ikeda H  and Hiai H. (1988). Oncogene, 3, 571 – 578.  	NO_MATCH
	Takahashi M, Ritz J and Cooper GM. (1985). Cell, 42, 581 –  588.  	NO_MATCH
	Thomas D and Bradshaw RA. (1997). J. Biol. Chem., 272,  22293 – 22299.  	NO_MATCH
	Trub T, Choi WE, Wolf G, Ottinger E, Chen YJ, Weiss M  and Shoelson SE. (1995). J. Biol. Chem., 270, 18205 –  18208.  	NO_MATCH
	Trupp M, Arenas E, Fainzilber M, Nilsson AS, Sieber BA,  Grigoriou M, KilKenny C, Salazar-Grueso E, Pachnis V  and Arumae U. (1996). Nature, 381, 785 – 788.  	NO_MATCH
	Trupp M, Scott R, Whittemore SR and Ibanez CF. (1999). J.  Biol. Chem., 274, 20885 – 20894.  	NO_MATCH
	Valius M, Bazenet C and Kazlauskas A. (1993). Mol. Cell.  Biol., 13, 133 – 143.  	NO_MATCH
	van Weering DHJ and Bos JL. (1997). J. Biol. Chem., 272,  249 – 254.  	NO_MATCH
v007p00083.pdf
v007p00155.pdf
v007p00146.pdf
v007p00135.pdf
Clin Infect Dis.-2001-Chandrasekar-546-51.pdf
	1. Nosanchuk JD, Sepkowitz KA, Pearse RN, et al. Infectious compli cations of autologous bone marrow and peripheral stem cell trans plantation for refractory leukemia and lymphoma. Bone Marrow  Transplant 1996; 18:355–9.  	8864446
	2. Mossad JB, Longworth DL, Goormastic M, et al. Early infectious com plications in autologous bone marrow transplantation: a review of 219  patients. Bone Marrow Transplant 1996; 18:265–71.  	8864433
	3. D’Antonio D, Iacone A, Pierelli L, et al. Patterns of recovery phase  infection after autologous blood progenitor cell transplantation in pa tients with malignancies. The Gruppo Italiano di Studio per la Man ipolazione Cellulare in Ematologia. Eur J Clin Microbiol Infect Dis  1995; 14:552–6.  	7588835
	4. Klumpp TR, Mangan KF, Goldbert SL, et al. Granulocyte colony-stim ulating factor accelerates neutrophil engraftment following peripheral  blood stem cell transplantation: a prospective, randomized trial. J Clin  Oncol 1995; 13:1323–7.  	7543563
	5. Hornedo J, Sola C, Solano C, et al. Multicenter, prospective, random ized study of the role of granulocyte colony-stimulating factor (G-CSF)  in the post transplant period following high-dose chemotherapy  (HDC), supported with G-CSF mobilized, peripheral blood stem cells  (PBSC), in breast cancer patients [abstract 2980]. Ann Oncol 1996;  7(Suppl 5):63.  	NO_MATCH
	6. Gilbert C, Meisenberg B, Vredenburgh J, et al. Sequential prophylactic  oral and empiric once-daily parenteral antibiotics for neutropenia and  fever after high-dose chemotherapy and autologous bone marrow sup port. J Clin Oncol 1994; 12:1005–11.  	8164024
	7. Peters WP, Ross M, Vredenburgh JJ, et al. The use of intensive clinic  support to permit outpatient autologous bone marrow transplantation  for breast cancer. Semin Oncol 1994; 21(Suppl 7):25–31.  	7916487
	8. Meisenberg B, Gollard R, Brehm T, et al. Prophylactic antibiotics elim inate bacteremia and allow safe outpatient management following high dose chemotherapy and autologous stem cell rescue. Support Care  Cancer 1996; 4:364–9.  	8883230
	9. Meisenberg BR, Miller WE, McMillan R, et al. Outpatient high-dose  chemotherapy with autologous stem-cell rescue for hematologic and  nonhematologic malignancies. J Clin Oncol 1997; 15:11–7.  	8996119
	10. Jagannath S, Vesole DH, Zhang M, et al. Feasibility and cost-effec tiveness of outpatient autotransplants in multiple myeloma. Bone Mar row Transplant 1997; 20:445–50.  	9313876
	11. Kolbe K, Domkin D, Derigs HG, Bhakdi S, Huber C, Aulitzky WE.  Infectious complications during neutropenia subsequent to peripheral  blood stem cell transplantation. Bone Marrow Transplant 1997; 19:  143–7.  	9116611
	12. Kirk JL, Greenfield RA, Slease RB, et al. Analysis of early infectious  complications after autologous bone marrow transplantation. Cancer  1988; 62:2445–50.  	3052792
	13. Ketterer N, Espinouse D, Chomarat M, et al. Infections following pe ripheral blood progenitor cell transplantation for lymphoproliferative  malignancies: etiology and potential risk factors. Am J Med 1999; 106:  191–7.  	10230749
	14. Bochud PY, Eggiman P, Calandra T, et al. Bacteremia due to viridans  streptococcus in neutropenic patients with cancer: clinical spectrum  and risk factors. Clin Infect Dis 1994; 18:25–31.  	8092175
	15. Salazar R, Sola´ C, Maroto P, et al. Infectious complications in 126  patients treated with high-dose chemotherapy and autologous periph eral blood stem cell transplantation. Bone Marrow Transplant 1999;  23:27–33.  	10037047
	16. Louie TJ, Bow EJ, Krulicki W, et al. Efficacy of quinolones for the  prevention of bacteremia in neutropenic rats. Rev Infect Dis 1989;  11(Suppl 5):1242–3.  	NO_MATCH
	17. Bow EJ, Mandell LA, Louis TJ, et al. Quinolone-based antibacterial  chemoprophylaxis in neutropenic patients: effect of augmented gram positive activity on infectious morbidity. Ann Intern Med 1996; 125:  183–90.  	NO_MATCH
	18. Goodman JL, Winston DJ, Greenfield RA, et al. Does fluconazole pre vent fungal infections in patients undergoing bone marrow transplan tation? Results of a randomized controlled trial. N Engl J Med 1992;  326:845–51.  	1542320
	19. Malik IA, Khan WA, Karim M, et al. Feasibility of outpatient man agement of fever in cancer patients with low-risk neutropenia: results  of a prospective randomized trial. Am J Med 1995; 98:224–31.  	7872337
	20. Talcott JA, Whalen A, Clark J, et al. Home antibiotic therapy for low risk cancer patients with fever and neutropenia: a pilot study of 30  patients based on a validated prediction rule. J Clin Oncol 1994; 12:  107–14.  	8270967
	21. Rubenstein EB, Rolston K. Outpatient management of febrile episodes  in neutropenic cancer patients. Support Care Cancer 1994; 2:369–73.  	7858928
	22. Bow EJ, Ronald AR. Antibacterial chemoprophylaxis for neutropenic  patients: where do we go from here? Clin Infect Dis 1993; 17:333–7.  	8218672
	23. Lee CK, Gingrich RD, Hohl RJ, et al. Engraftment syndrome in au tologous bone marrow and peripheral stem cell transplantation. Bone  Marrow Transplant 1995; 16:175–82.  	7581119
	24. Ravoet C, Feremans W, Husson B, et al. Clinical evidence for engraft ment syndrome associated with early and steep neutrophil recovery  after autologous blood stem cell transplantation. Bone Marrow Trans plant 1996; 18:943–7.  	8932849
	25. Vescio R, Schiller G, Stewart AK, et al. Multicenter phase III trial to  evaluate CD341 selected versus unselected autologous peripheral blood  progenitor cell transplantation in multiple myeloma. Blood 1999; 93:  1858–68.  	10068658
5600987a.pdf
	Andreasen PA, Kjoller L, Christensen L, Duffy MJ: The urokinase-type plasminogen  activator system in cancer metastasis: a review. Int J Cancer 72:1±22, 1997  	9212216
	Blasi F: uPA uPAR PAI-1: key intersection of proteolytic adhesive and chemotactic  highway? Immunol Today 18:415±417, 1997  	9293155
	Bode W, Fernandez-Catalan C, Tschesche H, Grams F, Nagase H, Maskos K:  Structural properties of matrix metalloproteinases. Cell Mol Life Sci 55:639±652,  1999  	10357232
	Burgle M, Koppitz M, Riemer C, et al: Inhibition of the interaction of urokinase type plasminogen activator (uPA) with its receptor (uPAR) by synthetic  peptides. Biol Chem 378:3±4, 1997  	9165076
	Claas C, Herrmann K, Matzku M, MoÈller P, ZoÈller M: Developmentally regulated  expression of metastasis-associated antigens in the rat. Cell Growth Diff 7:663±  678, 1996  	8732676
	Cubellis MV, Andreasen P, Ragno P, Mayer M, Dano K, Blasi F: Accessibility of  receptor-bound urokinase to type-1 plasminogen activator inhibitor. Proc Natl  Acad Sci USA 86:4828±4832, 1989  	2544876
	Curran S, Murray GI: Matrix metalloproteinases in tumour invasion and metastasis. J  Pathol 189:300±308, 1999  	10547590
	Farias-Eisner R, Vician L, Silver A, Reddy S, Rabbani SA, Herschman HR: The  urokinase plaminogen activator receptor (UPAR) is preferentially induced by  nerve growth factor in PC12 pheochromoblastoma cells and is required for  NGF-driven differentiation. J Neurosci 20:230±239, 2000  	10627600
	Ghiso JA, Alonso DF, Farias EF, Gomez DE, deKier-Joffe EB: Deregulation of the  signaling pathways controlling urokinase production. Its relationship with the  invasive phenotype. Eur J Biochem 263:295±304, 1999  	10406935
	Kim J, Yu W, Kovalski K, Ossowski L: Requirement for speci®c proteases in cancer  cell intravasation as revealed by a novel semiquantitative RT-PCR-based assay.  Cell 94:353±362, 1998  	9708737
	Kitajima Y, Aoyama Y, Seishima M: Transmembrane signaling for adhesive  regulation of desmosomes and hemidesmosomes, and for cell-cell  detachment induced by pemphigus IgG in cultured keratinocytes:  involvement of protein kinase C. J Invest Dermatol 4:137±144, 1999  	10536988
	Kristensen P: Localization of components from the plasminogen activation system in  mammalian tissues. APIMS 29:1±27, 1992  	1337257
	Kwaan HC: The plasminogen-plasmin system in malignancy. Cancer Metastasis Rev  11:291±311, 1992  	1423820
	Liotta LA, Stetler-Stevenson WG: Metalloproteinases and cancer invasion. Sem  Cancer Biol 1:99±106, 1990  	2103492
	Lund LR, Ellis V, Ronne E, Pyke C, Dano K: Transcriptional and post transcriptional regulation of the receptor for urokinase-type plasminogen  activator by cytokines and tumor promoters in the human lung carcinoma cell  line A549. Biochem J 310:345±352, 1995  	7646466
	Nagase H: Activation mechanisms of matrix metalloproteinases. Biol Chem 378:151±  160, 1997  	9165065
	Nguyen DH, Catling AD, Webb DJ, et al: Myosin light chain kinase functions  downstream of Ras/ERK to promote migration of urokinase-type  plasminogen activator-stimulated cells in an integrin-selective manner. J Cell  Biol 146:149±164, 1999  	10402467
	Ohtani H: Stromal reaction in cancer tissue: pathophysiologic signi®cance of the  expression of matrix-degrading enzymes in relation to matrix turnover and  immune/in¯ammatory reactions. Pathol Int 48:1±9, 1998  	9589457
	Plesner T, Behrendt N, Ploug M: Structure, function and expression on blood and  bone marrow cells of the urokinase-type plasminogen activator receptor,  uPAR. Stem Cells 15:398±408, 1997  	9402652
	Ploug M, Ellis V: Structure-function relationships in the receptor for urokinase-type  plasminogen activator. Comparison to other members of the Ly-6 family and  snake venom alpha-neurotoxins. FEBS Lett 349:163±168, 1994  	8050560
	Ploug M, Ronne E, Behrendt N, Jensen AL, Blasi F, Dano K: Cellular receptor for  urokinase plasminogen activator. Carboxyl terminal processing and membrane  anchoring by glycosyl phosphatidylinositol. J Biol Chem 266:1926±1933, 1991  	NO_MATCH
	Price JT, Bonovich MT, Kohn EC: The biochemistry of cancer dissemination. Crit  Rev Biochem Mol Biol 32:175±253, 1997  	9239493
	Reuning U, Magdolen V, Wilhelm O, Fischer K, Lutz V, Graeff H, Schmitt M:  Multifunctional potential of the plasminogen activation system in tumor  invasion and metastasis. Int J Oncol 13:893±906, 1998  	9772277
	RoÈsel M, Claas C, Herlevsen M, Seiter S, ZoÈller M: Identi®cation of a new  phosphatidyl-inositol anchored member of the family of plasminogen activators  as metastasis-associated molecule. Oncogene 17:1989±2002, 1998  	NO_MATCH
	Shetty S, Idell S: A urokinase receptor mRNA binding protein±mRNA interaction  regulates receptor expression and function in human pleural mesothelioma  cells. Arch Biochem Biophys 356:265±279, 1998  	9705217
	Taniguchi T, Kakkar AK, Tuddenham EG, Williamson RC, Lemoine NR:  Enhanced expression of the urokinase receptor induced through the tissue  factor VIIa pathway in human pancreatic cancer. Cancer Res 58:4461±4467,  1998  	9766679
	Wang GJ, Collinge M, Blasi F, Pradi R, Bender JR: Posttranscriptional regulation of  urokinase plasminogen activator receptor messenger RNA levels by leukocyte  integrin engagement. Proc Natl Acad Sci USA 95:6296±6301, 1998  	9600959
	Wie Y, Yang X, Liu Q, Wilkins JA, Chapman HA: A role for caveolin and the  urokinase receptor in integrin-mediated adhesion and signaling. J Cell Biol  144:1285±1294, 1999  	10087270
	WuÈrfel J, Selter S, Stassar M et al: Cloning of the human homologue of the metastasis associated rat C4.4A molecule. Gene, in press  	11179665
	Yu AE, Hewitt RE, Connor EW, Stetler-Stevenson WG: Matrix metalloproteinases.  Novel targets for directed cancer therapy. Drugs Aging 11:229±244, 1997  	9303281
5600968a.pdf
	Allavena P, Piemonti L, Longoni D, Bernasconi S, Stoppacciaro A, Ruco L,  Mantovani A: IL-10 prevents the differentiation of monocytes to dendritic cells  but promotes their maturation to macrophages. Eur J Immunol 28:359±369,  1998  	9485215
	Altmeyer P, Matthes U, Pawlak F, et al: Antipsoriatic effect of fumaric acid  derivatives. Results of a multicenter double-blind study in 100 patients. J Am  Acad Dermatol 30:977±981, 1994  	8188891
	Asadullah K, Schmid H, Friedrich M, Randow F, Volk HD, Sterry W, DoÈcke W-D:  In¯uence of monomethylfumarate on monocytic cytokine formationÐ  explanation for adverse and therapeutic effects in psoriasis? Arch Dermatol Res  189:623±630, 1997  	9444385
	Asadullah K, Sterry W, Stephanek K, et al: IL-10 is a key cytokine in psoriasis. Proof  of principle by IL-10 therapy: a new therapeutic approach. J Clin Invest  101:783±794, 1998  	9466973
	Barratt-Boyes SM, Kao H, Finn OJ: Chimpanzee dendritic cells derived in vitro from  blood monocytes and pulsed with antigen elicit speci®c immune responses in  vivo. J Immunother 21:142±148, 1998  	9551366
	De Jong P, Bezemer AC, Zomerdijk TPL, Van de Pouw-Kraan T, Ottenhoff THM,  Nibbering PH: Selective stimulation of T helper 2 cytokine responses by the  anti-psoriasis agent monomethylfumarate. Eur J Immunol 26:2067±2074, 1996  	NO_MATCH
	Drakesmith H, Chain B, Beverley P: How can dendritic cells cause autoimmune  disease? Immunol Today 21:214±217, 2000  	10782051
	Genestier L, Paillot R, Fournel S, Ferraro C, Miossec P, Revillard JP:  Immunosuppressive properties of methotrexate: apoptosis and clonal deletion  of activated peripheral T cells. J Clin Invest 102:322±328, 1998  	9664073
	Grewal IS, Flavell RA: CD40 and CD154 in cell-mediated immunity. Annu Rev  Immunol 16:111±135, 1998  	9597126
	Kalinski P, Hilkens CMU, Wierenga EA, Kapsenberg ML: T-cell priming by type-1  and type-2 polarized dendritic cells: the concept of a third signal. Immunol  Today 20:561±567, 1999  	10562707
	van Kooten C, Banchereau J: CD40±CD40 ligand. J Leukoc Biol 67:2±17, 2000  	NO_MATCH
	Loo DT, Rillema JR: Measurement of cell death. Methods Cell Biol 57:251±264, 1998  	9648109
	Mrowietz U, Christophers E, Altmeyer P: Treatment of severe psoriasis with fumaric  acid esters: scienti®c background and guidelines for therapeutic use. Br J  Dermatol 141:424±429, 1999  	NO_MATCH
	Muller WA, Randolph GJ: Migration of leukocytes across endothelium and beyond:  molecules involved in the transmigration and fate of monocytes. J Leukoc Biol  66:698±704, 1999  	10577496
	Nestle FO, Zheng XG, Thompson CB, Turka LA, Nickoloff BJ: Characterization of  dermal dendritic cells obtained from normal human skin reveals phenotypic  and functionally distinctive subsets. J Immunol 151:6535±6545, 1993  	7504023
	Nestle FO, Turka LA, Nickoloff BJ: Characterization of dermal dendritic cells in  psoriasis. Autostimulation of T lymphocytes and induction of Th1 type  cytokines. J Clin Invest 94:202±209, 1994  	8040262
	Ockenfels HM, Schultewolter T, Ockenfels G, Funk R, Goos M: The antipsoriatic  agent dimethylfumarate immunomodulates T-cell cytokine secretion and  inhibits cytokines of the psoriatic cytokine network. Br J Dermatol 139:390±  395, 1998  	9767281
	Ozawa M, Ferenczi K, Kikuchi T, et al: 312-nanometer ultraviolet B light (narrow band UVB) induces apoptosis of T cells within psoriatic lesions. J Exp Med  189:711±718, 1999  	9989986
	Penna G, Adorini L: 1 Alpha,25-dihydroxyvitamin D3 inhibits differentiation,  maturation, activation, and survival of dendritic cells leading to impaired  alloreactive T cell activation. J Immunol 164:2405±2411, 2000  	10679076
	Petres J, Kalkhoff KW, Baron D, Geiger R, Kunick I: Der Ein¯u von  FumarsaÈuremonoethylester auf die NukleinsaÈure- und Proteinsynthese PHA stimulierter menschlicher Lymphozyten. Arch Dermatol Res 251:295±300, 1975  	NO_MATCH
	Piemonti L, Monti P, Sironi M, Fraticelli P, Leone BE, Dal Cin E, Di Allavena PCV:  Vitamin D3 affects differentiation, maturation, and function of human  monocyte-derived dendritic cells. J Immunol 164:4443±4451, 2000  	10779743
	Reich K, BruÈck M, GraÈfe A, Vente C, Neumann C, Garbe C: Treatment of psoriasis  with interleukin-10. J Invest Dermatol 111:1235±1236, 1998  	9856850
	Sallusto F, Lanzavecchia A: Ef®cient presentation of soluble antigen by cultured  human dendritic cells is maintained by granulocyte/macrophage colony stimulating factor plus interleukin 4 and downregulated by tumor necrosis  factor alpha. J Exp Med 179:1109±1118, 1994  	8145033
	Schweckendiek W: Heilung von Psoriasis. Med Monatschr 13:103±104, 1959  	NO_MATCH
	SeboÈk B, Bonnekoh B, Geisel J, Mahrle G: Antiproliferative and cytotoxic pro®les of  antipsoriatic fumaric acid derivatives in keratinocyte cultures. Eur J Pharmacol  270:79±87, 1994  	8157084
	SeboÈk B, Mahrle G, Gollnick H, Bonnekoh B: Dimethylfumarat ist unter den  Fumadermq-Inhaltsstoffen der staÈrkste Induktor von Apoptose-PhaÈnomenen  in lympho-histiozytaÈren U-937-Zellen. Z Hautkr 75:1±5, 2000  	NO_MATCH
	Valdimarsson H, SigmundsdoÂttir H, JoÂnsdoÂttir I: Is psoriasis induced by streptococcal  superantigens and maintained by M-protein-speci®c T cells that cross-react  with keratin? Clin Exp Immunol 107(Suppl. 1):21±24, 1997  	9020931
	Zhang C, Ao Z, Seth A, Schlossman SF: A mitochondrial membrane protein de®ned  by a novel monoclonal antibody is preferentially detected in apoptotic cells. J  Immunol 157:3980±3987, 1996  	8892631
j.1432-1327.2001.01954.x.pdf
	1. Ozawa, E., Imamura, M., Noguchi, S. & Yoshida, M. (2000)  Dystrophinopathy and sarcoglycanopathy. Neuroscience News 3,  13±19.  	10791096
	2. Ervasti, J.M., Ohlendieck, K., Kahl, S.D., Gaver, M.G. &  Campbell, K.P. (1990) Deficiency of a glycoprotein component  of the dystrophin complex in dystrophic muscle. Nature 345,  315±319.  	2188135
	3. Yoshida, M. & Ozawa, E. (1990) Glycoprotein complex anchoring  dystrophin to sarcolemma. J. Biochem. 108, 748±752.  	2081733
	4. Yoshida, M., Noguchi, S., Wakabayashi, E., Piluso, G., Belsito, A.,  Nigro, V. & Ozawa, E. (1997) The fourth component of the  sarcoglycan complex. FEBS Lett. 403, 143±148.  	9042955
	5. Roberds, S.L., Leturcq, F., Allamand, V., Piccolo, F., Jeanpierr, M.,  Anderson, R.D., Lim, L.E., Lee, J.C., Tome, F.M.S., Romero,  N.B., Fardeau, M., Beckmann, J.S., Kaplan, J.-C. & Campbell, K.P.  (1994) Missense mutations in the adhalin gene linked to autosomal  recessive muscular dystrophy. Cell 78, 625±633.  	8069911
	6. Lim, L.E., Duclos, F., Broux, O., Bourg, N., Sunada, Y., Allamand,  V., Meyer, J., Richard, I., Moomaw, C., Slaughter, C., Tome,  F.M.S., Fardeau, M., Jackson, C.E., Beckmann, J.S. & Campbell,  K.P. (1995) b-Sarcoglycan: characterization and role in limb girdle muscular dystrophy linked to 4q12. Nat. Genet. 11,  257±265.  	7581448
	7. BoÈnnemann, C.G., Modi, R., Noguchi, S., Mizuno, Y., Yoshida, M.,  Gussoni, E., McNally, E.M., Duggan, D.J., Angelini, D.,  Hoffman, E.P., Ozawa, E. & Kunkel, L.M. (1995) b-Sarcoglycan  (A3b) mutations cause autosomal recessive muscular dystrophy  with loss of the sarcoglycan complex. Nat. Genet. 11, 266±273.  	7581449
	8. Noguchi, S., McNally, E.M., Othmane, K.B., Hagiwara, Y.,  Mizuno, Y., Yoshida, M., Yamamoto, H., BoÈnnemann, C.G.,  Gussoni, E., Denton, P.H., Kyriakides, T., Middleton, L.,  Hentati, F., Hamida, M.B., Nonaka, I., Vance, J.M., Kunkel, L.M.  & Ozawa, E. (1995) Mutations in the dystrophin-associated  protein-g-sarcoglycan in chromosome 13 muscular dystrophy.  Science 270, 819±822.  	7481775
	9. Nigro, V., Moreira, E.S., Piluso, G., Vainzof, M., Belsito, A.,  Politano, L., Puca, A.A., Passos-Bueno, M.R. & Zats, M. (1996)  The 5q autosomal recessive limb-girdle muscular dystrophy  (LGMD2F) is caused by a mutation in the d-sarcoglycan gene.  Nat. Genet. 14, 195±198.  	8841194
	10. Ozawa, E., Noguchi, S., Mizuno, Y., Hagiwara, Y. & Yoshida, M.  (1998) From dystrophinopathy to sarcoglycanopathy: evolution of  a concept of muscular dystrophy. Muscle Nerve 21, 421±438.  	9533777
	11. Noguchi, S., Wakabayashi, E., Imamura, M., Yoshida, M. &  Ozawa, E. (2000) Formation of sarcoglycan complex with  differentiation in cultured myocytes. Eur. J. Biochem. 267,  640±648.  	10651799
	12. Durbeej, M. & Campbell, K.P. (1999) Biochemical characteriza tion of the epithelial dystroglycan complex. J. Biol. Chem. 274,  26609±26616.  	10473626
	13. Ettinger, A.J., Feng, G. & Sanes, J.R. (1997) :-Sarcoglycan, a  broadly expressed homologue of the gene mutated in limb-girdle  muscular dystrophy 2D. J. Biol. Chem. 272, 32534±32538.  	9405466
	14. McNally, E.M., Ly, C.T. & Kunkel, L.M. (1998) Human epsilon sarcoglycan is highly related to alpha-sarcoglycan (adhalin), the  limb girdle muscular dystrophy 2D gene. FEBS Lett. 422, 27±32.  	9475163
	15. Straub, V., Ettinger, A.J., Durbeej, M., Venzke, D.P., Cutshall, S.,  Sanes, J.R. & Campbell, K.P. (1999) :-Sarcoglycan replaces  a-sarcoglycan in smooth muscle to form a unique dystrophin±  glycaprotein complex. J. Biol. Chem. 274, 27989±27996.  	10488149
	16. Liu, L.A. & Engvall, E. (1999) Sarcoglycan isoforms in skeletal  muscle. J. Biol. Chem. 274, 38171±38176.  	10608889
	17. Mizuno, Y., Yoshida, M., Yamamoto, H., Hirai, S. & Ozawa, E.  (1993) Distribution of dystrophin isoforms and dystrophin associated proteins 43DAG (A3a) and 50DAG (A2) in various  monkey tissues. J. Biochem. 114, 936±941.  	8138555
	18. Yamamoto, H., Mizuno, Y., Hayashi, K., Nonaka, I., Yoshida, M.  & Ozawa, E. (1994) Expression of dystrophin-associated protein  35DAG (A4) and 50DAG (A2) is confined to striated muscles.  J. Biochem. 115, 162±167.  	8188626
	19. Noguchi, S., Wakabayashi, E., Imamura, M., Yoshida, M. &  Ozawa, E. (1999) Developmental expression of sarcoglycan gene  products in cultured myocytes. Biochem. Biophys. Res. Commun.  262, 88±93.  	10448073
	20. Hoffman, E.P., Brown, R.H. Jr & Kunkel, L.M. (1987) Dystrophin:  the protein product of the Duchenne muscular dystrophy locus.  Cell 51, 919±928.  	3319190
	21. Galvagni, F., Lestingi, M., Cartocci, E. & Oliviero, S. (1997)  Serum response factor and protein-mediated DNA bending  contribute to transcription of the dystrophin muscle-specific  promoter. Mol. Cell. Biol. 17, 1731±1743.  	9032300
	22. Klamut, H.J., Bosnoyan-Collins, L.O., Worton, R.G., Ray, P.N. &  Davis, H.L. (1996) Identification of transcriptional enhancer  within muscle intron 1 of the human dystrophin gene. Hum.  Mol. Genet. 5, 1599±1606.  	8894694
	23. Firulli, A.B. & Olson, E.N. (1997) Modular regulation of muscle  gene transcription: a mechanism for muscle cell diversity. Trends  Genet. 13, 364±369.  	9287492
	24. Araishi, K., Sasaoka, T., Imamura, M., Noguchi, S., Hama, H.,  Wakabayashi, E., Yoshida, M., Hori, T. & Ozawa, E. (1999) Loss  of the sarcoglycan complex and sarcospan leads to muscular  dystrophy in b-sarcoglycan-deficient mice. Hum. Mol. Genet. 8,  1589±1598.  	10441321
	25. Laemmli, U.K. (1970) Cleavage of structural proteins during the  assembly of the head of bacteriophage T4. Nature 227, 680±685.  	5432063
	26. BoÈnnemann, C.G., Passos-Bueno, M.R., McNally, E.M.,  Vainzof, M., Moreira, E.D.S., Mrie, S.K., Pavanello, R.C.M.,  Noguchi, S., Ozawa, E., Zatz, M. & Kunkel, L.M. (1996) Genomic  screening for b-sarcoglycan gene mutations: missense mutations  may cause severe limg-girdle muscular dystrophy type 2E (LGMD  2E). Hum. Mol. Genet. 5, 1953±1961.  	8968749
	27. Sakamoto, A., Abe, M. & Masaki, T. (1999) Delineation of  genomic deletion in cardiomyopathic hamster. FEBS Lett. 447,  124±128.  	10218596
	28. Katoh, Y., Molkentin, J.D., Dave, V., Olson, E.N. & Periasamy, M.  (1998) MEF2B is component of a smooth muscle-specific  complex that binds an A / T-rich element important for smooth  muscle myosin heavy chain gene expression. J. Biol. Chem. 273,  1511±1518.  	9430690
	29. Apone, S. & Hauschka, S.D. (1995) Muscle gene E-box control  elements. J. Biol. Chem. 270, 21420±21427.  	NO_MATCH
	30. Liu, L., Vachon, P.H., Kuang, W., Xu, H., Wewer, U.M., Kylsten, P.  & Engvall, E. (1997) Mouse adhalin: primary structure and  expression during late stages of muscle differentiation in vitro.  Biochem. Biophys. Res. Commun. 235, 227±235.  	9196068
	31. Amacher, S.L., Buskin, J.N. & Hauschka, S.D. (1993) Multiple  regulatory elements contribute differentially to muscle creatine  kinase enhancer activity in skeletal and cardiac muscle. Mol. Cell.  Biol. 13, 2753±2764.  	8474439
	32. Yee, S.-P. & Rigby, W.J. (1993) The regulation of myogenin gene  expression during the embryonic development of the mouse.  Genes Dev. 7, 1277±1289.  	8391506
	33. Cheng, T.-C., Wallace, M.C., Merlie, J.P. & Olson, E.N. (1993)  Separable regulatory elements governing myogenin transcription  in mouse embyogenesis. Science 261, 215±218.  	8392225
	34. Lassar, A.B., Davis, R.L., Wright, W.E., Kadesch, T., Murre, C.,  Voronova, A., Baltimore, E. & Weintraub, H. (1991)  Functional activity of myogenic HLH proteins requires hetero oligomerization with E12/E47-like proteins in vivo. Cell 66,  305±315.  	1649701
	35. Molkentin, J.D., Li, L. & Olson, E.N. (1996) Combinatorial  control of muscle development by basic helix-loop-helix and  MADS-box transcription factors. J. Biol. Chem. 271,  17199±17204.  	8790335
	36. Cserjesi, P. & Olson, E.N. (1991) Myogenin induces the  myocyte-specific enhancer binding factor MEF-2 independently  of other muscle-specific gene products. Mol. Cell. Biol. 11,  4854±4862.  	1656214
	37. Sakamoto, A., Ono, K., Abe, M., Jasmin, G., Eki, T., Murakami, Y.,  Masaki, T., Toyo-oka, T. & Hanaoka, F. (1997) Both hypertrophic  and dilated cardiomyopathies are caused by mutation of the same  gene, delta-sarcoglycan, in hamster: an animal model of disrupted  dystrophin-associated glycoprotein complex. Proc. Natl Acad. Sci.  USA 94, 13873±13878.  	9391120
	38. Duggan, D.J., Gorospe, J.R., Fanin, M., Hoffman, E.P. &  Angelini, C. (1997) Mutations in the sarcoglycan genes in patients  with myopathy. N. Engl. J. Med. 336, 618±624.  	9032047
Mol Pharmacol-2001-Wade-532-42.pdf
	Barker EL, Westphal RS, Schmidt D and Sanders-Bush E (1994) Constitutively  active 5-hydroxytryptamine2C receptors reveal novel inverse agonist activity of  receptor ligands. J Biol Chem 269:11687–11690.  	7909313
	Berg KA, Stout BD, Cropper JD, Maayani S and Clarke WP (1999) Novel actions of  inverse agonists on 5-HT2C receptor systems. Mol Pharmacol 55:863–872.  	10220565
	Bond RA, Leff P, Johnson TD, Milano CA, Rockman HA, McMinn TR, Appar sundaram S, Hyek MF, Kenakin TP, Allen LF and Lefkowitz RJ (1995) Physio logical effects of inverse agonists in transgenic mice with myocardial overexpres sion of the b2-adrenoceptor. Nature (Lond) 374:272–276.  	7885448
	Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram  quantities of protein utilizing the principle of protein-dye binding. Anal Biochem  72:248–254.  	942051
	Brink CB, Wade SM and Neubig RR (2000) Agonist-directed trafficking of porcine  a2A-adrenergic receptor signaling in CHO cells. l-Isoproterenol selectively acti vates Gs. J Pharmacol Exp Ther 294:539–547.  	NO_MATCH
	Cayla C, Schaak S, Roquelaine C, Gales C, Quinchon F and Paris H (1999) Homol ogous regulation of the a2C-adrenoceptor subtype in human hepatocarcinoma,  HepG2. Br J Pharmacol 126:69–78.  	10051122
	Chen G, Way J, Armour S, Watson C, Queen K, Jayawickreme CK, Chen WJ and  Kenakin T (2000) Use of constitutive G protein-coupled receptor activity for drug  discovery. Mol Pharmacol 57:125–134.  	10617687
	Cheng Y and Prusoff WH (1973) Relationship between the inhibition constant (Ki)  and the concentration of inhibitor which causes 50 percent inhibition (IC50) of an  enzymatic reaction. Biochem Pharmacol 22:3099–3108.  	4202581
	Chidiac P, Hebert TE, Valiquette M, Dennis M and Bouvier M (1994) Inverse agonist  activity of b-adrenergic antagonists. Mol Pharmacol 45:490–499.  	7908406
	Convents A, De Keyser J, De Backer J-P and Vauquelin G (1989) [3H]Rauwolscine  labels a2-adrenoceptors and 5-HT1A receptors in human cerebral cortex. Eur  J Pharmacol 159:307–310.  	2537740
	Costa T and Herz A (1989) Antagonists with negative intrinsic activity at delta  opioid receptors coupled to GTP-binding proteins. Proc Natl Acad Sci USA 86:  7321–7325.  	2552439
	Costa T, Lang J, Gless C and Herz A (1990) Spontaneous association between opioid  receptors and GTP-binding regulatory proteins in native membranes: Specific  regulation by antagonists and sodium ions. Mol Pharmacol 37:383–394.  	2156152
	Daunt DA, Hurt C, Hein L, Kallio J, Feng F and Kobilka BK (1997) Subtype-specific  intracellular trafficking of a2-adrenergic receptors. Mol Pharmacol 51:711–720.  	9145909
	Eason MG, Kurose H, Holt BD, Raymond JR and Liggett SB (1992) Simultaneous  coupling of a2-adrenergic receptors to two G-proteins with opposing effects. Sub type-selective coupling of a2 C10, a2 C4, and a2 C2 adrenergic receptors to Gi and  Gs. J Biol Chem 267:15795–15801.  	1322406
	Ernsberger P and Haxhiu MA (1997) The I1-imidazoline-binding site is a functional  receptor mediating vasodepression via the ventral medulla. Am J Physiol 273:  R1572–R1579.  	9374796
	Gerhardt MA (1992) Coupling of the a2A-Adrenergic Receptor to the G-Proteins Gi2  and Gi3. Ph.D. Thesis, University of Michigan, Ann Arbor, MI.  	NO_MATCH
	Hein L, Limbird LE, Eglen RM and Kobilka BK (1999) Gene substitution/knockout  to delineate the role of a2-adrenoceptor subtypes in mediating central effects of  catecholamines and imidazolines. Ann NY Acad Sci 881:265–271.  	10415924
	Kenakin T (1995) Agonist-receptor efficacy. II. Agonist trafficking of receptor sig nals. Trends Pharmacol Sc 16:232–238.  	7667897
	Kjelsberg MA, Cotecchia S, Ostrowski J, Caron MG and Lefkowitz RJ (1992) Con stitutive activation of the a1B-adrenergic receptor by all amino acid substitutions  at a single site. Evidence for a region which constrains receptor activation. J Biol  Chem 267:1430–1433.  	1346134
	Limbird LE, Speck JL and Smith SK (1982) Sodium ion modulates agonist and  antagonist interactions with the human platelet a2-adrenergic receptor in mem brane and solubilized preparations. Mol Pharmacol 21:609–617.  	6125876
	MacMillan LB, Hein L, Smith MS, Piascik MT and Limbird LE (1996) Central  hypotensive effects of the a2a-adrenergic receptor subtype. Science (Wash DC)  273:801–805.  	8670421
	Meana JJ, Herrera-Marschitz M, Goiny M and Silveira R (1997) Modulation of  catecholamine release by a2-adrenoceptors and I1-imidazoline receptors in rat  brain. Brain Res 744:216–226.  	9027381
	Nagaraja S, Iyer S, Liu X, Eichberg J and Bond RA (1999) Treatment with inverse  agonists enhances baseline atrial contractility in transgenic mice with chronic  b2-adrenoceptor activation. Br J Pharmacol 127:1099–1104.  	10455254
	Neubig RR, Gantzos RD and Brasier RS (1985) Agonist and antagonist binding to  a2-adrenergic receptors in purified membranes from human platelets: Implica tions of receptor-inhibitory nucleotide binding protein stoichiometry. Mol Phar macol 28:475–486.  	2865672
	Neubig RR, Gantzos RD and Thomsen WJ (1988) Mechanism of agonist and antag onist binding to a2 adrenergic receptors: Evidence for a precoupled receptor guanine nucleotide protein complex. Biochemistry 27:2374–2384.  	2838071
	Neusy AJ and Lowenstein J (1989) Blood pressure and blood pressure variability  following withdrawal of propranolol and clonidine. J Clin Pharmacol 29:18–24.  	2708545
	Parma J, Duprez L, Van Sande J, Cochaux P, Gervy C, Mockel J, Dumont J and  Vassart G (1993) Somatic mutations in the thyrotropin receptor gene cause hy perfunctioning thyroid adenomas. Nature (Lond) 365:649–651.  	8413627
	Pauwels PJ and Wurch T (1998) Review: Amino acid domains involved in constitu tive activation of G-protein-coupled receptors. Mol Neurobiol 17:109–135.  	9887449
	Perez DM, Hwa J, Gaivin R, Mathur M, Brown F and Graham RM (1996) Consti tutive activation of a single effector pathway: Evidence for multiple activation  states of a G protein-coupled receptor. Mol Pharmacol 49:112–122.  	8569696
	Rao VR, Cohen GB and Oprian DD (1994) Rhodopsin mutation G90D and a molec ular mechanism for congenital night blindness. Nature (Lond) 367:639–642.  	8107847
	Ren Q, Kurose H, Lefkowitz RJ and Cotecchia S (1993) Constitutively active mutants  of the a2-adrenergic receptor. J Biol Chem 268:16483–16487.  	8393865
	Salomon Y, Londos C and Rodbell M (1974) A highly sensitive adenylate cyclase  assay. Anal Biochem 58:541–548.  	4827395
	Samama P, Cotecchia S, Costa T and Lefkowitz RJ (1993) A mutation-induced  activated state of the b2-adrenergic receptor. Extending the ternary complex  model. J Biol Chem 268:4625–4636.  	8095262
	Samama P, Pei G, Costa T, Cotecchia S and Lefkowitz RJ (1994) Negative antago nists promote an inactive conformation of the b2-adrenergic receptor. Mol Phar macol 45:390–394.  	7908404
	Shenker A, Laue L, Kosugi S, Merendino, JJ Jr, Minegishi T and Cutler, GB Jr  (1993) A constitutively activating mutation of the luteinizing hormone receptor in  familial male precocious puberty. Nature (Lond) 365:652–654.  	7692306
	Tian WN, Duzic E, Lanier SM and Deth RC (1994) Determinants of a2-adrenergic  receptor activation of G proteins: Evidence for a precoupled receptor/G protein  state. Mol Pharmacol 45:524–531.  	8145737
	Wade SM, Lim WK, Lan KL, Chung D, Nanamori M and Neubig RR (1999) Gi  activator region of a2A adrenergic receptors: Distinct basic residues mediate Gi vs  Gs activation. Mol Pharmacol 56:1005–1013.  	10531407
	Weiss JM, Morgan PH, Lutz MW and Kenakin TP (1996) The cubic ternary complex  receptor-occupancy model. III. Resurrecting efficacy. J Theor Biol 181:381–397.  	8949584
	Wreggett KA and De Lean A (1984) The ternary complex model: Its properties and  application to ligand interactions with the D2-dopamine receptor of the anterior  pituitary gland. Mol Pharmacol 26:214–227.  	6237254
	Wurch T, Colpaert FC and Pauwels PJ (1999) G-protein activation by putative  antagonists at mutant Thr373Lys a2A adrenergic receptors. Br J Pharmacol 126:  939–948.  	10193774
Mol Pharmacol-2001-Kanatani-501-5.pdf
	Blomqvist AG and Herzog H (1997) Y-receptor subtypes—how many more? Trends  Neurol Sci 20:294–298.  	9223221
	Clark JT, Kalra PS, Crowley WR and Kalra SP (1984) Neuropeptide Y and human  pancreatic polypeptide stimulate feeding behavior in rats. Endocrinology 115:427–  429.  	6547387
	Daniels AJ, Matthews JE, Slepetis RJ, Jansen M, Viveros OH, Tadepalli A, Har rington W, Heyer D, Landavazo A, Leban JJ and Spaltenstein A (1995) High affinity neuropeptide Y receptor antagonists. Proc Natl Acad Sci USA 92:9067–  9071.  	7568074
	Dryden S, Pickavance L, Frankish HM and Williams G (1995) Increased neuropep tide Y secretion in the hypothalamic paraventricular nucleus of obese (fa/fa)  Zucker rats. Brain Res 690:185–188.  	8535835
	Erickson JC, Hollopeter G and Palmiter RD (1996) Attenuation of the obesity  syndrome of ob/ob mice by the loss of neuropeptide Y. Science (Wash DC) 274:  1704–1707.  	8939859
	Gerald C, Walker MW, Criscione L, Gustafson EL, Batzl-Hartmann C, Smith KE,  Vaysse P, Durkin MM, Laz TM, Linemeyer DL, Schaffhauser AO, Whitebread S,  Hofbauer KG, Taber RI, Branchek TA and Weinshank RL (1996) A receptor  subtype involved in neuropeptide-Y-induced food intake. Nature (Lond) 382:168–  171.  	8700207
	Grynkiewicz G, Poeni M and Tsien RY (1985) A new generation of Ca21 indicators  with greatly improved fluorescence properties. J Biol Chem 260:3440–3450.  	3838314
	Guan X-M, Yu H and Van der Ploeg LHT (1998) Evidence of altered hypothalamic  pro-opiomelanocortin/neuropeptide Y mRNA expression in tubby mice. Mol Brain  Res 59:273–279.  	9729427
	Hipskind PA, Lobb KL, Nixon JA, Britton TC, Bruns RF, Catlow J, Dieckman McGinty DK, Gackenheimer SL, Gitter BD, Iyengar S, Schober DA, Simmons  RMA, Swanson S, Zarrinmayeh H, Zimmerman DM and Gehlert DR (1997) Potent  and selective 1,2,3-trisubstituted indole NPY Y-1 antagonists. J Med Chem 40:  3712–3714.  	9371234
	Inui A (1999) Neuropeptide Y feeding receptors: Are multiple subtypes involved?  Trends Pharmacol Sci 20:43–46.  	10101961
	Ishihara A, Tanaka T, Kanatani A, Fukami T, Ihara M and Fukuroda T (1998) A  potent neuropeptide Y antagonist, 1229U91, suppressed spontaneous food intake  in Zucker fatty rats. Am J Physiol 43:R1500–R1504.  	9612420
	Kalra SP, Dube MG, Sahu A, Phelps CP and Kalra PS (1991) Neuropeptide Y  secretion increases in the paraventricular nucleus in association with increased  appetite for food. Proc Natl Acad Sci USA 88:10931–10935.  	1961764
	Kanatani A, Ishihara A, Asahi S, Tanaka T, Ozaki S and Ihara M (1996) Potent  neuropeptide Y Y1 receptor antagonist, 1229U91: Blockade of neuropeptide Y induced and physiological food intake. Endocrinology 137:3177–3182.  	8754736
	Kanatani A, Ishihara A, Iwaasa H, Nakamura K, Okamoto O, Hidaka M, Ito J,  Fukuroda T, MacNeil DJ Van der Ploeg LHT, Ishii Y, Okabe T, Fukami T and  Ihara M (2000a) L-152,804 orally-active and selective neuropeptide Y Y5 receptor  antagonist. Biochem Biophys Res Commun 272:169–173.  	10872822
	Kanatani A, Ito J, Ishihara A, Iwaawa H, Fukuroda T, Fukami T, MacNeil DJ, Van  der Ploeg LHT and Ihara M (1998) NPY-induced feeding involves the action of a  Y1-like receptor in rodents. Regul Pept 75–76:409–415.  	9802437
	Kanatani A, Kanno T, Ishihara A, Hata M, Sakuraba A, Tanaka T, Tsuchiya Y, Mase  T, Fukuroda T, Fukami T and Ihara M (1999) The novel neuropeptide Y Y1  receptor antagonist J-104870: A potent feeding suppressant with oral bioavailabil ity. Biochem Biophys Res Commun 268:88–91.  	10581170
	Kanatani A, Mashiko S, Murai N, Sugimoto N, Ito J, Fukuroda T, Fukami T, Mroin  N, MacNeil DJ, Van der Ploeg LHT, Saga Y, Nishimura S and Ihara M (2000b)  Role of the Y1 receptor in the regulation of neuropeptide Y-mediated feeding:  Comparison of wild-type, Y1 receptor deficient, and Y5 receptor deficient mice.  Endocrinology 141:1011–1016.  	10698177
	Kesterson RA, Huszar D, Lynch CA, Simerly RB and Cone RD (1997) Induction of  neuropeptide Y gene expression in the dorsal medial hypothalamic nucleus in two  models of the agouti obesity syndrome. Mol Endocrinol 11:630–637.  	9139806
	Marsh DJ, Hollopeter G, Kafer KE and Palmiter RD (1998) Role of the Y5 neuropep tide Y receptor in feeding and obesity. Nat Med 4:718–721.  	9623983
	McKibbin PE, Cotton SJ, McMillan S, Holloway B, Mayers R, McCarthy HD and  Williams G (1991) Altered neuropeptide Y concentrations in specific hypothalamic  regions of obese (fa/fa) Zucker rats: Possible relationship to obesity and neuroen docrine disturbances. Diabetes 40:1423–1429.  	1657667
	Mullins DE, Guzzi M, Xia L and Parker EM (2000) Pharmacological characterization  of the cloned neuropeptide Y y6 receptor. Eur J Pharmacol 395:87–93.  	10794812
	O’Shea D, Morgan DGA, Meeran K, Edwards CMB, Turton MD, Choi SJ, Heath MM,  Gunn I, Taylor GM, Howard JK, Bloom CI, Small CJ, Haddo O, Ma JJ, Callinan  W, Smith DM, Ghatei MA and Bloom SR (1997) Neuropeptide Y induced feeding  in the rat is mediated by a novel receptor. Endocrinology 138:196–202.  	8977404
	Pedrazzini T, Seydoux J, Kunstner P, Aubert JF, Grouzmann E, Beermann F and  Brunner HR (1998) Cardiovascular response, feeding behavior and locomotor  activity in mice lacking the NPY Y1 receptor. Nat Med 4:722–726.  	9623984
	Sanacora G, Kershaw M, Finkelstein JA and White JD (1990) Increased hypotha lamic content of preproneuropeptide Y messenger ribonucleic acid in genetically  obese Zucker rats and its regulation by food deprivation. Endocrinology 127:730–  737.  	2373052
	Stanley BG, Kyrkouli SE, Lampert S and Leibowitz SF (1986) Neuropeptide Y  chronically injected into the hypothalamus: A powerful neurochemical inducer of  hyperphagia and obesity. Peptides 7:1189–1192.  	3470711
	Stanley BG and Leibowitz SF (1984) Neuropeptide Y: Stimulation of feeding and  drinking by injection into the paraventricular nucleus. Life Sci 35:2635–2642.  	6549039
	Stephens TW, Basinski M, Bristow PK, Bue-Valleskey JM, Burgett SG, Craft L, Hale  J, Hoffmann J, Hsiung HM, Kriauciunas A, MacKellar W, Rosteck PR, Schoner B,  Smith D, Tinsley FC, Zhang X-Y and Heiman M (1995) The role of neuropeptide Y  in the antiobesity action of the obese gene product. Nature (Lond) 377:530–532.  	7566151
	Tatemoto K and Mutt V (1980) Isolation of two novel candidate hormones using a  chemical method for finding naturally occurring polypeptides. Nature (Lond) 285:  417–418.  	6892950
	Tatemoto K, Carlquist M and Mutt V (1982) Neuropeptide Y - a novel brain peptide  with structural similarities to peptide YY and pancreatic polypeptide. Nature  (Lond) 296:659–660.  	6896083
	Wieland HA, Engel W, Eberlein W, Rudolf K and Doods HN (1998) Subtype selec tivity of the novel nonpeptide neuropeptide Y Y1 receptor antagonist BIBO 3304  and its effect on feeding in rodents. Br J Pharmacol 125:549–555.  	9806339
	White JD, Olchovsky D, Kershaw M and Berelowitz M (1990) Increased hypotha lamic content of preproneuropeptide-Y messenger ribonucleic acid in streptozoto cin-diabetic rats. Endocrinology 126:765–772.  	2404748
	Zarjevski N, Cusin I, Vettor R, Rohner-Jeanrenaud F and Jeanrenaud B (1993)  Chronic intracerebroventricular neuropeptide-Y administration to normal rats  mimics hormonal and metabolic changes of obesity. Endocrinology 133:1753–1758.  	8404618
mk000503.pdf
	Collas, P. (1999). Sequential PKC-, and Cdc2-mediated, phosphory lation events elicit zebrafish nuclear envelope disassembly. J. Cell  Sci. 112, 977–987.  	10036247
	Ellenberg, J., Siggia, E.D., Moreira, J.E., Smith, C.L., Presley, J.F., Worman,  H.J., and Lippincott-Schwartz, J. (1997). Nuclear membrane dynamics and  reassembly in living cells: targeting of an inner nuclear membrane protein  in interphase and mitosis. J. Cell Biol. 138, 1193–1206.  	9298976
	Favreau, C., Worman, H.J., Wozniak, R.W., Frappier, T., and Courvaline,  J.-C. (1996). Cell cycle-dependent phosphorylation of nucleoporins and  nuclear pore membrane protein gfp210. Biochemistry 35, 8035–8044.  	8672508
	Gallant, P., and Nigg, E.A. (1992). Cyclin B2 undergoes cell cycle-depen dent nuclear translocation and, when expressed as a non-destructible  mutant, causes mitotic arrest in HeLa cells. J. Cell Biol. 117, 213–224.  	1532584
	Gerace, L., and Blobel, G. (1980). The nuclear envelope lamina is reversibly  depolymerized during mitosis. Cell 19, 277–287.  	7357605
	Heald, R., and McKeon, F. (1990). Mutations of phosphorylation sites in  lamin A that prevent nuclear lamina disassembly in mitosis. Cell 61,  579–589.  	2344612
	Hiramoto, Y. (1962). Microinjection of live spermatozoa into sea urchin  eggs. Exp. Cell Res. 27, 416–426.  	13954730
	Kanatani, H., Shirai, H., Nakanishi, K., and Kurokawa, T. (1969). Isolation  and identification of meiosis inducing substance in starfish Asterias amu rensis. Nature 221, 273–274.  	5812580
	Lee, K.K., Gruenbaum, Y., Spann, P., Liu, J., and Wilson, K.L. (2000). C.  elegans nuclear envelope proteins emerin, MAN1, lamin, and nucleoporins  reveal unique timing of nuclear envelope breakdown during mitosis. Mol.  Biol. Cell 11, 3089–3099.  	10982402
	Luby-Phelps, K., Taylor, D.L., and Lanni, F. (1986). Probing the structure of  cytoplasm. J. Cell Biol., 102, 2015–2022.  	2423529
	Macaulay, C., Meier, E., and Forbes, D.J. (1995). Differential mitotic phos phorylation of proteins of the nuclear pore complex. J. Biol. Chem. 207,  254–262.  	7814383
	Newport, J., and Spann, T, 1987. Disassembly of the nucleus in mitotic  extracts: membrane vesicularization, lamin disassembly, and chromosome  condensation are independent processes. Cell 48, 219–230.  	3026636
	Ookata, K., Hisanaga, S., Okano, T., Tachibana, K., and Kishimoto, T.  (1992). Relocation and distinct subcellular localization of p34 cdc2-cyclin B  complex at meiosis reinitiation in starfish oocytes. EMBO J. 11, 1763–1772.  	1316272
	Otto, J.J., and Schroeder, T.E. (1984). Microtubule arrays in the cortex and  near the germinal vesicle of immature starfish oocytes. Dev. Biol. 101,  274–281.  	6363161
	Perez-Mongiovi, D., Chang, P., and Houliston, E. (1998). A propagated  wave of MPF activation accompanies surface contraction waves at first  mitosis in Xenopus. J. Cell Sci. 111, 385–393.  	9427686
	Peter, M., Nakagawa, J., Doree, M., Labbe, J.C., and Nigg, E.A. (1990). In  vitro disassembly of the nuclear lamina and M phase-specific phosphor ylation of lamins by cdc2 kinase. Cell 61, 591–602.  	2188731
	Peters, R. (1983). Nuclear envelope permeability measured by fluorescence  microphotolysis of single liver cell nuclei. J. Biol. Chem. 258, 11427–11429.  	6194152
	Peters, R. (1984). Nucleo-cytoplasmic flux and intracellular mobility in  single hepatocytes measured by fluorescence microphotolysis. EMBO J. 3,  1831–1836.  	6207019
	Rolls, M.M., Stein, P.A., Taylor, S.S., Ha, E., McKeon, F., and Rapoport,  T.A. (1999). A visual screen of a GFP-fusion library identifies a new type  of nuclear envelope membrane protein. J. Cell Biol. 146, 29–44.  	10402458
	Rout, M.P., Aitchison, J.D., Suprapto, A., Hjertaas, K., Zhao, Y., and Chait,  B.T. (2000). The yeast nuclear pore complex: composition, architecture,  and transport mechanism. J. Cell Biol. 148, 635–651.  	10684247
	Schaff, J., Fink, C.C., Slepchenko, B., Carson, J.H., and Loew, L.M. (1997). A  general computational framework for modeling cellular structure and  function. Biophys. J. 73, 1135–1146.  	9284281
	Stafstrom, J.P., and Staehelin, L.A. (1984). Dynamics of the nuclear enve lope and of nuclear pore complexes during mitosis in the Drosophila  embryo. Eur. J. Cell Biol. 34, 179–189.  	6428889
	Terasaki, M., and Jaffe, L.A. (1993) Imaging of the endoplasmic reticulum  in living marine eggs. In: Methods in Cell Biology: Cell Biological Appli cations of Confocal Microscopy, vol. 38, ed. B. Matsumoto, Orlando, FL:  Academic Press, 211-220.  	8246782
	Terasaki, M. (1994). Redistribution of cytoplasmic components during  germinal vesicle breakdown in starfish oocytes. J. Cell Sci. 107, 1797–1805.  	7527047
	Terasaki, M., Jaffe, L.A., Hunnicutt, G.R., and Hammer III, J.A. (1996).  Structural change of the endoplasmic reticulum during fertilization: evi dence for loss of membrane continuity using the green fluorescent protein.  Dev. Biol. 179, 320–328.  	8903348
	Terasaki, M. (2000). Dynamics of the ER and Golgi apparatus during early  sea urchin development. Mol. Biol. Cell 11, 897–914.  	NO_MATCH
	Ward, G.E., and Kirschner, M.W. (1990). Identification of cell cycle-regu lated phosphorylation sites on nuclear lamin C. Cell 61, 561–577.  	2188730
	Weast, R.C. (ed.) (1972). Handbook of Chemistry and Physics.  Cleveland, Ohio: The Chemical Rubber Co., F-47.  	NO_MATCH
	Yang, L., Guan, T., and Gerace, L. (1997). Integral membrane proteins of  the nuclear envelope are dispersed throughout the endoplasmic reticulum  during mitosis. J. Cell Biol. 137, 1199–1210.  	9182656
	Zaal, K.J., Smith, C.L., Polishchuk, R.S., Altan, N., Cole, N.B., Ellenberg, J.,  Hirschberg, K., Presley, J.F., Roberts, T.H., Siggia, E., Phair, R.D., and  Lippincott-Schwartz, J. (1999). Golgi membranes are absorbed into and  reemerge from the ER during mitosis. Cell 99, 589–601.  	10612395
tjp0531-0265.pdf
tjp0531-0219.pdf
5.pdf
	1. Huyse FJ: From consultation to complexity of care prediction and health service  needs assessment (editorial). J Psychosomatic Res 1997; 43:233–240  	9304549
	2. Huyse FJ, Lyons JS, Stiefel FC, et al: INTERMED: a method to assess health  service needs: I. Development and reliability. Gen Hosp Psychiatry 1999; 21:39–  48  	10068919
	3. Stiefel FC, de Jonge P, Huyse FJ, et al: INTERMED: A method to assess health  service needs: II. Results on its validity and clinical use. Gen Hosp Psychiatry  1999; 21:49–56  	10068920
	4. Stiefel FC, de Jonge P, Huyse FJ, et al: INTERMED: An assessment and clas sification system for case complexity: results in patients with low back pain.  Spine 1999; 24:378–385  	10065523
	5. Engel GL: The clinical application of the biopsychosocial model. Am J Psychi atry 1980; 137:525–544  	7264472
	6. Engel GL: The need for a new medical model: a challenge for biomedicine.  Science 1977; 196:129–136  	847460
	7. Leigh H, Feinstein AR, Reiser MF: The patient evaluation grid: a systematic  approach to comprehensive care. Gen Hosp Psychiatry 1980; 2:3–9  	7380246
	8. Huyse FJ, Strain JJ, Hengeveld MW, et al: Interventions in consultation/liaison  psychiatry: The development of a schema and a checklist for operationalized  interventions. Gen Hosp Psychiatry 1988; 10:88–101  	3360316
	9. Lyons JS, Colletta J, Devens M, et al: Validity of the severity of psychiatric  12   Psychosomatics 42:1, January-February 2001  illness rating scale in a sample of inpatients on a psychogeriatric unit. Int Psy chogeriatics 1995; 7:407–416  	NO_MATCH
	10. Lyons JS, Stutsman J, Neme J, et al: Predicting psychiatric emergency admis sions and hospital outcome. Medical Care 1997; 35:792–800  	9268252
	11. Ewing JA: Detecting alcoholism, the CAGE questionnaire. JAMA 1984;  252:1905–1907  	6471323
	12. Fink P, Ewald H, Jensen J, et al: Screening for somatization and hypochondriasis  in primary care and neurological in-patients: a seven-item scale for hypochon driasis and somatisation. J Psychosomatic Res 1999; 46:261–273  	10193917
	13. Folstein MF, Folstein SE, McHugh PR: Mini-Mental State Examination: a prac tical method for grading the cognitive state of patients for the clinician. J Psy chiatric Res 1975; 12:189–198  	1202204
	14. Frasure-Smith N, Lesperance F, Talajic M: Depression following myocardial  infarction. Impact on 6-month survival. JAMA 1993; 270:1819–1825  	8411525
	15. Curley C, McEachern JE, Speroff T: A firm trial of interdisciplinary rounds on  the inpatient medical wards. Medical Care 1998; 36:AS4-AS12  	NO_MATCH
	16. Slaets JP, Kauffmann RH, Duivenvoorde HJ, et al: A randomized trial of geriatric  liaison intervention in elderly medical inpatients. Psychosomatic Medicine 1997;  59:585–591  	9407576
	17. Strain JJ, Lyons JS, Hammer JS et al: Cost offset from a psychiatric consultation liaison intervention with elderly hip fracture patients. Am J Psychiatry 1991;  148:1044–1049  	1853954
	18. Inouye SK, Bogardus ST, Charpentier PA, et al: A multicomponent intervention  to prevent delirium in hospitalized older patients. New Eng J Med 1999;  340:669–676  	10053175
	19. Stewart S, Marley JE, Horowitz JD: Effects of a multidisciplinary, home-based  intervention on unplanned readmissions and survival among patients with  chronic congestive heart failure: a randomised controlled study. The Lancet  1999; 354:1077–1083  	10509499
	20. Mazzocato C, Stiefel F, de Jonge P, et al: Comprehensive assessment of patients  in palliative care: a descriptive study utilizing the INTERMED. J Pain Symptom  Manage 2000; 19:83–90  	10699535
	21. Fischer CJ, Stiefel FC, de Jonge P, et al: Case complexity and clinical outcome  in diabetes mellitus: a prospective study using the INTERMED. Diabetes Metab  2000; 4:295–302  	11011222
	22. de Jonge P, Huyse FJ, Stiefel FC, et al: INTERMED A clinical instrument for  biopsychosocial assessment. Psychosomatics, in press  	11239122
	23. de Jonge P, Huyse FJ, Ruinemans GMF, et al: The timing of psychiatric con sultation: The impact of social vulnerability and level of psychiatric dysfunction.  Psychosomatics 2000; 6:505–511  	11110114
	24. Gordon M: Nursing Diagnosis. Process and Application, edited by Griswold TM.  3rd Edition, Mosby, St. Louis, MO, 1994  	NO_MATCH
	25. de Jonge P, Huyse FJ, Herzog T, et al: Risk factors for complex care needs in  general medical inpatients: results from a European study. Accepted for publi cation in Psychosomatics  	11351109
	26. Huyse FJ, de Jonge P, Slaets JPJ, et al: COMPRI: an instrument to detect patients  with complex care needs: results from a European study. Accepted for publica tion in Psychosomatics  	11351110
	27. de Jonge P, Huyse FJ, Lobo A, et al: Care complexity in the general hospital:  results from a European study. Accepted for publication in Psychosomatics  	11351108
	28. de Jonge P: Detection of complex patients in the general hospital. Amsterdam,  Thela Thesis, 1999  	NO_MATCH
v077p00126.pdf
j.1432-1327.2001.01837.x.pdf
	1. Barton, N.W., Furbish, F.S., Murray, G.J. & Brady, R.O. (1990)  Therapeutic response to intravenous infusion of glucocerebrosidase  in a patient with Gaucher disease. Proc. Natl Acad. Sci. USA 87,  1913±1916.  	2308952
	2. Stahl, P.D., Wileman, T.E., Diment, S. & Shepherd, V.L. (1984)  Mannose-specific oligosaccharide recognition by mononuclear pha gocytes. Biol. Cell 51, 215±218.  	6240304
	3. Fan, J.-Q., Ishii, S., Asano, N. & Suzuki, Y. (1999) Accelerated  transport and maturation of lysosomal a-galactosidase A in Fabry  lymphoblasts by an enzyme inhibitor. Nat. Med. 5, 112±115.  	9883849
	4. Nash, R.J., Bell, E.A. & Williams, J.M. (1985) 2-Hydroxymethyl-3,4 dihydroxypyrrolidine in fruits of Angylocalyx boutiqueanus.  Phytochemistry 24, 1620±1622.  	NO_MATCH
	5. Molyneux, R.J., Pan, Y.T., Tropea, J.E., Elbein, A.D., Lawyer, C.H.,  Hughes, D.J. & Fleet, G.W.J. (1993) 2-Hydroxymethyl-3,4 dihydroxy-6-methylpyrrolidine (6-deoxy-DMDP), an alkaloid  b-mannosidase inhibitor from seeds of Angylocalyx pynaertii. J.  Nat. Prod. 56, 1356±1364.  	8229017
	6. Evans, S.V., Fellows, L.E., Shing, T.K.M. & Fleet, G.W.J. (1985)  Glycosidase inhibition by plant alkaloids which are structural  analogues of monosaccharides. Phytochemistry 24, 1953±1955.  	NO_MATCH
	7. Skudlarek, M.D., Tulsiani, D.R.P. & Orgebin-Crist, M.-C. (1992) Rat  epididymal liminal fluid acid b-d-galactosidase optimally hydrolyses  glycoprotein substrate at neutral pH. Biochem. J. 286, 907±914.  	1417750
	8. Asano, N., Tomioka, E., Kizu, H. & Matsui, K. (1994) Sugars with  nitrogen in the ring isolated from the leaves of Morus bombysis.  Carbohydr. Res. 253, 235±245.  	8156550
	9. Asano, N., Oseki, K., Tomioka, E., Kizu, H. & Matsui, K. (1994)  N-Containing sugars from Morus alba and their glycosidase  inhibitory activities. Carbohydr. Res. 259, 243±255.  	8050098
	10. Asano, N., Kizu, H., Oseki, K., Tomioka, E., Matsui, K., Okamoto, M.  & Baba, M. (1995) N-Alkylated nitrogen-in-the-ring sugars:  conformational basis of inhibition of glycosidases and HIV-1  replication. J. Med. Chem. 38, 2349±2356.  	7608901
	11. Fleet, G.W.J., Namgoong, S.K., Barker, C., Baines, S., Jacob, G.S. &  Winchester, B. (1989) Iminoheptitols as glycosidase inhibitors:  synthesis of and specific a-l-fucosidase inhibition by b-l-homo fuconojirimycin and 1-b-C-substituted deoxymannojirimycins.  Tetrahedron Lett. 30, 4439±4442.  	NO_MATCH
	12. Asano, N., Kato, A., Miyauchi, M., Kizu, H., Kameda, Y., Watson,  A.A., Nash, R.J. & Fleet, G.W.J. (1998) Nitrogen-containing furanose  and pyranose analogues from Hyacinthus orientalis. J. Nat. Prod. 61,  625±628.  	9599261
	13. Asano, N., Kameda. Y. & Matsui, K. (1991) All eight possible mono-b d-glucosides of validoxylamine A. I. Preparation and structure  determination. J. Antibiot. 44, 1406±1416.  	1778791
	14. Welter, A., Jadot, J., Dardenne, G., Marlier, M. & Casimir, J. (1976)  2,5-Dihydroxymethyl 3,4-dihydroxypyrrolidine dans les feuilles de  Derris elliptica. Phytochemistry 15, 747±749.  	NO_MATCH
	15. Nash, R.J., Asano, N. & Watson, A.A. (1996) Polyhydroxylated  alkaloids that inhibit glycosidases. In Alkaloids: Chemical and  Biological Perspectives (Pelletier, S.W., ed. ), Vol. 11, pp. 345±376.  Elsevier Science, Oxford.  	NO_MATCH
	16. Asano, N., Oseki, K., Kizu, H. & Matsui, K. (1994) Nitrogen-in-the ring pyranoses and furanoses: structural basis of inhibition of  mammalian glycosidases. J. Med. Chem. 37, 3701±3706.  	7966130
	17. Fuhrmann, U., Bause, E., Legler, G. & Ploegh, H. (1984) Novel  mannosidase inhibitor blocking conversion of high mannose to  complex oligosaccharides. Nature 307, 755±758.  	6230538
	18. Bischoff, J. & Kornfeld, R. (1984) The effect of 1-deoxymannojir imycin on rat liver a-mannosidases. Biochem. Biophys. Res.  Commun. 125, 324±331.  	NO_MATCH
	19. Winchester, B., Barker, C., Baines, S., Jacob, G.S., Namgoong, S.K. &  Fleet, G. (1990) Inhibition of a-l-fucosidase by derivatives of  deoxyfuconojirimycin and deoxymannojirimycin. Biochem. J. 265,  277±282.  	2137330
	20. Fleet, G.W.J., Shaw, A.N., Evans, S.V. & Fellows, L.E. (1985)  Synthesis from d-glucose of 1,5-dideoxy-1,5-imino-l-fucitol, a  potent a-l-fucosidase inhibitor. J. Chem. Soc. Chem. Commun.,  841±842.  	NO_MATCH
	21. Andrews, D.M., Bird, M.I., Cunningham, M.M. & Ward, P. (1993)  Synthesis of and glycosidase inhibition by a-l-homofuconojirimycin.  Bioorg. Med. Chem. Lett. 3, 2533±2536.  	NO_MATCH
	22. Asano, N., Nishida, M., Kizu, H., Matsui, K., Watson, A.A. &  Nash, R.J. (1997) Homonojirimycin isomers and glycosides from  Aglaonema treubii. J. Nat. Prod. 60, 98±101.  	NO_MATCH
	23. Asano, N., Nishida, M., Kato, A., Kizu, H., Matsui, K., Shimada, Y.,  Itoh, T., Baba, M., Watson, A.A., Nash, R.J., de Lilley, P.M.Q.,  Watkin, D.J. & Fleet, G.W.J. (1998) Homonojirimycin isomer and  N-alkylated homonojirimycins: structural and conformational basis of  inhibition of glycosidases. J. Med. Chem. 41, 2565±2571.  	9651160
	24. Zhou, P., Salleh, H.M., Chan, P.C.M., Lajoie, G., Honek, F., Nambiar,  P.T.C. & Ward, O.P. (1993) A chemoenzymic synthesis of 1,5 dideoxy-1,5-imino-l-mannitol and -l-rhamnitol and investigation of  their effects on glycosidases. Carbohydr. Res. 239, 155±166.  	NO_MATCH
	25. Asano, N., Ishii, S., Kizu, H., Ikeda, K., Yasuda, K., Kato, A., Martin,  O.R. & Fan, J.-Q. (2000) In vitro inhibition and intracellular  enhancement of lysosomal a-galactosidase A in Fabry lymphoblasts  by 1-deoxygalactonojirimycin and its derivatives. Eur. J. Biochem.  267, 4179±4186.  	10866822
	26. Alhadeff, J.A. (1981) Human a-l-fucosidases and fucosidosis. In  Lysosomes and Lysosomal Storage Diseases (Callahan, J.W. &  Lowden, J.A., eds), pp. 299±313. Raven Press, New York.  	NO_MATCH
	27. Rao Veeramachaneni, D.N., Smith, M.O. & Ellinwood, N.M. (1998)  Deficiency of fucosidase results in acrosomal dysgenesis and  impaired sperm maturation. J. Androl. 19, 444±449.  	9733147
	28. Hoshi, M., De Santis, R., Pinto, M.R., Cotelli, F. & Rosati, F. (1983) Is  sperm a-l-fucosidase responsible for sperm-egg binding in Ciona  intestinalis? in the Sperm Cell (Andre, J., ed.), pp. 107±110.  Martinus-Nijhoff Publishers, The Hague.  	NO_MATCH
	29. Tesarik, J., Mendoza, C., Ramirez, J.P. & Moos, J. (1993) Solubilized  human zona pellucida competes with a fucosylated neoglycoprotein  for binding sites on the human sperm surface. Fertil. Steril. 60,  344±350.  	8339835
	30. Lucas, H., Bercegeay, S., Le Pendu, J., Jean, M., Mirallie, S. &  Barriere, P. (1994) A fucose-containing epitope potentially involved  in gamete interaction on the human zona pellucida. Hum. Reprod. 9,  1532±1538.  	7527423
	31. De Cerezo, J.M., Marquinez, A.C., Sarchi, M.I. & Cerezo, A.S. (1996)  Fucosylated glycoconjugates of the human spermatozoon. Com parison of the domains of these glycoconjugates with the  a-fucosyl binding sites, and with lactosaminic glycoconjugates and  b-d-galactosyl binding site domains. Biocell. 20, 11±20.  	8653155
j.1432-1327.2001.01861.x.pdf
	1. Cotton, R.G.H. (1997). Mutation Detection. Oxford University Press,  Oxford, UK.  	NO_MATCH
	2. Ronai, Z. & Yakubovskaya, M.G. (1995) PCR in clinical diagnosis.  J. Clin. Lab. Anal. 9, 269±281.  	7562245
	3. Cotton, R.G.H. & Horaitis, Q. (2000) Quality control in the discovery,  reporting, and recording of genomic variation. Hum. Mutat. 15,  16±21.  	10612817
	4. Cotton, R.G.H., Rodrigues, N.R. & Campbell, R.D. (1988)  Reactivity of cytosine and thymine in single-base-pair  mismatches with hydroxylamine and osmium tetroxide and its  application to the study of mutations. Proc. Natl Acad. Sci. USA 85,  4397±4403.  	3260032
	5. Lambrinakos, A., Humphrey, K.E., Babon, J.J., Ellis, T.P. &  Cotton, R.G.H. (1999) Reactivity of potassium permanganate  and tetraethylammonium chloride with mismatched bases and a  simple mutation detection protocol. Nucleic Acids Res. 27,  1866±1873.  	10101195
	6. Cotton, R.G.H. & Campbell, R.D. (1989) Chemical reactivity of  matched cytosine and thymine bases near mismatched and  unmatched bases in a heteroduplex between DNA strands with  multiple differences. Nucleic Acids Res. 17, 4223±4233.  	2787020
	7. Lu, A.-L. & Hsu, I.-C. (1992) Detection of single DNA base  mutations with mismatch repair enzymes. Genomics 14, 249±253.  	1427840
	8. Youil, R., Kemper, B. & Cotton, R.G.H. (1995) Screening for  mutations by enzyme mismatch cleavage with T4 endonuclease VII.  Proc. Natl Acad. Sci. USA 92, 87±93.  	7816853
	9. Youil, R., Kemper, B. & Cotton, R.G.H. (1996) Detection of 81 of 81  known mouse beta-globin promoter mutations with T4 endo nuclease VII: the EMC method. Genomics 32, 431±437.  	8838807
	10. Mashal, R.D., Koontz, J. & Sklar, J. (1995) Detection of mutations by  cleavage of DNA heteroduplexes with bacteriophage resolvases.  Nat. Genet. 9, 177±182.  	7719346
	11. Gaillard, C. & Strauss, F. (1994) Association of poly (CA) poly (TG)  DNA fragments into four-stranded complexes bound by HMG1 and  2. Science 264, 433±436.	8153633
	12. Belotserkovskii, B.P. & Johnston, B.H. (1996) Polypropylene tube  surfaces may induce denaturation and multimerization of DNA.  Science 271, 222±223.  	8539626
	13. Gaillard, C. & Strauss, F. (1996) Polypropylene tube surfaces may  induce denaturation and multimerization of DNA-Response. Science  271, 223.  	NO_MATCH
	14. Belotserkovskii, B.P. & Johnston, B.H. (1997) Denaturation and  association of DNA sequences by certain polypropylene surfaces.  Anal. Biochem. 251, 251±262.  	9299024
	15. Yakubovskaya, M.G., Neschastnova, A.A., Popenko, V.I., Lipatova,  Zh.V. & Belitsky, G.A. (1999) Holliday junctions are formed in  concentrated solutions of purified products of DNA amplification.  Biochemistry (Moscow) 64, 1310±1314.  	10611538
	16. Gaillard, C., Flavin, M., Woisard, A. & Strauss, F. (1999) Association  of double-stranded DNA fragments into multistranded DNA  structures. Biopolymers 50, 679±689.  	10547523
	17. Panyutin, I.G. & Hsieh, P. (1994) The kinetics of spontaneous DNA  branch migration. Proc. Natl Acad. Sci. USA 91, 2021±2025.  	8134343
	18. Holliday, R. (1964) A mechanism for gene conversion in fungi.  Genet. Res. Camb. 5, 282±287.  	NO_MATCH
	19. Potter, H. & Dressler, D. (1976) On the mechanism of genetic  recombination: electron microscopic observation of recombination  intermediates. Proc. Natl Acad. Sci. USA 73, 3000±3004.  	787981
	20. Lopez, B., Rousset, S. & Coppey, J. (1987) Homologous  recombination intermediates between two duplex DNA catalysed  by human cell extracts. Nucleic Acids Res. 15, 5643±5655.  	3302944
	21. Wasserman, S.A. & Cozzarelli, N.R. (1986) Biochemical topology:  applications to DNA recombination and replication. Science 232,  951±960.  	3010458
	22. Whithouse, H.L.K. (1982). Genetic Recombination: Understanding  the Mechanism. Wiley, New York, USA.  	NO_MATCH
	23. Cox, M.M. & Lehman, I.R. (1987) Enzymes of general recombina tion. Annu. Rev. Biochem. 56, 229±254.  	3304134
	24. Lilley, D.M.J. & Clegg, R.M. (1993) The structure of the four-way  junction in DNA. Annu. Rev. Biophys. Biomol. Struct. 22, 299±328.  	8347993
	25. Lilley, D.M.J. (1997) All change at Holliday junction. Proc. Natl  Acad. Sci. USA 94, 9513±9515.  	9275153
	26. Duckett, D.R., Murchie, A.I., Diekmann, S., von Kitzing, E.,  Kemper, B. & Lilley, D.M. (1988) The structure of the Holliday  junction, and its resolution. Cell 55, 79±89.  	3167979
	27. Mizuuchi, K., Kemper, B., Hays, J. & Weisberg, R.A. (1982) T4  endonuclease VII cleaves Holliday structures. Cell 29, 357±365.  	6288255
	28. Buchman, V.L., Chumakov, P.M., Ninkina, N.N., Samarina, O.P. &  Georgiev, G.P. (1988) A variation in the structure of the protein coding region of the human p53 gene. Gene 30, 245±252.  	2905688
	29. Smith, M.J., Gardner, R.J., Knight, M.A., Forrest, S.M., Beyreuther,  K., Storey, E., McLean, C.A., Cotton, R.G.H., Cappal, R. &  Masters, C.L. (1999) Early-onset Alzheimer's disease caused by a  novel mutation at codon 219 of the presenilin-1 gene. Neuroreport  25, 503±507.  	10208579
	30. Sambrook, J., Fritsch, E.F. & Maniatis, T. (1989) Molecular Cloning:  a Laboratory Manual. 2nd edn. Cold Spring Harbor Laboratory  Press, Cold Spring Harbor, NY, USA.  	NO_MATCH
	31. Southern, E.M. (1975) Detection of specific sequences among DNA  fragments separated by gel electrophoresis. J. Mol. Biol. 96,  503±517.  	1195397
	32. Davis, R.W. & Hyman, R.W. (1971) A study in evolution: the DNA  base sequence homology between coliphages T7 and T3. J. Mol.  Biol. 62, 287±301.  	4944929
	33. Lu, M., Guo, Q., Marky, L.A., Seeman, N.C. & Kallenbach, N.R.  (1992) Thermodynamics of DNA branching. J. Mol. Biol. 223,  781±789.  	1542118
	34. Duguid, J.G. & Bloomfield, V.A. (1995) Aggregation of melted DNA  by divalent metal ion-mediated cross-linking. Biophys. J. 69,  2642±2648.  	8599670
	35. Henderson, E., Hardin, C.C., Wolk, S.K., Tinoco, I. & Blackburn,  E.H. (1987) Telomeric DNA oligonucleotides form novel intra molecular structures containing guanine-guanine base pairs. Cell 51,  899±908.  	3690664
	36. Hardin, C.C., Henderson, E., Watson, T. & Prosser, J.K. (1991)  Monovalent cation induced structural transitions in telomeric DNAs:  G-DNA folding intermediates. Biochemistry 30, 4460±4472.  	2021636
	37. Mueller, J.E., Newton, C.J., Jensch, F., Kemper, B., Cunningham,  R.P., Kallenbach, N.R. & Seeman, N.C. (1990) Resolution of  Holliday junction analogs by T4 endonuclease VII can be directed  by substrate structure. J. Biol. Chem. 265, 13918±13924.  	2199447
	38. Muck, S.M., Fee, R.S., Millar, D.P. & Chazin, W.J. (1997) Crossover  isomer bias is the primary sequence-dependent property of  immobilised Holliday junctions. Proc. Natl Acad. Sci. USA 94,  9080±9084.  	9256438
	39. Saenger, W. (1984). Principles of Nucleic Acid Structure. Springer Verlag, New York, USA.  	NO_MATCH
	40. Nonin, S., Leroy, J.L. & Gueron, M. (1995) Terminal base pairs of  oligodeoxynucleotides: imino proton exchange and fraying.  Biochemistry 34, 10652±10659.  	7654719
	41. Renalldo, R.P., Vologodskii, A.V., Neri, B.P. & Lyamichev, V.I. (2000)  The kinetics of oligonucleotide replacements. J. Mol. Biol. 297,  511±520.  	10715217
	42. Boan, F., Rodriguez, J.M. & Gomez-Marquez, J. (1998) A non hypervariable human minisatellite strongly stimulates in vitro  intramolecular homologous recombination. J. Mol. Biol. 278,  499±492.  	9600833
	42a. Eichman, B.F., Vargason, J.M., Mooers, B.H. & Ho, P.S. (2000) The  Holliday junction in an inverted repeat DNA sequence: sequence  effects on the structure of four-way junctions. Proc. Natl Acad. Sci.  USA 97, 3971±3976.  	10760268
	43. Benet, A. & Azorin, F. (1999) The formation of triple-stranded  DNA prevents spontaneous branch-migration. J. Mol. Biol. 294,  851±857.  	10588891
	44. Frank-Kamenetskii, M.D. & Mirkin, S.M. (1995) Triplex DNA  structures. Annu. Rev. Biochem. 64, 65±95.  	7574496
	45. Gierer, A. (1966) Model for DNA and protein interactions and  function of the operator. Nature (London) 212, 1480±1481.  	NO_MATCH
	46. Bhattacharyy, A., Murchie, A.I., von Kitzing, E., Diekmann, S.,  Kemper, B. & Lilley, D.M. (1991) Model for the interaction of  DNA junctions and resolving enzymes. J. Mol. Biol. 221,  1191±1207.  	1658336
	47. Smith, M.J., Humphrey, K.E., Cappai, R., Beyreuther, K.,  Masters, C.L. & Cotton, R.G. (2000) Correct heteroduplex  formation for mutation detection analysis. Mol. Diag. 5, 67±73.  	10837092
	48. Verpy, E., Biasotto, M., Brai, M., Misiano, G., Meo, T. & Tosi, M.  (1996) Exhaustive mutation scanning by fluorescence-assisted  mismatch analysis discloses new genotype±phenotype correlations  in angiodema. Am. J. Hum. Genet. 59, 308±319.  	8755917
	49. Hansen, L.L., Justesen, J. & Kruse, T.A. (1996) Sensitive and fast  mutation detection by solid phase chemical cleavage. Hum. Mutat.  7, 256±263.  	8829659
46.pdf
	1. Klerman GL, Weissman MM, Rounsaville BJ, et al: Interper sonal Psychotherapy of Depression. New York, Basic Books,  1984  	NO_MATCH
	2. Wilfley DE, Agras WS, et al: Group cognitive behavioural ther apy and group interpersonal therapy for the nonpurging bu limic individual: a controlled comparison. J Consult Clin  Psychol 1993; 61:296–305  	8473584
	3. Fairburn CG, Jones R, Peveler RC, et al: Psychotherapy and  bulimia nervosa: the longer term effects of interpersonal psy chotherapy and cognitive behavior therapy. Arch Gen Psychi atry 1993; 50:419–428  	NO_MATCH
	4. Piper WE, Joyce AS: A consideration of factors influencing the  utilization of time-limited, short-term group therapy. Int J  Group Psychother 1996: 46:311–328  	8753150
	5. McRoberts C, Burlingame GM, Hoag MJ: Comparative effi cacy of individual and group psychotherapy: a meta-analytic  perspective. Group Dynamics: Theory, Research, and Practice  1998: 2:101–117  	NO_MATCH
	6. Wilfley DE, MacKenzie KR, Ayres VE, et al: Interpersonal Psy chotherapy for Group. New York, Basic Books, 2000  	NO_MATCH
	7. Burlingame GM, Lambert MJ, Reisinger CW, et al: Pragmatics of tracking mental health outcomes in a managed care setting.  The Journal of Mental Health Administration 1995; 22:226–236  	10144458
	8. American Psychiatric Association: Diagnostic and Statistical  Manual of Mental Disorders, 4th edition. Washington, DC,  American Psychiatric Association, 1994  	NO_MATCH
	9. MacKenzie KR: Time-Managed Group Psychotherapy: Effec tive Clinical Applications. Washington DC, American Psychi atric Press, 1997  	NO_MATCH
	10. Battle CC, Imber SD, Hoehn-Saric R, et al: Target complaints  as a criteria of improvement. Am J Psychother 1966; 20:184–  192  	5906081
	11. Beck AT, Ward CH, Mendelson M, et al: An inventory for  measuring depression. Arch Gen Psychiatry 1961; 4:561–571  	13688369
	12. Beck AT, Steer RA: Beck Depression Inventory Manual. San  Antonio, TX, The Psychological Corporation, 1993 edition  	NO_MATCH
	13. Barkham M, Hardy GE, Startup M: The IIP-32: a short version  of the Inventory of Interpersonal Problems. British Journal of  Clinical Psychology 1996; 35:21–35  	8673033
	14. Weissman MM, Klerman GL, Prusoff BA, et al: Depressed out patients: results one year after treatment with drugs and/or in terpersonal psychotherapy. Arch Gen Psychiatry 1981; 38:51–  55  	7006558
ac000345.pdf
	1. Canigia, L. F., A. D. Martino, M. Litterio, L. Castello, M. I. Fernandez, R.  Rollett, G. Greco, S. Predari, and H. Bianchini. 1999. Comparative in vitro  activities of four macrolides at two pH values against Gram-negative anaer obic rods other than the Bacteroides fragilis group. Anaerobe 5:451–454.  	NO_MATCH
	2. Edlund, C., E. Sillerstrom, E. Wahlund, and C. E. Nord. 1998. In vitro activity  of HMR 3647 against anaerobic bacteria. J. Chemother. 10:280–284.  	9720465
	3. Goldstein, E. J. C., D. M. Citron, S. H. Gerardo, M. Hudspeth, and C. V.  Merriam. 1998. Activities of HMR 3004 and HMR 3647 compared to those of  erythromycin, azithromycin, clarithromycin, roxithromycin, and eight other  antimicrobial agents against unusual aerobic and anaerobic human and ani mal bite pathogens isolated from skin and soft tissue infections in humans.  Antimicrob. Agents Chemother. 42:1127–1132.  	9593139
	4. Goldstein, E. J. C., V. L. Sutter, Y. Y. Kwok, R. P. Lewis, and S. M. Finegold.  1981. Effect of carbon dioxide on the susceptibility of anaerobic bacteria to  erythromycin. Antimicrob. Agents Chemother. 20:705–708.  	6798927
	5. National Committee for Clinical Laboratory Standards. 1997. Methods for  antimicrobial susceptibility testing of anaerobic bacteria, 4th ed. Approved  standard, NCCLS document M11–A4. National Committee for Clinical Lab oratory Standards, Wayne, Pa.  	NO_MATCH
ac000327.pdf
	1. Abruzzo, G. K., A. M. Flattery, C. J. Gill, L. Kong, J. G. Smith, V. B.  Bikounis, J. M. Balkovec, A. F. Bouffard, J. F. Dropinski, H. Rosen, H.  Kropp, and K. Bartizal. 1997. Evaluation of the echinocandin antifungal  MK-0991 (L-743,872): efficacies in mouse models of disseminated aspergil losis, candidiasis, and cryptococcosis. Antimicrob. Agents Chemother. 41:  2333–2338.  	9371329
	2. Abruzzo, G. K., A. M. Flattery, C. J. Gill, L. Kong, J. G. Smith, D. Krupa,  V. B. Pkounis, H. Kropp, and K. Bartizal. 1995. Evaluation of water-soluble  pneumocandin analogs L-733560, L-705589, and L-731373 with mouse mod els of disseminated aspergillosis, candidiasis, and cryptococcosis. Antimi crob. Agents Chemother. 39:1077–1081.  	7625792
	3. Arikan, S., M. Lozano-Chiu, V. Paetznick, S. Nangia, and J. H. Rex. 1999.  Microdilution susceptibility testing of amphotericin B, itraconazole, and  voriconazole against clinical isolates of Aspergillus and Fusarium species.  J. Clin. Microbiol. 37:3946–3951.  	10565912
	4. Bartizal, K., C. J. Gill, G. K. Abruzzo, A. M. Flattery, L. Kong, P. M. Scott,  J. G. Smith, C. E. Leighton, A. Bouffard, J. F. Dropinski, and J. Balkovec.  1997. In vitro preclinical evaluation studies with the echinocandin antifungal  MK-0991 (L-743,872). Antimicrob. Agents Chemother. 41:2326–2332.  	9371328
	5. Del Poeta, M., W. A. Schell, and J. R. Perfect. 1997. In vitro antifungal  activity of pneumocandin L-743,872 against a variety of clinically important  molds. Antimicrob. Agents Chemother. 41:1835–1836.  	9257774
	6. Denning, D. W. 1997. Echinocandins and pneumocandins—a new antifungal  class with a novel mode of action. J. Antimicrob. Chemother. 40:611–614.  	9421307
	7. Denning, D. W., S. A. Radford, K. L. Oakley, L. Hall, E. M. Johnson, and  D. W. Warnock. 1997. Correlation between in-vitro susceptibility testing to  itraconazole and in-vivo outcome of Aspergillus fumigatus infection. J. Anti microb. Chemother. 40:401–414.  	9338494
	8. Ernst, E. J., M. E. Klepser, M. E. Ernst, S. A. Messer, and M. A. Pfaller.  1999. In vitro pharmacodynamic properties of MK-0991 determined by time kill methods. Diagn. Microbiol. Infect. Dis. 33:75–80.  	10091029
	9. Ernst, M. E., M. E. Klepser, E. J. Wolfe, and M. A. Pfaller. 1996. Antifungal  dynamics of LY 303366, an investigational echinocandin B analog, against  Candida spp. Diagn. Microbiol. Infect. Dis. 26:125–131.  	9078447
	10. Espinel-Ingroff, A. 1998. Comparison of in vitro activities of the new triazole  SCH56592 and the echinocandins MK-0991 (L-743,872) and LY303366  against opportunistic filamentous and dimorphic fungi and yeasts. J. Clin.  Microbiol. 36:2950–2956.  	9738049
	11. Franzot, S. P., and A. Casadevall. 1997. Pneumocandin L-743,872 enhances  the activities of amphotericin B and fluconazole against Cryptococcus neo formans in vitro. Antimicrob. Agents Chemother. 41:331–336.  	9021188
	12. Graybill, J. R., L. K. Najvar, M. F. Luther, and A. W. Fothergill. 1997.  Treatment of murine disseminated candidiasis with L-743, 872. Antimicrob.  Agents Chemother. 41:1775–1777.  	9257759
	13. Klepser, M. E., E. J. Ernst, M. E. Ernst, S. A. Messer, and M. A. Pfaller.  1998. Evaluation of endpoints for antifungal susceptibility determinations  with LY303366. Antimicrob Agents Chemother. 42:1387–1391.  	9624481
	14. Klepser, M. E., E. J. Ernst, M. E. Ernst, and M. A. Pfaller. 1997. Growth  medium effect on the antifungal activity of LY 303366. Diagn. Microbiol.  Infect. Dis. 29:227–31.  	9458979
	15. Krishnarao, T. V., and J. N. Galgiani. 1997. Comparison of the in vitro  activities of the echinocandin LY303366, the pneumocandin MK-0991, and  fluconazole against Candida species and Cryptococcus neoformans. Antimi crob. Agents Chemother. 41:1957–1960.  	9303393
	16. Kurtz, M. B., I. B. Heath, J. Marrinan, S. Dreikorn, J. Onishi, and C.  Douglas. 1994. Morphological effects of lipopeptides against Aspergillus fu migatus correlate with activities against (1,3)-b-D-glucan synthase. Antimi crob. Agents Chemother. 38:1480–1489.  	7979276
	17. Martinez-Suarez, J. V., and J. L. Rodriguez-Tudela. 1996. In vitro activities  of semisynthetic pneumocandin L-733,560 against fluconazole-resistant and  -susceptible Candida albicans isolates. Antimicrob Agents Chemother. 40:  1277–1279.  	8723483
	18. National Committee for Clinical Laboratory Standards. 1998. Reference  method for broth dilution antifungal susceptibility testing of conidium-form ing filamentous fungi. Proposed standard. NCCLS document M38-P. Na tional Committee for Clinical Laboratory Standards, Wayne, Pa.  	NO_MATCH
	19. Nelson, P. W., M. Lozano-Chiu, and J. H. Rex. 1997. In vitro growth inhibitory activity of pneumocandins L-733,560 and L-743,872 against puta tively amphotericin B- and fluconazole-resistant Candida isolates: influence  of assay conditions. J. Med. Vet. Mycol. 35:285–287.  	9292427
	20. Pfaller, M. A., F. Marco, S. A. Messer, and R. N. Jones. 1998. In vitro activity  of two echinocandin derivatives, LY303366 and MK-0991 (L-743,792),  against clinical isolates of Aspergillus, Fusarium, Rhizopus, and other fila mentous fungi. Diagn. Microbiol. Infect. Dis. 30:251–255.  	9582584
	21. Pfaller, M. A., S. A. Messer, and S. Coffman. 1997. In vitro susceptibilities of  clinical yeast isolates to a new echinocandin derivative, LY303366, and other  antifungal agents. Antimicrob. Agents Chemother. 41:763–766.  	9087485
	22. Pfaller, M. A., S. A. Messer, S. Gee, S. Joly, C. Pujol, D. J. Sullivan, D. C.  Coleman, and D. R. Soll. 1999. In vitro susceptibilities of Candida dublini ensis isolates tested against the new triazole and echinocandin antifungal  agents. J. Clin. Microbiol. 37:870–872.  	9986880
	23. Uzun, O., S. Kocagoz, Y. Cetinkaya, S. Arikan, and S. Unal. 1997. In vitro  activity of a new echinocandin, LY303366, compared with those of ampho tericin B and fluconazole against clinical yeast isolates. Antimicrob. Agents  Chemother. 41:1156–1157.  	9145888
	24. Vazquez, J. A., M. Lynch, D. Boikov, and J. D. Sobel. 1997. In vitro activity  of a new pneumocandin antifungal, L-743,872, against azole-susceptible and  -resistant Candida species. Antimicrob. Agents Chemother. 41:1612–1614.  	9210698
	25. Wanger, A., K. Mills, P. W. Nelson, and J. H. Rex. 1995. Comparison of Etest  and National Committee for Clinical Laboratory Standards broth macrodi lution method for antifungal susceptibility testing: enhanced ability to detect  amphotericin B-resistant Candida isolates. Antimicrob. Agents Chemother.  39:2520–2522.  	8585737
	26. Zhanel, G. G., J. A. Karlowsky, G. A. J. Harding, T. V. Balko, S. A. Zelen itsky, M. Friesen, A. Kabani, M. Turik, and D. J. Hoban. 1997. In vitro  activity of a new semisynthetic echinocandin, LY-303366, against systemic  isolates of Candida species, Cryptococcus neoformans, Blastomyces dermati tidis, and Aspergillus species. Antimicrob. Agents Chemother. 41:863–865.  	9087508
2_1.pdf
	1. Teramoto A, Hirakawa K, Sanno N, Osamura Y.  Incidental pituitary lesions in 1,000 unselected  autopsy specimens. Neuroradiology 1994; 93:  161–164.  	8090885
	2. Sumida M, Uozumi T, Mukada K, Arita K, Kurisu  K, Eguchi K. Rathke's cleft cysts: correlation of  enhanced MR and surgical ˆndings. AJNR 1994;  15:525–532.  	8197952
	3.  El-Mahdy W, Powell M. Transsphenoidal manage ment of 28 symptomatic Rathke's cleft cysts, with  special reference to visual and hormonal recovery.  Neurosurgery 1998; 42:7–17.  	9442498
	4. Brassier G, Morandi X, Tayiar E, et al. Rathke's  cleft cysts: sugical-MRI correlation in 16 sympto matic cases. J Neuroradiol 1999; 26:162–171.  	10655672
	5. Christophe C, Flamant-Durand J, Hanquinet S, et  al. MRI in seven cases of Rathke's cleft cyst in  infants and children. Pediatr Radiol 1993; 23:  79–82.  	8516048
	6. Keyaki A, Kim YJ, Nabeshima S. Clinical study of  Rathke cleft cyst. No Shinkei Geka (Jpn) 1999;  27:625–631.  	NO_MATCH
	7. Saeki N, Sunami K, Sugaya Y, Yamaura A. MRI  ˆndings and clinical manifestations in Rathke's  cleft cyst. Acta Neurochir (Wien) 1999; 141:  1055–1061.  	10550649
	8. Asari S, Ito T, Tsuchida S, Tsutsui T. MR appear ance and cyst content of Rathke cleft cysts. J Com put Assist Tomogr 1990; 14:532–535.  	2370351
	9. Hua F, Asato R, Miki Y, et al. DiŠerentiation  of suprasellar non-neoplastic cysts from cystic  neoplasms by Gd-DTPA MRI. J Comput Assist  Tomogr 1992; 16:744–749.  	1522267
	10. Byun MB, Kim OL, Kim DS. MR imaging ˆndings  of Rathke's cleft cysts: signiˆcance of intracystic  nodules. AJNR 2000; 21:485–488.  	10730639
	11. Kucharczyk W, Peck WW, Kelly WM, Norman D,  Newton TH. Rathke cleft cysts: CT, MR Imaging,  and pathologic features. Radiology 1987; 165:  491–495.  	3659372
	12. Naylor MF, Scheithauer BW, Forbes GS,  Tomlinson FH, Young WF. Rathke cleft cyst: CT,  MR, and pathology of 23 cases. J Comput Assist  Tomogr 1995; 19:853–859.  	8537515
	13. Shin JL, Asa SL, Woodhous LJ, Smyth HS, Ezzat  S. Cystic lesions of the pituitary: clinicopathologi cal features distinguishing craniopharyngioma,  Rathke's cleft cyst, and arachnoic cyst. J Clin  Endocrinol Metab 1999; 84:3972–3982.  	10566636
	14. Ross DA, Norman D, Wilson CB. Radiologic  characteristics and results of surgical management  of Rathke's cysts in 43 patients. Neurosurgery  1992; 30:173–179.  	1545884
	15. Volker JL, Campbell RJ, Muller J. Clinical, radio graphic, and pathological features of symptomatic  Rathke's cleft cysts. J Neurosurg 1991; 74:535–  544.  	2002366
	16. Hayashi Y, Tachibana O, Muramatsu N, et al.  Rathke cleft cyst: MR and biochemical analysis of  cyst content. J Comput Assist Tomogr 1999; 23:  34–38.  	10050804
	17. Nishioka H, Ito H, Miki T, Hashimoto T, Nojima  H, Matsumura H. Rathke's cleft cyst with pitui tary apoplexy: case report. Neuroradiology 1999;  41:832–834.  	10602857
	18. Rottenberg GT, Chong WK, Powell M, Kendall  BE. Cyst formation of the craniopharyngeal duct.  Clin Radiol 1994; 49:126–129.  	8124891
	19. Kuwahara T, Shinohara Y, Sugiura M, Hiramatsu  H. A Rathke's cleft cyst with a moving mass in the  cyst. No Shinkei Geka (Jpn) 1997; 25:177–180.  	9027896
	20. Sumida M, Uozumi T, Yamanaka M, et al. Dis placement of the normal pituitary gland by sellar  and juxtasellar tumors: surgical-MRI correlation  and use in diŠerential diagnosis. Neuroradiol 1994;  36:372–375.  	7936178
	21. Donovan JL, Nesbit GM. Distinction of masses in volving the sella and suprasellar spaces: speciˆcity  of imaging of features. AJR 1996; 167:597–603.  	8751659
	22. Hald JK, Eldevik OP, Brunberg JA, Chandler  WF. Craniopharyngiomas—the utility of contrast  medium enhancement for MR imaging at 1.5T.  Acta Radiol 1994; 35:520–525.  	7946671
	23. Pusey E, Kortman KE, Flannigan BD, Tsuruda J,  Bradley WG. MR of craniopharyngiomas: tumor  delineation and characterization. AJNR 1987; 8:  439–444.  	3496766
	24. Hald JK, Eldevik OP, Skalpe IO. Craniopharyn gioma identiˆcation by CT and MR Imaging. Acta  Radiol 1995; 36:142–147.  	NO_MATCH
	25. Freeman MP, Kessler RM, Allen JH, Price AC.  Craniopharyngioma: CT and MR imaging in nine  cases. J Comput Assist Tomogr 1987; 11:810–814.  	3655043
ar1032.pdf
	Cooper GS, Dooley MA, Treadwell EL, St Clair EW, Parks CG,  Gilkeson GS: Hormonal, environmental, and infectious risk  factors for developing systemic lupus erythematosus. Arthritis  Rheum 1998, 41:1714-1724.  	9778212
	Robson MG, Walport MJ: Pathogenesis of systemic lupus ery thematosus. Clin Exp Allergy 2001, 31:678-685.  	11422126
	Du Clos TW: C-reactive protein as a regulator of autoimmu nity and inflammation. Arthritis Rheum 2003, 48:1475-1477.  	12794811
	Nauta AJ, Daha MR, Kooten C, Roos A: Recognition and clear ance of apoptotic cells: a role for complement and pentraxins.  Trends Immunol 2003, 24:148-154.  	12615211
	Nagata S, Suda T: Fas and Fas ligand: lpr and gld mutations.  Immunol Today 1995, 16:39-43.  	7533498
	6. Napirei M, Karsunky H, Zevnik B, Stephan H, Mannherz HG,  Moroy T: Features of systemic lupus erythematosus in  DNase1-deficient mice. Nat Genet 2000, 25:177-181.  	10835632
	Emlen W, Niebur J, Kadera R: Accelerated in vitro apoptosis of  lymphocytes from patients with systemic lupus erythemato sus. J Immunol 1994, 152:3685-3692.  	8144943
	Botto M, Dell’Agnola C, Bygrave AE, Petry F, Loos M, Pandolfi  PP, Walport MJ: Homozygous C1q deficiency causes glomeru lonephritis associated with multiple apoptotic bodies. Nat  Genet 1998, 19:56-59.  	9590289
	Shoshan Y, Shapira I, Toubi E, Frolkis I, Yaron M, Mevorach D:  Accelerated Fas-mediated apoptosis of monocytes and  maturing macrophages from patients with systemic lupus  erythematosus: relevance to in vitro impairment of interaction  with iC3b-opsonized apoptotic cells. J Immunol 2001, 167:  5963-5969.  	11698475
	10. Herrmann M, Voll RE, Zoller OM, Hagenhofer M, Ponner BB,  Kalden JR: Impaired phagocytosis of apoptotic cell material by  monocyte-derived macrophages from patients with systemic  lupus erythematosus. Arthritis Rheum 1998, 41:1241-1250.  	9663482
	11. Fishelson Z, Attali G, Mevorach D: Complement and apoptosis.  Mol Immunol 2001, 38:207-219.  	11532282
	12. Charles PJ: Defective waste disposal: does it induce autoanti bodies in SLE? Ann Rheum Dis 2003, 62:1-3.  	12480659
	13. Voll RE, Roth EA, Girkontaite I, Fehr H, Herrmann M, Lorenz HM,  Kalden JR: Histone-specific Th0 and Th1 clones derived from  systemic lupus erythematosus patients induce double stranded DNA antibody production. Arthritis Rheum 1997, 40:  2162-2171.  	9416853
	14. Mohan C, Adams S, Stanik V, Datta SK: Nucleosome: a major  immunogen for pathogenic autoantibody-inducing T cells of  lupus. J Exp Med 1993, 177:1367-1381.  	8478612
	15. Spronk PE, Limburg PC, Kallenberg CGM: Serological markers  of disease activity in systemic lupus erythematosus. Lupus  1995, 4:86-94.  	7795629
	16. Gewurz H, Zhang XH, Lint TF: Structure and function of the  pentraxins. Curr Opin Immunol 1995, 7:54-64.  	7772283
	17. Nauta AJ, Bottazzi B, Mantovani A, Salvatori G, Kishore U,  Schwaeble WJ, Gingras AR, Tzima S, Vivanco F, Egido J, Tijsma  O, Hack EC, Daha MR, Roos A: Biochemical and functional  characterization of the interaction between pentraxin 3 and  C1q. Eur J Immunol 2003, 33:465-473.  	12645945
	18. Thompson D, Pepys MB, Wood SP: The physiological structure  of human C-reactive protein and its complex with phospho choline. Structure Fold Des 1999, 7:169-177.  	10368284
	19. Motie M, Brockmeier S, Potempa LA: Binding of model soluble  immune complexes to modified C-reactive protein. J Immunol  1996, 156:4435-4441.  	8666818
	20. Mold C, Baca R, Du Clos TW: Serum amyloid P component  and C-reactive protein opsonize apoptotic cells for phagocy tosis through FcγRs. J Autoimmun 2002, 19:147-154.  	12419285
	21. Du Clos TW: The interaction of C-reactive protein and serum  amyloid P component with nuclear antigens. Mol Biol Rep  1996, 23:253-260.  	9112237
	22. Gershov D, Kim S, Brot N, Elkon KB: C-Reactive protein binds  to apoptotic cells, protects the cells from assembly of the ter minal complement components, and sustains an anti-inflam matory innate immune response: implications for systemic  autoimmunity. J Exp Med 2000, 192:1353-1364.  	11067883
	23. Diehl EE, Haines GK III, Radosevich JA, Potempa LA: Immuno histochemical localization of modified C-reactive protein  antigen in normal vascular tissue. Am J Med Sci 2000, 319:79 83.  	10698090
	24. Kresl JJ, Potempa LA, Anderson BE: Conversion of native  oligomeric to a modified monomeric form of human C-reac tive protein. Int J Biochem Cell Biol 1998, 30:1415-1426.  	9924810
	25. Sjöwall C, Eriksson P, Almer S, Skogh T: Autoantibodies to C reactive protein is a common finding in SLE, but not in  primary Sjögren’s syndrome, rheumatoid arthritis or inflam matory bowel disease. J Autoimmun 2002, 19:155-160.  	12419286
	26. Bell SA, Faust H, Schmid A, Meurer M: Autoantibodies to C reactive protein (CRP) and other acute-phase proteins in sys temic autoimmune diseases. Clin Exp Immunol 1998, 113:  327-332.  	9737658
	27. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH,  and the Committee on Prognosis Studies in SLE: Derivation of  the SLEDAI. Arthritis Rheum 1992, 35:630-640.  	NO_MATCH
	28. Sturfelt G, Roux-Lombard P, Wollheim FA, Dayer JM: Low levels  of interleukin-1 receptor antagonist coincide with kidney  involvement in systemic lupus erythematosus. Br J Rheumatol  1997, 36:1283-1289.  	9448589
	29. Potempa LA, Siegel JN, Fiedel BA, Potempa RT, Gewurz H:  Expression, detection and assay of a neoantigen (Neo-CRP)  associated with a free, human C-reactive protein subunit. Mol  Immunol 1987, 24:531-541.  	2443837
	30. Mullis KB, Faloona FA: Specific synthesis of DNA in vitro via a  polymerase-catalyzed chain reaction. Methods Enzymol 1987,  155:335-350.  	3431465
	31. Gladman D, Ginzler E, Goldsmith C, Fortin P, Liang M, Urowitz M,  Bacon P, Bombardieri S, Hanly J, Hay E, Isenberg D, Jones J,  Kalunian K, Maddison P, Nived O, Petri M, Richter M, Sanchez Guerrero J, Snaith M, Sturfelt G, Symmons D, Zoma A: The  development and initial validation of the Systemic Lupus  International Collaborating Clinics/American College of  Rheumatology damage index for systemic lupus erythemato sus. Arthritis Rheum 1996, 39:363-369.  	8607884
	32. Jonsson H, Sturfelt G, Mårtensson U, Truedsson L, Sjöholm AG:  Prospective analysis of C1 dissociation and complement acti vation in patients with systemic lupus erythematosus. Clin  Exp Rheumatol 1995, 13:573-580.  	8575134
	33. Amoura Z, Koutouzov S, Piette JC: The role of nucleosomes in  lupus. Curr Opin Rheumatol 2000, 12:369-373.  	10990171
	34. Vigushin DM, Pepys MB, Hawkins PN: Metabolic and scinti graphic studies of radioiodinated human C-reactive protein in  health and disease. J Clin Invest 1993, 91:1351-1357.  	8473487
	35. Sturfelt G, Sjöholm AG: Complement components, comple ment activation, and acute phase response in systemic  lupus erythematosus. Int Archs Allergy Appl Immun 1984, 75:  75-83.  	6086533
	36. Stein MP, Mold C, Du Clos TW: C-reactive protein binding to  murine leukocytes requires FcγRs. J Immunol 2000, 164:1514 1520.  	10640769
	37. Khreiss T, Jozsef L, Hossain S, Chan JS, Potempa LA, Filep JG:  Loss of pentameric symmetry of C-reactive protein is associ ated with delayed apoptosis of human neutrophils. J Biol  Chem 2002, 277:40775-40781.  	12198121
	38. Samberg NL, Bray RA, Gewurz H, Landay AL, Potempa LA: Pref erential expression of neo-CRP epitopes on the surface of  human peripheral blood lymphocytes. Cell Immunol 1988,  116:86-98.  	2458846
	39. Bray RA, Samberg NL, Gewurz H, Potempa LA, Landay AL: C reactive protein antigenicity on the surface of human periph eral blood lymphocytes. Characterization of lymphocytes  reactive with anti-neo-CRP. J Immunol 1988, 140:4271-4278.  	2453575
	40. Cocca BA, Cline AM, Radic MZ: Blebs and apoptotic bodies  are B cell autoantigens. J Immunol 2002, 169:159-166.  	12077241
	41. Perniok A, Wedekind F, Herrmann M, Specker C, Schneider M:  High levels of circulating early apoptic peripheral blood  mononuclear cells in systemic lupus erythematosus. Lupus  1998, 7:113-118.  	9541096
	42. Courtney PA, Crockard AD, Williamson K, Irvine AE, Kennedy AL,  Bell AL: Increased apoptotic peripheral blood neutrophils in  systemic lupus erythematosus: relation with disease activity,  antibodies to double stranded DNA, and neutropenia. Ann  Rheum Dis 1999, 58:309-314.  	10225817
	43. Pascual M, Schifferli JA: Another function of erythrocytes:  transport of circulating immune complexes. Infusionther Trans fusionsmed 1995, 22:310-315.  	8924746
	44. Klint C, Gullstrand B, Sturfelt G, Truedsson L: Binding of  immune complexes to erythrocyte CR1 (CD35): difference in  requirement of classical pathway components and indication  of alternative pathway-mediated binding in C2-deficiency.  Scand J Immunol 2000, 52:103-108.  	10886790
	45. Skogh T, Stendahl O: Complement-mediated delay in immune  complex clearance from the blood owing to reduced deposi tion outside the reticuloendothelial system. Immunology 1983,  49:53-59.  	6404812
v14n3a13.pdf
	1. Abrahams JJ. The role of diagnostic imaging in dental  implantology. Radiol Clin North Am 1993;31:163-180.  	8419972
	2. Frederiksen NL. Diagnostic imaging in dental implantology. Oral  Surg Oral Med Oral Pathol Oral Radiol Endod 1995;80:540-554.  	8556464
	3. Dharmar S. Locating the mandibular canal in panoramic radio graphs. Int J Oral Maxillofac Implants 1997;12:113-117.  	9048463
	4. Lindh C, Petersson A. Radiologic examination for location of the  mandibular canal: a comparison between panoramic radiography  and conventional tomography. Int J Oral Maxillofac Implants  1989;4:249-253.  	2639123
	5. Lindh C, Petersson A, Klinge B. Visualisation of the mandibular  canal by different radiographic techniques. Clin Oral Impl Res  1992;3:90-97.  	NO_MATCH
	6. Stella JP, Tharanon W. A precise radiographic method to deter mine the location of the inferior alveolar canal in the posterior  edentulous mandible: implications for dental implants. Part 2:  clinical application. Int J Oral Maxillofac Implants 1990;5:23-29.  	2391136
	7. Lee S, Morgano SM. A diagnostic stent for endosseous implants  to improve conventional tomographic radiographs. J Prosthet  Dent 1994;71:482-485.  	8006844
	8. Silverstein LH, Melkonian RW, Kurtzman D, Garnick JJ, Lefkove  MD. Linear tomography in conjunction with pantomography in  the assessment of dental implant recipient sites. J Oral Implantol  1994;20:111-117.  	7869413
	9. Butterfield KJ, Dagenais M, Clokie C. Linear tomography’s clini cal accuracy and validity for presurgical dental implant analysis.  Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1997;84:203 209.  	9269023
	10. Gher ME, Richardson AC. The accuracy of dental radiographic  techniques used for evaluation of implant fixture placement. Int J  Periodont Rest Dent 1995;15:268-283.  	7558660
	11. Mayfield-Donahoo TL, Stokely EM, Jeffcoat MK. Blur reduction  of conventional film-based tomograms for pre-surgical evalua tion of potential mandibular implant sites. J Periodontol  1997;68:362-368.  	9150041
	12. Todd AD, Gher ME, Quintero G, Richardson C. Interpretation of  linear and computed tomograms in the assessment of implant  recipient sites. J Periodontol 1993;64:1243-1249.  	8106953
	13. Potter BJ, Shrout MK, Russell CM, Sharawy M. Implant site  assessment using panoramic cross-sectional tomographic imag ing. Oral Surg Oral Med Oral Pathol Oral Radiol Endod  1997;84:436-442.  	9347511
	14. Oliveira RAP. Avaliação da precisão da tomografia linear e do  sistema de digitalização indireta de imagens na mensuração da  região anterior da mandíbula. [Master´s thesis]. Porto Alegre:  Faculty of Dentistry, PUCRS; 1999. 109p.  	NO_MATCH
	15. Kaeppler G. New radiographic programs for transverse conven tional tomograms in the dentomaxillofacial region. Quintessence  Int 1999;30:541-549.  	10635267
	16. Wyatt CCL, Pharoah MJ. Imaging techniques and image interpre tation for dental implant treatment. Int J Prosthodont  1998;11:442-452.  	9922736
	17. Bahlis A. Avaliação in vitro, em mandíbulas secas, da confiabili dade das medidas nas tomografias lineares. [Master´s thesis].  Porto Alegre: Faculty of Dentistry, PUCRS; 1999. 75p.  	NO_MATCH
	18. Catic A, Celebic A, Valentic-Peruzovic M, Catovic A,  Vjekoslav J, Muretic I. Evaluation of the precision of dimen sional measurements of the mandible on panoramic radiographs.  Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1998;86:242 248.  	9720102
	19. Batenburg RHK, Stellingsma K, Raghoebar GM, Vissink A.  Bone height measurements on panoramic radiographs: the  effect of shape and position of edentulous mandibles. Oral  Surg Oral Med Oral Pathol Oral Radiol Endod 1997;84:430 435.  	9347510
	20. Xie Q, Soikkonen K, Wolf J, Mattila K, Gong M, Ainamo A.  Effect of head positioning in panoramic radiography on vertical  measurements: an in vitro study. Dentomaxillofac Radiol  1996;25:61-66.  	NO_MATCH
v14n3a09.pdf
	1. Byström A, Sundqvist G. Bacteriologic evaluation of the efficacy  of mechanical root canal instrumentation in endodontic therapy.  Scand J Dent Res 1981;89:321-328.  	6947391
	2. Ohara PK, Torabinejad M, Kettering JD. Antibacterial effect of  various endodontic irrigants on selected anaerobic bacteria.  Endod Dent Traumatol 1993;9:95-100.  	8243347
	3. Silva CAG. Efetividade antimicrobiana do hipoclorito de sódio e  clorexidina como irrigantes endodônticos. [Master’s thesis]. Porto  Alegre: Universidade Luterana de Brasil, 1999.  	NO_MATCH
	4. Ayhan H, Sultan N, Cirak M, Ruhi MZ, Bodur H. Antimicrobial  effects of various endodontic irrigants on selected microorgan isms. Int Endod J 1999;32:99-102.  	10371903
	5. Gomes BPFA, Ferraz CCR, Vianna ME, Berber VB, Teixeira FB,  Souza-Filho FJ. In vitro antimicrobial activity of several concen trations of sodium hypochlorite and chlorhexidine gluconate in  the elimination of Enterococcus faecalis. Int Endod J 2001;34:  424-428.  	11556507
	6. Byström A, Sundqvist G. The antibacterial action of sodium  hypochlorite and EDTA in 60 cases of endodontic therapy. Int  Endod J 1985;18:35-40.  	3922900
	7. Heling I, Chandler NP. Antimicrobial effect of irrigant combina tions within dentinal tubules. Int Endod J 1998;31:8-14.  	9823123
	8. Jeansonne MJ, White RR. A comparison of 2% chlorhexidine  gluconate and 5.25% sodium hypochlorite as antimicrobial endo dontic irrigant. J Endod 1994;20:276-278.  	7931023
	9. Ringel AM, Patterson SS, Newton CW, Miller CH, Mulhern JM.  In vivo evaluation of chlorhexidine gluconate solution and so dium hypochlorite solution as root canal irrigants. J Endod  1982;8:200-204.  	6955420
	10. Siqueira JF, Batista MD, Fraga RC, Uzeda M. Antimicrobial  effects of endodontic irrigants on black-pigmented Gram-nega tive anaerobes and facultative bacteria. J Endod 1998;24:414 416.  	9693585
	11. Estrela C, Estrela CRA, Barbin EL, Spanó JC, Marchesan MA,  Pécora JD. Mechanism of action of sodium hypochlorite. Brazil  Dent J 2002;2:113-117.  	12238801
	12. Spangberg L, Engstrom B, Langeland K. Biological effect of  dental materials: 3 toxicity and antimicrobial effects of endodon tic antiseptics in vitro. Oral Surg Oral Med Oral Pathol  1973;36:856-871.  	4208832
	13. Holland R, Soares IJ, Soares IM. Influence of irrigation and  intracanal dressing on the healing process of dog’s teeth with  apical periodontitis. Endod Dent Traumatol 1992;8:223-229.  	1302685
	14. Costa CAS. Teste de biocompatibilidade dos materiais  odontológicos. In: Metodologia Científica: ensino e pesquisa em  odontologia. Estrela C, ed. São Paulo: Artes Médicas, 2001.  	NO_MATCH
	15. Estrela C, Ribeiro RG, Estrela CRA, Pécora JD, Sousa-Neto MD.  Antimicrobiol effect of 2% sodium hypochlorite and 2%  chlorhexidine tested by different methods. Braz Dent J 2003; 14:  58-62.  	12656467
	16. Spanó JCE, Barbin EL, Santos TC, Guimarães LF, Pécora JD.  Solvent action of sodium hypochlorite on bovine pulp and  physico-chemical properties of resulting liquid. Braz Dent J  2001;12:154-157.  	11696909
	17. Emilson CG. Susceptibility of various microorganisms to chlor hexidine. J Dent Res 1977;85:255-265.  	266752
	18. Emilson CG. Potential efficacy of chlorhexidine against mutans  streptococci and human dental caries. J Dent Res 1994;73:682 691.  	8163738
	19. Buck RA, Cai J, Eleaser PD, Staat RH, Hurst HE. Detoxification  of endotoxin by endodontic irrigants and calcium hydroxide. J  Endod 2001;27:325-327.  	11485249
	20. Barbosa SV, Spangberg LSW, Almeida D. Low surface tension of  calcium hydroxide solutions in an effective antiseptic. Int Endod  J 1994; 27:6-10.  	7806414
amia2003_0954.pdf
amia2003_0951.pdf
	1.Stulbarg MS, Carrieri-Kohlman V, Demir-Deviren S,   Nguyen HQ, et al. Effect of exercise training on dyspnea,   exercise performance and health related quality of life: how   much training is enough? Journal of Cardiopulmonary   Rehabilitation. 2002;22:109-21.  	NO_MATCH
amia2003_0948.pdf
J Pharmacol Exp Ther-2004-Patki-874-9.pdf
	Allen MD, Greenblatt DJ, Harmatz JS, and Shader RI (1980) Desmethyldiazepam  kinetics in the elderly after oral prazepam. Clin Pharmacol Ther 28:196–202.  	6772370
	Beaune PH, Kremers PG, Kaminsky LS, De Graeve J, Albert A, and Guengerich FP  (1986) Comparison of monooxygenase activities and cytochrome P-450 isozyme  concentrations in human liver microsomes. Drug Metab Dispos 14:437–442.  	2873991
	Bertz RJ, Kroboth PD, Kroboth FJ, Reynolds IJ, Salek F, Wright CE, and Smith RB  (1997) Alprazolam in young and elderly men: sensitivity and tolerance to psy chomotor, sedative and memory effects. J Pharmacol Exp Ther 281:1317–1329.  	9190868
	Cotreau MM, von Moltke LL, and Greenblatt DJ (2004) The influence of age and sex  on the clearance of cytochrome P450 (CYP) 3A substrates. Clin Pharmacokinet, in  press.  	15634031
	George J, Byth K, and Farrell GC (1995) Age but not gender selectively affects  expression of individual cytochrome P450 proteins in human liver. Biochem Phar macol 50:727–730.  	7669077
	Greenblatt DJ, Abernethy DR, Locniskar A, Harmatz JS, Limjuco RA, and Shader RI  (1984) Effect of age, gender and obesity on midazolam kinetics. Anesthesiology  61:27–35.  	6742481
	Greenblatt DJ, Abernethy DR, and Shader RI (1986) Pharmacokinetic aspects of  drug therapy in the elderly. Ther Drug Monit 8:249–255.  	3750364
	Greenblatt DJ, Divoll M, Abernethy DR, Moschitto LJ, Smith RB, and Shader RI  (1983a) Reduced clearance of triazolam in old age: relation to antipyrine oxidizing  capacity. Br J Clin Pharmacol 15:303–309.  	6133545
	Greenblatt DJ, Divoll M, Abernethy DR, Moschitto LJ, Smith RB, and Shader RI  (1983b) Alprazolam kinetics in the elderly: relation to antipyrine disposition. Arch  Gen Psychiatry 40:287–290.  	6131657
	Greenblatt DJ, Harmatz JS, Shapiro L, Engelhardt N, Gouthro TA, and Shader RI  (1991) Sensitivity to triazolam in the elderly. N Engl J Med 324:1691–1698.  	2034245
	Greenblatt DJ, Sellers EM, and Shader RI (1982) Drug disposition in old age. N Engl  J Med 306:1081–1088.  	NO_MATCH
	Greenblatt DJ, Shader RI, and Harmatz JS (1989) Implications of altered drug  disposition in the elderly: studies of benzodiazepines. J Clin Pharmacol 29:866–  872.  	2574189
	Harris RZ, Benet LZ, and Schwartz JB (1995) Gender effects in pharmacokinetics  and pharmacodynamics. Drugs 50:222–239.  	8521756
	Hunt CM, Westerkam WR, and Stave GM (1992) Effect of age and gender on the  activity of human hepatic CYP3A. Biochem Pharmacol 44:275–283.  	1642641
	Kanamori M, Takahashi H, and Echizen H (2002) Developmental changes in the  liver weight- and body weight-normalized clearance of theophylline, phenytoin and  cyclosporine in children. Int J Clin Pharmacol Ther 40:485–492.  	12698985
	Kremers P, Beaune P, Cresteil T, de Graeve J, Columelli S, Leroux JP, and Gielen  JE (1981) Cytochrome P-450 monooxygenase activities in human and rat liver  microsomes. Eur J Biochem 118:599–606.  	7297566
	Murry DJ, Crom WR, Reddick WE, Bhargava R, and Evans WE (1995) Liver volume  as a determinant of drug clearance in children and adolescents. Drug Metab Dispos  23:1110–1116.  	8654200
	Patki KC, von Moltke LL, and Greenblatt DJ (2003) In vitro metabolism of midazo lam, triazolam, nifedipine and testosterone by human liver microsomes and re combinant cytochromes P450: role of CYP3A4 and CYP3A5. Drug Metab Dispos  31:938–944.  	12814972
	Perloff MD, von Moltke LL, Court MH, Kotegawa T, Shader RI, and Greenblatt DJ  (2000) Midazolam and triazolam biotransformation in mouse and human liver  microsomes: relative contribution of CYP3A and CYP2C isoforms. J Pharmacol  Exp Ther 292:618–628.  	10640299
	Reith DM, Appleton DB, Hooper W, and Eadie MJ (2000) The effect of body size on  the metabolic clearance of carbamazepine. Biopharm Drug Dispos 21:103–111.  	11113883
	Schmucker DL (1985) Aging and drug disposition: an update. Pharmacol Rev 37:  133–148.  	3901045
	Schmucker DL (2001) Liver function and phase I drug metabolism in the elderly: a  paradox. Drugs Aging 18:837–851.  	11772124
	Schmucker DL, Woodhouse KW, Wang RK, Wynne H, James OF, McManus M, and  Kremers P (1990) Effects of age and gender on in vitro properties of human liver  microsomal monooxygenases. Clin Pharmacol Ther 48:365–373.  	2121408
	Schrag ML and Wienkers LC (2001) Triazolam substrate inhibition: evidence of  competition for heme-bound reactive oxygen within the CYP3A4 active site. Drug  Metab Dispos 29:70–75.  	11124232
	Shimada T, Yamazaki H, Mimur M, Inui Y, and Guengerich FP (1994) Interindi vidual variations in human liver cytochrome P-450 enzymes involved in the  oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes  of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 270:414–423.  	8035341
	Smith MT, Heazlewood V, Eadie MJ, Brophy TO, and Tyrer JH (1984) Pharmaco kinetics of midazolam in the aged. Eur J Clin Pharmacol 26:381–388.  	6734699
	Sotaniemi EA, Arranto AJ, Pelkonen O, and Pasanen M (1997) Age and cytochrome  P450-linked drug metabolism in humans: an analysis of 226 subjects with equal  histopathologic conditions. Clin Pharmacol Ther 61:331–339.  	9091249
	Stevens JC, Hines RN, Gu C, Koukouritaki SB, Manro JR, Tandler PJ, and Zaya MJ  (2003) Developmental expression of the major human hepatic CYP3A enzymes.  J Pharmacol Exp Ther 307:573–582.  	12975492
	Transon C, Lecoeur S, Leemann T, Beaune P, and Dayer P (1996) Interindividual  variability in catalytic activity and immunoreactivity of three major human liver  cytochrome P450 isozymes. Eur J Clin Pharmacol 51:79–85.  	8880056
	Tuenissen MW, Srivastava AK, and Breimer DD (1987) Influence of sex and oral  contraceptives on antipyrine metabolite formation. Clin Pharmacol Ther 32:240–  246.  	NO_MATCH
	Vestal RE (1982) Pharmacology and ageing. J Am Geriatr Soc 30:191–200.  von Moltke LL, Greenblatt DJ, Harmatz JS, Duan SX, Harrel LM, Cotreau-Bibbo  MM, Pritchard GA, Wright CE, and Shader RI (1996a) Triazolam biotransforma tion by human liver microsomes in vitro: effects of metabolic inhibitors and clinical  confirmation of a predicted interaction with ketoconazole. J Pharmacol Exp Ther  276:370–379.  	7037916
	von Moltke LL, Greenblatt DJ, Harmatz JS, and Shader RI (1993) Alprazolam  metabolism in vitro: studies of human, monkey, mouse and rat liver microsomes.  Pharmacology 47:268–276.  	8234416
	von Moltke LL, Greenblatt DJ, Harmatz JS, and Shader RI (1995a) Psychotropic  drug metabolism in old age: principles and problems of assessment, in Psychop harmacology: The Fourth Generation of Progress (Bloom FE and Kupfer DJ eds) pp  1461–1469, Raven Press, New York.  von Moltke LL, Greenblatt DJ, Schmider J, Duan SX, Wright CE, Harmatz JS, and  Shader RI (1996b) Midazolam hydroxylation by human liver microsomes in vitro:  inhibition by fluoxetine, norfluoxetine and by azole antifungal agents. J Clin  Pharmacol 36:783–791.  	NO_MATCH
	von Moltke LL, Greenblatt DJ, Schmider J, Harmatz JS, and Shader RI (1995b)  Metabolism of drugs by cytochrome P450–3A isoforms: implications for drug  interactions in psychopharmacology. Clin Pharmacokinet 29 (Suppl 1):33–44.  	8846621
	Westlind-Johnsson A, Malmebo S, Johansson A, Otter C, Andersson TB, Johansson  I, Edwards RJ, Boobis AR, and Ingelman-Sundberg M (2003) Comparative anal ysis of CYP3A expression in human liver suggests only a minor role for CYP3A5 in  drug metabolism. Drug Metab Dispos 31:755–761.  	12756208
	Williams JA, Ring BJ, Cantrell VE, Jones DR, Eckstein J, Ruterbories K, Hamman  MA, Hall SD, and Wrighton SA (2002) Comparative metabolic capabilities of  CYP3A4, CYP3A5, and CYP3A7. Drug Metab Dispos 30:883–891.  	12124305
	Wynne HA, Mutch E, James OFW, Wright P, Rawlins MD, and Woodhouse KW  (1988) The effect of age upon the affinity of microsomal monooxygenase enzymes  for substrates in human liver. Age Ageing 17:401–405.  	3266441
J Pharmacol Exp Ther-2004-Xu-887-95.pdf
	Alonso-Galicia M, Maier KG, Greene AG, Cowley AW, and Roman RJ (2002) Role of  20-hydroxyeicosatetraenoic acid in the renal and vasoconstrictor actions of angio tensin II. Am J Physiol 283:R60–R68.  	12069931
	Bylund J, Harder AG, Maier KG, Roman RJ, and Harder DR (2003) Leukotriene B4  -side chain hydroxylation by CYP4F5 and CYP4F6. Arch Biochem Biophys 412:  34–41.  	12646265
	Bylund J and Oliw EH (2001) Cloning and characterization of CYP4F21: a prosta glandin E2 20-hydroxylase of ram seminal vesicles. Arch Biochem Biophys 389:  123–129.  	11370662
	Chen L and Hardwick JP (1993) Identification of a new P450 subfamily, CYP4F1,  expressed in rat hepatic tumors. Arch Biochem Biophys 300:18–23.  	8424651
	Christmas P, Jones JP, Patten CJ, Rock DA, Zheng Y, Cheng SM, Weber BM,  Carlesso N, Scadden DT, Rettie AE, et al. (2001) Alternative splicing determines  the function of CYP4F3 by switching substrate specificity. J Biol Chem 276:  38166–38172.  	11461919
	Cui X, Kawashima H, Barclay TB, Peters JM, Gonzalez FJ, Morgan ET, and Strobel  HW (2001) Molecular cloning and regulation of expression of two novel mouse  CYP4F genes: expression in peroxisome proliferator-activated receptor -deficient  mice upon lipopolysaccharide and clofibrate challenges. J Pharmacol Exp Ther  296:542–550.  	11160642
	Cui X, Nelson DR, and Strobel HW (2000) A novel human cytochrome P450 4F  isoform (CYP4F11): cDNA cloning, expression and genomic structural character ization. Genomics 68:161–166.  	10964514
	Dawson JH and Sono M (1987) Cytochrome P-450 and chloroperoxidase: thiolate ligated heme enzymes. Spectroscopic determination of their active-site structures  and mechanistic implications of thiolate ligation. Chem Rev 87:1255–1276.  	NO_MATCH
	Dierks EA, Davis SC, and Ortiz de Montellano PR (1998) Glu-320 and Asp-323 are  determinants of the CYP4A1 hydroxylation regiospecificity and resistance to in activation by 1-aminobenzotriazole. Biochemistry 37:1839–1847.  	9485309
	Escalante B, Erlij D, Falck JR, and McGiff JC (1994) Cytochrome P-450 arachidonate  metabolites affect ion fluxes in rabbit medullary thick ascending limb. Am J  Physiol 266:C1775–C1782.  	8023907
	Estabrook RW, Peterson J, Baron J, and Hildebrandt A (1972) The spectrophoto metric measurement of turbid suspensions of cytochromes associated with drug  metabolism, in Methods in Pharmacology (Chignell CF ed) pp 303–350, Appleton Century Crofts, New York.  	NO_MATCH
	Falck JR, Belosludtsev YY, Reddy KK, Reddy KM, Shortt MF, Chauhan K, Capdev ila JH, and Wei S (1997) Eicosanoid biosynthesis: differential inhibition of cyto chrome P450 epoxygenase and -hydroxylase. Bioorg Med Chem Lett 7:3053–3056.  	NO_MATCH
	Hashizume T, Imaoka S, Hiroi T, Terauchi Y, Fujii T, Miyazaki H, Kamataki T, and  Funae Y (2001) cDNA cloning and expression of a novel cytochrome P450  (CYP4F12) from human small intestine. Biochem Biophys Res Commun 280:1135–  1141.  	11162645
	Hoch U, Zhang Z, Kroetz DL, and Ortiz de Montellano PR (2000) Structural deter mination of the substrate specificities and regioselectivities of the rat and human  fatty acid -hydroxylases. Arch Biochem Biophys 373:63–71.  	10620324
	Kalsotra A, Anakk S, Boehme CL, and Strobel HW (2002) Sexual dimorphism and  tissue specificity in the expression of CYP4F forms in Sprague Dawley rats. Drug  Metab Dispos 30:1022–1028.  	12167568
	Kawashima H, Kusunose E, Thompson CM, and Strobel HW (1997) Protein expres sion, characterization and regulation of CYP4F4 and CYP4F5 cloned from rat  brain. Arch Biochem Biophys 347:148–154.  	9344476
	Kawashima H and Strobel HW (1995) cDNA cloning of three new forms of rat brain  cytochrome P450 belonging to the CYP4F subfamily. Biochem Biophys Res Com mun 217:1137–1144.  	8554568
	Kikuta Y, Kusunose E, Endo K, Yamamoto S, Sogawa K, Fujii-Kuriyama Y, and  Kusunose M (1993) A novel form of cytochrome P-450 family 4 in human polymor phonuclear leukocytes. cDNA cloning and expression of leukotriene B4 -hydrox ylase. J Biol Chem 268:9376–9380.  	8486631
	Kikuta Y, Kusunose E, Ito M, and Kusunose M (1999) Purification and character ization of recombinant rat hepatic CYP4F1. Arch Biochem Biophys 369:193–196.  	10486137
	Kroetz DL, Huse LM, Thuresson A, and Grillo MP (1997) Developmentally regulated  expression of the CYP4A genes in the spontaneously hypertensive rat kidney. Mol  Pharmacol 52:362–372.  	9281597
	Lasker JM, Chen WB, Wolf I, Bloswick BP, Wilson PD, and Powell PK (2000)  Formation of 20-hydroxyeicosatetraenoic acid, a vasoactive and natriuretic eico sanoid, in human kidney. Role of CYP4F2 and CYP4A11. J Biol Chem 275:4118–  4126.  	10660572
	LeBrun LA, Xu F, Kroetz DL, and Ortiz de Montellano PR (2002) Covalent attach ment of the heme prosthetic group in the CYP4F cytochrome P450 family. Bio chemistry 41:5931–5937.  	11980497
	Nguyen X, Wang MH, Reddy KM, Falck JR, and Schwartzman ML (1999) Kinetic  profile of the rat CYP4A isoforms: arachidonic acid metabolism and isoform specific inhibitors. Am J Physiol 276:R1691–R1700.  	10362749
	Okita RT, Clark JE, Okita JR, and Masters BS (1991) - and (-1)-hydroxylation of  eicosanoids and fatty acids by high-performance liquid chromatography. Methods  Enzymol 206:432–441.  	1784228
	Omura T and Sato R (1964a) The carbon monoxide-binding pigment of liver micro somes. J Biol Chem 239:2379–2385.  	NO_MATCH
	Omura T and Sato R (1964b) The carbon monoxide-binding pigment of liver micro somes. I. Evidence for its hemoprotein nature. J Biol Chem 239:2370–2378.  	14209971
	Schwartzman M, Ferreri NR, Carroll MA, Songu-Mize E, and McGiff JC (1985)  Renal cytochrome P450-related arachidonate metabolite inhibits Na,K-ATPase.  Nature (Lond) 314:620–622.  	2986008
	Stec DE, Deng AY, Rapp JP, and Roman RJ (1996) Cytochrome P4504A genotype  cosegregates with hypertension in Dahl S rats. Hypertension 27:564–568.  	8613204
	Stec DE, Flasch A, Roman RJ, and White JA (2003) Distribution of cytochrome P-450  4A and 4F isoforms along the nephron in mice. Am J Physiol 284:F95–F102.  	12388424
	Su P, Kaushal KM, and Kroetz DL (1998) Inhibition of renal arachidonic acid  -hydroxylase activity with ABT reduces blood pressure in the SHR. Am J Physiol  275:R426–R438.  	9688677
	Sumimoto J, Takeshige K, and Minakami S (1988) Characterization of human  neutrophil leukotriene B4 -hydroxylase as a system involving a unique cyto chrome P-450 and NADPH-cytochrome P-450 reductase. Eur J Biochem 172:315–  324.  	3127205
	Wang MH, Brand-Schieber E, Zand BA, Nguyen X, Falck JR, Balu N, and Schwartz man ML (1998) Cytochrome P450-derived arachidonic acid metabolism in the rat  kidney: characterization of selective inhibitors. J Pharmacol Exp Ther 284:966–  973.  	9495856
	Wang MH, Zhang F, Marji J, Zand BA, Nasjletti A, and Laniado-Schwartzman M  (2001) CYP4A1 antisense oligonucleotide reduces mesenteric vascular reactivity  and blood pressure in SHR. Am J Physiol 280:R255–R261.  	11124159
	Wang W and Lu M (1995) Effect of arachidonic acid on activity of the apical K  channel in the thick ascending limb of the rat kidney. J Gen Physiol 106:727–743.  	8576704
	Xu F, Straub WO, Pak W, Su P, Maier KG, Yu M, Roman RJ, Ortiz De Montellano  PR, and Kroetz DL (2002) Antihypertensive effect of mechanism-based inhibition  of renal arachidonic acid -hydroxylase activity. Am J Physiol 283:R710–R720.  	12185006
	Zhang X, Chen L, and Hardwick JP (2000) Promoter activity and regulation of the  CYP4F2 leukotriene B4 -hydroxylase gene by peroxisomal proliferators and reti noic acid in HepG2 cells. Arch Biochem Biophys 378:364–376.  	10860554
	Zou AP, Fleming JT, Falck JR, Jacobs ER, Gebremedhin D, Harder DR, and Roman  RJ (1996) 20-HETE is an endogenous inhibitor of the large-conductance Ca2 activated K channel in renal arterioles. Am J Physiol 270:R228–R237.  	8769806
	Zou AP, Imig JD, Kaldunski M, Ortiz de Montellano PR, Sui Z, and Roman RJ  (1994a) Inhibition of renal vascular 20-HETE production impairs autoregulation  of renal blood flow. Am J Physiol 266:F275–F282.  	8141328
	Zou AP, Imig JD, Ortiz de Montellano PR, Sui Z, Falck JR, and Roman RJ (1994b)  Effect of P-450 -hydroxylase metabolites of arachidonic acid on tubuloglomerular  feedback. Am J Physiol 266:F934–F941.  	8023972
	Zou AP, Ma YH, Sui ZH, Ortiz de Montellano PR, Clark JE, Masters BS, and Roman  RJ (1994c) Effects of 17-octadecynoic acid, a suicide-substrate inhibitor of cyto chrome P450 fatty acid -hydroxylase, on renal function in rats. J Pharmacol Exp  Ther 268:474–481.  	8301590
gb-2003-4-11-r73.pdf
	Dehal P, Satou Y, Campbell RK, Chapman J, Degnan B, De Tomaso A,  Davidson B, Di Gregorio A, Gelpke M, Goodstein DM, et al.: The  draft genome of Ciona intestinalis: insights into chordate and  vertebrate origins. Science 2002, 298:2157-2167.  	12481130
	Schmidtke J, Epplen JT, Engel W: Genome analysis of Amphioxus  and speculation as to the origin of contrasting vertebrate  genome organization patterns. Comp Biochem Physiol 1979,  63:455-458.  	NO_MATCH
	Simmen MW, Bird A: Sequence analysis of transposable ele ments in the sea squirt, Ciona intestinalis. Mol Biol Evol 2000,  17:1685-1694.  	11070056
	4. Charlesworth B, Sniegowski P, Stephan W: The evolutionary  dynamics of repetitive DNA in eukaryotes. Nature 1994,  371:215-220.  	8078581
	Finnegan DJ: Eukaryotic transposable elements and genome  evolution. Trends Genet 1989, 5:103-107.  	2543105
	Finnegan DJ: Transposable elements. Curr Opin Genet Dev 1992,  2:861-867.  	1335807
	Xiong Y, Eickbush TH: Origin and evolution of retroelements  based upon their reverse transcriptase sequences. EMBO J  1990, 9:3353-3362.  	1698615
	Luan DD, Korman MH, Jakubczak JL, Eickbush TH: Reverse tran scription of R2Bm RNA is primed by a nick at the chromo somal target site: a mechanism for non-LTR  retrotransposition. Cell 1993, 72:595-605.  	7679954
	Burch JB, Davis DL, Haas NB: Chicken repeat 1 elements con tain a pol-like open reading frame and belong to the non long terminal repeat class of retrotransposons. Proc Natl Acad  Sci USA 1993, 90:8199-8203.  	8396264
	10. Martín F, Olivares M, López MC: Do non-long terminal repeat  retrotransposons have nuclease activity? Trends Biochem Sci  1996, 21:283-285.  	8772379
	11. Malik HS, Burke WD, Eickbush TH: The age and evolution of non LTR retrotransposable elements. Mol Biol Evol 1999, 16:793-805.  	10368957
	12. Malik HS, Eickbush TH: NeSL-1, an ancient lineage of site-spe cific non-LTR retrotransposons from Caenorhabditis elegans.  Genetics 2000, 154:193-203.  	10628980
	13. Volff JN, Korting C, Schartl M: Multiple lineages of the non-LTR  retrotransposon Rex1 with varying success in invading fish  genomes. Mol Biol Evol 2000, 17:1673-1684.  	11070055
	14. Lovsin N, Gubensek F, Kordi D: Evolutionary dynamics in a  novel L2 clade of non-LTR retrotransposons in  Deuterostomia. Mol Biol Evol 2001, 18:2213-2224.  	11719571
	15. Aparicio S, Chapman J, Stupka E, Putnam N, Chia JM, Dehal P, Christ offels A, Rash S, Hoon S, Smit A, et al.: Whole-genome shotgun  assembly and analysis of the genome of Fugu rubripes. Science  2002, 297:1301-1310.  	12142439
	16. Albalat R, Permanyer J, Cañestro C, Martínez-Mir A, Gonzàlez Angulo O, Gonzàlez-Duarte R: The first non-LTR retrotranspo son characterised in the cephalochordate amphioxus,  BfCR1, shows similarities to CR1-like elements. Cell Mol Life Sci  2003, 60:803-809.  	12785727
	17. Tu Z, Isoe J, Guzova JA: Structural, genomic, and phylogenetic  analysis of Lian, a novel family of non-LTR retrotransposons  in the yellow fever mosquito, Aedes aegypti. Mol Biol Evol 1998,  15:837-853.  	9656485
	18. Burke WD, Malik HS, Jones JP, Eickbush TH: The domain structure  and retrotransposition mechanism of R2 elements are con served throughout arthropods. Mol Biol Evol 1999, 16:502-511.  	10331276
	19. Cañestro C, Albalat R, Gonzàlez-Duarte R: Isolation and charac terization of the first non-autonomous transposable element  in amphioxus, ATE-1. Gene, in press.  	14585499
	20. Yoder JA, Walsh CP, Bestor TH: Cytosine methylation and the  ecology of intragenomic parasites. Trends Genet 1997, 13:335 340.  	9260521
	21. Simmen MW, Leitgeb S, Charlton J, Jones SJ, Harris BR, Clark VH,  Bird A: Nonmethylated transposable elements and methyl ated genes in a chordate genome. Science 1999, 283:1164-1167.  	10024242
	22. Chaboissier MC, Bucheton A, Finnegan DJ: Copy number control  of a transposable element, the I factor, a LINE-like element  in Drosophila. Proc Natl Acad Sci USA 1998, 95:11781-11785.  	9751742
	23. Jensen S, Gassama MP, Heidmann T: Taming of transposable ele ments by homology-dependent gene silencing. Nat Genet 1999,  21:209-212.  	9988275
	24. Flavell RB: Inactivation of gene expression in plants as a con sequence of specific sequence duplication. Proc Natl Acad Sci  USA 1994, 91:3490-3496.  	8170935
	25. Altschul SF, Madden TL, Schaffer AA, Zhang J, Zhang Z, Miller W, Lip man DJ: Gapped BLAST and PSI-BLAST: a new generation of  protein database search programs. Nucleic Acids Res 1997,  25:3389-3402.  	9254694
	26. DOE Joint Genome Institute  [http://www.jgi.doe.gov]  	NO_MATCH
	27. Church GM, Gilbert W: Genomic sequencing. Proc Natl Acad Sci  USA 1984, 81:1991-1995.  	6326095
	28. Thompson JD, Gibson TJ, Plewniak F, Jeanmougin F, Higgins DG: The  CLUSTAL_X windows interface: flexible strategies for mul tiple sequence alignment aided by quality analysis tools.  Nucleic Acids Res 1997, 25:4876-4882.  	9396791
	29. Page RDM: TREEVIEW: An application to display phyloge netic trees on personal computers. Comput Appl Biosci 1996,  12:357-358.  	8902363
	30. Berezikov E, Bucheton A, Busseau I: A search for reverse tran scriptase-coding sequences reveals new non-LTR retrotrans posons in the genome of Drosophila melanogaster. Genome Biol  2000, 1:research0012.1-0012.15.  	11178266
	31. Holt RA, Subramanian GM, Halpern A, Sutton GG, Charlab R, Nussk ern DR, Wincker P, Clark AG, Ribeiro JM, Wides R, et al.: The  genome sequence of the malaria mosquito Anopheles  gambiae. Science 2002, 298:129-149.  	12364791
	32. Fawcett DH, Lister CK, Kellett E, Finnegan DJ: Transposable ele ments controlling I-R hybrid dysgenesis in D. melanogaster  are similar to mammalian LINEs. Cell 1986, 47:1007-1015.  	2430722
gb-2003-4-11-r72.pdf
	Wang Z, Moult J: SNPs, protein structure, and disease. Hum  Mutat 2001, 17:263-270.  	11295823
	Sunyaev S, Ramensky V, Koch I, Lathe W 3rd, Kondrashov AS, Bork  P: Prediction of deleterious human alleles. Hum Mol Genet 2001,  10:591-597.  	11230178
	3. Ng PC, Henikoff S: Predicting deleterious amino acid  substitutions. Genome Res 2001, 11:863-874.  	11337480
	Chasman D, Adams M: Predicting the functional consequences  of non-synonymous single nucleotide polymorphisms: struc ture-based assessment of amino acid variation. J Mol Biol 2001,  307:683-706.  	11254390
	Miller MP, Kumar S: Understanding human disease mutations  through the use of interspecific variation. Hum Mol Genet 2001,  10:2319-2328.  	11689479
	6. Terp BN, Cooper DN, Christensen IT, Jorgensen FS, Bross P,  Gregersen N, Krawczak M: Assessing the relative importance of  the biophysical properties of amino acid substitutions associ ated with human genetic disease. Hum Mutat 2002, 20:98-109.	12124990
	McKusick VA: Mendelian Inheritance in Man. Catalogs of Human Genes  and Genetic Disorders 12th edition. Baltimore: John Hopkins University  Press; 1998.	17357067
	Bairoch A, Apweiler R: The SWISS-PROT protein sequence  data bank and its new supplement TrEMBL. Nucleic Acids Res  1996, 24:21-25.  	8594581
	Stephens JC, Schneider JA, Tanguay DA, Choi J, Acharya T, Stanley SE,  Jiang R, Messer CJ, Chew A, Han JH, et al.: Haplotype variation and  linkage disequilibrium in 313 human genes. Science 2001,  293:489-493.  	11452081
	10. Dayhoff MO: A model of evolutionary change in proteins. In  Atlas of Protein Sequence and Structure Edited by: Silver Spring: National  Biomedical Research Foundation. Dayhoff MO; 1978:345-352.   	NO_MATCH
	11. Halushka MK, Fan JB, Bentley K, Hsie L, Shen N, Weder A, Cooper  R, Lipshutz R, Chakravarti A: Patterns of single-nucleotide poly morphisms in candidate genes for blood-pressure  homeostasis. Nat Genet 1999, 22:239-247.  	10391210
	12. Cargill M, Altshuler D, Ireland J, Sklar P, Ardlie K, Patil N, Shaw N,  Lane CR, Lim EP, Kalyanaraman N, et al.: Characterization of sin gle-nucleotide polymorphisms in coding regions of human  genes. Nat Genet 1999, 22:231-238.  	10391209
	13. Hess ST, Blake JD, Blake RD: Wide variations in neighbor dependent substitution rates. J Mol Biol 1994, 236:1022-1033.  	8120884
	14. Sonnhammer EL, von Heijne G, Krogh A: A hidden Markov model  for predicting transmembrane helices in protein sequences.  Proc Int Conf Intell Syst Mol Biol 1998, 6:175-182.  	9783223
	15. Benner SA, Cohen MA, Gonnet GH: Amino acid substitution  during functionally constrained divergent evolution of pro tein sequences. Protein Eng 1994, 7:1323-1332.  	7700864
	16. Cooper DN, Youssoufian H: The CpG dinucleotide and human  genetic disease. Hum Genet 1988, 78:151-155.  	3338800
	17. Krawczak M, Ball EV, Cooper DN: Neighboring-nucleotide  effects on the rates of germ-line single base-pair substitution  in human genes. Am J Hum Genet 1998, 63:474-488.  	9683596
	18. Ng PC, Henikoff S: Accounting for human polymorphisms pre dicted to affect protein function. Genome Res 2002, 12:436-446.  	11875032
	19. Ramensky V, Bork P, Sunyaev S: Human non-synonymous SNPs:  server and survey. Nucleic Acids Res 2002, 30:3894-3900.  	12202775
	20. Ferrer-Costa C, Orozco M, de la Cruz X: Characterization of dis ease-associated single amino acid polymorphisms in terms  of sequence and structure properties. J Mol Biol 2002, 315:771 786.  	11812146
	21. Bustamante CD, Townsend JP, Hartl DL: Solvent accessibility and  purifying selection within proteins of Escherichia coli and Sal monella enterica. Mol Biol Evol 2000, 17:301-308.  	10677853
	22. Grantham R: Amino acid difference formula to help explain  protein evolution. Science 1974, 185:862-864.  	4843792
	23. Fay JC, Wyckoff GJ, Wu CI: Positive and negative selection on  the human genome. Genetics 2001, 158:1227-1234.  	11454770
	24. Terwilliger JD, Haghighi F, Heikkalinna TS, Goring HH: A biased  assessment of the use of SNPs in human complex traits. Curr  Opin Genet Dev 2002, 12:726-734.  	12433588
	25. Lohmueller KE, Pearce CL, Pike M, Lander ES, Hirschhorn JN: Meta analysis of genetic association studies supports a contribu tion of common variants to susceptibility to common  disease. Nat Genet 2003, 33:177-182.  	12524541
	26. Olins PO, Bauer SC, Braford-Goldberg S, Sterbenz K, Polazzi JO,  Caparon MH, Klein BK, Easton AM, Paik K, Klover JA, et al.: Satura tion mutagenesis of human interleukin-3. J Biol Chem 1995,  270:23754-23760.  	7559548
	27. Huang W, Petrosino J, Hirsch M, Shenkin PS, Palzkill T: Amino acid  sequence determinants of beta-lactamase structure and  activity. J Mol Biol 1996, 258:688-703.  	8637002
	28. Pakula AA, Sauer RT: Genetic analysis of protein stability and  function. Annu Rev Genet 1989, 23:289-310.  	2694933
	29. Matthews BW: Structural and genetic analysis of the folding  and function of T4 lysozyme. FASEB J 1996, 10:35-41.  	8566545
	30. Nachman MW, Crowell SL: Estimate of the mutation rate per  nucleotide in humans. Genetics 2000, 156:297-304.  	10978293
	31. Eyre-Walker A, Keightley PD: High genomic deleterious muta tion rates in hominids. Nature 1999, 397:344-347.  	9950425
	32. Henikoff S, Henikoff JG: Amino acid substitution matrices from  protein blocks. Proc Natl Acad Sci USA 1992, 89:10915-10919.  	1438297
	33. Templeton AR, Clark AG, Weiss KM, Nickerson DA, Boerwinkle E,  Sing CF: Recombinational and mutational hotspots within the  human lipoprotein lipase gene. Am J Hum Genet 2000, 66:69-83.  	10631137
	34. Zavolan M, Kepler TB: Statistical inference of sequence dependent mutation rates. Curr Opin Genet Dev 2001, 11:612 615.  	11682302
	35. Rogozin I, Kondrashov F, Glazko G: Use of mutation spectra  analysis software. Hum Mutat 2001, 17:83-102.  	11180592
	36. Wootton JC, Federhen S: Analysis of compositionally biased  regions in sequence databases. Methods Enzymol 1996, 266:554 571.  	8743706
	37. Holm L, Sander C: Removing near-neighbour redundancy from  large protein sequence collections. Bioinformatics 1998, 14:423 429.  	9682055
	38. Higgins DG, Thomposon JD, Gibson TJ: Using CLUSTAL for mul tiple sequence alignments. Methods Enzymol 1996, 266:383-402.  	8743695
	39. Altschul SF, Madden TL, Schaffer AA, Zhang J, Zhang Z, Miller W, Lip man DJ: Gapped BLAST and PSI-BLAST: a new generation of  protein database search programs. Nucleic Acid Res 1997,  25:3389-3402.  	9254694
	40. Bernstein FC, Koetzle TF, Williams GJB, Meyer EF Jr, Brice MD,  Rodgers JR, Kennard O, Shimanouchi T, Tasumi M: The Protein  Data Bank: A computer based archival file for macromolecu lar structures. J Mol Biol 1977, 112:535-542.  	626512
	41. Hubbard SJ, Thornton JM: NACCESS Computer Program London:  Department of Biochemistry and Molecular Biology, University Col lege London; 1993.   	NO_MATCH
	42. Mount DW: Bioinformatics Cold Spring Harbor, NY: Cold Spring Har bor Laboratory Press; 2001.   	NO_MATCH
621.full.pdf
	Blair RM, Geisert RD, Zavy MT, Short EC, Fulton RW and Yellin T (1991)  Endometrial morphological and secretory alterations associated with  embryonic mortality in gilts administered estradiol valerate on days 9  and 10 of gestation Biology of Reproduction 44 1063–1079  	1873382
	Bost F, Diarra-Mehrpour M and Martin JP (1998) Inter--trypsin inhibi tor proteoglycan family: a group of proteins binding and stabilizing  the extracellular matrix European Journal of Biochemistry 222 339–  346  	9546647
	Bowen JA, Bazer FW and Burghardt RC (1996) Spatial and temporal  analyses of integrin and MUC-1 expression in porcine uterine epithelium  and trophectoderm in vivo. Biology of Reproduction 55 1098–1106  	8902223
	Chen L, Mao SJT, McLean LR, Powers RW and Larsen WJ (1994) Proteins of  the inter--trypsin inhibitor family stabilize the cumulus extracellular  matrix through their direct binding with hyaluronic acid Journal of  Biological Chemistry 269 28 282–28 287  	7525572
	Chen L, Zhang H, Powers RW, Russell PT and Larsen WJ (1996) Covalent  linkage between proteins of the inter--inhibitor family and hyaluronic  acid is mediated by a factor produced by granulosa cells Journal of  Biological Chemistry 271 19 409–19 414  	8702628
	Choi-Miura N-H, Sano Y, Oda E, Nakano Y, Tobe T, Yanagishita T, Taniyama  M, Katagire T and Tomita M (1995) Purification and characterization of  a novel glycoprotein which has significant homology to heavy chains  of inter--trypsin inhibitor family from human plasma Journal of Bio chemistry 117 400–407  	7541790
	Choi-Miura N-H, Takahashi K, Yoda M, Saito K, Hori M, Ozaki H, Mazda T  and Tomita M (2000) The novel acute phase protein, IHRP, inhibits  actin polymerization and phagocytosis of polymorphonuclear cells  Inflammation Research 49 305–310  	10939621
	Dantzer V (1985) Electron microscopy of the initial stages of placentation  in the pig Anatomy and Embryology 172 281–293  	4061869
	Enghild JJ, Thogersen IB, Pizzo SV and Salvesen G (1989) Analysis of inter -trypsin inhibitor, pre--trypsin inhibitor, from human plasma Journal  of Biological Chemistry 264 15 975–15 981  	NO_MATCH
	Enghild JJ, Salvesen G, Hefta SA, Thogersen IB, Rutherfurd S and Pizzo  SV (1991) Chondroitin 4-sulfate covalently cross-links the chains of the  human blood protein pre--inhibitor Journal of Biological Chemistry  266 747–751  	1898736
	Fazleabas AT, Geisert RD, Bazer FW and Roberts RM (1983) Relationship  between release of plasminogen activator and estrogen by blastocysts  and secretion of plasmin inhibitor by uterine endometrium in the  pregnant pig Biology of Reproduction 29 225–238  	6225472
	Ford SP and Christenson RK (1979) Blood flow to uteri of sows during the  estrous cycle and early pregnancy: local effect of the conceptus on the  uterine blood supply Biology of Reproduction 21 617–624  	497319
	Ford SP, Christenson RK and Ford JJ (1982) Uterine blood flow and uterine  arterial, venous and lumenal concentrations of oestrogens on days 11,  13, and 15 after oestrus in pregnant and non-pregnant sows Journal of  Reproduction and Fertility 64 185–190  	7054493
	Geisert RD and Yelich JV (1997) Regulation of conceptus development and  attachment in pigs Journal of Reproduction and Fertility Supplement 52  133–149  	9602725
	Geisert RD, Renegar RH, Thatcher WW, Roberts RM and Bazer FW (1982)  Establishment of pregnancy in the pig. I. Interrelationships between  preimplantation development of the pig blastocyst and uterine endo metrial secretions Biology of Reproduction 27 925–939  	6959653
	Geisert RD, Dixon MJ, Pratt T, Schmitt RAM, Lessley BA and McCann  JP (1995) Isolation and characterization of a 30 kDa endometrial  glycoprotein synthesized during the estrous cycle and early pregnancy  in the pig Biology of Reproduction 53 942–954  	8527506
	Geisert RD, Yelich JV, Pratt T and Pomp D (1998) Expression of an inter- trypsin inhibitor heavy chain-like protein in the pig endometrium during  the oestrous cycle and early pregnancy Journal of Reproduction and  Fertility 114 35–43  	9875153
	Gries LK, Geisert RD, Zavy MT, Garrett JE and Morgan GL (1989) Uterine  secretory alterations coincident with embryonic mortality in the gilt after  exogenous estrogen administration Journal of Animal Science 67 276–  284  	2925548
	Hettinger AM, Allen MA, Zhang BR, Goad DW, Malayer JR and Geisert RD  (2001) Presence of acute phase protein, bikunin, in the endometrium of  gilts during estrous cycle and early pregnancy Biology of Reproduction  65 507–513  	11466219
	Jaeger LA, Johnson GA, KA H, Garlow JG, Burghardt RC, Spencer TE and  Bazer FW (2001) Functional analysis of autocrine and paracrine sig naling at the uterine–conceptus interface in pigs Reproduction Supple ment 58 191–207  	11980190
	Jessen TE, Odum L and Johnsen AH (1994) In vivo binding of human  inter--trypsin inhibitor free heavy chains to hyaluronic acid Biological  Chemistry Hoppe-Seyler 375 521–526  	7529027
	Keys JL and King GJ (1988) Morphological evidence for increased uterine  vascular permeability at the time of embryonic attachment in the pig  Biology of Reproduction 39 473–487  	3179392
	King GJ, Atkinson A and Robertson HA (1982) Implantation and early  placentation in domestic ungulates Journal of Reproduction and Fertility  Supplement 31 17–30  	6762430
	Nishimura H, Kakizaki I, Muta T, Sasaki N, Pu PX, Yamashita T and  Nagasawa S (1995) cDNA and deduced amino acid sequence of human  PK-120, a plasma kallikrein-sensitive glycoprotein FEBS Letters 357 207–  211  	7805892
	Roberts RM, Xie S and Trout WE (1993) Embryo–uterine interactions in  pigs during week 2 of pregnancy Journal of Reproduction and Fertility  Supplement 48 171–186  	8145203
	Rouet P, Daveau M and Salier J-P (1992) Electrophoretic pattern of the  inter--inhibitor family proteins in human serum, characterized by  chain specific antibodies Biological Chemistry Hoppe-Seyler 373 1019–  1024  	1384549
	Salier J-P, Rouet P, Raguenez G and Daveau M (1996) The inter--inhibitor  family: from structure to regulation Biochemical Journal 315 1–9  	8670091
	Samuel CA and Perry JS (1972) The ultrastructure of pig trophoblast  transplanted to an ectopic site in the uterine wall Journal of Anatomy  113 139–149  	4648479
	SAS/STAT (1988) User’s guide. SAS Institute, Inc., Cary, North Carolina  Stroband HWJ and Van der Lende T (1990) Embryonic and uterine  development during early pregnancy in pigs Journal of Reproduction  and Fertility Supplement 40 261–277  	NO_MATCH
	Vonnahme KA, Malayer JR, Spivey HO, Ford SP, Clutter A and Geisert RD  (1999) Detection of kallikrein gene expression and enzymatic activity  in porcine endometrium during the estrous cycle and early pregnancy  Biology of Reproduction 61 1235–1241  	10529269
	Yelich JV, Pomp D and Geisert RD (1997a) Detection of transcripts for  retinoic acid receptors, retinol binding protein, and transforming growth  factors during rapid trophoblastic elongation in the porcine conceptus  Biology of Reproduction 57 126–134  	9241041
	Yelich JV, Pomp D and Geisert RD (1997b) Ontogeny of elongation and  gene expression in the early developing porcine conceptuses Biology of  Reproduction 57 1256–1264  	9369195
	Xu Y, Carr PD, Guss JM and Ollis DL (1998) The crystal structure of bikunin  from the inter--inhibitor complex: a serine protease inhibitor with two  kunitz domains Journal of Molecular Biology 276 955–966  	9566199
	Zhuo L, Yoneda M, Zhao M, Yingsung W, Yoshida N, Kitagawa Y,  Kawamura K, Suzuki T and Kimata K (2001) Defect in SHAP-hyaluronan  complex causes severe female infertility: a study by inactivation of  the bikunin gene in mice Journal of Biological Chemistry 276 7693–  7696  	11145954
Authorize.PDF
	1. Gotlieb MS, Schanker HM, Fan PT, Saxon A, Weisman JD, Pozalski.  Pneumocystic pneumonia. Los Angeles MMWR Weekly 1981; 30:  250–252.  	NO_MATCH
	2. UNAIDS. Aids Epidemic Update. 1 December 2002.  	NO_MATCH
	3. Yunis NA, Stone VE. Cardiac Manifestations of HIV/AIDS: A review  of disease spectrum and clinical management. J Acq Imm Def Syndr  Hum Retrovirol 1998; 18: 145–154.  	9637579
	4. Hakim JG, Matenga JA, Siziya. Myocardial dysfunction in human  immunodeficiency virus infection: an echocardiographic study of 157  patients in hospital in Zimbabwe. Heart 1996; 76: 161–165.  	8795481
	5. Herskowitz A, Vlahov D, Willoughby S, et al. Prevalence and inci dence of left ventricular dysfunction in patients with human immuno deficiency infection. Am J Cardiol 1993; 71: 955–958.  	8465788
	6. Kinney EL, Brafman D, Wright RJ. Echocardiographic findings in  patients with acquired immunodeficiency syndrome (AIDS) and  AIDS-related complex (ARC). Cathet Cardiocvasc Diagnosis 1989;  16: 182–185.  	2920391
	7. Lassaigne D, Greder A, Hedoire F, Grollier G, Potier JC, Bazin C.  Myocardial involvement in AIDS: Echographic study in 85 human  immunodeficiency virus infected patients. Ann Med Interne Paris  1991; 142: 205–208.  	1854133
	8. Barbaro G, Di Lorenzo G, Grisario B, Bacbarini G. Incidence of dilat ed cardiomyopathy and detection of HIV in myocardial cells of HIV  positive patients. N Engl J Med 1998; 16: 1039–1099.  	NO_MATCH
	9. Longo-Mbenza B, Seghers KV, Phuati M, Nkiabungu Bikangi F,  Mubagwa K. Heart involvement in HIV infection in African patients:  Determinants of survival. Int J Cardiol 1998; 64: 63–73.  	9579818
	10. Kaul S, Fishbein MC, Siegel RJ. Cardiac manifestations of acquired  immune deficiency syndrome. Am Heart J 1991; 122: 535–544.  	1858638
	11. Anderson DW, Virmani R, Reilly JM, O’Leary T, Cunnion RE,  Robinowits M, et al. Prevalent myocarditis at necropsy in the acquired  immunodeficiency syndrome. J Am Coll Cardiol 1988; 11: 792–799.  	3351145
	12. Autron BR, Gorin I, Leibowitch M. AIDS in a Haitian woman with  Kaposi’s sarcoma and Whipple’s disease. Lancet 1983; 1: 767–768.  	6188005
	13. Cotton P. AIDS giving rise to cardiac problems. J Am Med Assoc 1990;  263: 2149.  	2319673
	14. Grody WW, Cheng L, Lewis W. Infection of the heart by the human  immunodeficiency virus. Am J Cardiol 1990; 66: 203–206.  	2371952
	15. Flomenbaum M, Soeiro Rm Udem SA, Kress Y, Factor SM.  Proliferative membranopathy and human immunodeficiency virus in  AIDS hearts. J AIDS 1989; 2: 129–135.  	2539451
	16. Herskowitz A, Nieumann DA, Ansari AA. Concepts of autoimmunity  applied to idiopathic dilated cardiomyopathy. J Am Coll Cardiol 1993;  22: 1385–1388.  	8227795
	17. Patel RC, Frishman WH. Cardiac involvement in HIV infection. Med  Clin North Am 1996; 80: 1493–1512.  	8941233
	18. Dworkin BM, Antonecchia PP, Smith F, et al. Reduced cardiac seleni um content in AIDS. J Parenter Enteral Nutr 1989; 13: 644–647.  	NO_MATCH
	19. Cegielski JP, Lwakatare J, Dukes CS, et al. Tuberculous pericarditis in  Tanzanian patients with and without HIV infection. Tuber Lung Dis  1994; 75: 429–434.  	7718831
	20. Longo_Mbenza B, Tonduangu K, Seghers KV, Mubazwa D. HIV  infection and pericardial disease invasion in Africa. Arch M Coeur  Vaiss 1997; 90: 1377–1384.  	9539838
	21. Flum DR, McGinn JT Jr, Tyras DH. The role of the ‘pericardial win dow’ in AIDS. Chest 1995; 107: 1522–1525.  	7781340
	22. Herskowitz A, Willonguby SB, BaughmanKL, Schulman SP, Bartlett  JD. Cardiomyopathy associated with antiretroviral therapy in patients  with HIV infection: a report of six cases. Ann Intern Med 1992; 116:  311–313.  	1733387
	23. Domanski MJ, Sloas MM, Follmann DA. Effect of zidovudine and  didanosine treatment on heart function in children infected with human  immunodeficiency virus. J Pediatr 1995; 127: 137–146.  	7608800
	24. Carr A, Samaras K, Burton S, Lan M, Freund J, Chrisholm DJ, Cooper  DA. A syndrome of peripheral lipodystrophy hyperlipidaemia and  insulin resistance in patients receiving HIV protease inhibitors. AIDS  1998; 12: 51–58.  	9619798
	25. Gallet B, Pulik M, Genet P, Chedin P, Hictgen M. Vascular complica tions associated with the use of HIV protease inhibitors (letter). Lancet  1998; 351: 1959.  	9654285
	26. Jütte A, Franzen C, Römer K, Cornely D, Diet F, Diehl V, Fätkenheuer  G, Salzberger B. Increased morbidity from myocardial infarction dur ing HIV protease inhibitor treatment (abstr 656). Sixth conference on  Retrovirus and Opportunistic infections. Chicago; January/February  1999.  	10509592
	27. Bozzette SA, Ake CF, Tam HK, et al. Cardiovascular and cerebrovas cular events in patients treated for human immunodeficiency virus  infection. N Engl J Med 2003; 348: 702.  	12594314
	28. Duong M, Buisson M, Cottin Y, Piroth L, Lhuillier I, Grappin M, et al.  Coronary heart disease associated with the use of human immunodefi ciency virus (HIV)-1 protease inhibitors: Report of four cases and  review. Clin Cardiol 2001; 24: 690–694.  	11594416
	29. Andrews S, Cotton M, Maartens G, Martin D, Miller S, Wood R, et al.  Clinical guidelines. Antiretroviral therapy in adults: June 2002 version.  Sth Afr J HIV Med 2002; 8: 22–29.  	NO_MATCH
JVS004-02-15.pdf
j.1432-1033.2003.03803.x.pdf
	1. dos Remedios, C.G., Chhabra, D., Kekic, M., Dedova, I.V.,  Tsubakihara, M., Berry, D.A. & Noseworthy, N.J. (2003) Actin  binding proteins: regulation of cytoskeletal microﬁlaments. Phy siol. Rev. 83, 433–473.  	12663865
	2. Sun, H.Q., Yamamoto, M., Mejillano, M. & Yin, H.L. (1999)  Gelsolin, a multifunctional actin regulatory protein. J. Biol. Chem.  274, 33179–33182.  	10559185
	3. Way, M. & Weeds, A.G. (1988) Nucleotide sequence of pig  plasma gelsolin. Comparison of protein sequence with human  gelsolin and other actin-severing proteins shows strong homo logies and evidence for large internal repeats. J. Mol. Biol. 203,  1127–1133.  	2850369
	4. Burtnick, L.D., Koepf, E.K., Grimes, J., Jones, E.Y., Stuart, D.I.,  McLaughlin, P.J. & Robinson, R.C. (1997) The crystal structure  of plasma gelsolin: Implications for actin severing, capping and  nucleation. Cell. 90, 661–670.  	9288746
	5. Robinson, R.C., Mejillano, M., Le, V.P., Burtnick, L.D., Yin,  H.L. & Choe, S. (1999) Domain movement in gelsolin: a calcium activated switch. Science. 286, 1939–1942.  	10583954
	6. Bryan, J. (1988) Gelsolin has three actin-binding sites. J. Cell Biol.  106, 1553–1562.  	2836434
	7. Pope, B., Way, M. & Weeds, A.G. (1991) Two of the three actin binding domains of gelsolin bind to the same subdomain of actin.  FEBS Lett. 280, 70–74.  	NO_MATCH
	8. Pope, B., Maciver, S. & Weeds, A.G. (1995) Localization of the  calcium-sensitive actin monomer binding site in gelsolin to seg ment 4 and identiﬁcation of calcium-binding sites. Biochemistry.  34, 1583–1588.  	7849017
	9. Xu, Y.-S., Kantorow, M., Davis, J. & Piatigorsky, J. (2000) Evi dence for gelsolin as a corneal crystallin in zebraﬁsh. J. Biol. Chem.  275, 24645–24652.  	10818094
	10. Steed, P.M., Nagar, S. &Wennogle, L.P. (1996) Phospholipase D  regulation by a physical interaction with the actin-binding protein  gelsolin. Biochemistry. 35, 5229–5237.  	8611508
	11. Ohtsu, M., Sakai, N., Fujita, H., Kashiwagi, M., Gasa, S., Shi mizu, S., Eguchi, Y., Tsujimoto, Y., Sakiyama, Y., Kobayashi, K.  & Kuzumaki, N. (1997) Inhibition of apoptosis by the actin regulatory protein gelsolin. EMBO J. 16, 4650–4656.  	9303309
	12. Harris, H.E., Bamburg, J.R. &Weeds, A.G. (1980) Actin ﬁlament  disassembly in blood plasma. FEBS Lett. 123, 49–53.  	6893965
	13. Haddad, J.G., Harper, K.D., Guoth, M., Pietra, G.G. & Sanger,  J.W. (1990) Angiogenic consequences of saturating the plasma  scavenger system for actin. Proc. Nat. Acad. Sci. 87, 1381–1385.  	2154744
	14. Cunningham, C.C., Stossel, T.P. & Kwiatkowski, D.J. (1991)  Enhanced motility in NIH 3T3 ﬁbroblasts that overexpress gel solin. Science. 251, 1233–1236.  	1848726
	15. Cunningham, C.C., Vegners, R., Bucki, R., Funaki, M., Korde,  N., Hartwig, J.H., Stossel, T.P. & Janmey, P.A. (2001) Cell per meant polyphsophoinositide-binding peptides that block cell  motililty and actin assembly. J. Biol. Chem. 276, 43390–43399.  	11533030
	16. Witke,W., Sharpe, A.H.H., Artwig, J.H., Azuma, T., Stossel, T.P.  & Kwiatkowski, D.J. (1995) Hemostatic, inﬂammatory and  ﬁbroblast responses are blunted in mice lacking gelsolin. Cell. 81,  41–51.  	7720072
	17. Patkowski, A., Seils, J., Hinssen, H. & Dorfmuller, T. (1990) Size,  shape parameters and calcium-induced conformational change of  the gelsolin molecule. A dynamic light scattering study. Biopoly mers. 30, 427–435.  	NO_MATCH
	18. Hellweg, T., Hinssen, H. & Eimer, W. (1993) The Ca2+-induced  conformational change of gelsolin is located in the carboxyl-ter minal half of the molecule. Biophys. J. 65, 799–805.  	8218904
	19. Choe, H., Burtnick, L.D., Mejillano, M., Yin, H.L., Robinson,  R.C. & Choe, S. (2002) The calcium activation of gelsolin: Insights  from the 3A˚ structure of the G4–G6/actin complex. J. Mol. Evol.  324, 691–702.  	12460571
	20. Kolappan, S.P., Gooch, J.T., Weeds, A.G. & McLaughlin, P.J.  (2003) Gelsolin domains 4–6 in active, actin free conformation  identiﬁes sites of regulatory calcium ions. J. Mol. Biol. 329, 85–92.  	12742020
	21. Lamb, J.A., Allen, P.G., Tuan, B.Y. & Janmey, P.A. (1993)  Modulation of gelsolin function – activation at low pH overrides  Ca2+ requirement. J. Biol. Chem. 268, 8999–9004.  	8386174
	22. Lagarrique, E., Maciver, S.K., Fattoum, A., Benyamin, Y. &  Roustan, C. (2003) Co-operation of domain-binding and calcium binding sites in the activation of gelsolin. Eur. J. Biochem. 270,  2236–2243.  	12752443
	23. Spudich, J.A. & Watt, S. (1971) The regulation of rabbit skeletal  muscle contraction. Biochemical studies of the interaction of the  tropomyosin-troponin complex with actin and the proteolytic  fragments of myosin. J. Biol. Chem. 246, 4866–4871.  	4254541
	24. Kouyama, T. & Mihashi, K. (1981) Fluorimetry study of N-(1 pyrenyl) iodoacetamide-labelled F-actin. Eur. J. Biochem. 114,  33–38.  	NO_MATCH
	25. Way,M., Pope, B., Gooch, J., Hawkins,M.&Weeds, A.G. (1990)  Identiﬁcation of a region of segment 1 of gelsolin critical for actin  binding. EMBO J. 9, 4103–4109.  	2174356
	26. Way, M., Pope, B. &Weeds, A.G. (1992) Evidence for functional  homology in the F-actin binding domains of gelsolin and alpha actinin: implications for the requirements of severing and capping.  J. Cell Biol. 119, 835–842.  	1331120
	27. Way,M., Gooch, J., Pope, B. &Weeds, A.G. (1989) Expression of  human plasma gelsolin in E. coli and dissection of actin binding  sites by segmental deletion mutagenesis. J. Cell Biol. 109, 593–605.  	2547804
	28. Kurokawa, H., Fujii, W., Ohmi, K., Sakurai, T. & Nonomura, Y.  (1990) Simple and rapid puriﬁcation of brevin. Biochem. Biophys.  Res. Comm. 168, 451–457.  	NO_MATCH
	29. Renoult, C., Blondin, L., Fattoum, A., Ternent, D., Maciver,  S.K., Raynaud, F., Benyamin, Y. &Roustan, C. (2001) Binding of  gelsolin domain 2 to actin. An actin interface distinct from that of  gelsolin domain 1 and from ADF/coﬁlin. Eur. J. Biochem. 268,  6165–6175.  	11733011
	30. Miki, M. & dos Remedios, C.G. (1988) Fluorescence quenching  studies of ﬂuorescein attached to Lys-61 or Cys-374 in actin:  eﬀects of polymerization, myosin subfragment-1 binding, and  tropomyosin-troponin binding. J. Biochem. 104, 232–235.  	3141394
	31. Papa, I., Astier, C., Kwiatek, O., Lebart, M.-C., Raynaud, F.,  Benyamin, Y. & Roustan, C. (1999) Use of a chaotropic anion  iodide in the puriﬁcation of Z-line proteins: isolation of CapZ.  from ﬁsh white muscle. Prot. Expr Purif. 17, 1–7.  	10497062
	32. Engvall, E. (1980) Enzyme immunoassay ELISA and EMIT.  Meth. Enzymol. 70, 419–439.  	6999296
	33. Me´jean, C., Lebart, M.C., Poyer, M., Roustan, C. & Benyamin,  Y. (1992) Localization and identiﬁcation of actin structures  involved in the ﬁlamin–actin interaction. Eur. J. Biochem. 209,  555–562.  	1425662
	34. Lakowicz, J.R. (1983) Principles of Fluorescence Spectroscopy.  Plenum Publishing Corp, New York.  	NO_MATCH
	35. Gill, S.C. & von Hippel, P.H. (1989) Calculation of protein  extinction coeﬃcients from amino acid sequence data. Anal. Bio chem. 182, 319–326.  	2610349
	36. Houmeida, A., Hanin, V., Feinberg, J., Benyamin, Y. & Roustan,  C. (1991) Deﬁnition of a Ca2+-sensitive interface in the plasma  gelsolin-actin complex. Biochem. J. 274, 753–757.  	1849405
	37. Lin, K.-M., Mejillano, M. & Yin, H.L. (2000) Ca2+ regulation of  gelsolin by its C-terminal tail. J.Biol. Chem. 275, 27746–27752.  	10862770
	38. Maciver, S.K., Ternent, D. & McLaughlin, P.J. (2000) Domain 2  of gelsolin binds directly to tropomyosin. FEBS Lett. 473, 71–75.  	10802062
	39. Kwiatkowski, D.J., Janmey, P.A. & Yin, H.L. (1989) Identiﬁca tion of critical functional and regulatory domains in gelsolin.  J. Cell Biol. 108, 1717–1726.  	2541138
	40. Lueck, A., Yin, H.L., Kwiatkowski, D.J. & Allen, P.G. (2000)  Calcium regulation of gelsolin and adseverin: a natural test of the  helix latch hypothesis. Biochemistry. 39, 5274–5279.  	10819996
	41. Hesterkamp, T.,Weeds, A.G. &Mannherz, H.G. (1993) The actin  monomers in the ternary gelsolin: 2 actin complex are in anti parallel orientation. Eur. J. Biochem. 218, 507–513.  	8269940
	42. McLaughlin, P.J., Gooch, J.T., Mannherz, H.G. & Weeds, A.G.  (1993) Structure of gelsolin segment-1-actin complex and the  mechanism of ﬁlament severing. Nature. 364, 685–692.  	8395021
	43. Chaponnier, C., Janmey, P.A. & Yin, H.L. (1986) The actin ﬁla ment-severing domain of plasma gelsolin. J. Cell Biol. 103,  1473–1481.  	3021782
	44. Selve, N. &Wegner, A. (1987) pH-dependent rate of formation of  the gelsolin-actin complex from gelsolin and monomeric actin.  Eur. J. Biochem. 161, 111–115.  	2822398
	45. Watanabe, K., Hamaguchi, M.S. & Hamaguchi, Y. (1997) Eﬀects  of intracellular pH on the mitotic apparatus and mitoitc stage in  the sand dollar egg. Cell Mot. Cytoskel. 37, 263–270.  	9227856
	46. VanDuijn, B. & Inouye, K. (1991) Regulation of movement speed  by intracellular pH during Dictyostelium discoideum chemotaxis.  Proc. Nat. Acad. Sci. 88, 4951–4955.  	NO_MATCH
	47. Schwiening, C.J. &Willoughby,D. (2002) Depolarization-induced  pH microdomains and their relationship to calcium transients in  isolated snail neurones. J. Physiol. 538, 371–382.  	11790806
	48. Yonezawa, N., Nishida, E. & Sakai, H. (1985) pH control of actin  polymerization by coﬁlin. J. Biol. Chem. 260, 14410–14412.  	4055781
	49. Edmonds, B.T., Murray, J. & Condeelis, J. (1995) pH regulation  of the F-actin binding properties of Dictyostelium elongation  factor 1a. J. Biol. Chem. 270, 15222–15230.  	7797506
291.full.pdf
	Andersson U & Scarpulla RC 2001 PGC-1-related coactivator, a  novel, serum-inducible coactivator of nuclear respiratory factor  1-dependent transcription in mammalian cells. Molecular and  Cellular Biology 21 3738–3749.  	11340167
	Basu A, Park K, Atchison ML, Carter RS & Avadhani NG 1993  Identification of a transcriptional initiator element in the  cytochrome c oxidase subunit Vb promoter which binds to  transcription factors NF-E1 (YY-1, delta) and Sp1. Journal of  Biological Chemistry 268 4188–4196.  	8382696
	Berry DL, Schwartzman RA & Brown DD 1998 The expression  pattern of thyroid hormone response genes in the tadpole tail  identifies multiple resorption programs. Developmental Biology 203  12–23.  	9806769
	Clement K, Viguerie N, Diehn M, Alizadeh A, Barbe P, Thalamas  C, Storey JD, Brown PO, Barsh GS & Langin D 2002 In vivo  regulation of human skeletal muscle gene expression by thyroid  hormone. Genome Research 12 281–291.  	11827947
	Davis PJ, Tillmann HC, Davis FB & Wehling M 2002 Comparison  of the mechanisms of nongenomic actions of thyroid hormone and  steroid hormones. Journal of Endocrinological Investigation 25 377–388.  	12030612
	Denver RJ, Pavgi S & Shi YB 1997 Thyroid hormone-dependent  gene expression program for Xenopus neural development. Journal  of Biological Chemistry 272 8179–8188.  	9079635
	Dümmler K, Müller S & Seitz HJ 1996 Regulation of adenine  nucleotide translocase and glycerol 3-phosphate dehydrogenase  expression by thyroid hormones in diﬀerent rat tissues. Biochemical  Journal 317 913–918.  	8760382
	Eisen MB & Brown PO 1999 DNA arrays for analysis of gene  expression. Methods in Enzymology 303 179–205.  	10349646
	Eisen MB, Spellman PT, Brown PO & Botstein D 1998 Cluster  analysis and display of genome-wide expression patterns. PNAS 95  14863–14868.  	9843981
	Evans MJ & Scarpulla RC 1989 Interaction of nuclear factors with  multiple sites in the somatic cytochrome c promoter.  Characterization of upstream NRF-1, ATF, and intron Sp1  recognition sequences. Journal of Biological Chemistry 264  14361–14368.  	2547796
	Feng X, Jiang Y, Meltzer P & Yen PM 2000 Thyroid hormone  regulation of hepatic genes in vivo detected by complementary  DNA microarray. Molecular Endocrinology 14 947–955.  	10894146
	Flores-Morales A, Gullberg H, Fernandez L, Stahlberg N, Lee NH,  Vennstrom B & Norstedt G 2002 Patterns of Liver Gene  Expression Governed by TRbeta. Molecular Endocrinology 16  1257–1268.  	12040013
	Garstka HL, Facke M, Escribano JR & Wiesner RJ 1994  Stoichiometry of mitochondrial transcripts and regulation of gene  expression by mitochondrial transcription factor A. Biochemical and  Biophysical Research Communications 200 619–626.  	8166737
	Halgren RG, Fielden MR, Fong CJ & Zacharewski TR 2001  Assessment of clone identity and sequence fidelity for 1189  IMAGE cDNA clones. Nucleic Acids Research 29 582–588.  	11139630
	Hsu MH, Savas U, Griﬃn KJ & Johnson EF 2001 Identification of  peroxisome proliferator-responsive human genes by elevated expression of the peroxisome proliferator-activated receptor alpha  in HepG2 cells. Journal of Biological Chemistry 276 27950–27958.  	11371553
	Knutti D & Kralli A 2001 PGC-1, a versatile coactivator. Trends in  Endocrinology and Metabolism 12 360–365.  	11551810
	Kressler D, Schreiber SN, Knutti D & Kralli A 2002 The PGC-1 related protein PERC is a selective coactivator of estrogen  receptor alpha. Journal of Biological Chemistry 277 13918–13925.  	11854298
	Li R, Luciakova K, Zaid A, Betina S, Fridell E & Nelson BD 1997  Thyroid hormone activates transcription from the promoter  regions of some human nuclear-encoded genes of the oxidative  phosphorylation system. Molecular and Cellular Endocrinology 128  69–75.  	9140077
	Lin J, Puigserver P, Donovan J, Tarr P & Spiegelman BM 2002  Peroxisome proliferator-activated receptor gamma coactivator 1  beta (PGC-1 beta), a novel PGC-1-related transcription  coactivator associated with host cell factor. Journal of Biological  Chemistry 277 1645–1648.  	11733490
	Lowell BB 1999 PPARgamma: an essential regulator of adipogenesis  and modulator of fat cell function. Cell 99 239–242.  	10555139
	Luciakova K & Nelson BD 1992 Transcript levels for nuclear encoded mammalian mitochondrial respiratory-chain components  are regulated by thyroid hormone in an uncoordinated fashion.  European Journal of Biochemistry 207 247–251.  	1321044
	Miller LD, Park KS, Guo QM, Alkharouf NW, Malek RL, Lee NH,  Liu ET & Cheng SY 2001 Silencing of Wnt signaling and  activation of multiple metabolic pathways in response to thyroid  hormone-stimulated cell proliferation. Molecular and Cellular Biology  21 6626–6639.  	11533250
	Müller MJ & Seitz HJ 1981 Starvation-induced changes of hepatic  glucose metabolism in hypo- and hyperthyroid rats in vivo. Journal  of Nutrition 111 1370–1379.  	6267236
	Poirier H, Niot I, Monnot MC, Braissant O, Meunier-Durmort C,  Costet P, Pineau T, Wahli W, Willson TM & Besnard P 2001  Diﬀerential involvement of peroxisome-proliferator-activated  receptors alpha and delta in fibrate and fatty-acid-mediated  inductions of the gene encoding liver fatty-acid-binding protein in  the liver and the small intestine. Biochemical Journal 355 481–488.  	11284737
	Puigserver P & Spiegelman BM 2003 Peroxisome proliferator-activated  receptor-gamma coactivator 1 alpha (PGC-1 alpha): transcriptional coactivator and metabolic regulator. Endocrine Reviews 24 78–90.  	12588810 
	Robyr D, Wolﬀe AP & Wahli W 2000 Nuclear hormone receptor  coregulators in action: diversity for shared tasks. Molecular  Endocrinology 14 329–347.  	10707952
	Sadow PM, Chassande O, Gauthier K, Samarut J, Xu J, O’Malley  BW & Weiss RE 2003 Specificity of thyroid hormone receptor  subtype and steroid receptor coactivator-1 on thyroid hormone  action. American Journal of Physiology Endocrinology and Metabolism 284  E36–E46.  	12388168
	Scarpulla RC 2002 Nuclear activators and coactivators in  mammalian mitochondrial biogenesis. Biochimica et Biophysica Acta  1576 1–14.  	12031478
	Scarpulla RC, Kilar MC & Scarpulla KM 1986 Coordinate  induction of multiple cytochrome c mRNAs in response to thyroid  hormone. Journal of Biological Chemistry 261 4660–4662.  	3007469
	Seelan RS & Grossman LI 1997 Structural organization and  promoter analysis of the bovine cytochrome c oxidase subunit  VIIc gene. A functional role for YY1. Journal of Biological Chemistry  272 10175–10181.  	9092564
	Shi YB, Wong J, Puzianowska-Kuznicka M & Stolow MA 1996  Tadpole competence and tissue-specific temporal regulation of  amphibian metamorphosis: roles of thyroid hormone and its  receptors. Bioessays 18 391–399.  	8639162
	Tagami T, Park Y & Jameson JL 1999 Mechanisms that mediate  negative regulation of the thyroid-stimulating hormone alpha gene  by the thyroid hormone receptor. Journal of Biological Chemistry 274  22345–22353.  	10428804
	Takeuchi Y, Murata Y, Sadow P, Hayashi Y, Seo H, Xu J,  O’Malley BW, Weiss RE & Refetoﬀ S 2002 Steroid receptor  coactivator-1 deficiency causes variable alterations in the  modulation of T(3)-regulated transcription of genes in vivo.  Endocrinology 143 1346–1352.  	11897691
	Tata JR, Ernster L, Lindberg O, Arrhenius, E Pedersen S &  Hedman R 1963 The action of thyroid hormone at the cell level.  Biochemical Journal 86 408–428.  	13993432
	Weitzel JM, Kutz S, Radtke C, Grott S & Seitz HJ 2001a Hormonal  regulation of multiple promoters of the rat mitochondrial  glycerol-3-phosphate dehydrogenase gene: identification of a  complex hormone-response element in the ubiquitous promoter B.  European Journal of Biochemistry 268 4095–4103.  	11454004
	Weitzel JM, Radtke C & Seitz HJ 2001b Two thyroid hormone mediated gene expression patterns in vivo identified by cDNA  expression arrays in rat. Nucleic Acids Research 29 5148–5155.  	11812848
	Weitzel JM, Iwen KAH & Seitz HJ 2003 Regulation of  mitochondrial biogenesis by thyroid hormone. Experimental  Physiology 88 121–128.  	12552316
	Wood WM, Sarapura VD, Dowding JM, Woodmansee WW,  Haakinson DJ, Gordon DF & Ridgway EC 2002 Early gene  expression changes preceding thyroid hormone-induced involution  of a thyrotrope tumor. Endocrinology 143 347–359.  	11796486
	Wu Z, Puigserver P, Andersson U, Zhang C, Adelmant G, Mootha  V, Troy A, Cinti S, Lowell B, Scarpulla RC & Spiegelman BM  1999 Mechanisms controlling mitochondrial biogenesis and respiration through the thermogenic coactivator PGC-1. Cell 98  115–124.  	10412986
	Yen PM 2001 Physiological and molecular basis of thyroid hormone  action. Physiological Reviews 81 1097–1142.  	11427693
	Yoon JC, Puigserver P, Chen G, Donovan J, Wu Z, Rhee J,  Adelmant G, Staﬀord J, Kahn CR, Granner DK, Newgard CB &  	NO_MATCH
	Spiegelman BM 2001 Control of hepatic gluconeogenesis through  the transcriptional coactivator PGC-1. Nature 413 131–138.  	11557972
	Zaid A, Li R, Luciakova K, Barath P, Nery S & Nelson BD 1999  On the role of the general transcription factor Sp1 in the  activation and repression of diverse mammalian oxidative  phosphorylation genes. Journal of Bioenergetics and Biomembranes 31  129–135.  	10449239
	Zhang J & Lazar MA 2000 The mechanism of action of thyroid  hormones. Annual Review of Physiology 62 439–466.  	10845098
	Zilz ND, Murray MB & Towle HC 1990 Identification of multiple  thyroid hormone response elements located far upstream from the  rat S14 promoter. Journal of Biological Chemistry 265 8136–8143.  	2159469
v060p00348.pdf
	1 Miller WR, Sharpe RM. Environmental oestrogens and human  reproductive cancers? Endocrine Related Cancer 1998;5:69–96.  	NO_MATCH
	2 Greenberg ER, Barrett JA, Lanzall LL, et al. Breast cancer in mothers  given diethylstilboestrol in pregnancy. N Engl J Med 1984;132:1059–  60.  	6493300
	3 Adami HO, Lipworth L, Titus-Ernstoff L, et al. Organochlorine compounds  and estrogen-related cancers in women. Cancer Causes Control  1995;6:551–66.  	8580305
	4 Scribner JD, Mottet NK. DDT acceleration of mammary gland tumours  induced in the male Sprague-Dawley rat by 2-acetamidophenanthrene.  Carcinogenesis 1981;2:123–39.  	7326823
	5 Robinson AK, Sirbasku DA, Stancel GM. DDT supports the growth of an  estrogen-responsive tumour. Toxicol Lett 1985;27:109–13.  	4060181
	6 Blair A, Grauman DJ, Lubin JH, et al. Lung cancer and other causes of  death among licensed pesticide applicators. J Natl Cancer Inst  1983;71:31–7.  	6575207
	7 Wolff MS, Toniolo PG, Lee RW, et al. Blood levels of organochlorine  residues and risk of breast cancer. J Natl Cancer Inst 1993;85:648–52.  	8468722
	8 Dewailly E, Dodin S, Verreault R, et al. High organochlorine body  burden in women with estrogen receptor-positive breast cancer. J Natl  Cancer Inst 1994;86:232–4.  	8283497
	9 Krieger N, Wolff MS, Hiatt RA, et al. Breast cancer and serum  organochlorines: a prospective study among white, black, and asian  women. J Natl Cancer Inst 1994;86:589–99.  	8145274
	10 Hunter DJ, Hankinson SE, Laden F, et al. Plasma organochlorine levels  and the risk of breast cancer. N Engl J Med 1997;337:1253–8.  	9345073
	11 Safe SH. Environmental and dietary estrogens and human health: is  there a problem? Environ Health Perspect 1995;103:346–51.  	7607134
	12 Wolff M, Zeleniach-Jacquotte A, Dubin N, et al. Risk of breast cancer  and organochlorine exposure. Cancer Epidemiol Biomarkers Prev  2000;9:271–7.  	10750665
	13 Demers A, Ayotte P, Brisson J, et al. Risk and aggressiveness of breast  cancer in relation to plasma organochlorine concentrations. Cancer  Epidemiol Biomarkers Prev 2000;9:161–6.  	10698476
	14 Wolff M, Toniolo PG. Environmental organochlorine exposure as a  potential etiologic factor in breast cancer. Environ Health Perspect  1995;103(suppl 7):141–5.  	8593861
	15 Hoyer AP, Grandjean P, Jorgensen T, et al. Organochlorine exposure  and risk of breast cancer. Lancet 1998;352:1816–20.  	9851382
	16 Hoffmann W. Organochlorine compounds: risk of Non-Hodgkin’s  lymphoma and breast cancer? Arch Environ Health 1996;51:189–92.  	8687239
	17 Davis DL, Bradlow HL, Wolff M, et al. Medical hypothesis:  xenoestrogens as preventable causes of breast cancer. Environ Health  Perspect 1993;101:372–7.  	8119245
	18 Romieu I, Hernandez-Avila M, Lazcano-Pence, et al. Breast cancer,  lactation history and serum organochlorines. Am J Epidemiol  2000;152:363–70.  	10968381
	19 Charlier C, Plomteux G. Determination of organochlorines pesticide  residues in blood of healthy individuals. Clin Chem Lab Med  2002;40:361–4.  	12059076
	20 Boyle P. Epidemiology of breast cancer. Baillieres Clin Oncol  1988;2:1–57.  	NO_MATCH
	21 Mac Mahon B, Cole P, Brown J. Etiology of human breast cancer: a  review. J Natl Cancer Inst 1973;50:21–42.  	4571238
	22 Gellert RJ, Leroy-Heinrichs W, Swerdloff RS. DDT homologues:  estrogen-like effects on the vagina, uterus and pituitary of the rat.  Endocrinology 1972;91:1095–100.  	5051333
	23 Key T, Reeves G. Organochlorines in the environment and breast cancer.  BMJ 1994;308:1520–1.  	8019303
	24 Nelson JA. Effects of dichlorodiphenyltrichloroethane (DDT) analogs and  polychlorinated biphenyl (PCB) mixtures on 17β-[3H]estradiol binding to  rate uterine receptor. Biochem Pharmacol 1974;23:447–51.  	4360348
	25 Unger M, Kiaer H, Blichert-Toft M. Organochlorine compounds in human  breast fat from deceased with and without breast cancer and in a biopsy  material from newly diagnosed patients undergoing breast surgery. Environ Res 1984;34:24–8. 	6426947
	26 Falck F, Ricci A, Wolff MS, et al. Pesticides and polychlorinated  biphenyl residues in human breast lipids and their relation to breast  cancer. Arch Environ Health 1992;47:143–6.  	1567239
	27 Mussalo-Rauhamaa H, Häsänen E, Pyysalo H, et al. Occurrence of  beta-hexachlorocyclohexane in breast cancer patients. Cancer  1990;66:2124–8.  	1699651
	28 Dorgan JF, Brock JW, Rothman N, et al. Serum organochlorine  pesticides and PCBs and breast cancer risk: results from a prospective  analysis. Cancer Causes Control 1999;10:1–11.  	10334636
	29 Bordet F, Mallet J, Maurice L, et al. Organochlorine pesticide and PCB  congener content of french human milk. Bull Environ Contam Toxicol  1993;50:425–32.  	8428123
	30 Larsen BR, Turrio-Baldassarri L, Nilsson T, et al. Toxic PCB congeners  and organochlorine pesticides in italian human milk. Ecotoxicol Environ  Saf 1994;28:1–13.  	7523063
	31 Dogheim SM, Mohamed E-Z, Gad Alla SA, et al. Monitoring of  pesticide residues in human milk, soil, water, and foot samples collected  from Kafr El-Zayat governorate. J AOAC Int 1996;79:111–16.  	8620102
	32 Liljegren G,Hardell L, Lindstrom G, et al. Case-control study on breast  cancer and adipose tissue concentrations of congener specific polychlorinated biphenyls, DDE and hexachlorobenzene. Eur J Cancer  Prev 1998;7:135–40.  	9818775
	33 Guttes S, Failing K, Neumann K, et al. Chlororganic pesticides and  polychlorinated biphenyls in breast tissue of women with benign and  malignant breast disease. Arch Environ Contam Toxicol 1998;35:140–7.  	9601932
	34 Zheng T, Holford TR, Mayne ST, et al. Environmental exposure to  hexachlorobenzene and risk of female breast cancer in Connecticut.  Cancer Epidemiol Biomarkers Prev 1999;8:407–11.  	10350435
	35 Kang KS, Wilson MR, Hayashi T, et al. Inhibition of gap junctional  intercellular communication in normal human breast epithelial cells after  treatment with pesticides, PCBs, and PBBs, alone or in mixtures. Environ  Health Perspect 1996;104:192–200.  	8820588
v060p00313.pdf
	1 Dockery DW, Pope CA, Xu XP, et al. An  association between air-pollution and mortality  in 6 United States cities. N Engl J Med  	8179653
	2 Pope CA III, Burnett RT, Thun MJ, et al. Lung  cancer, cardiopulmonary mortality, and  long-term exposure to fine particulate air  	11879110
	3 Shi T, Knaapen AM, Begerow J, et al.  Temporal variation of hydroxyl radical  generation and 8-hydroxy-2′-deoxyguanosine  formation by coarse and fine particulate  	12709515
J. Exp. Bot.-2003-Parry-1321-33.pdf
	Andersson I. 1996. Large structures at high resolution: the 1.6  angstrom crystal structure of spinach ribulose-1,5-bisphosphate  carboxylase/oxygenase complexed with 2-carboxyarabinitol  bisphosphate. Journal of Molecular Biology 259, 160±174.  	8648644
	Andersson I, Knight S, Schneider G, Lindqvist Y, Lindqvst T,  Branden CI, Lorimer GH. 1989. Crystal structure of the active  site of ribulose-1,5-bisphosphate carboxylase. Nature 337, 229±  234.  	NO_MATCH
	Andralojc PJ, Keys AJ, Kossmann J, Parry MAJ. 2002.  Elucidating the biosynthesis of 2-carboxyarabinitol 1-phosphate  through reduced expression of chloroplastic fructose 1,6 bisphosphate phosphatase and radiotracer studies with (CO2)-C 14. Proceedings of the National Academy of Sciences, USA 99,  4742±4747.	11917127
	Andrews TJ, Lorimer GH. 1978. Photorespiration still  unavoidable? FEBS Letters 90, 1±9.  	NO_MATCH
	Bainbridge G, Madgwick P, Parmar S, Mitchell R, Paul M, Pitts  J, Keys AJ, Parry MAJ. 1995. Engineering rubisco to change its  catalytic properties. Journal of Experimental Botany 46, 1269±  1276.  	NO_MATCH
	Bainbridge G, Andralojc PJ, Madgwick PJ, Pitts JE, Parry  MAJ. 1998. Effect of mutation of lysine-128 of the large subunit  of ribulose bisphosphate carboxylase/oxygenase from Anacystis  nidulans. Biochemical Journal 336, 387±393.  	9820816
	Bowes G, Ogren WL, Hageman R. 1971. Phosphoglycolate  production catalysed by ribulose diphsophate carboxylase.  Biochemical and Biophysical Research Communications 45,  716±722.  	4331471
	Bradley D, Van der Vies SM, Gatenby A. 1986. Expression of  cyanobacterial and higher plant ribulose-1,5-bisphosphate  carboxylase genes in Escherichia coli. Philosophical  Transactions of the Royal Society of London 313, 305±324.  	NO_MATCH
	Cannell RQ, Bruns WA, Moss DN. 1969. A search for high net  photosynthetic rate among soybean genotypes. Crop Science 9,  840±841.  	NO_MATCH
	Chan PH, Sakano K, Singh S, Wildman SG. 1972. Crystalline  fraction 1 protein: preparation in large yield. Science 176, 1145±  1146.  	5035475
	Chan PH, Wildman SG. 1972. Chloroplast DNA codes for the  primary structure of the large subunit of Fraction 1 protein.  Biochimica et Biophysica Acta 277, 677±680.  	5070071
	Chapman MS, Won Suh S, Currie PMG, Cascio D, Smith WW,  Eisenberg D. 1988. Tertiary structure of plant Rubisco: domains  and their contacts. Science 241, 71±74.  	3133767
	Chen Z, Spreitzer RJ. 1989. Chloroplast intragenic supression  enhances the low speci®city of mutant ribulose-1,5-bisphosphate  carboxylase/oxygenase. Journal of Biological Chemistry 264,  3051±3053.  	2492528
	Chen ZX, Yu WZ, Lee JH, Diao R, Spreitzer RJ. 1991.  Complementing amino-acid substitutions within loop-6 of the  alpha-beta-barrel active-site in¯uence the CO2/O2 speci®city of  chloroplast ribulose-1,5-bisphosphate carboxylase oxygenase.  Biochemistry 30, 8846±8850.  	1909574
	CheÁne P, Day AG, Fersht AR. 1992. Mutation of asparagine 111  of Rubisco from Rhodospirillum rubrum alters the carboxylase/  oxygenase speci®city. Journal of Molecular Biology 225, 891±  896.  	1602488
	Cleland WW, Andrews TJ, Gutteridge S, Hartman FC, Lorimer  GH. 1998. Mechanism of Rubisco: the carbamate as general base.  Chemical Reviews 98, 549±561.  	NO_MATCH
	Collatz GJ, Berry JA, Farquhar GD, Pierce J. 1990. The  relationship between the Rubisco reaction mechanism and models  of photosynthesis. Plant, Cell and Environment 13, 219±225.  	NO_MATCH
	Cook CM, Mulligan RM, Tolbert NE. 1985. Inhibition and  stimulation of ribulose-1,5-bisphosphate carboxylase-oxygenase  by glyoxylate. Archives of Biochemistry and Biophysics 240,  392±401.  	3860188
	Crafts-Brandner SJ, Salvucci ME. 2000. Rubisco activase  constrains the photosynthetic potential of leaves at high  temperature and CO2. Proceedings of the National Academy of  Sciences, USA 97, 13430±13435.  	11069297
	Crafts-Brandner SJ, Van De Loo FJ, Salvucci ME. 1997. The  two forms of ribulose-1,5-bisphosphate carboxylase/oxygenase  activase differ in sensitivity to elevated temperature. Plant  Physiology 114, 439±444.  	NO_MATCH
	Dalling MJ, Boland G, Wilson JH. 1976. Relation between acid  proteinase activity and redistribution of nitrogen during grain  development in wheat. Australian Journal of Plant Physiology 3,  721±730.  	NO_MATCH
	Edwards GE, Walker DA. 1983. C3, C4-Mechanisms and cellular  and environmental regulation of photosynthesis. Oxford, UK:  Blackwell.  Ellis RJ. 1979. The most abundant protein in the world. Trends in  Biochemical Science 4, 241±244.  	NO_MATCH
	Ellis RJ. 1981. Chloroplast proteins: synthesis, transport and  assembly. Annual Review of Plant Physiology 32, 111±137.  	NO_MATCH
	Farquhar GD, Von Caemmerer S, Berry JA. 1980. A  biochemical model of photosynthetic CO2 assimilation in leaves  of C-3 species. Planta 149, 78±90.  	NO_MATCH
	Feller U, Crafts-Brandner SJ, Salvucci ME. 1998. Moderately  high temperatures inhibit ribulose-1,5-bisphosphate carboxylase/  oxygenase (Rubisco) activase-mediated activation of Rubisco.  Plant Physiology 116, 539±546.  	NO_MATCH
	Furbank RT, Chitty JA, von Caemmerer S, Jenkins CLD. 1996.  Antisense RNA inhibition of rbcS gene expression reduces  Rubisco level and photosynthesis in the C-4 plant Flaveria  bidentis. Plant Physiology 111, 725±734.  	NO_MATCH
	Gatenby AA, Castleton JA, Saul MW. 1981. Expression in E. coli  of maize and wheat chloroplast genes for large subunit of ribulose  bisphosphate carboxylase. Nature 291, 117±121.  	7015143
	Gatenby AA, Ellis RJ. 1990. Chaperone functionÐthe assembly of  ribulose bisphosphate carboxylase-oxygenase. Annual Review of  Cell Biology 6, 125±149.  	1980417
	Gatenby A, Van der Vies SM, Bradley D. 1985. Assembly in E.  coli of a functional multisubunit ribulose bisphosphate  carboxylase from blue-green alga. Nature 314, 617±620.  	NO_MATCH
	Gutteridge S, Gatenby AA. 1995. Rubisco synthesis, assembly,  mechanism and regulation. The Plant Cell 7, 809±819.  	NO_MATCH
	Gutteridge S, Rhoades DF, Herrmann C. 1993. Site-speci®c  mutations in a loop region of the C-terminal domain of the large  subunit of ribulose-1,5-bisphosphate carboxylase/oxygenase that  in¯uence substrate partitioning. Journal of Biological Chemistry  268, 7818±7824.  	8463309
	Gutteridge S, Sigal I, Thomas B, Arentzen R, Cordova A,  Lorimer GH. 1984. A site-speci®c mutation within the active  site of ribulose-1,5-bisphosphate carboxylase of Rhodospirillum  rubrum. EMBO Journal 3, 2737±2743.  	NO_MATCH
	Hammond ET, Andrews TJ, Woodrow IE. 1998. Regulation of  ribulose-1,5-bisphosphate carboxylase/oxygenase by carbamyl ation and 2-carboxyarabinitol 1-phosphate in tobacco: insights  from studies of antisense plants containing reduced amounts of  Rubisco activase. Plant Physiology 118, 1463±1471.  	NO_MATCH
	Hartman FC, Lee EH. 1989. Examination of the function of the  active site lysine 329 of ribulose-1,5-bisphosphate carboxylase/  oxygenase as revealed by proton exchange reactions. Journal of  Biological Chemistry 246, 11784±11789.  	2545684
	Hatch MD. 1976. Photosynthesis: the path of carbon. In: Bonner J,  Varner J, eds. Plant biochemistry, 3rd edn. New York, San  Francisco, London: Academic Press, 797±844.  	NO_MATCH
	He ZL, von Caemmerer S, Hudson GS, Price GD, Badger MR,  Andrews TJ. 1997. Ribulose-1,5-bisphosphate carboxylase/  oxygenase activase de®ciency delays senescence of ribulose 1,5-bisphosphate carboxylase/oxygenase, but progressively  impairs its catalysis during tobacco leaf development. Plant  Physiology 115, 1569±1580.  	9414564
	Hudson GS, Evans JR, von Caemmerer S, Arvidsson YBC,  Andrews TJ. 1992. Reduction of ribulose-1,5-bisphosphate  carboxylase oxygenase content by antisense RNA reduces  photosynthesis in transgenic tobacco plants. Plant Physiology  98, 294±302.  	NO_MATCH
	Jiang CZ, Kliebenstien D Ke N, Rodermel S. 1994.  Destabilization of rbcS sense transcripts by antisense RNA.  Plant Molecular Biology 25, 569±576.  	8049381
	JimeneÂz ES, Medrano L, MartÂõnez-Barajas E. 1995. Rubisco  activase, a possible new member of the molecular chaperone  family. Biochemistry 34, 2826±2831.  	7893695
	Kane HJ, VIIL, Entsch B, Paul K, Morell MK, Andrews TJ.  1994. An improved method for measuring the CO2/O2 speci®city  of ribulose bishosphate carboxylase-oxygenase. Australian  Journal of Plant Physiology 21, 449±461.  	NO_MATCH
	Kanevski I, Maliga P. 1994. Relocation of the plastid rbcL gene to  the nucleus yields functional ribulose-1,5-bisphosphate  carboxylase in tobacco chloroplasts. Proceedings of the  National Academy of Sciences, USA 5, 1969±1973.  	8127916
	Kanevski I, Maliga P, Rhoades DF, Gutteridge S. 1999. Plastome  engineering of ribulose-1,5-bisphosphatecarboxylase/oxygenase  in tobacco to form a sun¯ower large subunit and tobacco small  subunit hybrid. Plant Physiology 119, 133±141.  	9880354
	Kawashima N, Wildman SG. 1972. Studies of fraction protein. IV.  Mode of inheritance of primary structure in relation to whether  chloroplast or nuclear DNA contains the code for a chloroplastic  protein. Biochimica et Biophysica Acta 262, 42±49.  	5017708
	Khan S, Andralojc PJ, Lea PJ, Parry MAJ. 1999. 2¢-carboxy-D arabinitol 1-phosphate (CA1P) protects ribulose-1,5-bisphosphate  carboxylase/oxygenase against proteolytic breakdown. European  Journal of Biochemsitry 266, 840±847.  	10583377
	King BJ, Siddiqi MY, Ruth TJ, Warner RL, Glass ADM. 1993.  Feedback-regulation of nitrate in¯ux in barley roots by nitrate,  nitrite and ammonium. Plant Physiology 102, 1279±1286.  	NO_MATCH
	Knight S, Andersson I, Branden CI. 1990. Crystallographic  analysis of ribulose1,5-bisphosphate carboxylase from spinach at  2.4 A resolution. Journal of Molecular Biology 215, 113±160.  	NO_MATCH
	Kung SD. 1976. Tobacco fraction 1 protein: a unique genetic  marker. Science 191, 429±434.  	1108201
	Kuroda H, Maliga P. 2001. Sequences downstream of the  translation initiation codon are important determinants of  translation ef®ciency in chloroplasts. Plant Physiology 125,  430±436.  	11154350
	Larson EM, Larimer FW, Hartman FC. 1995. Mechanistic  insights provided by deletion of a ¯exible loop at the active site of  ribulose-1,5-bisphosphate carboxylase/oxygenase. Biochemistry  34, 4531±4537.  	7718555
	Larson EM, O'Brien CM, Zhu GH, Spreitzer RJS, Portis AR.  1997. Speci®city for activase is changed by a Pro 89 to Arg  substitution in the large subunit of ribulose 1,5-bisphosphate  carboxylase/oxygenase. Journal of Biological Chemistry 272,  17033±17037.  	9202018
	Lauerer M, Saftic D, Quick WP, Labate C, Fichtner K, Schulze  ED, Rodermel SR, Bogorad L, Stitt M. 1993. Decreased  ribulose-1,5-bisphosphate carboxylase-oxygenase in transgenic  tobacco transformed with antisense rbcs. VI. Effect on  photosynthesis in plants grown at different irradiance. Planta  190, 332±345.  	NO_MATCH
	Lee GJ, Mcdonald KA, Mcfadden BA. 1993. Leucine-332  in¯uences the CO2/O2 speci®city factor of ribulose-1,5 bisphosphate carboxylase oxygenase from Anacystis-nidulans.  Protein Science 2, 1147±1154.  	8358297
	Lorimer GH. 1981. The carboxylation and oxygenation of ribulose  1,5-bisphosphate: the primary events in photosynthesis and  photorespiration. Annual Review of Plant Physiology 32, 349±  383.  	NO_MATCH
	Lorimer GH, Miziorko HM. 1980. Carbamate formation on the  e-amino group of a lysyl residue as the basis for the activation of  ribulosebisphosphate carboxylase by CO2 and Mg 2+.  Biochemistry 19, 5321±5324.  	6778504
	Madgwick PJ, Colliver SP, Banks FM, Habash DZ, Dulieu H,  Parry MAJ, Paul MJ. 2002. Genetic manipulation of rubisco:  Chromatium vinosum rbcL is expressed in Nicotiana tabacum but  does not form a functional protein. Annals of Applied Biology  140, 13±19.  	NO_MATCH
	Madgwick PJ, Parmar S, Parry MAJ. 1998. Effect of mutations  of residue 340 in the large subunit polypeptide of Rubisco from  Anacystis nidulans. European Journal of Biochemistry 253, 476±  479.  	9654099
	Makino A, Harada M, Kaneko K, Mae T, Shimada T,  Yamamoto N. 2000. Whole-plant growth and allocation in  transgenic rice plants with decreased content of ribulose-1,5 bisphosphate carboxylase under different CO2 partial pressures.  Australian Journal of Plant Physiology 27, 1±12.  	NO_MATCH
	Makino A, Shimada T, Takumi S, Kaneko K, Matsuoka M,  Shimamoto K, Nakano H, Miyao-Tokutomi M, Mae T,  Yamamoto N. 1997. Does decrease in ribulose-1,5, bisphosphate carboxylase by `antisense' rbcS lead to a higher  nitrogen-use ef®ciency of photosynthesis under conditions of  saturating CO2 and light in rice plants? Plant Physiology 114,  483±491.  	NO_MATCH
	Masle J, Hudson GS, Badger MR. 1993. Effects of ambient CO2  concentration on growth and nitrogen use in tobacco (Nicotiana  tabacum) plants transformed with an antisense gene to the small subunit of ribulose-1,5-bisphosphate carboxylase oxygenase.  Plant Physiology 103, 1075±1088.  	NO_MATCH
	Mate CJ, Hudson GS, von Caemmerer S, Evans JR, Andrews  TJ. 1993. Reduction of ribulose bisphosphate carboxylase  activase levels in tobacco (Nicotiana tabacum) by antisense RNA reduces ribulose bisphosphate carboxylase carbamylation  and impairs photosynthesis. Plant Physiology 102, 1119±1128.  	8278543
	Mate CJ, von Caemmerer S, Evans JR, Hudson GS, Andrews  TJ. 1996. The relationship between CO2-assimilation rate,  Rubisco carbamylation and Rubisco activase content in  activase-de®cient transgenic tobacco suggests a simple model  of activase action. Planta 198, 604±613.  	NO_MATCH
	Medlyn BE. 1996. The optimal allocation of nitrogen within the C 3 photosynthetic system at elevated CO2. Australian Journal of  Plant Physiology 23, 593±603.  	NO_MATCH
	Medrano H, Keys AJ, Lawlor DW, Parry MAJ, Azcon Bieto J,  Delgado E. 1995. Improving plant-production by selection for  survival at low CO2 concentrations. Journal of Experimental  Botany 46, 1389±1396.  	NO_MATCH
	Medrano H, Primo-Millo E. 1985. Selection of Nicotiana tabacum  haploids of high photosynthetic ef®ciency. Plant Physiology 79,  505±508.  	NO_MATCH
	Mehta RA, Fawcett TW, Porath D, Mattoo AK. 1992. Oxidative  stress causes rapid membrane translocation and in vivo  degradation of ribulose-1,5-bisphosphate carboxylase/  oxygenase. Journal of Biological Chemistry 267, 2810±2816.  	1733975
	Menz KM, Moss DN, Cannell RQ, Brun WA. 1969. Screening for  photosynthetic ef®ciency. Crop Science 9, 692±694.  	NO_MATCH
	Millard P, Catt JW. 1988. The in¯uence of nitrogen supply on the  use of nitrate and ribulose1,5-bisphosphate carboxylase/  oxygenase as leaf nitrogen stores for growth of potato tubers  (Solanum tuberosum L.). Journal of Experimental Botany 39,  1±11.  	NO_MATCH
	Mitchell RAC, Theobald JC, Parry MAJ, Lawlor DW. 2000. Is  there scope for improving balance between RUBP-regeneration  and carboxylation capacities in wheat at elevated CO2? Journal of  Experimental Botany 51, 391±397.  	10938847
	Nakano H, Makino A, Mae T. 1997. The effect of elevated partial  pressures of CO2 on the relationship between photosynthetic  capacity and N content in rice leaves. Plant Physiology 115, 191±  198.  	NO_MATCH
	Nasyrov YS. 1978. Genetic control of photosynthesis and  improving of crop productivity. Annual Review of Plant  Physiology 29, 215±237.  	NO_MATCH
	Newman A, Gutteridge S. 1993. The X-ray structure of  Synechoccus ribulose-1,5-bisphosphate carboxylase/oxygenase  activated quaternary complex at 2.2 AÊ resolution. Journal of  Biological Chemistry 268, 25876±25886.  	8245022
	Ogawa T, Amichay D, Gurevitz M. 1994. isolation and  characterization of the ccmm gene required by the  cyanobacterium Synechocystis PCC6803 for inorganic carbon  utilization. Photosynthesis Research 39,183±190.  	NO_MATCH
	Ogren WL. 1984. Photorespiration: pathways, regulation and  modi®cation. Annual Review of Plant Physiology 35, 415±442.  	NO_MATCH
	Ogren WL, Bowes G. 1971. Ribulose diphosphate carboxylase  regulates soybean photorespiration. Nature New Biology 230,  159±160.  	5279476
	Paoli GC, Tabita FR. 1998. Aerobic chemolithoautotrophic  growth and Rubisco function in Rhodobacter capsulatus and a  spontaneous gain of function mutant of Rhodobacter sphaeroides.  Archives of Microbiology 170, 8±17.  	9639598
	Parry MAJ, Keys AJ, Gutteridge S. 1989. Variation in the  speci®city factor of C-3 higher-plant Rubisco determined by the  total consumption of ribulose-P-2. Journal of Experimental  Botany 40, 317±320.  	NO_MATCH
	Parry MAJ, Loveland JE, Andralojc PJ. 1999. Regulation of  Rubisco. In: Bryant JA, Burrell MM, Kruger NJ, eds. Plant  carbohdrate biochemistry. Oxford: Bios Scienti®c Publishers Ltd,  127±145.  	NO_MATCH
	Parry MAJ, Madgwick P, Parmar S, Cornelius MJ, Keys AJ.  1992. Mutations in loop six of the large subunit of ribulose-1,5 bisphosphate carboxylase affect substrate speci®city. Planta 187,  109±112.  	NO_MATCH
	Pellny T, Paul MJ, Goddijn JM. 2002. Unravelling the role of  trehalose-6-phosphate in metabolic signalling in photosynthetic  tissue. Comparative Biochemsitry and Physiology 132, S102.  	NO_MATCH
	Peoples MB, Pate JS, Atkins CA. 1983. Mobilization of nitrogen  in fruiting plants of a cultivar of cowpea. Journal of Experimental  Botany 34, 563±578.  	NO_MATCH
	Portis AR. 1990. Partial reduction in ribulose-1,5-bisphosphate  carboxylase/oxygenase activity by carboxypeptidase A. Archives  of Biochemistry and Biophysics 283, 397±400.  	2275551
	Portis AR. 1992. Regulation of ribulose 1,5-bisphosphate  carboxylase/oxygenase activity. Annual Review of Plant  Physiology and Plant Molecular Biology 43, 415±437.  	NO_MATCH
	Quick WP, Fichtner K, Schulze ED, Wendler R, Leegood RC,  Mooney H, Rodermel SR, Bogorad L, Stitt M. 1992. Decreased  ribulose-1,5-bisphosphate carboxylase-oxygenase in transgenic  tobacco transformed with antisense rbcs. 4. impact on  photosynthesis in conditions of altered nitrogen supply. Planta  188, 522±531.  	NO_MATCH
	Quick WP, Schurr U, Scheibe R, Schulze ED, Rodermel SR,  Bogorad L. Stitt M. 1991. Decreased ribulose-1,5-bisphosphate  carboxylase-oxygenase in transgenic tobacco transformed with  antisense rbcs. 1. Impact on photosynthesis in ambient growth conditions. Planta 183, 542±554.  	NO_MATCH
	Read BA, Tabita FR. 1992. A hybrid ribulose bisphosphate  carboxylase oxygenase enzyme exhibiting a substantial increase  in substrate-speci®city. Biochemistry 31, 5553±5560.  	1610800
	Read BA, Tabita FR. 1994. High substrate-speci®city factor  ribulose-bisphosphate carboxylase oxygenase from eukaryotic  marine-algae and properties of recombinant cyanobacterial  Rubisco containing algal residue modi®cations. Archives of  Biochemistry and Biophysics 312, 210±218.  	8031129
	Ramage RT, Read BA, Tabita FR. 1998. Alteration of the alpha  helix region of cyanobacterial ribulose 1,5-bisphosphate  carboxylase/oxygenase to re¯ect sequences found in high  substrate speci®city enzymes. Archives of Biochemistry and  Biophysics 349, 81±88.  	9439585
	Reynolds MP, van Ginkel M, Ribaut JM. 2000. Avenues for  genetic modi®cation of radiation use ef®ciency in wheat. Journal  of Experimental Botany 51, 459±473.  	10938854
	Robinson SP, Portis AR. 1988. Release of the nocturnal inhibitor,  carboxyarabinitol-1-phosphate, from ribulose bisphosphate  carboxylase/oxygenase by Rubisco activase. FEBS Letters 233,  413±416.  	NO_MATCH
	Robinson SP, Portis AR. 1989. Adenosine triphosphate hydrolysis  by puri®ed Rubisco activase. Archives of Biochemistry and  Biophysics 268, 93±99.  	2912385
	Rodermel SR, Abbott MS, Bogorad L. 1988. Nuclear±organelle  interactionsÐnuclear antisense gene inhibits ribulose  bisphosphate carboxylase enzyme levels in transformed tobacco  plants. Cell 55, 673±681.  	3052855
	Rokka A, Zhang L, Aro EM. 2001. Rubisco activase: an enzyme  with a temperature-dependent dual function? The Plant Journal  25, 463±471.  	11260502
	Sage RF. 1994. Acclimation of photosynthesis to increasing  atmospheric CO2Ðthe gas-exchange perspective. Photosynthesis  Research 39, 351±368.  	NO_MATCH
	Sage RF. 2002. Variation in the kcat of Rubisco in C3 and C4 plants  and some implications for photosynthetic performance at high  and low temperature. Journal of Experimental Botany 53, 609±  620.  	11886880
	Salvucci ME, Portis AR, Ogren WL. 1985. A soluble chloroplast  protein catalyzes ribulose bisphosphate carboxylase/oxygenase  activation in vivo. Photosynthesis Research 7, 193±201.  	NO_MATCH
	Schneider G, Lindqvist Y, Branden CI, Lorimer GH. 1986.  Three dimensional structure of ribulose-1,5-bisphosphate  carboxylase/oxygenase from Rhodospirillum rubrum at 2.9 AÊ  resolution. EMBO Journal 5, 3409±3415.  	3959081
	Schoefs B, Darko E, Rodermel S. 2001. Photosynthetic pigments,  photosynthesis and plastid ultrastructure in rbcS antisense DNA  mutants of tobacco (Nicotiana tabacum). Zeitschrift fuÈr  Naturforschung 56, 1067±1074.  	11837659
	Smith EW, Tolbert NE, Ku HS. 1976. Variables affecting the CO2  compensation point. Plant Physiology 58, 143.  	NO_MATCH
	Somerville CR, Portis AR, Ogren WL. 1982. A mutant of  Arabidopsis thaliana which lacks activation of RUBP  carboxylase in vivo. Plant Physiology 70, 381±387.  	NO_MATCH
	Somerville CR, Somerville SC. 1984. Cloning and expression of  the Rhodospirillum rubrum ribulose bisphosphate carboxylase  gene in E. coli. Molecular and General Genetics 193, 214±219.  	NO_MATCH
	Somerville CR, Somerville SC. 1986. Regulation of  photorespiration. In: Neyra CA, ed. A biochemical basis of  plant breeding, Vol. I. Boca Raton (Florida): CRC Press, Inc.,  89±131.  	NO_MATCH
	Soper TS, Larimer FW, Mural RJ, Lee EH, Hartman FC. 1992.  Role of asparagine 111 at the active site of ribulose-1,5 bisphosphate carboxylase/oxygenase from Rhodospirillum  rubrum as demonstrated by site directed mutagenesis. Journal  of Biological Chemistry 267, 8452±8457.  	1569095
	Soper TS, Mural RJ, Larimer FW, Lee EH, Machanoff R,  Hartman FC. 1988. Essentiality of Lys-329 of ribulose-1,5 bisphosphate carboxylase/oxygenase from Rhodospirillum  rubrum as demonstrated by site-directed mutagenesis. Protein  Engineering 2, 39±44.  	3151016
	Spreitzer RJ. 1993. Genetic dissection of Rubisco structure and  function. Annual Review of Plant Physiology and Plant  Molecular Biology 44, 411±434.  	NO_MATCH
	Spreitzer RJ. 1999. Questions about the complexity of chloroplast  ribulose-1,5-bisphosphate carboxylase/oxygenase. Phostosynthesis  Research 60, 29±42.  	NO_MATCH
	Spreitzer RJ, Salvucci ME. 2002. Rubisco: structure, regulatory  interactions, and possibilities for a better enzyme. Annual Review  of Plant Biology 53, 449±475.  	12221984
	Spreitzer RJ, Thow G, Zhu GH. 1995. Pseudoreversion  substitution at large-subunit residue-54 in¯uences the CO2/O2  speci®city of chloroplast ribulose-bisphosphate carboxylase  oxygenase. Plant Physiology 109, 681±685.  	7480352
	Steer MW, Gunning BES, Graham TA, Carr DJ. 1966. Isolation  and properties of fraction 1 protein from Avena sativa L. Planta  79, 256±267.  	NO_MATCH
	Stitt M, Krapp A. 1999. The interaction between elevated carbon  dioxide and nitrogen nutrition: the physiological and molecular  background. Plant, Cell and Environment 22, 583±621.  	NO_MATCH
	Stitt M, Quick WP, Schurr U, Schulze ED, Rodermel SR,  Bogorad L. 1991. Decreased ribulose-1,5-bisphosphate  carboxylase-oxygenase in transgenic tobacco transformed with  antisense rbcs. 2. ¯ux-control coef®cients for photosynthesis in  varying light, CO2 and air humidity. Planta 183, 555±566.  	NO_MATCH
	Stitt M, Schulze D. 1994. Does Rubisco control the rate of  photosynthesis and plant-growthÐan exercise in molecular  ecophysiology. Plant, Cell and Environment 17, 465±487.  	NO_MATCH
	Streusand VJ, Portis AR. 1987. Rubisco activase mediates ATP dependent activation of ribulose bisphosphate carboxylase. Plant  Physiology 85, 152±154.  	NO_MATCH
	Sugawara H, Yamamoto H, Shihata N, Inoue T, Okada S,  Miyake C, Yokota A, Kai Y. 1999. Crystal structure of  carboxylase reaction-oriented ribulose 1,5-bisphosphate  carboxylase oxygenase from a thermophilic red alga, Galdieria  partita. Journal of Biological Chemistry 274, 15655±15661.  	10336462
	Taylor TC, Backlund A, Bjorhall K, Spreitzer RJ, Andersson I.  2001. First crystal structure of Rubisco from a green alga,  Chlamydomonas reinhardtii. Journal of Biological Chemistry  276, 48159±48164.  	11641402
	Theobald JC, Mitchell RAC, Parry MAJ, Lawlor DW. 1998.  Estimating the excess investment in ribulose-1,5-bisphosphate  carboxylase/oxygenase in leaves of spring wheat grown under  elevated CO2. Plant Physiology 118, 945±955.  	NO_MATCH
	Thow G, Zhu GH, Spreitzer RJ. 1994. Complementing  substitutions within loop region-2 and region-3 of the alpha/  beta-barrel active-site in¯uence the CO2/O2 speci®city of  chloroplast ribulose-1,5-bisphosphate carboxylase/oxygenase.  Biochemistry 33, 5109±5114.  	8172885
	Uemura K, Suzuki Y, Shikanai T, Wadano A, Jensen RG,  Chmara W, Yokota A. 1996. A rapid and sensitive method for  determination of relative speci®city of Rubisco from various  species by anion exchange chromatography. Plant Cell  Physiology 37, 325±331.  	NO_MATCH
	von Caemmerer S, Millgate A, Farquhar GD, Furbank RT.  1997. Reduction of ribulose-1,5-bisphosphate carboxylase/  oxygenase by antisense RNA in the C-4 plant Flaveria bidentis  leads to reduced assimilation rates and increased carbon isotope  discrimination. Plant Physiology 113, 469±477.  	NO_MATCH
	Wang Z-Y, Snyder GW, Esau BD, Portis AR, Ogren WL. 1992.  Species dependent variation in the interaction of substrate-bound  ribulose-1,5-bisphosphate carboxylase/oxygenase (Rubisco) and  Rubisco activase. Plant Physiology 100, 1858±1862.  	NO_MATCH
	Wang ZY, Portis AR. 1992. Dissociation of ribulose-1,5 bisphosphate bound to ribulose-1,5-bisphosphate carboxylase/  oxygenase and its enhancement by ribulose-1,5-bisphosphate  carboxylase/oxygenase activase-mediated hydrolysis of ATP.  Plant Physiology 99, 1348±1353.  	NO_MATCH
	Wang YL, Zhou JH, Wang YF, Bao JS, Chen HB. 2001.  Properties of hybrid enzymes between Synechococcus large  subunits and higher plant small subunits of ribulose-1,5 bisphosphate carboxylase/oxygenase in Escherichia coli.  Archives of Biochemistry and Biophysics 396, 35±42.  	11716459
	Warburg O. 1920. UÈ ber die Geschwindigkeit der photochemischen  KohlensaÃurezersetung in lebenden Zellen II. Biochemische  Zeitschrift 100, 188±217.  	NO_MATCH
	Whitney SM, Andrews TJ. 2001a. The gene for the ribulose-1,5 bisphosphate carboxylase/oxygenase (Rubisco) small subunit  relocated to the plastid genome of tobacco directs the synthesis  of small subunits that assemble into Rubisco. The Plant Cell 13,  193±205.  	11158539
	Whitney SM, Andrews TJ. 2001b. Plastome-encoded bacterial  ribulose-1,5-bisphosphate carboxylase/oxygenase (Rubisco)  supports photosynthesis and growth in tobacco. Proceedings of  the National Academy of Sciences, USA 98, 14738±14743.  	11724961
	Whitney SM, Baldett P, Hudson GS, Andrews TJ. 2001. Form I  Rubiscos from non-green algae are expressed abundantly but not  assembled in tobacco chloroplasts. The Plant Journal 26, 535±  547.  	11439139
	Whitney SM, von Caemmerer S, Hudson GS, Andrews TJ.  1999. Directed mutation of the Rubisco large subunit of tobacco  in¯uences photorespiration and growth. Plant Physiology 121,  579±588.  	10517850
	Wildner GF. 1981. Ribulose-1,5-bisphosphate carboxylase oxygenase; aspects and products. Physiologia Plantarum 52,  385±389.  	NO_MATCH
	Wingler A, Lea PJ, Leegood RC. 1999. Photorespiratory  metabolism of glyoxylate and formate in glycine-accumulating  mutants of barley and Amaranthus edulis. Planta 207,  518±526.  	NO_MATCH
	Zhang N, Portis AR. 1999. Mechanism of light regulation of  Rubisco: a speci®c role for the larger Rubisco activase isoform  involving reductive activation by thioredoxin-f. Proceedings of  the National Academy of Sciences, USA 96, 9438±9443.  	10430961
	Zhang N, Kallis RP, Ewy RG, Portis AR. 2002. Light modulation  of Rubisco in Arabidopsis requires a capacity for redox regulation  of the larger Rubisco activase isoform. Proceedings of the  National Academy of Sciences, USA. 99, 3330±3334.  	11854454
	Zhu GH, Jensen RG, Bohnert HJ, Wildner GF, Schlitter J.  1998. Dependence of catalysis and CO2/O2 speci®city of Rubisco  on the carboxy-terminus of the large subunit different  temperatures. Photosynthesis Research 57, 71±79.  	NO_MATCH
	Zhu GH, Spreitzer RJ. 1996. Directed mutagenesis of chloroplast  ribulose-1,5-bisphosphate carboxylase/oxygenaseÐLoop 6  substitutions complement for structural stability but decrease  catalytic ef®ciency. Journal of Biological Chemistry 271, 18494±  18498.  	8702495
J. Exp. Bot.-2003-Battey-1313-6.pdf
	Danielson DR. 2000. The book of the cosmos. Massachusetts: Perseus.  	NO_MATCH
	Dempsey C. 1992. The portrayal of love: Botticelli’s Primavera and humanist  culture at the time of Lorenzo the Magnificent. Princeton: Princeton  University Press.  	NO_MATCH
	Levi d’Ancona M. 1983. Botticelli’s Primavera: a botanical interpretation  including astrology, alchemy and the Medici. Firenze: LS Olschki.  	NO_MATCH
	Lightbown R. 1978. Sandro Botticelli: Vol. II. Complete catalogue. London:  Paul Elek.  	NO_MATCH
	Lucretius. The nature of the universe, 1951 edn. Translated by RE Latham.  London: Penguin.  	NO_MATCH
	McWatters HG, Roden LC, Staiger D. 2001. Picking out parallels: plant  circadian clocks in context. Philosophical Transactions of the Royal Society of  London B 356, 1735-1743.  	11710980
	Nagle BR. 1995. Ovid’s Fasti. Indianapolis: Indiana University Press.  	NO_MATCH
	Pittendrigh CS. 1981. Circadian organization and the photoperiodic  phenomena. In: Follett BK, Follett DE, eds. Biological clocks in seasonal  reproductive cycles. Bristol: Wright, 1-35.  	NO_MATCH
	Samach A, Coupland G. 2000. Time measurement and the control of  flowering in plants. BioEssays 22, 38-47.  	10649289
	Suarez-Lopez P, Wheatley K, Robson F, Onouchi H, Valverde F, Coupland  G. 2001. CONSTANS mediates between the circadian clock and the  control of flowering in Arabidopsis. Nature 410, 1116-1120.  	11323677
	Thomas B,Vince-Prue D. 1997. Photoperiodism in plants. London:  Academic Press.  	NO_MATCH
20030218s00018p433.pdf
	1. Gold MR, Siegel JE, Russell LB, Weinstein MC, editors. Cost–effectiveness in  health and medicine. Oxford: Oxford University Press; 1996.  	NO_MATCH
	2. Drummond M, McGuire A. Economic evaluation in health care. Merging theory  with practice. Oxford: Oxford University Press; 2001.  	NO_MATCH
	3. Smith KJ, Roberts MS. The cost–effectiveness of sildenafil. Ann Intern Med  2000;132:933-7.  	10858175
	4. Gold MR, Siegel JE, Russell LB, Weinstein MC, editors. Cost–effectiveness in  health and medicine. Oxford: Oxford University Press; 1996. p. 8.  	NO_MATCH
	5. Nord E. Cost–value analysis in health care. Making sense out of QALYs. New  York: Cambridge University Press; 1999.  	NO_MATCH
	6. Volk RJ, Cantor SB, Spann SJ, Cass AR, Cardenas MP, Warren MM. Prefer ences of husbands and wives for prostate cancer screening. Arch Fam Med  1997;6:2-78.  	9003176
	7. Drummond M, Torrance T, Mason J. Cost–effectiveness league tables: More  harm than good? Soc Sci Med 1993;37:33-40.  	8332922
	8. Gold MR, Siegel JE, Russell LB, Weinstein MC, editors. Cost–effectiveness in  health and medicine. Oxford: Oxford University Press; 1996. p. 119.  	NO_MATCH
	9. Read JL, Quinn RJ, Berwick DM, Fineberg HV, Weinstein MC. Preferences  for health outcomes. Comparison of assessment methods. Med Decis Making  1984;4(3):315-29.  	6335216
	10. Groome PA, Hutchinson TA, Tousignant P, Hanley JA. The repeatability of  three methods for measuring prospective patients’ values in the context of  treatment for end-stage renal failure. J Clin Epidemiol 1999;52(9):849-60.  	10529026
	11. Fleming C, Wasson JH, Albertsen PC, Barry MJ, Wennberg JE. A decision  analysis of alternative treatment strategies for clinically localized prostate can cer. JAMA 1993;269:2650-8.  	8371423
	12. Krahn MD, Mahoney JE, Eckman MH, Trachtenberg J, Pauker SG, Detsky  AS. Screening for prostate cancer. A decision analytic view. JAMA 1994;272:  773-80.  	7521400
20030218s00013p403.pdf
	1. Dornhorst A, Chan SP. The elusive diagnosis of gestational diabetes. Diabet  Med 1998;15(1):7-10.  	9472857
	2. Buchanan TA, Kjos SL. Gestational diabetes: Risk or myth? J Clin Endocrinol  Metab 1999;84(6):1854-7.  	10372674
	3. Jarrett RJ. Gestational diabetes: a non-entity? BMJ 1993;306(6869):37-8.  	8435576
	4. Ratner RE. Clinical review 47. Gestational diabetes mellitus: After three in ternational workshops do we know how to diagnose and manage it yet? J Clin  Endocrinol Metab 1993;77(1):1-4.  	8325931
	5. WHO Study Group. Prevention of diabetes mellitus. Report of a WHO Study  Group. No 844 of Technical Reports series. Geneva, Switzerland: World Health  Organization; 1994.  	NO_MATCH
	6. American Diabetes Association. Gestational diabetes mellitus. Diabetes Care  2002;25(Suppl 1):S94-6.  	11291978
	7. Meltzer S, Leiter L, Daneman D, Gerstein HC, Lau D, Ludwig S, et al. 1998  clinical practice guidelines for the management of diabetes in Canada. CMAJ  1998;159(8 Suppl):S1-29.  	NO_MATCH
	8. Canadian Task Force on the Periodic Health Examination. Periodic health  examination, 1992 update: 1. Screening for gestational diabetes mellitus.  CMAJ 1992;147(4):435-43.  	NO_MATCH
	9. Solomon CG, Willett WC, Rich-Edwards J, Hunter DJ, Stampfer MJ,  Colditz GA, et al. Variability in diagnostic evaluation and criteria for gesta tional diabetes. Diabetes Care 1996;19(1):12-6.  	8720526
	10. Kjos SL, Buchanan TA. Gestational diabetes mellitus. N Engl J Med 1999;341  (23):1749-56.  	10580075
	11. O’Sullivan JB, Mahan CM. Criteria for the oral glucose tolerance test in  pregnancy. Diabetes 1964;13(3):278-85.  	14166677
	12. O’Sullivan JB, Charles D, Mahan CM, Dandrow RV. Gestational diabetes  and perinatal mortality rate. Am J Obstet Gynecol 1973;116(7):901-4.  	4718217
	13. Naylor CD, Sermer M, Chen E, Farine D. Selective screening for gestational  diabetes mellitus. N Engl J Med 1997;337(22):1591-6.  	NO_MATCH
	14. Arbuckle TE, Wilkins R, Sherman GJ. Birth weight percentiles by gestational  age in Canada. Obstet Gynecol 1993;81(1):39-48.  	8416459
	15. Kramer MS, Platt RW, Wen SW, Joseph KS, Allen A, Abrahamowicz M, et  al, for the Fetal/Infant Study Group of the Canadian Perinatal Surveillance  System. A new and improved population-based Canadian reference for birth  weight for gestational age. Pediatrics 2001;108(2):e35. Available: www.pedi atrics.org/cgi/content/full/108/2/e35 (accessed 2003 Jan 7).  	NO_MATCH
	16. National Diabetes Data Group. Classification and diagnosis of diabetes melli tus and other categories of glucose intolerance. Diabetes 1979;28(12):1039-57.  	NO_MATCH
	17. Swets JA. Measuring the accuracy of diagnostic systems. Science 1988;240  (4857):1285-93.  	3287615
	18. Hanley JA, McNeil BJ. The meaning and use of the area under a receiver op erating characteristic (ROC) curve. Radiology 1982;143(1):29-36.  	7063747
	19. Sermer M, Naylor CD, Gare DJ, Kenshole AB, Ritchie JWK, Farine D, et al.  Impact of increasing carbohydrate intolerance on maternal-fetal outcomes in  3637 women without gestational diabetes. Toronto Tri-Hospital Gestational  Diabetes Project. Am J Obstet Gynecol 1995;173(1):146-56.  	7631672
	20. Persson B, Hanson U. Neonatal morbidities in gestational diabetes mellitus.  Diabetes Care 1998;21(Suppl 2):B79-84.  	9704232
	21. Landy HJ, Gomez-Marin O, O’Sullivan MJ. Diagnosing gestational diabetes  mellitus: use of a glucose screen without administering the glucose tolerance  test. Obstet Gynecol 1996;87(3):395-400.  	8598962
	22. Langer O, Mazze R. The relationship between large-for-gestational-age in fants and glycemic control in women with gestational diabetes. Am J Obstet  Gynecol 1988;159(6):1478-83.  	3207126
	23. Moses RG, Calvert D. Pregnancy outcomes in women without gestational di abetes mellitus related to the maternal glucose level. Is there a continuum of  risk? Diabetes Care 1995;18(12):1527-33.  	8722047
	24. Sacks DA, Greenspoon JS, Abu-Fadil S, Henry HM, Wolde-Tsadik G, Yao  JF. Toward universal criteria for gestational diabetes: the 75-gram glucose  tolerance test in pregnancy. Am J Obstet Gynecol 1995;172(2 Pt 1):607-14.  	7856693
	25. Goldman M, Kitzmiller JL, Abrams B, Cowan RM, Laros RK Jr. Obstetric  complications with GDM. Effects of maternal weight. Diabetes 1991;40(Suppl  2):79-82.  	1748271
	26. Knopp RH, Bergelin RO, Wahl PW, Walden CE. Relationships of infant birth  size to maternal lipoproteins, apoproteins, fuels, hormones, clinical chemistries,  and body weight at 36 weeks gestation. Diabetes 1985;34(Suppl 2):71-7.  	3922827
	27. Green JR, Schumacher LB, Pawson IG, Partridge JC, Kretchmer N. Influ ence of maternal body habitus and glucose tolerance on birth weight. Obstet  Gynecol 1991;78(2):235-40.  	2067768
	28. Langer O. Gestational diabetes: a contemporary management approach. En docrinologist 1995;5(3):180-8.  	NO_MATCH
	29. Sacks DA. Fetal macrosomia and gestational diabetes: What’s the problem?  Obstet Gynecol 1993;81(5 Pt 1):775-81.  	8469471
	30. Homko CJ, Sivan E, Nyirjesy P, Reece EA. The interrelationship between  ethnicity and gestational diabetes in fetal macrosomia. Diabetes Care  1995;18(11):1442-5.  	8722067
	31. Green JR, Pawson IG, Schumacher LB, Perry J, Kretchmer N. Glucose toler ance in pregnancy: ethnic variation and influence of body habitus. Am J Obstet  Gynecol 1990;163(1 Pt 1):86-92.  	2375375
	32. Berkus MD, Langer O. Glucose tolerance test periodicity: the effect of glu cose loading. Obstet Gynecol 1995;85(3):423-7.  	7862384
	33. Castro A, Scott JP, Grettie DP, Macfarlane D, Bailey RE. Plasma insulin and  glucose responses of healthy subjects to varying glucose loads during three hour oral glucose tolerance tests. Diabetes 1970;19(11):842-51.  	5480737
	34. Brustman LE, Gela BD, Moore M, Reilly KD, Langer O. Variations in oral  glucose tolerance tests: the 100- versus 75-g controversy. J Assoc Acad Minor  Phys 1995;6(2):70-2  	7772935
	35. Walkinshaw SA. Dietary regulation for “gestational diabetes” [Cochrane re view]. In: The Cochrane Library; Issue 1, 2002. Oxford: Update Software.  	NO_MATCH
20030218s00008p400.pdf
	1. Chris A. Norwalk-like viruses: When the runs  can slow you down. CMAJ 2003;168(1):64-5.  	12515788
Cancer Res-2003-Fan-873-7.pdf
	1. Shafman, T., Khanna, K. K., Kedar, P., Spring, K., Kozlov, S., Yen, T., Hobson, K.,  Gatei, M., Zhang, N., Watters, D., Egerton, M., Shiloh, Y., Kharbanda, S., Kufe, D.,  and Lavin, M. F. Interaction between ATM protein and c-Abl in response to DNA  damage. Nature (Lond.), 387: 520–523, 1997.  	9168117
	2. Baskaran, R., Wood, L. D., Whitaker, L. L., Canman, C. E., Morgan, S. E., Xu, Y.,  Barlow, C., Baltimore, D., Wynshaw-Boris, A., Kastan, M. B., and Wang, J. Y.  Ataxia telangiectasia mutant protein activates c-Abl tyrosine kinase in response to  ionizing radiation. Nature (Lond.), 387: 516–519, 1997.  	9168116
	3. Plattner, R., Kadlec, L., DeMali, K. A., Kazlauskas, A., and Pendergast, A. M. c-Abl  is activated by growth factors and src family kinases and has a role in the cellular  response to PDGF. Genes Dev., 13: 2400–2411, 1999.  	10500097
	4. Franz, W. M., Berger, P., and Wang, J. Y. Deletion of an N-terminal regulatory  domain of the c-abl tyrosine kinase activates its oncogenic potential. EMBO J., 8:  137–147, 1989.  	2496972
	5. Jackson, P., and Baltimore, D. N-terminal mutations activate the leukemogenic  potential of the myristoylated form of c-abl. EMBO J., 8: 449–456, 1989.  	2542016
	6. Barila, D., and Superti-Furga, G. An intramolecular SH3-domain interaction regulates  c-Abl activity. Nat. Genet., 18: 280–282, 1998.  	9500553
	7. Pluk, H., Dorey, K., and Superti-Furga, G. Autoinhibition of c-Abl. Cell, 108:  247–259, 2002.  	11832214
	8. Wen, S. T., and Van Etten, R. A. The PAG gene product, a stress-induced protein with  antioxidant properties, is an Abl SH3-binding protein and a physiological inhibitor of  c-Abl tyrosine kinase activity. Genes Dev., 11: 2456–2467, 1997.  	9334312
	9. McWhirter, J. R., Galasso, D. L., and Wang, J. Y. A coiled-coil oligomerization  domain of Bcr is essential for the transforming function of Bcr-Abl oncoproteins.  Mol. Cell. Biol., 13: 7587–7595, 1993.  	8246975
	10. McWhirter, J. R., and Wang, J. Y. Effect of Bcr sequences on the cellular function of  the Bcr-Abl oncoprotein. Oncogene, 15: 1625–1634, 1997.  	9349495
	11. Golub, T. R., Goga, A., Barker, G. F., Afar, D. E., McLaughlin, J., Bohlander, S. K.,  Rowley, J. D., Witte, O. N., and Gilliland, D. G. Oligomerization of the ABL tyrosine  kinase by the Ets protein TEL in human leukemia. Mol. Cell. Biol., 16: 4107–4116,  1996.  	8754809
	12. Okuda, K., D’Andrea, A., Etten, R. A., and Griffin, J. D. A chimeric receptor/  oncogene that can be regulated by a ligand in vitro and in vivo. J. Clin. Investig., 100:  1708–1715, 1997.  	9312168
	13. Jackson, P., Baltimore, D., and Picard, D. Hormone-conditional transformation by  fusion proteins of c-Abl and its transforming variants. EMBO J., 12: 2809–2819,  1993.  	8334997
	14. Smith, K. M., and Van Etten, R. A. Activation of c-Abl kinase activity and transfor mation by a chemical inducer of dimerization. J. Biol. Chem., 276: 24372–9, 2001.  	11320088
	15. Fan, P. D., and Goff, S. P. Abl interactor 1 binds to sos and inhibits epidermal growth  factor- and v-Abl-induced activation of extracellular signal-regulated kinases. Mol.  Cell. Biol., 20: 7591–601, 2000.  	11003655
	16. Schlessinger, J. Cell signaling by receptor tyrosine kinases. Cell, 103: 211–225, 2000.  	11057895
	17. Lewis, J. M., Baskaran, R., Taagepera, S., Schwartz, M. A., and Wang, J. Y. Integrin  regulation of c-Abl tyrosine kinase activity and cytoplasmic- nuclear transport. Proc.  Natl. Acad. Sci. USA, 93: 15174–9, 1996.  	8986783
	18. Wen, S. T., Jackson, P. K., and Van Etten, R. A. The cytostatic function of c-Abl is  controlled by multiple nuclear localization signals and requires the p53 and Rb tumor  suppressor gene products. EMBO J., 15: 1583–1595, 1996.  	8612582
	19. Taagepera, S., McDonald, D., Loeb, J. E., Whitaker, L. L., McElroy, A. K., Wang,  J. Y., and Hope, T. J. Nuclear-cytoplasmic shuttling of C-ABL tyrosine kinase. Proc.  Natl. Acad. Sci. USA, 95: 7457–7462, 1998.  	9636171
	20. Courtney, K. D., Grove, M., Vandongen, H., Vandongen, A., LaMantia, A. S., and  Pendergast, A. M. Localization and phosphorylation of Abl-interactor proteins, Abi-1  and Abi-2, in the developing nervous system. Mol. Cell. Neurosci., 16: 244–257,  2000.  	10995551
	21. Stradal, T., Courtney, K. D., Rottner, K., Hahne, P., Small, J. V., and Pendergast,  A. M. The Abl interactor proteins localize to sites of actin polymerization at the tips  of lamellipodia and filopodia. Curr. Biol., 11: 891–895, 2001.  	11516653
2020.pdf
	1. Au, W. C., P. A. Moore, W. Lowther, Y. T. Juang, and P. M. Pitha. 1995.  Identification of a member of the interferon regulatory factor family that  binds to the interferon-stimulated response element and activates expression  of interferon-induced genes. Proc. Natl. Acad. Sci. USA 92:11657–11661.  	8524823
	2. Bello, L. J., A. J. Davison, M. A. Glenn, A. Whitehouse, N. Rethmeier, T. F.  Schulz, and J. Barklie Clements. 1999. The human herpesvirus-8 ORF 57  gene and its properties. J. Gen. Virol. 80:3207–3215.  	10567653
	3. Best, S., J. B. Wolfinbarger, and M. E. Bloom. 2002. Caspase activation is  required for permissive replication of Aleutian mink disease parvovirus in  vitro. Virology 292:224–234.  	11878925
	4. Blesofsky, W. A., K. Mowen, R. M. Arduini, D. P. Baker, M. A. Murphy, D. D.  Bowtell, and M. David. 2001. Regulation of STAT protein synthesis by c-Cbl.  Oncogene 20:7326–7333.  	11704862
	5. Boyle, K. A., R. L. Pietropaolo, and T. Compton. 1999. Engagement of the  cellular receptor for glycoprotein B of human cytomegalovirus activates the  interferon-responsive pathway. Mol. Cell. Biol. 19:3607–3613.  	10207084
	6. Boyle, S. M., V. Ruvolo, A. K. Gupta, and S. Swaminathan. 1999. Association  with the cellular export receptor CRM 1 mediates function and intracellular  localization of Epstein-Barr virus SM protein, a regulator of gene expression.  J. Virol. 73:6872–6881.  	10400785
	7. Braselmann, S., P. Graninger, and M. Busslinger. 1993. A selective tran scriptional induction system for mammalian cells based on Gal4-estrogen  receptor fusion proteins. Proc. Natl. Acad. Sci. USA 90:1657–1661.  	8446579
	8. Buisson, M., F. Hans, I. Kusters, N. Duran, and A. Sergeant. 1999. The  C-terminal region but not the Arg-X-Pro repeat of Epstein-Barr virus pro tein EB2 is required for its effect on RNA splicing and transport. J. Virol.  73:4090–4100.  	10196305
	9. Buisson, M., E. Manet, M. C. Trescol-Biemont, H. Gruffat, B. Durand, and  A. Sergeant. 1989. The Epstein-Barr Virus (EBV) early protein EB2 is a  posttranscriptional activator expressed under the control of EBV transcrip tion factors EB1 and R. J. Virol. 63:5276–5284.  	2555554
	10. Chee, M., and B. Barrell. 1990. Herpesviruses: a study of parts. Trends  Genet. 6:86–91.  	2183417
	11. Cheung, P., K. S. Ellison, R. Verity, and J. R. Smiley. 2000. Herpes simplex  virus ICP27 induces cytoplasmic accumulation of unspliced polyadenylated  alpha-globin pre-mRNA in infected HeLa cells. J. Virol. 74:2913–2919.  	10684311
	12. Chevalier-Greco, A., E. Manet, P. Chavrier, C. Mosnier, J. Daillie, and A.  Sergeant. 1986. Both Epstein-Barr virus (EBV)-encoded trans-acting fac tors, EB1 and EB2, are required to activate transcription from an EBV early  promoter. EMBO J. 5:3243–3249.  	3028777
	13. Chin, K. C., and P. Cresswell. 2001. Viperin (cig5), an IFN-inducible anti viral protein directly induced by human cytomegalovirus. Proc. Natl. Acad.  Sci. USA 98:15125–15130.  	11752458
	14. Cho, M. S., K. T. Jeang, and S. D. Hayward. 1985. Localization of the coding  region for an Epstein-Barr virus early antigen and inducible expression of  this 60-kilodalton nuclear protein in transfected fibroblast cell lines. J. Virol.  56:852–859.  	2999441
	15. Darnell, J. E., Jr., I. M. Kerr, and G. R. Stark. 1994. Jak-STAT pathways and  transcriptional activation in response to IFNs and other extracellular signal ing proteins. Science 264:1415–1421.  	8197455
	16. Darzynkiewicz, Z., and G. Juan. 1997. Nucleic acid analysis, p. 7.5.2. In P.  Robinson (ed.), Current protocols in molecular cytometry, vol. 1. John Wiley  and Sons, New York, N.Y.  	NO_MATCH
	17. Davison, A. J., and P. Taylor. 1987. Genetic relations between varicella zoster virus and Epstein-Barr virus. J. Gen. Virol. 68:1067–1079.  	3033126
	18. Der, S. D., A. Zhou, B. R. Williams, and R. H. Silverman. 1998. Identification  of genes differentially regulated by interferon alpha, beta, or gamma using  oligonucleotide arrays. Proc. Natl. Acad. Sci. USA 95:15623–15628.  	9861020
	19. de Veer, M. J., M. Holko, M. Frevel, E. Walker, S. Der, J. M. Paranjape,  R. H. Silverman, and B. R. Williams. 2001. Functional classification of  interferon-stimulated genes identified using microarrays. J. Leukoc. Biol.  69:912–920.  	11404376
	20. Farjot, G., M. Buisson, M. Duc Dodon, L. Gazzolo, A. Sergeant, and I.  Mikaelian. 2000. Epstein-Barr virus EB2 protein exports unspliced RNA via  a Crm-1-independent pathway. J. Virol. 74:6068–6076.  	10846090
	21. Farrell, P. 1989. Epstein-Barr virus genome. Adv. Viral Oncol. 8:103–132.  	NO_MATCH
	22. Farrell, P. J., R. J. Broeze, and P. Lengyel. 1979. Accumulation of an mRNA  and protein in interferon-treated Ehrlich ascites tumour cells. Nature 279:  523–525.  	571963
	23. Fu, X. Y., D. S. Kessler, S. A. Veals, D. E. Levy, and J. E. Darnell, Jr. 1990.  ISGF3, the transcriptional activator induced by interferon alpha, consists of  multiple interacting polypeptide chains. Proc. Natl. Acad. Sci. USA 87:8555–  8559.  	2236065
	24. Fu, X. Y., C. Schindler, T. Improta, R. Aebersold, and J. E. Darnell, Jr. 1992.  The proteins of ISGF-3, the interferon alpha-induced transcriptional activa tor, define a gene family involved in signal transduction. Proc. Natl. Acad.  Sci. USA 89:7840–7843.  	1502204
	25. Guo, J., D. J. Hui, W. C. Merrick, and G. C. Sen. 2000. A new pathway of  translational regulation mediated by eukaryotic initiation factor 3. EMBO J.  19:6891–6899.  	11118224
	26. Gupta, A. K., V. Ruvolo, C. Patterson, and S. Swaminathan. 2000. The  human herpesvirus 8 homolog of Epstein-Barr virus SM protein (KS-SM) is  a posttranscriptional activator of gene expression. J. Virol. 74:1038–1044.  	10623771
	27. Huang, M. T. F., and C. M. Gorman. 1990. Intervening sequences increase  efficiency of RNA 3	 processing and accumulation of cytoplasmic RNA.  Nucleic Acids Res. 18:937–947.  	1690394
	28. Improta, T., C. Schindler, C. M. Horvath, I. M. Kerr, G. R. Stark, and J. E.  Darnell, Jr. 1994. Transcription factor ISGF-3 formation requires phosphor ylated Stat91 protein, but Stat113 protein is phosphorylated independently  of Stat91 protein. Proc. Natl. Acad. Sci. USA 91:4776–4780.  	8197134
	29. Inchauspe, G., S. Nagpal, and J. M. Ostrove. 1989. Mapping of two varicella zoster virus-encoded genes that activate the expression of viral early and late  genes. Virology 173:700–709.  	2556848
	30. Kenney, S., J. Kamine, E. Holley-Guthrie, E. C. Mar, J. C. Lin, D. Marko vitz, and J. Pagano. 1989. The Epstein-Barr virus immediate-early gene  product, BMLF1, acts in trans by a posttranscriptional mechanism which is  reporter gene dependent. J. Virol. 63:3870–3877.  	2548002
	31. Kenney, S., J. Kamine, D. Markovitz, R. Fenrick, and J. Pagano. 1988. An  Epstein-Barr virus immediate-early gene product trans-activates gene ex pression from the human immunodeficiency virus long terminal repeat. Proc.  Natl. Acad. Sci. USA 85:1652–1656.  	2830625
	32. Kieff, E. 1996. Epstein-Barr virus and its replication, p. 2343–2396. In B. N.  Fields, D. M. Knipe, and P. M. Howley (ed.), Virology. Lipincott-Raven,  Philadelphia, Pa.  	NO_MATCH
	33. Kirshner, J. R., D. M. Lukac, J. Chang, and D. Ganem. 2000. Kaposi’s  sarcoma-associated herpesvirus open reading frame 57 encodes a posttran scriptional regulator with multiple distinct activities. J. Virol. 74:3586–3597.  	10729134
	34. Kumar, A., M. Commane, T. W. Flickinger, C. M. Horvath, and G. R. Stark.  1997. Defective TNF-alpha-induced apoptosis in STAT1-null cells due to  low constitutive levels of caspases. Science 278:1630–1632.  	9374464
	35. Lawn, R. M., J. Adelman, T. J. Dull, M. Gross, D. Goeddel, and A. Ullrich.  1981. DNA sequence of two closely linked human leukocyte interferon  genes. Science 212:1159–1162.  	6165082
	36. Lawn, R. M., J. Adelman, A. E. Franke, C. M. Houck, M. Gross, R. Najarian,  and D. V. Goeddel. 1981. Human fibroblast interferon gene lacks introns.  Nucleic Acids Res. 9:1045–1052.  	6164984
	37. Levy, D., A. Larner, A. Chaudhuri, L. E. Babiss, and J. E. Darnell, Jr. 1986.  Interferon-stimulated transcription: isolation of an inducible gene and iden tification of its regulatory region. Proc. Natl. Acad. Sci. USA 83:8929–8933.  	3466167
	38. Luo, M. J., and R. Reed. 1999. Splicing is required for rapid and efficient  mRNA export in metazoans. Proc. Natl. Acad. Sci. USA 96:14937–14942.  	10611316
	39. Markovitz, D. M., S. Kenney, J. Kamine, M. S. Smith, M. Davis, and E.-S.  Huang. 1989. Disparate effects of two herpesvirus immediate-early gene  trans-activators on the HIV LTR. Virology 173:750–754.  	2556854
	40. McCarthy, A. M., L. McMahan, and P. A. Schaffer. 1989. Herpes simplex  virus type 1 ICP27 deletion mutants exhibit altered patterns of transcription  and are DNA deficient. J. Virol. 63:18–27.  	2535723
	41. Menezes, J., W. Liebold, G. Klein, and G. Clements. 1975. Establishment and  characterization of an Epstein-Barr virus (EBV)-negative lymphoblastoid B  cell line (BJA-B) from an exceptional EBV-genome-negative African Bur kitt’s lymphoma. Biomedicine 22:276–284.  	179629
	42. Morrison, T. E., A. Mauser, A. Wong, J. P. Ting, and S. C. Kenney. 2001.  Inhibition of IFN-gamma signaling by an Epstein-Barr virus immediate-early  protein. Immunity 15:787–799.  	11728340
	43. Mossman, K. L., P. F. Macgregor, J. J. Rozmus, A. B. Goryachev, A. M.  Edwards, and J. R. Smiley. 2001. Herpes simplex virus triggers and then  disarms a host antiviral response. J. Virol. 75:750–758.  	11134288
	44. Mowen, K., and M. David. 2000. Regulation of STAT1 nuclear export by  Jak1. Mol. Cell. Biol. 20:7273–7281.  	10982844
	45. Mowen, K. A., J. Tang, W. Zhu, B. T. Schurter, K. Shuai, H. R. Herschman,  and M. David. 2001. Arginine methylation of STAT1 modulates IFN/ induced transcription. Cell 104:731–741.  	11257227
	46. Muller, M., C. Laxton, J. Briscoe, C. Schindler, T. Improta, J. E. Darnell,  Jr., G. R. Stark, and I. M. Kerr. 1993. Complementation of a mutant cell  line: central role of the 91 kDa polypeptide of ISGF3 in the interferon-alpha  and -gamma signal transduction pathways. EMBO J. 12:4221–4228.  	7693454
	47. Navarro, L., K. Mowen, S. Rodems, B. Weaver, N. Reich, D. Spector, and M.  David. 1998. Cytomegalovirus activates interferon immediate-early response  gene expression and an interferon regulatory factor 3-containing interferon stimulated response element-binding complex. Mol. Cell. Biol. 18:3796–  3802.  	9632763
	48. Ouchi, T., S. W. Lee, M. Ouchi, S. A. Aaronson, and C. M. Horvath. 2000.  Collaboration of signal transducer and activator of transcription 1 (STAT1)  and BRCA1 in differential regulation of IFN-gamma target genes. Proc.  Natl. Acad. Sci. USA 97:5208–5213.  	10792030
	49. Ramana, C. V., M. P. Gil, Y. Han, R. M. Ransohoff, R. D. Schreiber, and  G. R. Stark. 2001. Stat1-independent regulation of gene expression in re sponse to IFN-gamma. Proc. Natl. Acad. Sci. USA 98:6674–6679.  	11390994
	50. Ramana, C. V., N. Grammatikakis, M. Chernov, H. Nguyen, K. C. Goh, B. R.  Williams, and G. R. Stark. 2000. Regulation of c-myc expression by IFN gamma through Stat1-dependent and -independent pathways. EMBO J.  19:263–272.  	10637230
	51. Ruvolo, V., A. K. Gupta, and S. Swaminathan. 2001. Epstein-Barr virus SM  protein interacts with mRNA in vivo and mediates a gene-specific increase in  cytoplasmic mRNA. J. Virol. 75:6033–6041.  	11390605
	52. Ruvolo, V., E. Wang, S. Boyle, and S. Swaminathan. 1998. The Epstein-Barr  virus nuclear protein SM is both a post-transcriptional inhibitor and activator  of gene expression. Proc. Natl. Acad. Sci. USA 95:8852–8857.  	9671768
	53. Sample, J., G. Lancz, and M. Nonoyama. 1986. Mapping of genes in BamHI  fragment M of Epstein-Barr virus DNA that may determine the fate of viral  infection. J. Virol. 57:145–154.  	2867227
	54. Schindler, C., X. Y. Fu, T. Improta, R. Aebersold, and J. E. Darnell, Jr. 1992.  Proteins of transcription factor ISGF-3: one gene encodes the 91- and 84 kDa ISGF-3 proteins that are activated by interferon alpha. Proc. Natl.  Acad. Sci. USA 89:7836–7839.  	1502203
	55. Semmes, O. J., L. Chen, R. T. Sarisky, Z. Gao, L. Zhong, and S. D. Hayward.  1998. Mta has properties of an RNA export protein and increases cytoplas mic accumulation of Epstein-Barr virus replication gene mRNA. J. Virol.  72:9526–9534.  	9811685
	56. Shuai, K., C. M. Horvath, L. H. Huang, S. A. Qureshi, D. Cowburn, and J. E.  Darnell, Jr. 1994. Interferon activation of the transcription factor Stat91  involves dimerization through SH2-phosphotyrosyl peptide interactions. Cell  76:821–828.  	7510216
	57. Shuai, K., C. Schindler, V. R. Prezioso, and J. E. Darnell, Jr. 1992. Activa tion of transcription by IFN-gamma: tyrosine phosphorylation of a 91-kD  DNA binding protein. Science 258:1808–1812.  	1281555
	58. Shuai, K., G. R. Stark, I. M. Kerr, and J. E. Darnell, Jr. 1993. A single  phosphotyrosine residue of Stat91 required for gene activation by interferon gamma. Science 261:1744–1746.  	7690989
	59. Stark, G. R., I. M. Kerr, B. R. Williams, R. H. Silverman, and R. D.  Schreiber. 1998. How cells respond to interferons. Annu. Rev. Biochem.  67:227–264.  	9759489
	60. Swaminathan, S., R. Hesselton, J. Sullivan, and E. Kieff. 1993. Epstein-Barr  virus recombinants with specifically mutated BCRF1 genes. J. Virol. 67:  7406–7413.  	7693971
	61. Taniguchi, T., and A. Takaoka. 2002. The interferon-alpha/beta system in  antiviral responses: a multimodal machinery of gene regulation by the IRF  family of transcription factors. Curr. Opin. Immunol. 14:111–116.  	11790540
	62. Tavernier, J., R. Derynck, and W. Fiers. 1981. Evidence for a unique human  fibroblast interferon (IFN-beta 1) chromosomal gene, devoid of intervening  sequences. Nucleic Acids Res. 9:461–471.  	6164047
	63. Veals, S. A., C. Schindler, D. Leonard, X. Y. Fu, R. Aebersold, J. E. Darnell,  Jr., and D. E. Levy. 1992. Subunit of an alpha-interferon-responsive tran scription factor is related to interferon regulatory factor and Myb families of  DNA-binding proteins. Mol. Cell. Biol. 12:3315–3324.  	1630447
	64. Wathelet, M., S. Moutschen, P. Defilippi, A. Cravador, M. Collet, G. Huez,  and J. Content. 1986. Molecular cloning, full-length sequence and prelimi nary characterization of a 56-kDa protein induced by human interferons.  Eur. J. Biochem. 155:11–17.  	3753936
	65. Wilson, A. D., and A. J. Morgan. 2002. Primary immune responses by cord  blood CD4 T cells and NK cells inhibit Epstein-Barr virus B-cell transfor mation in vitro. J. Virol. 76:5071–5081.  	11967323
	66. Wong, K.-M., and A. J. Levine. 1986. Identification and mapping of Epstein Barr virus early antigens and demonstration of a viral gene activator that  functions in trans. J. Virol. 60:149–156.  	3018282
1777.pdf
	1. Allison, S. L., K. Stiasny, K. Stadler, C. W. Mandl, and F. X. Heinz. 1999.  Mapping of functional elements in the stem-anchor region of tick-borne  encephalitis virus envelope protein E. J. Virol. 73:5605–5612.  	10364309
	2. Bhamarapravati, N., S. Yoksan, T. Chayaniyayothin, S. Angsubphakorn,  and A. Bunyaratvej. 1987. Immunization with a live attenuated dengue-2 virus candidate vaccine (16681-PDK 53): clinical, immunological and bio logical responses in adult volunteers. Bull. W. H. O. 65:189–195.  	3496985
	3. Bhamarapravati, N., and Y. Sutee. 2000. Live attenuated tetravalent dengue  vaccine. Vaccine 18(Suppl. 2):S44–S48.  	10821973
	4. Blok, J., S. M. McWilliam, H. C. Butler, A. J. Gibbs, G. Weiller, B. L.  Herring, A. C. Hemsley, J. G. Aaskov, S. Yoksan, and N. Bhamarapravati.  1992. Comparison of a dengue-2 virus and its candidate vaccine derivative:  sequence relationships with the flaviviruses and other viruses. Virology 187:  573–590.  	1312269
	5. Bray, M., R. Men, and C.-J. Lai. 1996. Monkeys immunized with intertypic  chimeric dengue viruses are protected against wild-type virus challenge.  J. Virol. 70:4162–4166.  	8648761
	6. Bray, M., R. Men, I. Tokimatsu, and C.-J. Lai. 1998. Genetic determinants  responsible for acquisition of dengue type 2 virus mouse neurovirulence.  J. Virol. 72:1647–1651.  	9445071
	7. Butrapet, S., C. Y.-H. Huang, D. J. Pierro, N. Bhamarapravati, D. J. Gubler,  and R. M. Kinney. 2000. Attenuation markers of a candidate dengue type 2  vaccine virus, strain 16681 (PDK-53), are defined by mutations in the 5  noncoding region and nonstructural proteins 1 and 3. J. Virol. 74:3011–3019.  	10708415
	8. Calisher, C. H., N. Karabatsos, J. M. Dalrymple, R. E. Shope, J. S. Porter field, E. G. Westaway, and W. E. Brandt. 1989. Antigenic relationships  between flaviviruses as determined by cross-neutralization tests with poly clonal antisera. J. Gen. Virol. 70:37–43.  	2543738
	9. Caufour, P. S., M. C. A. Motta, A. M. Y. Yamamura., S. Vazquez, I. I.  Ferreira, A. V. Jabor, M. C. Bonaldo, M. S. Freire, and R. Galler. 2001.  Construction, characterization and immunogenicity of recombinant yellow  fever 17D-dengue type 2 viruses. Virus Res. 79:1–14.  	11551641
	10. Chambers, T. J., D. W. McCourt, and C. M. Rice. 1990. Production of yellow  fever virus proteins in infected cells: identification of discrete polyprotein  species and analysis of cleavage kinetics using region-specific polyclonal  antisera. Virology 177:159–174.  	2353452
	11. Chambers, T. J., C. S. Hahn, R. Galler, and C. M. Rice. 1990. Flavivirus  genome organization, expression, and replication. Annu. Rev. Microbiol.  44:649–688.  	2174669
	12. Chambers, T. J., A. Nestorowicz, P. W. Mason, and C. M. Rice. 1999. Yellow  fever/Japanese encephalitis chimeric viruses: construction and biological  properties. J. Virol. 73:3095–3101.  	10074160
	13. Edelman, R., C. O. Tacket, S. S. Wasserman, D. W. Vaughn, K. H. Eckels,  D. R. Dubois, P. L. Summers, and C. H. Hoke. 1994. A live attenuated  dengue-1 vaccine candidate (45AZ5) passaged in primary dog kidney cell  culture is attenuated and immunogenic for humans. J. Infect. Dis. 170:1448–  1455.  	7995984
	14. Fitzgeorge. R., and C. J. Bradish. 1980. The in vivo differentiation of strains  of yellow fever virus in mice. J. Gen. Virol. 46:1–13.  	6766176
	15. George, R., and L. C. S. Lum. 1997. Clinical spectrum of dengue infection,  p. 89–114. In D. J. Gubler and G. K. Kuno (ed.), Dengue and dengue  hemorrhagic fever. CAB International, New York, N.Y.  	NO_MATCH
	16. Gualano, R. C., M. J. Pryor, M. R. Cauchi, P. J. Wright, and A. D. Davidson.  1998. Identification of a major determinant of mouse neurovirulence of  dengue virus type 2 using stably cloned genomic-length cDNA. J. Gen. Virol.  79:437–446.  	9519821
	17. Gubler, D. J. 1997. Dengue and dengue hemorrhagic fever: its history and  resurgence as a global public health problem, p. 1–23. In D. J. Gubler and G.  Kuno (ed.), Dengue and dengue hemorrhagic fever. CAB International,  Wallingford, United Kingdom.  	9665979
	18. Guirakhoo, F., Z.-X. Zhang, T. J. Chambers, S. Delagrave, J. Arroyo, A. D. T.  Barrett, and T. P. Monath. 1999. Immunogenicity, genetic stability, and  protective efficacy of a recombinant, chimeric yellow fever-Japanese enceph alitis virus (ChimeriVax-JE) as a live, attenuated vaccine candidate against  Japanese encephalitis. Virology 257:363–372.  	10329547
	19. Guirakhoo, F., R. Weltzin, T. J. Chambers, Z.-X. Zhang, K. Soike, M.  Ratteree, J. Arroyo, K. Georgakopoulos, J. Catalan, and T. P. Monath. 2000.  Recombinant chimeric yellow fever-dengue type 2 virus is immunogenic and  protective in nonhuman primates. J. Virol. 74:5477–5485.  	10823852
	20. Guirakhoo, F., J. Arroyo, K. V. Pugachev, C. Miller, Z. X. Zhang, R. Weltzin,  K. Georgakopoulos, J. Catalan, S. Ocran, K. Soike, M. Ratterree, and T. P.  Monath. 2001. Construction, safety, and immunogenicity in nonhuman pri mates of a chimeric yellow fever-dengue virus tetravalent vaccine. J. Virol.  75:7290–7304.  	11462001
	21. Halstead, S. B., J. S. Chou, and N. J. Marchette. 1973. Immunological  enhancement of dengue virus replication. Nat. New Biol. 243:24–25.  	NO_MATCH
	22. Halstead, S. B., and E. J. O’Rourke. 1977. Antibody-enhanced dengue virus  infection in primate leukocytes. Nature 265:739–741.  	404559
	23. Halstead, S. B. 1979. In vivo enhancement of dengue virus infection in rhesus  monkeys by passively transferred antibodies. J. Infect. Dis. 140:527–533.  	117061
	24. Hoke, C. H., F. J. Malinoski, K. H. Eckels, R. M. Scott, D. R. Dubois, P. L.  Summers, T. Simms, J. Burrous, S. E. Hasty, and W. H. Bancroft. 1990.  Preparation of an attenuated dengue 4 (341750 Carib) virus vaccine. II.  Safety and immunogenicity in humans. Am. J. Trop. Med. Hyg. 43:219–226.  	2389825
	25. Huang, C. Y.-H., S. Butrapet, D. J. Pierro, G.-J. J. Chang, A. R. Hunt, N.  Bhamarapravati, D. J. Gubler, and R. M. Kinney. 2000. Chimeric dengue  type 2 (vaccine strain PDK-53)/dengue type 1 virus as a potential candidate  dengue type 1 virus vaccine. J. Virol. 74:3020–3028.  	10708416
	26. Innis, B. L. 1997. Antibody responses to dengue virus infection, p. 221–243.  In D. J. Gubler and G. Kuno (ed.), Dengue and dengue hemorrhagic fever.  CAB International, Wallingford, United Kingdom.  	NO_MATCH
	27. Kawano, H., V. Rostapshov, L. Rosen, and C.-J. Lai. 1993. Genetic deter minants of dengue type 4 virus neurovirulence for mice. J. Virol. 67:6567–  6575.  	8411360
	28. Kelly, E. P., J. J. Greene, A. D. King, and B. L. Innis. 2000. Purified dengue  2 virus envelope glycoprotein aggregates produced by baculovirus are im munogenic in mice. Vaccine 18:2549–2559.  	10775789
	29. Kinney, R. M., S. Butrapet, G.-J. J. Chang, K. R. Tsuchiya, J. T. Roehrig, N.  Bhamarapravati, and D. J. Gubler. 1997. Construction of infectious cDNA  clones for dengue 2 virus: strain 16681 and its attenuated vaccine derivative,  strain PDK-53. Virology 230:300–308.  	9143286
	30. Kliks, S. C., A. Nisalak, W. E. Brandt, L. Wahl, and D. S. Burke. 1989.  Antibody-dependent enhancement of dengue virus growth in human mono cytes as a risk factor for dengue hemorrhagic fever. Am. J. Trop. Med. Hyg.  40:444–451.  	2712199
	31. Kochel, T. J., K. Raviprakash, C. G. Hayes, D. M. Watts, K. L. Russell, A. S.  Gozalo, I. A. Phillips, D. F. Ewing., G. S. Murphy, and K. R. Porter. 2000. A  dengue virus serotype-1 DNA vaccine induces virus neutralizing antibodies  and provides protection from viral challenge in Aotus monkeys. Vaccine  28:3166–3173.  	10856796
	32. Konishi, E., M. Yamaoka, I. Kurane, and P. W. Mason. 2000. A DNA  vaccine expressing dengue type 2 virus premembrane and envelope genes  induces neutralizing antibody and memory B cells in mice. Vaccine 18:1133–  1139.  	10590335
	33. Kuno, G., G.-J. J. Chang, K. R. Tsuchiya, N. Karabatsos, and C. B. Cropp.  1998. Phylogeny of the genus Flavivirus. J. Virol. 72:73–83.  	9420202
	34. Leitmeyer, K. C., D. W. Vaughn, D. M. Watts, R. Salas, I. Villalobos de  Chacon, C. Ramos, and R. Rico-Hesse. 1999. Dengue virus structural differ ences that correlate with pathogenesis. J. Virol. 73:4738–4747.  	10233934
	35. Mackow, E., Y. Makino, B. Zhao, Y.-M. Zhang, L. Markoff, A. Buckler White, M. Guiler, R. Chanock, and C.-J. Lai. 1987. The nucleotide sequence  of dengue type 4 virus: analysis of genes coding for nonstructural proteins.  Virology 159:217–228.  	3039728
	36. Mangada, M. N. M., and A. Igarashi. 1998. Molecular and in vitro analysis  of eight dengue type 2 viruses isolated from patients exhibiting different  disease severities. Virology 244:458–466.  	9601513
	37. Markoff, L. 1989. In vitro processing of dengue virus structural proteins:  cleavage of the pre-membrane protein. J. Virol. 63:3345–3352.  	2501515
	38. Monath, T. P. 1971. Neutralizing antibody responses in the major immuno globulin classes to yellow fever 17D vaccination. Am. J. Epidemiol. 93:122–  129.  	5101137
	39. Monath, T. P. 1986. Pathobiology of the flaviviruses, p. 375–440. In S.  Schlesinger and M. J. Schlesinger (ed.), The Togaviridae and the Flaviviri dae. Plenum Press, New York, N.Y.  	NO_MATCH
	40. Monath, T. P. 1994. Dengue: the risk to developed and developing countries.  Proc. Natl. Acad. Sci. USA 91:2395–2400.  	8146129
	41. Monath, T. P. 1994. Yellow fever and dengue: the interactions of virus,  vector and host in the re-emergence of epidemic disease. Semin. Virol.  5:133–143.  	NO_MATCH
	42. Monath, T. P., K. Soike, I. Levenbook, Z.-X. Zhang, J. Arroyo, S. Delagrave,  G. Myers, A. D. T. Barrett, R. E. Shope, M. Ratterree, T. J. Chambers, and  F. Guirakhoo. 1999. Recombinant, chimeric live, attenuated vaccine (Chi meriVax) incorporating the envelope genes of Japanese encephalitis (SA14–  14–2) virus and the capsid and nonstructural genes of yellow fever (17D)  virus is safe, immunogenic and protective in non-human primates. Vaccine  17:1869–1882.  	10217584
	43. Monath, T. P., K. McCarthy, P. Bedford, C. T. Johnson, R. Nichols, S.  Yoksan, R. Marchesani, M. Knauber, K. H. Wells, J. Arroyo, and F. Guira khoo. 2002. Clinical proof of principle for ChimeriVax™: recombinant live  attenuated vaccines against flavivirus infections. Vaccine 20:1004–1018.  	11803060
	44. Pletnev, A., G., M. Bray, J. Huggins, and C.-J. Lai. 1992. Construction and  characterization of chimeric tick-borne encephalitis/dengue type 4 viruses.  Proc. Natl. Acad. Sci. USA 89:10532–10536.  	1438242
	45. Porter, K. R., T. J. Kochel, S.-J. Wu, K. Raviprakash, I. Phillips, and C. G.  Hayes. 1998. Protective efficacy of a dengue 2 DNA vaccine in mice and the  effect of CpG immuno-stimulatory motifs on antibody responses. Arch. Vi rol. 143:997–1003.  	9645204
	46. Puri, B., W. M. Nelson, E. A. Henchal, C. H. Hoke, K. H. Eckels, D. R.  Dubois, K. R. Porter, and C. G. Hayes. 1997. Molecular analysis of dengue  virus attenuation after serial passage in primary dog kidney cells. J. Gen.  Virol. 78:2287–2291.  	9292016
	47. Putnak, R., D. A. Barvir, J. M. Burrous, D. R. Dubois, V. M. D’Andrea, C. H.  Hoke, J. C. Sadoff, and K. H. Eckels. 1996. Development of a purified,  inactivated, dengue-2 virus vaccine prototype in vero cells: immunogenicity  and protection in mice and rhesus monkeys. J. Infect. Dis. 174:1176–1184.  	8940206
	48. Putnak, R., K. Cassidy, N. Conforti, R. Lee, D. Sollazzo, T. Truong, E. Ing,  D. Dubois, J. Sparkuhl, W. Gastle, and C. Hoke. 1996. Immunogenic and  protective responses in mice immunized with a purified, inactivated den gue-2 virus vaccine prototype made in fetal rhesus lung cells. Am. J. Trop.  Med. Hyg. 55:504–510.  	8940981
	49. Rice, C. M., A. Grakoui, R. Galler, and T. J. Chambers. 1989. Transcription  of infectious yellow fever virus RNA from full-length cDNA templates pro duced by in vitro ligation. New Biol. 1:285–296.  	NO_MATCH
	50. Rothman, A. L., and F. A. Ennis. 1999. Immunopathogenesis of dengue  hemorrhagic fever. Virology 257:1–6.  	10208914
	51. Schlesinger, J. J., M. W. Brandriss, and E. E. Walsh. 1985. Protection  against 17D yellow fever encephalitis in mice by passive transfer of mono clonal antibodies to the nonstructural glycoprotein gp48 and by active im munization with gp48. J. Immunol. 135:2805–2809.  	4031501
	52. Simmons, M., W. M. Nelson, S. J. Wu, and C. G. Hayes. 1998. Evaluation of  the protective efficacy of a recombinant dengue envelope B domain fusion  protein against dengue 2 virus infection in mice. Am. J. Trop. Med. Hyg.  58:655–662.  	9598457
	53. Simmons, M., G. S. Murphy, T. Kochel, K. Raviprakash, and C. G. Hayes.  2001. Characterization of antibody responses to combinations of a dengue-2  DNA and dengue-2 recombinant subunit vaccine. Am. J. Trop. Med. Hyg.  65:420–426.  	11716093
	54. Simmons, M., G. S. Murphy, and C. G. Hayes. 2001. Short report: antibody  response of mice immunized with a tetravalent dengue recombinant protein  subunit vaccine. Am. J. Trop. Med. Hyg. 65:159–161.  	11508393
	55. Smith, G. W., and P. J. Wright. 1985. Synthesis of proteins and glycoproteins  in dengue type 2 virus-infected Vero and Aedes albopictus cells. J. Gen. Virol.  66:559–571.  	3973563
	56. van der Most, R. G., K. Murali-Krishna, R. Ahmed, and J. H. Strauss. 2000.  Chimeric yellow fever/dengue virus as a candidate dengue vaccine: quanti tation of the dengue virus-specific CD8 T-cell response. J. Virol. 74:8094–  8101.  	10933719
	57. Wheelock, E. F., and W. A. Sibley. 1965. Circulating virus, interferon and  antibody after vaccination with the 17D strain of yellow fever virus. N. Engl.  J. Med. 273:194–198.  	14306335
	58. Zanotto, P. M., E. A. Gould, G. F. Gao, P. H. Harvey, and E. C. Holmes.  1996. Population dynamics of flaviviruses revealed by molecular phylogenies.  Proc. Natl. Acad. Sci. USA 93:548–553.  	8570593
	59. Zhao, B., E. Mackow, A. Buckler-White, L. Markoff, R. M. Chanock, C.-J.  Lai, and Y. Makino. 1986. Cloning full-length dengue type 4 viral DNA se quences: analysis of genes coding for structural proteins. Virology 155:77–88.  	3022479
	60. Zhao, B., G. Prince, R. Horswood, K. Eckels, P. Summers, R. Chanock, and  C.-J. Lai. 1987. Expression of dengue virus structural proteins and nonstructural  protein NS1 by a recombinant vaccinia virus. J. Virol. 61:4019–4022.  	3316711
2117.pdf
	1. Bauer, M., V. Redecke, J. W. Ellwart, B. Scherer, J. P. Kremer, H. Wagner,  and G. B. Lipford. 2001. Bacterial CpG-DNA triggers activation and matu ration of human CD11c, CD123 dendritic cells. J. Immunol. 166:5000–  5007.  	11290780
	2. Behl, C., J. B. Davis, R. Lesley, and D. Schubert. 1994. Hydrogen peroxide  mediates amyloid beta protein toxicity. Cell 77:817–827.  	8004671
	3. Bonecchi, R., G. Bianchi, P. P. Bordignon, D. D’Ambrosio, R. Lang, A.  Borsatti, S. Sozzani, P. Allavena, P. A. Gray, A. Mantovani, and F. Sini gaglia. 1998. Differential expression of chemokine receptors and chemotactic  responsiveness of type 1 T helper cells (Th1s) and Th2s. J. Exp. Med. 187:  129–134.  	9419219
	4. Bowen, J. C., S. K. Nair, R. Reddy, and B. T. Rouse. 1994. Cholera toxin acts  as a potent adjuvant for the induction of cytotoxic T-lymphocyte responses  with non-replicating antigens. Immunology 81:338–342.  	8206507
	5. Brander, C., T. Wyss-Coray, D. Mauri, F. Bettens, and W. J. Pichler. 1993.  Carrier-mediated uptake and presentation of a major histocompatibility  complex class I-restricted peptide. Eur. J. Immunol. 23:3217–3223.  	8258336
	6. Chackerian, B., D. R. Lowy, and J. T. Schiller. 2001. Conjugation of a  self-antigen to papillomavirus-like particles allows for efficient induction of  protective autoantibodies. J. Clin. Investig. 108:415–423.  	11489935
	7. Chu, R. S., O. S. Targoni, A. M. Krieg, P. V. Lehmann, and C. V. Harding.  1997. CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1  (Th1) immunity. J. Exp. Med. 186:1623–1631.  	9362523
	8. Coffman, R. L., K. Varkila, P. Scott, and R. Chatelain. 1991. Role of cyto kines in the differentiation of CD4 T-cell subsets in vivo. Immunol. Rev.  123:189–207.  	1684779
	9. Davis, H. L., R. Weeratna, T. J. Waldschmidt, L. Tygrett, J. Schorr, A. M.  Krieg, and R. Weeranta. 1998. CpG DNA is a potent enhancer of specific  immunity in mice immunized with recombinant hepatitis B surface antigen.  J. Immunol. 160:870–876.  	9551923
	10. Decker, T., and M. L. Lohmann-Matthes. 1988. A quick and simple method  for the quantitation of lactate dehydrogenase release in measurements of  cellular cytotoxicity and tumor necrosis factor (TNF) activity. J. Immunol.  Methods 115:61–69.  	3192948
	11. Deml, L., G. Kratochwil, N. Osterrieder, R. Knuchel, H. Wolf, and R.  Wagner. 1997. Increased incorporation of chimeric human immunodefi ciency virus type 1 gp120 proteins into Pr55gag virus-like particles by an  Epstein-Barr virus gp220/350-derived transmembrane domain. Virology 235:  10–25.  	9300033
	12. Edinger, A. L., M. Ahuja, T. Sung, K. C. Baxter, B. Haggarty, R. W. Doms,  and J. A. Hoxie. 2000. Characterization and epitope mapping of neutralizing  monoclonal antibodies produced by immunization with oligomeric simian  immunodeficiency virus envelope protein. J. Virol. 74:7922–7935.  	10933700
	13. Gallichan, W. S., R. N. Woolstencroft, T. Guarasci, M. J. McCluskie, H. L.  Davis, and K. L. Rosenthal. 2001. Intranasal immunization with CpG oli godeoxynucleotides as an adjuvant dramatically increases IgA and protection  against herpes simplex virus-2 in the genital tract. J. Immunol. 166:3451–  3457.  	11207303
	14. Gomez, R. S., J. E. da Costa, T. M. Lorentz, A. Garrocho Ade, and J. A.  Nogueira-Machado. 1994. Chemoluminescence generation and MTT dye  reduction by polymorphonuclear leukocytes from periodontal disease pa tients. J. Periodontal Res. 29:109–112.  	8158498
	15. Haffar, O., J. Garrigues, B. Travis, P. Moran, J. Zarling, and S.-L. Hu. 1990.  Human immunodeficiency virus-like, nonreplicating, gag-env particles as semble in a recombinant vaccinia virus expression system. J. Virol. 64:2653–  2659.  	2186175
	16. Hameleers, D. M., I. van der Ven, J. Biewenga, and T. Sminia. 1991. Mucosal  and systemic antibody formation in the rat after intranasal administration of  three different antigens. Immunol. Cell Biol. 69:119–125.  	1916902
	17. Hemmi, H., O. Takeuchi, T. Kawai, T. Kaisho, S. Sato, H. Sanjo, M. Mat sumoto, K. Hoshino, H. Wagner, K. Takeda, and S. Akira. 2000. A Toll-like  receptor recognizes bacterial DNA. Nature 408:740–745.  	11130078
	18. Horner, A. A., S. K. Datta, K. Takabayashi, I. M. Belyakov, T. Hayashi, N.  Cinman, M. D. Nguyen, J. H. Van Uden, J. A. Berzofsky, D. D. Richman, and  E. Raz. 2001. Immunostimulatory DNA-based vaccines elicit multifaceted  immune responses against HIV at systemic and mucosal sites. J. Immunol.  167:1584–1591.  	11466380
	19. Horner, A. A., A. Ronaghy, P. M. Cheng, M. D. Nguyen, H. J. Cho, D. Broide,  and E. Raz. 1998. Immunostimulatory DNA is a potent mucosal adjuvant.  Cell. Immunol. 190:77–82.  	9826449
	20. Isaka, M., Y. Yasuda, M. Mizokami, S. Kozuka, T. Taniguchi, K. Matano, J.  Maeyama, K. Mizuno, K. Morokuma, K. Ohkuma, N. Goto, and K. Tochi kubo. 2001. Mucosal immunization against hepatitis B virus by intranasal  co-administration of recombinant hepatitis B surface antigen and recombi nant cholera toxin B subunit as an adjuvant. Vaccine 19:1460–1466.  	11163669
	21. Johansson, E. L., C. Rask, M. Fredriksson, K. Eriksson, C. Czerkinsky, and  J. Holmgren. 1998. Antibodies and antibody-secreting cells in the female  genital tract after vaginal or intranasal immunization with cholera toxin B  subunit or conjugates. Infect. Immun. 66:514–520.  	9453604
	22. Jones, D. H., B. W. McBride, M. A. Roff, and G. H. Farrar. 1995. Efficient  purification and rigorous characterisation of a recombinant gp120 for HIV  vaccine studies. Vaccine 13:991–999.  	8525694
	23. Jones, D. H., B. W. McBride, M. A. Roff, V. Maloney, and G. H. Farrar. 1994.  Purification and characterization of simian immunodeficiency virus  (SIVmac) envelope glycoprotein gp130 from virus-infected cells. Vaccine  12:250–258.  	8165858
	24. Jones, T. R., N. Obaldia III, R. A. Gramzinski, Y. Charoenvit, N. Kolodny,  S. Kitov, H. L. Davis, A. M. Krieg, and S. L. Hoffman. 1999. Synthetic  oligodeoxynucleotides containing CpG motifs enhance immunogenicity of a  peptide malaria vaccine in Aotus monkeys Vaccine 17:3065–3071.  	10462241
	25. Kadowaki, N., S. Antonenko, S. Ho, M. C. Rissoan, V. Soumelis, S. A.  Porcelli, L. L. Lanier, and Y. J. Liu. 2001. Distinct cytokine profiles of  neonatal natural killer T cells after expansion with subsets of dendritic cells.  J. Exp. Med. 193:1221–1226.  	11369793
	26. Kameyoshi, Y., A. Dorschner, A. I. Mallet, E. Christophers, and J. M.  Schroder. 1992. Cytokine RANTES released by thrombin-stimulated plate lets is a potent attractant for human eosinophils. J. Exp. Med. 176:587–592.  	1380064
	27. Klinman, D. M., A. K. Yi, S. L. Beaucage, J. Conover, and A. M. Krieg. 1996.  CpG motifs present in bacteria DNA rapidly induce lymphocytes to secrete  interleukin 6, interleukin 12, and interferon gamma. Proc. Natl. Acad. Sci.  USA 93:2879–2883.  	8610135
	28. Korzeniewski, C., and D. M. Callewaert. 1983. An enzyme-release assay for  natural cytotoxicity. J. Immunol. Methods 64:313–320.  	6199426
	29. Krausslich, H. G., C. Ochsenbauer, A. M. Traenckner, K. Mergener, M.  Facke, H. R. Gelderblom, and V. Bosch. 1993. Analysis of protein expression  and virus-like particle formation in mammalian cell lines stably expressing  HIV-1 gag and env gene products with or without active HIV proteinase.  Virology 192:605–617.  	8421902
	30. Krieg, A. M., A. K. Yi, S. Matson, T. J. Waldschmidt, G. A. Bishop, R.  Teasdale, G. A. Koretzky, and D. M. Klinman. 1995. CpG motifs in bacterial  DNA trigger direct B-cell activation. Nature 374:546–549.  	7700380
	31. Kuper, C. F., P. J. Koornstra, D. M. Hameleers, J. Biewenga, B. J. Spit, A. M.  Duijvestijn, P. J. Breda Vriesman, and T. Sminia. 1992. The role of naso pharyngeal lymphoid tissue. Immunol. Today 13:219–224.  	1627250
	32. Lacour, M., J. F. Arrighi, K. M. Muller, C. Carlberg, J. H. Saurat, and C.  Hauser. 1994. cAMP up-regulates IL-4 and IL-5 production from activated  CD4 T cells while decreasing IL-2 release and NF-AT induction. Int.  Immunol. 6:1333–1343.  	7819141
	33. Lagranderie, M., N. Winter, A. M. Balazuc, B. Gicquel, and M. Gheorghiu.  1998. A cocktail of Mycobacterium bovis BCG recombinants expressing the  SIV Nef, Env, and Gag antigens induces antibody and cytotoxic responses in  mice vaccinated by different mucosal routes. AIDS Res. Hum. Retroviruses  14:1625–1633.  	9870315
	34. Lian, T., T. Bui, and R. J. Ho. 1999. Formulation of HIV-envelope protein  with lipid vesicles expressing ganglioside GM1 associated to cholera toxin B  enhances mucosal immune responses. Vaccine 18:604–611.  	10547418
	35. Lillard, J. W., Jr., P. N. Boyaka, D. D. Taub, and J. R. McGhee. 2001.  RANTES potentiates antigen-specific mucosal immune responses. J. Immu nol. 166:162–169.  	11123289
	36. Lim, E. M., M. Lagranderie, R. Le Grand, J. Rauzier, M. Gheorghiu, B.  Gicquel, and N. Winter. 1997. Recombinant Mycobacterium bovis BCG pro ducing the N-terminal half of SIVmac251 Env antigen induces neutralizing  antibodies and cytotoxic T lymphocyte responses in mice and guinea pigs.  AIDS Res. Hum. Retroviruses 13:1573–1581.  	9430249
	37. Lipford, G. B., M. Bauer, C. Blank, R. Reiter, H. Wagner, and K. Heeg. 1997.  CpG-containing synthetic oligonucleotides promote B and cytotoxic T cell  responses to protein antigen: a new class of vaccine adjuvants. Eur. J. Im munol. 27:2340–2344.  	9341778
	38. Matsukura, S., F. Kokubu, H. Kubo, T. Tomita, H. Tokunaga, M. Kadokura,  T. Yamamoto, Y. Kuroiwa, T. Ohno, H. Suzaki, and M. Adachi. 1998.  Expression of RANTES by normal airway epithelial cells after influenza  virus A infection. Am. J. Respir. Cell Mol. Biol. 18:255–264.  	9476913
	39. McCluskie, M. J., and H. L. Davis. 1998. CpG DNA is a potent enhancer of  systemic and mucosal immune responses against hepatitis B surface antigen  with intranasal administration to mice. J. Immunol. 161:4463–4466.  	9794366
	40. McCluskie, M. J., R. D. Weeratna, and H. L. Davis. 2000. Intranasal immu nization of mice with CpG DNA induces strong systemic and mucosal re sponses that are influenced by other mucosal adjuvants and antigen distri bution. Mol. Med. 6:867–877.  	11126201
	41. McCluskie, M. J., R. D. Weeratna, and H. L. Davis. 2001. The potential of  oligodeoxynucleotides as mucosal and parenteral adjuvants. Vaccine 19:  2657–2660.  	11257405
	42. Meyer, D., and J. V. Torres. 1999. Induction of cytotoxic and helper T cell  responses by modified simian immunodeficiency virus hypervariable epitope  constructs. Viral Immunol. 12:117–129.  	10413358
	43. Moldoveanu, Z., L. Love-Homan, W. Q. Huang, and A. M. Krieg. 1998. CpG  DNA, a novel immune enhancer for systemic and mucosal immunization  with influenza virus. Vaccine 16:1216–1224.  	9682382
	44. Moldoveanu, Z., A. N. Vzorov, W. Q. Huang, J. Mestecky, and R. W. Com pans. 1999. Induction of immune responses to SIV antigens by mucosally  administered vaccines. AIDS Res. Hum. Retroviruses. 15:1469–1476.  	10555110
	45. Montefiori, D. C., J. T. Safrit, S. L. Lydy, A. P. Barry, M. Bilska, H. T. T. Vo,  M. Klein, J. Tartaglia, H. L. Robinson, and B. Rovinski. 2001. Induction of  neutralizing antibodies and Gag-specific cellular immune responses to an R5  primary isolate of human immunodeficiency virus type 1 in rhesus macaques.  J. Virol. 75:5879–5890.  	11390589
	46. Morris, C. B., E. Cheng, A. Thanawastien, L. Cardenas-Freytag, and J. D.  Clements. 2000. Effectiveness of intranasal immunization with HIV-gp160  and an HIV-1 env CTL epitope peptide (E7) in combination with the  mucosal adjuvant LT(R192G). Vaccine 18:1944–1951.  	10699345
	47. Munoz, E., A. M. Zubiaga, M. Merrow, N. P. Sauter, and B. T. Huber. 1990.  Cholera toxin discriminates between T helper 1 and 2 cells in T cell receptor mediated activation: role of cAMP in T cell proliferation. J. Exp. Med.  172:95–103.  	2162906
	48. Neote, K., D. DiGregorio, J. Y. Mak, R. Horuk, and T. J. Schall. 1993.  Molecular cloning, functional expression, and signaling characteristics of a  C-C chemokine receptor. Cell 72:415–425.  	7679328
	49. Niks, M., M. Otto, B. Busova, and J. Stefanovic. 1990. Quantification of  proliferative and suppressive responses of human T lymphocytes following  ConA stimulation. J. Immunol. Methods 126:263–271.  	2137495
	50. Notka, F., C. Stahl-Hennig, U. Dittmer, H. Wolf, and R. Wagner. 1999.  Accelerated clearance of SHIV in rhesus monkeys by virus-like particle  vaccines is dependent on induction of neutralizing antibodies. Vaccine 18:  291–301.  	10506654
	51. Oliva, A., A. L. Kinter, M. Vaccarezza, A. Rubbert, A. Catanzaro, S. Moir, J.  Monaco, L. Ehler, S. Mizell, R. Jackson, Y. Li, J. W. Romano, and A. S.  Fauci. 1998. Natural killer cells from human immunodeficiency virus (HIV) infected individuals are an important source of CC-chemokines and suppress  HIV-1 entry and replication in vitro. J. Clin. Investig. 102:223–231.  	9649576
	52. Olszewska-Pazdrak, B., A. Casola, T. Saito, R. Alam, S. E. Crowe, F. Mei,  P. L. Ogra, and R. P. Garofalo. 1998. Cell-specific expression of RANTES,  MCP-1, and MIP-1 by lower airway epithelial cells and eosinophils infected  with respiratory syncytial virus. J. Virol. 72:4756–4764.  	9573240
	53. Paliard, X., Y. Liu, R. Wagner, H. Wolf, J. Baenziger, and C. M. Walker.  2000. Priming of strong, broad, and long-lived HIV type 1 p55gag-specific  CD8 cytotoxic T cells after administration of a virus-like particle vaccine in  rhesus macaques. AIDS Res. Hum. Retroviruses 16:273–282.  	10710215
	54. Porgador, A., H. F. Staats, B. Faiola, E. Gilboa, and T. J. Palker. 1997.  Intranasal immunization with CTL epitope peptides from HIV-1 or ovalbu min and the mucosal adjuvant cholera toxin induces peptide-specific CTLs  and protection against tumor development in vivo. J. Immunol. 158:834–841.  	8993001
	55. Roman, M., E. Martin-Orozco, J. S. Goodman, M. D. Nguyen, Y. Sato, A.  Ronaghy, R. S. Kornbluth, D. D. Richman, D. A. Carson, and E. Raz. 1997.  Immunostimulatory DNA sequences function as T helper-1-promoting ad juvants. Nat. Med. 3:849–854.  	9256274
	56. Rudzik, O., R. L. Clancy, D. Y. Perey, J. Bienenstock, and D. P. Singal. 1975.  The distribution of a rabbit thymic antigen and membrane immunoglobulins  in lymphoid tissue, with special reference to mucosal lymphocytes. J. Immu nol. 114:1–4.  	803523
	57. Saito, T., R. W. Deskin, A. Casola, H. Haeberle, B. Olszewska, P. B. Ernst,  R. Alam, P. L. Ogra, and R. Garofalo. 1997. Respiratory syncytial virus  induces selective production of the chemokine RANTES by upper airway  epithelial cells. J. Infect. Dis. 175:497–504.  	9041319
	58. Schall, T. J., K. Bacon, K. J. Toy, and D. V. Goeddel. 1990. Selective  attraction of monocytes and T lymphocytes of the memory phenotype by  cytokine RANTES. Nature 347:669–671.  	1699135
	59. Shi, Y. F., B. M. Sahai, and D. R. Green. 1989. Cyclosporin A inhibits  activation-induced cell death in T-cell hybridomas and thymocytes. Nature  339:625–626.  	2786609
	60. Simmons, C. P., P. Mastroeni, R. Fowler, M. Ghaem-Maghami, N. Lycke, M.  Pizza, R. Rappuoli, and G. Dougan. 1999. MHC class I-restricted cytotoxic  lymphocyte responses induced by enterotoxin-based mucosal adjuvants.  J. Immunol. 163:6502–6510.  	10586042
	61. Sparwasser, T., E. S. Koch, R. M. Vabulas, K. Heeg, G. B. Lipford, J. W.  Ellwart, and H. Wagner. 1998. Bacterial DNA and immunostimulatory CpG  oligonucleotides trigger maturation and activation of murine dendritic cells.  Eur. J. Immunol. 28:2045–2054.  	9645386
	62. Spit, B. J., E. G. Hendriksen, J. P. Bruijntjes, and C. F. Kuper. 1989. Nasal  lymphoid tissue in the rat. Cell Tissue Res. 255:193–198.  	2736604
	63. Stacey, K. J., D. P. Sester, M. J. Sweet, and D. A. Hume. 2000. Macrophage  activation by immunostimulatory DNA. Curr. Top. Microbiol. Immunol.  247:41–58.  	10689778
	64. Taub, D. D., J. R. Ortaldo, S. M. Turcovski-Corrales, M. L. Key, D. L.  Longo, and W. J. Murphy. 1996. Beta chemokines costimulate lymphocyte  cytolysis, proliferation, and lymphokine production. J. Leukoc. Biol. 59:81–  89.  	8558072
	65. Tilney, N. L. 1971. Patterns of lymphatic drainage in the adult laboratory rat.  J. Anat. 109:369–383.  	5153800
	66. Tochikubo, K., M. Isaka, Y. Yasuda, S. Kozuka, K. Matano, Y. Miura, and  T. Taniguchi. 1998. Recombinant cholera toxin B subunit acts as an adjuvant  for the mucosal and systemic responses of mice to mucosally co-administered  bovine serum albumin. Vaccine 16:150–155.  	9607023
	67. van der Ven, I., and T. Sminia. 1993. The development and structure of  mouse nasal-associated lymphoid tissue: an immuno- and enzyme-histo chemical study. Reg. Immunol. 5:69–75.  	8217554
	68. Vzorov, A. N., and R. W. Compans. 1996. Assembly and release of SIV env  proteins with full-length or truncated cytoplasmic domains. Virology 221:  22–33.  	8661411
	69. Wagner, R., V. J. Teeuwsen, L. Deml, F. Notka, A. G. Haaksma, S. S.  Jhagjhoorsingh, H. Niphuis, H. Wolf, and J. L. Heeney. 1998. Cytotoxic T  cells and neutralizing antibodies induced in rhesus monkeys by virus-like  particle HIV vaccines in the absence of protection from SHIV infection.  Virology 245:65–74.  	9614868
	70. Wu, H. Y., H. H. Nguyen, and M. W. Russell. 1997. Nasal lymphoid tissue  (NALT) as a mucosal immune inductive site. Scand. J. Immunol. 46:506–513.  	9393634
	71. Xu-Amano, J., R. J. Jackson, K. Fujihashi, H. Kiyono, H. F. Staats, and J. R.  McGhee. 1994. Helper Th1 and Th2 cell responses following mucosal or  systemic immunization with cholera toxin. Vaccine 12:903–911.  	7975832
	72. Xu-Amano, J., H. Kiyono, R. J. Jackson, H. F. Staats, K. Fujihashi, P. D.  Burrows, C. O. Elson, S. Pillai, and J. R. McGhee. 1993. Helper T cell  subsets for immunoglobulin A responses: oral immunization with tetanus  toxoid and cholera toxin as adjuvant selectively induces Th2 cells in mucosa  associated tissues. J. Exp. Med. 178:1309–1320.  	8376936
	73. Yamshchikov, G. V., G. D. Ritter, M. Vey, and R. W. Compans. 1995.  Assembly of SIV virus-like particles containing envelope proteins using a  baculovirus expression system. Virology 214:50–58.  	8525638
	74. Yang, S. K., L. Eckmann, A. Panja, and M. F. Kagnoff. 1997. Differential and  regulated expression of C-X-C, C-C, and C-chemokines by human colon  epithelial cells. Gastroenterology 113:1214–1223.  	9322516
	75. Yao, Q., F. M. Kuhlmann, R. Eller, R. W. Compans, and C. Chen. 2000.  Production and characterization of simian-human immunodeficiency virus like particles. AIDS Res. Hum. Retroviruses 16:227–236.  	10710211
	76. Yao, Q., V. Vuong, M. Li, and R. W. Compans. 2002. Intranasal immuniza tion with SIV virus-like particles (VLPs) elicits systemic and mucosal immu nity. Vaccine 20:2537–2545.  	12057610
	77. Yasutomi, Y., T. J. Palker, M. B. Gardner, B. F. Haynes, and N. L. Letvin.  1993. Synthetic peptide in mineral oil adjuvant elicits simian immunodefi ciency virus-specific CD8 cytotoxic T lymphocytes in rhesus monkeys. J. Im munol. 151:5096–5105.  	7691965
475.full.pdf
	Alvarez, I. and Navascués, J. (1990). Shaping, invagination and closure of  the chick embryo otic vesicle: Scanning electron microscope and  quantitative study. Anat. Rec. 228, 315-326.  	2260786
	Arenz, C., Thutewohl, M., Block, O., Waldmann, H., Altenbach, H.-J. and  Giannis, A. (2001). Manumycin A and its analogues are irreversible  inhibitors of neutral sphingomyelinase. Chembiochem. 2, 141-143.  	11828438
	Barrett, G. L. (2000). The p75 neurotrophin receptor and neural apoptosis.  Prog. Neurobiol. 61, 205-229.  	10704998
	Beutler, B. and van Huffel, C. (1994). Unraveling function in the TNF ligand  and receptor families. Science 264, 667-668.  	8171316
	Bibel, M. and Barde, Y. (2000). Neurotrophins: key regulators of cell fate and  cell shape in the vertebrate nervous system. Genes Dev. 14, 2919-2937.  	11114882
	Bissonnette, J. P. and Fekete, D. M. (1996). Standard atlas of the gross  anatomy of the developing inner ear of the chicken. J. Comp. Neurol. 368,  620-630.  	8744448
	Blaschke, A. J., Staley, K. and Chun, J. (1996). Widespread programmed  cell death in proliferative and postmitotic regions of the fetal cerebral cortex.  Development 122, 1165-1174.  	8620843
	Bligh, E. G. and Dyer, W. J. (1959). A rapid method of total lipid extraction  and purification. Can. J. Biochem. Physiol. 37, 911-917.  	13671378
	Brann, A. B., Scott, R., Neuberger, Y., Abulafia, D., Boldin, S., Fainzilber,  M. and Futerman, A. H. (1999). Ceramide signalling downstream of the  p75 neurotrophin receptor mediates the effects of nerve growth factor on  outgrowth of cultured hippocampal neurons. J. Neurosci. 19, 8199-8206.  	10493721
	Brazil, D. P. and Hemmings, B. A. (2001). Ten years of protein kinase B  signalling: a hard Akt to follow. Trends Biochem. Sci. 26, 657-664.  	11701324
	Burow, M. E., Weldon, C. B., Collins-Burow, B. M., Ramsey, N., McKee,  A., Klippel, A., McLachlan, J. A., Clejan, S. and Beckman, B. S. (2000).  Cross-talk between phosphatidylinositol 3-kinase and sphingomyelinase  pathways as a mechanism for cell survival/death decisions. J. Biol. Chem.  275, 9628-9635.  	10734114
	Camarero, G., Avendaño, C., Fernández-Moreno, C., Villar, A., Contreras,  J., de Pablo, F., Pichel, J. G. and Varela-Nieto, I. (2001). Delayed inner  ear maturation and neuronal loss in postnatal Igf-1-deficient mice. J.  Neurosci. 21, 7630-7641.  	11567053
	Casaccia-Bonnefil, P., Carter, B. D., Dobrowsky, R. T. and Chao, M. V.  (1996). Death of oligodendrocytes mediated by the interaction of nerve  growth factor with its receptor p75. Nature 383, 716-719.  	8878481
	Casaccia-Bonnefil, P., Gu, A., Khursigara, G. and Chao, M. V. (1999). The  p75 neurotrophin receptor as a modulator of survival and death decisions.  Microsc. Res. Tech. 45, 217-224.  	10383114
	Chao, M. V. and Bothwell, M. (2002). Neurotrophins: to cleave or not to  cleave. Neuron 33, 9-12.  	11779474
	Chatterjee, M. and Wu, S. (2001). Cell line dependent involvement of  ceramide in ultraviolet light-induced apoptosis. Mol. Cell Biochem. 219, 21 27.  	11354249
	Chinnaiyan, A. M., Tepper, C. G., Seldin, M. F., O’Rourke, K., Kischkel,  F. C., Hellbardt, S., Krammer, P., Peter, M. and Dixit, V. M. (1996).  FADD/MORT1 is a common mediator of CD95 (Fas/APO-1) and tumor  necrosis factor receptor-induced apoptosis. J. Biol. Chem. 271, 4961-4965.  	8617770
	Cho, H., Thorvaldsen, J. L., Chu, Q., Feng, F. and Birnbaum, M. J. (2001).  Akt1/PKB  ais required for normal growth but dispensable for maintenance  of glucose homeostasis in mice. J. Biol. Chem. 276, 38349-38352.  	11533044
	Chrysis, D., Calikoglu, A. S., Ye, P. and D’Ercole, A. J. (2001). Insulin-like  growth factor-I overexpression attenuates cerebellar apoptosis by altering  the expresión of Bcl family proteins in a developmentally specific manner.  J. Neurosci. 21, 1481-1489.  	11222638
	Craighead, M., Pole, J. and Waters, C. (2000). Caspases mediate C2 ceramide-induced apoptosis of the human oligodendroglial cell line,  MO3.13. Neurosci. Lett. 278, 125-128.  	10653009
	Cutler, R. G. and Mattson, M. P. (2001). Sphingomyelin and ceramide as  regulators of development and lifespan. Mech. Ageing Dev. 122, 895-908.  de la Rosa, E. J. and de Pablo, F. (2000). Cell death in early neural  development: beyond the neurotrophic theory. Trends Neurosci. 23, 454 458.  	11348657
	Diaz, B., Pimentel, B., de Pablo, F. and de la Rosa, E. J. (1999). Apoptotic  cell death of proliferating neuroepithelial cells in the embryonic retina is  prevented by insulin. Eur. J. Neurosci. 11, 1624-1632.  	10215915
	D’Mello, S. R. (1998). Molecular regulation of neuronal apoptosis. Curr. Top.  Dev. Biol. 39, 187-213.   	9476001
	Dobrowsky, R. T. and Carter, B. D. (2000). p75 neurotrophin receptor  signalling: mechanisms for neurotrophic modulation of cell stress? J.  Neurosci. Res. 61, 237-243.  	10900070
	Dobrowsky, R. T., Werner, M. H., Castellino, A. M., Chao, M. V. and  Hannun, Y. A. (1994). Activation of the sphingomyelin cycle through the  low affinity neurotrophin receptor. Science 265, 1596-1599.  	8079174
	Dobrowsky, R. T., Jenkins, G. M. and Hannun, Y. A. (1995). Neurotrophins  induce sphingomyelin hydrolysis. J. Biol. Chem. 270, 22135-22142.  	NO_MATCH
	Dressler, K. A. and Kolesnick, R. N. (1990). Ceramide-1-Phosphate, a novel  phospholipid in human leukaemia (HL-60) cells. J. Biol. Chem. 265, 14917 14921.  	NO_MATCH
	Dudek, H., Datta, S. R., Franke, T. F., Birnbaum, M. J., Yao, R., Cooper,  G. M., Segal, R. A., Kaplan, D. R. and Greenberg, M. E. (1997).  Regulation of neuronal survival by the serine-threonine protein kinase Akt.  Science 275, 661-665.  	9005851
	Fekete, D. M., Hamburger, S. A., Waring, M. T., Riedl, A. E. and García,  L. F. (1997). Involvement of programmed cell death in morphogenesis of  the vertebrate inner ear. Development 124, 2451-2461.  	9199371
	Frade, J. M. (2000). Unschedule re-entry into the cell cycle induced by  NGF precedes cell death in nascent retinal neurones. J. Cell Sci. 113,  1139-1148.  	10704365
	Frade, J. M. and Barde, Y. A. (1998). Nerve growth factor: two receptors,  multiple functions. BioEssays 20, 137-145.  	9631659
	Frade, J. M., Rodríguez-Tebar, A. and Barde, Y. A. (1996). Induction of  cell death by endogenous nerve growth factor through p75. Nature 383, 166 168.  	8774880
	Frago, L. M., León, Y., de la Rosa, E. J., Gómez-Muñoz, A. and Varela Nieto, I. (1998). Nerve growth factor and ceramides modulate cell death in  the early developing inner ear. J. Cell Sci. 111, 549-556.  	9454729
	Frago, L. M., Camarero, G., Cañón, S., Pañeda, C., Sanz, C., León, Y.,  Giráldez, F. and Varela-Nieto, I. (2000). Role of diffusible and  transcription factors in inner ear development: implications in regeneration.  Histol. Histopathol. 15, 657-666.   	10809387
	Glücksmann, A. (1951). Cell death in normal vertebrate ontogeny. Biol. Rev.  26, 59-86.  	NO_MATCH
	Gómez del Pulgar, T., Velasco, G., Sánchez, C., Haro, A. and Guzmán, M.  (2002). De novo-synthesized ceramide is involved in cannabinoid-induced  apoptosis. Biochem. J. 363, 183-188.  	11903061
	González-Hoyuela, M., Barbas, J. A. and Rodríguez-Tébar, A. (2001). The  autoregulation of retinal ganglion cell number. Development 128, 117-124.  	11092817
	Grullich, C., Sullards, M. C., Fuks, Z., Merrill, A. H. and Kolesnick, R.  (2000). CD95(Fas/APO-1) signals ceramide generation independent of the  effector stage of apoptosis. J. Biol. Chem. 275, 8650-8656.  	10722705
	Gu, C., Cassaccia-Bonnefil, P., Srinivasan, A. and Chao, M. V. (1999).  Oligodendrocyte apoptosis mediated by caspase activation. J. Neurosci. 19,  3043-3049.  	10191321
	Hallbook, F., Ayer-Lelievre, C., Ebendal, T. and Persson, H. (1990).  Expression of nerve growth factor receptor mRNA during early development  Cell death and survival in the otic vesicle485  of the chicken embryo: emphasis on cranial ganglia. Development 108, 693 704.  	2167199
	Hamburger, V. and Hamilton, H. L. (1951). A series of normal stages in the  development of the chick embryo. J. Morphol. 88, 49-92.  	NO_MATCH
	Hartfield, P. J., Bilney, A. J. and Murray, A. W. (1998). Neurotrophic factors  prevent ceramide-induced apoptosis downstream of c-Jun N-terminal kinase  activation in PC-12 cells. J. Neurochem. 71, 161-169.  	9648862
	Hemond, S. G. and Morest, D. K. (1991). Ganglion formation from the otic  placode and the otic crest in the chick embryo: mitosis, migration, and the  basal lamina. Anat. Embryol. 184, 1-13.  	1928740
	Herget, T., Esdar, C., Oehrlein, S. A., Heinrich, M., Schütze, S., Maelicke,  A. and van Echten-Deckert, G. (2000). Production of ceramides causes  apoptosis during early neural differentiation in vitro. J. Biol. Chem. 275,  30344-30354.  	10862608
	Huber, L. J. and Chao, M. V. (1995). Mesenchymal and neuronal cell  expression of the p75 neurotrophin receptor gene occur by different  mechanisms. Dev. Biol. 167, 227-238.  	7851645
	Jacobson, M. D., Weil, M. and Raff, M. C. (1997). Programmed cell death  in animal development. Cell 88, 347-354.  	9039261
	Jiang, Y., Sakane, F., Kanoh, H. and Walsh, J. P. (2000). Selectivity of the  diacylglycerol kinase inhibitor 3-[2-(4-[bis-(4-fluorophenyl)methylene]-1 piperidinyl)ethyl]-2,3-dihydro-2-thioxo-4(1H) quinazolinone (R59949)  among diacylglycerol kinase subtypes. Biochem. Pharmacol. 59, 763-772.  	10718334
	Kaplan, D. R. and Miller, F. D. (2000). Neurotrophin signal transduction in  the nervous system. Curr. Opin. Neurobiol. 10, 381-391.  	10851172
	Kishikawa, K., Chalfant, C. E., Perry, D. K., Bielawska, A. and Hannun,  Y. A. (1999). Phosphatidic acid is a potent and selective inhibitor of protein  phosphatase 1 and an inhibitor of ceramide-mediated responses. J. Biol.  Chem. 274, 21335-21341.  	10409693
	Klesse, L. J. and Parada, L. F. (1999). Trks: Signal transduction and  intracellular pathways. Microsc. Res Tech. 45, 210-215.  	10383113
	Large, T. H., Weskamp, G., Helder, J. C., Radeke, M. J., Misko, T. P.,  Shooter, E. M. and Reichardt, L. F. (1989). Structure and developmental  expression of the Nerve Growth Factor receptor in the chicken central  nervous system. Neuron 2, 1123-1134  	2560385
	Lazebnik, Y. A., Kaufmann, S. H., Desnoyers, S., Poirier, G. G. and  Earnshaw, W. C. (1994). Cleavage of poly(ADP-ribose)polymerase by a  proteinase with properties like ICE. Nature 371, 346-347.  	8090205
	Lee, F. S., Kim, A. H., Khursigara, G. and Chao, M. V. (2001). The  uniqueness of being a neurotrophin receptor. Curr. Opin. Neurobiol. 11, 281 286.  	11399425
	León, Y., Sanz, C., Giráldez, F. and Varela-Nieto, I. (1998). Induction of  cell growth by insulin and insulin-like growth factor-I is associated with Jun  expression in the otic vesicle. J. Comp. Neurol. 398, 323-332.  	9714146
	León, Y., Sanz, C., Frago, L. M., Camarero, G., Cañón, S., Varela-Nieto,  I. and Giráldez, F. (1999). Involvement of Insulin-like growth factor-I  in inner ear organogenesis and regeneration. Horm. Metab. Res. 31,  126-132.  	10226792
	Liepinsh, E., Ilag, L. L., Otting, G. and Ibáñez, C. F. (1997). NMR structure  of the death domain of the p75. EMBO J. 16, 4999-5005.  	NO_MATCH
	Lievremont, J. P., Sciorati, C., Morandi, E., Paolucci, C., Bunone, G., de  lla Valle, G., Meldolesi, J. and Clementi, E. (1999). The p75(NTR) induced apoptotic program develops through a ceramide-caspase pathway  negatively regulated by nitric oxide. J. Biol. Chem. 274, 15466-15472.  	10336437
	Mizushima, N., Koike, R., Kohsaka, H., Kushi, Y., Handa, S., Yagita, H.  and Miyasaka, N. (1996). Ceramide induces apoptosis via CPP32  activation. FEBS Lett. 395, 267-271.  	8898109
	Mochizuki, T., Asai, A., Saito, N., Tanaka, S., Katagiri, H., Asano, T.,  Nakane, M., Tamura, A., Kuchini, Y., Kitanaka, C. and Kirino, T.  (2002). Akt protein kinase inhibits non-apoptotic programmed cell death  induced by ceramide. J. Biol. Chem. 277, 2790-2797.  	11706021
	Morita, Y., Perez, G. I., Paris, F., Miranda, S. R., Ehleiter, D., Haimovitz Friedman, A., Fuks, Z., Xie, Z., Reed, J. C., Schuchman, E. H. et al.  (2000). Oocyte apoptosis is suppressed by disruption of the acid  sphingomyelinase gene or by sphingosine-1-phosphate therapy. Nat. Med.  6, 1109-1114.  	11017141
	Oppenheim, R. M., Flavell, R. A., Vinsant, S., Prevette, D., Kuan, C. Y.  and Rakic, P. (2001). Programmed cell death of developing mammalian  neurons after genetic deletion of caspases. J. Neurosci. 21, 4752-4760.  	11425902
	Paradis, S. and Ruvkun, G. (1998). Caenorhabditis elegans Akt/PKB  transduces insulin receptor-like signals from AGE-1 PI3 kinase to the DAF 16 transcription factor. Genes Dev. 12, 2488-2498.  	9716402
	Peña, L.A., Fuks, Z. and Kolesnick, R. (1997). Stress-induced apoptosis and  the sphingomyelin pathway. Biochem. Pharmacol. 53, 615-621.  486 Journal of Cell Science 116 (3)  	9113079
	Raff, M. C. (1992). Social controls on cell survival and cell death. Nature 356,  397-400.  	1557121
	Raff, M. C., Barres, B. A., Burne, J. F., Coles, H. S., Ishizaki, Y. and  Jacobson, M. D. (1993). Programmed cell death and the control of cell  survival: lessons from the nervous system. Science 262, 695-700.   	8235590
	Roux, P. P., Bhakar, A. L., Kennedy, T. E. and Barker, P. A. (2001). The  p75 neurotrophin receptor activates Akt (Protein Kinase B) through a  phosphatidylinositol 3-kinase-dependent pathway. J. Biol. Chem. 276,  23097-23104.  	11312266
	Sanz, C., León, Y., Cañón, S., Alvarez, L., Giráldez, F. and Varela-Nieto,  I. (1999a). Pattern of expression of the Jun family of transcription factors  during the early development of the inner ear: implications in apoptosis. J.  Cell Sci. 112, 3967-3974.  	10547357
	Sanz, C., León, Y., Troppmair, J., Rapp, U. R. and Varela-Nieto, I. (1999b).  Strict regulation of c-Raf kinase levels is required for early organogenesis  of the vertebrate inner ear. Oncogene 18, 429-437.  	9927199
	Schecterson, L. C. and Bothwell, M. (1994). Neurotrophin and  neurotrophin receptor mRNA expression in developing inner ear. Hearing  Res. 73, 92-100.  	8157510
	Schneider, E. G. and Kennedy, E. P. (1973). Phosphorylation of ceramide by  diglyceride kinase preparations from Escherichia coli. J. Biol. Chem. 248,  3739-3741.  	4573983
	Schubert, K. M., Scheid, M. P. and Duronio, V. (2000). Ceramide inhibits  protein kinase B/Akt by promoting dephosphorylation of serine 473. J. Biol.  Chem. 275, 13330-13335.  	10788440
	Sugiura, M., Kono, K., Liu, H., Shimizugawa, T., Minekura, H., Spiegel,  S. and Kohama, T. (2002). Ceramide kinase, a novel lipid kinase.  Molecular cloning and functional characterization. J. Biol. Chem. 277,  23294-23300.  	11956206
	Sweeney, E. A., Inokuchi, J. and Igarashi, Y. (1998). Inhibition of  sphingolipid induced apoptosis by caspase inhibitors indicates that  sphingosine acts in an earlier part of the apoptotic pathway than ceramide.  FEBS Lett. 425, 61-65.  	9541007
	Teruel, T., Hernandez, R. and Lorenzo, M. (2001). Ceramide mediates  insulin resistance by tumor necrosis factor- ain brown adipocytes by  maintaining Akt in an inactive dephosphorylated state. Diabetes 50, 2563 2571.  	11679435
	Torres, M. and Giraldez, F. (1998). The development of the vertebrate inner  ear. Mech. Dev. 71, 5-21.  	9507049
	Vaux, D. L. and Korsmeyer, S. J. (1999). Cell death in development. Cell 22,  245-254.  	9988219
	Verdu, J., Buratovich, M. A., Wilder, E. L. and Birnbaum, M. J. (1999).  Cell-autonomous regulation of cell and organ growth in Drosophila by  Akt/PKB. Nat. Cell. Biol. 1, 500-506.  	10587646
	von Bartheld, C. S., Patterson, S. L., Heuer, J. G., Wheeler, E. F., Bothwell,  M. and Rubel, E. W. (1991). Expression of nerve growth factor receptors  in the developing inner ear of chick and rat. Development 113, 455-470.  	1664321
	von Schack, D., Casademunt, E., Schweigreiter, R., Meyer, M., Bibel, M.  and Dechant, G. (2001). Complete ablation of the neurotrophin receptor  p75NTR causes defects both in the nervous and the vascular system. Nat.  Neurosci. 4, 977-978.  	11559852
	Wilkinson, D. G. (1992). Whole mount in situ hybridisation of vertebrate  embryos. In In situ hybridisation, pp. 75-83. Oxford: IRL press.  	NO_MATCH
	Woods, K., Camacho-Hubner, C., Savage, M. and Clark, A. (1996).  Intrauterine growth retardation and postnatal growth failure associated with  deletion of the insulin-like growth factor I gene. N. Engl. J. Med. 335, 1363 1367.  	8857020
	Woods, K. A., Camacho-Hubner, C., Barter, D., Clark, A. J. and Savage, M.  O. (1997). Insulin-like growth factor I gene deletion causing intrauterine  growth retardation and severe short stature. Acta Paediatr. Suppl. 423, 39-45.  	9401537
	Wu, D. K. and Oh, S. H. (1996). Sensory organ generation in the chick inner  ear. J. Neurosci. 16, 6454-6462.  	8815924
	Yoon, S. O., Casaccia-Bonnefil, P., Carter, B. and Chao, M. V. (1998).  Competitive signaling between trkA and p75 nerve growth factor receptors  determines cell survival. J. Neurosci. 18, 3273-3281.  	9547236
	Zheng, W. H., Kar, S., Dore, S. and Quirion, R. (2000). Insulin-like growth  factor-1 (IGF-I): a neuroprotective trophic factor acting via the Akt kinase  pathway. J. Neural. Transm. Suppl. 60, 261-272.  	11205145
	Zundel, W. and Giaccia, A. (1998). Inhibition of the anti-apoptotic  PI(3)K/Akt/Bad pathway by stress. Genes Dev. 12, 1941-1946.  	9649498
453.full.pdf
	Baudino, T. A., Kraichely, D. M., Jefcoat, S. C., Jr, Winchester, S. K.,  Partridge, N. C. and MacDonald, P. N. (1998). Isolation and  characterization of a novel coactivator protein, NCoA-62, involved in  vitamin D-mediated transcription. J. Biol. Chem. 273, 16434-16441.  	9632709
	Boucher, P., Liu, P., Gotthardt, M., Hiesberger, T., Anderson, R. G. and  Herz, J. (2002). Platelet-derived growth factor mediates tyrosine  phosphorylation of the cytoplasmic domain of the low Density lipoprotein  receptor-related protein in caveolae. J. Biol. Chem. 277, 15507-15513.  	11854295
	Bunn, R. C., Jensen, M. A. and Reed, B. C. (1999). Protein interactions with  the glucose transporter binding protein GLUT1CBP that provide a link  between GLUT1 and the cytoskeleton. Mol. Biol. Cell 10, 819-832.  	10198040
	Christensen, E. I., Gliemann, J. and Moestrup, S. K. (1992). Renal tubule  gp330 is a calcium binding receptor for endocytic uptake of protein. J.  Histochem. Cytochem. 40, 1481-1490.  	1382088
	Das, A. K., Cohen, P. W. and Barford, D. (1998). The structure of the  tetratricopeptide repeats of protein phosphatase 5: implications for TPR mediated protein-protein interactions. EMBO J. 17, 1192-1199.  	9482716
	D’Arcangelo, G., Miao, G. G., Chen, S. C., Soares, H. D., Morgan, J. I.  and Curran, T. (1995). A protein related to extracellular matrix proteins  deleted in the mouse mutant reeler. Nature 374, 719-723  	7715726
	D’Arcangelo, G., Homayouni, R., Keshvara, L., Rice, D. S., Sheldon, M.  and Curran, T. (1999). Reelin is a ligand for lipoprotein receptors. Neuron  24, 471-479.  	10571240
	Fraker, P. J. and Speck, J. C. (1978). Protein and cell membrane iodinations  with a sparingly soluble chloroamide, 1,3,4,6-tetrachloro-3a,6a diphenylglycoluril. Biochem. Biophys. Res. Commun. 80, 849-857.  	637870
	Fu, X., McGrath, S., Pasillas, M., Nakazawa, S. and Kamps, M. P. (1999).  EB-1, a tyrosine kinase signal transduction gene, is transcriptionally  activated in the t(1;19) subset of pre-B ALL, which express oncoprotein  E2a-Pbx1. Oncogene 18, 4920-4929.  	10490826
	Garcia, C. K., Wilund, K., Arca, M., Zuliani, G., Fellin, R., Maioli, M.,  Calandra, S., Bertolini, S., Cossu, F., Grishin, N., Barnes, R., Cohen, J.  C. and Hobbs, H. H. (2002). Autosomal recessive hypercholesterolemia  caused by mutations in a putative LDL receptor adaptor protein. Science  292, 1394-1398.  	11326085
	Gotthardt, M., Trommsdorff, M., Nevitt, M. F., Shelton, J., Richardson,  J. A., Stockinger, W., Nimpf, J. and Herz, J. (2001). Interactions of the  low density lipoprotein receptor gene family with cytosolic adaptor and  scaffold proteins suggest diverse biological functions in cellular  communication and signal transduction. J. Biol. Chem. 275, 25616-25624.  	10827173
	Herz, J. and Bock, H. H. (2002). Lipoprotein receptors in the nervous system.  Annu. Rev. Biochem. 71, 405-434.  	12045102
	Herz, J. and Strickland, D. K. (2002). LRP: a multifunctional scavenger and  signaling receptor. J. Clin. Invest. 108, 779-784.  	11560943
	Hiesberger, T., Trommsdorff, M., Howell, B. W., Goffinet, A., Mumby, M.  C., Cooper, J. A. and Herz, J. (1999). Direct binding of Reelin to VLDL  receptor and ApoE receptor 2 induces tyrosine phosphorylation of disabled 1 and modulates tau phosphorylation. Neuron 24, 481-489.  	10571241
	Hilpert, J., Wellner, M., Thykjaer, T., Schlichting, U., Orntoft, T. F.,  Bachmann, S., Nykjaer, A. and Willnow, T. E. (2002). Expression  profiling confirms role of endocytic receptor megalin in renal vitamin D  metabolism. Kidney Int. (in press).  	12371967
	Jackson, F. R., Banfi, S., Guffanti, A. and Rossi, E. (1997). A novel zinc  finger-containing RNA-binding protein conserved from fruitflies to humans.  Genomics 41, 444-452.  	9169144
	Kester, H. A., Blanchetot, C., den Hertog, J., van der Saag, P. T. and van  der Burg, B. (1999). Transforming growth factor-beta-stimulated clone-22  is a member of a family of leucine zipper proteins that can homo- and  heterodimerize and has transcriptional repressor activity. J. Biol. Chem. 274,  27439-27447.  	10488076
	Kirchhausen, T., Bonifacino, J. S. and Riezman, H. (1997). Linking cargo  to vesicle formation: receptor tail interactions with coat proteins. Curr. Opin.  Cell Biol. 9, 488-495.  	9261055
	Lamb, J. R., Tugendreich, S. and Hieter, P. (1995). Tetratrico peptide repeat  interactions: to TPR or not to TPR? Trends Biochem. Sci. 20, 257-259.  	7667876
	Loukinova, E., Ranganathan, S., Kuznetsov, S., Gorlatova, N., Migliorini,  M. M., Loukinov, D., Ulery, P. G., Mikhailenko, I., Lawrence, D. A. and  Strickland, D. K. (2002). Platelet-derived growth factor (PDGF)-induced  tyrosine phosphorylation of the low density lipoprotein receptor-related  protein (LRP). Evidence for integrated co-receptor function between LRP  and the PDGF. J. Biol. Chem. 277, 15499-15506.  	11854294
	McCarthy, R. A., Barth, J. L., Chintalapudi, M. R., Knaak, C. and  Argraves, W. S. (2002). Megalin functions as an endocytic sonic hedgehog  receptor. J. Biol. Chem. 277, 25660-25667.  	11964399
	Muller, D., Ankermann, T., Stephani, U., Kirschstein, M., Szelestei, T.,  Luft, F. C. and Willnow, T. E. (2001). Holoprosencephaly and low  molecular weight proteinuria: the human homologue of murine megalin  deficiency. Am. J. Kidney. Dis. 37, 624-628.  	11228189
	Nykjaer, A., Dragun, D., Walther, D., Vorum, H., Jacobsen, C., Herz, J.,  Melsen, F., Christensen, E. I. and Willnow, T. E. (1999). An endocytic  pathway essential for renal uptake and activation of the steroid 25-(OH)  vitamin D3. Cell 96, 507-515.  	10052453
	Nykjaer, A., Fyfe, J. C., Kozyraki, R., Leheste, J. R., Jacobsen, C., Nielsen,  M. S., Verroust, P. J., Aminoff, M., de la Chapelle, A., Moestrup, S. K.  et al. (2001). Cubilin dysfunction causes abnormal metabolism of the steroid  hormone 25(OH) vitamin D(3). Proc. Natl. Acad. Sci. USA 98, 13895 13900.  	11717447
	Nykjaer, A. and Willnow, T. E. (2002). The low-density lipoprotein receptor  gene family: a cellular Swiss army knife? Trends. Cell Biol. 12, 273-280.  	12074887
	Oleinikov, A. V., Zhao, J. and Makker, S. P. (2001). Cytosolic adaptor  protein Dab2 is an intracellular ligand of endocytic receptor gp600/megalin.  Biochem. J. 347, 613-621.  	10769163
	Patrie, K. M., Drescher, A. J., Goyal, M., Wiggins, R. C. and Margolis, B.  (2001). The membrane-associated guanylate kinase protein MAGI-1 binds  megalin and is present in glomerular podocytes. J. Am. Soc. Nephrol. 12,  667-677.  	11274227
	Potocki, L., Chen, K. S. and Lupski, J. R. (1999). Subunit 3 of the COP9  signal transduction complex is conserved from plants to humans and maps  within the smith-magenis syndrome critical region in 17p11.2. Genomics  57, 180-182.  	10191102
	Rader, K., Orlando, R. A., Lou, X. and Farquhar, M. G. (2001).  Characterization of ANKRA, a novel ankyrin repeat protein that interacts  with the cytoplasmic domain of megalin. J. Am. Soc. Nephrol. 11, 2167 2178.  	11095640
	Sambrook, J. and Russel, D. W. (eds) (2001). Molecular Cloning. Cold  Spring Harbor, NJ: Cold Spring Harbor Laboratory Press.  	NO_MATCH
	Sheldon, M., Rice, D. S., D’Arcangelo, G., Yoneshima, H., Nakajima, K.,  Mikoshiba, K., Howell, B. W., Cooper, J. A., Goldowitz, D. and Curran,  T. (1997). Scrambler and yotari disrupt the disabled gene and produce a  reeler-like phenotype in mice. Nature 389, 730-733.  	9338784
	Shiratsuchi, T., Nishimori, H., Ichise, H., Nakamura, Y. and Tokino, T.  (1997). Cloning and characterization of BAI2 and BAI3, novel genes  homologous to brain-specific angiogenesis inhibitor 1 (BAI1). Cytogenet.  Cell. Genet. 79, 103-108.  	9533023
	Stockinger, W., Brandes, C., Fasching, D., Hermann, M., Gotthardt, M.,  Herz, J., Schneider, W. J. and Nimpf, J. (2002). The reelin receptor  ApoER2 recruits JNK-interacting proteins-1 and -2. J. Biol. Chem. 275,  25625-25632.  	NO_MATCH
	The RIKEN Genome Exploration Research Group (2001). Functional  annotation of a full-length mouse cDNA collection. Nature 409, 685-690.  	NO_MATCH
	Trommsdorff, M., Gotthardt, M., Hiesberger, T., Shelton, J., Stockinger,  W., Nimpf, J., Hammer, R. E., Richardson, J. A. and Herz, J. (1999). Reeler/Disabled-like disruption of neuronal migration in knockout mice  lacking the VLDL receptor and ApoE receptor 2. Cell 97, 689-701.  	NO_MATCH
	Weston, C. R. and Davis, R. J. (2002). The JNK signal transduction pathway.  Curr. Op. Genet. Dev. 12, 14-21.  	11790549
	Willnow, T. E., Hilpert, J., Armstrong, S. A., Rohlmann, A., Hammer,  R. E., Burns, D. K. and Herz, J. (1996). Defective forebrain development  in mice lacking gp330/ megalin. Proc. Natl. Acad. Sci. USA 93, 8460 8464.  	8710893
	Yasuda, J., Whitmarsh, A. J., Cavanagh, J., Sharma, M. and Davis, R. J.  (1999). The JIP group of mitogen-activated protein kinase scaffold proteins.  Mol. Cell. Biol. 19, 7245-7254.  	10490659
	Zhang, X. J., Staudinger, J. and Huganir, R. L. (1999). Clustering of AMPA  receptors by the synaptic PDZ domain-containing protein PICK1. Neuron  22, 179-187.  	10027300
	Zhang, C., Baudino, T. A., Dowd, D. R., Tokumaru, H., Wang, W. and  MacDonald, P. N. (2002). Ternary complexes and cooperative interplay  between NCoA-62/Ski-interacting protein and steroid receptor coactivators  in vitamin D receptor-mediated transcription. J. Biol. Chem. 276, 40614 40620.  	11514567
435.full.pdf
	Arai, A., Nosaka, Y., Kanda, E., Yamamoto, K., Miyasaka, N. and Miura,  O. (2001). Rap1 is activated by erythropoietin or interleukin-3 and is  involved in regulation of beta1 integrin-mediated hematopoietic cell  adhesion. J. Biol. Chem. 276, 10453-10462.  	11124936
	Asha, H., de Ruiter, N. D., Wang, M. G. and Hariharan, I. K. (1999). The  Rap1 GTPase functions as a regulator of morphogenesis in vivo. EMBO J.  18, 605-615.  	9927420
	Beglova, N., Blacklow, S. C., Takagi, J. and Springer, T. A. (2002).  Cysteine-rich module structure reveals a fulcrum for integrin rearrangement  upon activation. Nat. Struct. Biol. 9, 282-287.  	11896403
	Béranger, F., Goud, B., Tavitian, A. and de Gunzburg, J. (1991).  Association of the Ras-antagonistic Rap1/Krev-1 proteins with the Golgi  complex. Proc. Natl Acad. Sci. USA 88, 1606-1610.  	1900364
	Bertoni, A., Tadokoro, S., Eto, K., Pampori, N., Parise, L. V., White, G.  C. and Shattil, S. J. (2002). Relationships between Rap1b, affinity  modulation of integrin alpha IIbbeta 3, and the actin cytoskeleton. J. Biol.  Chem. 277, 25715-25721.  	11994301
	Bos, J. L., de Rooij, J. and Reedquist, K. A. (2001). Rap1 signalling:  adhering to new models. Nat. Rev. Mol. Cell Biol. 2, 369-377.  	11331911
	Braga, V. (2000). Epithelial cell shape: cadherins and small GTPases. Exp.  Cell Res. 261, 83-90.  	11082278
	Caron, E. and Hall, A. (1998). Identification of two distinct mechanisms of  phagocytosis controlled by different Rho GTPases. Science 282, 1717-1721.  	9831565
	Caron, E., Self, A. J. and Hall, A. (2000). The GTPase Rap1 controls  functional activation of macrophage integrin alphaMbeta2 by LPS and other  inflammatory mediators. Curr. Biol. 10, 974-978.  	10985384
	Chen, F., Barkett, M., Ram, K. T., Quintanilla, A. and Hariharan,  I. K. (1997). Biological characterization of Drosophila Rapgap1, a  GTPase activating protein for Rap1. Proc. Natl Acad. Sci. USA 94, 12485 12490.  	9356476
	Cook, S. J., Rubinfeld, B., Albert, I. and McCormick, F. (1993). RapV12  antagonizes Ras-dependent activation of ERK1 and ERK2 by LPA and EGF  in Rat-1 fibroblasts. EMBO J. 12, 3475-3485.  	8253074
	de Bruyn, K. M., Rangarajan, S., Reedquist, K. A., Figdor, C. G. and Bos,  J. L. (2002). The small GTPase Rap1 is required for Mn(2+)- and antibody induced LFA-1- and VLA-4-mediated cell adhesion. J. Biol. Chem. 277,  29468-29476.  	12171996
	Gao, X., Satoh, T., Liao, Y., Song, C., Hu, C. D., Kariya Ki, K. and  Kataoka, T. (2001). Identification and characterization of RA-GEF-2, a Rap  guanine nucleotide exchange factor that serves as a downstream target of  M-Ras. J. Biol. Chem. 276, 42219-42225.  	11524421
	Garin, J., Diez, R., Kieffer, S., Dermine, J. F., Duclos, S., Gagnon, E.,  Sadoul, R., Rondeau, C. and Desjardins, M. (2001). The phagosome  proteome: insight into phagosome functions. J. Cell Biol. 152, 165-180.  	11149929
	Gulli, M.-P. and Peter, M. (2001). Temporal and spatial regulation of Rho type guanine-nucleotide exchange factors: the yeast perspective. Genes Dev.  15, 365-379.  	11230144
	Haas, T. A. and Plow, E. F. (1997). Development of a structural model for  the cytoplasmic domain of an integrin. Protein Eng. 10, 1395-1405.  	9543001
	Hariharan, I. K., Carthew, R. W. and Rubin, G. M. (1991). The Drosophila  roughened mutation: activation of a rap homolog disrupts eye development  and interferes with cell determination. Cell 67, 717-722.  	1934069
	Harris, E. S., McIntyre, T. M., Prescott, S. M. and Zimmerman, G. A.  (2000). The leukocyte integrins. J. Biol. Chem. 275, 23409-23412.   	10801898
	Hughes, P. E. and Pfaff, M. (1998). Integrin affinity modulation. Trends Cell  Biol. 8, 359-364.  	9728397
	Hughes, P. E., Renshaw, M. W., Pfaff, M., Forsyth, J., Keivens, V. M.,  Schwartz, M. A. and Ginsberg, M. H. (1997). Suppression of integrin  activation: a novel function of a Ras/Raf-initiated MAP kinase pathway. Cell  88, 521-530.  	9038343
	Janoueix-Lerosey, I., Pasheva, E., de Tand, M. F., Tavitian, A. and de Gunzburg, J. (1998). Identification of a specific effector of the small GTP binding protein Rap2. Eur. J. Biochem. 252, 290-298.  	9523700
	Kang, P. J., Sanson, A., Lee, B. and Park, H. O. (2001). A GDP/GTP  exchange factor involved in linking a spatial landmark to cell polarity.  Science 292, 1376-1378.  	11313501
	Kang, R., Kae, H., Ip, H., Spiegelman, G. B. and Weeks, G. (2002).  Evidence for a role for the Dictyostelium Rap1 in cell viability and the  response to osmotic stress. J. Cell Sci. 115, 3675-3682.  	12186953
	Katagiri, K., Hattori, M., Minato, N., Irie, S., Takatsu, K. and Kinashi, T.  (2000). Rap1 is a potent activation signal for leukocyte function-associated  antigen 1 distinct from protein kinase C and phosphatidylinositol-3-OH  kinase. Mol. Cell. Biol. 20, 1956-1969.  	10688643
	Katagiri, K., Hattori, M., Minato, N. and Kinashi, T. (2002). Rap1  functions as a key regulator of T-cell and antigen-presenting cell interactions  and modulates T-cell responses. Mol. Cell. Biol. 22, 1001-1015.  	11809793
	Kitayama, H., Sugimoto, Y., Matsuzaki, T., Ikawa, Y. and Noda, M. (1989).  A ras-related gene with transformation suppressor activity. Cell 56, 77-84.  	2642744
	Klinger, M., Kudlacek, O., Seidel, M. G., Freissmuth, M. and Sexl, V.  (2002). MAP kinase stimulation by cAMP does not require RAP1 but SRC  family kinases. J. Biol. Chem. 277, 32490-32497.  	12082090
	Knox, A. L. and Brown, N. H. (2002). Rap1 GTPase regulation of adherens  junction positioning and cell adhesion. Science 295, 1285-1288.  	11847339
	Kurachi, H., Wada, Y., Tsukamoto, N., Maeda, M., Kubota, H., Hattori,  M., Iwai, K. and Minato, N. (1997). Human SPA-1 gene product  selectively expressed in lymphoid tissues is a specific GTPase-activating  protein for Rap1 and Rap2. Segregate expression profiles from a rap1GAP  gene product. J. Biol. Chem. 272, 28081-28088.  	9346962
	Laroche-Joubert, N., Marsy, S., Michelet, S., Imbert-Teboul, M. and  Doucet, A. (2002). Protein kinase A-independent activation of ERK and  H,K-ATPase by cAMP in native kidney cells: role of Epac I. J. Biol. Chem.  277, 18598-18604.  	11897793
	Lou, L., Urbani, J., Ribeiro-Neto, F. and Altschuler, D. L. (2002). cAMP  inhibition of Akt is mediated by activated and phosphorylated Rap1b. J.  Biol. Chem. 277, 32799-32806.  	12089143
	Lova, P., Paganini, S., Sinigaglia, F., Balduini, C. and Torti, M. (2002). A  Gi-dependent pathway is required for activation of the small GTPase Rap1B  in human platelets. J. Biol. Chem. 277, 12009-12015.  	11815620
	Magie, C. R., Pinto-Santini, D. and Parkhurst, S. M. (2002). Rho1 interacts  with p120(ctn) and alpha-catenin, and regulates cadherin-based adherens  junction components in Drosophila. Development 129, 3771-3782.  	12135916
	McLeod, S. J., Li, A. H., Lee, R. L., Burgess, A. E. and Gold, M. R. (2002).  The Rap GTPases regulate B cell migration toward the chemokine stromal  cell-derived factor-1 (CXCL12): potential role for Rap2 in promoting B cell  migration. J. Immunol. 169, 1365-1371.  	12133960
	Mochizuki, N., Yamashita, S., Kurokawa, K., Ohba, Y., Nagai, T.,  Miyawaki, A. and Matsuda, M. (2001). Spatio-temporal images of growth factor-induced activation of Ras and Rap1. Nature 411, 1065-1068.  	11429608
	Ohba, Y., Ikuta, K., Ogura, A., Matsuda, J., Mochizuki, N., Nagashima,  K., Kurokawa, K., Mayer, B. J., Maki, K., Miyazaki, J. and Matsuda,  M. (2001). Requirement for C3G-dependent Rap1 activation for cell  adhesion and embryogenesis. EMBO J. 20, 3333-3341.  	11432821
	Pak, D. T., Yang, S., Rudolph-Correia, S., Kim, E. and Sheng, M. (2001).  Regulation of dendritic spine morphology by SPAR, a PSD-95-associated  RapGAP. Neuron 31, 289-303.  	11502259
	Palsson, E. M., Popoff, M., Thelestam, M. and O’Neill, L. A. (2000).  Divergent roles for Ras and Rap in the activation of p38 mitogen-activated  protein kinase by interleukin-1. J. Biol. Chem. 275, 7818-7825.  	10713096
	Park, H. O., Kang, P. J. and Rachfal, A. W. (2002). Localization of the  Rsr1/Bud1 GTPase involved in selection of a proper growth site in yeast. J.  Biol. Chem. 277, 26721-26724.  	12058023
	Pizon, V., Chardin, P., Lerosey, I., Olofsson, B. and Tavitian, A. (1988).  Human cDNAs rap1 and rap2 homologous to the Drosophila gene Dras3  encode proteins closely related to ras in the ‘effector’ region. Oncogene 3,  201-204.  	3045729
	Pizon, V., Desjardins, M., Bucci, C., Parton, R. G. and Zerial, M. (1994).  Association of Rap1a and Rap1b proteins with late endocytic/phagocytic  compartments and Rap2a with the Golgi complex. J. Cell Sci. 107, 1661 1670.  	7962206
	Polakis, P. G., Rubinfeld, B., Evans, T. and McCormick, F. (1991).  Purification of a plasma membrane-associated GTPase-activating protein  specific for rap1/Krev-1 from HL60 cells. Proc. Natl Acad. Sci. USA 88,  239-243.  	1846040
	Prevost, N., Woulfe, D., Tanaka, T. and Brass, L. F. (2002). Interactions  between Eph kinases and ephrins provide a mechanism to support platelet  aggregation once cell-to-cell contact has occurred. Proc. Natl. Acad. Sci.  USA 99, 9219-9224.  	12084815
	Rebstein, P. J., Cardelli, J., Weeks, G. and Spiegelman, G. B. (1997).  Mutational analysis of the role of Rap1 in regulating cytoskeletal function  in Dictyostelium. Exp. Cell Res. 231, 276-283.  	9087168
	Reedquist, K. A., Ross, E., Koop, E. A., Wolthuis, R. M., Zwartkruis, F.  J., van Kooyk, Y., Salmon, M., Buckley, C. D. and Bos, J. L. (2000). The  small GTPase, Rap1, mediates CD31-induced integrin adhesion. J. Cell  Biol. 148, 1151-1158.  	10725328
	Reuther, G. W. and Der, C. J. (2000). The Ras branch of small GTPases: Ras  family members don’t fall far from the tree. Curr. Opin. Cell Biol. 12, 157 165.  	10712923
	Ribeiro-Neto, F., Urbani, J., Lemee, N., Lou, L. and Altschuler, D. L.  (2002). On the mitogenic properties of Rap1b: cAMP-induced G(1)/S entry  requires activated and phosphorylated Rap1b. Proc. Natl Acad. Sci. USA 99,  5418-5423.  	11959997
	Schmidt, A., Caron, E. and Hall, A. (2001). Lipopolysaccharide-induced  activation of beta2-integrin function in macrophages requires Irak kinase  activity, p38 mitogen-activated protein kinase, and the Rap1 GTPase. Mol.  Cell. Biol. 21, 438-448.  	11134332
	Schmitt, J. M. and Stork, P. J. (2001). Cyclic AMP-mediated inhibition of  cell growth requires the small G protein Rap1. Mol. Cell. Biol. 21, 3671 3683.  	11340161
	Schoenwaelder, S. M. and Burridge, K. (1999). Bidirectional signaling  between the cytoskeleton and integrins. Curr. Opin. Cell Biol. 11, 274-286.  	10209151
	Seastone, D. J., Zhang, L., Buczynski, G., Rebstein, P., Weeks, G.,  Spiegelman, G. and Cardelli, J. (1999). The small Mr Ras-like GTPase  Rap1 and the phospholipase C pathway act to regulate phagocytosis in  Dictyostelium discoideum. Mol. Biol. Cell 10, 393-406.  	9950684
	Sebzda, E., Bracke, M., Tugal, T., Hogg, N. and Cantrell, D. A. (2002).  Rap1A positively regulates T cells via integrin activation rather than  inhibiting lymphocyte signaling. Nat. Immunol. 3, 251-258.  	11836528
	Self, A. J., Caron, E., Paterson, H. F. and Hall, A. (2001). Analysis of R Ras signalling pathways. J. Cell Sci. 114, 1357-1366.  	11257001
	Suga, K., Katagiri, K., Kinashi, T., Harazaki, M., Iizuka, T., Hattori, M.  and Minato, N. (2001). CD98 induces LFA-1-mediated cell adhesion in  lymphoid cells via activation of Rap1. FEBS Lett. 489, 249-253.  	11165259
	Takai, Y., Sasaki, T. and Matozaki, T. (2001). Small GTP-binding proteins.  Physiol. Rev. 81, 153-208.   	11152757
	Tsukamoto, N., Hattori, M., Yang, H., Bos, J. L. and Minato, N. (1999).  Rap1 GTPase-activating protein SPA-1 negatively regulates cell adhesion.  J. Biol. Chem. 274, 18463-18469.  	10373454
	van den Berghe, N., Cool, R. H., Horn, G. and Wittinghofer, A. (1997).  Biochemical characterization of C3G: an exchange factor that discriminates  between Rap1 and Rap2 and is not inhibited by Rap1A(S17N). Oncogene  15, 845-850.  van Kooyk, Y. and Figdor, C. G. (2000). Avidity regulation of integrins: the  driving force in leukocyte adhesion. Curr. Opin. Cell Biol. 12, 542-547.  	9266971
	Vetter, I. R., Linnemann, T., Wohlgemuth, S., Geyer, M., Kalbitzer, H. R.,  Herrmann, C. and Wittinghofer, A. (1999). Structural and biochemical  analysis of Ras-effector signaling via RalGDS. FEBS Lett. 451, 175-180.  	10371160
	Vinogradova, O., Velyvis, A., Velyviene, A., Hu, B., Haas, T., Plow, E. and  Qin, J. (2002). A structural mechanism of integrin alpha(IIb)beta(3) “inside out” activation as regulated by its cytoplasmic face. Cell 110, 587-597.  	12230976
	Woulfe, D., Jiang, H., Mortensen, R., Yang, J. and Brass, L. F. (2002).  Activation of Rap1B by G(i) family members in platelets. J. Biol. Chem.  277, 23382-23390.  	11970953
	Xiong, J. P., Stehle, T., Diefenbach, B., Zhang, R., Dunker, R., Scott, D. L.,  Joachimiak, A., Goodman, S. L. and Arnaout, M. A. (2001). Crystal  structure of the extracellular segment of integrin alpha Vbeta3. Science 294,  339-345.  	11546839
	Zhang, Z., Vuori, K., Wang, H., Reed, J. C. and Ruoslahti, E. (1996).  Integrin activation by R-ras. Cell 85, 61-69.  	8620538
	Zhu, J., Qin, Y., Zhao, M., van Aelst, L. and Malinow, R. (2002). Ras and  Rap control AMPA receptor trafficking during synaptic plasticity. Cell 110,  443-455.  	12202034
441.full.pdf
	Barbaux, S., Niaudet, P., Gubler, M. C., Grunfeld, J. P., Jaubert, F.,  Kuttenn, F., Fekete, C. N., Souleyreau-Therville, N., Thibaud, E.,  Fellous, M. and McElreavey, K. (1997). Donor splice-site mutations in  WT1 are responsible for Frasier syndrome. Nat. Genet. 17, 467-470.   	9398852
	Bergstrom, D. E., Young, M., Albrecht, K. H. and Eicher, E. M. (2000).  Related function of mouse SOX3, SOX9, and SRY HMG domains assayed  by male sex determination. Genesis 28, 111-124.   	11105052
	Bowles, J., Cooper, L., Berkman, J. and Koopman, P. (1999). Sry requires  a CAG repeat domain for male sex determination in Mus musculus. Nat.  Genet. 22, 405-408.  	10431249
	Clarkson, M. J. and Harley, V. R. (2002). Sex with two SOX on: SRY and  SOX9 in testis development. Trends Endocrinol. Metab. 13, 106-111.   	11893523
	Collignon, J., Sockanathan, S., Hacker, A., Cohen-Tannoudji, M., Norris,  D., Rastan, S., Stevanovic, M., Goodfellow, P. N. and Lovell-Badge, R.  (1996). A comparison of the properties of Sox-3 with Sry and two related  genes, Sox-1 and Sox-2. Development 122, 509-520.   	8625802
	Davies, R. C., Calvio, C., Bratt, E., Larsson, S. H., Lamond, A. I. and  Hastie, N. D. (1998). WT1 interacts with the splicing factor U2AF65 in an  isoform-dependent manner and can be incorporated into spliceosomes.  Genes Dev. 12, 3217-3225.  	9784496
	Ferrari, S., Harley, V. R., Pontiggia, A., Goodfellow, P. N., Lovell-Badge,  R. and Bianchi, M. E. (1992). SRY, like HMG1, recognizes sharp angles  in DNA. EMBO J. 11, 4497-4506.   	1425584
	Hammes, A., Guo, J.-K., Lutsch, G., Leheste, J.-R., Landrock, D., Ziegler,  U., Gubler, M.-C. and Schedl, A. (2001). Two splice variants of the Wilms’  Tumor 1 gene have distinct functions during sex determination and nephron  formation. Cell 106, 319-329.   	11509181
	Haqq, C. M., King, C.-Y., Ukiyama, E., Falsafi, S., Haqq, T. N., Donahoe,  P. K. and Weiss, M. A. (1994). Molecular basis of mammalian sexual  determination: activation of Müllerian inhibiting substance gene expression  by SRY. Science 266, 1494-1500.  	7985018
	Harley, V. R., Jackson, D. I., Hextall, P. J., Hawkins, J. R., Berkovitz, G.  D., Sockanathan, S., Lovell-Badge, R. and Goodfellow, P. N. (1992). DNA binding activity of recombinant SRY from normal males and XY  females. Science 255, 453-456.  	NO_MATCH
	Harley, V. R., Lovell-Badge, R. and Goodfellow, P. N. (1994). Definition of  a consensus DNA binding site for SRY. Nucleic Acids Res. 22, 1500-1501.   	8190643
	Kamachi, Y., Uchikawa, M. and Kondoh, H. (2000). Pairing SOX off with  partners in the regulation of embryonic development. Trends Genet. 16, 182 187.   	10729834
	Larsson, S. H., Charlieu, J.-P., Miyagawa, K., Engelkamp, D.,  Rassoulzadegan, M., Ross, A., Cuzin, F., van Heyningen, V. and Hastie,  N. D. (1995). Subnuclear localization of WT1 in splicing or transcription  factor domains is regulated by alternative splicing. Cell 81, 391-401.   	7736591
	Little, N. A., Hastie, N. D. and Davies, R. C. (2000). Identification of WTAP,  a novel Wilms’ tumour 1-associating protein. Hum. Mol. Genet. 9, 2231 2239.   	11001926
	Marin, I. and Baker, B. S. (1998). The evolutionary dynamics of sex  determination. Science 281, 1990-1994.   	9748152
	McElreavey, K., Vilain, E., Abbas, N., Herskowitz, I. and Fellous, M.  (1993). A regulatory cascade hypothesis for mammalian sex determination:  SRY represses a negative regulator of male development. Proc. Natl. Acad.  Sci. USA 90, 3368-3372.  	8475082
	Misteli, T. (2000). Cell biology of transcription and pre-mRNA splicing:  nuclear architecture meets nuclear function. J. Cell Sci. 113, 1841-1849.   	10806095
	Ohe, K., Lalli, E. and Sassone-Corsi, P. (2002). A direct role of SRY and  SOX proteins in pre-mRNA splicing. Proc. Natl. Acad. Sci. USA 99, 1146 1151.  	11818535
	Ottolenghi, C. and McElreavey, K. (2000). Deletions of 9p and the quest for  a conserved mechanism of sex determination. Mol. Genet. Metab. 71, 397 404.   	11001833
	Pailhoux, E., Vigier, B., Chaffaux, S., Servel, N., Taourit, S., Furet, J. P.,  Fellous, M., Grosclaude, F., Cribiu, E. P., Cotinot, C. and Vaiman, D.  (2001). A 11.7-kb deletion triggers intersexuality and polledness in goats.  Nat. Genet. 29, 453-458.  	11726932
	Pontiggia, A., Rimini, R., Harley, V. R., Goodfellow, P. N., Lovell-Badge,  R. and Bianchi, M. E. (1994). Sex-reversing mutations affect the  architecture of SRY-DNA complexes. EMBO J. 13, 6115-6127.  	7813448
	Raymond, C. S., Shamu, C. E., Shen, M. M., Seifert, K. J., Hirsch, B.,  Hodgkin, J. and Zarkower, D. (1998). Evidence for evolutionary  conservation of sex-determining genes. Nature 391, 691-695.  	9490411
	Raymond, C. S., Murphy, M. W., O’Sullivan, M. G., Bardwell, V. J. and  Zarkower, D. (2000). Dmrt1, a gene related to worm and fly sexual  regulators, is required for mammalian testis differentiation. Genes Dev. 14,  2587-2595.  	11040213
	Schütt, C. and Nöthiger, R. (2000). Structure, function and evolution of sex determining systems in Dipteran insects. Development 127, 667-677.   	10648226
	Sinclair, A. H., Berta, P., Palmer, M. S., Hawkins, J. R., Griffiths, B. L.,  Smith, M. J., Foster, J. W., Frischauf, A. M., Lovell-Badge, R. and  Goodfellow, P. N. (1990). A gene from the human sex-determining region  encodes a protein with homology to a conserved DNA-binding motif. Nature  346, 240-244.  	1695712
	Staley, J. P. and Guthrie, C. (1998). Mechanical devices of the spliceosome:  motors, clocks, springs, and things. Cell 92, 315-326.   	9476892
	Steitz, J. A. (1992). Splicing takes a Holliday. Science 257, 888-889.   	1386941
	Swain, A. and Lovell-Badge, R. (1999). Mamalian sex determination: a  molecular drama. Genes Dev. 13, 755-767.  	10197976
	Trimmer, E. E., Zamble, D. B., Lippard, S. J. and Essigmann, J. M. (1998).  Human testis-determining factor SRY binds to the major DNA adduct of  cisplatin and a putative target sequence with comparable affinities.  Biochemistry 37, 352-362.   	9425057
	Vaiman, D. and Pailhoux, E. (2000). Mammalian sex reversal and  intersexuality: deciphering the sex-determination cascade. Trends Genet. 16,  488-494.   	11074290
	Vainio, S., Heikkila, M., Kispert, A., Chin, N. and McMahon, A. P. (1999).  Female development in mammals is regulated by Wnt-4 signalling. Nature  397, 405-409.  	9989404
	Veretnik, S. and Gribskov, M. (1999). RNA binding domain of HDV antigen  is homologous to the HMG box of SRY. Arch. Virol. 144, 1139-1158.   	10446649
	Wegner, M. (1999). From head to toes: the multiple facets of Sox proteins.  Nucleic Acids Res. 27, 1409-1420.   	10037800
	Wilkins, A. S. (1995). Moving up the hierarchy: a hypothesis on the evolution  of a genetic sex determination pathway. BioEssays 17, 71-77.   	7702596
	Zarkower, D. (2001). Establishing sexual dimorphism: conservation amidst  diversity? Nat. Rev. Genet. 2, 175-185.  	11256069
	Zhou, Z., Licklider, L. J., Gygl, S. P. and Reed, R. (2002). Comprehensive  proteomic analysis of the human spliceosome. Nature 419, 182-185.   	12226669
pdf_40390.pdf
12149567.pdf
	1. Cogan DG, Toussaint D, Kuwabara T. (1961) Retinal vascu lar patterns. IV. Diabetic retinopathy. Arch. Ophthalmol. 66:  366–378.  	13694291
	2. Yamagishi S, Kobayashi K, Yamamoto H. (1993) Vascular  pericytes not only regulate growth, but also preserve  prostacyclin-producing ability and protect against lipid   peroxide-induced injury of co-cultured endothelial cells.  Biochem. Biophys. Res. Commun. 190: 418–425.  	8427585
	3. Yamagishi S, Hsu CC, Kobayashi K, Yamamoto H. (1993) En dothelin 1 mediates endothelial cell-dependent proliferation  of vascular pericytes. Biochem. Biophys. Res. Commun. 191:  840–846.  	8466522
	4. Podestá F, Romeo G, Liu WH, et al. (2000) Bax is increased  in the retina of diabetic subjects and is associated with peri cyte apoptosis in vivo and in vitro. Am. J. Pathol. 156: 1025–  1032.  	10702418
	5. Diabetes Control and Complications Trial Research Group.  (1993) The effects of intensive treatment of diabetes on the  development and progression of long-term complications in  insulin-dependent diabetes mellitus. N. Engl. J. Med. 329:  977–986.  	NO_MATCH
	6. United Kingdom Prospective Diabetes Study Group (UKPDS).  (1998) Intensive blood-glucose control with sulfonylureas or  insulin compared with conventional treatment and risk of  complications in patients with type 2 diabetes (UKPDS33).  Lancet 352: 837–853.  	NO_MATCH
	7. Heart Outcomes Prevention Evaluation (HOPE) Study. (2000)  Effects of ramipril on cardiovascular and microvascular  outcomes in people with diabetes mellitus: results of the  HOPE study and MICRO-HOPE substudy. Lancet 355:  253–259.  	NO_MATCH
	8. Orchard TJ, Kuller LH, Forrest KYZ, Becker DJ. (2001) Lipid  and blood pressure treatment goals for type 1 diabetes.  Diabetes Care 24: 1053–1059.  	NO_MATCH
	9. Shimabukuro M, Zhou YT, Levi M, Unger RH. (1998) Fatty  acid-induced  cell apoptosis: a link between obesity and  diabetes. Proc. Natl. Acad. Sci. U.S.A. 95: 2498–2502.  	9482914
	10. Bjorntorp P. (1994) Fatty acids, hyperinsulinemia and insulin  resistance: which comes first? Curr. Opin. Lipidol. 5: 166–174.  	7952910
	11. Inoguchi T, Li P, Umeda F, et al. (2000) High glucose level  and free fatty acid stimulate reactive oxygen species produc tion through protein kinase C-dependent activation of  NAD(P)H oxidase in cultured vascular cells. Diabetes 49:  1939–1945.  	11078463
	12. Yamagishi S, Hsu CC, Taniguchi M, et al. (1995) Receptor mediated toxicity to pericytes of advanced glycosylation   end products: a possible mechanism of pericyte loss in dia betic microangiopathy. Biochem. Biophys. Res. Commun. 213:  681–687.  	7646524
	13. Yamagishi S, Amano S, Inagaki Y, et al. (2002) Advanced gly cation end products-induced apoptosis and overexpression of  vascular endothelial growth factor in bovine retinal pericytes.  Biochem. Biophys. Res. Commun. 290: 973–978.  	11798169
	14. Yamagishi S, Fujimori H, Yonekura H, Yamamoto Y, Ya mamoto H. (1998) Advanced glycation endproducts inhibit  prostacyclin production and induce plasminogen activator  inhibitor-1 in human microvascular endothelial cells. Dia betologia 41: 1435–1441.  	9867210
	15. Yamagishi S, Yonekura H, Yamamoto Y, et al. (1999) Vascular  endothelial growth factor acts as a pericyte mitogen under hy poxic conditions. Lab. Invest. 79: 501–509.  	10212003
	16. Yamagishi S, Edelstein D, Du XL, Kaneda Y, Guzman M,  Brownlee M. (2001) Leptin induces mitochondrial superox ide production and monocyte chemoattractant protein-1  expression in aortic endothelial cells by increasing fatty acid  oxidation via protein kinase A. J. Biol. Chem. 276: 25096–  25100.  	11342529
	17. Yamagishi S, Yamamoto Y, Harada S, Hsu CC, Yamamoto H.  (1996) Advanced glycosylation end products stimulate the  growth but inhibit the prostacyclin-producing ability of en dothelial cells through interactions with their receptors. FEBS  Lett. 384: 103–106.  	8797813
	18. Yamagishi S, Yonekura H, Yamamoto Y, et al. (1997) Ad vanced glycation end products-driven angiogenesis in vitro.  Induction of the growth and tube formation of human mi crovascular endothelial cells through autocrine vascular en dothelial growth factor. J. Biol. Chem. 272: 8723–8730.  	9079706
	19. Yamagishi S, Kawakami T, Fujimori H, et al. (1999) Insulin  stimulates the growth and tube formation of human mi crovascular endothelial cells through autocrine vascular en dothelial growth factor. Microvasc. Res. 57: 329–339.  	10329259
	20. Yamagishi S, Fujimori H, Yonekura H, Tanaka N, Yamamoto H.  (1999) Advanced glycation endproducts accelerate calcification  in microvascular pericytes. Biochem. Biophys. Res. Commun. 258:  353–357.  	10329391
	21. Nomura M, Yamagishi S, Harada S, et al. (1995) Possible par ticipation of autocrine and paracrine vascular endothelial  growth factors in hypoxia-induced proliferation of endothe lial cells and pericytes. J. Biol. Chem. 270: 28316–28324.  	7499331
	22. Takeuchi M, Bucala R, Suzuki T, et al. (2000) Neurotoxicity of  advanced glycation end-products for cultured cortical neu rons. J. Neuropathol. Exp. Neurol. 59: 1094–1105.  	11138929
	23. Schwartzman RA, Cidlowski JA. (1993) Apoptosis: the bio chemistry and molecular biology of programmed cell death.  Endocrine Rev. 14: 133–151.  	8325248
	24. Listenberger LL, Ory DS, Schaffer JE. (2001) Palmitate induced apoptosis can occur through a ceramide-independent  pathway. J. Biol. Chem. 276: 14890–14895.  	11278654
	25. Chaturvedi N, Songini M, Sjoelie AK, et al. (2001) Markers  of insulin resistance are strong risk factors for retinopathy in cidence in type 1 diabetes. Diabetes Care 24: 284–289.  	11213880
	26. Tanaka N, Yonekura H, Yamagishi S, Fujimori H, Yamamoto  Y, Yamamoto H. (2000) The receptor for advanced glycation  end products is induced by the glycation products themselves  and tumor necrosis factor- through nuclear factor-B, and by  estradiol through Sp-1 in human vascular endothelial cells.   J. Biol. Chem. 275: 25781–25790.  	10829018
	27. Yan SD, Schmidt AM, Anderson GM, et al. (1994) Enhanced  cellular oxidant stress by the interaction of advanced glyca tion end products with their receptors/binding proteins.   J. Biol. Chem. 269: 9889–9897.  	8144582
v057p00752.pdf
	1 von Mutius E, Schwartz J, Neas LM, et al.  Relation of body mass index to asthma and  atopy in children: the National Health and  Nutrition Examination Study III. Thorax  	11641506
1479.2.full.pdf
	1. Aubert RE, Herman WH, Waters J, Moore  W, Sutton D, Peterson BL, Bailey CM, Ko plan JP: Nurse case management to im prove glycemic control in diabetic  patients in a Health Maintenance Organi zation. Ann Intern Med 129:605–612, 1998  	9786807
	2. Jaber LA, Halapy H, Fernet M, Tummala palli S, Diwakaran H: Evaluation of a phar maceutical care model on diabetes manage ment. Ann Pharmacother 30:238–243, 1996  	8833557
	3. Coast-Senior EA, Kroner BA, Kelley CL,  Trilli LE: Management of patients with  type 2 diabetes mellitus by pharmacists in  primary care clinics. Ann Pharmacother  32:636–641, 1998  	9640480
	4. Ho M, Marger M, Beart J, Yip I, Shekelle P:  Is the quality of diabetes care better in a  diabetes clinic or in a general medicine  clinic? Diabetes Care 20:472–475, 1997  	9096962
1464.full.pdf
	1. Cavaghan MK, Ehrmann DA, Byrne MM,  Polonsky KS: Treatment with the oral an tidiabetic agent troglitazone improves  -cell responses to glucose in subjects  with impaired glucose tolerance. J Clin In vest 100:530–537, 1997  	9239399
	2. Ehrmann DA, Schneider DJ, Sobel BE,  Cavaghan MK, Imperial J, Rosenfield RL,  Polonsky KS: Troglitazone improves de fects in insulin action, insulin secretion,  ovarian steroidogenesis, and fibrinolysis  in women with polycystic ovary syn drome. J Clin Endocrinol Metab 82:2108–  2116, 1997  	9215280
	3. Buchanan TA, Xiang AH, Peters RK, Kjos  SL, marroquin A, Goico J, Ochoa C, Tan  S, Azen SP: Protection from type 2 diabe tes persists in the TRIPOD cohort eight  months after stopping troglitazone  (Abstract). Diabetes 50 (Suppl. 2):A81,  2001  	NO_MATCH
	4. Sakuraba H, Mizukami H, Yagihashi N,  Wada R, Hanyu C, Yagihashi S: Reduced  beta-cell mass and expression of oxidative  stress-related DNA damage in the islet of  Japanese type II diabetic patients. Diabe tologia 45:85–96, 2002  	11845227
	5. Finegood DT, McArthur MD, Kojwang D,  Thomas MJ, Topp BG, Leonard T, Buck ingham RE: Beta-cell mass dynamics in  Zucker diabetic fatty rats: rosiglitazone  prevents the rise in net cell death. Diabetes  50:1021–1029, 2001  	11334404
	6. Zulewski H, Abraham EJ, Gerlach MJ,  Daniel PB, Moritz W, Muller B, Vallejo M,  Thomas MK, Habener JF: Multipotential  nestin-positive stem cells isolated from  adult pancreatic islets differentiate ex vivo  into pancreatic endocrine, exocrine, and  hepatic phenotypes. Diabetes 50:521–  533, 2001  	11246871
	7. Duez H, Fruchart JC, Staels B: PPRAs in  inflammation, atherosclerosis and throm bosis. J Cardiovasc Risk 8:187–194, 2001  	11550996
	8. Li AC, Brown KK, Silvestre MJ, Willson  TM, Palinski W, Glass CK: Peroxisome  proliferator-activated receptor gamma li gands inhibit development of atheroscle rosis in LDL receptor-deficient mice J Clin  Invest 106:523–531, 2000  	10953027
	9. Mokdad AH, Serdula MK, Dietz WH,  Bowman BA, Marks JS, Koplan JP: The  continuing epidemic of obesity in the  United States. JAMA 284:1650–1651,  2000  	11015792
	10. Schiffman SS, Graham BG, Sattely-Miller  EA, Peterson-Dancy M: Elevated and sus tained desire for sweet taste in African Americans: a potential factor in the  development of obesity. Nutrition 16:  886–893, 2000  	11054593
	11. Woods SC, Seeley RJ: Adiposity signals  and the control of energy homeostasis.  Nutrition 16:894–902, 2000  	11054594
	12. Mokdad AH, Ford ES, Bowman BA, Nel son DE, Engelgau MM, Vinicor F, Marks  JS: Diabetes trends in the U.S.: 1990–  1998. Diabetes Care 23:1278–1283, 2000  	NO_MATCH
	13. Carey DG, Jenkins AB, Campbell LV,  Freund J, Chisholm DJ: Abdominal fat  and insulin resistance in normal and over weight women: direct measurements re veal a strong relationship in subjects at  both low and high risk of NIDDM. Diabe tes 45:633–638, 1996  	8621015
	14. Pan XR, Li GW, Hu YH, Wang JX, Yang  WY, An ZX, Hu ZX, Lin J, Xiao JZ, Cao  HB, Liu PA, Jiang XG, Jiang YY, Wang JP,  Zheng H, Zhang H, Bennett PH, Howard  BV: Effects of diet and exercise in prevent ing NIDDM in people with impaired glu cose tolerance. The Da Qing IGT and  Diabetes Study. Diabetes Care. 1997;20:  537–544, 1997  	9096977
	15. Tuomilehto J, Lindstrom J, Eriksson JG,  Valle TT, Hamalainen H, Ilanne-Parikka  P, Keinanen-Kiukaanniemi S, Laakso M,  Louheranta A, Rastas M, Salminen V,  Uusitupa M: Prevention of type 2 diabetes  mellitus by changes in lifestyle among  subjects with impaired glucose tolerance.  N Engl J Med 344:1343–1350, 2001  	11333990
	16. Diabetes Prevention Program Research  Group: Reduction in the incidence of type  2 diabetes with lifestyle intervention or  metformin. N Engl J Med 346:393–403,  2002  	NO_MATCH
	17. Knowler WC, Pettitt DJ, Savage PJ, Ben nett PH: Diabetes incidence in Pima indi ans: contributions of obesity and parental  diabetes. Am J Epidemiol 113:144–156,  1981  	7468572
	18. Foster GD, Wadden TA, Vogt RA, Brewer  G: What is a reasonable weight loss? Pa tients’ expectations and evaluations of  obesity treatment outcomes. J Consult  Clin Psychol. 1997;65:79–85, 1997  	9103737
	19. Wadden TA, Berkowitz RI, Sarwer DB,  Prus-Wisniewski R, Steinberg C: Benefits  of lifestyle modification in the pharmaco logic treatment of obesity: a randomized  trial. Arch Intern Med 161:218–227, 2001  	11176735
	20. James WP, Astrup A, Finer N, Hilsted J,  Kopelman P, Rossner S, Saris WH, Van  Gaal LF: Effect of sibutramine on weight  maintenance after weight loss: a random ised trial. STORM Study Group. Sibutra mine Trial of Obesity Reduction and  Maintenance. Lancet 356:2119–2125,  2000  	11191537
	21. Drent ML, Larsson I, William-Olsson T,  Quaade F, Czubayko F, von Bergmann K,  Strobel W, Sjostrom L, van der Veen EA:  Orlistat (Ro 18–0647), a lipase inhibitor,  in the treatment of human obesity: a mul tiple dose study. Int J Obes Relat Metab  Disord 19:221–226, 1995  	7627244
	23. Heymsfield SB, Greenberg AS, Fujioka K,  Dixon RM, Kushner R, Hunt T, Lubina JA,  Patane J, Self B, Hunt P, McCamish M:  Recombinant leptin for weight loss in  obese and lean adults: a randomized, con trolled, dose-escalation trial. JAMA 282:  1568–1575, 1999  	10546697
	22. UK Prospective Diabetes Study (UKPDS)  Group: Effect of intensive blood-glucose  control with metformin on complications  in overweight patients with type 2 diabe tes (UKPDS 34). Lancet 352:854–865,  1998  	NO_MATCH
	25. Yki-Jarvinen H: Combination therapies  with insulin in type 2 diabetes. Diabetes  Care 24:758–767, 2001  	11315844
	26. Wing RR, Marcus MD, Epstein LH, Salata  R: Type II diabetic subjects lose less  weight than their overweight nondiabetic  spouses. Diabetes Care 10:563–566, 1987  	3677974
	27. Heath MJ, Chong E, Weinstein SP, Seaton  TB: Sibutramine enhances weight loss  and improves glycemic control and  plasma lipid profile in obese patients with  type 2 diabetes (Abstract). Diabetes 48  (Suppl. 1):A308, 1999  	NO_MATCH
	28. Hollander PA, Elbein SC, Hirsch IB,  Kelley D, McGill J, Taylor T, Weiss SR,  Crockett SE, Kaplan RA, Comstock J, Lu cas CP, Lodewick PA, Canovatchel W,  Chung J, Hauptman J: Role of orlistat in  the treatment of obese patients with type  2 diabetes: a 1-year randomized double blind study. Diabetes Care 21:1288–  1294, 1998  	9702435
	29. Bray GA, Pi-Sunyer FX, Hollander P,  Kelley DE: Effect of orlistat in overweight  patients with type 2 diabetes receiving in sulin therapy (Abstract). Diabetes 50  (Suppl. 2):A107, 2001  	NO_MATCH
	30. Executive Summary of The Third Report  of The National Cholesterol Education  Program (NCEP) Expert Panel on Detec tion, Evaluation, And Treatment of High  Blood Cholesterol In Adults (Adult Treat ment Panel III). JAMA 285:2486–2497,  2001  	12439378
	31. The sixth report of the Joint National  Committee on Prevention, Detection,  Evaluation, and Treatment of High Blood  Pressure. Arch Intern Med 157:2413–  2446, 1997  	NO_MATCH
	32. American Diabetes Association: Evi dence-based nutrition principles and rec ommendations for the treatment and  prevention of diabetes and related com plications (Position Statement). Diabetes  Care 25 (Suppl. 1):S50—S60, 2002  	NO_MATCH
	33. Bray GA: Complications of Obesity. Ann  Intern Med 103:1052–1062, 1985  	4062125
	35. Watts NB, Spanheimer RG, DiGirolamo  M, Gebhart SS, Musey VC, Siddiq YK,  Phillips LS: Prediction of glucose re sponse to weight loss in patients with  non-insulin-dependent diabetes mellitus.  Arch Intern Med 150:803–806, 1990  	2327840
	36. Lean ME, Powrie JK, Anderson AS, Garth waite PH: Obesity, weight loss and prog nosis in type 2 diabetes. Diabet Med  7:228–233, 1990  	2139394
	37. Steppan CM, Bailey ST, Bhat S, Brown EJ,  Banerjee RR, Wright CM, Patel HR,  Ahima RS, Lazar MA: The hormone resis tin links obesity to diabetes. Nature 409:  307–312, 2001  	11201732
	38. Anderson RJ, Freedland KE, Clouse RE,  Lustman P: The prevalence of comorbid  depression in adults with diabetes: a  meta-analysis. Diabetes Care 24:1069–  1078, 2001  	11375373
	39. Ford ES, Giles WH, Dietz WH: Prevalence  of the metabolic syndrome among US  adults: findings from the Third National  Health and Nutrition Examination Sur vey. JAMA 287:356–359, 2002  	11790215
	40. Whorwood CB, Donovan SJ, Flanagan D,  Phillips DI, Byrne CD: Increased glu cocorticoid receptor expression in human  skeletal muscle cells may contribute to the  pathogenesis of the metabolic syndrome.  Diabetes 51:1066–1075, 2002  	11916927
	41. Masuzaki H, Paterson J, Shinyama H,  Morton NM, Mullins JJ, Seckl JR, Flier JS:  A transgenic model of visceral obesity and  the metabolic syndrome. Science 294:  2166–2170, 2001  	11739957
	42. Hubert HB, Eaker ED, Garrison RJ, Cas telli WP: Life-style correlates of risk factor  change in young adults: an eight-year  study of coronary heart disease risk fac tors in the Framingham offspring. Am J  Epidemiol 125:812–831, 1987  	3565356
	43. Jain P, Rademaker AW, McVary KT: Tes tosterone supplementation for erectile  dysfunction: results of a meta-analysis.  J Urol 164:371–375, 2000  	10893588
	44. Granata AR, Rochira V, Lerchl A, Mar rama P, Carani C: Relationship between  sleep-related erections and testosterone lev els in men. J Androl 18:522–527, 1997  	9349750
	45. Goldstein I, Lue TF, Padma-Nathan H,  Rosen RC, Steers WD, Wicker PA: Oral  sildenafil in the treatment of erectile dys function. Sildenafil Study Group. N Engl  J Med 338:1397–404, 1998  	9580646
	46. Sa´enz D Tejada I, Emmick J, Anglin G,  Fredlund P, Pullman W: The effect of on demand IC351 treatment of erectile dys function in men with diabetes (Abstract).  Eur Urol 39 (Suppl. 5):16, 2001  	NO_MATCH
	47. Shakir SA, Wilton LV, Boshier A, Layton  D, Heeley E: Cardiovascular events in us ers of sildenafil: results from first phase of  prescription event monitoring in En gland. BMJ 322:651–652, 2001  	11250850
1439.full.pdf
	1. Garcia MJ, McNamara PM, Gordon T,  Kannel WB: Morbidity and mortality in  diabetics in the Framingham population:  sixteen-year follow up study. Diabetes 23:  105–111, 1974  	4359625
	2. Zilversmit DB: Atherogenesis a post-pran dial phenomenon. Circulation 60:473–  485, 1979  	222498
	3. Ebenbichler CF, Kirchmair R, Egger C,  Patsch JR: Postprandial state and athero sclerosis. Curr Opin Lipidol 6:286–290,  1995  	NO_MATCH
	4. Lefebvre PJ, Scheen AJ: The postprandial  state and risk of cardiovascular disease.  Diabet Med 15 (Suppl. 4):S63–S68, 1998  	9868996
	5. Ceriello A: The post-prandial state and  cardiovascular disease: relevance to dia betes mellitus. Diabete Metab Res Rev 16:  125–132, 2000  	10751752
	6. Ceriello A: The emerging role of post prandial hyperglycaemic spikes in the  pathogenesis of diabetic complications.  Diabet Med 15:188–193, 1998  	9545118
	7. Giugliano D, Ceriello A, Paolisso G: Oxi dative stress and diabetic vascular compli cations. Diabetes Care 19:257–267, 1996  	8742574
	8. Ceriello A, Bortolotti N, Motz E, Crescen tini A, Lizzio S, Russo A, Tonutti L,  Taboga C: Meal-generated oxidative stress  in type 2 diabetic patients. Diabetes Care  21:1529–1533, 1998  	9727904
	9. Cosentino F, Hishikawa K, Katusic ZS,  Lu¨scher TF: High glucose increases nitric  oxide synthase expression and superox ide anion generation in human aortic en dothelial cells. Circulation 96:25–28, 1997  	9236411
	10. Beckman JS, Koppenol WH: Nitric oxide,  superoxide, and peroxynitrite: the good,  the bad, and ugly. Am J Physiol 271:  C1424–C1437, 1996  	8944624
	11. Ischiropoulos H: Biological tyrosine nitra tion: a pathophysiological function of ni tric oxide and reactive oxygen species.  Arch Biochem Biophys 356:1–11, 1998  	9681984
	12. Ceriello A, Mercuri F, Quagliaro L, Assa loni R, Motz E, Tonutti L, Taboga C: De tection of nitrotyrosine in the diabetic  plasma: evidence of oxidative stress. Dia betologia 44:834–838, 2001  	11508267
	13. Marfella R, Quagliaro L, Nappo F, Ceri ello A, Giugliano D: Acute hyperglycemia  induces an oxidative stress in healthy sub jects (Letter). J Clin Invest 108:635–636,  2001  	11518739
	14. Brange J, Volund A: Insulin analogs with  improved pharmacokinetics profiles. Adv  Drug Del Rev 35:307–335, 1999  	NO_MATCH
	15. Rosenfalck AM, Thorsby P, Kjems L, Bir keland K, Dejgaard A, Hanssen KF, Mads bad S: Improved postprandial glycaemic  control with insulin aspart in diabetic pa tients treated with insulin. Acta Diabetol  37:41–46, 2000  	10928235
	16. Staprans I, Hardman DA, Pan XM, Fein gold KR: Effect of oxidized lipids in the  diet on oxidized lipid levels in postpran dial serum chylomicrons of diabetic pa tients. Diabetes Care 22:300–306, 1999  	10333949
	17. Ter Steege JCA, Koster-Kamphuis L, Van  Straaten E, Forget P, Buurman WA: Nitro tyrosine in plasma of celiac disease pa tients as detected by a new sandwich  ELISA. Free Radical Biol Med 25:953–963,  1998  	9840741
	18. Sokolovsky M, Riordan JF, Valle BL: Tet ranitromethane: a reagent for the nitra tion of tyrosil residues in proteins.  Biochemistry 5:3582–3589, 1966  	5339594
	19. Secchi C, Berrini A, Borromeo V: An en zyme-linked immunosorbent assay for  the determination of bovine prolactin in  plasma. J Immunol Methods 136:17–22,  1991  	1995708
	20. Altman DG: Clinical trials. In Practical  Statistics for Medical Research. Altman DG,  Ed. London, Chapman & Hall, 1991, p.  440–476  	NO_MATCH
	21. Lyall F, Gibson JL, Greer IA, Brocman DE,  Eis ALW, Myatt L: Increased nitrotyrosine  in the diabetic placenta: evidence for oxi dative stress. Diabetes Care 21:1753–  1758, 1998  	9773743
	22. Thuraisingham RC, Nott CA, Dodd SM,  Yaqoob MM: Increased nitrotyrosine  staining in kidneys from patients with di abetic nephropathy. Kidney Int 57:1968–  1972, 2000  	NO_MATCH
	23. Pennathur S, Wagner JD, Leeuwenburgh  C, Litwak KN, Heinecke JW: A hydroxyl  radical-like species oxidizes cynomolgus  monkey artery wall proteins in early dia betic vascular disease. J Clin Invest 107:  853–860, 2001  	11285304
	24. Ceriello A, Quagliaro L, D’Amico M, Di  Filippo C, Martella R, Nappo F, Berrino L,  Rossi F, Giugliano D: Acute hyperglyce mia induces nitrotyrosine formation and  apoptosis in perfused heart from rat. Dia betes 51:1076–1082, 2002  	11916928
	25. Groot PH, van Stiphout WA, Krauss XH,  Jansen H, van Tol A, van Ramshorst E,  Chin-On S, Hofman A, Cresswell SR,  Havekes L: Postprandial lipoprotein me tabolism in normolipidemic men with  and without coronary artery disease. Ar terioscler Thromb 11:653–662, 1991  	2029503
	26. Patsch JR, Hopferwieser T, Miesenboeck  G, Muehlberger V, Knapp E, Dunn JK,  Gotto AM Jr, Patsch W: The relationship  of triglyceride metabolism and coronary  artery disease: studies in the postprandial  state. Arterioscler Thromb 12:1336–1345,  1992  	1420093
	27. Teno S, Uto Y, Nagashima H, Endoh Y,  Iwamoto Y, Omori Y, Takizawa T: Asso ciation of postprandial hypertriglyceride mia and carotid intima-media thickness  in patients with type 2 diabetes. Diabetes  Care 23:1401–1406, 2000  	10977041
	28. Bonora E, Muggeo M: Postprandial blood  glucose as a risk factor for cardiovascular  disease in type II diabetes: the epidemio logical evidence. Diabetologia 44:2107–  2114, 2001  	11793012
	29. Moriel P, Abdalla DS: Nitrotyrosine  bound to beta-VLDL-apoproteins: a bio marker of peroxynitrite formation in  experimental atherosclerosis. Biochem  Biophys Res Commun 232:332–335, 1997  	9125175
	30. Van der Vliet A, Smith D, O’Neill CA,  Kaur H, Darley-Usmar V, Cross CE, Hal liwell H: Interactions of peroxynitrite  with human plasma and its constituents:  oxidative damage and antioxidant deple tion. Biochem J 303:295–301, 1994  	7945255
	31. MacMillan-Crow LA, Crow JP, Thomp son JA: Peroxynitrite-mediated inactiva tion of manganese superoxide dismutase  involves nitration and oxidation of critical  tyrosine residues. Biochemistry 37:1613–  1622, 1998  	9484232
	32. Beckman JS, Beckman TW, Chen J, Mar shall PA, Freeman BA: Apparent hydroxyl  radical production by peroxynitrite: im plications for endothelial injury from ni tric oxide and superoxide. Proc Natl Acad  Sci U S A 87:1620–1624, 1990  	2154753
	33. Frustaci A, Kajstura J, Cimenti C, Jako niuk I, Leri A, Maseri A, Nadal-Ginard B,  Anversa P: Myocardial cell death in hu man diabetes. Circ Res 87:1123–1132,  2000  	11110769
	34. Kajstura J, Fiordaliso F, Andreoli AM, Li  B, Cimenti S, Medow MS, Limana F,  Nadal-Ginard B, Leri A, Anversa P: IGF-1  overexpression inhibits the development  of diabetic cardiomyopathy and angioten sin II-mediated oxidative stress. Diabetes  50:1414–1424, 2001  	11375343
	35. Mihm MJ, Jing L, Bauer JA: Nitrotyrosine  causes selective vascular endothelial dys function and DNA damage. J Cardiovasc  Pharmacol 36:182–187, 2000  	10942159
	36. Beckmann JS, Ye YZ, Anderson PG, Chen  J, Accavitti MA, Tarpey MM, White CR:  Extensive nitration of protein tyrosines in  human atherosclerosis detected by immu nohistochemistry. Biol Chem 375:81–88,  1994  	8192861
31.pdf
	1. Hirschfield RM: Efficacy of SSRIs and newer antidepressants in  severe depression: comparison with TCAs. J Clin Psychiatry  1999; 60:326–335  	10362442
	2. Settle EC: Antidepressant drugs: disturbing and potentially  dangerous adverse effects. J Clin Psychiatry 1998; 59(suppl 16):  25–30  	9796863
	3. Garattini S, Barbui C, Saraceno B: Antidepressant agents: from  tricyclics to serotonin uptake inhibitors. Psychol Med 1998; 28:  1169–1178  	9794024
	4. Kuny S, Stassen HH: Cognitive performance in patients recov ering from depression. Psychopathology 1995; 28:190–207  	7480575
	5. Allain H, Lieury A, Brunet-Bourgin F, et al: Antidepressants and  cognition: comparative effects of moclobemide, viloxazine and  maprotiline. Psychopharmacology (Berl) 1992; 106:S56–S61  	1546142
	6. Cole JO, Branconnier R, Solomon M, et al: Tricyclic use in the  cognitively impaired elderly. J Clin Psychiatry 1983; 44:14–19  	6355072
	7. Anderson IM, Tomenson BM: The efficacy of selective serotonin  re-uptake inhibitors in depression: a meta-analysis of studies  against tricyclic antidepressants. J Psychopharmacol 1994; 8:238–  249  	NO_MATCH
	8. Perry PJ: Pharmacotherapy for major depression with melancholic  features: relative efficacy of tricyclic versus selective serotonin  reuptake inhibitor antidepressants. J Affect Disord 1996; 39:1–6  	8835647
	9. Oxman TE: Antidepressants and cognitive impairment in the el derly. J Clin Psychiatry 1996; 57(suppl 5):38–44  	8647791
	10. van Laar MW, van Willigenburg APP, Volkerts ER: Acute and  subchronic effects of nefazodone and imipramine on highway  driving, cognitive functions, and daytime sleepiness in healthy  adult and elderly subjects. J Clin Psychopharmacol 1995; 15:  30–40  	7714226
	11. Gray SL, Lai KV, Larson EB: Drug-induced cognition disorders  in the elderly. Drug Saf 1999; 21:101–122  	NO_MATCH
	12. Moore AR, O’Keeffe ST: Drug-induced cognitive impairment in  the elderly. Drugs Aging 1999; 15:15–28  	10459729
	13. Lyketsos CG, Chen L, Anthony JC: Cognitive decline in adult hood: an 11.5 year follow-up of the Baltimore Epidemiologic  Catchment Area Study. Am J Psychiatry 1999; 156:58–65  	9892298
	14. Folstein M, Anthony JC, Parhad I, et al: The meaning of cognitive  impairment in the elderly. J Am Geriatr Soc 1985; 33:228–235  	3989183
	15. Bleecker ML, Bolla-Wilson K, Kawas C, et al: Age-specific norms  for the Mini-Mental State Exam. Neurology 1988; 38:1565–1568  eration of each patient’s best interest for both immediate  and long-term outcomes when selecting the proper phar macologic intervention.  	3419600
	16. Crum RM, Anthony JC, Bassett SS, et al: Population-based norms  for the Mini-Mental State Examination by age and educational  level. JAMA 1993; 269:2386–2391  	8479064
	17. Tangalos EG, Smith GE, Ivnik RJ, et al: The Mini-Mental State  Examination in general medical practice: clinical utility and ac ceptance. Mayo Clin Proc 1996; 71:829–837  	8790257
	18. Tombaugh TN, McIntryre NJ: The Mini-Mental State Examina tion: a comprehensive review. J Am Geriatr Soc 1992; 40:922–  935  	1512391
	19. U.S. Department of Commerce, Bureau of the Census: Current  Population Survey (CPS). Washington, DC, US Government  Printing Office, 1997  	NO_MATCH
	20. Le Houezec J, Benowitz NL: Basic and clinical psychopharma cology of nicotine. Clin Chest Med 1991; 12:681–699  	1747987
	21. Rezvani AH, Levin ED: Cognitive effects of nicotine. Biol Psy chiatry 2001; 49:258–267  	11230877
	22. Launer LJ, Feskens EJ, Kalmijn S, et al: Smoking, drinking and  thinking. The Zutphen Elderly Study. Am J Epidemiol 1996;  143:219–227  	8561155
	23. Leibovici D, Ritchie K, Ledesert B, et al: The effects of wine  and tobacco consumption on cognitive performance in the el derly: a longitudinal study of relative risk. Int J Epidemiol 1999;  28:77–81  	10195668
	24. Spilich CJ, June L, Renner J: Cigarette smoking and cognitive  performance. Br J Addict 1992; 87:1313–1326  	1392553
	25. Barefoot JC, Schroll M: Symptoms of depression, acute myocar dial infarction, and total mortality in a community sample. Cir culation 1996; 93:1976–1980  	8640971
	26. Penninx BW, Geerlings SW, Deeg DJ, et al: Minor and major  depression and the risk of death in older persons. Arch Gen Psy chiatry 1999; 56:889–895  	10530630
	27. Davidson JR, Meltzer-Brody SE: The underrecognition and under treatment of depression: what is the breadth and depth of the prob lem? J Clin Psychiatry 1999; 60(suppl 7):4–9  	10326869
	28. Hirschfeld RM, Keller MB, Panico S, et al: The National Depres sive and Manic-Depressive Association consensus statement on  the undertreatment of depression. JAMA 1997; 277:333–340  	9002497
	29. Foy A, O’Connell D, Henry D, et al: Benzodiazepine use as a  cause of cognitive impairment in elderly hospital inpatients. J Ger ontol A Biol Sci Med Sci 1995; 50:M99–M106  	7874596
tjp0540-0237.pdf
	B, K. J. (1978). Typical sympathetic noradrenergic endings in  a muscle spindle of the cat. Journal of Physiology 285, 61–62P.  	NO_MATCH
	B, D. & S, M. (1981). Autonomic innervation of receptors  and muscle fibres in cat skeletal muscle. Proceedings of the Royal  Society B 212, 317–332.  	6115396
	B, D. & S, H. (1987). Adrenergic innervation of rat jaw  muscles. Journal of Physiology 391, 114P.  	NO_MATCH
	B, I. A. (1985). Intrafusal muscle fibres in the cat and their motor  control. In Feedback and Motor Control in Invertebrates and  Vertebrates, ed. B, W. J. P. & G, M. H., pp. 123–144.  Croom Helm, London.  C, C. & S, R. B. (1986). Amplitude modulation of the  soleus H-reflex in the human during walking and standing. Journal  of Neuroscience 6, 1308–1313.  	NO_MATCH
	C, C. & S, R. B. (1987). Difference in the amplitude of  the human soleus H reflex during walking and running. Journal of  Physiology 392, 513–522.  	3446790
	C, J. E., B, R. B. & P, G. G. (1998). The  effects of muscle fatigue on shoulder joint position sense.  American Journal of Sports Medicine 26, 262–265.  	NO_MATCH
	C, F. W. J., L, R. W. H. & T, A. (1972). A functional  analysis of the components of the mesencephalic nucleus of the  fifth nerve in the cat. Journal of Physiology 226, 249–261.  	4263681
	D, R. A. (1992). Skeletal muscle tone and the misunderstood  stretch reflex. Neurology 42, 951–963.  	NO_MATCH
	D, F., R, S., G, C., U, R., M, G. &  P, M. (1996). Sympathetically-induced changes in  microvascular cerebral blood and in the morphology of its low frequency waves. Journal of the Autonomic Nervous System 59,  66–74.  	NO_MATCH
	D, V. (1992). Human neuronal control of automatic functional  movements: interaction between central programs and afferent  input. Physiological Reviews 72, 33–69.  	NO_MATCH
	E, E., S, H. N. & B, J. (1960). Response  of muscle spindles to simulation of the sympathetic trunk.  Experimental Neurology 2, 13–25.  	NO_MATCH
	F, M. (2000). Effects of chlorobutanol on primary and  secondary endings of isolated cat muscle spindles. Brain Research  854, 106–121.  	NO_MATCH
	F, B. (1952). Impulse frequency in sympathetic vasomotor  fibres correlated to the release and elimination of the transmitter.  Acta Physiologica Scandinavica 25, 49–76.  	NO_MATCH
	F, F., P, P., P, L. & S, G. (1978). Effects  of sympathetic catecholamines (adrenaline and noradrenaline)  injected intra arterially and of ischemia on the tonic vibration  reflex (TVR) of the ankle extensor muscle in decerebrate cat .  Bollettino della Società Italiana di Biologia Sperimentale 54,  	NO_MATCH
	G, S. C. & B, D. (1992). Does the nervous system  depend on kinaesthetic information to control natural limb  movements? Behavioural Brain Sciences 15, 614–632.  	NO_MATCH
	G, M. H. (1976). Structural features relative to the function  of intrafusal muscle fibres in the cat. Progress in Brain Research 44,  51–59.  	NO_MATCH
	G, C., D, F., A, E. & P, M. (1993a).  Modulation of the jaw jerk reflex by the sympathetic nervous  system. Archives Italiennes de Biologie 131, 213–226.  	NO_MATCH
	G, C., D, F. & P, M. (1993b). Effect of  sympathetic nervous system activation on the tonic vibration  reflex in rabbit jaw closing muscles. Journal of Physiology 469,  601–613.  	NO_MATCH
	G, C., D, F., R, S., S, R., A, G. B. &  P, M. (1996). Sympathetic control of skeletal muscle  function: possible co-operation between noradrenaline and  neuropeptide Y in rabbit jaw muscles. Neuroscience Letters 212,  204–208.  	NO_MATCH
	H, F., T, J., R, S., L, M.,  P, M. & J, H. (2001). Discharge responses of  muscle spindles to stimulation of the cervical sympathetic nerve in  cat neck muscles. XXXIV International Congress of Physiological  Sciences (IUPS), Aug 26–31 2001, Christchurch, New Zealand.  	NO_MATCH
	H, J. C. & R, W. Z. (1981). Neural control of muscle length  and tension. In Handbook of Physiology, section 1, The Nervous  System, vol. II, Motor Control, ed. B, J. M.,  M, V. B., B, V. B. & G, S.R., pp. 257–324,  American Phsysiological Society, Bethesda, MD, USA.  	NO_MATCH
	H, C. C. (1960). The effect of sympathetic stimulation on  mammalian muscle spindle. Journal of Physiology 151, 332–341.  	NO_MATCH
	H, C. C., J, L. & L, Y. (1982). Effects of stimulating  the lumbar sympathetic trunk on cat hindlimb muscle spindles.  Archives Italiennes de Biologie 120, 371–384.  	NO_MATCH
	I, H., M, T. & K, Y. (1981). Response  characteristics and classification of muscle spindles of the masseter  muscle in the cat. Experimental Neurology 74, 548–560.  	NO_MATCH
	L, J. R. & DZ, P. A. (2000). Aspects of body self calibration. Trends in Cognitive Sciences 4, 279–288.  	NO_MATCH
	L, E. S. & G, L. J. (1981). Neural mechanisms of  mandibular control: mastication and voluntary biting. In  Handbook of Physiology, section 1, The Nervous System, vol. II,  Motor Control, ed. B, J. M., M, V. B.,  B, V. B. & G, S.R., pp. 1237–1274. American  Physiological Society, Bethesda, MD, USA.  	NO_MATCH
	M, E., B, R. & D, C. (1966). Eye muscle  proprioception and the semilunar ganglion. Experimental  Neurology 16, 226–236.  	NO_MATCH
	M, M., E, U., B, J. & M, S. (1991).  Protective role of sympathetic nerve activity to exercising skeletal  muscle in the regulation of capillary pressure and fluid filtration.  Acta Physiologica Scandinavica 141, 351–361.  	NO_MATCH
	M, Y., M, T., H, O., K, T., M, R.,  I, T., K, M. & T, A. (1997). Modulation of  jaw muscle spindle discharge during mastication in the rabbit.  Journal of Neurophysiology 77, 2227–2231.  	NO_MATCH
	M, R., I, A., N, T. & M, T. (1995).  Inhibitory effect of sympathetic stimulation on activities of  masseter muscle spindles and the jaw jerk reflex in rats. Journal of  Physiology 483, 239–250.  	NO_MATCH
	M, P. B. C. (1972). Mammalian Muscle Receptors and their  Central Actions. Edward Arnold, London.  M, T., I, H. & K, Y. (1982). Diameter spectra  of sensory and motor fibers in nerves to jaw-closing and jaw opening muscles in the cat. Japanese Journal of Physiology 32,  171–182.  	NO_MATCH
	N, L. M. (1976). Adapting reflexes controlling the human  posture. Experimental Brain Research 26, 59–72.  	NO_MATCH
	P, M., D, F., G, C. & R, S. (1996a). A  comparative study of changes operated by sympathetic nervous  system activation on spindle afferent discharge and on tonic vibration reflex in rabbit jaw muscles. Journal of the Autonomic  Nervous System 57, 163–167.  	NO_MATCH
	P, M., D, F., R, S., G, C. & M, G.  (1996b). Effects of cervical sympathetic nerve stimulation on the  cerebral microcirculation: possible clinical implications. Acta  Neurobiologiae Experimentalis 56, 117–127.  	NO_MATCH
	P, M., G, C. & F, G. M. (1985). Sympathetically induced development of tension in jaw muscles: the possible  contraction of intrafusal muscle fibres. Pflügers Archiv 405,  297–304.  	NO_MATCH
	P, M., L, M. L., F, G. M., M, E. &  B, R. (1983). Localization of neurons innervating  masticatory muscle spindle and periodontal receptors in the  mesencephalic trigeminal nucleus and their reflex actions. Archives  Italiennes de Biologie 121, 117–130.  	NO_MATCH
	P, M., R, S., D, F. & G, C. (1997).  Sympathetic nervous system activation reduces muscle spindle  sensitivity to ramp stretch, in rabbit jaw muscle. XXXIII International Congress of Physiological Sciences, St Petersburg,  P70.06.  	NO_MATCH
	P, K. G. (1993). Common principles of motor control in  vertebrates and invertebrates. Annual Review of Neuroscience 16,  265–297.  	NO_MATCH
	P, J., L, J., H, F., D, M. &  J, H. (1999). Localized muscle fatigue decreases the  acuity of the movement sense in the human shoulder. Medicine  and Science in Sports and Exercise 31, 1047–1052.  	NO_MATCH
	P, A. (1989). Sensorimotor gain control: a basic strategy of  motor systems? Progress in Neurobiology 33, 281–307.  	NO_MATCH
	P, A. (1996). Proprioceptive feedback and movement  regulation. In Handbook of Physiology, section 12, Exercise:  Regulation and Integration of Multiple Systems, ed. R, L. &  S, J. T., pp. 89–127. Oxford University Press, New York.  	NO_MATCH
	P, U. & C, R. W. (1995). The sensitivity of mammalian  muscle spindles to neuromuscular blocking agents. In Alpha and  Gamma Motor Systems, ed. T, A., G, M. H. &  D, R., pp. 261–266. Plenum Press, New York and London.	NO_MATCH 
	R, P. M. H. (1981). Limitations of somatosensory feedback in  control of posture and movement. In Handbook of Physiology,  section 1, The Nervous System, vol. II, Motor Control, ed. B, J. M., M, V. B., B, V. B. &  G, S.R., pp. 229–256. American Physiological Society,  Bethesda, MD, USA.  	NO_MATCH
	R, D., M, B., S, L., D, I. & L, U.  (2000). Surface EMG and psychophysiological stress reactions in  women during repetitive work. European Journal of Applied  Physiology 83, 215–222.  	NO_MATCH
	R, S., D, F., A, E. & P, M. (1996). A  simple, non-invasive and inexpensive method for evaluating the  displacement of local tissue surfaces: from vascular changes to  muscle contraction. Clinical Physiology 16, 83–94.  	NO_MATCH
	R, A. (1898). On the minute anatomy of the neuromuscular  spindles of the cat, and on their physiological significance. Journal  of Physiology 23, 190–208.  	NO_MATCH
	S, M. & I, Y. (1971). The fine structure of thin  unmyelinated axons within muscle spindles. Brain Research 33,  289–302.  	NO_MATCH
	S, R. J. & K, J. (1990). The movement disorder  of reflex sympathetic dystrophy. Neurology 40, 57–61.  	2022431
	S, D. R. & V, R. G. (1991). Regulation of muscle  sympathetic nerve activity during exercise in humans. Exercise and  Sport Sciences Reviews 19, 313–349.  	NO_MATCH
	S, M. H. & M, T. S. (1993). Position sense at the elbow  after fatiguing contractions. Experimental Brain Research 94,  179–182.  	NO_MATCH
	S, G., L, U. & K, R. (2000). The role of  muscle activity and mental load in the development of pain and  degenerative processes at the muscle cell level during computer  work. European Journal of Applied Physiology 83, 99–105.  	NO_MATCH
	S, H. B., W, M. P., H, J. A., C, D. W. &  B, R. L. (1986). Effect of fatigue on joint position sense of  the knee. Journal of Orthopedic Research 4, 112–118.  	NO_MATCH
	S, R. D., M, H. Q. & N, W. T. (1968). Direct  projections from the masseteric nerve to the mesencephalic  nucleus. Journal of Comparative Neurology 133, 495–502.  	NO_MATCH
	T, A., D, R. & R, J. F. (1992a). The  classification of afferents from muscle spindles of the jaw-closing  muscles of the cat. Journal of Physiology 456, 609–628.  	NO_MATCH
	T, A., R, J. F., F, A. J. & D, R. (1992b). The  effect of succinylcholine on cat gastrocnemius muscle spindle  afferents of different types. Journal of Physiology 456, 629–644.  	NO_MATCH
	T, J., H, F., L, M., R, S.,  J, H. & P, M. (2000). The influence of cervical  sympathetic nerve stimulation on muscle spindles in dorsal neck  muscles in the cat. Forum of European Neuroscience (FENS), June  24–28, Brighton, UK.  	NO_MATCH
	W, M. (2000). Human muscle activity related to non biomechanical factors in the workplace. European Journal of  Applied Physiology 83, 151–158.  	11104055
686.full.pdf
	1. Yamamoto, S., Yamamoto, T., Tokunaga, T. (2000) The discovery of  immunostimulatory DNA sequence. Springer Semin. Immunopathol. 22,  11–19.  	10944796
	2. Pisetsky, D. S., Reich, C., Crowley, S. D., Halpern, M. D. (1995) Immu nological properties of bacterial DNA. Ann. N. Y. Acad. Sci. 772, 152–  163.  	8546388
	3. Krieg, A. M. (1996) An innate immune defense mechanism based on the  recognition of CpG motifs in microbial DNA. J. Lab. Clin. Med. 128,  128–133.  	8765208
	4. Lipford, G. B., Heeg, K., Wagner, H. (1998) Bacterial DNA as immune  cell activator. Trends Microbiol. 6, 496–500.  	10036729
	5. Klinman, D. M., Verthelyi, D., Takeshita, F., Ishii, K. J. (1999) Immune  recognition of foreign DNA: a cure for bioterrorism. Immunity 11, 123–  129.  	10485647
	6. Wloch, M. K., Pasquini, S., Ertl, H. C., Pisetsky, D. S. (1998) The  influence of DNA sequence on the immunostimulatory properties of plas mid DNA vectors. Hum. Gene Ther. 9, 1439–1447.  	9681415
	7. Pisetsky, D. S., Reich, C. F. (2000) Inhibition of murine macrophage IL-12  production by natural and synthetic DNA. Clin. Immunol. 96, 198–204.  	10964537
	8. Krieg, A. M., Wu, T., Weeratna, R., Efler, S. M., Love-Homan, L., Yang,  L., Yi, A. K., Short, D., Davis, H. L. (1998) Sequence motifs in adenoviral  DNA block immune activation by stimulatory CpG motifs. Proc. Natl.  Acad. Sci. USA 95, 12631–12636.  	9770537
	9. Chen, Y., Lenert, P., Weeratna, R., McCluskie, M., Wu, T., Davis, H. L.,  Krieg, A. M. (2001) Identification of methylated CpG motifs as inhibitors  of the immune stimulatory CpG motifs. Gene Ther. 8, 1024–1032.  	11438837
	10. Nathan, C. (1992) Nitric oxide as a secretory product of mammalian cells.  FASEB J. 6, 3051–3064.  	1381691
	11. Weinberg, J. B. (1998) Nitric oxide production and nitric oxide synthase  type 2 expression by human mononuclear phagocytes: a review. Mol. Med.  4, 557–591.  	9848075
	12. Ma, X., Aste-Amezaga, M., Trinchieri, G. (1996) Regulation of interleu kin-12 production. Ann. N. Y. Acad. Sci. 795, 13–25.  	8958913
	13. MacMicking, J., Xie, Q. W., Nathan, C. (1997) Nitric oxide and macro phage function. Annu. Rev. Immunol. 15, 323–350.  	9143691
	14. Stacey, K. J., Sweet, M. J., Hume, D. A. (1996) Macrophages ingest and  are activated by bacterial DNA. J. Immunol. 157, 2116–2122.  	8757335
	15. Gao, J. J., Zuvanich, E. G., Xue, Q., Horn, D. L., Silverstein, R., Morrison,  D. C. (1999) Cutting edge: bacterial DNA and LPS act in synergy in  inducing nitric oxide production in RAW 264.7 macrophages. J. Immunol.  163, 4095–4099.  	10510342
	16. Chace, J. H., Hooker, N. A., Mildenstein, K. L., Krieg, A. M., Cowdery,  J. S. (1997) Bacterial DNA-induced NK cell IFN-gamma production is  dependent on macrophage secretion of IL-12. Clin. Immunol. Immuno pathol. 84, 185–193.  	9245551
	17. Pisetsky, D. S. (2000) Mechanisms of immune stimulation by bacterial  DNA. Springer Semin. Immunopathol. 22, 21–33.  	10944797
	18. Mosmann, T. (1983) Rapid colorimetric assay for cellular growth and  survival: application to proliferation and cytotoxicity assays. J. Immunol.  Methods 65, 55–63.  	6606682
	19. Green, L. C., Wagner, D. A., Glogowski, J., Skipper, P. L., Wishnok, J. S.,  Tannenbaum, S. R. (1982) Analysis of nitrate, nitrite, and [15N]nitrate in  biological fluids. Anal. Biochem. 126, 131–138.  	7181105
	20. Matsukura, M., Zon, G., Shinozuka, K., Stein, C. A., Mitsuya, H., Cohen,  J. S., Broder, S. (1988) Synthesis of phosphorothioate analogues of ligode oxyribonucleotides and their antiviral activity against human immunode ficiency virus (HIV). Gene 72, 343–347.  	3243433
	21. Stein, C. A., Subasinghe, C., Shinozuka, K., Cohen, J. S. (1988) Physico chemical properties of phosphorothioate oligodeoxynucleotides. Nucleic  Acids Res. 16, 3209–3221.  	2836790
	22. Halpern, M. D., Pisetsky, D. S. (1995) In vitro inhibition of murine IFN  gamma production by phosphorothioate deoxyguanosine oligomers. Immu nopharmacology 29, 47–52.  	7768671
	23. Krieg, A. M., Yi, A. K., Matson, S., Waldschmidt, T. J., Bishop, G. A.,  Teasdale, R., Koretzky, G. A., Klinman, D. M. (1995) CpG motifs in  bacterial DNA trigger direct B-cell activation. Nature 374, 546–549.  	7700380
	24. Manzel, L., Macfarlane, D. E. (1999) Lack of immune stimulation by  immobilized CpG-oligodeoxynucleotide. Antisense Nucleic Acid Drug  Dev. 9, 459–464.  	10555153
	25. Tapping, R. I., Gegner, J. A., Kravchenko, V. V., Tobias, P. S. (1998)  Roles for LBP and soluble CD14 in cellular uptake of LPS. Prog. Clin.  Biol. Res. 397, 73–78.  	9575548
	26. Sweet, M. J., Hume, D. A. (1996) Endotoxin signal transduction in  macrophages. J. Leukoc. Biol. 60, 8–26.  	8699127
	27. Yi, A. K., Krieg, A. M. (1998) Rapid induction of mitogen-activated  protein kinases by immune stimulatory CpG DNA. J. Immunol. 161,  4493–4497.  	9794373
	28. Hacker, H., Mischak, H., Miethke, T., Liptay, S., Schmid, R., Sparwasser,  T., Heeg, K., Lipford, G. B., Wagner, H. (1998) CpG-DNA-specific  activation of antigen-presenting cells requires stress kinase activity and is  preceded by non-specific endocytosis and endosomal maturation. EMBO  J. 17, 6230–6240.  	9799232
	29. Pisetsky, D. S., Reich III, C. F. (1998) The influence of base sequence on  the immunological properties of defined oligonucleotides. Immunophar macology 40, 199–208.  	9858063
	30. Campbell, J. M., Bacon, T. A., Wickstrom, E. (1990) Oligodeoxynucleo side phosphorothioate stability in subcellular extracts, culture media, sera  and cerebrospinal fluid. J. Biochem. Biophys. Methods 20, 259–267.  	2188993
	31. Stein, C. A., Cheng, Y. C. (1993) Antisense oligonucleotides as therapeu tic agents—is the bullet really magical? Science 261, 1004–1012.  	8351515
	32. Yamamoto, T., Yamamoto, S., Kataoka, T., Tokunaga, T. (1994) Ability of  oligonucleotides with certain palindromes to induce interferon production  and augment natural killer cell activity is associated with their base  length. Antisense Res. Dev. 4, 119–122.  	7950298
	33. Sester, D. P., Naik, S., Beasley, S. J., Hume, D. A., Stacey, K. J. (2000)  Phosphorothioate backbone modification modulates macrophage activa tion by CpG DNA. J. Immunol. 165, 4165–4173.  	11035048
	34. Dziarski, R., Tapping, R. I., Tobias, P. S. (1998) Binding of bacterial  peptidoglycan to CD14. J. Biol. Chem. 273, 8680–8690.  	9535844
	35. Pisetsky, D. S., Reich, C. (1993) Stimulation of in vitro proliferation of  murine lymphocytes by synthetic oligodeoxynucleotides. Mol. Biol. Rep.  18, 217–221.  	8114689
	36. Poltorak, A., He, X., Smirnova, I., Liu, M. Y., Huffel, C. V., Du, X.,  Birdwell, D., Alejos, E., Silva, M., Galanos, C., Freudenberg, M., Ric ciardi-Castagnoli, P., Layton, B., Beutler, B. (1998) Defective LPS sig naling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene.  Science 282, 2085–2088.  	9851930
	37. Hemmi, H., Takeuchi, O., Kawai, T., Kaisho, T., Sato, S., Sanjo, H.,  Matsumoto, M., Hoshino, K., Wagner, H., Takeda, K., Akira, S. (2000) A  Toll-like receptor recognizes bacterial DNA. Nature 408, 740–745.  	11130078
	38. Chu, W., Gong, X., Li, Z., Takabayashi, K., Ouyang, H., Chen, Y., Lois,  A., Chen, D. J., Li, G. C., Karin, M., Raz, E. (2000) DNA-PKcs is required  for activation of innate immunity by immunostimulatory DNA. Cell 103,  909–918.  	11136976
	39. Medzhitov, R. (2001) CpG DNA: security code for host defense. Nat.  Immunol. 2, 15–16.  	11135571
	40. Kimura, Y., Sonehara, K., Kuramoto, E., Makino, T., Yamamoto, S.,  Yamamoto, T., Kataoka, T., Tokunaga, T. (1994) Binding of oligoguanylate  to scavenger receptors is required for oligonucleotides to augment NK cell  activity and induce IFN. J. Biochem. (Tokyo) 116, 991–994.  	7534760
	41. Sen, D., Gilbert, W. (1988) Formation of parallel four-stranded complexes  by guanine-rich motifs in DNA and its implications for meiosis. Nature  334, 364–366.  	3393228
	42. Williamson, J. R. (1994) G-quartet structures in telomeric DNA. Annu.  Rev. Biophys. Biomol. Struct. 23, 703–730.  	7919797
	43. Lang, R., Hultner, L., Lipford, G. B., Wagner, H., Heeg, K. (1999)  Guanosine-rich oligodeoxynucleotides induce proliferation of macrophage  progenitors in cultures of murine bone marrow cells. Eur. J. Immunol. 29,  3496–3506.  	10556804
	44. Michel, T., Feron, O. (1997) Nitric oxide synthases: which, where, how,  and why? J. Clin. Investig. 100, 2146–2152.  	9410890
	45. Sutterwala, F. S., Mosser, D. M. (1999) The taming of IL-12: suppressing  the production of proinflammatory cytokines. J. Leukoc. Biol. 65, 543–551.  	10331481
	46. Bogdan, C., Rollinghoff, M., Diefenbach, A. (2000) Reactive oxygen and  reactive nitrogen intermediates in innate and specific immunity. Curr.  Opin. Immunol. 12, 64–76.  	10679404
	47. Feng, G. J., Goodridge, H. S., Harnett, M. M., Wei, X. Q., Nikolaev, A. V.,  Higson, A. P., Liew, F .Y. (1999) Extracellular signal-related kinase  (ERK) and p38 mitogen-activated protein (MAP) kinases differentially  regulate the lipopolysaccharide- mediated induction of inducible nitric  oxide synthase and IL-12 in macrophages: Leishmania phosphoglycans  subvert macrophage IL-12 production by targeting ERK MAP kinase.  J. Immunol. 163, 6403–6412.  	10586030
	48. Platt, N., da Silva, R. P., Gordon, S. (1998) Recognizing death: the  phagocytosis of apoptotic cells. Trends Cell Biol. 8, 365–372.  	9728398
	49. Weinberg, J. B., Granger, D. L., Pisetsky, D. S., Seldin, M. F., Misukonis,  M. A., Mason, S. N., Pippen, A. M., Ruiz, P., Wood, E. R., Gilkeson, G. S.  (1994) The role of nitric oxide in the pathogenesis of spontaneous murine  autoimmune disease: increased nitric oxide production and nitric oxide  synthase expression in MRL-lpr/lpr mice, and reduction of spontaneous  glomerulonephritis and arthritis by orally administered NG-monomethyl L-arginine. J. Exp. Med. 179, 651–660.  	7507509
	50. Connor, J. R., Manning, P. T., Settle, S. L., Moore, W. M., Jerome, G. M.,  Webber, R. K., Tjoeng, F. S., Currie, M. G. (1995) Suppression of  adjuvant-induced arthritis by selective inhibition of inducible nitric oxide  synthase. Eur. J. Pharmacol. 273, 15–24.  	7537678
	51. Klinman, D. M., Kamstrup, S., Verthelyi, D., Gursel, I., Ishii, K. J.,  Takeshita, F., Gursel, M. (2000) Activation of the innate immune system  by CpG oligodeoxynucleotides: immunoprotective activity and safety.  Springer Semin. Immunopathol. 22, 173–183.  	10944812
J ANIM SCI-2002-Bonnet-723-8.pdf
J ANIM SCI-2002-Piva-670-80.pdf
nihms143246.pdf
	Beal SL, Sheiner LB. Estimating population kinetics. CRC Critical Reviews in Biomedical Engineering  1982;8:195–222.  	6754254
	Brumback BA, Rice JA. Smoothing spline models for the analysis of nested and crossed samples of  curves. Journal of the American Statistical Association 1998;93:961–976.  	NO_MATCH
	Daniels MJ, Kass RE. Shrinkage estimators for covariance matrices. Biometrics 2001;57:1173–1184.  [PubMed: 11764258]  	11764258
	Daniels, MJ.; Pourahmadi, M. Bayesian analysis of covariance matrices and dynamic models for  longitudinal data. Department of Statistics, Iowa State University; Ames: 2001. Preprint 2001–03  	NO_MATCH
	Davidian, M.; Giltinan, DM. Nonlinear Models for Repeated Measurements. New York: Chapman and  Hall; 1995.  	NO_MATCH
	Diggle, PJ.; Liang, KY.; Zeger, SL. Analysis of Longitudinal Data. Oxford: Oxford University Press;  1994.  	NO_MATCH
	Gibbons RD, Hedeker D, Elkin I, Waternaux C, Kraemer HC, Greenhouse JB, Shea MT, Imber SD,  Sotsky SM, Watkins JT. Some conceptual and statistical issues in the analysis of longitudinal  psychiatric data. Archives of General Psychiatry 1993;50:739–750. [PubMed: 8357299]  	NO_MATCH
	Heitjan DF. Nonlinear modeling of serial immunologic data: A case study. Journal of the American  	NO_MATCH
	Hogan JW, Laird NM. Mixture models for the joint distribution of repeated measures and event times.  Statistics in Medicine 1997;16:239–257. [PubMed: 9004395]  	9004395
	Laird NM, Ware JJ. Random-effects models for longitudinal data. Biometrics 1982;38:973–979.  	7168798
	Lindsey, JK. Models for Repeated Measurements. Vol. 2. Oxford: Clarendon Press; 1999.  	NO_MATCH
	McCullagh, P.; Nelder, JA. Generalized Linear Models. Vol. 2. Cambridge: Chapman and Hall; 1989.  	NO_MATCH
	Mikulich SK, Zerbe GO, Jones RH, Crowley TJ. Relating the classical covariance adjustment techniques  of multivariate growth curve models to modern univariate mixed effects models. Biometrics  1999;55:957–964. [PubMed: 11315035]  	NO_MATCH
	Pothoff RF, Roy SN. A generalized multivariate analysis of variance model useful especially for growth  curve problems. Biometrika 1964;52:313–326.  	NO_MATCH
	Pourahmadi M. Joint mean-covariance models with applications to longitudinal data: Unconstrained  parameterisation. Biometrika 1999;86:677–690.  	NO_MATCH
	Pourahmadi M. Maximum likelihood estimation of generalized linear models for multivariate normal  covariance matrix. Biometrika 2000;87:425–435.  	NO_MATCH
	Rahiala M. Random coefficient autoregressive models for longitudinal data. Biometrika 1999;86:718–  722.  	NO_MATCH
	Ramsay, JO.; Silverman, BW. Functional Data Analysis. New York: Springer; 1997.  	NO_MATCH
	Rao CR. Some statistical methods for comparison of growth curves. Biometrics 1958;14:1–17.  	NO_MATCH
	Rice JA, Silverman BW. Estimating the mean and covariance structure nonparametrically when the data  are curves. Journal of the Royal Statistical Society, Series B 1991;53:233–243.  	NO_MATCH
	Scott, MA.; Handcock, MS. IEE Working Paper 13. Institute of Education and the Economy, Columbia  University; 1999. Latent curve covariance models for longitudinal data.  	NO_MATCH
	Sheiner LB, Rosenberg B, Melmon KL. Modelling of individual pharmacokinetics for computer-aided  drug dosing. Computers and Biomedical Research 1972;5:441–459.  	4634367
	Spiegelhalter, DJ.; Best, NG.; Carlin, BP.; Van der Linde, A. Bayesian measures of model complexity  and fit. Division of Biostatistics, University of Minnesota; Minneapolis: 2001. Report 2001–013  	NO_MATCH
	Tanner MA, Wong WH. The calculation of posterior distributions by data augmentation. Journal of the  American Statistical Association 1987;82:528–540.  	NO_MATCH
	Thase ME, Greenhouse JB, Frank E, Reynolds CF III, Pilkonis PA, Hurley K, Grochocinski V, Kupfer  DJ. Treatment of major depression with psychotherapy or psychotherapy–pharmacotherapy  combinations. Archives of General Psychiatry 1997;54:1009–1015. [PubMed: 9366657]  	9366657
	Verbyla AP, Cullis BR, Kenward MG, Welham SJ. The analysis of designed experiments and longitudinal  data by using smoothing splines (with discussion). Applied Statistics 1999;48:269–311.  	NO_MATCH
	Vonesh EF, Carter RL. Mixed effects non-linear regression for unbalanced measures. Biometrics  1992;48:1–18. [PubMed: 1581479]  	1581479
	Wang Y. Smoothing spline models with correlated random errors. Journal of the American Statistical  Association 1998;93:341–348.  	NO_MATCH
pq0202000655.pdf
pq0202001076.pdf
pq0202000878.pdf
5601508a.pdf
	Alexandrow MG, Moses HL: Transforming growth factor b1 inhibits mouse  keratinocytes late in G1 independent of effects on gene transcription. Cancer  Res 55:3928±3932, 1995  	7641212
	Chiang C, Swan RZ, Grachtchouk M, et al: Essential role for sonic hedgehog during  hair follicle morphogenesis. Dev Biol 205:1±9, 1999  	9882493
	Dasch JR, Pace DR, Waegell W, Inenaga D, Ellingsworth L: Monoclonal antibodies  recognizing TGF-b. Bioactivity neutralization and TGF-b2 af®nity  puri®cation. J Immunol 142:1536±1541, 1989  	NO_MATCH
	Demetrious M, Binker C, Sukhu B, Tenenbaum HC, Dennis JW: Fetuin/ae2-HS  glycoprotein is a TGF-b-type II receptor mimic and cytokine antagonist. J Biol  Chem 271:12755±12761, 1996  	NO_MATCH
	Dickson MC, Martin JS, Cousins FM, Kulkarin AB, Karlsson SK, Akhurst RJ:  Defective haematopoiesis and vasculogenesis in TGF-b1 knock out mice.  Development 121:1845±1854, 1995  	NO_MATCH
	Foitzik K, Lndner G, Mueller-Roever S, et al: Control of murine hair cycle  regression (catagen) by TGF-b1 in vivo. FASEB J 14:752±760, 2000  	10744631
	Glick AB, Sporn MB, Yuspa SH: Altered regulation of TGF-b and TGF-a in  primary keratinocytes and papillomas expressing v-Ha-ras. Mol Carcinog 4:210±  219, 1991  	2064727
	Hoodless PA, Wrana JL: Mechanism and function of signaling by the TGF-b  superfamily. Curr Top Microbiol Immunol 228:235±272, 1998  	9401209
	Kaartinen V, Voncken JW, Shuler C, Warburton D, Bu D, Heisterkamp N, Groffen  J: Abnormal lung development and cleft palate in mice lacking TGF-b3  indicates defects of epithelial±mesenchymal interaction. Nature Genet 11:415±  421, 1995  	7493022
	Kligman AM: The human hair cycle. J Invest Dermatol 33:307±316, 1959  	14409844
	Letterio JJ, Geiser AG, Kulkarni AB, Roche NS, Sporn MB, Roberts AB: Maternal  rescue of transforming growth factor-b1 null mice. Science 264:1936±1938,  1994  	NO_MATCH
	Massague J: TGF-b signal transduction. Annu Rev Biochem 67:753±791, 1998  	9759503
	Massague J, Cheifetz S, Laiho M, Ralph DA, Weis FM, Zentella A: Transforming  growth factor-beta. Cancer Surv 12:81±103, 1992  	1889609
	Millar SE, Willert K, Salinas PC, Roelink H, Nusse R, Suuman DJ, Barsh GS: WNT  signaling in the control of hair growth and structure. Dev Biol 207:133±149,  1999  	10049570
	Oberhammer FA, Pavelka M, Sharman S, Tiefenbacher R, Purchio A, Bursch W,  Schulte-Hermann R: Induction of apoptosis in cultured hepatocytes and in  regressing liver by transforming growth factor-b1. Proc Natl Acad Sci USA  89:5408±5412, 1992  	1608949
	Ohta S, Yanagihara K, Nagata Y: Mechanism of apoptotic cell death of human gastric  carcinoma cells mediated by transforming growth factor b. Biochem J 324:777±  782, 1994  	NO_MATCH
	Paus R, Foitzik K, Werker P, Bulfone-Paus S, Eichmuller S: Transforming growth  factor-b receptor type I and type II expression during hair development and  cycling. J Invest Dermatol 109:518±526, 1997  	9326384
	Roberts AB, Sporn MB: The transforming growth factor-bs. In: MB Sporn, AB  Robert (eds). Peptide Growth Factors and Their ReceptorsÐHandbook of  Experimental Pharmacology. Heidelberg: Springer-Verlag, 1990, pp 419±472  	NO_MATCH
	Schmid P, Cox D, Bilbe G, Maier R, McMaster GK: Differential expression of TGF b1, b2 and b3 genes during mouse embryogenesis. Development 111:117±130,  1991  	2015789
	Seiberg M, Marthinuss J, Stenn KS: Changes in expression of apoptosis-associated  genes in skin mark early catagen. J Invest Dermatol 104:78±82, 1995  	7798646
	Snaford LP, Ormsby I: Gittenburger-de Groot AC, et al: TGF-b2 knockout mice  have multiple developmental defects that are no overlapping with other TGF-b  knockout phenotype. Development 124:2659±2670, 1997  	9217007
	Soma T, Ogo M, Suzuki J, Takahasi T, Hibino T: Analysis of apoptotic cell death in  human hair follicles. J Invest Dermatol 112:518±526, 1998  	NO_MATCH
	St-Jacques B, Dassule HR, Karavanova I, et al: Sonic hedgehog signaling is essential  for hair development. Curr Biol 8:1058±1068, 1998  	9768360
5601506a.pdf
	Aboussekhra A, Biggerstaff M, Shivji MKK, et al: Mammalian DNA nucleotide  excision repair reconstituted with puri®ed protein components. Cell 80:859±  868, 1995  	7697716
	Arlett CF, Harcourt SA, Lehmann AR, Stevens S, Ferguson-Smith WA, Morley  WN: Studies of a new case of xeroderma pigmentosum (XP3BR) from  complementation group G with cellular sensitivity to ionizing radiation.  Carcinogenesis 1:745±751, 1980  	NO_MATCH
	Barrett SF, Tarone RE, Moshell AN, Ganges MB, Robbins JH: The post-UV  colony-forming ability of normal ®broblast strains and of the xeroderma  pigmentosum group G strain. J Invest Dermatol 76:59±62, 1981  	7462668
	Bootsma D, Kraemer KH, Cleaver JE, Hoeijmakers JHJ: Nucleotide excision repair  syndromes: xeroderma pigmentosum, Cockayne syndrome, and  trichothiodystrophy. In: Vogelstein B, Kinzler KW, eds. The Genetic Basis of  Human Cancer. New York: McGraw-Hill, 1998:pp 245±274  	NO_MATCH
	Busch DB, Cleaver JE, Glaser DA: Large-scale isolation of UV-sensitive clones of  CHO cells. Somatic Cell Genet 6:407±418, 1980  	7404271
	Cantani A, Bamonte G, Bellioni P, Tucci Bamonte M, Ceccoli D, Tacconi ML:  Rare syndromes. I. Cockayne syndrome: a review of the 129 cases so far  reported in the literature. Riv Eur Sci Med Farmacol 9:9±17, 1987  	NO_MATCH
	Carreau M, Eveno E, Quilliet X, et al: Development of a new easy complementation  assay for DNA repair de®cient human syndromes using cloned repair genes.  Carcinogenesis 16:1003±1009, 1995  	7767957
	Cheesbrough MJ, Kinmont PDC: Xeroderma pigmentosum ± a unique variant with  neurological involvement. Br J Dermatol 99:61±61, 1978  	698095
	Cleaver JE: Sensitivity of excision repair in normal human, xeroderma pigmentosum  variant and Cockayne's syndrome ®broblasts to inhibition by cytosine  arabinoside. J Cell Physiol 108:163±173, 1981  	7263770
	Cleaver JE, Charles WC, Thomas GH, McDowell ML: A deletion and an insertion  in the alleles for the xeroderma pigmentosum (XPA) DNA-binding protein in  mildly affected patients. Hum Mol Genet 4:1685±1687, 1995  	8541864
	Cleaver JE, Thompson LH, Richardson AS, States JC: A summary of mutations in  the UV-sensitive disorders: xeroderma pigmentosum, Cockayne syndrome,  and trichothiodystrophy. Hum Mutat 14:9±22, 1999  	10447254
	Clingen PH, Arlett CF, Cole J, et al: Correlation of UVC and UVB cytotoxicity with  the induction of speci®c photoproducts in T-lymphocytes and ®broblasts from  normal human donors. Photochem Photobiol 61:163±170, 1995  	7899505
	Constantinou A, Gunz D, Evans E, Lalle P, Bates PA, Wood RD, Clarkson SG:  Conserved residues of human XPG protein important for nuclease activity and  function in nucleotide excision repair. J Biol Chem 274:5637±5648, 1999  	10026181
	Cooper PK, Nouspikel T, Clarkson SG, Leadon SA: Defective transcription-coupled  repair of oxidative base damage in Cockayne syndrome patients from XP group  G. Science 275:990±993, 1997  	9020084
	De Laat WL, Jaspers NGJ, Hoeijmakers JHJ: Molecular mechanism of nucleotide  excision repair. Genes Dev 13:768±785, 1999  	10197977
	Emmert S, Kobayashi N, Khan SG, Kraemer KH: The xeroderma pigmentosum  group C gene leads to selective repair of cyclobutane pyrimidine dimers rather  than 6±4 photoproducts. Proc Natl Acad Sci USA 97:2151±2156, 2000  	10681431
	Emmert S, Schneider TD, Khan SG, Kraemer KH: The human XPG gene: gene  architecture, alternative splicing and single nucleotide polymorphisms. Nucl  Acids Res 29:1443±1452, 2001  	11266544
	Hamel BCK, Raams A, Schuitema-Dijkstra AR, Simons P, Van der Burgt I, Jaspers  NGJ, Kleijer WJ: Xeroderma pigmentosum±Cockayne syndrome complex: a  further case. J Med Genet 33:607±610, 1996  	8818951
	Ichihashi M, Fujiwara Y, Uehara Y, Matsumoto A: A mild form of xeroderma  pigmentosum assigned to complementation group G and its repair  heterogeneity. J Invest Dermatol 85:284±287, 1985  	4031543
	Jaeken J, Klocker H, Schwaiger H, Bellmann R, Hirsch-Kauffmann M, Schweiger  M: Clinical and biochemical studies in three patients with severe early infantile  Cockayne syndrome. Hum Genet 83:339±346, 1989  	2478446
	Johnson RE, Kondratick CM, Prakash S, Prakash L: hRAD30 mutations in the  variant form of xeroderma pigmentosum [see comments]. Science 285:263±265,  1999  	10398605
	Keijzer W, Jaspers NG, Abrahams PJ, et al: A seventh complementation group in  excision-de®cient xeroderma pigmentosum. Mutat Res 62:183±190, 1979  	492197
	Khan SG, Levy HL, Legerski R, et al: Xeroderma pigmentosum group C splice  mutation associated with autism and hypoglycinemia. J Invest Dermatol  111:791±796, 1998  	9804340
	Khan SG, Metter EJ, Tarone RE, et al: A new xeroderma pigmentosum group C  poly (AT) insertion/deletion polymorphism. Carcinogenesis 21:1821±1825,  2000  	11023539
	Klungland A, Hoss M, Gunz D, et al: Base excision repair of oxidative DNA damage  activated by XPG protein. Mol Cell 3:33±42, 1999  	10024877
	Knauf JA, Pendergrass SH, Marrone BL, Strniste GF, MacInnes MA, Park MS:  Multiple nuclear localization signals in XPG nuclease. Mutat Res DNA Repair  363:67±75, 1996  	8632779
	Kraemer KH, Coon HG, Petinga RA, Barrett SF, Rahe AE, Robbins JH: Genetic  heterogeneity in xeroderma pigmentosum: complementation groups and their  relationship to DNA repair rates. Proc Natl Acad Sci USA 72:59±63, 1975  	164028
	Kraemer KH, Slor H: Xeroderma pigmentosum. Clin Dermatol 3:33±69, 1985  	3833325
	Kraemer KH, Lee MM, Scotto J: Xeroderma pigmentosum. Cutaneous, ocular, and  neurologic abnormalities in 830 published cases. Arch Dermatol 123:241±250,  1987  	3545087
	Kraemer KH, Herlyn M, Yuspa SH, Clark WH Jr, Townsend GK, Neises GR,  Hearing VJ: Reduced DNA repair in cultured melanocytes and nevus cells  from a patient with xeroderma pigmentosum. Arch Dermatol 125:263±268,  1989  	2913963
	Kraemer KH, Lee M-M, Andrews AD, Lambert WC: The role of sunlight and DNA  repair in melanoma and nonmelanoma skin cancer: the xeroderma  pigmentosum paradigm. Arch Dermatol 130:1018±1021, 1994  	8053698
	Lalle P, Nouspikel T, Constantinou A, Thorel F, Clarkson SG: The founding  members of xeroderma pigmentosum group G produce XPG protein with  severely impaired endonuclease activity. J Invest Dermatol 118:344±351, 2002  	11841555
	Le Page F, Gentil A, Sarasin A: Repair and mutagenesis survey of 8-hydroxyguanine  in bacteria and human cells. Biochimie 81:147±153, 1999  	10214919
	Le Page F, Kwoh EE, Avrutskaya A, Gentil A, Leadon SA, Sarasin A, Cooper PK:  Transcription-coupled repair of 8-oxoguanine: requirement for XPG, TFIIH,  and CSB and implications for Cockayne syndrome. Cell 101:159±171, 2000  	10786832
	Lindenbaum Y, Dickson D, Rosenbaum P, Kraemer K, Robbins I, Rapin I:  Xeroderma pigmentosum/Cockayne syndrome complex: ®rst  neuropathological study and review of eight other cases. Europ J Paediatr  Neurol 5:225±242, 2001  	11764181
	MacInnes MA, Dickson JA, Hernandez RR, et al: Human ERCC5 cDNA-cosmid  complementation for excision repair and bipartite amino acid domains  conserved with RAD proteins of Saccharomyces cerevisiae and  Schizosaccharomyces pombe. Mol Cell Biol 13:6393±6402, 1993  	8413238
	Madura K, Prakash S: Nucleotide sequence, transcript mapping, and regulation of the  RAD2 gene of Saccharomyces cerevisiae. J Bacteriol 166:914±923, 1986  	3011752
	Masutani C, Kusumoto R, Yamada A, et al: The XPV (xeroderma pigmentosum  variant) gene encodes human DNA polymerase eta. Nature 399:700±704, 1999  	10385124
	Moriwaki SI, Stefanini M, Lehmann AR, et al: DNA repair and ultraviolet  mutagenesis in cells from a new patient with xeroderma pigmentosum group G  and Cockayne syndrome resemble xeroderma pigmentosum cells. J Invest  Dermatol 107:647±653, 1996  	8823375
	Mu D, Hsu DS, Sancar A: Reaction mechanism of human DNA repair excision  nuclease. J Biol Chem 271:8285±8294, 1996  	8626523
	Mudgett JS, MacInnes MA: Isolation of the functional human excision repair gene  ERCC5 by intercosmid recombination. Genomics 8:623±633, 1990  	2276736
	Nagy E, Maquat LE: A rule for termination-codon position within intron-containing  genes: when nonsense affects RNA abundance. Trends Biochem Sci 23:198±199,  1998  	9644970
	Nance MA, Berry SA: Cockayne syndrome. Review of 140 cases. Am J Med Genet  42:68±84, 1992  	1308368
	Norris PG, Hawk JL, Avery JA, Giannelli F: Xeroderma pigmentosum  complementation group G ± report of two cases. Br J Dermatol 116:861±866,  1987  	3620347
	Nouspikel T, Clarkson SG: Mutations that disable the DNA repair gene XPG in a  xeroderma pigmentosum group G patient. Hum Mol Genet 3:963±967, 1994  	7951246
	Nouspikel T, Lalle P, Leadon SA, Cooper PK, Clarkson SG: A common mutational  pattern in Cockayne syndrome patients from xeroderma pigmentosum group  G. Implications for a second XPG function. Proc Natl Acad Sci USA 94:3116±  3121, 1997  	9096355
	O'Donovan A, Wood RD: Identical defects in DNA repair in xeroderma  pigmentosum group G and rodent ERCC group 5 [see comments]. Nature  363:185±188, 1993  	8483505
	Okinaka RT, Perez-Castro AV, Sena A, et al: Heritable genetic alterations in a  xeroderma pigmentosum group G/Cockayne syndrome pedigree. Mutat Res  385:107±114, 1997  	9447232
	Park MS, Knauf JA, Pendergrass SH, Coulon CH, Strniste GF, Marrone BL,  MacInnes MA: Ultraviolet-induced movement of the human DNA repair  protein, Xeroderma pigmentosum type G, in the nucleus. Proc Natl Acad Sci USA  93:8368±8373, 1996  	8710877
	Protic-Sabljic M, Kraemer KH: One pyrimidine dimer inactivates expression of a  transfected gene in xeroderma pigmentosum cells. Proc Natl Acad Sci USA  82:6622±6626, 1985  	2995975
	Rapin I, Lindenbaum Y, Dickson DW, Kraemer KH, Robbins JH: Cockayne  syndrome and xeroderma pigmentosum. Neurology 55:1442±1449, 2000  	11185579
	Richards B, Skoletsky J, Shuber AP, et al: Multiplex PCR ampli®cation from the  CFTR gene using DNA prepared from buccal brushes/swabs. Hum Mol Genet  2:159±163, 1993  	7684637
	Robbins JH, Kraemer KH, Lutzner MA, Festoff BW, Coon HG: Xeroderma  pigmentosum. An inherited disease with sun sensitivity, multiple cutaneous  neoplasms, and abnormal DNA repair. Ann Intern Med 80:221±248, 1974  	4811796
	Robbins JH: Xeroderma pigmentosum. Defective DNA repair causes skin cancer and  neurodegeneration [clinical conference]. JAMA 260:384±388, 1988  	3379749
	Runger TM, Emmert S, Schadendorf D, Diem C, Epe B, Hellfritsch D: Alterations  of DNA repair in melanoma cell lines resistant to cisplatin, fotemustine, or  etoposide. J Invest Dermatol 114:34±39, 2000  	10620112
	Satokata I, Tanaka K, Miura N, et al: Three nonsense mutations responsible for group  A xeroderma pigmentosum. Mutat Res 273:193±202, 1992  	1372102
	Scherly D, Nouspikel T, Corlet J, Ucla C, Bairoch A, Clarkson SG:  Complementation of the DNA repair defect in xeroderma pigmentosum  group G cells by a human cDNA related to yeast Rad2. Nature 363:182±185,  1993  	8483504
	Shiomi T, Harada Y, Saito T, Shiomi N, Okuno Y, Yamaizumi M: An ERCC5  gene with homology to yeast RAD2 is involved in group G xeroderma  pigmentosum. Mutat Res 314:167±175, 1994  	7510366
	Slor H, Batko S, Khan SG, et al: Clinical, cellular, and molecular features of an Israeli  xeroderma pigmentosum family with a frameshift mutation in the XPC gene:  sun protection prolongs life. J Invest Dermatol 115:974±980, 2000  	11121128
	Stefanini M, Fawcett H, Botta E, Nardo T, Lehmann AR: Genetic analysis of  twenty-two patients with Cockayne syndrome. Hum Genet 97:418±423, 1996  	8834235
	Takahashi E, Shiomi N, Shiomi T: Precise localization of the excision repair gene,  ERCC5, to human chromosome 13q32.3-q33.1 by direct R-banding  ¯uorescence in situ hybridization. Jpn J Cancer Res 83:1117±1119, 1992  	1483924
	Van Steeg H, Kraemer KH: Xeroderma pigmentosum and the role of UV-induced  DNA damage in skin cancer. Mol Med Today 5:86±94, 1999  	10200950
	Vermeulen W, Jaeken J, Jaspers NG, Bootsma D, Hoeijmakers JH: Xeroderma  pigmentosum complementation group G associated with Cockayne syndrome.  Am J Hum Genet 53:185±192, 1993  	8317483
	Wakasugi M, Reardon JT, Sancar A: The non-catalytic function of XPG protein  human nucleotide excision repair. J Biol Chem 272:16030±16034, 1997  	NO_MATCH
	Wood RD: DNA repair in eukaryotes. Annu Rev Biochem 65:135±167, 1996  	8811177
	Zafeiriou DI, Thorel F, Andreou A, et al: Xeroderma pigmentosum group G with  severe neurological involvement and features of Cockayne syndrome in  infancy. Pediatr Res 49:407±412, 2001  	11228268
5601504a.pdf
	Aberer E, Schmidt BL, Breier F, Kinaciyan T, Luger A: Ampli®cation of DNA of  borrelia burgdorferi in urine samples of patients with granuloma annulare and  lichen sclerosus et atrophicus. Arch Dermatol 135:210±212, 1999  	10052416
	Apostolou I, Takahama Y, Belmant C, et al: Murine natural killer T (NKT) cells  contribute to the granulomatous reaction caused by mycobacterial cell. Proc  Natl Acad Sci USA 96:5141±5146, 1999  	NO_MATCH
	Bergeron A, Bonay M, Kambouchner M, et al: Cytokine patterns in tuberculous and  sarcoid granulomas: correlations with histopathologic features of the  granulomatous response. J Immunol 159:3034±3043, 1997  	9300729
	Buechner SA, Winkelmann RK, Banks PM: Identi®cation of T cell subpopulations  in granuloma annulare. Arch Dermatol 119:125±128, 1983  	6218788
	Fayyazi A, Schweyer S, Eichmeyer B, Herms J, Hemmerlein B, Radzun HJ, Berger  H: Expression of IFNgamma, coexpression of TNFalpha and matrix  metalloproteinases and apoptosis of T lymphocytes and macrophages in  granuloma annulare. Arch Dermatol Res 292:384±390, 2000  	10994772
	Genevee C, Diu A, Nierat J, et al: An experimentally validated panel of subfamily speci®c oligonucleotide primers (V alpha 1-w29/V beta 1-w24) for the study of  human T cell receptor variable V gene segment usage by polymerase chain  reaction. Eur J Immunol 22:1261±1269, 1992  	1533591
	Hogan LH, Weinstock JV, Sandor M: TCR speci®city in infection induced  granulomas. Immunol Lett 68:115±120, 1999  	10397165
	Kammula US, Lee KH, Riker AI, Wang E, Ohnmacht GA, Rosenberg SA,  Marincola FM: Functional analysis of antigen-speci®c T lymphocytes by serial  measurement of gene expression in peripheral blood mononuclear cells and  tumor specimens. J Immunol 163:6867±6875, 1999  	10586088
	Lim A, Toubert A, Pannetier C, Dougados M, Charron DPK, Even J: Spread of  clonal T cell expansions in rheumatoid arthritis patients. Hum Immunol 48:77±  83, 1996  	8824576
	Mempel M, Flageul B, Suarez F, et al: Comparison of the T cell patterns in leprous  and cutaneous sarcoid granulomas. Presence of Valpha24-invariant natural  killer T cells in T cell-reactive leprosy together with a highly biased T cell  receptor Valpha repertoire. Am J Pathol 157:509±523, 2000  	10934154
	Modlin RL, Horwitz DA, Jordan RR, Gebhard JF, Taylor CR, Rea TH:  Immunopathologic demonstration of T lymphocyte subpopulations and  interleukin 2 in granuloma annulare. Pediatr Dermatol 2:26±32, 1984a  	6438616
	Modlin RL, Vaccaro SA, Gottlieb B, et al: Granuloma annulare. Identi®cation of  cells in the cutaneous in®ltrate by immunoperoxidase techniques. Arch Pathol  Laboratory Med 108:379±382, 1984b  	6370193
	Muchenberger S, Schopf E, Simon JC: Phototherapy with UV-A-I for generalized  granuloma annulare. Arch Dermatol 133:1605, 1997  	9420554
	Muhlbauer JE: Granuloma annulare. J Am Acad Dermatol 3:217±230, 1980  	7005273
	Musette P, Bureau JF, Gachelin G, Kourilsky P, Brahic M: T lymphocyte repertoire  in Theiler's virus encephalomyelitis: the nonspeci®c in®ltration of the central  nervous system of infected SJL/J mice is associated with a selective local T cell  expansion. Eur J Immunol 25:1589±1593, 1995  	7614986
	O'Moore EJ, Nandawni R, Uthayakumar S, Nayagam AT, Darley CR: HIV associated granuloma annulare (HAGA): a report of six cases. Br J Dermatol  142:1054±1056, 2000  	10809877
	Pannetier C, Even J, Kourilsky P: T cell repertoire diversity and clonal expansions in  normal and clinical samples. Immunol Today 16:176±181, 1995  	7734044
	Schmutz JL: PUVA therapy of granuloma annulare. Clin Exp Dermatol 25:451, 2000  	11012606
	Sparrow G, Abell E: Granuloma annulare and necrobiosis lipoidica treated by jet  injector. Br J Dermatol 93:85, 1975  	1191532
	Steinman L: A few autoreactive cells in an autoimmune in®ltrate control a vast  population of nonspeci®c cells: a tale of smart bombs and the infantry. Proc Natl  Acad Sci USA 93:2253±2256, 1996  	8637858
	Toro JR, Chu P, Yen TS, LeBoit PE: Granuloma annulare and human  immunode®ciency virus infection. Arch Dermatol 135:1341±1346, 1999  	10566832
	Umbert P, Winkelmann RK: Granuloma annulare and sarcoidosis. Br J Dermatol  97:481±486, 1977  	588462
	Wang XH, Ohmen JD, Uyemura K, Rea TH, Kronenberg M, Modlin RL:  Selection of T lymphocytes bearing limited T cell receptor beta chains in the  response to a human pathogen. Proc Natl Acad Sci USA 90:188±192, 1993  	8419921
	Yamamura M, Uyemura K, Deans RJ, Weinberg K, Rea TH, Bloom BR, Modlin  RL: De®ning protective responses to pathogens: cytokine pro®les in leprosy  lesions. Science 254:277±279, 1991  	1925582
5601501a.pdf
	Arribas M, Regazzi R, Garcia E, Wollheim CB, De Camilli P: The stimulatory effect  of rabphilin 3a on regulated exocytosis from insulin-secreting cells does not  require an association±dissociation cycle with membranes mediated by Rab 3.  European J Cell Biol 74:209±216, 1997  	9402469
	Bennett DC, Cooper PJ, Hart IR: A line of non-tumorigenic mouse melanocytes,  syngeneic with the B16 melanoma and requiring a tumor promoter for growth.  Int J Cancer 39:414±418, 1987  	3102392
	Bock JB, Matern HT, Peden AA, Scheller RH: A genomic perspective on membrane  compartment organization. Nature 409:839±841, 2001  	11237004
	Callaghan J, Nixon S, Bucci C, Toh BH, Stenmark H: Direct interaction of EEA1  with Rab5b. European J Biochem 265:361±366, 1999  	10491193
	Casey P, Saeabra MC: Protein prenyltransferases. J Biol Chem 271:5289±5292, 1996  	8621375
	Chen D, Guo J, Miki T, Tachibana M, Gahl WA: Molecular cloning and  characterization of Rab27a and Rab27b, novel human Rab proteins shared by  melanocytes and platelets. Biochem Mol Med 60:27±37, 1997  	9066979
	Christoforidis S, McBride HM, Burgoyne RD, Zerial M: The Rab5 effector EEA1 is  a core component of endosome docking. Nature 397:621±625, 1999  	10050856
	DiMaio D, Treisman R, Maniatis T: Bovine papillomavirus vector that propagates as  a plasmid in both mouse and bacterial cells. Proc Natl Acad Sci USA 79:4030±  4034, 1982  	6287462
	Dekker-Ohno K, Hayasaka S, Takagishi Y, et al: Endoplasmic reticulum is missing in  dendritic spines of Purkinje cells of the ataxic mutant rat. Brain Res 714:226±  230, 1996  	8861629
	Echard A, Jollivet F, Martinez O, Lacapere JJ, Rousselet A, Janoueix-Lerosey I,  Goud B: Interaction of a Golgi-associated kinesin-like protein with. Rab6.  Science 279:580±585, 1998  	9438855
	Gilman M: Preparation and analysis of RNA. In: Ausubel F, Brent R, Kingston R,  Moore D, Seidman J, Smith J, Struhl K, eds. Current Protocols in Molecular  Biology, New York: John Wiley & Sons, 1997:pp 414±452  	NO_MATCH
	Haddad EK, Wu X, Hammer JA 3rd, Henkart PA: Defective granule exocytosis in  Rab27a-de®cient lymphocytes from Ashen mice. [see comments].. J Cell Biol  152:835±842, 2001  	11266473
	Horiuchi H, Lippe R, McBride HM, et al: A novel Rab5 GDP/GTP exchange factor  complexed to Rabaptin-5 links nucleotide exchange to effector recruitment  and function. Cell 90:1149±1159, 1997  	9323142
	Hughes EN, August JT: Characterization of plasma membrane proteins identi®ed by  monoclonal antibodies. J Biol Chem 256:664±671, 1981  	7451466
	Hume A, Collinson L, Rapak A, Gomes A, Hopkins C, Seabra M: Rab27a regulates  the peripheral distribution of melanosomes in melanocytes. J Cell Biol 152:F21±  F24, 2001  	11266470
	Jimenez M, Tsukamoto K, Hearing VJ: Tyrosinases from two different loci are  expressed by normal and by transformed melanocytes. J Biol Chem 266:1147±  1156, 1991  	1898730
	Jimbow K, Park JS, Kato F, Hirosaki K, Toyofuku K, Hua C, Yamashita T:  Assembly, target-signaling and intracellular transport of tyrosinase gene family  proteins in the initial stage of melanosome biogenesis. Pigment Cell Res 13:222±  229, 2000  	10952389
	Kobayashi T, Urabe K, Orlow SJ, et al: The Pmel 17/silver locus protein.  Characterization and investigation of its melanogenic function. J Biol Chem  269:29198±29205, 1994  	7961886
	Lin RC, Scheller RH: Mechanisms of synaptic vesicle exocytosis. Annu Rev Cell Dev  Biology 16:19±49, 2000  	11031229
	Masuda ES, Luo Y, Young C, et al: Rab37 is a novel mast cell speci®c GTPase  localized to secretory granules. FEBS Lett 470:61±64, 2000  	10722846
	Menasche G, Pastural E, Feldmann J, et al: Mutations in RAB27A cause Griscelli  syndrome associated with haemophagocytic syndrome. Nature Genet 25:173±  176, 2000  	10835631
	Nielsen E, Christoforidis S, Uttenweiler-Joseph S, et al: Rabenosyn-5, a novel Rab5  effector, is complexed with hVPS45 and recruited to endosomes through a  FYVE ®nger domain. J Cell Biol 151:601±612, 2000  	11062261
	Orlow SJ: The biogenesis of melanosomes. In: James E, Nordlund J, et al: eds. The  Pigmentary System: Physiology and Pathophysiology, New York: Oxford  University Press, 1998:pp 97±116  	NO_MATCH
	Pastural E, Barrat F, Dufourcq-Lagelouse R, et al: Griscelli disease maps to  chromosome 15q21 and is associated with mutations in the myosinVa gene.  Nat Genet 16:289±292, 1997  	9207796
	Pereira-Leal JB, Seabra MC: The mammalian Rab family of small GTPases:  de®nition of family and subfamily sequence motifs suggests a mechanism for  functional speci®city in the Ras superfamily. J Mol Biol 301:1077±1087, 2000  	10966806
	Pfeffer SR: Transport-vesicle targeting: tethers before snares Nature Cell Biol 1:E17±  E22, 1999  	10559876
	Quevedo WC, Fitzpatrick TB, SzaboÂ G, Jimbow K: Biology of melanocytes. In:  Dermatology in General Medicine. New York: McGraw-Hill, 1987:pp 224±251  	NO_MATCH
	Ramalho J, Tolmachova T, Hume A, McGuigan A, Gregory-Evans C, Huxley C,  Seabra M: Chromosomal mapping, gene structure and characterization of the  human and murine RAB27B gene. BMC Genet 2:2±13, 2001  	11178108
	Raposo G, Tenzaa D, Murphyb DM, Bersonb JF, Marksb MS: Distinct protein  sorting and localization to premelanosomes, melanosomes, and lysosomes in  pigmented melanocytic cells. J Cell Biol 152:809±824, 2001  	11266471
	Sawada K, Komatsu S, Haga H, Oda S, Fukui Y: Abnormal expression of tyrosine  hydroxylase immunoreactivity in Purkinje cells precedes the onset of ataxia in  dilute-lethal mice. Brain Res 844:188±191, 1999  	10536275
	Tolmachova T, Ramalho JS, Anant JS, Schultz RA, Huxley CM, Seabra MC:  Cloning, mapping and characterization of the human RAB27A gene. Gene  239:109±116, 1999  	10571040
	Westbroek W, Lambert J, Naeyaert J: The dilute locus and Griscelli syndrome:  gateways towards a better understanding of melanosome transport. Pigment Cell  Res 14:320±327, 2001  	11601653
	Wilson SM, Yip R, Swing DA, et al: A mutation in Rab27a causes the vesicle  transport defects observed in ashen mice. Proc Natl Acad Sci USA 97:7933±  7938, 2000  	10859366
	Woodman P: Vesicle transport: more work for the Rabs? Curr Biol 8:R199±R201,  1998  	9606091
	Woodman P: Biogenesis of the sorting endosome: the role of Rab5. Traf®c 9:695±  701, 2000  	11208157
	Wu WJ, Erickson JW, Lin R, Cerione RA: The gamma-subunit of the coatomer  complex binds Cdc42 to mediate transformation. [see comments]. Nature  405:800±804, 2000  	10866202
	Wu X, Bowers B, Wei Q, Kocher B, HammerJA III: Myosin V associates with  melanosomes in mouse melanocytes: evidence that myosin V is an organelle  motor. J Cell Sci 110:847±859, 1997  	9133672
	Wu X, Bowers B, Rao K, Wei Q, Hammer JA: Visualization of melanosome  dynamics within wild-type and dilute melanocytes suggests a paradigm for  myosin V function in vivo, J Cell Biol 143:1899±1918, 1998  	NO_MATCH
	Wu X, Rao K, Bowers M, Copeland N, Jenkins N, Hammer JA: Rab27a enables  myosin Va-dependent melanosome capture by recruiting the myosin to the  organelle. J Cell Sci 114:1091±1100, 2001  	11228153
	Zerial M, McBride H: Rab proteins as membrane organizers. Nature Rev Mol Cell  Biology 2:107±117, 2001  	11252952
	Zhang W, Efanov A, Yang SN, et al: Munc-18 associates with syntaxin and serves as  a negative regulator of exocytosis in the pancreatic beta-cell. J Biol Chem  275:41521±41527, 2000  	11024017
5601499a.pdf
	Allavena P, Bianchi D, Zhou D, van Damme J, Jilek P, Sozzani S, Mantovani A:  Induction of natural killer cell migration by monocyte chemoattractant  protein-1, -2 and -3. Eur J Immunol 24:3233±3236, 1994  	7805752
	Anisowicz A, Bardwell L, Sager R: Constitutive overexpression of a growth regulated gene in transformed Chinese hamster and human cells. Proc Natl Acad  Sci USA 84:7188±7192, 1987  	2890161
	Appay V, Dunbar PR, Cerundolo V, McMichael A, Czaplewski L, Rowland-Jones  SL: RANTES activates antigen-speci®c cytotoxic T lymphocytes in a mitogen like manner through cell surface aggregation. Int Immunol 8:1173±1182, 2000  	10917892
	Appay V, Rowland-Jones SL: RANTES. a versatile and controversial chemokine.  Trends Immunol 22:83±87, 2001  	11286708
	Baggiolini M, Walz A, Kunkel SL: Neutrophil-activating peptide-1/interleukin-8, a  novel cytokine that activates neutrophils. J Clin Invest 84:1045±1049, 1989  	2677047
	Baggiolini M, Dewald B, Moser B: Interleukin-8 and related chemotactic  cytokinesÐCXC and CC chemokines. Adv Immunol 55:97±179, 1994  	8304236
	Balentien E, Mufson BE, Shattuck RL, Derynck R, Richmond A: Effects of MGSA/  GRO alpha on melanocyte transformation. Oncogene 6:1115±1124, 1991  	1861861
	Balkwill F, Mantovani A: In¯ammation and cancer: back to Virchow? Lancet  357:539±544, 2001  	11229684
	Belperio JA, Keane MP, Arenberg DA, Addison CL, Ehlert JE, Burdick MD, Strieter  RM: CXC chemokines in angiogenesis. J Leukoc Biol 68:1±8, 2000  	10914483
	Berger EA, Murphy PM, Farber JM: Chemokine receptors as HIV-1 coreceptors:  roles in viral entry, tropism and disease. Annu Rev Immunol 17:657±670, 1999  	10358771
	Bonecchi R, Bianchi G, Bordignon PP, et al: Differential expression of chemokine  receptors and chemotactic responsiveness of type 1 T helper cells. J Exp Med  187:129±134, 1998  	9419219
	Bordoni R, Fine R, Murray D, Richmond A: Characterization of the role of  melanoma growth stimulating activity MGSA in the growth of normal  melanocytes, nevocytes and malignant melanocytes. J Cell Biochem 44:207±219,  1990  	2095366
	Boring L, Gosling J, Chensue SW, Kunkel SL, Farese RV: Severe reduction in  leukocyte adhesion and monocyte extravasation in mice de®cient in CC  chemokine receptor 2. Proc Natl Acad Sci USA 94:12053±12058, 1997  	NO_MATCH
	Boring L, Gosling J, Cleary M, Charo IF: Decreased lesion formation in CCR2±1±  mice reveals a role for chemokines in the initiation of atherosclerosis. Nature  394:894±897, 1998  	9732872
	Bottazzi B, Walter S, Govoni D, Colotta F, Mantovani A: Monocyte chemotactic  cytokine gene transfer modulates macrophage in®ltration, growth, and  susceptibility to IL-2 therapy of a murine melanoma 148:1280±1285, 1992  	1737940
	Brinckerhoff LH, Thompson LW, Slingluff CLJ: Melanoma vaccines. Curr Opin  Oncol 12:163±173, 2000  	10750729
	BroÈcker EB, Zwadlo G, Holzmann B, Macher E, Sorg C: In¯ammatory cell  in®ltrates in human melanoma at different stages of tumor progression. Int J  Cancer 41:562±567, 1988  	3128489
	Campisi J, Gray HE, Pardee AB, Dean M, Sonenshein GE: Cell-cycle control of c myc but not c-ras expression is lost following chemical transformation. Cell  36:241±247, 1984  	6692471
	Carr MW, Rioth SJ, Luther E, Rose SS, Springer A: Monocyte chemoattractant  protein 1 acts as a T-lymphocyte chemoattractant. Proc Natl Acad Sci USA  91:3652±3656, 1994  	8170963
	Clark EA, Golub TR, Lander ES, Hynes RO: Genomic analysis of metastasis reveals  an essential role for Rho C. Nature 406:532±535, 2000  	10952316
	Colombo MP, Maccalli C, Mattei S, Melani C, Radrizzani M, Parmiani G:  Expression of cytokine genes, including IL-6, in human malignant melanoma  cell lines. Melanoma Res 2:181±189, 1992  	1450672
	D'Ambosio D, Iellem A, Bonecchi R, Mazzeo D, Sozzani S, Montovani A,  Sinigaglia F: Selective up-regulation of chemokine receptors CCR4 and  CCR8 upon activation of polarized human type 2 Th cells. J Immunol  161:5111±5115, 1998  	9820476
	Dieu MC, Vanbervliet B, Vicari A, et al: Selective recruitment of immature and  mature dendritic cells by distinct chemokines expressed in different anatomic  sites. J Exp Med 188:373±386, 1999  	9670049
	Fishman D, Irena B, Kellman-Pressman S, Karas M, Segal S: The role of MHC class I  glycoproteins in the regulation of induction of cell death in immunocytes by  malignant melanoma cells. Proc Natl Acad Sci USA 98:1740±1744, 2001  	11172021
	FoÈrster E, Kirnbauer R, Urbanski A, Keck A, Luger TA, Schwartz T: Human  melanoma cells produce interleukin-8 which functions as an autocrine growth  factor. Arch Dermatol Res 283:26, 1991  	NO_MATCH
	FoÈrster R, Schubel A, Breit®eld D, Kremmer E, Renner-Muller I, Wolf E, Lipp M:  CCR7 coordinates the primary immature response by establishing functional  microenvironments in secondary lymphoid organs. Cell 99:23±33, 1999  	10520991
	Fujisawa N, Hayashi S, Miller EJ: A synthetic peptide inhibitor for a-chemokines  inhibits the tumor growth and pulmonary metastasis of human melanoma cells  in nude mice. Melanoma Res 9:105±114, 1999  	10380932
	Geiser T, Dewald B, Ehrengruber MU, Clark-Lewis I, Baggiolini M: The  interleukin-8-related chemotactic cytokines GRO alpha, GRO beta, and  GRO gamma activate human neutrophil and basophil leukocytes. J Biol Chem  268:15419±15424, 1993  	8340371
	Gerber BO, Zanni MP, Uguccioni M, et al: Functional expression of the eotaxin  receptor CCR3 in T lymphocytes co-localizing with eosinophils. Curr Biol  7:836±843, 1997  	9480044
	Giavazzi R, Garofalo A, Bani MR, et al: Interleukin 1-induced augmentation of  experimental metastases from a human melanoma in nude mice. Cancer Res  50:4771±4775, 1990  	2196116
	Gonzolez EB, Wiley H, Hwang ST: CC chemokine receptor 7 (CCR-7)  transduced B16 melanoma cells show enhanced early metastasis to regional  lymph nodes. Meet Soc Invest Dermatol 35:200, 2001  	NO_MATCH
	Graves DT, Barnhill R, Galanopoulos T, Antoniades HN: Expression of monocyte  chemotactic protein-1 in human melanoma in vivo. Am J Pathol 140:9±14,  1992  	1731532
	Greene MH, Sanders RJ, Chu FC, Clark WH, Elder DE, Cogan DG: The familial  occurrence of cutaneous melanoma, intraocular melanoma, and the dysplastic  nevus syndrome. Am J Opthalmol 96:238±245, 1983  	6881247
	Gruis N, Sandkuijl L, Weber J, Zee A, Borgstein A, Bergman W, Frants R: Linkage  analysis in Dutch familial atypical multiple mole±melanoma syndrome families.  Effect of naevus count. Melanoma Res 3:271±277, 1993  	8219760
	Gutman M, Singh RK, Xie K, Bucana CD, Fidler IJ: Regulation of interleukin-8  expression in human melanoma cells by the organ environment. Cancer Res  55:2470±2475, 1995  	7758001
	Hadida F, Vieillard V, Autran B, Clark-Lewis I, Baggiolini M, Debre P: HIV-speci®c  T cell cytotoxicity mediated by RANTES via the chemokine receptor CCR3.  J Exp Med 188:609±614, 1998  	9687538
	Halpern AC, Guery D 4th, Elder DE, Clark WH Jr, Synnestvedt M, Norman S,  Ayerle R: Dysplastic nevi as risk markers of sporadic (nonfamilial) melanoma.  Arch Dermatol 127:995±999, 1991  	2064418
	Hammond MEW, Shyamala V, Siani MA, et al: Receptor recognition and speci®city  of interleukin-8 is determined by residues that cluster near a surface-accessible  hydrophobic pocket. J Biol Chem 271:8228±8235, 1996  	8626516
	Haskill S, Peace A, Morris J, et al: Identi®cation of three related human GRO genes  encoding cytokine functions. Proc Natl Acad Sci USA 87:7732±7736, 1990  	2217207
	Hillibrand EF, Neville AM, Coventry BJ: Immunohistochemical localization of  CD1a-positive putative tumor in®ltrating dendritic cells in human breast  tumors. Br J Cancer 79:940±944, 1999  	10070894
	Hofman UB, Westphal JR, Waas ET, Becker JC, Ruiter DJ, van Muijen GNP:  Coexpression of integrin avb3 and matrix metalloproteinase-2 (MMP-2)  coincides with MMP-2 activation: Correlation with melanoma progression. J  Invest Deratol 115:625±632, 2000  	10998134
	Hogaboam C, Bone-Larson C, Steinhauser M, et al: Novel CXCR2-dependent liver  regenerative qualities of ELR-containing CXC chemokines. FASEB J  13:1565±1574, 1999  	10463948
	Holmes WE, Lee J, Kuang WJ, Rice GC, Wood WI: Structure and functional  expression of a human interleukin-8 receptor. Science 253:1278±1280, 1991  	1840701
	Homey B, Wang W, Soto H, et al: Cutting edge: the orphan chemokine receptor G  protein-coupled receptor-2 (GPR-2, CCR10) binds the skin-associated  chemokine CCL27 (CTAK/ALP/ILC). J Immunol 164:3465±3470, 2000  	10725697
	Hussussian C, Struewing JP, Goldstein AM, et al: Germline p16 mutations in familial  melanoma. Nat Genet 8:15±21, 1994  	7987387
	Imai T, Nagira M, Takagi S, et al: Selective recruitment of CCR4-bearing Th2 cells  toward antigen-presenting cells by the CC chemokines thymus and activation regulated chemokine and macrophage-derived chemokine. Int Immunol 11:81±  88, 1999  	10050676
	Kirkwood J, Strawderman M, Ernstoff M, Smith T, Borden E, Blum R: Interferon  alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern  Cooperative Oncology Group Trial EST 1684. J Clin Oncol 14:7±17, 1996  	8558223
	Kulke R, Bornscheuer E, Schluter C, Bartels J, Rowert J, Sticherling M,  Christophers E: The CXC receptor 2 is overexpressed in psoriatic epidermis.  J Invest Dermatol 110:90±94, 1998  	9424095
	Kurihara T, Warr G, Loy J, Bravo R: Defects in macrophage recruitment and host  defense in mice lacking the CCR2 chemokine receptor. J Exp Med 186:1757±  1762, 1997  	9362535
	Kuziel WA, Morgan SJ, Dawson TC, Grif®n S, Smithies O, Ley K, Maeda N: Severe  reduction in leukocyte adhesion and monocyte extravasation in mice de®cient  in CC chemokine receptor 2. Proc Natl Acad Sci USA 94:12053±12058, 1997  	NO_MATCH
	Lawson DH, Thomas HG, Roy RG, Gordon DS, Chawla RK, Nixon DW,  Richmond A: Preparation of a monoclonal antibody to a melanoma growth stimulatory activity released into serum-free culture medium by Hs0294  malignant melanoma cells. J Cell Biochem 34:169±185, 1987  	3611199
	Lee J, Horuk R, Rice GC, Bennett GL, Camerato T, Wood WI: Characterization of  two high af®nity human interleukin-8 receptors. J Biol Chem 267:16283±  16287, 1992  	1379593
	Lee J, Cacalano G, Camerato T, Toy K, Moore M, Wood W: Chemokine binding  and activities mediated by the mouse IL-8 receptor. J Immunol 155:2158±2164,  1995  	7636264
	Luca M, Huang S, Gershenwald JE, Singh RK, Reich R, Bar-Eli M: Expression of  interleukin-8 by human melanoma cells up-regulates MMP-2 activity and  increases tumor growth and metastasis. Am J Pathol 151:1105±1113, 1997  	9327744
	Luther SA, Cyster JG: Chemokines as regulators of T cell differentiation. Nature  Immunol 2:102±107, 2001  	11175801
	MacDougall JR, Bani MR, Muschel RJ, Kebel RS: ``Proteolytic switching'' opposite  patterns of regulation of gelatinase B and its inhibitor TIMP-1 during human  melanoma progression and consequences of gelatinase B overexpression. Br J  Cancer 80:504±512, 1999  	10408860
	Mantovani A, Bottazzi B, Colotta F, Sozzani S, Ruco L: The origin and function of  tumor-associated macrophages. Immunol Today 13:265±270, 1992  	1388654
	Matsushima K, Morishita K, Yoshimura T, et al: Molecular cloning of a human  monocyte-derived neutrophil chemotactic factor (MDNCF) and the induction  of MDNCF mRNA by interleukin 1 and tumor necrosis factor. J Exp Med  167:1883±1893, 1988  	3260265
	Mohler T, Scheibenbogen C, Hafele J, Willhauck M, Keilholz U: Regulation of  interleukin-8 mRNA expression and protein secretion in a melanoma cell line  by tumor necrosis factor-alpha and interferon-gamma. Melanoma Res 6:307±  311, 1996  	8873050
	Moore JP, Trkola A: HIV type 1 coreceptors, neutralization serotypes, and vaccine  development. AIDS Res Hum Retroviruses 13:733±736, 1997  	9171216
	Morales J, Homey B, Vicari AP, et al: CTAK, a skin-associated chemokine that  preferentially attracts skin-homing memory T cells. Proc Natl Acad Sci USA  96:14470±14475, 1999  	10588729
	Mrowietz U, Schwenk U, Maune S, et al: The chemokine RANTES is secreted by  human melanoma cells and is associated with enhanced tumour formation in  nude mice. Br J Cancer 79:1025±1031, 1999  	10098731
	Mueller SG, Schraw WP, Richmond A: Melanoma growth stimulatory activity  enhances the phosphorylation of the class II interleukin-8 receptor in non hematopoietic cells. J Biol Chem 269:1973±80, 1994  	NO_MATCH
	Mueller SG, Schraw WP, Richmond A: Activation of protein kinase C enhances the  phosphorylation of the type B interleukin-8 receptor and stimulates its  degradation in non-hematopoietic cells. J Biol Chem 270:10439±10448, 1995  	7737978
	Mueller SG, White JR, Schraw WP, Lam C, Richmond A: Ligand-induced  desensitization of the human CXC chemokine receptor-2 is modulated by  multiple serine residues in the carboxyl-terminal domain of the receptor. J Biol  Chem 272:8207±8214, 1997  	9079638
	Mukaida N: Interleukin 8. An expanding universe beyond neutrophil chemotaxis  and activation. Int J Hematol 72:391±398, 2000  	11197203
	Muller A, Homey B, Soto H, et al: Involvement of chemokine receptors in breast  cancer metastasis. Nature 410:50±56, 2001  	11242036
	Murphy PM: Chemokine receptors: structure, function and role in microbial  pathogenesis. Cytokine Growth Factor Rev 7:47±64, 1996  	8864354
	Murphy PM, Tiffany HL: Cloning of complementary DNA encoding a functional  human interleukin-8 receptor. Science 253:1280±1283, 1991  	1891716
	Nesbit M, Schaider H, Miller TH, Herlyn M: Low-level monocyte chemoattractant  protein-1 stimulation of monocytes leads to tumor formation in  nontumorigenic melanoma cells. J Immunol 166:6483±6490, 2001  	11359798
	Newton-Bishop JA, Bataille V, Pinney E, Bishop DT: Family studies in melanoma:  identi®cation of atypical mole syndrome. Melanoma Res 4:199±206, 1994  	NO_MATCH
	Newton-Bishop JA, Wachsmuth RC, Harland M, et al: Genotype/phenotype and  penetrance studies in melanoma families with germline CDKN2A mutations. J  Invest Dermatol 114:28±33, 2000  	10620111
	Nieto M, Frade JMR, Sancho D, Mellado M, Martinez AC, Sanchez-Madrid F:  Polarization of chemokine receptors to the leading edge during lymphocyte  chemotaxis. J Exp Med 186:153±158, 1997  	9207004
	Norgauer J, Metzner B, Schraufstutter I: Expression and growth-promoting function  of the IL-8 receptor beta in human melanoma cells. J Immunol 156:1132±1137,  1996  	8557989
	O'Garra A, McEvoy LM, Zlotnik A: T-cell subsets: chemokine receptors guide the  way. Curr Biol 8:R646±R649, 1998  	9740797
	Owen JD, Strieter R, Burdick M, Haghnegahdar H, Nanney L, Shattuck-Brandt R,  Richmond A: Enhanced tumor-forming capacity for immortalized  melanocytes expressing melanoma growth stimulatory activity/growth regulated cytokine b and g proteins. Int J Cancer 73:94±103, 1997  	9334815
	Petersen F, Flad H-D, Brandt E: Neutrophil-activating peptides NAP-2 and IL-8  bind to the same sites on neutrophils but interact in different ways:  Discrepancies in binding af®nities, receptor densities, and biologic effects. J  Immunol 152:2467±2478, 1994  	8133058
	Platz A, Hansson J, Ringborg U: Screening of germline mutations in the CDK4,  CDKN2C and TP53 genes in familial melanoma: a clinic-based population  study. Int J Cancer 78:13±15, 1998  	9724087
	Platz A, Ringborg U, Hansson J: Hereditary cutaneous melanoma. Cancer Biol  10:319±326, 2000  	10966854
	Richmond A, Lawson DH, Nixon DW, Stevens JS, Chawla RK: Characterization of  autostimulatory and transforming growth factors from human melanoma cells.  Cancer Res 45:6390±6394, 1985  	3864531
	Richmond A, Thomas HG: Puri®cation of melanoma growth stimulatory activity. J  Cell Physiol 129:375±384, 1986  	3465735
	Richmond A, Balentien E, Thomas HG, et al: Molecular characterization of  melanoma growth stimulatory activity, a growth factor structurally related to b thromboglobulin. EMBO J 7:2025±2033, 1988  	NO_MATCH
	Romagnani P, Annunziato F, Lasagni L, et al: Cell cycle-dependent expression of  CXC chemokine receptor 3 by endothelial mediates angiostatic activity. J Clin  Invest 107:53±63, 2001  	11134180
	Rottman JB, Smith TL, Ganley KG, Kikuchi T, Krueger JG: Potential role of the  chemokine receptors CXCR3, CCR4 and integrin alphaEbeta7 in the  pathogenesis of psoriasis vulgaris. Lab Invest 81:335±347, 2001  	11310827
	Salcedo R, Resau JH, Halverson D, et al: Differential expression and responsiveness  of chemokine receptors (CXCR1-3) by human microvascular endothelial cells  and umbilical vein cells. FASEB J 14:2055±2064, 2000  	NO_MATCH
	Sallusto F, Mackay CR, Lanzavecchia A: Selective expression of the eotaxin receptor  CCR3 by human T helper 2 cells. Science 277:2005, 1997  	NO_MATCH
	Sallusto F, Lenig D, Mackay CR, Lanzavecchia A: Flexible programs of chemokine  receptor expression in human polarized T helper 1 and 2 lymphocytes. J Exp  Med 187:875±883, 1998  	9500790
	Sallusto F, Mackay CR, Lanzavecchia A: The role of chemokine receptors in primary  effector and memory immune responses. Annu Rev Immunol 18:593±620, 2000  	10837070
	Schadendorf D, Mueller A, Alermissen B, Worm M, Sticherling M, Czarnetzki BM:  IL-8 produced by human malignant melanoma cells in vitro is an essential  autocrine growth factor. J Immunol 151:2667±2675, 1993  	8360485
	Schall TJ, Bacon K, Toy KJ, Goeddel DV: Selective attraction of monocytes and T  lymphocytes of the memory phenotype by cytokine RANTES. Nature Immunol  347:669±671, 1990  	1699135
	Schall TJ: Biology of the RANTES/SIS cytokine family. Cytokine 3:165±183, 1999  	NO_MATCH
	SchroÈder J, Christophers E: Secretion of novel and homologous neutrophil-activating  peptides by LPS-stimulated human endothelial cells. J Immunol 142:244±251,  1989  	2642504
	SchroÈder J, Mrowietz U, Morita E, Christophers E: Puri®cation and partial  biochemical characterization of a human monocyte-derived, neutrophil activating peptide that lacks interleukin 1 activity. J Immunol 139:3474±3483,  1987  	2824608
	SchroÈder JM, Sticherling M, Henneicke HH, Preissner WC, Christophers E: IL-1a  or tumor necrosis factor-a stimulate release of three NAP-1/IL-8-related  neutrophil chemotactic proteins in human dermal ®broblasts. J Immunol  144:2223±2232, 1990  	2179408
	Sebastiani S, Allavena P, Albanesi C, et al: Chemokine receptor expression and  function in CD4+ T lymphocytes with regulatory activity. J Immunol 166:996±  1002, 2001  	11145678
	Shattuck-Brandt RL, Richmond A: Enhanced degradation of IkB contributes to  endogenous activaiton of NFkB. Cancer Res 57:3032±3039, 1997  	NO_MATCH
	Sica A, Saccani A, Borsatti CA, et al: Bacterial lipopolysaccharide rapidly inhibits  expression of C-C chemokine receptors in human monocytes. J Expm Med  185:969±974, 1997  	9120403
	Sica A, Saccani A, Bottazzi B, et al: Defective expression of the monocyte  chemotactic protein-1 receptor CCR2 in macrophages associates with human  ovarian carcinoma. J Immunol 164:733±738, 2000  	10623817
	Singh RK, Gutman M, Radinsky R, Bucana CD, Fidler IJ: Expression of interleukin  8 correlates with the metastatic potential of human melanoma cells in nude  mice. Cancer Res 54:3242±3247, 1994  	8205546
	Singh RK, Gutman M, Reich R, Bar-Eli M: Ultraviolet B irradiation promotes  tumorigenic and metastatic properties in primary cutaneous melanoma via  induction of interleukin 8. Cancer Res 55:3669±3674, 1995  	7543020
	Singh RK, Varney ML: Regulation of interleukin 8 expression in human malignant  melanoma cells. Cancer Res 58:1532±15367, 1998  	9537260
	Sozzani S, Allavena P, D'Amico G, et al: Cutting edge: Differential regulation of  chemokine receptors during dendritic maturation: a model for their traf®cking  properties. J Immunol 161:1083±1086, 1998  	9686565
	Strieter RM, Polverini PJ, Kunkel SL, et al: The functional role of the ELR motif in  CXC chemokine-mediated angiogenesis. J Biol Chem 270:27348±27357, 1995  	7592998
	Torisu H, Ono MH, Kiryu H, et al: Macrophage in®ltration correlates with tumor  stage and angiogenesis in human melanoma. Possible involvement of TNF-a  and IL-1a. Int J Cancer 85:182±188, 2000  	10629075
	Ueno T, Toi M, Saji H, et al: Signi®cance of macrophage chemoattractant protein-1  in macrophage recruitment, angiogenesis and survival in human breast cancer.  Clin Cancer Res 6:3282±3289, 2000  	10955814
	Valente AJ, Graves CE, Vialle-Valentin R, Delgado R, Schwartz CJ: Puri®cation of a  monocyte chemotactic factor secreted by nonhuman primate vascular cells in  culture. Biochemistry 27:4162±4168, 1988  	3415979
	Van Ravenswaay-Claasen HH, Kluin PM, Fleuren GJ: Tumor in®ltrating cells in  human cancer. On the possible role of CD16+ macrophages in antitumor  cytotoxicity. Lab Invest 67:166±174, 1992  	1501443
	Walz A, Peverni P, Aschauer H, Bagglioni M: Puri®cation and amino acid  sequencing of NAF, a novel neutrophil-activating factor produced by  monocytes. Biochem Biophys Res Commun 149:755±761, 1987  	3322281
	Wang JM, Taraboretti G, Matsushima K, Van Damme J, Mantovani A: IL-8 induces  haptotaxis and chemotaxis of melanoma cells. Biochem Biophys Res Commun  169:165±169, 1990  	NO_MATCH
	Ward SG, Westwick J: Chemokines: understanding their role in T-lymphocyte  biology. Biochem 333:457±470, 1998  	9677302
	Wu GD, Lai EJ, Huang N, Wen X: Oct-1 and CCAAT/enhancer-binding protein  (C/EBP) bind to overlapping elements within the interleukin-8 promoter: the  role of Oct-1 as a transcriptional repressor. J Biol Chem 272:2396±2403, 1997  	8999951
	Yang J, Richmond A: Constitutive Ikb kinase activity correlates with nuclear factor kB activation in human melanoma cells. Cancer Res 61:4901±4909, 2001  	11406569
	Yang T-Y, Chen S-C, Leach MW, et al: Transgenic expression of the chemokine  receptor encoded by human herpesvirus 8 induces an angioproliferative disease  resembling Kaposi's sarcoma. J Exp Med 191:445±454, 2000  	10662790
	Yang W, Wang D, Richmond A: Role of clathrin-mediated endocytosis in CXCR2  sequestration, resensitization and signal transduction. J Biol Chem 274:11328±  11333, 1999  	10196223
	Yla-Herttuala S, Lipton B, Rosenfeld M, et al: Expression of monocyte  chemoattractant protein 1 in macrophage-rich areas of human and rabbit  atherosclerotic lesions. Proc Natl Acad Sci USA 88:5252±5256, 1991  	2052604
	Yoshimura T, Matsushima K, Tanaka S, Robinson EA, Appella E, Oppenheim JJ,  Leonard EJ: Puri®cation of a human monocyte-derived neutrophil chemotactic  factor that has peptide sequence similarity to other host defense cytokines. Proc  Natl Acad Sci USA 84:9233±9237, 1987  	3480540
	Yoshimura T, Yuhki N, Moore SK, Appella E, Lerman MI: Human monocyte  chemoattractant protein-1. Full length DNA cloning, expression in mitogen stimulated blood mononuclear leukocytes, and sequence similarity to mouse  competence gene JE. FEBS Lett 244:487±493, 1989  	2465924
	Zella D, Barabitskaja O, Burns JM, et al: Interferon-gamma increases expression of  chemokine receptors CCR1, CCR3 and CCR5, but no CXCR4 in  monocytoid U937 cells. Blood 91:444±450, 1991  	NO_MATCH
	Zhang H, Shepherd AT, Eason DD, et al: Retinoblastoma protein expression leads to  reduced Oct-1 DNA binding activity and enhances interleukin-8 expression.  Cell Growth Differ 10:457±465, 1999  	10437913
	Zingoni A, Soto H, Hedrick JA, et al: The chemokine receptor CCR8 is  preferentially expressed in Th2 but not in Th1 cells. J Immunol 161:547±551,  1998  	9670926
	Zlotnik A, Yoshie O: Chemokines: a new classi®cation system and their role in  immunity. Immunity 12:121±127, 2000  	10714678
[36-6]0311211200_p580.pdf
	Bewley, J. D. and Marcus, A. (1990) Gene expression in seed  development and germination. Prog. Nucleic Acid Res. Mol.  Biol. 38, 165-193.  	2183293
	Butler, W. M. and Cuming, A. C. (1993) Differential molecular  responses to abscisic acid and osmatic stress in viviparous  maize embryos. Planta 189, 47-54.  	NO_MATCH
	Caliskan, M. and Cuming, A. C. (1998) Spatial specificity of  H2O2-generating oxalate oxidase gene expression during wheat  embryo germination. Plant J. 15, 165-71.  	9721675
	Caliskan, M. and Cuming, A. C. (2000) Temporal and spatial  determination of germin biosynthesis in wheat tissues. Turk. J.  Biol. 24, 775-782.  	NO_MATCH
	Caliskan, M. (2000) Germin, an oxalate oxidase, has a function in  many aspects of plant life. Turk. J. Biol. 24, 717-724.  	NO_MATCH
	Caliskan, M. (2001) In situ localization of germin gene expression  during auxin induced callus formation. Turk. J. Biol. 25, 387 396.  	NO_MATCH
	Cuming, A. C., Turet, M. and Butler, W. M. (1996) Gene  expression and embryonic maturation in cereals; in  Embryogenesis: the generation of a plant, Wang, T. L. and  Cuming, A. C. (eds), pp. 113-132, BIOS Scientific Publishers,  Oxford, UK  	NO_MATCH
	Fincher, G. B. (1989) Molecular and cellular biology associated  with endosperm mobilization in germinating cereal grains. Ann.  Rev. Plant Physiol. Plant Mol. Biol. 40, 305-346.  	NO_MATCH
	Futers, T. S., Onde, S. and Cuming, A. C. (1993) Sequence  analysis of two tandemly linked Em genes from wheat. Plant  Mol. Biol. 23, 1067-1072.  	8260627
	Goldberg, R. B., Barker, S. J. and Perez-Grau, L. (1989)  Regulation of gene expression during plant embryogenesis. Cell  56, 149-160.  	2643470
	Gurr, S. J., McPherson, M. J., Scollon, C., Atkinson, H. J. and  Bowles, D. J. (1991) Gene expression in nematode-infected  plant roots. Mol. Gen. Genet. 226, 361-366.  	2038302
	Jackson, D. P. (1991) In situ hybridization in plants; in Molecular  plant pathology: a practical approach, Bowles, D. J., Gurr, S.  J. and McPhereson, M. (eds), pp. 163-174, Oxford University  Press, Oxford, UK  	NO_MATCH
	Knight, C. D. Seghal, A., Atwal, K., Wallace, J. C., Cove, D. J.,  Coates, D., Quatrano, R. S., Bahadur, S., Stockley, P. G. and  Cuming, A. C. (1995) Molecular responses to abscisic acid and  stress are conserved between moss and cereals. Plant Cell 7,  499-506.  	NO_MATCH
	Lane, B. G. (2002) Oxalate, germins, and higher-plant pathogens.  IUBMB Life 53, 67-75.  	12049198
	Maniatis, T., Fritsch, E. F. and Sambrook, J. (1982) Molecular  Cloning: A Laboratory Manual, 2nd ed., Cold Spring Harbor  Laboratory Press, New York, USA  	NO_MATCH
	Morris, P. C., Kumar, A., Bowles, D. J. and Cuming, A. C. (1990)  Osmatic stress and abscisic acid induce expression of the wheat  Em genes. Eur. J. Biochem. 190, 625-630.  	2142646
	Reed, K. C. and Mann, D. A. (1985) Rapid transfer of DNA from  agarose gels to nylon membranes. Nucleic Acids Res. 13, 7207 7221.  	4059056
	Rogers, S. O. and Quatrano, R. S. (1983) Morphological staging  of wheat caryopsis development. Amer. J. Bot. 70, 308-311.  	NO_MATCH
	Scutt, C. P. and Gilmartin, P. M. (1997) High-stringency  subtraction for the identification of differentially regulated  cDNA clones. Biotechniques 23, 468-470.  	9298218
	Williamson, J. D., Quatrano, R. S. and Cuming, A. C. (1985) Em  polypeptide and its messenger RNA levels are modulated by  abscisic acid during embryogenesis in wheat. Eur. J. Biochem.  152, 501-507.  	2932332
[36-6]0311211158_p552.pdf
	Armand, P., Kirshenbaum, K., Goldsmith, R. A., Farr-Jones, S.,  Barron, A. E., Truong, K. T., Dill, K. A., Mierke, D. F.,  Cohen, F. E., Zuckermann, R. N. and Bradley, E. K. (1998)  NMR determination of the major solution conformation of a  peptoid pentamer with chiral side-chains. Proc. Natl. Acad. Sci.  USA 95, 4309-4314.  	9539733
	Baek, B.-H., Lee, M.-R., Kim, K.-Y., Cho, U.-I., Boo, D. W. and  Shin, I. (2003) Novel consecutive beta- and gamma-turn  mimetics composed of alpha-aminooxy tripeptides Org. Lett. 5,  971-974.  	12659551
	Bax, A. and Davis, D. G. (1985) MLEV-17 based 2D  homonuclear magnetization transfer spectroscopy. J. Magn.  Reson. 65, 355-360.  	NO_MATCH
	Brüger, A. T., Adams, P. D., Clore, G. M., DeLano, W. L., Gros,  P., Gross-Kunstleve, R. W., Jing, J.-S., Kuszewski, J., Nilges,  M., Pannu, N. S., Read, R. J., Rice, L. M., Simonson, T. and  Warren, G. (1998) Crystallography and NMR system-a new  software suite for macromolecular structure determination. Acta  Cryst. D54, 905-921.  	9757107
	Chung Y. J., Huck, B. R., Christianson, L. A., Stanger, H. E.,  Krauthauser, S., Powell, D. R. and Gellman, S. H. (2000)  Stereochemical control of hairpin formation in beta-peptides  containing dinipecotic acid reverse turn segments. J. Am. Chem.  Soc. 122, 3995-4004.  	NO_MATCH
	Clore, G. M., Brunger, A. T., Karplus, M. and Gronenborn, A. M.  (1986) Application of molecular dynamics with interproton  distance restraints to three-dimensional protein structure  determination. A model study of crambin. J. Mol. Biol. 191,  523-551.  	3029386
	Crisma, M., Formaggio, F., Toniolo, C., Yoshikawa, T. and  Wakamiya, T. (1999) Flat peptides. J. Am. Chem. Soc. 121,  3272-3278.  	NO_MATCH
	Datta, A. and Veeresa, G. (2000) A stereoselective route to  hydroxyethylamine dipeptide isosteres. J. Org. Chem. 65, 7609 7611.  	11076622
	Davis, D. G. and Bax, A. (1985) Assignment of complex 1H  NMR spectra via two-dimensional homonuclear Hartmann Hahn spectroscopy. J. Am. Chem. Soc. 107, 2820-2821.  	NO_MATCH
	Déziel, R., Plante, R., Caron, V., Grenier, L., Llinas-Brunet, M.,  Duceppe, J.-S., Malenfant, E. and Moss, N. (1996) Practical  and diastereoselective synthesis of ketomethylene dipeptide  isosteres of the type AA-psi(Coch2)Asp. J. Org. Chem. 61,  2901-2903.  	NO_MATCH
	Gante, J. (1994) Peptidomimetics-tailored enzyme inhibitors.  Angew. Chem. Int. Ed. Engl. 33, 1699-1720.  	NO_MATCH
	Gellman, S. H. (1998) Foldamers-A manifesto. Acc. Chem. Res.  31, 173-180.  	NO_MATCH
	Hagihara, M., Anthony, N. J., Stout, T. J., Clardy, J. and  Schreiber, S. L. (1992) Vinylogous polypeptides-an alternative  peptide backbone. J. Am. Chem. Soc. 114, 6568-6570.  	NO_MATCH
	Huff, J. R. (1991) HIV Protease: A novel chemotherapeutic target  for AIDS. J. Med. Chem. 34, 2305-2314.  	1875332
	Huixiong, C., Noble, F., Coric, P., Fournie-Zaluski, M. and  Roques, B. P. (1998) Aminophosphinic Inhibitors as Transition state analogs of enkephalin-degrading enzymes-a class of  central analgesics. Proc. Natl. Acad. Sci. USA 96, 12028 12033.  	9751784
	Kirshenbaum, K., Barron, A. E., Goldsmith, R. A., Armand, P.,  Bradley, E. K., Truong, K. T., Dill, K. A., Cohen, F. E. and  Zuckermann, R. N. (1998) Sequence-Specific Polypeptoids - A Diverse Family of Heteropolymers with Stable Secondary  Structure. Proc. Natl. Acad. Sci. USA 95, 4303-4308.  	NO_MATCH
	Koo, B. -K., Kim, M. -H., Lee, S. -T. and Lee, W. (2002)  Purification and spectroscopic characterization of the human  tyrosine kinase-6 SH3 domain. J. Biochem. Mol. Biol. 35, 343 347.  	12297019
	Li, S.-Z., Lee, J.-H., Lee, W., Yoon, C.-J., Baik, J.-H. and Lim, S. K. (1999) Type I β-turn conformation is important for  biological activity of the melanocyte-stimulating hormone  analogues. Eur. J. Biochem. 265, 1-12.  	10491201
	Peter, C., Daura, X. and van Gunsteren, W. F. (2000) Peptides of  aminoxy acids: A molecular dynamics simulation study of  conformational equilibria under various conditions. J. Am.  Chem. Soc. 122, 7461-7466.  	NO_MATCH
	Shin, I., Lee, M-r., Lee, J., Jung, M., Lee, W. and Yoon, J. (2000)  Synthesis of optically-active phthaloyl D-aminooxy acids from  L-amino-acids or L-hydroxy acids as building-blocks for the  preparation of aminooxy peptides. J. Org. Chem. 65, 7667 7675.  	11076633
	Sieburth, S. M., Nittoli, T., Mutahi, A. M. and Guo, L. (1998)  Silanediols-A new class of potent protease inhibitor. Angew.  Chem. Int. Ed. 37, 812-814.  	NO_MATCH
	Smith, A. B. III., Benowitz, A. B., Sprengeler, P. A., Barbosa, J.,  Guzman, M. C., Hirshmann, R., Schweiger, E. J., Bolin, D. R.,  Nagy, Z., Campbell, R. M., Cox, D. C. and Olson, G. L.  (1999) Design and synthesis of a competent pyrrolinone peptide hybrid ligand for the class-II major histocompatibility  complex protein HLA-DR1. J. Am. Chem. Soc. 121, 9286 9298.  	NO_MATCH
	Yang, D., Ng, F.-F., Li, Z.-J., Wu, Y.-D., Chan, K. W. K. and  Wang, D. -P. (1996) An unusual turn structure in peptides  containing alpha-aminoxy acids. J. Am. Chem. Soc. 118, 9794 9795.  	NO_MATCH
	Yang, D., Qu, J., Ng, F.-F., Wang, X.-C., Cheung, K.-K., Wang,  D.-P. and Wu, Y.-D. (1999) Novel turns and helices in peptides  of chiral alpha-aminoxy acids. J. Am Chem. Soc. 121, 589-590.  	NO_MATCH
	Wu, Y.-D., Wang, D.-P., Chan, K. W. K. and Yang, D. (1999)  Theoretical-study of peptides formed by aminoxy acids. J. Am.  Chem. Soc. 121, 11189-11196.  	NO_MATCH
	Wuthrich, K. (1986) NMR of proteins and nucleic acids, Wiley,  New York, USA.  	NO_MATCH
gb-2003-4-12-r80.pdf
	1.   Buck L, Axel R: A novel multigene family may encode odorant  receptors: a molecular basis for odor recognition. Cell 1991,  65:175-187.  	1840504
	Young JM, Trask BJ: The sense of smell: genomics of vertebrate  odorant receptors. Hum Mol Genet 2002, 11:1153-1160.  	12015274
	3. International Human Genome Sequencing Consortium: Initial  sequencing and analysis of the human genome. Nature 2001,  409:860-921.  	NO_MATCH
	Sharon D, Glusman G, Pilpel Y, Horn-Saban S, Lancet D: Genome  dynamics, evolution, and protein modeling in the olfactory  receptor gene superfamily. Ann N Y Acad Sci 1998, 855:182-193.	9929603 
	Parmentier M, Libert F, Schurmans S, Schiffmann S, Lefort A, Egger ickx D, Ledent C, Mollereau C, Gerard C, Perret J, et al.: Expression  of members of the putative olfactory receptor gene family in  mammalian germ cells. Nature 1992, 355:453-455.  	1370859
	Ben-Arie N, Lancet D, Taylor C, Khen M, Walker N, Ledbetter DH,  Carrozzo R, Patel K, Sheer D, Lehrach H, et al.: Olfactory receptor  gene cluster on human chromosome 17: possible duplication  of an ancestral receptor repertoire. Hum Mol Genet 1994, 3:229 235.  	8004088
	Rouquier S, Taviaux S, Trask BJ, Brand-Arpon V, van den Engh G,  Demaille J, Giorgi D: Distribution of olfactory receptor genes in  the human genome. Nat Genet 1998, 18:243-250.  	9500546
	Ressler KJ, Sullivan SL, Buck LB: A zonal organization of odorant  receptor gene expression in the olfactory epithelium. Cell  1993, 73:597-609.  	7683976
	Vanderhaeghen P, Schurmans S, Vassart G, Parmentier M: Specific  repertoire of olfactory receptor genes in the male germ cells  of several mammalian species. Genomics 1997, 39:239-246.  	9119360
	10. Matarazzo V, Tirard A, Renucci M, Belaich A, Clement JL: Isolation  of putative olfactory receptor sequences from pig nasal  epithelium. Neurosci Lett 1998, 249:87-90.  	9682823
	11. Ngai J, Dowling MM, Buck L, Axel R, Chess A: The family of genes  encoding odorant receptors in the channel catfish. Cell 1993,  72:657-666.  	7916654
	12. Freitag J, Ludwig G, Andreini I, Rossler P, Breer H: Olfactory recep tors in aquatic and terrestrial vertebrates. J Comp Physiol A  1998, 183:635-650.  	9839455
	13. Freitag J, Beck A, Ludwig G, von Buchholtz L, Breer H: On the origin  of the olfactory receptor family: receptor genes of the jaw less fish (Lampetra fluviatilis). Gene 1999, 226:165-174.  	10084886
	14. Sun H, Kondo R, Shima A, Naruse K, Hori H, Chigusa SI: Evolution ary analysis of putative olfactory receptor genes of medaka  fish Oryzias latipes. Gene 1999, 231:137-145.  	10231578
	15. Clyne PJ, Warr CG, Freeman MR, Lessing D, Kim J, Carlson JR: A  novel family of divergent seven-transmembrane proteins:  candidate odorant receptors in Drosophila. Neuron 1999,  22:327-338.  	10069338
	16. Vosshall LB, Amrein H, Morozov PS, Rzhetsky A, Axel R: A spatial  map of olfactory receptor expression in the Drosophila  antenna. Cell 1999, 96:725-736.  	10089887
	17. Troemel ER, Chou JH, Dwyer ND, Colbert HA, Bargmann CI: Diver gent seven transmembrane receptors are candidate chemo sensory receptors in C. elegans. Cell 1995, 83:207-218.  	7585938
	18. Bargmann CI: Neurobiology of the Caenorhabditis elegans  genome. Science 1998, 282:2028-2033.  	9851919
	19. Glusman G, Yanai I, Rubin I, Lancet D: The complete human  olfactory subgenome. Genome Res 2001, 11:685-702.  	11337468
	20. The Human Olfactory Receptor Data Exploratorium  [http://  bioinfo.weizmann.ac.il/HORDE]  	NO_MATCH
	21. Zhang X, Firestein S: The olfactory receptor gene superfamily  of the mouse. Nat Neurosci 2002, 5:124-133.  	11802173
	22. Young JM, Friedman C, Williams EM, Ross JA, Tonnes-Priddy L, Trask  BJ: Different evolutionary processes shaped the mouse and  human olfactory receptor gene families. Hum Mol Genet 2002,  11:535-546.  	11875048
	23. Issel-Tarver L, Rine J: Organization and expression of canine  olfactory receptor genes. Proc Natl Acad Sci USA 1996, 93:10897 10902.  	8855279
	24. Priat C, Hitte C, Vignaux F, Renier C, Jiang Z, Jouquand S, Chéron A,  André C, Galibert F: A whole-genome radiation hybrid map of  the dog genome. Genomics 1998, 54:361-378.  	9878239
	25. Vignaux F, Hitte C, Priat C, Chuat JC, André C, Galibert F: Con struction and optimization of a dog whole-genome radiation  hybrid panel. Mamm Genome 1999, 10:888-894.  	10441740
	26. Rouquier S, Blancher A, Giorgi D: The olfactory receptor gene  repertoire in primates and mouse: evidence for reduction of  the functional fraction in primates. Proc Natl Acad Sci USA 2000,  97:2870-2874.  	10706615
	27. Issel-Tarver L, Rine J: The evolution of mammalian olfactory  receptor genes. Genetics 1997, 145:185-195.  	9017400
	28. Thorne C: Feeding behaviour of domestic dogs and the role of  experience. In The Domestic Dog: Its Evolution, Behaviour and Interac tions with People Edited by: Serpell J. Cambridge University Press,  Cambridge, UK; 1995:104-114.   	NO_MATCH
	29. Guyon R, Lorentzen T, Hitte C, Kim L, Cadieu E, Parker HG, Quignon  P, Lowe JK, Renier C, Gelfenbeyn B, et al.: A 1-Mb resolution radi ation hybrid map of the canine genome. Proc Natl Acad Sci USA  2003, 100:5296-301.  	12700351
	30. The canine radiation hybrid project  [http://www-recom  gen.univ-rennes1.fr/doggy.html]  	NO_MATCH
	31. NCBI BLAST  [http://www.ncbi.nlm.nih.gov/BLAST]  	NO_MATCH
	32. Ewing B, Hillier L, Wendl MC, Green P: Base-calling of automated  sequencer traces using phred. I. Accuracy assessment.  Genome Res 1998, 8:175-185.  	9521921
	33. Ewing B, Green P: Base-calling of automated sequencer traces  using phred. II. Error probabilities. Genome Res 1998, 8:186-194.  	9521922
	34. Gordon D, Abajian C, Green P: Consed: a graphical tool for  sequence finishing. Genome Res 1998, 8:195-202.  	9521923
	35. Venter JC, Adams MD, Myers EW, Li PW, Mural RJ, Sutton GG, Smith  HO, Yandell M, Evans CA, Holt RA, et al.: The sequence of the  human genome. Science 2001, 291:1304-1351.  	11181995
	36. Vinogradov AE: Genome size and GC-percent in vertebrates  as determined by flow cytometry: the triangular  relationship. Cytometry 1998, 31:100-109.  	9482279
	37. Pearson WR, Lipman DJ: Improved tools for biological sequence  comparison. Proc Natl Acad Sci USA 1988, 85:2444-2448.  	3162770
	38. Rozen S, Skaletsky H: Primer3 on the WWW for general users  and for biologist programmers. Methods Mol Biol 2000, 132:365 386.  	10547847
	39. Matise TC, Perlin M, Chakravarti A: Automated construction of  genetic linkage maps using an expert system (MultiMap): a  human genome linkage map. Nat Genet 1994, 6:384-390.  	8054979
	40. Mellersh CS, Hitte C, Richman M, Vignaux F, Priat C, Jouquand S,  Werner P, André C, DeRose S, Patterson DF, et al.: An integrated  linkage-radiation hybrid map of the canine genome. Mamm  Genome 2000, 11:120-130.  	10656926
	41. Services sur le Web d'Infobiogen  [http://www.infobiogen.fr/  services/menuserv.html]  	NO_MATCH
	42. Thompson JD, Higgins DG, Gibson TJ: CLUSTAL W: improving  the sensitivity of progressive multiple sequence alignment  through sequence weighting, position-specific gap penalties  and weight matrix choice. Nucleic Acids Res 1994, 22:4673-4680.	7984417
v074p01530.pdf
	1 Benton D. Do low cholesterol levels slow mental processing? Psychosom Med  1995;57:50–3.  	7732160
	2 Muldoon MF, Ryan CM, Matthews KA, et al. Serum cholesterol and intellectual  performance. Psychosom Med 1997;59:382–7.  	9251158
	3 Ross R. Mechanisms of disease: atherosclerosis – an inflammatory disease.  N Engl J Med 1999;340:115–26.  	10539839
	4 Haan MN, Shemanski L, Jagust WJ, et al. The role of APOE epsilon4 in  modulating effects of other risk factors for cognitive decline in elderly persons.  JAMA 1999;282:40–6.  	10404910
	5 Notkola IL, Sulkava R, Pekkanen J, et al. Serum total cholesterol,  apolipoprotein E e4 allele, and Alzheimer’s disease. Neuroepidemiology  1998;17:14–20.  	9549720
	6 Moroney JT, Tang MX, Berglund L, et al. Low-density lipoprotein cholesterol  and the risk of dementia with stroke. JAMA 1999;282:254–60.  	10422994
	7 Evans RM, Emsley CL, Gao S, et al. Serum cholesterol, APOE genotype, and  the risk of Alzheimer’s disease: a population-based study of African  Americans. Neurology 2000;54:240–2.  	10636159
	8 Swan GE, LaRue A, Carmelli D, et al. Decline in cognitive performance in  aging twins: heritability and biobehavioral predictors from the National Heart,  Lung, and Blood Institute twin study. Arch Neurol 1992;49:476–81.  	1580808
	9 Lindberg G, Rastam L, Gullberg B, et al. Low serum cholesterol concentration  and short term mortality from injuries in men and women. BMJ  1992;305:277–9.  	1392858
	10 Modai I, Valevski A, Dror S, et al. Serum cholesterol levels and suicidal  tendencies in psychiatric inpatients. J Clin Psychiatry 1994;55:252–4.  	8071280
	11 Kunugi H, Takei N, Aoki H, et al. Low serum cholesterol in suicide attempters.  Biol Psychiatry 1997;41:196–200.  	9018390
	12 Morgan RE, Palinkas LA, Barrett-Connor E, et al. Plasma cholesterol and  depressive symptoms in older men. Lancet 1993;341:75–9.  	8093404
	13 Dennerstein L, Smith AMA, Morse CA, et al. Menopausal symptomatology:  the experience of Australian women. Med J Aust 1993;159:232–6.  	NO_MATCH
	14 Burger HG, Dudley EC, Hopper JL, et al. The endocrinology of the  menopausal transition: a cross-sectional study of a population-based sample.  J Clin Endocrinol Metab 1995;80:3537–45.  	8530596
	15 Collie A, Shafiq-Antonacci R, Maruff P, et al. Norms and the effects of  demographic variables on a neuropsychological battery for use in  healthy ageing Australian populations. Aust N Z J Psychiatry  1999;33:568–75.  	10483853
	16 Dennerstein L, Lehert P, Burger H, et al. Mood and the menopausal transition.  J Nerv Ment Dis 1999;187:685–91.  	10579597
	17 Dennerstein L, Lehert P, Dudley E, et al. Factors contributing to positive mood  during the menopause transition. J Nerv Ment Dis 2001;189:84–9.  	11225691
	18 Kammann R, Flett R. Affectometer 2: a scale to measure current level of  general happiness. Australian Psychology 1983;35:259–65.  	NO_MATCH
	19 Shelley JM, Green A, Smith AMA, et al. Relationship of endogenous sex  hormones to lipids and blood pressure in mid-aged women. Ann Epidemiol  1998;8:39–45.  	9465992
	20 Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of  low-density lipoprotein cholesterol in plasma, without use of the preparative  ultracentrifuge. Clin Chem 1972;18:499–502.  	4337382
	21 Taffe J, Dennerstein L. Retrospective self-report compared with menstrual  diary data prospectively kept during the menopausal transition. Climacteric  2000;3:183–91.  	NO_MATCH
	22 Vermeulen A, Verdonck L. Sex hormone concentrations in post-menopausal  women: relation to obesity, fat mass, age and years post-menopause. Clin  Endocrinol (Oxf) 1978;9:59–66.  	679502
	23 Lobo RA. Effects of hormonal replacement on lipids and lipoproteins in  postmenopausal women. J Clin Endocrinol Metab 1991;52:156–8.  	1939531
	24 Petersen RC, Smith GE, Waring SC, et al. Mild cognitive impairment: clinical  characterization and outcome. Arch Neurol 1999;56:303–8.  	10190820
	25 Yeagle PL. Modulation of membrane function by cholesterol. Biochimie  1991;73:1303–10.  	1664240
	26 Howland DS, Trusko SP, Savage MJ, et al. Modulation of secreted b-amyloid  precursor protein and amyloid b-peptide in brain by cholesterol. J Biol Chem  1998;273:16576–82.  	9632729
	27 Yaffe K, Barrett-Connor E, Lin F, et al. Serum lipoprotein levels,  statin use, and cognitive function in older women. Arch Neurol  2002;59:378–84.  	11890840
	28 Paganini-Hill A, Henderson VW. The effects of hormone replace therapy,  lipoprotein cholesterol levels, and other factors on a clock drawing task in  older women. J Am Geriatr Soc 1996;44:818–22.  	8675931
	29 Refolo LM, Pappolla MA, LaFrancois J, et al. A cholesterol-lowering drug  reduces beta-amyloid pathology in a transgenic mouse model of Alzheimer’s  disease. Neurobiol Dis 2001;8:890–9.  	11592856
	30 Selkoe DJ. Alzheimer’s disease: genes, proteins, and therapy. Physiol Rev  2001;81:741–6.  	11274343
	31 Wolozin B, Kellman W, Ruosseau P, et al. Decreased prevalence of Alzheimer  disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase  inhibitors. Arch Neurol 2000;57:1439–43.  	11030795
	32 Jick H, Zornberg GL, Jick SS, et al. Statins and the risk of dementia. Lancet  2000;356:1627–31.  	11089820
	33 Rockwood K, Kirkland S, Hogan DB, et al. Use of lipid-lowering agents,  indication bias, and the risk of dementia in community-dwelling elderly  people. Arch Neurol 2002;59:223–7.  	11843693
	34 Haley RW, Dietschy JM. Is there a connection between the concentration of  cholesterol circulating in plasma and the rate of neuritic plaque formation in  Alzheimer disease? Arch Neurol 2000;57:1410–12.  	11030791
	35 Vaughan CJ, Delanty N. Neuroprotective properties of statins in cerebral  ischemia and stroke. Stroke 1999;30:1969–73.  	10471452
	36 Brown SL, Salive ME, Harris TB, et al. Low cholesterol concentrations and  severe depressive symptoms in elderly people. BMJ 1994;308:1328–32.  	8019218
	37 Wardle J, Rogers P, Judd P, et al. Randomized trial of the effects of  cholesterol-lowering dietary treatment on psychological function. Am J Med  2000;108:547–53.  	10806283
	38 Muldoon MF, Barger SD, Ryan CM, et al. Effects of lovastatin on  cognitive function and psychological well-being. Am J Med  2000;108:538–47.  	10806282
	39 Elias MF, Berger A, Wolf PA, et al. The preclinical phase of Alzheimer’s  disease: a 22-year prospective study of the Framingham cohort. Arch Neurol  2000;57:808–13.  	10867777
	40 Eggersten G, Tegelman R, Ericsson S, et al. Apolipoprotein E polymorphism in  a healthy Swedish population: variation of allele frequency with age and  relation to serum lipid concentrations. Clin Chem 1993;39:2125–9.  	8403397
	41 Top 200 brand-name drugs by units in 2001. DrugTopics.Com: The Online  News Magazine for Pharmacists, March 4, 2002. www.drugtopics.com.  Accessed January 2003.	NO_MATCH
v074p01461.pdf
	1 Rutter M, Graham P, Yule W. A neuropsychiatric  study in childhood. London: Heinemann Medical,  1970.  	NO_MATCH
	2 Deb S, Hunter D. Psychopathology of people with  mental handicap and epilepsy. I. Maladaptive  behaviour. Br J Psychiatry 1991;159:822–6.  	1790451
	3 Deb S, Hunter D. Psychopathology of people with  mental handicap and epilepsy. II. Psychiatric  illness. Br J Psychiatry 1991;159:826–30.  	1790452
	4 Espie CA, et al. Psychopathology in people with  epilepsy and intellectual disability; an  investigation of potential explanatory variables.  J Neurol Neurosurg Psychiatry  2003;74:1485–92.  	14617702
	5 Besag FMC. Behavioural effects of the new  anticonvulsants. Drug Safety 2001;24:513–36.  	11444724
11.03.1019.pdf
	1. MacIntyre NR, Cook DJ, Ely EW Jr, Epstein SK, Fink JB, Heffner  JE, et al; American College of Chest Physicians; American Associ ation for Respiratory Care; American College of Critical Care Med icine. Evidence-based guidelines for weaning and discontinuing ven tilatory support: a collective task force facilitated by the American  College of Chest Physicians; the American Association for Respi ratory Care; and the American College of Critical Care Medicine.  Chest 2001;120(6 Suppl):375S–395S.  	11742959
	2. Meade M, Guyatt G, Cook D, Griffith L, Sinuff T, Kergl C, et al.  Predicting success in weaning from mechanical ventilation. Chest  2001;120(6 Suppl):400S–424S.  	11742961
	3. Ely EW, Baker AM, Dunagan DP, Burke HL, Smith AC, Kelly PT,  et al. Effect on the duration of mechanical ventilation of identifying  patients capable of breathing spontaneously. N Engl J Med 1996;  335(25):1864–1869.  	8948561
	4. Esteban E, Alia I, Tobin MJ, Gil A, Gordo F, Vallverdu I, et al.  Effect of spontaneous breathing trial duration on outcome of at tempts to discontinue mechanical ventilation. Spanish Lung Failure  Collaborative Group. Am J Respir Crit Care Med 1999;159(2):512–  518.  	9927366
	5. Vallverdu I, Calaf N, Subirana M, Net A, Benito S, Mancebo J. Clin ical characteristics, respiratory functional parameters, and outcome  of a two-hour T-piece trial in patients weaning from mechanical  ventilation. Am J Respir Crit Care Med 1998;158(6):1855–1862.  	9847278
	6. Marelich GP, Murin S, Battistella F, Inciardi J, Vierra T, Roby M.  Protocol weaning of mechanical ventilation in medical and surgical  patients by respiratory care practioners and nurses: effect on weaning  time and incidence of ventilator-associated pneumonia. Chest 2000;  118(2):459–467.  	10936141
	7. Zeggwagh AA, Abouqal R, Madani N, Zekraoui A, Kerkeb O. Wean  ing from mechanical ventilation: a model for extubation. Intensive  Care Med 1999;25(10):1077–1083.  	10551962
	8. Miller R, Cole RP. Association between reduced cuff leak volume  and postextubation stridor. Chest 1996;110(4):1035–1040.  	8874265
	9. Coplin WM, Pierson DJ, Cooley KD, Newell DW, Rubenfeld GD.  Implications of extubation delay in brain-injured patients meeting  standard weaning criteria. Am J Respir Crit Care Med 2000;161(5):  1530–1536.  	10806150
	10. Salam A, Smina M, Gada P, Tilluckdharry L, Upadya A, Amoateng Adjepong Y, Manthous CA. The effect of arterial blood gas values  on extubation decisions. Respir Care 2003;48(11):1033-1037.  	14585115
	11. Millbern SM, Downs JB, Jumper LC, Modell JH. Evaluation of  criteria for discontinuing mechanical ventilatory support. Arch Surg  1978;113(12):1441–1443.  	367313
	12. Ferrer M, Esquinas A, Arancibia F, Bauer TT, Gonzalez G, Carrillo  A, et al. Noninvasive ventilation during persistent weaning failure: a  randomized controlled trial. Am J Respir Crit Care Med 2003;168(1):  70–76.  	12689847
	13. Soo Hoo GW, Park L. Variations in the measurement of weaning  parameters: a survey of respiratory therapists. Chest 2002;121(6):  1947–1955.  	12065362
	14. Epstein SK, Ciubotaru RL, Wong JB. Effect of failed extubation on  the outcome of mechanical ventilation. Chest 1997;112(1):186–192.  	9228375
	15. Torres A, Gatell JM, Aznar E, el-Ebiary M, Puig de la Bellacasa J,  Gonzalez J, et al. Re-intubation increases the risk of nosocomial  pneumonia in patients needing mechanical ventilation. Am J Respir  Crit Care Med 1995;152(1):137–141.  	7599812
1472-6963-3-19.pdf
	Primatesta P and Erens B: Health Survey for England: Cardiovas cular disease. London, TSO 1998.  	NO_MATCH
	Department of Health: National Service Framework for Coro nary Heart Disease. 2001.  	NO_MATCH
	Kirk S: Treatment of obesity: theory into practice. Proceedings  of the Nutrition Society 1999, 58(1):53-58.  	10343340
	Harvey E, Glenny A-M, Kirk S and Summerbell C: An updated sys tematic review of interventions to improve health profes sionals' management of obesity. Obesity Reviews 2002, 3:45-55.  	12119659
	Perri MG, Sears SF Jr and Clark JE: Strategies for improving  maintenance of weight loss. Toward a continuous care  model of obesity management. Diabetes Care 1993,  16(1):200-209.  	8422776
	Glenny AM, O'Meara S, Melville A, Sheldon TA and Wilson C: The  treatment and prevention of obesity: a systematic review of  the literature. International Journal of Obesity & Related Metabolic Dis orders 1997, 21(9):715-737.  	9376884
	Which Report: Dieting and the Internet. London, Consumers Asso ciation 2001.  	NO_MATCH
	Agras WS, Taylor CB, Feldman DE and Losch M: Developing com puter-assisted therapy for the treatment of obesity. Behavior  Therapy 1990, 21(1):99-109.  	NO_MATCH
	Tate DF, Wing RR and Winett RA: Using Internet Technology to  Deliver a Behavioural Weight loss Program. Journal of the Amer ican Medical Association 2001, 285(9):1172-1177.  	11231746
	10. Kirk SF, Cade JE and Greenhalgh A: Dietitians and the internet:  are dietitians embracing the new technology? Journal of Human  Nutrition & Dietetics 2001, 14(6):477-484.  	11906590
1471-2296-4-16.pdf
	Harris MI, Flegal KM, Cowie CC, Eberhardt MS, Goldstein DE, Little  RR, Wiedmeyer HM and Byrd-Holt DD: Prevalence of diabetes,  impaired fasting glucose, and impaired glucose tolerance in  U.S. adults. The Third National Health and Nutrition Exam ination Survey, 1988-1994. Diabetes Care 1998, 21:518-524.  	9571335
	DHHS: Diabetes in America. Secondth edition. Washington DC,  DHHS; 1995.   	NO_MATCH
	Wahl PW, Savage PJ, Psaty BM, Orchard TJ, Robbins JA and Tracy RP:  Diabetes in older adults: comparison of 1997 American Dia betes Association classification of diabetes mellitus with  1985 WHO classification. Lancet 1998, 352:1012-1015.	9759743  
	Keen H: Impact of new criteria for diabetes on pattern of  disease. Lancet 1998, 352:1000-1001.  	9759736
	ADA: American Diabetes Association: clinical practice rec ommendations 1999. Diabetes Care 1999, 22:S1-S114.  	NO_MATCH
	Dinneen SF, Maldonado D, 3rd, Leibson CL, Klee GG, Li H, Melton L  J, 3rd and Rizza RA: Effects of changing diagnostic criteria on  the risk of developing diabetes. Diabetes Care 1998,  21:1408-1413.  	9727885
	Morley JE, Mooradian AD, Rosenthal MJ and Kaiser FE: Diabetes  mellitus in elderly patients. Is it different? Am J Med 1987,  83:533-544.  	3310623
	Martinson BC, O'Connor PJ and Pronk NP: Physical inactivity and  short-term all-cause mortality in adults with chronic disease.  Arch Intern Med 2001, 161:1173-1180.  	11343440
	Hofer TP, Vijan S and Hayward RA: Estimating the microvascular  benefits of screening for type 2 diabetes mellitus. Int J Technol  Assess Health Care 2000, 16:822-833.  	11028137
	10. Helseth LD, Sussman SJ, Crabtree BF and O'Connor PJ: Primary  care physicians' perceptions of diabetes management. A bal ancing act. J Fam Pract 1999, 48:37-42.  	9934381
	11. Glynn RJ, Monane M,, Gurwitz JH, Choodnovsky I and Avorn J:  Aging, comorbidity, and reduced rates of drug treatment for  diabetes mellitus. J Clin Epidemiol 1999, 52:781-790.  	10465323
	12. Brown AF, Mangione CM, Saliba D and Sarkisian CA: Guidelines for  improving the care of the older person with diabetes  mellitus. J. Am Geriatr Sc 2003, 51:S265-80.  	12694461
	13. Gilmer TP, O'Connor PJ, Manning WG and Rush WA: The cost to  health plans of poor glycemic control. Diabetes Care 1997,  20:1847-1853.  	NO_MATCH
	14. Testa MA and Simonson DC: Health economic benefits and  quality of life during improved glycemic control in patients  with type 2 diabetes mellitus: a randomized, controlled, dou ble-blind trial. JAMA 1998, 280:1490-1496.  	9809729
	15. O'Connor PJ and Jacobson AM: Assessment of functional health  status in elderly diabetic persons. Geriatric Clinics of North Am  1990, 6:865-882.  	NO_MATCH
	16. Savage PJ: Cardiovascular complications of diabetes mellius:  what we know and what we need to know about their  prevention. Ann Intern Med 1996, 124:123-136.  	8554203
	17. Shorr RI, Franse LV, Resnick HE, Di Bari M, Johnson KC and Pahor M:  Glycemic control of older adults with type 2 diabetes: find ings from the Third National Health and Nutrition Examina tion Survey, 1988-1994. J Am Geriatr Soc 2000, 48:264-267.  	10733051
	18. ICSI: Health Care Guidelines: 1995-1996. Bloomington, MN, Insti tute for Clinical Systems Integration; 1996.   	NO_MATCH
	19. ICSI: Clinical care guideline: treatment of type 2 diabetes  mellitus. Bloomington, MN, Institute for Clinical Systems Integration;  1999.   	NO_MATCH
	20. ICSI: Clinical care guideline: treatment of type 2 diabetes  mellitus. Bloomington, MN, Institute for Clinical Systems Improvement;  2000.   	NO_MATCH
	21. O'Connor PJ, Crabtree BF and Yanoshik MK: Differences between  diabetic patients who do and do not respond to a diabetes  care intervention: a qualitative analysis. Fam Med 1997,  29:424-428.  	9193915
	22. O'Connor P, Rush WA, Pronk N and Cherney LM: Identifying dia betes mellitus or heart disease among health maintenance  organization members: sensitivity, specificity, predictive  value and cost of survey and database methods. Am J Manag  Care 1998, 4:335-342.  	10178496
	23. Huisman TH, Henson JB and Wilson JB: A new high-performance  liquid chromatographic procedure to quantitate hemo globin A1c and other minor hemoglobins in blood of normal,  diabetic, and alcoholic individuals. J Lab Clin Med 1983,  102:163-173.  	6190972
	24. Hosmer DW and Lemeshow S: Applied logistic regression.  Applied probability and mathematical statistics New York, Wiley; 1989:xiii,  307.   	NO_MATCH
	25. Bender R and Lange S: Adjusting for multiple testing--when and  how? J Clin Epidemiol 2001, 54:343-349.  	11297884
	26. Johnson PE, Veazie PJ, Kochevar L, O'Connor PJ, Potthoff SJ, Verma  D and Dutta P: Understanding variation in chronic disease  outcomes. Health Care Manag Sci 2002, 5:175-189.  	12363045
	27. Krein SL, Hofer TP, Kerr EA and Hayward RA: Whom should we  profile? Examining diabetes care practice variation among  primary care providers, provider groups, and health care  facilities. Health Serv Res 2002, 37:1159-1180.  	12479491
	28. Thompson BL, O'Connor P, Boyle R, Hindmarsh M, Salem N, Sim mons KW, Wagner E, Oswald J and Smith SM: Measuring clinical  performance: comparison and validity of telephone survey  and administrative data. Health Serv Res 2001, 36:813-825.  	11508641
	29. O'Connor PJ, Rush WA, Peterson J, Morben P, Cherney L, Keogh C  and Lasch S: Continuous quality improvement can improve  glycemic control for HMO patients with diabetes. Arch Fam  Med 1996, 5:502-506.  	8930220
	30. O'Connor PJ, Pronk NP, Tan AW, Rush WA and Gray RJ: Does pro fessional advice influence aspirin use to prevent heart dis ease in an HMO population? Eff Clin Pract 1998, 1:26-32.  	10345257
	31. Weiner JP, Parente ST, Garnick DW, Fowles J, Lawthers AG and  Palmer RH: Variation in office-based quality. A claims-based  profile of care provided to Medicare patients with diabetes.  JAMA 1995, 273:1503-1508.  	7739076
	32. Peterson K: Diabetes care by primary care physicians in Min nesota and Wisconsin. J Fam Pract 1994, 38:361-367.  	8163960
	33. Peters A, Legorreta A, Ossorio C and Davidson M: Quality of out patient care provided to diabetic patients: A Health Mainte nance Organization experience. Diabetes Care 1996, 19:601-606.  	8725859
	34. Ford E and Mokdad A: Trends in glycosylated hemoglobin con centrations among United States adults. Diabetes 2003, 52  (Suppl 1):A219.  	NO_MATCH
	35. Effect of intensive blood-glucose control with metformin on  complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS)  Group. Lancet 1998, 352:854-865.  	NO_MATCH
	36. Intensive blood-glucose control with sulphonylureas or insu lin compared with conventional treatment and risk of com plications in patients with type 2 diabetes (UKPDS 33). UK  Prospective Diabetes Study (UKPDS) Group. Lancet 1998,  352:837-853.  	NO_MATCH
	37. Aspirin effects on mortality and morbidity in patients with  diabetes mellitus. Early Treatment Diabetic Retinopathy  Study report 14. ETDRS Investigators. JAMA 1992,  268:1292-1300.  	NO_MATCH
	38. Curb JD, Pressel SL, Cutler JA, Savage PJ, Applegate WB, Black H,  Camel G, Davis BR, Frost PH, Gonzalez N, Guthrie G, Oberman A,  Rutan GH and Stamler J: Effect of diuretic based antihyperten sive treatment on cardiovascular disease risk in older dia betic patients with isolated systolic hypertension. Systolic  Hypertension in Elderly Program Cooperative Research  Group. JAMA 1996, 276:1886-1892.  	8968014
	39. Hansson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D, Julius  S, Menard J, Rahn KH, Wedel H and Westerling S: Effects of inten sive blood-pressure lowering and low-dose aspirin in patients  with hypertension: principal results of the Hypertension  Optimal Treatment (HOT) randomized trial. Lancet 1998,  351:1755-1762.  	9635947
	40. Efficacy of atenolol and captopril in reducing risk of macrov ascular and microvascular complications in type 2 diabetes:  UKPDS 39. UK Prospective Diabetes Study Group. BMJ 1998,  317:713-720.  	NO_MATCH
	41. Cost effectiveness analysis of improved blood pressure con trol in hypertensive patients with type 2 diabetes: UKPDS 40. UK Prospective Diabetes Study Group. BMJ 1998,  317:720-726.  	NO_MATCH
	42. Pyorala K, Pedersen TR, Kjekshus J, Faergeman O, Olsson AG and  Thorgeirsson G: Cholesterol lowering with simvastatin  improves prognosis of diabetic patients with coronary heart  disease. A subgroup analysis of the Scandinavian Simvastatin  Survival Study (4S). Diabetes Care 1997, 20:614-620.  	9096989
	43. Haffner SM, Alexander CM, Cook TJ, Boccuzzi SJ, Musliner TA, Ped ersen TR, Kjekshus J and Pyorala K: Reduced coronary events in  simvastatin-treated patients with coronary heart disease  and diabetes or impaired fasting glucose levels: subgroup  analyses in the Scandinavian Simvastatin Survival Study. Arch  Intern Med 1999, 159:2661-2667.  	10597756
	44. Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH and Pedersen O:  Multifactorial intervention and cardiovascular disease in  patients with type 2 diabetes. N Engl J Med 2003, 348:383-393.  	12556541
	45. Cost-effectiveness of intensive glycemic control, intensified  hypertension control, and serum cholesterol level reduction  for type 2 diabetes. The CDC Diabetes Cost-effectiveness  Group. JAMA 2002, 287:2542-2551.  	NO_MATCH
	46. Wagner EH, Austin BT and Korff M. Von: Organizing care for  patients with chronic illness. Milbank Mem Fund Q 1996,  74:511-544.  	8941260
	47. Pronk NP and O'Connor PJ: Systems approach to population  health improvement. J Ambulatory Care Manage 1997, 20:24-31.  	10181620
	48. Solberg LI, Kottke TE, Conn SA, Brekke ML, Calomeni CA and Con boy KS: Delivering clinical preventive services is a systems  problem. Ann Behav Med 1997, 19:271-278.  	9603701
	49. Sperl-Hillen J, O'Connor PJ, Carlson RR, Lawson TB, Halstenson C,  Crowson T and Wuorenma J: Improving diabetes care in a large  health care system: an enhanced primary care approach. Jt  Comm J Qual Improv 2000, 26:615-622.  	11098424
	50. Sidorov J, Gabbay R, Harris R, Shull RD, Girolami S, Tomcavage J,  Starkey R and Hughes R: Disease management for diabetes  mellitus: impact on Hemoglobin A1c. Am J Manag Care 2000,  6:1217-1226.  	11185847
	51. Nyman MA, Murphy ME, Schryver PG, Naessens JM and Smith SA:  Improving performance in diabetes care: a multicomponent  intervention. Eff Clin Pract 2000, 3:205-212.  	11185325
	52. Sutherland JE, Hoehns JD, O'Donnell B and Wiblin RT: Diabetes  management quality improvement in a family practice resi dency program. J Am Board Fam Pract 2001, 14:243-251.  	11458966
	53. Aubert RE, Herman WH, Waters J, Moore W, Sutton D, Peterson  BL, Bailey CM and Koplan JP: Nurse case management to  improve glycemic control in diabetic patients in a health  maintenance organization.  A randomized, controlled trial.  Ann Intern Med 1998, 129:605-612.  	9786807
	54. Pronk NP, Goodman MJ, O'Connor PJ and Martinson BC: Relation ship between modifiable health risks and short-term health  care charges. JAMA 1999, 282:2235-2239.  	10605975
	55. Blair SN, Kampert JB, Kohl HW, Barlow CE, Macera CA, Paffenbarger  RS and Gibbons LW: Influences of cardiorespiratory fitness and  other precursors on cardiovascular disease and all-cause  mortality in men and women. JAMA 1996, 276:205-210.  	8667564
	56. Paffenbarger R. S., Jr., Hyde RT, Wing AL, Lee IM, Jung DL and Kam pert JB: The association of changes in physical-activity level  and other lifestyle characteristics with mortality among  men. N Engl J Med 1993, 328:538-545.  	8426621
	57. Haffner SM, Lehto S, Ronnemaa T, Pyorala K and Laakso M: Mortal ity from coronary heart disease in subjects with type 2 diabe tes and in nondiabetic subjects with and without prior  myocardial infarction. N Engl J Med 1998, 339:229-234.  	9673301
	58. Kleinman A: The illness narratives. Monograph New York, Basic  Books; 1988:284.   	NO_MATCH
	59. Johnson P, Veazie P, O'Connor P, Kochevar L and Verma D et al.:  Understanding variation in chronic disease outcomes. J Fam  Pract Health Care Manag Sci  in press.   	12363045
	60. Crabtree BF, Miller WL, Aita VA, Flocke SA and Stange KC: Primary  care practice organization and preventive services delivery:  a qualitative analysis. J Fam Pract 1998, 46:403-409.  	9597998
	61. Griffin S: Diabetes care in general practice: meta-analysis of  randomised control trials. BMJ 1998, 317:390-396.  	9694757
	62. Blaum CS, Ofstedal MB, Langa KM and Wray LA: Functional Status  and Health Outcomes in Older Americans with Diabetes  Mellitus. J Am Geriatr Soc 2003, 51:745-753.  	12757559
	63. Boyle RG, O'Connor PJ, Pronk NP and Tan A: Stages of change for  physical activity, diet, and smoking among HMO members  with chronic conditions. Am J Health Promot 1998, 12:170-175.  	10176091
	64. Hammond KR and Summers DA: Cognitive control. Psychol Rev  1972, 79:58-67.  	NO_MATCH
	65. Pine BJ II: Mass-customizing products and services. Mass  Customization Boston, MA, Harvard Business School Press; 1999:171-212.   	NO_MATCH
	66. Schafer J, Konstan J and Reidl J: Recommender systems in e-com merce. ACM on Electronic Conference Edited by: ACM. Association for  Computing Machinery; 1999.   	NO_MATCH
	67. O'Connor PJ, Sperl-Hillen JM, Pronk NP and Murray T: Primary  care clinic-based chronic disease care. Disease Management  Health Outcomes 2001, 9:691-698.  	NO_MATCH
	68. Solberg LI, Brekke ML, Fazio CJ, Fowles J, Jacobsen DN, Kottke TE  and et al: Lessons from experienced guideline implementers:  attend to many factors and use multiple strategies. Jt Comm J  Qual Improv 2000, 26:171-188.  	10749003
	69. Klein R, Klein BE, Moss SE, DeMets DL, Kaufman I and Voss PS: Prev alence of diabetes mellitus in southern Wisconsin. Am J  Epidemiol 1984, 119:54-61.  	6691336
x329_Hess.pdf
	  1. Weiss W. Smoking and pulmonary fibrosis. J Occup Med  1988;30:33–9.  	3280757
	  2. Morgan WKC. Prevalence of radiographic appearance of  pneumoconiosis in an unexposed blue collar population [let ter]. Am Rev Respir Dis 1985;132:1139.  	4062045
	  3. Kilburn KH. Classification of data on the etiologic role of  cigarette smoking in pulmonary fibrosis [letter]. Am J Ind Med  1984;5:420.  	NO_MATCH
	  4. Kilburn KH, Lilis R, Anderson HA, Miller A, Warshaw RH.  Interaction of asbestos, age, and cigarette smoking in produc ing radiographic evidence of diffuse pulmonary fibrosis. Am J  Med 1986;80:377–81.  	3953615
	  5. Castellan RM, Sanderson WT, Petersen MR. Prevalence of  radiographic appearance of pneumoconiosis in an unexposed  blue collar population. Am Rev Respir Dis 1985;131:684–6.  	4003914
	  6. Blanc PD, Gamsu G. Cigarette smoking and pneumoconiosis:  structuring the debate. Am J Ind Med 1989;16:1–4.  	2665481
	  7. Cohen D, Arai SF, Brain JD. Smoking impairs long-term dust  clearance from the lung. Science 1979;204:514–7.  	432655
	  8. Weiss W. Cigarette smoke, asbestos, and small irregular opac ities. Am Rev Respir Dis 1984;130:293–301.  	6380358
	  9. Gough J. Emphysema in relation to occupation. Ind Med Surg  1960;29:283–5.  	NO_MATCH
	10. Chamberlain MJ, Morgan WKC, Vinitski S. Factors influenc ing the regional deposition of inhaled particles in man. Clin  Sci 1983;64:69–78.  	6822051
	11. International Labour Organization (ILO). International classi fication of radiographs of pneumoconioses. Geneva: ILO;  1980.  	NO_MATCH
	12. Cooper WC, Sargent EN. Study of chest radiographs and  pulmonary functions in perlite workers. J Occup Med 1986;  28:199–206.  	3009754
	13. Crosbie WA. Respiratory health of carbon black workers.  Arch Environ Health 1986;41:346–53.  	3619491
	14. Dick JA, Morgan WKC, Muir DFC, Reger RB, Sargent N.  The significance of irregular opacities on the chest roentgeno gram. Chest 1992;102:251–60.  	1623762
	15. Irwig LM, Rocks P. Lung function and respiratory symptoms  in silicotic and nonsilicotic gold miners. Am Rev Respir Dis  1978;117:429–35.  	629477
	16. International Labour Organization (ILO). ILO U/C Interna tional classification of radiographs of pneumoconioses 1971.  Geneva: ILO; 1972.  	NO_MATCH
	17. Cowie RL, Mabena SK. Silicosis, chronic airflow limitation,  and chronic bronchitis in South African gold miners. Am Rev  Respir Dis 1991;143:80–4.  	1986688
	18. Swaen GMH, Meijers JMM. Lung cancer risk among workers  with silicosis: potential confounding by smoking habits. Am J  Ind Med 1987;12:223–5.  	3661574
	19. Swaen GMH, Passier PECA, van Attekum AMNG. Preva lence of silicosis in the Dutch fine-ceramic industry. Int Arch  Occup Environ Health 1988;60:71–4.  	3258285
	20. Meijers JMM, Swaen GMH, van Vliet K, Borm PJA. Epide miologic studies of inorganic dust-related lung diseases in The  Netherlands. Exp Lung Res 1990;16:15–23.  	2307146
	21. Cherry NM, Burgess GL, Turner S, McDonald JC. Crystalline  silica and risk of lung cancer in the potteries. Occup Environ  Med 1998;55:779–85.  	9924456
	22. McDonald JC, Burgess GL, Turner S, Cherry NM. Cohort  study of Staffordshire pottery workers (III) lung cancer, radio graphic changes, silica exposure and smoking habit. Ann Oc cup Hyg 1997;41 Suppl 1:412–4.  	NO_MATCH
	23. Graham WGB, Ashikaga T, Hemenway D, Weaver S,  O’Grady RV. Radiographic abnormalities in Vermont granite  workers exposed to low levels of granite dust. Chest 1991;  100:1507–14.  	1659976
	24. Harber P, Dahlgren J, Bunn W, Lockey J, Chase G. Radio graphic and spirometric findings in diatomaceous earth work ers. J Occup Environ Med 1998;40:22–8.  	9467117
	25. Ng T-P, Tsin TW, O’Kelly FJ, Chan SL. A survey of the  respiratory health of silica-exposed gemstone workers in Hong  Kong. Am Rev Respir Dis 1987;135:1249–54.  	3035974
	26. Hessel PA, Sluis-Cremer GK, Lee SL. Distribution of silicotic  collagenization in relation to smoking habits. Am Rev Respir  Dis 1991;144:297–301.  	1859051
	27. Glover JR, Bevan C, Cotes JE, Elwood PC, Hodges NG, Kell  RL, et al. Effects of exposure to slate dust in North Wales. Br J  Ind Med 1980;37:152–62.  	7426466
	28. Ng T-P, Chan S-L. Lung function in relation to silicosis and  silica exposure in granite workers. Eur Respir J 1992;5:986–  91.  	1330677
	29. Wang X, Yano E. Pulmonary dysfunction in silica-exposed  workers: a relationship to radiographic signs of silicosis and  emphysema. Am J Ind Med 1999;36:299–306.  	10398938
	30. Finkelstein MM. Silicosis surveillance in Ontario from 1979 to  1992. Scand J Work Environ Health 1995;21 Suppl 2:55–7.  	NO_MATCH
	31. Gardner LU, Middleton EL, Orenstein AI. Report upon medi cal aspects of silicosis, including etiology, pathology, and  diagnostics: resolution adopted by the international conference  held in at Johannesburg, South Africa, Aug, 1930: p 12–27.  	NO_MATCH
	32. Cavariani F, Di Pietro A, Miceli M, Forastiere F, Biggeri A,  Scavalli P, et al. Incidence of silicosis among ceramic workers  in central Italy. Scand J Work Environ Health 1995;21 Suppl  2:58–62.  	NO_MATCH
	33. Hnizdo E, Sluis-Cremer GK. Effect of tobacco smoking on the  presence of asbestosis at postmortem and on the reading or  irregular opacities on roentgenograms in asbestos-exposed  workers. Am Rev Respir Dis 1988;138:1207–12.  	3202481
	34. Thurlbeck WM, Churg AM. Pathology of the Lung. New  York: Theime; 1995. p 612–5.  	NO_MATCH
	35. Remy-Jardin M, Remy J, Boulenguez C, Sobaszek A, Edme  J-L, Furon D. Morphologic effects of cigarette smoking on  airways and pulmonary parenchyma in healthy adult volun teers: CT evaluation and correlation with pulmonary function  tests. Radiology 1993;186:107–15.  	8416548
	36. Finkelstein MM. Radiographic silicosis and lung cancer risk  among workers in Ontario. Am J Ind Med 1998;34:244–51.  	9698993
	37. Finkelstein MM. Radiographic abnormalities and the risk of  lung cancer among workers exposed to silica dust in Ontario.  Can Med Assoc J 1995;152:37–43.  	7804920
ymj-44-939.pdf
3270150.pdf
3270134.pdf
el-ppr126.pdf
3270121A.pdf
Am J Physiol Gastrointest Liver Physiol-2003-Savoye-Collet-G1147-52.pdf
	1. Bateman DN and Whittingham TA. Measurement of gastric  emptying by real-time ultrasound. Gut 23: 524–527, 1982.  	7076028
	2. Bolondi L, Bortolotti M, Santi V, Calletti T, Gaiani S, and  Labo G. Measurement of gastric emptying time by real time  ultrasonography. Gastroenterology 89: 752–759, 1985.  	3896910
	3. Ehrlein HJ, Schemann M, and Siegle ML. Motor patterns of  small intestine determined by closely spaced extraluminal trans ducers and videofluoroscopy. Am J Physiol Gastrointest Liver  Physiol 253: G259–G267, 1987.  	3631262
	4. Faas H, Hebbard GS, Feinle C, Kunz P, Brasseur JG,  Indireshkumar K, Dent J, Boesiger P, Thumshirn M,  Fried M, and Schwizer W. Pressure-geometry relationship in  the antroduodenal region in humans. Am J Physiol Gastrointest  Liver Physiol 281: G1214–G1220, 2001.  	11668030
	5. Fass J, Silny J, Braun J, Heindrichs U, Dreuw B,  Schumpelick V, and Rau G. Measuring esophageal motility  with a new intraluminal impedance device. First clinical results  in reflux patients. Scand J Gastroenterol 29: 693–702, 1994.  	7973429
	6. Frieling T, Hermannn S, Kuhlbusch R, Enck P, Silny J,  and Lu¨bke HJ. Comparison between intraluminal multiple  electrical impedance measurement and manometry in the oesoph agus. Neurogastroenterol Motil 8: 45–50, 1996.  	8697184
	7. Geall MG, Philipps SF, and Summerskill WHJ. Profile of  gastric potential difference in man. Gastroenterology 8: 437–443,  1970.  	NO_MATCH
	8. Hausken T, Gilja OH, Odegaard S, and Berstad A. Flow  across the human pylorus soon after ingestion of food, studied  with duplex sonography. Effect of glyceryl trinitrate. Scand J  Gastroenterol 33: 484–490, 1998.  	9648986
	9. Hausken T, Gilja OH, Undeland KA, and Berstad A. Timing  of postprandial dyspeptic symptoms and transpyloric passage of  gastric contents. Scand J Gastroenterol 33: 822–827, 1998.  	9754729
	10. Hausken T, Mundt M, and Samsom M. Low antroduodenal  pressure gradients are responsible for gastric emptying of a low  caloric liquid meal in humans. Neurogastroenterol Motil 14:  97–105, 2002.  	11874558
	11. Hausken T, Odegaard S, Matre K, and Berstad A. Antroduo denal motility and movements of luminal contents studied by  duplex sonography. Gastroenterology 102: 1583–1590, 1992.  	1568568
	12. Heddle R, Dent J, Toouli J, and Read NW. Topography and  measurement of pyloric pressure waves and tone in humans.  Am J Physiol Gastrointest Liver Physiol 255: G490–G497, 1988.  	3140675
	13. Holt S, McDicken WN, Anderson T, Stewart IC, and Head ing RC. Dynamic imaging of the stomach by real-time ultra sound, a method for the study of gastric motility. Gut 21: 597–  601, 1980.  	7429323
	14. Horowitz M and Dent J. The study of gastric mechanics and  flow: a mad hatter’s tea party starting to make sense? Gastro enterology 107: 302–306, 1994.  	8020676
	15. Hveem K, Hausken T, and Berstad A. Ultrasonographic  assessment of fasting liquid content in the human stomach.  Scand J Gastroenterol 29: 786–789, 1994.  	7824856
	16. Hveem K, Jones KL, Chatterton BE, and Horowitz M.  Scintigraphic measurment of gastric emptying and ultrasono graphic assessment of antral area: relation to appetite. Gut 38:  816–821, 1996.  	8984016
	17. Hveem K, Sun WM, Hebbard G, Horowitz M, Doran S, and  Dent J. Relationship between ultrasonically detected phasic  antral contractions and antral pressure. Am J Physiol Gastro intest Liver Physiol 281: G95–G101, 2001.  	11408259
	18. Indireshkumar K, Brasseur JG, Faas H, Hebbard GS,  Kunz P, Dent J, Feinle C, Li M, Boesiger P, Fried M, and  Schwizer W. Relative contributions of pressure pump and peri staltic pump to gastric emptying. Am J Physiol Gastrointest  Liver Physiol 278: G604–G616, 2000.  	10762615
	19. Jones K, Edelbroek M, Horowitz M, Sun WM, Dent J,  Roelofs J, Muecke T, and Akkermans L. Evaluation of antral  motility in humans using manometry and scintigraphy. Gut 37:  643–638, 1995.  	8549939
	20. Kerlin P, Zinsmeister A, and Philipps S. Relationship of  motility to flow of contents in the human small intestine. Gas troenterology 82: 701–706, 1982.  	7060888
	21. King PM, Adam RD, Pryde A, McDicken WN, and Heading  RC. Relationships of human antroduodenal motility and  transpyloric fluid movement: non-invasine observations with  real-time ultrasound. Gut 25: 1384–1391, 1984.  	6392035
	22. King PM, Heading RC, and Pryde A. Coordinated motor  activity of the human gastroduodenal region. Dig Dis Sci 30:  219–224, 1985.  	3971833
	23. Malbert CH and Mathis C. Antropyloric modulation of  transpyloric flow of liquids in pigs. Gastroenterology 107: 37–46,  1994.  	8020687
	24. Nguyen HN, Silny J, Albers D, Roeb E, Gartung C, Rau G,  and Matern S. Dynamics of esophageal bolus transport in  healthy subjects studied using multiple intraluminal impedan cometry. Am J Physiol Gastrointest Liver Physiol 273: G958–  G964, 1997.  	9357841
	25. Nguyen HN, Silny J, Wu¨ller S, Marshall HU, Rau G, and  Matern S. Chyme transport patterns in human duodenum de termined by multiple intraluminal impedancemetry. Am J  Physiol Gastrointest Liver Physiol 268: G700–G708, 1995.  	7733294
	26. Nguyen HN, Silny J, Wu¨ller S, Marshall HU, Rau G, and  Matern S. Abnormal postprandial duodenal chyme transport in  patients with long standing insulin dependent diabetes mellitus.  Gut 41: 624–631, 1997.  	9414968
	27. Pallotta N, Cicala M, Frandina C, and Corazziari E. Antro pyloric contractile patterns and transpyloric flow after meal  ingestion in humans. Am J Gastroenterol 93: 2513–2522, 1998.  	9860417
	28. Rao ASC, Lu R, and Schulze-Delrieu K. Duodenum as an  immediate brake to gastric outflow: a videofluoroscopic and man ometric assessment. Gastroenterology 110: 740–747.  	8608883
	29. Savoye G, Savoye-Collet C, Oors J, and Smout A. Interdi gestive transpyloric fluid transport assessed by intraluminal  impedance recording. Am J Physiol Gastrointest Liver Physiol  284: G663–G669, 2003.  	12490430
	30. Sifrim D, Holloway R, Silny J, Xin Z, Lerut A, and Jans sens J. Acid, and gas reflux in patients with gastroesophageal  reflux disease during ambulatory recordings. Gastroenterology  120: 1588–1598, 2001.  	NO_MATCH
	31. Sifrim D, Silny J, Holloway RH, and Janssens JJ. Patterns  of gas and liquid reflex during transient lower oesophageal  sphincter relaxation: a study using intraluminal electrical im pedance. Gut 44: 47–54, 1999.  	9862825
	32. Silny J. Intraluminal multiple electric impedance procedure for  measurement of gastrointestinal motility. Neurogastroenterol  Motil 3: 151–162, 1991.  	NO_MATCH
	33. Silny J, Knigge KP, Fass J, Rau G, Matern S, and  Schumpelick V. Verification of the intraluminal multiple elec trical impedance measurement for the recording of gastrointes tinal motility. Neurogastroenterol Motil 5: 107–122, 1993.  	NO_MATCH
	34. Skopnik H, Silny J, Heiber O, Schulz J, Rau G, and  Heimann G. Gastroesophageal reflux in infants: evaluation of a  new intraluminal impedance technique. J Pediatr Gastroenterol  Nutr 23: 591–598, 1996.  	8985851
	35. Srinivasan R, Vela MF, Katz PO, Tutuian R, Castell JA,  and Castell DO. Esophageal function testing using multichan nel intraluminal impedance. Am J Physiol Gastrointest Liver  Physiol 280: G456–G462, 2001.  	11171628
	36. Sun WM, Hebbard GS, Malbert CH, Jones KL, Doran S,  Horowitz M, and Dent J. Spatial patterns of fasting and fed  antropyloric pressure wave in humans. J Physiol 503: 455–462,  1997.  	9306286
	37. Tougas G, Anvari M, Dent J, Somers S, Richards D, and  Stevenson GW. Relation of pyloric motility to pyloric opening  and closure in healthy subjects. Gut 33: 466–471, 1992.  	1582588
	38. Vela MF, Camacho-Lobato L, Srinivasan R, Tutuian R,  Katz PO, and Castell DO. Simultaneous intraesophageal im pedance and pH measurement of acid and non-acid gastroesoph ageal reflux: effects of omeprazole. Gastroenterology 120: 1599–  1606, 2001.  	11375942
Am J Physiol Heart Circ Physiol-2003-Kuzume-H2463-70.pdf
	1. Bausback HH and Ward PE. Degradation of low-molecular weight opioid peptides by vascular plasma membrane aminopep tidase M. Biochim Biophys Acta 882: 437–444, 1986.  	2873842
	2. Birincioglu M, Yang XM, Critz SD, Cohen MV, and  Downey JM. S-T segment voltage during sequential coronary  occlusions is an unreliable marker of preconditioning. Am J  Physiol Heart Circ Physiol 277: H2435–H2441, 1999.  	10600866
	3. Chien GL and Van Winkle DM. Naloxone blockade of myocar dial ischaemic preconditioning is stereoselective. J Mol Cell  Cardiol 28: 1895–1900, 1996.  	NO_MATCH
	4. Chien GL, Wolff RA, Davis RF, and Van Winkle DM. “Nor mothermic range” temperature affects myocardial infarct size.  Cardiovasc Res 28: 1014–1017, 1994.  	7954586
	5. Cohen MV, Yang XM, Liu GS, Heusch G, and Downey JM.  Acetylcholine, bradykinin, opioids, and phenylephrine, but not  adenosine, trigger preconditioning by generating free radicals  and opening mitochondrial KATP channels. Circ Res 89: 273–278,  2001.  	11485978
	6. Dana A, Baxter GF, Walker JM, and Yellon DM. Prolonging  the delayed phase of myocardial protection: repetitive adenosine  A1 receptor activation maintains rabbit myocardium in a precon ditioned state. J Am Coll Cardiol 31: 1142–1149, 1998.  	9562020
	7. Fryer RM, Eells JT, Hsu AK, Henry MM, and Gross GJ.  Ischemic preconditioning in rats: role of mitochondrial KATP  channel in preservation of mitochondrial function. Am J Physiol  Heart Circ Physiol 278: H305–H312, 2000.  	10644614
	8. Fryer RM, Hsu AK, Nagase H, and Gross GJ. Opioid-induced  cardioprotection against myocardial infarction and arrhythmias:  mitochondrial versus sarcolemmal ATP-sensitive potassium  channels. J Pharmacol Exp Ther 294: 451–457, 2000.  	10900218
	9. Goto M, Liu Y, Yang XM, Ardell JL, Cohen MV, and  Downey JM. Role of bradykinin in protection of ischemic pre conditioning in rabbit hearts. Circ Res 77: 611–621, 1995.  	7641331
	10. Hashimi MW, Thornton JD, Downey JM, and Cohen MV.  Loss of myocardial protection from ischemic preconditioning  following chronic exposure to R()-N6-(2-phenylisopropyl)aden osine is related to defect at the adenosine A1 receptor. Mol Cell  Biochem 186: 19–25, 1998.  	9774181
	11. Jung O, Englert HC, Jung W, Gogelein H, Scholkens BA,  Busch AE, and Linz W. The KATP channel blocker HMR 1883  does not abolish the benefit of ischemic preconditioning on myo cardial infarct mass in anesthetized rabbits. Naunyn Schmiede bergs Arch Pharmacol 361: 445–451, 2000.  	10763861
	12. Kato R and Foe¨x P. Fentanyl reduces infarction but not stun ning via 	-opioid receptors and protein kinase C in rats. Br J  Anaesth 84: 608–614, 2000.  	10844838
	13. Kloner RA, Das S, Poole WK, Perrit R, Muller J, Cannon  CP, and Braunwald E. Seasonal variation of myocardial in farct size. Am J Cardiol 88: 1021–1024, 2001.  	11704000
	14. Krenz M, Oldenburg O, Wimpee H, Cohen MV, Garlid KD,  Critz SD, Downey JM, and Benoit JN. Opening of ATP sensitive potassium channels causes generation of free radicals  in vascular smooth muscle cells. Basic Res Cardiol 97: 365–373,  2002.  	12200636
	15. Liu GS, Thornton J, Van Winkle DM, Stanley AWH, Olsson  RA, and Downey JM. Protection against infarction afforded by  preconditioning is mediated by A1 adenosine receptors in rabbit  heart. Circulation 84: 350–356, 1991.  	2060105
	16. Llorens-Cortes C, Huang H, Vicart P, Gasc JM, Paulin D,  and Corvol P. Identification and characterization of neutral  endopeptidase in endothelial cells from venous or arterial ori gins. J Biol Chem 267: 14012–14018, 1992.  	1629199
	17. Miki T, Cohen MV, and Downey JM. Opioid receptor contrib utes to ischemic preconditioning through protein kinase C acti vation in rabbits. Mol Cell Biochem 186: 3–12, 1998.  	9774179
	18. Patel HH, Hsu AK, Peart JN, and Gross GJ. Sarcolemmal  KATP channel triggers opioid-induced delayed cardioprotection  in the rat. Circ Res 91: 186–188, 2002.  	12169643
	19. Schultz JEJ, Hsu AK, and Gross GJ. Morphine mimics the  cardioprotective effect of ischemic preconditioning via a gliben clamide-sensitive mechanism in rat heart. Circ Res 78: 1100–  1104, 1996.  	8635241
	20. Schultz JEJ, Rose E, Yao Z, and Gross GJ. Evidence for  involvement of opioid receptors in ischemic preconditioning in  rat hearts. Am J Physiol Heart Circ Physiol 268: H2157–H2161,  1995.  	7771566
	21. Schulz R, Gres P, and Heusch G. Role of endogenous opioids  in ischemic preconditioning but not in short-term hibernation in  pigs. Am J Physiol Heart Circ Physiol 280: H2175–H2181, 2001.  	11299219
	22. Schulz R, Post H, Vahlhaus C, and Heusch G. Ischemic  preconditioning in pigs: a graded phenomenon. Its relation to  adenosine and bradykinin. Circulation 98: 1022–1029, 1998.  	9737523
	23. Schwartz JC, Malfroy B, and de la Baume S. Biological  inactivation of enkephalins and the role of enkephalin-dipepti dyl-carboxypeptidase (“enkephalinase”) as neuropeptidase. Life  Sci 29: 1715–1740, 1981.  	6272046
	24. Sigg DC, Coles JA Jr, Oeltgen PR, and Iaizzo PA. Role of  	-opioid receptor agonists on infarct size reduction in swine.  Am J Physiol Heart Circ Physiol 282: H1953–H1960, 2002.  	NO_MATCH
	25. Takasaki Y, Wolff RA, Chien GL, and Van Winkle DM.  Met5-enkephalin protects isolated adult rabbit cardiomyocytes  via 	-opioid receptors. Am J Physiol Heart Circ Physiol 277:  H2442–H2450, 1999.  	10600867
	26. Thornton JD, Liu GS, Olsson RA, and Downey JM. Intra venous pretreatment with A1-selective adenosine analogues pro tects the heart against infarction. Circulation 85: 659–665, 1992.  	1735160
	27. Tsuchida A, Thompson R, Olsson RA, and Downey JM. The  anti-infarct effect of an adenosine A1-selective agonist is dimin ished after prolonged infusion as is the cardioprotective effect of  ischaemic preconditioning in rabbit heart. J Mol Cell Cardiol 26:  303–311, 1994.  	8028014
	28. Valtchanova-Matchouganska A and Ojewole JA. Involve ment of opioid delta (	)- and kappa ()-receptors in ischemic  preconditioning in a rat model of myocardial infarction. Methods  Find Exp Clin Pharmacol 24: 139–144, 2002.  	12087875
	29. Wall TM, Sheehy R, and Hartman JC. Role of bradykinin in  myocardial preconditioning. J Pharmacol Exp Ther 270: 681–  688, 1994.  	8071859
	30. Wu JP, Chen YT, and Lee YS. Opioids in myocardial ischae mia: potentiating effects of dynorphin on ischaemic arrhythmia,  bradycardia and cardiogenic shock following coronary artery  occlusion in the rat. Eur Heart J 14: 1273–1277, 1993.  	7901021
	31. Yao Z and Gross GJ. Acetylcholine mimics ischemic precondi tioning via a glibenclamide-sensitive mechanism in dogs. Am J  Physiol Heart Circ Physiol 264: H2221–H2225, 1993.  	8322953
	32. Zhu BO, Sun YP, Sudhir K, Sievers RE, Browne AE, Gao L,  Hutchison SJ, Chou TM, Deedwania PC, Chatterjee K,  Glantz SA, and Parmley WW. Effects of second-hand smoke  and gender on infarct size of young rats exposed in utero and in  the neonatal to adolescent period. J Am Coll Cardiol 30: 1878–  1885, 1997.  	9385922
Ann Oncol-2003-Kerr-971.pdf
	1. Boyle P, Autier P, Bartelink H et al. European Code Against Cancer and  scientific justification: third version (2003). Ann Oncol 2003; 14: 973–  1005.  	12853336
	2. Quinn MJ, d’Onofrio A, Møller B et al. Cancer mortality trends in the EU  and acceding countries up to 2015. Ann Oncol 2003; 14: 1148–1152.  	NO_MATCH
	3. Boyle P, d’Onofrio A, Maisonneuve P et al. Measuring progress against  cancer in Europe: has the 15% decline targeted for 2000 come about? Ann  Oncol 2003; 14: In press.  	NO_MATCH
Am J Physiol Cell Physiol-2003-Broderick-C1207-18.pdf
	1. Abdel-Latif AA. Cross talk between cyclic nucleotides and poly phosphoinositide hydrolysis, protein kinases, and contraction in  smooth muscle. Exp Biol Med (Maywood) 226: 153–163, 2001.  	11361033
	2. Bachmann S. Nitric oxide in the kidney: synthesis, localization,  and function. Am J Kidney Dis 24: 112–129, 1994.  	7517625
	3. Bader M, Peters J, Baltatu O, Muller DN, Luft FC, and  Ganten D. Tissue renin-angiotensin systems: new insights from  experimental animal models in hypertension research. J Mol  Med 79: 76–102, 2001.  	11357942
	4. Biel M, Zong X, Distler M, Bosse E, Klugbauer N, Mu rakami M, Flockerzi V, and Hofmann F. Another member of  the cyclic nucleotide-gated channel family, expressed in testis,  kidney, and heart [see comments]. Proc Natl Acad Sci USA 91:  3505–3509, 1994.  	8170936
	5. Broderick KE. Cyclic cGMP-Dependent Signalling in D. mela nogaster Malpighian Tubules. Glasgow, Scotland: University of  Glasgow, 2002.  	NO_MATCH
	6. Cabrero P, Radford JC, Broderick KE, Veenstra J, Spana  E, Davies S, and Dow JAT. The CRF gene of Drosophila  melanogaster encodes a diuretic peptide that activates cAMP  signalling. J Exp Biol 205: 3799–3807, 2002.  	NO_MATCH
	7. Chiang AS, Wen CJ, Lin CY, and Yeh CH. Nadph-diaphorase  activity in corpus allatum cells of the cockroach, Diploptera  punctata. Insect Biochem Mol Biol 30: 747–753, 2000.  	10876118
	8. Chini CC, Grande JP, Chini EN, and Dousa TP. Compart mentalization of cAMP signaling in mesangial cells by phospho diesterase isozymes PDE3 and PDE4. Regulation of superoxida tion and mitogenesis. J Biol Chem 272: 9854–9859, 1997.  	9092521
	9. Colasanti M and Venturini G. Nitric oxide in invertebrates.  Mol Neurobiol 17: 157–174, 1998.  	9887451
	10. Corbin JD, Turko IV, Beasley A, and Francis SH. Phosphor ylation of phosphodiesterase-5 by cyclic nucleotide-dependent  protein kinase alters its catalytic and allosteric cGMP-binding  activities. Eur J Biochem 267: 2760–2767, 2000.  	10785399
	11. Davies SA. Nitric oxide signalling in insects. Insect Biochem  Mol Biol 30: 1123–1138, 2000.  	11044659
	12. Davies SA, Huesmann GR, Maddrell SHP, O’Donnell MJ,  Skaer NJV, Dow JAT, and Tublitz NJ. CAP2b, a cardioaccel eratory peptide, is present in Drosophila and stimulates tubule  fluid secretion via cGMP. Am J Physiol Regul Integr Comp  Physiol 269: R1321–R1326, 1995.  	8594932
	13. Davies SA, Stewart EJ, Huesmann GR, Skaer NJV, Mad drell SHP, Tublitz NJ, and Dow JAT. Neuropeptide stimu lation of the nitric oxide signaling pathway in Drosophila mela nogaster Malpighian tubules. Am J Physiol 42: R823–R827,  1997.  	9277574
	14. Dimopoulos G, Seeley D, Wolf A, and Kafatos FC. Malaria  infection of the mosquito Anopheles gambiae activates immune responsive genes during critical transition stages of the parasite  life cycle. EMBO J 17: 6115–6123, 1998.  	9799221
	15. Dow JA and Davies SA. Integrative physiology, functional  genomics and epithelial function in a genetic model organism.  Physiol Rev 83: 687–729, 2003.  	12843407
	16. Dow JA, Maddrell SH, Davies SA, Skaer NJ, and Kaiser K.  A novel role for the nitric oxide-cGMP signaling pathway: the  control of epithelial function in Drosophila. Am J Physiol Regul  Integr Comp Physiol 266: R1716–R1719, 1994.  	8203655
	17. Dow JAT. The multifunctional Drosophila melanogaster V ATPase is encoded by a multigene family. J Bioenerg Biomembr  31: 75–83, 1999.  	10340851
	18. Dow JAT and Davies SA. The Drosophila melanogaster mal pighian tubule. Advances Insect Physiol 28: 1–83, 2001.  	NO_MATCH
	19. Hanafy K, Krumenacker J, and Murad F. NO, nitrotyrosine,  and cyclic GMP in signal transduction. Med Sci 7: 801–819,  2001.  	11433215
	20. Kean L, Cazenave W, Costes L, Broderick KE, Graham S,  Pollock VP, Davies SA, Veenstra JA, and Dow JA. Two  nitridergic peptides are encoded by the gene capability in Dro sophila melanogaster. Am J Physiol Regul Integr Comp Physiol  282: R1297–R1307, 2002.  	11959669
	21. Klein U. The insect V-ATPase, a plasma-membrane proton  pump energizing secondary active transport–immunological ev idence for the occurrence of a V-ATPase in insect ion-transport ing epithelia. J Exp Biol 172: 345–354, 1992.  	NO_MATCH
	22. Kramer RH and Molokanova E. Modulation of cyclic-nucle otide-gated channels and regulation of vertebrate phototrans duction. J Exp Biol 204: 2921–2931, 2001.  	11551982
	23. Krebs RA and Feder ME. Tissue-specific variation in Hsp70  expression and thermal damage in Drosophila melanogaster  larvae. J Exp Biol 200: 2007–2015, 1997.  	NO_MATCH
	24. Kurjak M, Fritsch R, Saur D, Schusdziarra V, and  Allescher HD. Functional coupling between nitric oxide synthe sis and VIP release within enteric nerve terminals of the rat:  involvement of protein kinase G and phosphodiesterase 5.  J Physiol 534: 827–836, 2001.  	11483712
	25. Kuzin B, Regulski M, Stasiv Y, Scheinker V, Tully T, and  Enikolopov G. Nitric oxide interacts with the retinoblastoma  pathway to control eye development in Drosophila. Curr Biol 10:  459–462, 2000.  	10801421
	26. Lang R, Lee G, Liu W, Tian S, Rafi H, Orias M, Segal AS,  and Desir GV. KCNA10: a novel ion channel functionally re lated to both voltage-gated potassium and CNG cation channels.  Am J Physiol Renal Physiol 278: F1013–F1021, 2000.  	10836990
	27. Liang M and Knox FG. Nitric oxide reduces the molecular  activity of Na,K-ATPase in opossum kidney cells. Kidney Int  56: 627–634, 1999.  	10432402
	28. Lincoln TM and Cornwell TL. Intracellular cyclic GMP re ceptor proteins. FASEB J 7: 328–338, 1993.  	7680013
	29. MacPherson MR, Pollock VP, Broderick KB, Dow JA, and  Davies SA. The role of TRP channels in epithelial fluid trans port. A Dros Res Conf 41: 816B, 2000.  	NO_MATCH
	30. MacPherson MR, Pollock VP, Broderick KB, Kean L,  O’Connell FC, Dow JAT, and Davies SA. Model organisms:  new insights into ion channel and transporter function: L-type  calcium channels regulate epithelial fluid transport in Drosoph ila melanogaster. Am J Physiol Cell Physiol 280: C394–C407,  2001.  	11208535
	31. Morin X, Daneman R, Zavortink M, and Chia W. A protein  trap strategy to detect GFP-tagged proteins expressed from their  endogenous loci in Drosophila. Proc Natl Acad Sci USA 98:  15050–15055, 2001.  	11742088
	32. Mullershausen F, Friebe A, Feil R, Thompson WJ, Hof mann F, and Koesling D. Direct activation of PDE5 by cGMP:  long-term effects within NO/cGMP signaling. J Cell Biol 160:  719–727, 2003.  	12604588
	33. Murthy KS. Activation of phosphodiesterase 5 and inhibition of  guanylate cyclase by cGMP-dependent protein kinase in smooth  muscle. Biochem J 360: 199–208, 2001.  	11696008
	34. Pietrantonio PV and Gill SS. Immunolocalization Of the  17-kDa vacuolar H-ATPase subunit-C in Heliothis-virescens  midgut and malpighian tubules with an antipeptide antibody. J  Exp Biol 198: 2609–2618, 1995.  	8576687
	35. Regulski M and Tully T. Molecular and biochemical charac terization of dNOS–a Drosophila Ca2 calmodulin-dependent  nitric-oxide synthase. Proc Natl Acad Sci USA 92: 9072–9076,  1995.  	7568075
	36. Rosay P, Davies SA, Yu Y, Sozen MA, Kaiser K, and Dow  JAT. Cell-type specific calcium signalling in a Drosophila epi thelium. J Cell Sci 110: 1683–1692, 1997.  	9264456
	37. Schubiger M, Feng Y, Fambrough DM, and Palka J. A  mutation of the Drosophila sodium pump alpha subunit gene  results in bang-sensitive paralysis. Neuron 12: 373–381, 1994.  	8110464
	38. Schulz S, Chinkers M, and Garbers DL. The guanylate  cyclase/receptor family of proteins. FASEB J 3: 2026–2035,  1989.  	NO_MATCH
	39. Stuehr DJ. Mammalian nitric oxide synthases. Biochim Bio phys Acta 1411: 217–230, 1999.  	10320659
	40. Theilig F, Bostanjoglo M, Pavenstadt H, Grupp C, Holland  G, Slosarek I, Gressner AM, Russwurm M, Koesling D, and  Bachmann S. Cellular distribution and function of soluble gua nylyl cyclase in rat kidney and liver. J Am Soc Nephrol 12:  2209–2220, 2001.  	11675397
	41. Thomas RE, Armstrong DT, and Gilchrist RB. Differential  effects of specific phosphodiesterase isoenzyme inhibitors on  bovine oocyte meiotic maturation. Dev Biol 244: 215–225, 2002.  	11944932
	42. Wang T. Role of nitric oxide synthase (iNOS and eNOS) in  modulating proximal tubule transport and acid-base balance.  Am J Physiol Renal Physiol 283: F658–F662, 2002.  	NO_MATCH
	43. Welch WJ and Wilcox CS. What is brain nitric oxide synthase  doing in the kidney? Curr Opin Nephrol Hypertens 11: 109–115,  2002.  	11753095
	44. Wendehenne D, Pugin A, Klessig DF, and Durner J. Nitric  oxide: comparative synthesis and signaling in animal and plant  cells. Trends Plant Sci 6: 177–183, 2001.  	11286923
	45. Wu F, Park F, Cowley AW Jr, and Mattson DL. Quantifica tion of nitric oxide synthase activity in microdissected segments  of the rat kidney. Am J Physiol Renal Physiol 276: F874–F881,  1999.  	10362776
	46. Zhao Y, Brandish PE, Ballou DP, and Marletta MA. A  molecular basis for nitric oxide sensing by soluble guanylate  cyclase. Proc Natl Acad Sci U S A 96: 14753–14758, 1999.  	10611285
Am J Physiol Cell Physiol-2003-Guo-C1174-87.pdf
	1. Adams CL, Nelson WJ, and Smith SJ. Quantitative analysis  of cadherin-catenin-actin reorganization during development of  cell-cell adhesion. J Cell Biol 135: 1899–1911, 1996.  	NO_MATCH
	2. Alexander JS, Blaschuk OW, and Haselton FR. An N-cad herin-like protein contributes to solute barrier maintenance in  cultured endothelium. J Cell Physiol 156: 610–618, 1993.  	8360263
	3. Angres B, Barth A, and Nelson WJ. Mechanism for transition  from initial to stable cell-cell adhesion: kinetic analysis of E cadherin-mediated cell adhesion using a quantitative adhesion  assay. J Cell Biol 134: 549–557, 1996.  	8707837
	4. Angst BD, Marcozzi C, and Magee AI. The cadherin super family: diversity in form and function. J Cell Sci 114:629–641,  2001.  	11171368
	5. Bradford MM. A rapid and sensitive method for the quantita tion of microgram quantities of protein utilizing the principle of  protein-dye binding. Anal Biochem 72: 248–254, 1976.  	942051
	6. Cereijido M, Shoshani L, and Contreras RG. Molecular  physiology and pathophysiolgy of tight junctions. I. Biogenesis of  tight junctions and epithelial polarity. Am J Physiol Gastrointest  Liver Physiol 279: G477–G482, 2000.  	10960345
	7. Cereijido M, Valdes J, Shoshani L, and Contreras RG. Role  of tight junctions in establishing and maintaining cell polarity.  Annu Rev Physiol 60: 161–177, 1998.  	9558459
	8. Chung SSW, Lee WM, and Cheng CY. Study on the formation  of specialized inter-Sertoli cell junctions in vitro. J Cell Physiol  181: 258–272, 1999.  	10497305
	9. Collares-Buzato CB, McEwan GT, Jepson MA, Simmons  NL, and Hirst BH. Paracellular barrier and junctional protein  distribution depend on basolateral extracellular Ca2 in cultured  epithelia. Biochim Biophys Acta 1222: 147–158, 1994.  	8031850
	10. Duizer E, Gilde AJ, Versantvoort CH, and Groten JP.  Effects of cadmium chloride on the paracellular barrier function  of intestinal epithelial cell lines. Toxicol Appl Pharmacol 155:  117–126, 1999.  	10053166
	11. Fujimori T and Takeichi M. Disruption of epithelial cell-cell  adhesion by exogenous expression of a mutated nonfunctional  N-cadherin. Mol Biol Cell 4: 37–47, 1993.  	8443408
	12. Gassler N, Rohr C, Schneider A, Kartenbeck J, Bach A,  Obermuller N, Otto H, and Autschbach F. Inflammatory  bowel disease is associated with changes of enterocytic junctions.  Am J Physiol Gastrointest Liver Physiol 281: G216–G228, 2001.  	11408275
	13. Gumbiner B, Stevenson B, and Grimaldi A. The role of the  cell adhesion molecule uvomorulin in the formation and main tenance of the epithelial junctional complex. J Cell Biol 107:  1575–1587, 1988.  	3049625
	14. Gumbiner BM. Cell adhesion: the molecular basis of tissue  architecture and morphogenesis. Cell 84: 345–357, 1996.  	8608588
	15. Guo X, Rao JN, Liu L, Rizvi M, Turner DJ, and Wang JY.  Polyamines regulate -catenin tyrosine phosphorylation via  Ca2 during intestinal epithelial cell migration. Am J Physiol  Cell Physiol 283: C722–C734, 2002.  	12176729
	16. Hanby AM, Chinery R, Poulsom R, Playford RJ, and Pig natelli M. Down regulation of E-cadherin in the reparative  epithelium of the human gastrointestinal tract. Am J Pathol  148: 723–729, 1996.  	8774128
	17. Harter JL. Critical values for Duncan’s new multiple range  tests. Biometrics 16: 671–685, 1960.  	NO_MATCH
	18. Hermiston ML and Gordon JI. Inflammatory bowel disease  and adenomas in mice expressing a dominant negative N-cad herin. Science 270: 1203–1207, 1995.  	7502046
	19. Itoh M, Nagafuchi A, Moroi S, and Tsukita S. Involvement of  ZO-1 in cadherin-based cell adhesion through its direct binding  to -catenin and actin filaments. J Cell Biol 138: 181–192, 1997.  	9214391
	20. Jankowski JAZ, Bedford FK, Boulton RA, Cruickshank N,  Hall C, Elder J, Allan R, Forbes A, Kim YS, Wright NA, and  Sanders DSA. Alterations in classical cadherins associated  with progression in ulcerative and Crohn’s colitis. Lab Invest 78:  1155–1167, 1998.  	9759659
	21. Janssens B, Goossens S, Staes K, Gilbert B, Hengel JV,  Colpaert C, Bruyneel E, Mareel M, and Roy FV. T-catenin:  a novel tissue-specific -catenin-binding protein mediating  strong cell-cell adhesion. J Cell Sci 114: 3177–3188, 2001.  	11590244
	22. Kucharzik T, Walsh SV, Chen J, Parkos CA, and Nusrat A.  Neutrophil transmigration in inflammatory bowel disease is  associated with differential expression of epithelial intercellular  junction proteins. Am J Pathol 159: 2001–2009, 2001.  	11733350
	23. Laemmli UK. Cleavage of structural proteins during the assem bly of the head of bacteriophage T4. Nature 227: 680–685, 1990.  	NO_MATCH
	24. Li L, Liu L, Rao JN, Esmaili A, Strauch ED, Bass BL, and  Wang JY. JunD stabilization results in inhibition of normal  intestinal epithelial cell growth through p21 after polyamine  depletion. Gastroenterology 123: 764–779, 2002.  	12198703
	25. Li L, Rao JN, Bass BL, and Wang JY. NF-B activation and  susceptibility to apoptosis after polyamine depletion in intesti nal epithelial cells. Am J Physiol Gastrointest Liver Physiol 280:  G992–G1004, 2001.  	11292609
	26. Li L, Rao JN, Guo X, Liu L, Santora R, Bass BL, and Wang  JY. Polyamine depletion stabilizes p53 resulting in inhibition of  normal intestinal epithelial cell proliferation. Am J Physiol Cell  Physiol 281: C941–C953, 2001.  	11502571
	27. Ma TY, Nguyen D, Bui V, Nguyen H, and Hoa N. Ethanol  modulation of intestinal epithelial tight junction barrier. Am J  Physiol Gastrointest Liver Physiol 276: G965–G974, 1999.  	10198341
	28. Madara JL. Regulation of the movement of solutes across tight  junctions. Annu Rev Physiol 60: 143–159, 1998.  	9558458
	29. Man Y, Hart VJ, Ring CJA, Sanjar S, and West MR. Loss of  epithelial integrity resulting from E-cadherin dysfunction pre disposes airway epithelial cells to adenoviral infection. Am J  Respir Cell Mol Biol 23: 610–617, 2000.  	11062139
	30. McCormack SA, Wang JY, and Johnson LR. Polyamine  deficiency causes reorganization of F-actin and tropomyosin in  IEC-6 cells. Am J Physiol Cell Physiol 267: C715–C722, 1994.  	7524334
	31. Mitic LL and Anderson JM. Molecular architecture of tight  junctions. Annu Rev Physiol 60: 121–142, 1998.  	9558457
	32. Mizuno M, Okayama N, Kasugai K, Yoshida T, Miyata M,  Nitta M, Kataoka H, Akita S, Joh T, Itoh M, Asai K, and  Kato T. Acid stimulates E-cadherin surface expression on gas tric epithelial cells to stabilize barrier functions via influx of  calcium. Eur J Gastroenterol Hepatol 13: 127–136, 2001.  	11246611
	33. Nusrat A, Parkos CA, Verkade P, Foley CS, Liang TW,  Innis-Whitehouse Eastburn KK, and Madara JL. Tight  junctions are membrane microdomains. J Cell Sci 113: 1771–  1781, 2000.  	10769208
	34. Parekh AB and Penner R. Store depletion and calcium influx.  Physiol Rev 77:901–930, 1997.  	9354808
	35. Patel AR, Li J, Bass BL, and Wang JY. Expression of the  transforming growth factor- gene during growth inhibition fol lowing polyamine depletion. Am J Physiol Cell Physiol 275:  C590–C598, 1998.  	9688614
	36. Patel AR and Wang JY. Polyamines modulate transcription  but not posttranscription of c-myc and c-jun in IEC-6 cells. Am J  Physiol Cell Physiol 273: C1020–C1029, 1997.  	9316423
	37. Pollard KJ, Samuels ML, Crowley KA, Hansen JC, and  Peterson CL. Functional interaction between GCN5 and poly amines: a new role for core histone acetylation. EMBO J 18:  5622–5633, 1999.  	10523306
	38. Prozialeck WC. Evidence that E-cadherin may be a target for  cadmium toxicity in epithelial cells. Toxicol Appl Pharmacol 164:  231–249, 2000.  	10799334
	39. Quaroni A, Wands J, Trelstad RL, and Isselbacher KJ.  Epithelial cell cultures from rat small intestine. J Cell Biol 80:  248–265, 1979.  	NO_MATCH
	40. Rao JN, Guo X, Liu L, Zou T, Murthy KS, Yuan JXJ, and  Wang JY. Polyamines regulate Rho-kinase and myosin phos phorylation during intestinal epithelial restitution. Am J  Physiol Cell Physiol 284: C848–C859, 2003.  	12466151
	41. Rao JN, Li L, Golovina VA, Li L, Platoshyn O, Strauch ED,  Yuan JXJ, and Wang JY. Ca2-RhoA signaling pathway re quired for polyamine-dependent intestinal epithelial cell migra tion. Am J Physiol Cell Physiol 280: C993–C1007, 2001.  	11245616
	42. Rao JN, Li J, Li L, Bass BL, and Wang JY. Differentiated  intestinal epithelial cells exhibit increased migration through  polyamines and myosin II. Am J Physiol Gastrointest Liver  Physiol 277: G1149–G1159, 1999.  	10600811
	43. Rao JN, Platoshyn O, Li L, Guo X, Golovina VA, Yuan JXJ,  and Wang JY. Activation of K channels and increased migra tion of differentiated intestinal epithelial cells after wounding.  Am J Physiol Cell Physiol 282: C885–C898, 2002.  	11880277
	44. Ray R, Viar MJ, Yuan Q, and Johnson LR. Polyamine de pletion delays apoptosis of rat intestinal epithelial cells. Am J  Physiol Cell Physiol 278: C480–C489, 2000.  	10712236
	45. Rimm DL, Koslov ER, Kebriaei P, Cianci CD, and Morrow  JS. 1(E)-catenin is an actin-binding and bundling protein me diating the attachment of F-actin to the membrane adhesion  complex. Proc Natl Acad Sci USA 92:8813–8817, 1995.  	7568023
	46. Shore EM and Nelson WJ. Biosynthesis of the cell adhesion  molecule uvomorulin (E-cadherin) in Madin-Darby canine kid ney epithelial cells. J Biol Chem 266: 19672–19680, 1991.  	NO_MATCH
	47. Siliciano JD and Goodenough DA. Localization of the tight  junction protein, ZO-1, is modulated by extracellular calcium  and cell-cell contact in Madin-Darby canine kidney epithelial  cells. J Cell Biol 107: 2389–2399, 1988.  	3058722
	48. Suh E and Traber PG. An intestine-specific homeobox gene  regulates proliferation and differentiation. Mol Cell Biol 16:  619–625, 1996.  	8552090
	49. Tabor CW and Tabor H. Polyamines. Annu Rev Biochem 53:  749–790, 1984.  	6206782
	50. Takeichi M. Cadherins: a molecular family important in selec tive cell-cell adhesion. Annu Rev Biochem 59: 237–252, 1990.  	2197976
	51. Troxell ML, Chen YT, Cobb N, Nelson WJ, and Marrs JA.  Cadherin function in junctional complex rearrangement and  posttranslational control of cadherin expression. Am J Physiol  Cell Physiol 276: C404–C418, 1999.  	9950768
	52. Troxell ML, Gopalakrishnan S, McCormack J, Poteat BA,  Pennington J, Garringer SM, Schneeberger EE, Nelson  WJ, and Marrs JA. Inhibiting cadherin function by dominant  mutant E-cadherin expression increases the extent of tight junc tion assembly. J Cell Sci 113: 985–996, 2000.  	10683147
	53. Varlamov O, Fricker LD, Furukawa H, Steiner DF, Lang ley SH, and Leiter EH. -Cell lines derived from transgenic  Cpefat/Cpefat mice are defective in carboxypeptidase E and pro insulin processing. Endocrinology 138: 4883–4892, 1997.  	9348219
	54. Venkiteswaran K, Xiao K, Summers S, Calkins CC, Vin cent PA, Pumiglia K, and Kowalczyk AP. Regulation of  endothelial barrier function and growth by VE-cadherin, plako globin, and -catenin. Am J Physiol Cell Physiol 283: C811–  C821, 2002.  	12176738
	55. Vielkind U and Swierenga SH. A simple fixation procedure  for immunofluorescence detection of different cytoskeletal com ponents within the same cell. Histochemistry 91: 81–88, 1989.  	2925451
	56. Wang JY and Johnson LR. Luminal polyamines stimulate  repair of gastric mucosal stress ulcers. Am J Physiol Gastrointest  Liver Physiol 259: G584–G592, 1990.  	1699428
	57. Wang JY and Johnson LR. Polyamines and ornithine decar boxylase during repair of duodenal mucosa after stress damage  in rats. Gastroenterology 100: 333–343, 1991.  	1702074
	58. Wang JY, McCormack SA, and Johnson LR. Role of non muscle myosin II in polyamine-dependent intestinal epithelial  cell migration. Am J Physiol Gastrointest Liver Physiol 270:  G355–G362, 1996.  	8779979
	59. Wang JY, Viar MJ, Li J, Shi HJ, McCormack SA, and  Johnson LR. Polyamines are necessary for normal expression  of the transforming growth factor- gene during cell migration.  Am J Physiol Gastrointest Liver Physiol 272: G713–G720, 1997.  	9142900
	60. Wang JY, Wang J, Golovina VA, Li L, Platoshyn O, and  Yuan JXJ. Role of K channel expression in polyamine-depen dent intestinal epithelial cell migration. Am J Physiol Cell  Physiol 278: C303–C314, 2000.  	10666025
	61. Watabe M, Nagafuchi A, Tsukita S, and Takeichi M.  Induction of polarized cell-cell association and retardation of  growth by activation of the E-cadherin-catenin adhesion sys tem in a dispersed carcinoma line. J Cell Biol 127: 247–256,  1994.  	7929567
	62. Weiss EF, Kroemker M, Rudiger AH, Jockusch BM, and  Rudiger M. Vinculin is part of the cadherin-catenin junctional  complex: complex formation between -catenin and vinculin.  J Cell Biol 141: 755–764, 1998.  	9566974
	63. Wong V and Gumbiner BM. A synthetic peptide corresponding  to the extracellular domain of occludin perturbs the tight junc tion permeability barrier. J Cell Biol 136: 399–409, 1997.  	9015310
	64. Yano T, Hernandez-Blazquez FJ, Omori Y, and Yamasaki  H. Reduction of malignant phenotype of HEPG2 cell is associ ated with the expression of connexin 26 but not connexin 32.  Carcinogenesis 22: 1593–1600, 2001.  	11576997
	65. Yap A, Brieher WM, and Gumbiner BM. Molecular and  functional analysis of cadherin-based adherens junctions. Annu  Rev Cell Dev Biol 13: 119–146, 1997.  	9442870
	66. Youakim A and Ahdieh M. Interferon-decreases barrier  function in T84 cells by reducing ZO-1 levels and disrupting  apical actin. Am J Physiol Gastrointest Liver Physiol 276:  G1279–G1288, 1999.  	10330020
Ann Bot-2003-BERTIN-415-24.pdf
10125.pdf
	1. Arnaudov D: Comparative studies of the virulent and immunogenic   properties of the Toxoplasma strains isolated from domestic animals. Vet   Med Nauki 1978, 15, 38-46 (in Bulgarian).   	749328
	2. Bergmann V, Heidrich R, Kiupel H: Acute toxoplasmosis outbreak   in rabbit flocks. Angew Parasitol 1980, 21, 1-6 (in German).   	7377623
	3. Beverley JK, Caley JP, Roseman CJ: Human Toxoplasma infection.   	13152363
	4. Desmonts G, Remington JS: Direct agglutination test for diagnosis   of Toxoplasma infection: method for increasing sensitivity and   specificity. J Clin Microbiol 1980, 11, 562-568.    	7000807
	5. Dubey JP, Beattie CP: Toxoplasmosis of Animals and Man. CRC Press, Boca Raton, FL 1988.   	NO_MATCH
	6. Dubey JP, Brown CA, Carpenter JL, Moore JJ: Fatal toxoplasmosis   in domestic rabbits in the USA. Vet Parasitol 1992, 44, 305-309.    	1466139
	7. Gustafsson K, Uggla A, Jarplid B: Toxoplasma gondii infection in   the mountain hare (Lepus timidus) and domestic rabbit (Oryctolagus   cuniculus). I. Pathology. J Comp Pathol 1997, 117, 351-360.    	9502271
	8. Ibragimova NM, Lopatinkiova VN et al.: Rabbit as an important   source of toxoplasmosis in humans. Trudy Med Inst Alma Ata 1964, 21,   	NO_MATCH
	9. Ishikawa T, Nishino H, Ohara M, Shimosato T, Nanba K: The   identification of a rabbit-transmitted cervical toxoplasmosis mimicking   malignant lymphoma. Am J Clin Pathol 1990, 94, 107-110.   	2193505
	10. Janitschke K: Animals as a source of Toxoplasma infection in   man. Dtsch Med Wschr 1971, 96, 78-83 (in German).    	4996231
	11. Kapperud G: Survey for toxoplasmosis in wild and domestic   animals from Norway and Sweden. J Wildl Dis 1978, 14, 157-162.   	650778
	12. Lainson R: Toxoplasmosis in England. The rabbit (Oryctolagus   cuniculus) as a host of Toxoplasma gondii. Ann Trop Med Parasitol 1955,   	13283508
	13. Leland MM, Hubbard GB, Dubey JP: Clinical toxoplasmosis in   domestic rabbits. Lab Anim Sci 1992, 42, 318-319.    	1320169
	14. Levaditi C, Schoen R, Sanchis-Bayarhi V: Spontaneous encephalitis   in rabbit evoked by Toxoplasma cuniculi. C R Soc Biol 1927, 97, 1692 1693 (in French).    	NO_MATCH
	15. Lin S, Ling ZC, Zeng BC, Yang HY: Prevalence of Toxoplasma   gondii infection in man and animals in Guangdong, Peoples Republic of   China. Vet Parasitol 1990, 34, 357-360.    	2316181
	16. Siim JC, Biering Sorensen U, Møller T: Toxoplasmosis in domestic   animals. Adv Vet Sci 1963, 8, 350-360.    	NO_MATCH
	17. Šima O, Rašin K: Toxoplasma gondii Nicolle et Manceaux 1909 -   antibodies in domestic rabbits. Vet Med (Praha) 1973, 18, 633-640 (in   Czech).   	NO_MATCH
	18. Splendore A: Novel protozoan parasite of rabbit. Rev Soc Sci Sao Paulo 1908, 3, 109-112 (in Portuguese).  	19630136
	19. Sroka J: Seroepidemiology of toxoplasmosis in the Lublin region. Ann Agric Environ Med 2001, 8, 25-31. 	11426921
	20. 7R-Luty S: Invasiveness of two selected strains of Toxoplasma   gondii with respect to mice, rats and rabbits. Wiad Parazytol 1976, 22, 237-244 (in Polish).   	NO_MATCH
	21. Werner H: Spontaneous Toxoplasma infection in the domestic   rabbit (Oryctolagus cuniculus L.). Zbl Bakteriol Orig 1966, 199, 259 263 (in German).   	NO_MATCH
	22. Zhang GN: Epidemiological study on Toxoplasma infection in   human beings and animals in Shandong Province. Zhonghua Liu Xing   Bing Xue Za Zhi 1989, 10, 30-33 (in Chinese).   	2736611
10073.pdf
	1. Avila R, Lacey J: The role of Penicillium frequentans in suberosis (respiratory disease in workers in the cork industry). Clin Allergy 1974, 4(2), 109-117. 	4842936
	2. Bauer J, Gareis M: Ochratoxin A in der Nahrungsmittelkette. J Vet   Med B 1987, 34, 613-627.   	NO_MATCH
	3. Breitholtz-Emanuelsson A, Olsen M, Oskarsson A, Palminger I,   Hult K: Ochratoxin A in cow’s milk and in human milk with corresponding   human blood samples. J AOAC Int 1993, 76, 842-846.   	8374329
	4. Breitholtz-Emanuelsson A, Fuchs R, Hult K: Toxicokinetics of   ochratoxin A in rat following intratracheal administration. Nat Toxins 1995, 3, 101-103.   	7613733
	5. Creppy EE, Betbeder AM, Gharbi A, Counord J, Castegnaro M,   Bartsch H, Moncharmont P, Fouillet B, Chambon P, Dirheimer G:   Human ochratoxicosis in France. In: Castegnaro M, Pleština R, Dirheimer   G, Chernozemsky IN, Bartsch H (Eds): Mycotoxins, Endemic Nephropathy   and Urinary Tract Tumours, 145-151. IARC, Lyon 1991.    	1820319
	6. Di Paolo N, Guarnieri A, Loi F, Sacchi G, Mangiarotti AM, Di Paolo M: Acute renal failure from inhalation of mycotoxins. Nephron 1993, 64, 621-625. 	8366990
	7. Eduard W: Exposure to non-infectious microorganisms and endotoxins   in agriculture. Ann Agric Environ Med 1997, 4, 179-186.   	NO_MATCH
	8. Frisvad JC, Samson A: Mycotoxins produced by species of Penicillium   and Aspergillus occurring in cereals. In: Chelkowski J (Ed): Cereal   Grain. Mycotoxins, Fungi and Quality in Drying and Storage, 441-476.   Elsevier, 1991.    	NO_MATCH
	9. Gareis M, Märtlbauer E, Bauer J, Gedek B: Bestimmung von Ochratoxin A in Muttermilch. Zeitschrift für lebensmittel-untersuchung   und forschung 1988, 186, 114-117.   	NO_MATCH
	10. Hald B: Ochratoxin A in human blood in European countries. In:   Castegnaro M, Pleština R, Dirheimer G, Chernozemsky IN, Bartsch H   (Eds): Mycotoxins, Endemic Nephropathy and Urinary Tract Tumours,   159-164. IARC, Lyon 1991.   	1820330
	11. Hill RA, Lacey J: Penicillium species associated with barley grain   in the U.K. Trans Br Mycol Soc 1984, 82, 297-303.    	NO_MATCH
	12. Hjort C, Andersen P, Schonheyder H, Stenderup A: Occurrence of   Aspergillus umbrosus antibodies in Danish farmers. Allergy 1986, 41, 104-109.   	3085531
	13. Höhler D: Ochratoxin A in food and feed: occurrence, legislation   and mode of action. Zeitschrift für Ernährungswissenschaft 1998, 37, 2-12.   	9556861
	14. Holmberg T, Breitholtz-Emanuelsson A, Haggblom P, Schwan O,   Hult K: Penicillium verrucosum in feed of ochratoxin A-positive swine   herds. Mycopathologia 1991, 116, 169-176.   	1795733
	15. IARC. Monographs on the evaluation of carcinogenic risks to   humans. Some naturally occurring substances: food items and constituents,   heterocyclic aromatic amines and mycotoxins. Lyon: IARC 1993, Vol. 56.   	NO_MATCH
	16. Jørgensen K: Survey of pork, poultry, coffee, beer and pulses for   ochratoxin A. Food Addit Contam 1998, 15, 550-554.   	9829039
	17. Karlsson K, Malmberg P: Characterization of exposure to molds   and actinomycetes in agricultural dusts by scanning electron microscopy,   fluorescence microscopy and the culture method. Scand J Work Environ   Health 1989, 15, 353-359.   	2678431
	18. Katila ML, Ojanen TH, Mantyjarvi RA: Significance of IgG   antibodies against environmental microbial antigens in a farming population. Clin Allergy 1986, 16 (5), 459-67. 	3779941
	19. Krogh P: Ochratoxins in food. In: Krogh P (Ed): Mycotoxins in   food. Food Science and Technology. A Series of Monographs. 97-121. Academic Press 1987    	NO_MATCH
	20. Laitinen S, Linnainmaa M, Laitinen J, Kiviranta H, Reiman M,   Liesivuori J: Endotoxins and IgG antibodies as indicators of occupational   exposure to the microbial contaminants of metal-working fluids. Int Arch   Occup Environ Health 1999, 72, 443-450.    	10541909
	21. Lowry OH, Rosenbrough NJ, Farr AL, Randall RJ: Protein   measurement with the folin phenol reagent. J Biol Chem 1951, 193, 265-275.   	14907713
	22. Micco C, Miraglia M, Brera C, Corneli S, Ambruzzi A: Evaluation   of ochratoxin A in human milk in Italy. Food Addit Contam 1995, 12, 351-354.   	7664927
	23. Mills JT: Mycotoxins and toxigenic fungi on cereal grains in western Canada. Can J Physiol Pharmacol 1990, 68, 982-986.   	2200591
	24. Mills JT, Seifert KA, Frisvad JC, Abramson D: Nephrotoxigenic Penicillium species occurring on farm-stored cereal grains in western Canada. Mycopathologia 1995, 130, 23-28.    	7666923
	25. Palli D, Miraglia M, Saieva C, Masala G, Cava E, Colatosti M,   Corsi AM, Russo A, Brera C: Serum levels of ochratoxin A in healthy   adults in Tuscany: correlation with individual characteristics and between   repeat measurements. Cancer Epidemiol Biomarkers Prev 1999, 8, 265-269.   	10090305
	26. Pitt JI: Penicillium viridicatum, Penicillium verrucosum and   production of ochratoxin A. Appl Environ Microbiol 1987, 53, 266-269.   	3566267
	27. Rautalahti M, Terho EO, Ojanen T: Changes in the titers of IgG   antibodies against farmer’s lung antigens in the sera of healthy dairy   farmers. Ann Allergy 1990, 64, 455-458.   	2337263
	28. Scott PM, Kanhere SR, Lau BPY, Lewis DA, Hayward S, Ryan   JJ, Kuiper-Goodman T: Survey of Canadian human blood plasma for   ochratoxin A. Food Addit Contam 1998, 15, 555-562.   	9829040
	29. Scudamore KA, Clarke JH, Hetmanski MT: Isolation of Penicillium   strains producing ochratoxin A, citrinin, xanthomegnin, viomellein and   vioxanthin from stored cereal grains. Lett Appl Microbiol 1993, 17, 82-87.    	NO_MATCH
	30. Scudamore KA, Hetmanski MT: Natural occurrence of mycotoxins   and mycotoxigenic fungi in cereals in the United Kingdom. Food Addit  Contam 1995, 12, 377-382. 	7664931
	31. Skaug MA, Størmer FC, Saugstad OD: Ochratoxin A: a naturally   occurring mycotoxin found in human milk samples from Norway. Acta  Paediatr 1998, 87, 1275-1279. 	9894829
	32. Skaug MA: Analysis of Norwegian milk and infant formulas for   ochratoxin A. Food Addit Contam 1999, 16, 75-78.    	10435076
	33. Skaug MA, Eduard W, Størmer FC: Ochratoxin A in airborne   dust and fungal conidia. Mycopathologia 2001, 151, 93-98.   	11554583
	34. Skaug MA, Helland I, Solvoll K, Saugstad OD: Presence of   ochratoxin A in human milk in relation to dietary intake. Food Addit Contam 2001, 18, 321-327.  	11339267
	35. Škrinjar M, Stubblefield RD, Vujicic IF: Ochratoxigenic moulds   and ochratoxin A in forages and grain feeds. Acta Vet Hung 1992, 40, 185-190. 	1298163
	36. Smith JE, Anderson JG, Lewis CW, Murad YM: Cytotoxic fungal   spores in the indoor atmosphere of the damp domestic environment. FEMS Microbiol Lett 1992, 79, 337-343. 	1478468
	37. Speijers GJA, van Egmond HP: Worldwide ochratoxin A levels in   food and feeds. In: Creppy EE, Castegnaro M, Dirheimer G (Eds): Human   ochratoxicosis and its pathologies, 231, 85-100. Colloque INSERM, John   Libbey Eurotext Ltd, Montrouge, France 1993    	NO_MATCH
	38. Thuvander A, Paulsen JE, Axberg K, Johansson N, Vidnes A,   Enghardt-Barbieri H, Trygg K, Lund-Larsen K, Jahrl S, Widenfalk A,   Bosnes V, Alexander J, Hult K, Olsen M: Levels of ochratoxin A in   blood from Norwegian and Swedish blood donors and their possible   correlation with food consumption. Food Chem Toxicol 2001, 39, 1145 1151.   	11696389
	39. Ueno Y, Maki S, Lin J, Furuya M, Sugiura Y, Kawamura O: A 4 year study of plasma ochratoxin A in a selected population in Tokyo by   immunoassay and immunoaffinity column-linked HPLC. Food Chem   Toxicol 1998, 36, 445-449.   	9662420
	40. Vd Stegen G, Jorissen U, Pittet A, Saccon M, Steiner W, Vincenzi   M, Winkler M, Zapp J, Schlatter C: Screening of European coffee final   products for occurrence of ochratoxin A (OTA). Food Addit Contam 1997,   14, 211-216.   	9135718
	41. Virtanen T, Vilhunen P, Husman K, Mäntijärvi R: Sensitation of   dairy farmers to bovine antigens and effects of exposure on specific IgG   and IgE titers. Int Arch Allergy Appl Immunol 1988, 87, 171-177.    	3192304
	42. Virtanen T, Kalliokoski P, Vilhunen P, Taivainen A, Mäntijärvi R: Concentrations of specific dusts in swineries and the humoral   response of swinery workers. Allergy 1990, 45, 354-362.   	2378439
	43. Zimmerli B, Dick R: Determination of ochratoxin A at the ppt   level in human blood, serum, milk and some foodstuffs by high performance liquid chromatography with enhanced fluorescence detection   and immunoaffinity column cleanup: methodology and Swiss data. J   Chromatogr B 1995, 666, 85-99.   	7655625
	44. Zimmerli B, Dick R: Ochratoxin A in table wine and grape-juice:   occurrence and risk assessment. Food Addit Contam 1996, 13, 655-668.   	8871123
AJHGv73p430.pdf
	Balendran N, Clough RL, Arguello JR, Barber R, Veal C, Jones  AB, Rosbotham JL, Little AM, Madrigal A, Barker JN, Powis SH, Trembath RC (1999) Characterization of the ma jor susceptibility region for psoriasis at chromosome 6p21.3.  J Invest Dermatol 113:322–328  	10469328
	Barker JN (1998) Pathogenesis of psoriasis. J Dermatol 25:  778–781  	9990768
	Becker KG, Simon RM, Bailey-Wilson JE, Freidlin B, Biddison  WE, McFarland HF, Trent JM (1998) Clustering of non major histocompatibility complex susceptibility candidate loci  in human autoimmune diseases. Proc Natl Acad Sci USA 95:  9979–9984  	9707586
	Bhalerao J, Bowcock AM (1998) The genetics of psoriasis: a  complex disorder of the skin and immune system. Hum Mol  Genet 7:1537–1545  	9735374
	Borgiani P, Vallo L, D’Apice MR, Giardina E, Pucci S, Capon  F, Nistic S, Chimenti S, Pallone F, Novelli G (2002) Exclusion  of CARD15/NOD2 as a candidate susceptibility gene to pso riasis in the Italian population. Eur J Dermatol 12:540–542  	12459523
	Broman KW, Murray JC, Sheffield VC, White RL, Weber JL  (1998) Comprehensive human genetic maps: individual and  sex-specific variation in recombination. Am J Hum Genet  63:861–869  	9718341
	Camp RDR (1998) Psoriasis. In: Champion RH, Burton JL,  Burns DA, Breathnach SM (eds) Textbook of dermatology.  Vol 2. Blackwell, London, pp 1589–1650  	NO_MATCH
	Capon F, Munro M, Barker J, Trembath R (2002) Searching  for the major histocompatibility complex psoriasis suscep tibility gene. J Invest Dermatol 118:745–751  	11982750
	Capon F, Novelli G, Semprini S, Clementi M, Nudo M, Vul taggio P, Mazzanti C, Gobello T, Botta A, Fabrizi G, Dal lapiccola B (1999) Searching for psoriasis susceptibility genes  in Italy: genome scan and evidence for a new locus on chro mosome 1. J Invest Dermatol 112:32–35  	9886260
	Curtis D, Sham PC (1995) A note on the application of the  transmission disequilibrium test when a parent is missing. Am  J Hum Genet 56:811–812  	7887437
	Dib C, Faure S, Fizames C, Samson D, Drouot N, Vignal A,  Millasseau P, Marc S, Hazan J, Seboun E, Lathrop M, Gya pay G, Morissette J, Weissenbach J (1996) A comprehensive  genetic map of the human genome based on 5,264 micro satellites. Nature 380:152–154  	8600387
	Elder JT, Nair RP, Henseler T, Jenisch S, Stuart P, Chia N,  Christophers E, Voorhees JJ (2001) The genetics of psoriasis  2001: the odyssey continues. Arch Dermatol 137:1447–1454  	11708947
	Elder JT (1998) Psoriasis. In: JL Jameson (ed) Principles of  molecular medicine. Humana, Totowa, NJ, pp 793–800  	NO_MATCH
	Enlund F, Samuelsson L, Enerback C, Inerot A, Wahlstrom J,  Yhr M, Torinsson A, Riley J, Swanbeck G, Martinsson T  (1999) Psoriasis susceptibility locus in chromosome region  3q21 identified in patients from southwest Sweden. Eur J  Hum Genet 7:783–790  	10573011
	Hugot JP, Chamaillard M, Zouali H, Lesage S, Cezard JP,  Belaiche J, Almer S, Tysk C, O’Morain CA, Gassull M,  Binder V, Finkel Y, Cortot A, Modigliani R, Laurent-Puig  P, Gower-Rousseau C, Macry J, Colombel JF, Sahbatou M,  Thomas G (2001) Association of NOD2 leucine-rich repeat  variants with susceptibility to Crohn’s disease. Nature 411:  599–603  	11385576
	Karason A, Gudjonsson JE, Upmanyu R, Antonsdottir AA,  Hauksson VB, Runasdottir EH, Jonsson HH, Gudbjartsson  DF, Frigge ML, Kong A, Stefansson K, Valdimarsson H,  Gulcher JR (2003) A susceptibility gene for psoriatic arthritis  maps to chromosome 16q: evidence for imprinting. Am J  Hum Genet 72:125–131  	12474146
	Kruglyak L, Daly MJ, Reeve-Daly MP, Lander ES (1996) Para metric and nonparametric linkage analysis: a unified mul tipoint approach. Am J Hum Genet 58:1347–1363  	8651312
	Lander E, Kruglyak L (1995) Genetic dissection of complex  traits: guidelines for interpreting and reporting linkage re sults. Nat Genet 11:241–247  	7581446
	Lee Y-A, Ru¨schendorf F, Windemuth C, Schmitt-Egenolf M,  Stadelmann A, Nu¨rnberg G, Sta¨nder M, Wienker TF, Reis  A, Traupe H (2000) Genomewide scan in German families  reveals evidence for a novel psoriasis-susceptibility locus on  chromosome 19p13. Am J Hum Genet 67:1020–1024  	10986047
	Markianos K, Daly MJ, Kruglyak L (2001) Efficient multipoint  linkage analysis through reduction of inheritance space. Am  J Hum Genet 68:963–977  	11254453
	Martin ER, Bass MP, Kaplan NL (2001) Correcting for a po tential bias in the pedigree disequilibrium test. Am J Hum  Genet 68:1065–1067  	11254459
	Martin ER, Monks SA, Warren LL, Kaplan NL (2000) A test  for linkage and association in general pedigrees: the pedigree  disequilibrium test. Am J Hum Genet 67:146–154  	10825280
	Matthews D, Fry L, Powles A, Weber J, McCarthy M, Fisher  E, Davies K, Williamson R (1996) Evidence that a locus for  familial psoriasis maps to chromosome 4q. Nat Genet 14:  231–233  	8841203
	Nair RP, Henseler T, Jenisch S, Stuart P, Bichakjian CK, Lenk  W, Westphal E, Guo SW, Christophers E, Voorhees JJ, Elder  JT (1997) Evidence for two psoriasis susceptibility loci (HLA  and 17q) and two novel candidate regions (16q and 20p) by  genome-wide scan. Hum Mol Genet 6:1349–1356  	9259283
	Nair RP, Stuart P, Henseler T, Jenisch S, Chia NVC, Westphal  E, Schork NJ, Kim J, Lim HW, Christophers E, Voorhees  JJ, Elder JT (2000) Localization of psoriasis-susceptibility  locus PSORS1 to a 60-kb interval telomeric to HLA-C. Am  J Hum Genet 66:1833–1844  	10801386
	Nair RP, Stuart P, Ogura Y, Inohara N, Chia NV, Young L,  Henseler T, Jenisch S, Christophers E, Voorhees JJ, Nunez  G, Elder JT (2001) Lack of association between NOD2  3020InsC frameshift mutation and psoriasis. J Invest Der matol 117:1671–1672  	11886540
	O’Connell JR, Weeks DE (1998) PedCheck: a program for iden tification of genotype incompatibilities in linkage analysis. Am  J Hum Genet 63:259–266  	9634505
	Ogura Y, Bonen DK, Inohara N, Nicolae DL, Chen FF, Ramos  R, Britton H, Moran T, Karaliuskas R, Duerr RH, Achkar  JP, Brant SR, Bayless TM, Kirschner BS, Hanauer SB, Nunez  G, Cho JH (2001) A frameshift mutation in NOD2 associated  with susceptibility to Crohn’s disease. Nature 411:603–606  	11385577
	Oka A, Tamiya G, Tomizawa M, Ota M, Katsuyama Y, Ma kino S, Shiina T, Yoshitome M, Iizuka M, Sasao Y, Iwashita  K, Kawakubo Y, Sugai J, Ozawa A, Ohkido M, Kimura M,  Bahram S, Inoko H (1999) Association analysis using refined  microsatellite markers localizes a susceptibility locus for  psoriasis vulgaris within a 111 kb segment telomeric to  the HLA-C gene. Hum Mol Genet 8:2165–2170  	10545595
	Risch N (1990) Linkage strategies for genetically complex traits.  I. Multilocus models. Am J Hum Genet 46:222–228  	2301392
	Risch NJ (2000) Searching for genetic determinants in the new  millennium. Nature 405:847–856  	10866211
	Samuelsson L, Enlund F, Torinsson A, Yhr M, Inerot A, Ener back C, Wahlstrom J, Swanbeck G, Martinsson T (1999) A  genome-wide search for genes predisposing to familial pso riasis by using a stratification approach. Hum Genet 105:  523–529  	10647885
	Tomfohrde J, Silverman A, Barnes R, Fernandez-Vina MA,  Young M, Lory D, Morris L, Wuepper KD, Stastny P, Men ter A, Bowcock AM (1994) Gene for familial psoriasis sus ceptibility mapped to the distal end of human chromosome  17q. Science 264:1141–1145  	8178173
	Trembath RC, Clough RL, Rosbotham JL, Jones AB, Camp  RD, Frodsham A, Browne J, Barber R, Terwilliger J, Lathrop  GM, Barker JN (1997) Identification of a major susceptibility  locus on chromosome 6p and evidence for further disease  loci revealed by a two stage genome-wide search in psoriasis.  Hum Mol Genet 6:813–820  	9158158
	Veal CD, Capon F, Allen MH, Heath EK, Evans JC, Jones A,  Patel S, Burden D, Tillman D, Barker JNWN, Trembath RC  (2002) Family-based analysis using a dense single-nucleotide  polymorphism–based map defines genetic variation at  PSORS1, the major psoriasis-susceptibility locus. Am J Hum  Genet 71:554–564  	12148091
	Veal CD, Clough RL, Barber RC, Mason S, Tillman D, Ferry  B, Jones AB, Ameen M, Balendran N, Powis SH, Burden  	NO_MATCH
	AD, Barker JN, Trembath RC (2001) Identification of a novel  psoriasis susceptibility locus at 1p and evidence of epistasis  between PSORS1 and candidate loci. J Med Genet 38:7–13  	11134234
	Young C, Allen MH, Cuthbert A, Ameen M, Veal C, Leman  J, Burden AD, Kirby B, Griffiths CEM, Trembath RC, Ma thew CG, Barker JNWN (2003) A Crohn’s disease-associ ated insertion polymorphism (3020insC) in the NOD2 gene  is not associated with psoriasis vulgaris, palmo-plantar  pustular psoriasis or guttate psoriasis. Exper Dermatol 12:  506–509  	12930309
	Zhang XJ, He PP, Wang ZX, Zhang J, Li YB, Wang HY,  Wei SC, Chen SY, Xu SJ, Jin L, Yang S, Huang W (2002)  Evidence for a major psoriasis susceptibility locus at  6p21(PSORS1) and a novel candidate region at 4q31 by  genome-wide scan in Chinese Hans. J Invest Dermatol 119:  1361–1366  	12485440
blagosklonnyCC2-2.pdf
15886.pdf
	ADAY, L. A. & ANDERSEN, R., 1974. A framework for  study of access to medical care. Health Services  Research, 9:208-220.  	4436074
	ANDERSEN, R., 1995. Revisiting the behavioral model  and access to medical care: does it matter? Jour nal of Health and Social Behavior, 36:1-10.  	7738325
	ANDERSEN, R. & NEWMAN, J. F., 1973. Societal and  individual determinants of medical care utiliza tion in the United States. Milbank Memorial Fund  Quarterly, 51:95-124.   	4198894
	BORGES-YAÑES, A. S. & GOMES-DANTES, H., 1998.  Uso de los servícios de salud por la población de  60 años y más em México. Salud Pública de Méxi co, 40:13-23.  	NO_MATCH
	BOULT, C.; DOWD, B.; McCAFFEY, B. A.; BOULT,  L.; HERNANDEZ, R. & KRULEWITCH, H., 1993.  Screening elders for risk of hospital admission.  Journal of American Geriatric Society, 41:811-817.  	8340558
	BRANCH, L.; JETTE, A.; EVASHWICK, C.; POLANSKY,  M.; ROWE, G. & DIEHR, P., 1981. Toward under standing elder’s health service utilization. Journal  of Community Health, 7:80-92.  	7328199
	COLEMAN, E. A.; WAGNER, E. H.; GROTHAUS, L. C.;  HECHT, J.; SAVARINO, J. & BUCHNER, D. M.,  1998. Predicting hospitalizations and functional  decline in older health plan enrollees: Are admin istrative data as accurate as self-report? Journal  of American Geriatric Society, 46:419-425.  	9560062
	CORONI-HUNTLEY, J. C.; BROCK, D. B.; OSTFELD, A.  M.; TAYLOR, J. O. & WALLACE, R. B. (ed.), 1986. Es tablished Populations for Epidemiological Stud ies of the Elderly. NIH Publications 86-2443.  Washington, DC: National Institute on Aging.   	NO_MATCH
	DATASUS (Departamento de Informática do SUS),  1997. Movimento de Autorizações de Internações  Hospitalares – 1996. CD-ROM. Brasília: Ministério  da Saúde.  	NO_MATCH
	EVANS, R. L.; HENDRICKS, R. D.; LAWRENCE, K.V. &  BISHOP, D. S., 1988. Identifying factors associat ed with health care use: A hospital-based risk  screening index. Social Science and Medicine,  27:947-954.  	3227391
	FREEBORN, D. K.; POPE, C. R.; MULLOOLY, J. P. & Mc FARLAND, B. H., 1990. Consistently high users  of medical care among elderly. Medical Care, 28:  567-585.  	2355758
	GREENLAND, S., 1989. Modeling and variation selec tion in epidemiologic analysis. American Journal  of Public health, 79:340-349.  	2916724
	GUERRA, H. L.; FIRMO, J. O. A.; UCHÔA, E. & LIMA COSTA, M. F. F., 2001. The Bambuí Health and  Ageing Study: Factors associated with hospital izations among older adults in the community.  Cadernos de Saúde Pública, 17:1345-1356.  	NO_MATCH
	HALTER, J. B., 1999. Diabetes mellitus, In: Princi ples of Geriatric Medicine And Gerontology (W. R.  	NO_MATCH
	Hazzard, J. P. Blass, W. H. Ettinger, J. B. Halter & J.  G. Ouslander, ed.), pp. 1013-1028, New York: Mc Graw Hill.  	NO_MATCH
	HAMILTON, L. C., 1993. Interpreting multinomial lo gistic regression. Stata Technical Bulletin, 13:24 28.  	NO_MATCH
	HANLON, P.; WALSH, D.; WHYTE, B. W.; SCOTT, S. N.;  LIGHTBODY, P. & GILHOOLY, M. L. M., 1998. Hos pital use by an ageing cohort: An investigation  between biological, behavioural, and social risk  markers and subsequent hospital utilization.  Journal of Public Health, 20:467-476.  	9923956
	HOSMER, D. W. & LAMENSHOW, S., 1989. Applied Lo gistic Regression. New York: John Wiley & Sons.   	NO_MATCH
	HURD, M. D. & McGARRY, K., 1997. Medical insur ance and the use of health care services by the el derly. Journal of Health Economics, 16:129-154.  	NO_MATCH
	IBGE (Fundação Instituto Brasileiro de Geografia e  Estatística), 1992. Censo Demográfico, 1991. Rio  de Janeiro: IBGE.  	NO_MATCH
	JNC ( Joint National Committee), 1993. The fifth re port of the Joint Committee on Detection, Evalu ation, and Treatment of High Blood Pressure  (JNC V ). Archives of Internal Medicine, 153: 154 183.   	NO_MATCH
	JACOBS, D.; BLACKBURN, H.; HIGGINS, M.; REED,  D.; ISO, H.; McMILLAN, G.; NEATON, J.; NELSON,  J.; POTTER, J. & RIFKIND, B., 1992. Report of the  conference on low blood cholesterol: Mortality  associations. Circulation, 86:1046-1060.  	1355411
	KAPLAN, G. A.; HAAN, M. N. & COHEN, R. D., 1992.  Risk factors and the study of prevention in the el derly: Methodological issues. In: The Epidemio logic Study of the Elderly (R. D. Wallace & R. F.  Woolson, ed.), pp. 20-36, New York: Oxford Uni versity Press.  	NO_MATCH
	LIMA-COSTA, M. F. F.; BARRETO, S. M.; GUERRA, H. L.;  FIRMO, J. O. A.; UCHOA, E. & VIDIGAL, P. G., 2001.  Aging with Trypanosoma cruzi infection in a  community where the transmission has been in terrupted: The Bambuí Health and Ageing Study  (BHAS). International Journal of Epidemiology,  30:887-893.  	11511622
	LIMA-COSTA, M. F. F.; GUERRA, H. L.; BARRETO, S.  M. & MAIA, R., 2000b. Diagnóstico da situação de  saúde da população idosa brasileira: Um estudo  da mortalidade e das internações hospitalares  públicas. Informe Epidemiológico do SUS, 9:23 41.   	NO_MATCH
	LIMA-COSTA, M. F. F.; UCHOA, E.; GUERRA, H. L.;  FIRMO, J. O. A.; VIDIGAL, P. G. & BARRETO, S. M.,  2000a. The Bambuí Health and Ageing Study  (BHAS): Methodological approach and prelimi nary results of a population-based cohort study  of the elderly in Brazil. Revista de Saúde Pública,  34:126-135.  	10881147
	McCALL, N. & WAI, H. S., 1983. An analysis of use of  medicare services by the continuously enrolled  aged. Medical Care, 21:567-585.  	6345946
	MILLER, J. E.; RUSSEL, L. B.; DAVIS, D. M.; MILAN, E.;  CARSON, J. L. & TAYLOR, W. C., 1998. Biomedical  risk factors for hospital admission in older adults.  Medical Care, 36:411-421.  	9520964
	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE,  1998. Clinical Guidelines on the Identification,  Evaluation, and Treatment of Overweight and  Obesity in Adults: The Evidence Report. Bethesda:  US Departament of Health and Human Services,  National Institutes of Health.   	NO_MATCH
	PACALA, J. T.; BOULT, C.; REED, R. L. & ALIBERTI,  R. N., 1997. Predictive validity of Pra instrument  among older recipients of managed care. Journal  of American Geriatric Society, 45:614-617.  	9158585
	PINHEIRO, R. S. & TRAVASSOS, C., 1999. Estudo da  desigualdade na utilização de serviços de saúde  por idosos em três regiões da cidade do Rio de Ja neiro. Cadernos de Saúde Pública, 15:487-496.  	NO_MATCH
	ROOS, N. P. & SHAPIRO, E., 1981. The Manitoba lon gitudinal study on aging: Preliminary findings on  health care utilization by the elderly. Medical  Care, 19:644-657.  	7266114
	ROOS, N. P.; SHAPIRO, E. & TATE, R., 1989. Does a  small minority of elderly account for a majority  of health care expenditures? A sixteen-year per spective. Millbank Memorial Fund Quartely, 67:  347-369.  	2517569
	SATISH, S.; WINOGRAD, C. H.; CHAVES, C. & BLOCH,  D. A., 1996. Geriatric targeting criteria as predic tors of survival and health care utilization. Jour nal of American Geriatric Society, 44:914-921.  	8708300
	SHARP, S. J. & POCOCK, S. J., 1997. Time trends in  serum cholesterol before cancer deaths. Epidemi ology, 8:132-136.  	9229203
	TAYBACK, M.; KUMANYIKA, S. & CHEE, E., 1990. Body  weight as a risk factor in the elderly. Archives of  Internal Medicine, 150:1065-1072.  	2331187
	WOLINSKY, F. D.; JOHNSON, R. J. & FITZGERALD, J.  F., 1992. The effect of falling on health status and  the use of health services by older adults. Medical  Care, 30:587-597.  	1940101
	ZAR, J. H., 1984. Biostatistical Analysis. New Jersey:  Prentice-Hall.  	NO_MATCH
	ZOOK, C. J. & MOORE, F. D., 1980. High-cost users of  medical care. New England Journal of Medicine,  302:996-1002.  	6767975
15884.pdf
	BRODEUR, J. M.; LAURIN, D.; VALLEE, R. &  LACHAPELLE, D., 1993. Nutrient intake and gas trointestinal disorders related to masticatory per formance in the edentulous elderly. Journal of  Prosthodontic Dentistry, 70:468-473.  	8254553
	CARLOS, J. P. & WOLFE, M. D., 1989. Methodological  and nutritional issues in assessing oral health of  aged subjects. American Journal of Clinical Nu trition, 50:1210-1218.  	2683731
	CHAUNCEY, H. H.; MUENCH, M. E.; KAPUR, K. K. &  WAYLER, A. H., 1984. The effect of the loss of teeth  on diet and nutrition. International Dental Jour nal, 34:98-104.  	6588038
	DOH (Department of Health), 1994. An Oral Health  Strategy for England. London: DOH.  	NO_MATCH
	FINCH, S.; DOYLE, W.; LOWE, C.; BATES, C. J.; PREN TICE, A.; SMITHERS, G. & CLARKE, P. C., 1998.  National Diet and Nutrition Survey: People Aged  65 and Over. Report of the Diet and Nutrition Sur vey, v. 1. London: The Stationary Office.  	NO_MATCH
	GEISSLER, C. A. & BATES, J. F., 1984. The nutritional  effects of tooth loss. American Journal of Clinical  Nutrition, 39:478-489.  	6364777
	HOLLISTER, M. C. & WEINTRAUB, J. A., 1993. The  association of oral status with systemic health,  quality of life, and economic productivity. Jour nal of Dental Education, 57:901-911.  	8263237
	KRALL, E.; HAYES, C. & GARCIA, R., 1998. How denti tion status and masticatory function affect nutri tion intake. Journal of American Dental Associa tion, 129:1261-1269.  	9766107
	MOYNIHAN, P. J., 1995. The relationship between di et, nutrition and dental health: An overview and  update for the 90s. Nutrition Research Review, 8:  193-224.  	NO_MATCH
	MOYNIHAN, P. J.; SNOW, S.; JEPSON, N. J. A. & BUT LER, T. J., 1994. Intake of non-starch polysaccha ride (dietary fibre) in edentulous and dentate  persons: An observational study. British Dental  Journal, 177: 243-247.  	7917631
	PAPAS, A. S.; PALMER, C. A.; ROUNDS, M. C. & RUS SELL, R. M., 1998. The effects of denture status on  nutrition. Special Care in Dentistry, 18:17-25.  	9791303
	PAPAS, A. S.; PALMER, C. A.; ROUNDS, M. C.; HER MAN, J.; McGRANDY, R.; HATZ, S.; RUSSELL, R.  M. & DePAOLA, P., 1989. Longitudinal relation ships between nutrition and oral health. Annals  of the New York Academy of Science, 561:124-142.  	2735672
	STEELE, J. G.; SHEIHAM, A.; MARCENES, W. & WALLS,  A. W. G., 1998. National diet and Nutrition Survey:  People Aged 65 Years and Over. Report of the Oral  Health Survey, v. 2. London: The Stationary Office.  	NO_MATCH
	WAYLER, A. H.; MUENCH, M. E.; KAPUR, K. K. &  CHAUNCEY, H. H., 1984. Masticatory perfor mance and food acceptability in persons with re movable partial dentures, full dentures, and in tact natural dentition. Journal of Gerontology,  39:284-289.  	6715804
15872.pdf
a08v36n2.pdf
	1. Aguillon JC, Bastos C, Vallejos P, Hemosilla T, Morello A, Pepetto  Y, Hellman V, Om A, Ferreira A. Purification and preliminary  sequencing of Tc 45 an immunodominant Trypanosoma cruzi  antigen: Absence of homology with cruzipain, cruzain and 46  kilodalton protein. American Journal of Tropical Medicine and  Hygiene 53: 211-215, 1995.  	7677227
	2. Anonymous. Recommendations from a Satellite Meeting,  Memórias do Instituto Oswaldo Cruz 94 (supl 1): 429-432, 1999.  	NO_MATCH
	3. Araujo FG, Heilman B, Tighe L. Antigens of Trypanosoma cruzi  detected by different classes and subclasses of antibodies.  Transactions of the Royal Society of Tropical Medicine and  Hygiene 72: 672-677, 1984.  described this antigen in trypomastigote forms and  related it to resistance and protection. Apparently this  polypeptide is not related to the parasites in the scent  glands13, since none of the animals in the experiments  presented parasites in this organ.  	6438837
	4. Camargo M. Fluorescent antibody test for the serodiagnosis of  American Trypanosomiasis. Technical modification employing  preserved cultured forms of Trypanosoma cruzi in a slide test. Revista  do Instituto de Medicina Tropical de São Paulo 8: 227-234, 1996.  	NO_MATCH
	5. Carreira JC, Jansen AM, Lenzi H,  Deane MP. Histopathological  study of  Didelphis marsupialis Natural and Experimental  infections by Trypanosoma cruzi. Memórias do Instituto Oswaldo  Cruz 91: 609-618, 1996.  	NO_MATCH
	6. De Gaspari EN, Umezawa ES, Zingales B, Stolf AM, Colli W,  Abrahamsohn IA, Trypanosoma cruzi: serum antibody reactivity  to the parasite antigens in susceptible and resistant mice.  Memórias do Instituto Oswaldo Cruz 85: 261-270, 1990.  	NO_MATCH
	7. Deane MP, Lenzi HL, Jansen A, Trypanosoma cruzi: vertebrate and  invertebrate cycles in the same mammal host, the opossum Didelphis  marsupialis. Memórias do Instituto Oswaldo Cruz 79: 513-515, 1984.  	6442753
	8. Eakim AE, Mills AA, Harth G, Mckerow JH, Craik S. The sequence  organization and expression of the major cysteine protease  (Cruzain) from Trypanosoma cruzi. Journal of Biology and  Chemistry 267: 7411-7420, 1992.  	1559982
	9. Fernandes O, Mangia RH, Lisboa CV, Pinho AP, Morel CM,  Zingales B, Campbell DA, Jansen AM. The complexity of the  sylvatic cycle of Trypanosoma cruzi  in Rio de Janeiro State  (Brazil) revealed by the non-transcribed spacer of the mini-exon  gene. Parasitology 118: 161-166, 1999.  	10028530
	10. Grogi M, Kuhn E. Identification of antigens of Trypanosoma cruzi  which induce antibodies during experimental Chagas Disease.  Journal of Parasitology 71: 183-191, 1983.  	NO_MATCH
	11. Isralesky DM, Sadler R, Araújo FG. Antibody response and antigen  recognition in human infection with Trypanosoma cruzi. American  Journal of Tropical Medicine and Hygiene 39: 445-455, 1988.  	3143270
	12. Jansen AM, Leon L, Machado GM, Da Silva MH, Souza-Leão  SM, Deane MP. Trypanosoma cruzi in the opossum Didelphis  marsupialis: Parasitological and serological follow-up of the acute  infection. Experimental Parasitology 73: 249-259, 1991.  	1915740
	13. Jansen AM, Madeira MF, Carreira JCA, Deane MP. Trypanosoma  cruzi in the opossum Didelphis marsupialis: a study on the  correlations and kinetics of the systemic and scent glands  infection in naturally and experimentally infected animals.  Experimental Parasitology 86: 37-44, 1997.  	9149239
	14. Jansen AM, Moriearty PL, Galvão-Castro B, Deane MP.  Trypanosoma cruzi in the opossums Didelphis marsupialis: an  indirect fluorescent antibody test for the diagnosis and follow up  of natural and experimental infections. Transactions of the Royal  Society of Tropical Medicine and Hygiene 79: 474-477, 1985.  	3936240
	15. Jansen AM, Pinho AP, Lisboa CV, Cupolillo E, Mangia RH, Fernandes  O. The Sylvatic Cycle of Trypanosoma cruzi: A still Unsolved Puzzle.  Memórias do Instituto Oswaldo Cruz 94: 203-206, 1999.  	10677716
	16. Juri MA, Ferreira A, Ramos A, Hoecker G. Non-lytic antibodies in  H-2 controlled resistance to Trypanosoma cruzi. Brazilian Journal  of Medical and Biological Research 23: 685-695, 1990.  	NO_MATCH
	17. Laemmli UK. Cleavage of structural proteins during the assembly  of the head of bacteriophage T4.  Nature 227: 680-685, 1970.  	5432063
	18. Legey AP, Pinho AP, Xavier SCC, Leon L, Jansen AM. Humoral  Immune response kinetics in Philander opossum  and Didelphis  marsupialis  infected and immunized by Trypanosoma cruzi.  Memórias do Instituto Oswaldo Cruz 94: 371-373, 1999.  	NO_MATCH
	19. Pinho AP, Cupolillo E, Mangia RH, Fernandes O, Jansen AM.  Trypanosoma cruzi in the sylvatic environment: distinct  transmission cycles involving two sympatric marsupials.  Transactions of the Royal Society of Tropical Medicine and  Hygiene 94:1-6, 2000.  	11132378
	20. Scharfstein J, Rodrigues MM, Alves CA, De Souza W, Previato  JO, Mendonça-Previato L. Trypanosoma cruzi: description of a  highly purified surface antigen defined by human antibodies.  Journal of Immunology 131: 972-976, 1983.  	6345675
	21. Schofield CJ. Trypanosoma cruzi – The Vector-parasite paradox,  Memórias do Instituto Oswaldo Cruz  95: 535-544, 2000.  	10904412
	22. Silva LHP, Nussenzweig V. Sobre uma cepa de Trypanosoma  cruzi altamente virulenta para o camundongo branco. Folha  Clínica e Biológica 20: 191-208, 1953.  	NO_MATCH
	23. Stevens J, Noyes H, Gibson W. The evolution of trypanosomes  infecting humans and primates. Memórias do Instituto Oswaldo  Cruz 93: 669-676, 1998.  	9830536
	24. Taibi A, Espinoza AG, Ouaissi A. Trypanosoma cruzi analysis of  cellular and humoral response against a protective recombinant  antigen during experimental Chagas’ disease. Immunology Letters  48: 193-200, 1995.  	8867851
	25. Towbin H, Stachelin T, Gordon J. Electrophoretic transfer proteins  from polyacrylamide gels to nitrocellulose sheets: procedure and  some applications, Proceedings of  National Academy of Science  USA 76:4350-4354, 1979.  	388439
	26. Umekita LF, Barbaro KC, Mota I. Specificity and role of anti Trypanosoma cruzi clearance antibodies. Brazilian Journal of  Medicine and Biology Research 29: 25-31, 1996.  	8731328
	27. Umezawa ES, Stolf AM, Zingales B. Trypanosoma cruzi: different  surface antigens of trypomastigotes are targets of lytic antibodies.  Acta Tropica 54: 41-53, 1993.  	7690181
	28. Winge H. Jordfundne og nulevende Pungdyr (Marsupialia) fra  Lagoa Santa, Minas Gerais, Brasilien, Med. Udsight over  Pungdyrenes Saegtskab. E. Museu Lundi 11: 1-149, 1893.  	NO_MATCH
	29. Yoshida N, Blanco SA, Araguth MF, Russo M, Gonzalez G. The  stage-specific 90 kilodalton surface antigen of metacyclic  trypomastigote of Trypanosoma cruzi. Molecular Biochemical  Parasitology 39: 39-45, 1990.  	2106076
	30. Zingales B, Andrews NW, Kuwajima VY, Colli W. Cell surface  antigens of Trypanosoma cruzi: Possible correlation with the  interiorization process in mammalian cells. Molecular  Biochemical Parasitology 6:111-124, 1982.  	6182464
6015.full.pdf
	1. Jordan J, Shannon JR, Grogan E, Biaggioni I, Robertson D 1999 A potent  pressor response elicited by drinking water. Lancet 353:723  	10073520
	2. Jordan J, Shannon JR, Black BK, Ali Y, Farley M, Costa F, Diedrich A,  Robertson RM, Biaggioni I, Robertson D 2000 The pressor response to water  drinking in humans: a sympathetic reflex? Circulation 101:504–509  	10662747
	3. Scott EM, Greenwood JP, Gilbey SG, Stoker JB, Mary DA 2001 Water in gestion increases sympathetic vasoconstrictor discharge in normal human  subjects. Clin Sci Colch 100:335–342  	11222121
	4. Tank J, Schroeder C, Stoffels M, Diedrich A, Sharma AM, Luft FC, Jordan  J 2003 Pressor effect of water drinking in tetraplegic patients may be a spinal  reflex. Hypertension 41:1234–1239  	12719442
	5. Geelen G, Greenleaf JE, Keil LC 1996 Drinking-induced plasma vasopressin  and norepinephrine changes in dehydrated humans. J Clin Endocrinol Metab  81:2131–2135  	8964840
	6. Nonogaki K 2000 New insights into sympathetic regulation of glucose and fat  metabolism. Diabetologia 43:533–549  	10855527
	7. Jordan J, Tank J, Stoffels M, Franke G, Christensen NJ, Luft FC, Boschmann  M 2001 Interaction between -adrenergic receptor stimulation and nitric oxide  release on tissue perfusion and metabolism. J Clin Endocrinol Metab 86:2803–  2810  	11397891
	8. Boschmann M, Krupp G, Luft FC, Klaus S, Jordan J 2002 In vivo response to  (1)-adrenoreceptor stimulation in human white adipose tissue. Obes Res  10:555–558  	12055332
	9. Ferrannini E 1988 The theoretical bases of indirect calorimetry: a review.  Metabolism 37:287–301  	3278194
	10. Cariga P, Mathias CJ 2001 Haemodynamics of the pressor effect of oral water  in human sympathetic denervation due to autonomic failure. Clin Sci (Lond)  101:313–319  	11524049
	11. Schroeder C, Bush VE, Norcliffe LJ, Luft FC, Tank J, Jordan J, Hainsworth  R 2002 Water drinking acutely improves orthostatic tolerance in healthy sub jects. Circulation 106:2806–2811  	12451007
	12. Routledge HC, Chowdhary S, Coote JH, Townend JN 2002 Cardiac vagal  response to water ingestion in normal human subjects. Clin Sci (Lond) 103:  157–162  	12149107
	13. Shannon JR, Gottesdiener K, Jordan J, Chen K, Flattery S, Larson PJ, Can delore MR, Gertz B, Robertson D, Sun M 1999 Acute effect of ephedrine on  24-h energy balance. Clin Sci Colch 96:483–491  	10209080
	14. Hickner RC, Ekelund U, Mellander S, Ungerstedt U, Henriksson J 1995  Muscle blood flow in cats: comparison of microdialysis ethanol technique with  direct measurement. J Appl Physiol 79:638–647  	7592229
	15. Hickner RC, Rosdahl H, Borg I, Ungerstedt U, Jorfeldt L, Henriksson J 1992  The ethanol technique of monitoring local blood flow changes in rat skeletal  muscle: implications for microdialysis. Acta Physiol Scand 146:87–97  	1442130
	16. Simoneau JA, Lortie G, Boulay MR, Thibault MC, Theriault G, Bouchard C  1985 Skeletal muscle histochemical and biochemical characteristics in seden tary male and female subjects. Can J Physiol Pharmacol 63:30–35  	3986689
	17. Jordan J 2002 Acute effect of water on blood pressure. What do we know? Clin  Auton Res 12:250–255  	12357278
	18. Rossi P, Andriesse GI, Oey PL, Wieneke GH, Roelofs JM, Akkermans LM  1998 Stomach distension increases efferent muscle sympathetic nerve activity  and blood pressure in healthy humans. J Neurol Sci 161:148–155  	9879696
	19. Ploutz-Snyder L, Foley J, Ploutz-Snyder R, Kanaley J, Sagendorf K, Meyer  R 1999 Gastric gas and fluid emptying assessed by magnetic resonance im aging. Eur J Appl Physiol Occup Physiol 79:212–220  	10048625
	20. Haberich FJ 1968 Osmoreception in the portal circulation. Fed Proc 27:1137–  1141  	5673264
	21. Adachi A 1984 Thermosensitive and osmoreceptive afferent fibers in the he patic branch of the vagus nerve. J Auton Nerv Syst 10:269–273  	6384336
	22. Andrews WH, Orbach J 1974 Sodium receptors activating some nerves of  perfused rabbit livers. Am J Physiol 227:1273–1275  	4440772
5995.full.pdf
	1. Roberts JM, Taylor RN, Musci TJ, Rodgers GM, Hubel CA, McLaughlin MK  1989 Preeclampsia: an endothelial cell disorder. Am J Obstet Gynecol 161:  1200–1204  	2589440
	2. Roberts JM, Taylor RN, Goldfien A 1991 Clinical and biochemical evidence  of endothelial cell dysfunction in the pregnancy syndrome preeclampsia. Am J  Hypertens 4:700–708  	1930853
	3. Sacks GP, Studena K, Sargent I, Redman C 1998 Normal pregnancy and  pre-eclampsia both produce inflammatory changes in peripheral blood leu kocytes akin to those of sepsis. Am J Obstet Gynecol 179:80–86  	9704769
	4. Redman C, Sacks G, Sargent I 1999 Preeclampsia: An excessive maternal  inflammatory response to pregnancy. Am J Obstet Gynecol 180:499–506  	9988826
	5. Redman CW 1991 Current topic: pre-eclampsia and the placenta. Placenta  12:301–308  	1946241
	6. Vince GS, Starkey PM, Austgulen R, Kwiatkowski D, Redman CW 1995  Interleukin-6, tumour necrosis factor and soluble tumour necrosis factor re ceptors in women with pre-eclampsia. BJOG 102:20–25  	7833306
	7. Conrad KP, Miles TM, Benyo DF 1998 Circulating levels of immunoreactive  cytokines in women with pre-eclampsia. Am J Reprod Immunol 40:102–111  	9764352
	8. Teran E, Escudero C, Moya W, Flores M, Vallance P, Lopez-Jaramillo P 2001  Elevated C-reactive protein and pro-inflammatory cytokines in Andean  women with pre-eclampsia. Int J Gynaecol Obstet 75:243–249  	11728484
	9. Smarason AK, Sargent IL, Starkey PM, Redman CWG 1993 The effect of  placental syncytiotrophoblast microvillous membranes from normal and pre eclamptic women on the growth of endothelial cells in vitro. BJOG 100:943–949  	8217980
	10. Knight M, Redman CWG, Linton EA, Sargent IL 1998 Syncytiotrophoblast  microvilli are shed into the maternal circulation in increased amounts in  pre-eclamptic pregnancy. BJOG 105:632–640  	NO_MATCH
	11. Granger JP, Alexander BT, Llinas MT, Bennett WA, Khalil RA 2001 Patho physiology of hypertension during preeclampsia linking placental ischemia  with endothelial dysfunction. Hypertension 38:718–722  	11566964
	12. De Jong FH, Grootenhuis AJ, Klaij IA, Van Beurden WM 1990 Inhibin and  related proteins: localization, regulation and effects. Adv Exp Med Biol 274:  271–293  	2239428
	13. Luisi S, Florio P, Reis FM, Petraglia F 2001 Expression and secretion of activin  A: possible physiological and clinical implications. Eur J Endocrinol 145:225–  236  	11517001
	14. Petraglia F, Garuti GC, Calza L, Roberts V, Giardino L, Genazzani AR, Vale  W, Meunier H 1991 Inhibin subunits in human placenta: localization and  messenger ribonucleic acid levels during pregnancy. Am J Obstet Gynecol  165:750–758  	1892206
	15. Mather JP, Moore A, Li RH 1997 Activins, inhibins and follistatins: further  thoughts on a growing family of regulators. Proc Soc Exp Biol Med 215:209–222  	9207855
	16. Mather JP 1996 Follistatins and 2-macroglobulins are soluble binding pro teins for inhibin and activin. Horm Res 45:207–210  	8964585
	17. Hashimoto O, Nakamura T, Shoji H, Shimasaki S, Hayashi Y, Sugino H 1997  A novel role of follistatin, an activin-binding protein, in the inhibition of activin  action in rat pituitary cells. J Biol Chem 272:13835–13842  	NO_MATCH
	18. Lewis KA, Gray PC, Blount AL, MacConell LA, Wiater E, Bilezikjian LM,  Vale W 2000 Betaglycan binds inhibin and can mediate functional antagonism  of activin signalling. Nature 404:411–414  	10746731
	19. Muttukrishna S, George L, Fowler PA, Groome NP, Knight PG 1996 Serum  concentrations of ‘total’ activin-A during the human menstrual cycle and  pregnancy. J Clin Endocrinol Metab 81:3328–3334  	NO_MATCH
	20. Muttukrishna S, Knight PG, Groome NP, Redman CW, Ledger WL 1997  Activin A and inhibin A as possible endocrine markers for pre-eclampsia.  Lancet 349:1285–1288  	9142063
	21. Bersinger NA, Smarason AK, Muttukrishna S, Groome NP, Redman CW  2003 Women with preeclampsia have increased serum levels of pregnancy associated plasma protein A (PAPP-A), inhibin A, activin A and soluble E selectin. Hypertens Pregnancy 22:45–55  	12648442
	22. Muttukrishna S, North RA, Morris J, Schellenberg JC, Taylor RS, Asselin J,  Ledger W, Groome N, Redman CWG 2000 Serum inhibin A and activin A are  elevated prior to the onset of pre-eclampsia. Hum Reprod 15:1640–1645  	10875882
	23. Blackburn CA, Keelan JA, Taylor RS, North RA 2003 Maternal serum activin  A is not elevated before preeclampsia in women who are at high risk. Am J  Obstet Gynecol 188:807–811  	12634661
	24. Davidson EJ, Riley SC, Roberts SA, Shearing CH, Groome NP, Martin CW  2003 Maternal serum activin, inhibin, human chorionic gonadotrophin and  -fetoprotein as second trimester predictors of pre-eclampsia. BJOG 110:46–52  	12504935
	25. Florio P, Reis FM, Pezzani I, Luisi S, Severi FM, Petraglia F 2003 The addition  of activin A and inhibin A measurement to uterine artery Doppler velocimetry  to improve the early prediction of pre-eclampsia. Ultrasound Obstet Gynecol  21:165–169  	12601840
	26. Jackson N, Biddolph SC, Ledger W, Groome NP, Manek S 2000 Inhibin  expression in normal and pre-eclamptic placental tissue. Int J Gynecol Pathol  19:219–224  	10907169
	27. Manuelpillai U, Schneider-Kolsky M, Dole A, Wallace EM 2001 Activin A  and activin receptors in gestational tissue from preeclamptic pregnancies. J  Endocrinol 171:57–64  	11572790
	28. Florio P, Ciarmela P, Luisi S, Palumbo MA, Lambert-Messerlian G, Severi  FM, Petraglia F 2002 Pre-eclampsia with fetal growth restriction: placental and  serum activin A and inhibin A levels. Gynecol Endocrinol 16:365–372  	12587530
	29. Silver H, Lambert-Messerlian G, Reis F, Diblasio A, Petraglia F, Canick J  2002 Mechanism of increased maternal serum total activin A and inhibin A in  pre-eclampsia. J Soc Gynecol Investig 9:308–312  	12383916
	30. Bersinger A, Groome N, Muttukrishna S 2002 Pregnancy-associated and  placental proteins in the placental tissue of normal pregnant women and  patients with pre-eclampsia at term. Eur J Endocrinol 147:785–793  	12457454
	31. Mohan A, Asselin J, Sargent IL, Groome NP, Muttukrishna S 2001 Effect of  cytokines and growth factors on the secretion of inhibin A, activin A and  follistatin by term placental villous trophoblasts in culture. Eur J Endocrinol  145:505–511  	11581011
	32. Munno I, Chiechi LM, Lacedra G, Putignano G, Patimo C, Lobascio A, Loizzi  P 1999 Spontaneous and induced release of prostaglandins, interleukin (IL)-1,  IL-6 and tumour necrosis factor- by placental tissue from normal and pre eclamptic pregnancies. Am J Reprod Immunol 42:369–374  	10622467
	33. Rinehart BK, Terrone DA, Lagoo-Deenadayalan S, Barber WH, Hale EA,  Martin Jr JN, Bennett WA 1999 Expression of the placental cytokines tumour  necrosis factor , interleukin 1 and interleukin 10 is increased in pre-eclamp sia. Am J Obstet Gynecol 181:915–920  	10521753
	34. Eramaa M, Hurme M, Stenman U-H, Ritvos O 1992 Activin A/erythroid  differentiation factor is induced during human monocyte activation. J Exp Med  176:1449–1452  	1402687
	35. Shao L-E, Frigon NL, Sehy DW, Yu AL, Lofgren J, Schwall R, Yu J 1992  Regulation of production of activin A in human marrow stromal cells and  monocytes. Exp Haematol 20:1235–1242  	1426103
	36. Shao L-E, Frigon NL, Yu AL, Palyash J, Yu J 1998 Contrasting effects of  inflammatory cytokines and glucocorticoids on the production of activin A in  human marrow stromal cells and their implications. Cytokine 10:227–235  	9576069
	37. Abe M, Shintani Y, Eto Y, Harada K, Fujinaka Y, Kosaka M, Matsumoto T  2001 Interleukin-1 enhances and interferon- suppresses activin A actions by  reciprocally regulating activin A and follistatin secretion from bone marrow  stromal fibroblasts. Clin Exp Immunol 126:64–68  	11678900
	38. Leung PH, Salamonsen LA, Findlay JK 1998 Immunolocalization of inhibin  and activin subunits in human endometrium across the menstrual cycle. Hum  Reprod 13:3469–3477  	9886535
	39. Kozian DH, Ziche M, Augustin HG 1997 The activin-binding protein fol listatin regulates autocrine endothelial cell activity and induces angiogenesis.  Lab Invest 76:267–276  	9042163
	40. McCarthy SA, Bicknell R 1993 Inhibition of vascular endothelial cell growth  by activin-A. J Biol Chem 268:23066–23071  	8226823
	41. Schneider-Kolsky M, Manuelpillai U, Gargett C, Wallace EM 2001 Activin  A-subunit and activin receptors in human myometrium at term and during  labour. BJOG 108:869–874  	11510715
	42. Schneider-Kolsky M, Manuelpillai U, Waldon K, Dole A, Wallace EM 2002  The distribution of activin and activin receptors in gestational tissues across  human pregnancy and during labour. Placenta 23:294–302  	11969340
	43. De Waard V, van den Berg VMM, Veken J, Schultz-Heienbrok J, Pannekoek  H, van Zonneveld A-J 1999 Serial analysis of gene expression to assess the  endothelial cell response to an atherogenic stimulus. Gene 226:1–8  	9889296
	44. Jaffe EA, Nachman RL, Becker CG, Minick CR 1973 Culture of human  endothelial cells derived from umbilical vein. Identification by morphologic  and immunologic criteria. J Clin Invest 52:2745–2756  	4355998
	45. Labarca C, Paigen K 1980 A simple, rapid and sensitive DNA assay procedure.  Anal Biochem 102:344–352  	6158890
	46. Knight PG, Muttukrishna S, Groome NP 1996 Development and application  of a two-site enzyme immunoassay for the measurement of total activin A  concentrations in serum and follicular fluid. J Endocrinol 148:267–279  	8699141
	47. Muttukrishna S, Fowler PA, Groome NP, Mitchell GG, Robertson WR,  Knight PG 1994 Serum concentrations of dimeric inhibin during the sponta neous human menstrual cycle and after treatment with exogenous gonado trophin. Hum Reprod 9:1634–1642  	7836513
	48. Evans LW, Muttukrishna S, Groome NP 1998 Development, validation and  application of an ultrasensitive two-site enzyme immunoassay for human  follistatin. J Endocrinol 156:275–282  	9518873
	49. Florio P, Cobellis L, Luisi S, Ciarmela P, Severi FM, Bocchi C, Petraglia F 2001  Changes in inhibins and activin secretion in healthy and pathological preg nancies. Mol Cell Endocrinol 180:123–130  	11451581
	50. Wallace EM, Schneider-Kolsky ME, Edwards A, Baker L, Jenkin G 2003  Maternal serum activin A levels in association with intrauterine fetal growth  restriction. BJOG 110:306–310  	12628273
	51. Jenkin G, Ward J, Hooper S, O’Connor A, de Kretser D, Wallace E 2001  Feto-placental hypoxemia regulates the release of fetal activin A and prosta glandin E(2). Endocrinology 142:963–966  	11159871
	52. Keelan JA, Taylor R, Schellenberg JC, Groome NP, Mitchell MD, North RA  2002 Serum activin A, inhibin A, and follistatin concentrations in preeclampsia  or small for gestational age pregnancies. Obstet Gynecol 99:267–274  	11814508
	53. Muttukrishna S, Child TJ, Groome NP, Ledger WL 1997b Source of circu lating levels of inhibin A, pro  C-containing inhibins and activin A in early  pregnancy. Hum Reprod 12:1089–1093  	9194671
	54. Beekhuizen H, van Furth R 1993 Monocyte adherence to human vascular  endothelium. J Leukoc Biol 54:363–378  	8409760
	55. Bretelle F, Sabatier F, Desprez D, Camoin L, Grunebaum L, Combes V,  D’Ercole C, Dignat-George F 2003 Circulating microparticles: a marker of  procoagulant state in normal pregnancy and pregnancy complicated by pre eclampsia or intrauterine growth restriction. Thromb Haemost 89:486–492  	12624632
	56. Barak V, Schwartz A, Kalickman I, Nisman B, Gurman G, Shoenfeld Y 1998  Prevalence of hypophosphatemia in sepsis and infection: the role of cytokines.  Am J Med 104:40–47  	9528718
	57. Briegel J, Jochum M, Gippner-Steppert C, Thiel M 2001 Immunomodulation  in septic shock: hydrocortisone differentially regulates cytokine responses.  J Am Soc Nephrol 12:S70–S74  	11251036
	58. Martin C, Boisson C, Haccoun M, Thomachot L, Mege JL 1997 Patterns of  cytokine evolution (tumor necrosis factor- and interleukin-6) after septic  shock, hemorrhagic shock, and severe trauma. Crit Care Med 25:1813–1819  	9366763
	59. D’Antona D, Reis FM, Benedetto C, Evans LW, Groome NP, de Kretser DM,  Wallace EM, Petraglia F 2000 Increased maternal serum activin A but not  follistatin levels in pregnant women with hypertensive disorders. J Endocrinol  165:157–162  	10750046
	60. Nusing RM, Barsig J 1999 Induction of prosanoid, nitric oxide, and cytokine  formation in rat bone marrow derived macrophages by activin A. Br J Phar macol 127:919–926  	10433499
	61. Wang M, Liu A, Garcia FU, Rhim JS, Stearns ME 1999 Growth of HPV-18  immortalized human prostatic intraepithelial neoplasia cell lines. Influence of  IL-10, follistatin, activin-A and DHT. Int J Oncol 14:1185–1195  	10339677
	62. Ohguchi M, Yamato K, Ishihara Y, Koide M, Ueda N, Okahashi N, Noguchi  T, Kizaki M, Ikeda Y, Sugino H, Nishihara T 1998 Activin A regulates the  production of mature interleukin-1 and interleukin-1 receptor antagonist in  human monocytic cells. J Interferon Cytokine Res 18:491–498  	9712365
	63. Yu EW, Dolter KE, Shao L-E, Yu J 1998 Suppression of IL-6 biological activities  by activin A and implications for inflammatory arthropathies. Clin Exp Im munol 112:126–132  	9566800
	64. Russell CE, Hedger MP, Brauman JN, de Kretser DM, Phillips DJ 1999  Activin A regulates growth and acute phase proteins in the human liver cell  line, HepG2. Mol Cell Endocrinol 148:129–136  	10221778
5989.full.pdf
	1. Zhdanova IV, Wurtman RJ 1997 Efficacy of melatonin as a sleep-promoting  agent. J Biol Rhythms 12:644–650  	9406040
	2. Cagnacci A, Elliott JA, Yen SS 1992 Melatonin: a major regulator of the  circadian rhythm of core temperature in humans. J Clin Endocrinol Metab  75:447–452  	1639946
	3. Strassman RJ, Qualls CR, Lisansky EJ, Peake GT 1991 Elevated rectal tem perature produced by all-night bright light is reversed by melatonin infusion  in men. J Appl Physiol 71:2178–2182  	1778910
	4. Arangino S, Cagnacci A, Angiolucci M, Vacca AM, Longu G, Volpe A, Melis  GB 1999 Effects of melatonin on vascular reactivity, catecholamine levels, and  blood pressure in healthy men. Am J Cardiol 83:1417–1419  	10235107
	5. Kra¨uchi K, Cajochen C, Mori D, Graw P, Wirz-Justice A 1997 Early evening  melatonin and S-20098 advance circadian phase and nocturnal regulation of  core body temperature. Am J Physiol 272:R1178–R1188  	9140018
	6. Kra¨uchi K, Werth E, Wu¨st D, Renz C, Wirz-Justice A 1999 Interaction of  melatonin with core body cooling: sleepiness is primarily associated with heat  loss and not with a decrease in core body temperature. Sleep 22:S285  	NO_MATCH
	7. Savaskan E, Olivieri G, Brydon L, Jockers R, Krauchi K, Wirz-Justice A,  Muller-Spahn F 2001 Cerebrovascular melatonin MT1-receptor alterations in  patients with Alzheimer’s disease. Neurosci Lett 308:9–12  	11445273
	8. Braun AR, Balkin TJ, Wesenten NJ, Carson RE, Vargo M, Baldwin P, Selbie  S, Belenky G, Herscovitch 1997 Regional cerebral blood flow throughout the  sleep-wake cycle. An H2(15)O PET study. Brain 120:1173–1197  	9236630
	9. Cagnacci A, Arangino S, Angiolucci M, Maschio E, Longu G, Melis GB 1997  Potentially beneficial cardiovascular effects of melatonin administration in  women. J Pineal Res 22:16–19  	9062865
	10. Cagnacci A, Arangino S, Angiolucci M, Maschio E, Melis GB 1998 Influences  of melatonin administration on the circulation of women. Am J Physiol 274:  R335–R338  	9486289
	11. Cagnacci A, Arangino S, Angiolucci M, Melis BG, Facchinetti F, Malmusi S,  Volpe A 2001 Effect of exogenous melatonin on vascular reactivity and nitric  oxide in postmenopausal women: role of hormone replacement therapy. Clin  Endocrinol (Oxf) 54:261–266  	11207642
	12. Spilt A, Box FM, Van Der Geest RJ, Reiber JH, Kunz P, Kamper Am, Blauw  GJ, Van Buchem MA 2002 Reproducibility of total cerebral blood flow mea surements using phase contrast magnetic resonance imaging. J Magn Reson  Imaging 16:1–5  	12112496
	13. Van Someren EJW 2000 More than a marker: interaction between the circadian  regulation of temperature and sleep, age-related changes, and treatment pos sibilities. Chronobiol Int 17:313–354  	10841209
	14. Kitajima T, Kanbayashi T, Saitoh Y, Ogawa Y, Sugiyama T, Kaneko Y,  Susaki Y, Aizawa R, Shimisu T 2001 The effects of oral melatonin on the  autonomic function in healthy subjects. Psychiatry Clin Neurosci 55:299–300  	11422882
	15. Rubinstein EH, Sessler DI 1990 Skin-surface temperature gradients correlate  with fingertip blood flow in humans. Anesthesiology 73:541–545  	2393139
	16. Lavie P, Schnall RP, Sheffy J, Shlitner A 2000 Peripheral vasoconstriction during  REM sleep detected by a new plethysmographic method. Nat Med 6:606  	10835649
	17. Le Bars D, Thivolle P, Vitte PA, Bojkowski C, Chazot G, Arendt J, Frack owiak RS, Claustrat B 1991 PET and plasma pharmacokinetic studies after  bolus intravenous administration of [11C]melatonin in humans. Int J Rad Appl  Instrum 18:357–362  	2071448
	18. Van Mil AH, Spilt A, Van Buchem MA, Bolen ELEM, Teppema L, West endorp RGJ, Blauw GJ 2002 Nitric oxide mediates hypoxia-induced cerebral  vasodilation in humans. J Appl Physiol 92:962–966  	11842027
	19. Geoffriau M, Claustrat B, Veldhuis J 1999 Estimation of frequently sampled  nocturnal melatonin production in humans by deconvolution analysis: evi dence for episodic or ultradian secretion. J Pineal Res 27:139–144  	10535762
	20. Iguchi H, Kato KI, Ibayashi H 1982 Melatonin serum levels and metabolic  clearance rate in patients with liver cirrhosis. J Clin Endocrinol Metab 54:  1025–1027  	7061695
	21. Burgess HJ, Sletten T, Savic N, Gilbert SS, Dawson D 2001 Effects of bright  light and melatonin on sleep propensity, temperature, and cardiac activity at  night. J Appl Physiol 91:1214–1222  	11509518
	22. Harris AS, Burgess HJ, Dawson D 2001 The effects of day-time exogenous  melatonin administration on cardiac autonomic activity. J Pineal Res 31:199–  205  	11589753
	23. Nishiyama K, Yasue H, Moriyama Y, Tsunoda R, Ogawa Y, Yoshimura M,  Kugiyama K 2001A cute effects of melatonin administration on cardiovascular  autonomic regulation in healthy men. Am Heart J 141:E9  	11320384
	24. Doolen S, Krause DN, Dubocovich ML, Duckles SP 1998 Melatonin mediates  two distinct responses in vascular smooth muscle. Eur J Pharmacol 345:67–69  	9593596
	25. Weekley LB 1993 Effects of melatonin on pulmonary and coronary vessels are  exerted through perivascular nerves. Clin Auton Res 3:45–47  	7682878
5927.full.pdf
	1. Fontbonne A. M., Eschwege, E. M 1991 Insulin and cardiovascular disease.  Paris Prospective Study. Diabetes Care 14:461–469  	1864219
	2. Pyorala, M., Miettinen, H., Laakso, M., Pyorala, K 1998 Hyperinsulinemia  predicts coronary heart disease risk in healthy middle-aged men: the 22-year  follow-up results of the Helsinki Policemen Study. Circulation 98:398–404  	9714089
	3. Pyorala K, Savolainen E, Kaukola S, Haapakoski J 1985 Plasma insulin as  coronary heart disease risk factor: relationship to other risk factors and pre dictive value during 9 1/2-year follow-up of the Helsinki Policemen Study  population. Acta Med Scand 701:(Suppl)38–52  	3907294
	4. Despres JP, Lamarche B, Mauriege P, Cantin B, Dagenais GR, Moorjani S,  Lupien PJ 1996 Hyperinsulinemia as an independent risk factor for ischemic  heart disease. N Engl J Med 334:952–957  	8596596
	5. Howard G, O’Leary DH, Zaccaro D, Haffner S, Rewers M, Hamman R, Selby  JV, Saad MF, Savage P, Bergman R 1996 Insulin sensitivity and athero sclerosis. The Insulin Resistance Atherosclerosis Study (IRAS) Investigators.  Circulation 93:809–817  	NO_MATCH
	6. Reaven GM 1988 Role of insulin resistance in human disease. Diabetes 37:  1595–1607  	NO_MATCH
	7. Lillioja S, Mott DM, Spraul M, Ferraro R, Foley JE, Ravussin E, Knowler WC,  Bennett PH, Bogardus C 1993 Insulin resistance and insulin secretory dys function as precursors of non-insulin-dependent diabetes mellitus. Prospective  studies of Pima Indians. N Engl J Med 329:1988–1992  	8247074
	8. Haffner SM, Stern MP, Mitchell BD, Hazuda HP, Patterson JK 1990 Incidence  of type II diabetes in Mexican Americans predicted by fasting insulin and  glucose levels, obesity, and body-fat distribution. Diabetes 39:283–288  	2407581
	9. Bergstrom RW, Newell-Morris LL, Leonetti DL, Shuman WP, Wahl PW,  Fujimoto WY 1990 Association of elevated fasting C-peptide level and in creased intra-abdominal fat distribution with development of NIDDM in Jap anese-American men. Diabetes 39:104–111  	2210052
	10. Charles MA, Fontbonne A, Thibult N, Warnet JM, Rosselin GE, Eschwege  E 1991 Risk factors for NIDDM in white population. Paris prospective study.  Diabetes 40:796–799  	2060716
	11. Bogardus C, Lillioja S, Mott DM, Hollenbeck C, Reaven G 1985 Relationship  between degree of obesity and in vivo insulin action in man. Am J Physiol  248:286–291  	3883799
	12. Abate N, Garg A, Peshock RM, Stray-Gundersen J, Grundy SM 1995 Rela tionships of generalized and regional adiposity to insulin sensitivity in men.  J Clin Invest 96:88–98  	7615840
	13. UK Prospective Diabetes Study Group 1994 UK Prospective Diabetes Study.  XII. Differences between Asian, Afro-Caribbean and white Caucasian type 2  diabetic patients at diagnosis of diabetes. Diabetic Med 11:670–677  	NO_MATCH
	14. McKeigue PM, Shah B, Marmot MG 1991 Relation of central obesity and  insulin resistance with high diabetes prevalence and cardiovascular risk in  South Asians. Lancet 337:382–386  	1671422
	15. Chandalia M, Abate N, Garg A, Stray-Gundersen J, Grundy S. M 1999  Relationship between generalized and upper body obesity to insulin resistance  in Asian Indian men. J Clin Endocrinol Metab 84:2329–2335  	10404798
	16. Dowse GK, Gareeboo H, Zimmet PZ, Alberti KG, Tuomilehto J, Fareed D,  Brissonnette LG, Finch CF 1990 High prevalence of NIDDM and impaired  glucose tolerance in Indian, Creole, and Chinese Mauritians. Mauritius Non communicable Disease Study Group. Diabetes 39:390–396  	2307296
	17. Ramachandran A, Snehlatha C, Dharmaraj D, Viswanathan M 1992 Preva lence of glucose intolerance in Asian Indians. Urban-rural difference and  significance of upper body adiposity. Diabetes Care 15:1348–1355  	1425100
	18. Ramachandran A, Jali MV, Mohan V, Snehalatha C, Viswanathan M 1988  High prevalence of diabetes in an urban population in south India. Br Med J  297:587–90  	3139221
	19. Mather HM, Keen H 1985 The Southall Diabetes Survey: prevalence of known  diabetes in Asians and Europeans. Br Med J 291:1081–1084  	3931804
	20. McKeigue PM, Miller GJ, Marmot MG 1989 Coronary heart disease in south  Asians overseas. J Clin Epidemiol 42:597–609  	2668448
	21. Sarvotham SG, Berry JN 1968 Prevalence of coronary heart disease in an urban  population in northern India. Circulation 37:939–953  	5653054
	22. Dewan BD, Malhotra KC, Gupta SP 1974 Epidemiological study of coronary  heart disease in rural community in Haryana. Indian Heart J 26:68–78  	4419665
	23. Chadha SL, Radhakrishnan S, Ramachandran K, Kaul U, Gopinath N 1990  Epidemiological study of coronary heart disease in urban population of Delhi.  Indian J Med Res 92:424–430  	2079357
	24. Beckles GL, Miller GJ, Kirkwood BR, Alexis SD, Carson DC, Byam NT 1986  High total and cardiovascular disease mortality in adults of Indian descent in  Trinidad, unexplained by major coronary risk factors. Lancet 1:1298–1301  	2872431
	25. Groop L 2000 Genetics of the metabolic syndrome. Br J Nutr 83:39–48  	10889791
	26. Almind K, Inoue G, Pedersen O, Kahn CR 1996 A common amino acid  polymorphism in insulin receptor substrate-1 causes impaired insulin signal ing. Evidence from transfection studies. J Clin Invest 97:2569–2575  	8647950
	27. Hribal ML, Federici M, Porzio O, Lauro D, Borboni P, Accili, D, Lauro R,  Sesti G 2000 The Gly3Arg972 amino acid polymorphism in insulin receptor  substrate-1 affects glucose metabolism in skeletal muscle cells. J Clin Endo crinol Metab 85:2004–2013  	10843189
	28. Celi FS, Silver K, Waltson J, Knowler WC, Bogardus C, Shuldiner AR 1995  Lack of IRS-1 codon 513 and 972 polymorphism in Pima Indians. J Clin  Endocrinol Metab 80:2827–2829  	7673431
	29. Hitman GA, Hawrami K, McCarthy MI, Viswanathan M, Snehalatha C,  Ramachandran A, Tuomilehto J, Tuomilehto-Wolf E, Nissinen A, Pedersen  O 1995 Insulin receptor substrate-1 gene mutations in NIDDM; implications  for the study of polygenic disease. Diabetologia 38:481–486  	7796990
	30. Pizzutti A, Frittitta L, Argiolas A, Baratta R, Goldfine ID, Bozzali M, Ercolino  T, Scarlato G, Iacoviello L, Vigneri R, Tassi V, Trischitta V 1999 A poly morphism (K121Q) of the human glycoprotein PC-1 gene coding region is  strongly associated with insulin resistance. Diabetes 48:1881–1884  	10480624
	31. Frittitta L, Baratta R, Spampinato D, Di Paola R, Pizzuti A, Vigneri R,  Trischitta V 2001 The Q121 PC-1 variant and obesity have additive and  independent effects in causing insulin resistance. J Clin Endocrinol Metab  86:5888–5891  	11739459
	32. Maddux BA, Sbraccia P, Kamakura S, Sasson S, Youngren J, Fisher A,  Spencer S, Grupe A, Henzel W, Stewart TA 1995 Membrane glycoprotein  PC-1 and insulin resistance in non-insulin-dependent diabetes mellitus. Na ture 373:448–451  	7830796
	33. Maddux BA, Goldfine ID 2000 Membrane glycoprotein PC-1 inhibition of  insulin receptor function occurs via direct interaction with the receptor  subunit. Diabetes 49:13–19  	10615944
	34. Kumakura S, Maddux BA, Sung CK 1998 Overexpression of membrane gly coprotein PC-1 can influence insulin action at a post-receptor site. J Cell  Biochem 3:366–377  	9518262
	35. Youngren J, Maddux BA, Sasson S, Sbraccia P, Tapscott EB, Swanson MS,  Dohm GL, Goldfine ID 1996 Skeletal muscle content of membrane glyco protein PC-1 in obesity. Relationship to muscle glucose transport. Diabetes  45:1324–1328  	NO_MATCH
	36. Frittitta L, Youngren J, Sbraccia P, D’Adamo M, Buongiorno A, Vigneri R,  Goldfine ID, Trischitta V 1997 Increased adipose tissue PC-1 protein content,  but not tumour necrosis factor- gene expression, is associated with a reduc tion of both whole body insulin sensitivity and insulin receptor tyrosine-kinase  activity. Diabetologia 40:282–289  	9084965
	37. Frittitta L, Spampinato D, Solini A, Nosadini R, Goldfine ID, Vigneri R,  Trischitta V 1998 Elevated PC-1 content in cultured skin fibroblasts correlates  with decreased in vivo and in vitro insulin action in nondiabetic subjects:  evidence that PC-1 may be an intrinsic factor in impaired insulin receptor  signaling. Diabetes 47:1095–1100  	9648833
	38. Costanzo BV, Trischitta V, Di Paola R, Spampinato D, Pizzuti A, Vigneri R,  Frittitta L 2001 The Q allele variant (GLN121) of membrane glycoprotein PC-1  interacts with the insulin receptor and inhibits insulin signaling more effec tively than the common K allele variant (LYS121). Diabetes 50:831–836  	11289049
	39. Frittitta L, Youngren J, Vigneri R, Maddux BA, Trischitta V, Goldfine ID 1996  PC-1 content in skeletal muscle of non-obese, non-diabetic subjects: relation ship to insulin receptor tyrosine kinase and whole body insulin sensitivity.  Diabetologia 39:1190–1195  	8897006
	40. Siri WE 1961 Techniques for measuring body composition. Washington DC:  National Academy of Sciences; 223–224  	NO_MATCH
	41. DeFronzo RA, Tobin JD, Andres R 1979 Glucose clamp technique: a method  for quantifying insulin secretion and resistance. Am J Physiol 237:E214–E223  	382871
	42. Gu HF, Almgren P, Lindholm E, Frittitta L, Pizzuti A, Trischitta V, Groop  LC 2000 Association between the human glycoprotein PC-1 gene and elevated  glucose and insulin levels in a paired-sibling analysis. Diabetes 49:1601–1603  	10969847
	43. Kubaszek A, Pihlajamaki J, Karhapaa P, Vauhkonen I, Laakso M 2003 The  K121Q polymorphism of the PC-1 gene is associated with insulin resistance but  not with dyslipidemia. Diabetes Care 26:464–467  	12547881
	44. Gonza´lez-Sa´nchez JL, Martı´nez-Larrad MT, Ferna´ndez-Pe´rez C, Kubaszek  A, Laakso M, Serrano-Rı´os M 2003 K121Q PC-1 gene polymorphism is not  associated with insulin resistance in a Spanish population. Obes Res 11:  603–605  	12740448
	45. Rasmussen SK, Urhammer SA, Pizzuti A, Echwald SM, Ekstrom CT, Hansen  L, Hansen T, Borch-Johnsen K, Frittitta L, Trischitta V, Pedersen O 2000 The  K121Q variant of the human PC-1 gene is not associated with insulin resistance  or type 2 diabetes among Danish Caucasians. Diabetes 49:1608–1611  	10969849
	46. Kalhan R, Puthawala K, Agarwal S, Amini SB, Kalhan SC 2001 Altered lipid  profile, leptin, insulin, and anthropometry in offspring of South Asian immi grants in the United States. Metabolism 10:1197–1202  	11586493
	47. Neel JV 1962 Diabetes mellitus: a thrifty genotype rendered detrimental by  progress. Am J Hum Genet 14:353–362  	13937884
	48. Clausen JO, Hansen T, Bjorbaek C, Echwald SM, Urhammer SA, Rasmussen  S, Andersen CB, Hansen L, Almind K, Winther K, Haraldsdottir J, Borch Johnsen K 1995 Insulin resistance: interactions between obesity and a common  variant of insulin receptor substrate-1. Lancet 346:397–402  	7623569
818.pdf
	1. Refsum H, Ueland PM, Nygard O, Vollset SE. Homocysteine and cardiovas cular disease. Annu Rev Med 1998;49:31–62.  	9509248
	2. Seshadri S, Beiser A, Selhub J, Jacques PF, Rosenberg IH, D’Agostino RB,  et al. Plasma homocysteine as a risk factor for dementia and Alzheimer’s  disease. N Engl J Med 2002;346:476–83.  	11844848
	3. Pfeiffer CM, Huff DL, Smith SJ, Miller DT, Gunter EW. Comparison of plasma  total homocysteine measurements in 14 laboratories: an international  study. Clin Chem 1999;45:1261–8.  	10430793
	4. Clarke R, Woodhouse P, Ulvik A, Frost C, Sherliker P, Refsum H, et al.  Variability and determinants of total homocysteine concentrations in plasma  in an elderly population. Clin Chem 1998;44:102–7.  	9550566
	5. Garg UC, Zheng ZJ, Folsom AR, Moyer YS, Tsai MY, McGovern P, et al.  Short-term and long-term variability of plasma homocysteine measurement.  Clin Chem 1997;43:141–5.  	8990236
	6. Cobbaert C, Arentsen JC, Mulder P, Hoogerbrugge N, Lindemans J. Signifi cance of various parameters derived from biological variability of lipopro tein(a), homocysteine, cysteine, and total antioxidant status. Clin Chem  1997;43:1958–64.  	9342019
	7. Rossi E, Beilby JP, McQuillan BM, Hung J. Biological variability and reference  intervals for total plasma homocysteine. Ann Clin Biochem 1999;36:56–61.  	10370761
	8. van den Berg M, de Jong SC, Deville W, Rauwerda JA, Jakobs C, Pals G, et  al. Variability of fasting and post-methionine plasma homocysteine levels in  normo- and hyperhomocysteinaemic individuals. Neth J Med 1999;55:29–  38.  	10431553
	9. McKinley MC, Strain JJ, McPartlin J, Scott JM, McNulty H. Plasma homocys teine is not subject to seasonal variation. Clin Chem 2001;47:1430–6.  	11468233
	10. Guttormsen AB, Schneede J, Fiskerstrand T, Ueland PM, Refsum HM.  Plasma concentrations of homocysteine and other aminothiol compounds  are related to food intake in healthy human subjects. J Nutr 1994;124:  1934–41.  	7931702
	11. Thirup P, Ekelund S. Day-to-day, postprandial, and orthostatic variation of  total plasma homocysteine. Clin Chem 1999;45:1280–3.  	10430796
	12. Donnelly JG, Isotalo PA. Non-fasting reference intervals for the Abbott IMx  homocysteine and AxSYM plasma folate assays: influence of the methyl enetetrahydrofolate reductase 677C3T mutation on homocysteine. Ann  Clin Biochem 2000;37:390–8.  	10817256
	13. National Committee for Clinical Laboratory Standards. User evaluation of  precision performance of clinical chemistry devices, 2nd ed. Tentative  Guideline EP5–T2. Wayne, PA: NCCLS, 1992.  	NO_MATCH
	14. Fraser CG. Biological variation: from principles to practice. Washington:  AACC Press, 2001:1–151.  	NO_MATCH
	15. Edwards AL. An introduction to linear regression and correlation. San  Francisco, CA: WH Freeman and Company, 1976:1–213.  	NO_MATCH
	16. Ubbink JB, Vermaak WJ, van der Merwe A, Becker PJ. The effect of blood  sample aging and food consumption on plasma total homocysteine levels.  Clin Chim Acta 1992;207:119–28.  	1591859
	17. Fermo I, De Vecchi E, Vigano’ D’Angelo S, D’Angelo A, Paroni R. Total  plasma homocysteine: influence of some common physiological variables.  Amino Acids 1993;5:17–21.  	NO_MATCH
	18. Nurk E, Tell GS, Nygard O, Refsum H, Ueland PM, Vollset SE. Plasma total  homocysteine is influenced by prandial status in humans: the Hordaland  Homocysteine Study. J Nutr 2001;131:1214–6.  	11285329
810.pdf
	1. Rifai N, Ridker PM. High-sensitivity C-reactive protein: a novel and promising  marker of coronary heart disease [Review]. Clin Chem 2001;47:403–11.  	11238289
	2. Roberts WL, Moulton L, Law TC, Farrow G, Cooper-Anderson M, Savory J, et  al. Evaluation of nine automated high-sensitivity C-reactive protein methods:  implications for clinical and epidemiological applications. Part 2. Clin Chem  2001;47:418–25.  	11238291
	3. Ohtake T, Kano S, Watanabe K. Interference in turbidimetric immunoassay  for serum C-reactive protein due to serum protein abnormalities an immune  complex and rheumatoid factor. Rinsho Byori 2000;48:752–9.  	11064600
	4. Muller W, Mierau R, Wohltmann D. Interference of IgM rheumatoid factor  with nephelometric C-reactive protein determinations. J Immunol Methods  1985;80:77–90.  	3925019
	5. Tsuda H, Takata T, Nagafuchi S, Etoh F, Kurihara M, Okochi K, et al. Falsely  increased nephelometric results caused by a monoclonal rheumatoid factor.  Clin Chem 1990;36:1263–4.  	2357815
	6. Benoist JF, Orbach D, Biou D. False increase in C-reactive protein attribut able to heterophilic antibodies in two renal transplant patients treated with  rabbit antilymphocyte globulin. Clin Chem 1998;44:1980–5.  	9732987
	7. Klee GG. Human anti-mouse antibodies. Arch Pathol Lab Med 2000;124:  921–3.  	NO_MATCH
	8. Bernhisel-Broadbent J, Yolken RH, Sampson HA. Allergenicity of orally  administered immunoglobulin preparations in food-allergic children. Pediat rics 1991;87:208–14.  	1987533
	9. Rifai N, Ridker PM. Proposed cardiovascular risk assessment algorithm  using high-sensitivity C-reactive protein and lipid screening. Clin Chem  2001;47:28–30.  	11148173
	10. Warr GW, Magor KE, Higgins DA. IgY: clues to the origins of modern  antibodies [Review]. Immunol Today 1995;16:392–8.  	7546196
	11. Lindahl TL, Festin R, Larsson A. Studies of fibrinogen binding to platelets by  flow cytometry: an improved method for studies of platelet activation.  Thromb Haemost 1992;68:221–5.  	1412170
	12. Larsson A, Wejaker PE, Forsberg PO, Lindahl T. Chicken antibodies: a tool to  avoid interference by complement activation in ELISA. J Immunol Methods  1992;156:79–83.  	1431165
	13. Larsson A, Karlsson-Parra A, Sjo¨quist J. Use of chicken antibodies in enzyme  immunoassays to avoid interference by rheumatoid factors. Clin Chem  1991;37:411–4.  	2004449
	14. Larsson A, Mellstedt H. Chicken antibodies: a tool to avoid interference by  human anti-mouse antibodies in ELISA after in vivo treatment with murine  monoclonal antibodies. Hybridoma 1992;11:33–9.  	1737638
	15. Gassmann M, Thommes P, Weiser T, Hubscher U. Efficient production of  chicken egg yolk antibodies against a conserved mammalian protein. FASEB  J 1990;4:2528–32.  	1970792
	16. Schade R, Staak C, Hendriksen C, Erhard M, Hugl H, Koch G, et al. The  production of avian (egg yolk) antibodies: IgY. The report and recommenda tions of ECVAM Workshop 21. Altern Lab Anim 1996;24:925–34.  	NO_MATCH
805.pdf
	1. Armbruster DA. Fructosamine: structure, analysis, and clinical usefulness  [Review]. Clin Chem 1987;33:2153–63.  	3319287
	2. Lim YS, Staley MJ. Measurement of plasma fructosamine evaluated for  monitoring diabetes. Clin Chem 1985;31:731–3.  	3921282
	3. Baker JR, O’Connor JR, Metcalf PA, Lawson MR, Johnson RN. Clinical  usefulness of estimation of serum fructosamine concentration as a screen ing test for diabetes mellitus. Br Med J 1983;287:863–7.  	6412861
	4. MacDonald D, Pang CP, Cockram CS, Swaminathan R. Fructosamine mea surements in serum and plasma. Clin Chim Acta 1987;168:247–52.  	3677420
	5. Rodriguez-Segade S, Lojo S, Camina MF, Paz JM, Del Rio R. Effects of  various serum proteins on quantification of fructosamine. Clin Chem 1989;  35:134–8.  	2910553
	6. Lloyd DR, Marples J. Fructosamine and IgA: no correlation in non-diabetics  [Letter]. Clin Chem 1989;35:1556–7.  	2758621
	7. Montagna MP, Laghi F, Cremona G, Zuppi C, Barbaresi G, Castellana ML.  Influence of serum proteins on fructosamine concentration in multiple  myeloma. Clin Chim Acta 1991;204:123–30.  	1819455
	8. Nakamura F, Kaimori M, Takaya H, Fujita K, Suzuki N, Sakurabayashi I, et al.  Markedly elevated serum fructosamine in a non-diabetic patient with IgA-  type multiple myeloma. Rinsho Byori 1996;44:85–9.  	8691646
	9. Fujita k, Sakurabayashi I. Effects on M-protein on laboratory data. Rinsho  Byori 2001;49:682–5.  	11519131
	10. Scheidegger JJ. Une micro-me´thode de I’immunoe´lectrophore`se. Int Arch  Allergy 1955;7:103–10.  	NO_MATCH
	11. Hortin GL, Trimpe BL. Lectin affinity chromatography of proteins bearing  o-linked oligosaccharides: application of jacalin-agarose. Anal Biochem  1990;188:271–7.  	1699452
	12. Towbin H, Staechelin T, Gordon J. Electrophoretic transfer of proteins from  polyacrylamide gels to nitrocellulose sheets: procedure and some applica tions. Proc Natl Acad Sci U S A 1979;76:4350–4.  	388439
	13. Bunn HF. Nonenzymatic glycosylation of protein: relevance to diabetes. Am J  Med 1981;70:325–30.  	7468617
	14. Wahid ST, Sultan J, Handley G, Saeed BO, Weaver JU, Robinson ACJ. Serum  fructosamine as a marker of 5-year risk of developing diabetes mellitus in  patients exhibiting stress hyperglycaemia. Diabet Med 2002;19:543–8.  	12099956
	15. Seng LY, Staley MJ. Plasma fructosamine is a measure of all glycated  proteins [Technical Brief]. Clin Chem 1986;32:560.  	3948409
	16. Howey JEA, Browning MC, Fraser CG. Assay of serum fructosamine that  minimizes standardization and matrix problems: use to assess components  of biological variation. Clin Chem 1987;33:269–72.  	3802511
	17. Lemon M, Forrest ARW. Fructosamine activity of proteins in serum [Letter].  Clin Chem 1986;32:2101.  	3779956
	18. Zoppi F, Mosca A, Granata S, Montalbetti N. Glycated proteins in serum:  effect of their relative proportions on their alkaline reducing activity in the  fructosamine test. Clin Chem 1987;33:1895–7.  	2444360
	19. Singh J, Kulig KA. Effects of albumin and immunoglobulin A on fructosamine  assay. Clin Chem 1992;38:824–30.  	1597007
	20. Kerr MA. The structure and function of human IgA. Biochem J 1990;271:  285–96.  	NO_MATCH
	21. Austin GE, Mullins RH, Morin LG. Non-enzymic glycation of individual plasma  proteins in normoglycemic and hyperglycemic patients. Clin Chem 1987;33:  2220–4.  	3690840
	22. Mannik M. Binding of albumin to  A-myeloma proteins and Waldenstro¨m  macroglobulins by disulfide bonds. J Immunol 1967;99:899–906.  	4169036
	23. Tomasi TB, Hauptman SP. The binding of -1 antitrypsin to human IgA.  J Immunol 1974;112:2274–7.  	4207732
	24. Hauptman SP, Sobczak G. Origin of immunoglobulin-albumin complexes.  Nature 1976;263:64–7.  	958465
	25. Eilat D, Fischel R, Zlotnick A. Albumin-immunoglobulin complexes in human  serum: classification and immunochemical analysis. Scand J Immunol  1981;14:77–88.  	6171876
	26. Paraskevas F, Foerster J. Immunodiagnosis. In: Lee GR, Foerster J, eds.  Wintrobe’s clinical hematology. Baltimore: Williams & Wilkins, 1999:40pp.  	NO_MATCH
20030300s00015p65.pdf
	1. Pezzella AT, Silva WE, Lancey RA. Cardiothoracic trauma:  injuries of the thoracic aorta and great vessels. Curr Probl  Surg 1998;35(8):762-71.  	9739342
	2. Cuadros CL, Hutchinson JE 3rd, Mogtader AH. Lacera tion of a mitral papillary muscle and the aortic root as a re sult of blunt trauma to the chest. Case report and review of  the literature. J Thorac Cardiovasc Surg 1984;88:134-40.  	6738097
	3. Langanay T, Verhoye JP, Corbineau H, Agnino A, Derieux  T, Menestret P, et al. Surgical treatment of acute traumatic  rupture of the thoracic aorta a timing reappraisal? Eur J Car diothorac Surg 2002;21(2):282-7.  	11825736
	4. Galli R, Pacini D, Di Bartolomeo R, Fattori R, Turinetto B,  Grillone G, Pierangeli A. Surgical indications and timing of  repair of traumatic ruptures of the thoracic aorta. Ann Tho rac Surg 1998;65:461-4.  	9485246
	5. von Segesser LK, Fischer A, Vogt P, Turina M. Diagnosis  and management of blunt great vessel trauma. J Card Surg  1997;12(2 Suppl):181-92.  	9271744
	6. Peek GJ, Killer HM, Sosnowski AW, Firmin RK. Extracor poreal membrane oxygenation: potential for adults and chil dren? Hosp Med 1998;59(4):304-8.  	9722371
20030300s00012p50.pdf
	1. Cooper LT Jr, Berry GJ, Shabetai R. Idiopathic giant-cell  myocarditis—natural history and treatment. Multicenter  Giant Cell Myocarditis Study Group Investigators. N Engl  J Med 1997;336(26):1860-6.  	9197214
	2. Gries W, Farkas D, Winters GL, Costanzo-Nordin M.  Giant cell myocarditis: first report of disease recurrence in  the transplanted heart. J Heart Lung Transplant 1992;11(2  Pt 2):370-4.  	1576144
	3. Marelli D, Laks H, Amsel B, Jett GK, Couper G, Ardehali  A, et al. Temporary mechanical support with the BVS 5000  assist device during treatment of acute myocarditis. J Card  Surg 1997;12:55-9.  	9169372
	4. Marelli D, Laks, H, Fazio D, Hamilton MA, Fonarow GC,  Meehan DA, Mariguchi JD. Mechanical assist strategy  using the BVS 5000i for patients with heart failure. Ann  Thorac Surg 2000;70:59-66.  	10921683
	5. Champsaur G, Ninet J, Vigneron M, Cochet P, Neidecker  J, Boissonnat P. Use of the Abiomed BVS System 5000i as a  bridge to cardiac transplantation. J Thorac Cardiovasc Surg  1990;100:122-8.  	2366550
	6. Jett GK. ABIOMED BVS 5000. Experience and potential  advantages. Ann Thorac Surg 1996;61:301-4,311-3.  	8561594
	7. Kodama M, Hanawa H, Saeki M, Hosono H, Inomata T,  Suzuki K, Shibata A. Rat dilated cardiomyopathy after au toimmune giant cell myocarditis. Circ Res 1994;75(2):278 84.  	8033341
	8. Hanawa H, Inomata T, Okura Y, Hirono S, Ogawa Y, Izumi  T, et al. T cells with similar T-cell receptor beta-chain com plementarity-determining region 3 motifs infiltrate in f lammatory lesions of synthetic peptides inducing rat  autoimmune myocarditis. Circ Res 1998;83(2):133-40.  	9686752
	9. Cooper LT Jr. Giant cell myocarditis: diagnosis and treat ment. Herz 2000;25(3):291-8.  	10904855
	10. Nieminen MS, Salminen US, Taskinen E, Heikkila P, Par tanen J. Treatment of serious heart failure by transplanta tion in giant cell myocarditis diagnosed by endomyocardial  biopsy. J Heart Lung Transplant 1994;13:543-5.  	8061033
	11. Brilakis ES, Olson LJ, Berry GJ, Daly RC, Loisance D,  Zucker M, Cooper LT Jr. Survival outcomes of patients  with giant cell myocarditis bridged by ventricular assist de vices. ASAIO J 2000;46(5):569-72.  	11016508
	12. Tsai FC, Marelli D, Laks H, Moriguchi J, Sopher M, Bres son J, et al. Short-term bridge to heart transplant using the  BVS 5000 external ventricular assist device. Am J Trans plant 2002;2(7):646-51.  	12201366
	13. McCarthy RE 3rd, Boehmer JP, Hruban RH, Hutchins  GM, Kasper EK, Hare JM, Baughman KL. Long-term out come of fulminant myocarditis as compared with acute  (nonfulminant) myocarditis. N Engl J Med 2000;342:690 5.  	10706898
	14. Frustaci A, Chimenti C, Pieroni M, Gentiloni N. Giant cell  myocarditis responding to immunosuppressive therapy.  Chest 2000;117(3):905-7.  	10713027
20030300s00007p31.pdf
	1. Jaber SF, Koening SC, BhashkerRao B, VanHimbergen DJ,  Cerrito PB, Ewert DJ, et al. Role of graft f low measurement  technique in anastomotic quality assessment in minimally  invasive CABG. Ann Thorac Surg 1998;66:1087-92.  	9769009
	2. D’Ancona G, Karamanoukian HL, Ricci M, Schmid S,  Bergsland J, Salerno TA. Graft revision after transit time  f low measurement in off-pump coronary artery bypass  grafting. Eur J Cardiothorac Surg 2000;17:287-93.  	10758390
	3. Vetter HO, Driever R, Mertens H, Kempkes U, Cramer  BM. Contrast-enhanced magnetic resonance angiography  of mammary artery grafts after minimally invasive coronary  bypass surgery. Ann Thorac Surg 2001;71:1229-32.  	11308165
	4. Wintersperger BJ, Engelmann MG, von Smekal A, Knez A,  Penzkofer HV, Hofling B, et al. Patency of coronary bypass  grafts: assessment with breath-hold contrast-enhanced MR  angiography value of a non-electrocardiographically triggered  technique. Radiology 1998;208:345-51.  	9680557
	5. Langerak SE, Kunz P, Vliegen HW, Lamb HJ, Jukema JW,  van Der Wall EE, de Roos A. Improved MR flow mapping  in coronary artery bypass grafts during adenosine-induced  stress. Radiology 2001;218:540-7.  	11161176
	6. Beldi G, Bosshard A, Hess OM, Althaus U, Walpoth BH.  Transit time f low measurement: experimental validation  and comparison of three different systems. Ann Thorac  Surg 2000;70:212-7.  	10921710
	7. Walpoth BH, Bosshard A, Genyk I, Kipfer B, Berdat PA,  Hess OM, et al. Transit-time f low measurement for detec tion of early graft failure during myocardial revasculariza tion. Ann Thorac Surg 1998;66:1097-100.  	9769011
	8. Laustsen J, Pedersen EM, Terp K, Steinbruchel D, Kure  HH, Paulsen PK, et al. Validation of a new transit time   ultrasound f lowmeter in man. Eur J Vasc Endovasc Surg  1996;12(1):91-6.  	8696905
	9. Barstad RM, Fosse E, Vatne K, Andersen K, Tonnessen TI,  Svennevig JL, Geiran OR. Intraoperative angiography in  minimally invasive direct coronary artery bypass grafting.  Ann Thorac Surg 1997;64:1835-9.  	9436590
	10. Goldstein JA, Safian RD, Aliabadi D, O’Neill WW, Shan non FL, Bassett J, Sakwa M. Intraoperative angiography to  assess graft patency after minimally invasive coronary by pass. Ann Thorac Surg 1998;66:1978-82.  	9930480
	11. Canver CC, Dame N. Ultrasonic assessment of internal  thoracic artery graft f low in the revascularized heart. Ann  Thorac Surg 1994;58:135-8.  	8037511
	12. Louagie YA, Haxhe JP, Jamart J, Buche M, Schoevaerdts  JC. Intraoperative assessment of coronary artery bypass  grafts using a pulsed Doppler f lowmeter. Ann Thorac Surg  1994;58:742-9.  	7944697
	13. Walpoth BH, Mohadjer A, Gersbach P, Rogulenko R, Wal poth BN, Althaus U. Intraoperative internal mammary ar tery transit-time flow measurements: comparative evaluation  of two surgical pedicle preparation techniques. Eur J Cardio thorac Surg 1996;10:1064-70.  	NO_MATCH
	14. Louagie YA, Haxhe JP, Buche M, Schoevaerdts JC. Intraop erative electromagnetic f lowmeter measurements in coro nary artery bypass grafts. Ann Thorac Surg 1994;57:357 64.  	8311596
	15. Hirotani T, Kameda T, Shirota S, Nakao Y. An evaluation  of the intraoperative transit time measurements of coronary  bypass f low. Eur J Cardiothorac Surg 2001;19:848-52.  	11404141
	16. Wiklund L, Johansson M, Brandrup-Wongsen G, Bugge M,  Radberg G, Berglin E. Difficulties in the interpretation of  coronary angiogram early after coronary artery bypass sur gery on the beating heart. Eur J Cardiothorac Surg 2000;  17:46-51.  	10735411
	17. Dodge JT Jr, Brown BG, Bolson EL, Dodge HT. Lumen  diameter of normal human coronary arteries. Inf luence of  age, sex, anatomic variation, and left ventricular hypertro phy or dilation. Circulation 1992;86:232-46.  	1535570
	18. Wang Y, Riederer SJ, Ehman RL. Respiratory motion of the  heart: kinematics and the implications for the spatial reso lution in coronary imaging. Magn Reson Med 1995;33:  713-9.  	7596276
	19. Walpoth BH, Muller MF, Genyk I, Aeschbacher B, Kipfer  B, Althaus U, Carrel TP. Evaluation of coronary bypass  f low with color-Doppler and magnetic resonance imaging  techniques: comparison with intraoperative f low measure ments. Eur J Cardiothorac Surg 1999;15:795-802.  	10431861
	20. Kim WY, Danias PG, Stuber M, Flamm SD, Plein S, Nagel  E, et al. Coronary magnetic resonance angiography for the  detection of coronary stenoses. N Engl J Med 2001;345:  1863-9.  	11756576
01.pdf
	Atlas, R.M., Sayler, G., Burlage, R.S., and Bej, A.K. 1992.  Molecular approaches for environmental monitoring of  microorganisms. BioTechniques 12: 706-717.  	1515138
	Bruce, K.D., Hiorns, W.D., Hobman, J.L., Osborn, A.M.,  Strike, P., and Ritchie, D.A. 1992. Amplification of DNA  from native populations of soil bacteria by using the  polymerase chain reaction. Appl. Environ. Microbiol. 58:  3413-3416.  	1444376
	Courtois, S., Frostegård, Å., Göransson, P., Depret, G.,  Jeannin, P., and Simonet, P. 2001. Quantification of  bacterial subgroups in soil: comparison of DNA extracted  directly from soil or from cells previously released by  density gradient centrifugation. Environ. Microbiol. 3: 431 439.  	11553233
	Cullen, D.W. and Hirsch, P.R. 1998. Simple and rapid  method for direct extraction of microbial DNA from soil  for PCR. Soil Biol. Biochem. 30: 983-993.  	NO_MATCH
	Demeke, T. and Adams, R.P. 1992. The effects of plant  polysaccharides and buffer additives on PCR.  BioTechniques 12: 332-333.  	1571138
	Edgcomb, V.P., McDonald, J.H., Devereux, R., and Smith,  D.W. 1999. Estimation of bacterial cell numbers in humic  acid-rich salt marsh sediments with probes directed to  16S ribosomal DNA. Appl. Environ. Microbiol. 65: 1516 1523.  	NO_MATCH
	Edwards U., Rogall H., Blöcker H., Emde M., and Böttger  E.C. 1989. Isolation and direct complete nucleotide  determination of entire genes. Characterization of a gene  coding for 16S ribosomal RNA. Nucl. Acids Res. 17: 7843 7853.  	2798131
	Erb, R.W. and Wagner-Döbler, I. 1993. Detection of  polychlorinated biphenyl degradation genes in polluted  sediments by direct DNA extraction and polymerase chain  reaction. Appl. Environ. Microbiol. 59: 4065-4073.  	8285706
	Frostegård, Å., Courtois, S., Ramisse, V., Clerc, S.,  Bernillon, D., Le Gall, F., Jeannin, P., Nesme, X., and  Simonet, P. 1999. Quantification of bias related to each  step of an optimized protocol to extract, purify, and amplify  DNA from soils. Appl. Environ. Microbiol. 65: 5409-5420.  	NO_MATCH
	Greaves, M.P. and Wilson, M.J. 1969. The adsorption of  nucleic acids by montmorillonite. Soil Biol. Biochem. 1:  317-323.  	NO_MATCH
	Herrick, J.B., Madsen, E.L., Batt, C.A., and Ghiorse, W.C.  1993. Polymerase chain reaction amplification of  naphthalene-catabolic and 16S rRNA gene sequences  from indigenous sediment bacteria. Appl. Environ.  Microbiol. 59: 687-694.  	7683182
	Holben W.E. 1994. Isolation and purification of bacterial  DNA from soil. In: Methods of Soil Analysis, Part 2.  Microbiological and Biochemical Properties. Soil Science  Society of America, Madison. p. 727-751.  	NO_MATCH
	Holben, W.E., Jansson, J.K., Chelm, B.K., and Tiedje, J.M.  1988. DNA probe method for the detection of specific  microorganisms in the soil bacterial community. Appl.  Environ. Microbiol. 54: 703-711.  	NO_MATCH
	Holley, R.W., Apgar, J., Doctor, B.P., Farrow, J., Marini,  M.A., and Merrill, S.H. 1961. A simplified procedure for  the preparation of tyrosine- and valine-acceptor fraction  of yeast “soluble ribonucleic acid.” J. Biol. Chem. 236:  200-202.  	13715347
	Jackson, C.R., Harper, J.P., Willoughby, D., Rodin, E.E.,  and Churchill, P.F. 1997. A simple, efficient method for  the separation of humic substances and DNA from  environmental samples. Appl. Environ. Microbiol. 63:  4993-4995.  	NO_MATCH
	Jacobsen, C.S. and Rasmussen, O.F. 1992. Development  and application of a new method to extract bacterial DNA  from soil based on separation of bacteria from soil with  cation-exchange resin. Appl. Environ. Microbiol. 58: 2458 2462.  	NO_MATCH
	Josephson, K.L, Pillai, S.D, Way, J., Gerba, C.P., and  Pepper, I.L. 1991. Fecal coliforms in soil detected by  polymerase chain reaction and DNA-DNA hybridizations.  Soil Sci. Soc. Am. J. 55: 1326-1332.  	NO_MATCH
	Lorenz, M.G. and Wackernagel, W. 1987. Adsorption of  DNA to sand and variable degradation rates of adsorbed  DNA. Appl. Environ. Microbiol. 53: 2948-2952.  	3435148
	Lovell, C.R. and Piceno, Y. 1994. Purification of DNA from  estuarine sediments. J. Microbiol. Meth. 20: 161-174.  	NO_MATCH
	Madsen, E.L. 1998. Epistemology of environmental  microbiology. Environ. Sci. Technol. 32: 429-439.  	NO_MATCH
	Markov, G.G. and Ivanov, I.G. 1974. Hydroxyapatite column  chromatography in procedures for isolation of purified  DNA. Analyt. Biochem. 59: 555-563.  	4209157
	Moré, M.I., Herrick, J.B., Silva, M.C., Ghiorse, W.C., and  Madsen, E.L. 1994. Quantitative cell lysis of indigenous  microorganisms and rapid extraction of microbial DNA  from sediment. Appl. Environ. Microbiol. 60: 1572-1580.  	8017936
	Ogram, A., Sayler, G.S., and Barkay, T. 1987. The extraction  and purification of microbial DNA from sediments. J.  Microbiol. Meth. 7: 57-66.  	NO_MATCH
	Ogram, A., Sayler, G.S., Gustin, D., and Lewis, R.J. 1988.  DNA adsorption to soils and sediments. Environ. Sci.  Technol. 22: 982-984.  	NO_MATCH
	Picard, C., Ponsonnet, C., Paget, E., Nesme, X., and  Simonet, P. 1992. Detection and enumeration of bacteria  in soil by direct DNA extraction and polymerase chain  reaction. Appl. Environ. Microbiol. 58: 2717-2722.  	1444380
	Porteous, L.A. and Armstrong, J.L. 1991. Recovery of bulk  DNA from soil by a rapid, small-scale extraction method.  Curr. Microbiol. 22: 345-348.  	NO_MATCH
	Porteous, L.A., Seidler, R.J., and Watrud, L.S. 1997. An  improved method for purifying DNA from soil for  polymerase chain reaction amplification and molecular  ecology applications. Molec. Ecol. 6: 787-791.  	NO_MATCH
	Ranjard, L., Poly, F., Combrisson, J., Richaume, A., and  Nazaret, S. 1998. A single procedure to recover DNA from  the surface or inside aggregates and in various size  fractions of soil suitable for PCR-based assays of bacterial  communities. Eur. J. Soil Biol. 34: 89-97.  	NO_MATCH
	Rochelle, P.A. and Olson, B.H. 1991. A simple technique  for electroelution of DNA from environmental samples.  BioTechniques 11: 724-728.  	1809323
	Sambrook, J., Fritsch, E.F., and Maniatis, T. 1989.  Molecular Cloning: A Laboratory Manual, 2nd ed. Cold  Spring Harbor Laboratory Press, Plainview, NY.  	NO_MATCH
	Schneegurt, M.A. and Kulpa, C.F., Jr. 1998. Review: The  application of molecular techniques in environmental  biotechnology for monitoring microbial systems.  Biotechnol. Appl. Biochem. 27: 73-79.  	NO_MATCH
	Selenska, S. and Klingmüller, W. 1991. DNA recovery and  direct detection of Tn5 sequences from soil. Lett. Appl.  Microbiol. 13: 21-24.  	1369331
	Smalla, K., Cresswell, N., Mendonca-Hagler, L.C., Wolters,  A., and van Elsas, J.D. 1993. Rapid DNA extraction  protocol from soil for polymerase chain reaction-mediated  amplification. J. Appl. Biotechnol. 74: 78-85.  	NO_MATCH
	Steffan, R.J., Goksøyr, J., Bej, A.K., and Atlas, R.M. 1988.  Recovery of DNA from soils and sediments. Appl. Environ.  Microbiol. 54: 2908-2915.  	2851961
	Tebbe, C.C. and Vahjen, W. 1993. Interference of humic  acids and DNA extracted directly from soil in detection  and transformation of recombinant DNA from bacteria and  a yeast. Appl. Environ. Microbiol. 59: 2657-2665.  	7690221
	Torsvik, V.L. 1980. Isolation of bacterial DNA from soil. Soil  Biol. Biochem. 12: 15-21.  	NO_MATCH
	Torsvik, V., Goksøyr, J., and Daae, F.L. 1990. High diversity  in DNA of soil bacteria. Appl. Environ. Microbiol. 56: 782 787.  	2317046
	Tsai, Y.L. and Olson, B.H. 1990. Effects of Hg2+, CH3-Hg+,  and temperature on the expression of mercury resistance  genes in environmental bacteria. Appl. Environ. Microbiol.  56: 3266-3272.  	NO_MATCH
	Tsai, Y.-L. and Olson, B.H. 1991. Rapid method for direct  extraction of DNA from soil and sediments. Appl. Environ.  Microbiol. 57: 1070-1074.  	1647749
	Tsai, Y.-L. and Olson, B.H. 1992. Rapid method for the  separation of bacterial DNA from humic substances in  sediments for polymerase chain reaction. Appl. Environ.  Microbiol. 58: 2292-2295.  	1386212
	Ueda, T., Suga, Y., Yahiro, N., and Matsuguchi, T. 1995.  Remarkable N2-fixing bacterial diversity detected in rice  roots by molecular evolutionary analysis of nifH gene  sequences. J. Bacteriol. 177: 1414-1417.  	7868622
	Volossiouk, T., Robb, E.J., and Nazar, R.N. 1995. Direct  DNA extraction for PCR-mediated assays of soil  organisms. Appl. Environ. Microbiol. 61: 3972-3976.  	8526511
	Weyant, R.S., Edmonds, P., and Swaminathan, B. 1990.  Effect of ionic and nonionic detergents on the Taq  polymerase. Biofeedback 9: 308-309.  	2223070
	Zehr, J.P. and McReynolds, L.A. 1989. Use of degenerate  oligonucleotides for amplification of the nifH gene from  the marine cyanobacterium Trichodesmium thiebautii.  Appl. Environ. Microbiol. 55: 2522-2526.  	2513774
	Zhou, J., Bruns, M.A., and Tiedje, J.M. 1996. DNA recovery  from soils of diverse composition. Appl. Environ. Microbiol.  62: 316-322.  	8593035
375.pdf
	1. Wenger NK, Speroff L, Packard R. Cardiovascular health and disease in  women. N Engl J Med. 1992;329:247–256.  	8316269
	2. O’Connor GT, Morton JR, Diehl MJ, et al. Differences between men and  women in hospital mortality associated with coronary artery bypass graft  surgery. Circulation. 1993;88:2104–2110.  	NO_MATCH
	3. Kelsey SF, James M, Holubkov AL, et al. Results of percutaneous  transluminal coronary angioplasty in women: 1985–1986 National Heart,  Lung and Blood Institute’s Coronary Angioplasty Registry. Circulation.  1993;87:720–727.  	NO_MATCH
	4. Vaccarino V, Abramson JL, Veledar E, et al. Sex differences in hospital  mortality after coronary artery bypass surgery: evidence for a higher  mortality in younger women. Circulation. 2002;105:1176–1181.  	11889010
	5. Jacobs AK, Kelsey SF, Brooks MM, et al. Better outcome for women  compared with men undergoing coronary revascularization. a report from  the Bypass Angioplasty Revascularization Investigation (BARI). Circu lation. 1998;98:1279–1285.  	9751675
	6. Jacobs AK, Johnston JM, Haviland A, et al. Improved outcomes for  women undergoing contemporary percutaneous coronary intervention: a  report from the National Heart, Lung, and Blood Institute Dynamic  Registry. J Am Coll Cardiol. 2002;39:1606–1614.  	12020487
	7. Cho L, Topol EJ, Balog C, et al. Clinical benefit of glycoprotein IIb/IIIa  blockade with abciximab is independent of gender: pooled analysis from  EPIC, EPILOG and EPISTENT trials. J Am Coll Cardiol. 2000;36:  381–386.  	NO_MATCH
	8. Hogue CW Jr, Barzilai B, Pieper KS, et al. Sex differences in neuro logical outcomes and mortality after cardiac surgery: a Society of  Thoracic Surgery National Database report. Circulation. 2001;103:  2133–2137.  	11331252
	9. Peterson ED, Lansky AJ, Kramer J, et al. Effect of gender on the  outcomes of contemporary percutaneous coronary intervention. Am J  Cardiol. 2001;88:359–364.  	11545754
	10. Edwards FH, Carey JS, Grover FL, et al. Impact of gender on coronary  bypass operative mortality. Ann Thorac Surg. 1998;66:125–131.  	9692451
	11. Schunkert H, Harrel L, Palacios IF. Implications of small reference vessel  diameter in patients undergoing percutaneous coronary revascularization.  J Am Coll Cardiol. 1999;34:40–48.  	10399990
	12. Mendes LA, Davidoff R, Cupples LA, et al. Congestive heart failure in  patients with coronary artery disease: the gender paradox. Am Heart J.  1997;134:207–212.  	9313599
	13. Weinberg EO, Thienelt CD, Katz SE, et al. Gender differences in  molecular remodeling in pressure overload hypertrophy. J Am Coll  Cardiol. 1999;34:264–273.  	10400020
	14. Krumholz HM, Larson M, Levy D. Sex differences in cardiac adaptation  to isolated systolic hypertension. Am J Cardiol. 1993;72:310–313.  	8342510
	15. Wong SC, Sleeper LA, Monrad ES, et al. Absence of gender differences  in clinical outcomes in patients with cardiogenic shock complicating  acute myocardial infarction: a report from the SHOCK Trial Registry.  J Am Coll Cardiol. 2001;38:1395–1401.  	11691514
	16. Vaccarino V, Parsons L, Every NR, et al. Sex-based differences in early  mortality after myocardial infarction. N Engl J Med. 1999;341:314–322.  	NO_MATCH
	17. Wexler LF. Studies of acute coronary syndromes in women: lessons for  everyone. N Engl J Med. 1999;341:275–276.  	10413741
	18. Ferguson TB, Hammill BG, Peterson ED, et al. A decade of change: risk  profiles and outcomes for isolated coronary artery bypass grafting pro cedures, 1990–1999: a report from the STS National Database Com mittee and the Duke Clinical Research Institute. Society of Thoracic  Surgeons. Ann Thorac Surg. 2002;73:480–489.  	NO_MATCH
	19. Herlitz J, Brandrup-Wognsen G, Karlson BW, et al. Mortality, risk  indicators of death, mode of death and symptoms of angina pectoris  during 5 years after coronary artery bypass grafting in men and women.  J Intern Med. 2000;247:500–506.  	10792565
	20. Petro KR, Dullum MK, Garcia JM, et al. Minimally invasive coronary  revascularization in women: a safe approach for a high-risk group. Heart  Surg Forum. 2000;3:41–46.  	11064546
	21. Wantanabe CT, Maynard C, Ritchie JL. Comparison of short-term  outcomes following coronary artery stenting in men versus women. Am J  Cardiol. 2001;88:848–852.  	11676945
363.pdf
	1. Ridker PM. High-sensitivity C-reactive protein: potential adjunct for  global risk assessment in the primary prevention of cardiovascular  disease. Circulation. 2001;103:1813–1818.  	11282915
	2. Ridker PM, Cushman M, Stampfer MJ, et al. Inflammation, aspirin, and  the risk of cardiovascular disease in apparently healthy men. N Engl  J Med. 1997;336:973–979.  	9077376
	3. Ridker PM, Hennekens CH, Buring JE, et al. C-reactive protein and other  markers of inflammation in the prediction of cardiovascular disease in  women. N Engl J Med. 2000;342:836–843.  	10733371
	4. Ridker PM, Rifai N, Clearfield M, et al. Measurement of C-reactive  protein for the targeting of statin therapy in the primary prevention of  acute coronary events. N Engl J Med. 2001;344:1959–1965.  	11430324
	5. Ridker PM, Stampfer MJ, Rifai N. Novel risk factors for systemic ath erosclerosis: a comparison of C-reactive protein, fibrinogen, homo cysteine, lipoprotein(a), and standard cholesterol screening as predictors  of peripheral arterial disease. JAMA. 2001;285:2481–2485.  	11368701
	6. Ridker PM, Rifai N, Rose L, et al. Comparison of C-reactive protein and  low-density lipoprotein cholesterol levels in the prediction of first car diovascular events. N Engl J Med. 2002;347:1557–1565.  	12432042
	7. Tracy RP, Lemaitre RN, Psaty BM, et al. Relationship of C-reactive  protein to risk of cardiovascular disease in the elderly: results from the  Cardiovascular Health Study and the Rural Health Promotion Project.  Arterioscler Thromb Vasc Biol. 1997;17:1121–1127.  	9194763
	8. Koenig W, Sund M, Froelich M, et al. C-reactive protein, a sensitive  marker of inflammation, predicts future risk of coronary heart disease in  initially healthy middle-aged men: results from the MONICA (Moni toring trends and determinants in cardiovascular disease) Augsberg  Cohort Study, 1984 to 1992. Circulation. 1999;99:237–242.  	NO_MATCH
	9. Danesh J, Whincup P, Walker M, et al. Low grade inflammation and  coronary heart disease: prospective study and updated meta-analyses.  BMJ. 2000;321:199–204.  	10903648
	10. Pradhan AD, Manson JE, Rossouw JE, et al. Inflammatory biomarkers,  hormone replacement therapy, and incident coronary heart disease: pro spective analysis from the Women’s Health Initiative Observational  Study. JAMA. 2002;288:980–987.  	12190368
	11. Albert CM, Ma J, Rifai N, et al. Prospective study of C-reactive protein,  homocysteine, and plasma lipid levels as predictors of sudden cardiac  death. Circulation. 2002;105:2595–2599.  	12045163
	12. Kuller LH, Tracy RP, Shaten J, et al. Relation of C-reactive protein and  coronary heart disease in the MRFIT nested case-control study. Am J  Epidemiol. 1996;144:537–547.  	NO_MATCH
	13. Mendall MA, Strachan DP, Butland BK, et al. C-reactive protein: relation  to total mortality, cardiovascular mortality and cardiovascular risk factors  in men. Eur Heart J. 2000;21:1584–1590.  	10988010
	14. Harris TB, Ferrucci L, Tracy RP, et al. Associations of elevated  interleukin-6 and C-reactive protein levels with mortality in the elderly.  Am J Med. 1999;106:506–512.  	10335721
	15. Sakkinen P, Abbott RD, Curb JD, et al. C-reactive protein and myocardial  infarction. J Clin Epidemiol. 2002;55:445–451.  	12007546
	16. Albert MA, Danielson E, Rifai N, et al. Effect of statin therapy on  C-reactive protein levels: the Pravastatin Inflammation/CRP Evaluation  (PRINCE): a randomized trial and cohort study. JAMA. 2001;286;64–70.  	11434828
	17. Ridker PM, Glynn RJ, Hennekens CH. C-reactive protein adds to the  predictive value of total and HDL cholesterol in determining risk of first  myocardial infarction. Circulation. 1998;97:2007–2011.  	9610529
	18. Ridker PM, Buring JE, Cook NR, et al. C-reactive protein, the metabolic  syndrome, and risk of incident cardiovascular events: an 8-year follow-up  of 14 719 initially healthy American women. Circulation. 2003;107:  391–397.  	12551861
	19. Pradhan AD, Manson JE, Rifai N, et al. C-reactive protein, interleukin 6,  and the risk of developing type 2 diabetes mellitus. JAMA. 2001;286:  327–334.  	11466099
	20. Freeman DJ, Norrie J, Caslake MJ, et al. C-reactive protein is an inde pendent predictor of risk for the development of diabetes in the West of  Scotland Coronary Prevention Study. Diabetes. 2002;51:1596–1600.  	11978661
	21. Cushman M, Legault C, Barrett-Connor E, et al. Effect of postmeno pausal hormones on inflammation sensitive proteins: the Postmenopausal  Estrogen/Progestin Interventions (PEPI) study. Circulation. 1999;100:  717–722.  	10449693
	22. Ridker PM, Hennekens CH, Rifai N, et al. Hormone replacement therapy  and increased plasma concentration of C-reactive protein. Circulation.  1999;100:713–716.  	10449692
	23. Ockene IS, Matthews CD, Rifai N, et al. Variability and classification  accuracy of serial high-sensitivity C-reactive protein measurements in  healthy adults. Clin Chem. 2001;47:444–450.  	11238295
	24. Roberts WL, Moulton L, Law TC, et al. Evaluation of nine automated  high sensitivity C-reactive protein methods: implications for clinical and  epidemiological applications. Clin Chem. 2001;47:418–423.  	10759469
	25. Blake GJ, Ridker PM, Kuntz KM. Projected life-expectancy gains with  statin therapy for individuals with elevated C-reactive protein levels. J Am  Coll Cardiol. 2002;40:49–55.  	12103255
	26. Rifai N, Buring JE, Lee I-M, et al. Is C-reactive protein specific for  vascular disease in women? Ann Intern Med. 2002;136:529–533.  	11926788
	27. Blake GJ, Ridker PM. Novel clinical markers of vascular wall inflam mation. Circ Res. 2001;89:763–771.  	11679405
	28. Blake GJ, Otvos JD, Rifai N, et al. Low-density lipoprotein particle  concentration and size as determined by nuclear magnetic resonance  spectroscopy as predictors of cardiovascular disease in women. Circu lation. 2002;106:1930–1937.  	12370215
	29. Ridker PM, Rifai N, Pfeffer M, et al. Long-term effects of pravastatin on  plasma concentration of C-reactive protein. Circulation. 1999;100:  230–235.  	NO_MATCH
	30. Ridker PM, Rifai N, Pfeffer MA, et al. Inflammation, pravastatin, and the  risk of coronary events after myocardial infarction in patients with  average cholesterol levels. Circulation. 1998;98:839–844.  	NO_MATCH
	31. Ridker PM. Should statin therapy be considered for patients with elevated  C-reactive protein? The need for a definitive clinical trial. Eur Heart J.  2001;22:2135–2137.  	11913471
	32. Chew D, Bhatt DL, Robbins MA, et al. Effect of clopidogrel added to  aspirin before percutaneous coronary intervention on the risk associated  with C-reactive protein. Am J Cardiol. 2001;88:672–674.  	11564394
	33. Lincoff AM, Kereiakes DJ, Mascelli MA, et al. Abciximab suppresses the  rise in levels of circulating inflammatory markers after percutaneous  coronary revascularization. Circulation. 2001;104:163–167.  	11447080
	34. Bhatt DL, Topol EJ. Need to test the arterial inflammation hypothesis.  Circulation. 2002;106:136–140.  	12093783
	35. Haffner SM, Greenberg AS, Weston WM, et al. Effect of rosiglitazone  treatment on nontraditional markers of cardiovascular disease in patients  with type 2 diabetes mellitus. Circulation. 2002;106:679–684.  	12163427
	36. Liuzzo G, Biasucci LM, Gallimore JR, et al. The prognostic value of  C-reactive protein and serum amyloid a protein in severe unstable angina.  N Engl J Med. 1994;331:417–424.  	7880233
	37. Haverkate F, Thompson SG, Pyke SD, et al. Production of C-reactive  protein and risk of coronary events in stable and unstable angina:  European Concerted Action on Thrombosis and Disabilities Angina  Pectoris Study Group. Lancet. 1997;349:462–466.  	9040576
	38. Lindahl B, Toss H, Siegbahn A, et al. Markers of myocardial damage and  inflammation in relation to long-term mortality in unstable coronary  artery disease. N Engl J Med. 2000;343:1139–1147.  	NO_MATCH
	39. Morrow D, Rifai N, Antman E, et al. C-reactive protein is a potent  predictor of mortality independently and in combination with troponin  T in acute coronary syndromes. J Am Coll Cardiol. 1998;31:  1460 –1465.  	NO_MATCH
	40. Lindmark E, Diderholm E, Wallentin L, et al. Relationship between  interleukin-6 and mortality in patients with unstable coronary artery  disease: effects of an early invasive or noninvasive strategy. JAMA.  2001;286:2107–2113.  	11694151
	41. Mueller C, Buettner HJ, Hodgson JD, et al. Inflammation and long-term  mortality after non–ST-elevation acute coronary syndrome treated with a  very early invasive strategy in 1042 consecutive patients. Circulation.  2002;105:1412–1415.  	11914246
fj.02-0510fje.full.pdf
113.pdf
	1. Vacca A, Ribatti D, Roncali L, Ranieri G, Serio G, Silvestris F,  et al. Bone marrow angiogenesis and progression in multi ple myeloma. Br J Haematol 1994;87:503-8.  	7527645
	2. Di Raimondo F, Azzaro MP, Palumbo G, Bagnato S, Giustolisi  G, Floridia P, et al. Angiogenic factors in multiple myeloma:  higher levels in bone marrow than in peripheral blood.  Haematologica 2000;85:800-5.  	10942925
	3. Neufeld G, Cohen T, Gengrinovitch S, Poltorak Z. Vascular  endothelial growth factor (VEGF) and its receptors. FASEB J  1999;13:9-22.  	9872925
	4. Iwasaki T, Hamano T, Ogata A, Hashimoto N, Kitano M, Kak ishita E. Clinical significance of vascular endothelial growth  factor and hepatocyte growth factor in multiple myeloma.  Br J Haematol 2002;116:796-802.  	11886383
	5. Davis S, Aldrich TH, Jones PF, Acheson A, Compton DL, Jain  V, et al. Isolation of angiopoietin-1, a ligand for the TIE2  receptor, by secretion-trap expression cloning. Cell 1996;87:  1161-9.  	8980223
	6. Maisonpierre PC, Suri C, Jones PF, Bartunkova S, Wiegand SJ,  Radziejewski C, et al. Angiopoietin-2, a natural antagonist  for Tie2 that disrupts in vivo angiogenesis. Science 1997;  277:55-60.  	9204896
	7. Koga K, Todaka T, Morioka M, Hamada J, Kai Y, Yano S, et al.  Expression of angiopoietin-2 in human glioma cells and its  role for angiogenesis. Cancer Res 2001;61:6248-54.  	11507079
	8. Holash J, Maisonpierre PC, Compton D, Boland P, Alexander  CR, Zagzag D, et al. Vessel cooption, regression, and growth  in tumors mediated by angiopoietins and VEGF. Science  1999;284:1994-8.  	10373119
	9. Richardson PG, Schlossman RL, Weller E, Hideshima T, Mit siades C, Davies F, et al. Immunomodulatory drug CC-5013  overcomes drug resistance and is well tolerated in patients  with relapsed multiple myeloma. Blood 2002;100:3063-7.  	12384400
J. Biol. Chem.-2003-Castrillo-10443-9.pdf
	1. Brinckerhoff, C. E., and Matrisian, L. M. (2002) Nat. Rev. Mol. Cell Biol. 3,  207–214  	NO_MATCH
	2. Overall, C. M., and Lopez-Otin, C. (2002) Nat. Rev. Cancer 2, 657–672  	NO_MATCH
	3. Lopez-Otin, C., and Overall, C. M. (2002) Nat. Rev. Mol. Cell Biol. 3, 509–519  	NO_MATCH
	4. Galis, Z. S., and Khatri, J. J. (2002) Circ. Res. 90, 251–262  	NO_MATCH
	5. Woessner, J. F., Jr. (1999) Ann. N. Y. Acad. Sci. 878, 388–403  	NO_MATCH
	6. Galis, Z. S., Sukhova, G. K., Kranzhofer, R., Clark, S., and Libby, P. (1995)  Proc. Natl. Acad. Sci. U. S. A. 92, 402–406  	NO_MATCH
	7. Mason, D. P., Kenagy, R. D., Hasenstab, D., Bowen-Pope, D. F., Seifert, R. A.,  Coats, S., Hawkins, S. M., and Clowes, A. W. (1999) Circ. Res. 85,  1179–1185  	NO_MATCH
	8. Gum, R., Lengyel, E., Juarez, J., Chen, J. H., Sato, H., Seiki, M., and Boyd, D.  (1996) J. Biol. Chem. 271, 10672–10680  	NO_MATCH
	9. Dubois, B., Starckx, S., Pagenstecher, A., Oord, J., Arnold, B., and  Opdenakker, G. (2002) Eur. J. Immunol. 32, 2163–2171  	NO_MATCH
	10. Bond, M., Fabunmi, R. P., Baker, A. H., and Newby, A. C. (1998) FEBS Lett.  435, 29–34  	NO_MATCH
	11. Opdenakker, G., Van den Steen, P. E., and Van Damme, J. (2001) Trends  Immunol. 22, 571–579  	NO_MATCH
	12. Laffitte, B. A., Repa, J. J., Joseph, S. B., Wilpitz, D. C., Kast, H. R.,  Mangelsdorf, D. J., and Tontonoz, P. (2001) Proc. Natl. Acad. Sci. U. S. A.  98, 507–512  	NO_MATCH
	13. Joseph, S. B., Laffitte, B. A., Patel, P. H., Watson, M. A., Matsukuma, K. E.,  Walczak, R., Collins, J. L., Osborne, T. F., and Tontonoz, P. (2002) J. Biol.  Chem. 277, 11019–11025  	NO_MATCH
	14. Sanceau, J., Boyd, D. D., Seiki, M., and Bauvois, B. (2002) J. Biol. Chem. 277,  35766–35775  	NO_MATCH
	15. Castrillo, A., Pennington, D. J., Otto, F., Parker, P. J., Owen, M. J., and Bosca,  L. (2001) J. Exp. Med. 194, 1231–1242  	NO_MATCH
	16. O’Farrell, A. M., Liu, Y., Moore, K. W., and Mui, A. L. (1998) EMBO J. 17,  1006–1018  	NO_MATCH
	17. Castrillo, A., Diaz-Guerra, M. J., Hortelano, S., Martin-Sanz, P., and Bosca, L.  (2000) Mol. Cell. Biol. 20, 1692–1698  	NO_MATCH
	18. Laffitte, B. A., Joseph, S. B., Walczak, R., Pei, L., Wilpitz, D. C., Collins, J. L.,  10449  and Tontonoz, P. (2001) Mol. Cell. Biol. 21, 7558–7568  	NO_MATCH
	19. Joseph, S. B., McKilligin, E., Pei, L., Watson, M. A., Collins, A. R., Laffitte,  B. A., Chen, M., Noh, G., Goodman, J., Hagger, G. N., Tran, J., Tippin, T. K.,  Wang, X., Lusis, A. J., Hsueh, W. A., Law, R. E., Collins, J. L., Willson,  T. M., and Tontonoz, P. (2002) Proc. Natl. Acad. Sci. U. S. A. 99, 7604–7609  	NO_MATCH
	20. Joseph, S. B., Castrillo, A., Laffitte, B. A., Mangelsdorf, D. J., and Tontonoz, P.  (2003) Nat. Med. 9, 213–219  	NO_MATCH
	21. Laffitte, B. A., Joseph, S. B., Chen, M., Repa, J., Wilpitz, D. C., Castrillo A.,  Mangelsdorf, D. J., and Tontonoz, P. (2003) Mol. Cell. Biol., in press  	NO_MATCH
	22. Collins, J. L., Fivush, A. M., Watson, M. A., Galardi, C. M., Lewis, M. C.,  Moore, L. B., Parks, D. J., Wilson, J. G., Tippin, T. K., Binz, J. G., Plunket,  K. D., Morgan, D. G., Beaudet, E. J., Whitney, K. D., Kliewer, S. A., and  Willson, T. M. (2002) J. Med. Chem. 45, 1963–1966  	NO_MATCH
	23. Schultz, J. R., Tu, H., Luk, A., Repa, J. J., Medina, J. C., Li, L., Schwendner,  S., Wang, S., Thoolen, M., Mangelsdorf, D. J., Lustig, K. D., and Shan, B.  (2000) Genes Dev. 14, 2831–2838  	NO_MATCH
	24. Ma, Z., Qin, H., and Benveniste, E. N. (2001) J. Immunol. 167, 5150–5159  	NO_MATCH
	25. Jeng, A. Y., Chou, M., Sawyer, W. K., Caplan, S. L., Von Linden-Reed, J.,  Jeune, M., and Prescott, M. F. (1999) Ann. N. Y. Acad. Sci. 878, 555–558  	NO_MATCH
	26. Prescott, M. F., Sawyer, W. K., Von Linden-Reed, J., Jeune, M., Chou, M.,  Caplan, S. L., and Jeng, A. Y. (1999) Ann. N. Y. Acad. Sci. 878, 179–190  	NO_MATCH
	27. Matsumoto, S., Kobayashi, T., Katoh, M., Saito, S., Ikeda, Y., Kobori, M.,  Masuho, Y., and Watanabe, T. (1998) Am. J. Pathol. 153, 109–119  	NO_MATCH
	28. Eberhardt, W., Schulze, M., Engels, C., Klasmeier, E., and Pfeilschifter, J.  (2002) Mol. Endocrinol. 16, 1752–1766  	NO_MATCH
	29. Galis, Z. S., Johnson, C., Godin, D., Magid, R., Shipley, J. M., Senior, R. M., and  Ivan, E. (2002) Circ. Res. 91, 852–859  	NO_MATCH
	30. Sato, H., Kita, M., and Seiki, M. (1993) J. Biol. Chem. 268, 23460–23468  	NO_MATCH
	31. Venkateswaran, A., Laffitte, B. A., Joseph, S. B., Mak, P. A., Wilpitz, D. C.,  Edwards, P. A., and Tontonoz, P. (2000) Proc. Natl. Acad. Sci. U. S. A. 97,  12097–12102  	NO_MATCH
	32. Repa, J. J., and Mangelsdorf, D. J. (2002) Nat. Med. 8, 1243–1248  	NO_MATCH
	33. Chawla, A., Boisvert, W. A., Lee, C. H., Laffitte, B. A., Barak, Y., Joseph, S. B.,  Liao, D., Nagy, L., Edwards, P. A., Curtiss, L. K., Evans, R. M., and  Tontonoz, P. (2001) Mol. Cell 7, 161–171  	NO_MATCH
	34. Tangirala, R. K., Bischoff, E. D., Joseph, S. B., Wagner, B. L., Walczak, R.,  Laffitte, B. A., Daige, C. L., Thomas, D., Heyman, R. A., Mangelsdorf, D. J.,  Wang, X., Lusis, A. J., Tontonoz, P., and Schulman, I. G. (2002) Proc. Natl.  Acad. Sci. U. S. A. 99, 11896–11901  	NO_MATCH
	35. Schuster, G. U., Parini, P., Wang, L., Alberti, S., Steffensen, K. R., Hansson,  G. K., Angelin, B., and Gustafsson, J. A. (2002) Circulation 106, 1147–1153  	NO_MATCH
	36. Hansson, G. K., Libby, P., Schonbeck, U., and Yan, Z. Q. (2002) Circ. Res. 91,  281–291  	NO_MATCH
	37. Libby, P., and Galis, Z. S. (1995) Ann. N. Y. Acad. Sci. 748, 158–170  	NO_MATCH
	38. Libby, P., Ridker, P. M., and Maseri, A. (2002) Circulation 105, 1135–1143  	NO_MATCH
	39. Brown, D. L., Hibbs, M. S., Kearney, M., Loushin, C., and Isner, J. M. (1995)  Circulation 91, 2125–2131  	NO_MATCH
	40. Baker, A. H., Edwards, D. R., and Murphy, G. (2002) J. Cell Sci. 115,  3719–3727  	NO_MATCH
	41. Shaulian, E., and Karin, M. (2002) Nat. Cell Biol. 4, E131–136  	NO_MATCH
	42. Ghosh, S., and Karin, M. (2002) Cell 109, (suppl.) S81–S96  	NO_MATCH
	43. Brand, K., Page, S., Rogler, G., Bartsch, A., Brandl, R., Knuechel, R., Page, M.,  Kaltschmidt, C., Baeuerle, P. A., and Neumeier, D. (1996) J. Clin. Invest.  97, 1715–1722  	NO_MATCH
	44. Ehrt, S., Schnappinger, D., Bekiranov, S., Drenkow, J., Shi, S., Gingeras, T. R.,  Gaasterland, T., Schoolnik, G., and Nathan, C. (2001) J. Exp. Med. 194,  1123–1140  	NO_MATCH
	45. Li, A. C., Brown, K. K., Silvestre, M. J., Willson, T. M., Palinski, W., and Glass,  C. K. (2000) J. Clin. Invest. 106, 523–531  	NO_MATCH
	46. Ricote, M., Li, A. C., Willson, T. M., Kelly, C. J., and Glass, C. K. (1998) Nature  391, 79–82  	NO_MATCH
	47. Chawla, A., Barak, Y., Nagy, L., Liao, D., Tontonoz, P., and Evans, R. M. (2001)  Nat. Med. 7, 48–52  	NO_MATCH
J. Biol. Chem.-2003-Seck-10408-16.pdf
	1. Azria, M. (1989) The Calcitonins: Physiology and Pharmacology, Karger,  Basel, Switzerland  	NO_MATCH
	2. Hall, R. A., Premont, R. T., and Lefkowitz, R. J. (1999) J. Cell Biol. 145,  927–932  	NO_MATCH
	3. Tsao, P., Cao, T., and von Zastrow, M. (2001) Trends Pharmacol. Sci. 22, 91–96  	NO_MATCH
	4. Ferguson, S. S., Zhang, J., Barak, L. S., and Caron, M. G. (1998) Life Sci. 62,  1561–1565  	NO_MATCH
	5. Lefkowitz, R. J., Pitcher, J., Krueger, K., and Daaka, Y. (1998) Adv. Pharma col. 42, 416–420  	NO_MATCH
	6. Carman, C. V., and Benovic, J. L. (1998) Curr. Opin. Neurobiol. 8, 335–344  	NO_MATCH
	7. Signoret, N., Oldridge, J., Pelchen-Matthews, A., Klasse, P. J., Tran, T., Brass,  L. F., Rosenkilde, M. M., Schwartz, T. W., Holmes, W., Dallas, W., Luther,  M. A., Wells, T. N., Hoxie, J. A., and Marsh, M. (1997) J. Cell Biol. 139,  651–664  	NO_MATCH
	8. Baratti-Elbaz, C., Ghinea, N., Lahuna, O., Loosfelt, H., Pichon, C., and  Milgrom, E. (1999) Mol. Endocrinol. 13, 1751–1765  	NO_MATCH
	9. Roseberry, A. G., and Hosey, M. M. (1999) J. Biol. Chem. 274, 33671–33676  	NO_MATCH
	10. Shapiro, M., Trejo, J., Zeng, D., and Coughlin, S. R. (1996) J. Biol. Chem. 271,  32874–32880  	NO_MATCH
	11. Hein, L., Meinel, L., Pratt, R., Dzau, V., and Kobilka, B. (1997) Mol. Endocri nol. 11, 1266–1277  	NO_MATCH
	12. Anborgh, P. H., Seachrist, J. L., Dale, L. B., and Ferguson, S. S. (2000) Mol.  Endocrinol. 14, 2040–2053  	NO_MATCH
	13. Parent, J., Labrecque, P., Rochdi, M., and Benovic, J. L. (2001) J. Biol. Chem.  276, 7079–7085  	NO_MATCH
	14. Dale, L. B., Bhattacharya, M., Seachrist, J. L., Anborgh, P. H., and Ferguson,  S. S. (2001) Mol. Pharmacol. 60, 1243–1253  	NO_MATCH
	15. Zhang, Z., Hernandez-Lagunas, L., Horne, W. C., and Baron, R. (1999) J. Biol.  Chem. 274, 25093–25098  	NO_MATCH
	16. Shyu, J. F., Zhang, Z., Hernandez-Lagunas, L., Camerino, C., Chen, Y., Inoue,  D., Baron, R., and Horne, W. C. (1999) Eur. J. Biochem. 262, 95–101  	NO_MATCH
	17. Wakioka, T., Sasaki, A., Kato, R., Shouda, T., Matsumoto, A., Miyoshi, K.,  Tsuneoka, M., Komiya, S., Baron, R., and Yoshimura, A. (2001) Nature 412,  647–651  	NO_MATCH
	18. Herskovits, J. S., Burgess, C. C., Obar, R. A., and Vallee, R. B. (1993) J. Cell  Biol. 122, 565–578  	NO_MATCH
	19. Stossel, T. P., Condeelis, J., Cooley, L., Hartwig, J. H., Noegel, A., Schleicher,  M., and Shapiro, S. S. (2001) Nat. Rev. Mol. Cell. Biol. 2, 138–145  	NO_MATCH
	20. Cunningham, C., Gorlin, J. B., Kwiatkowski, D. J., Hartwig, J. H., Janmey,  P. A., Byers, H., and Stossel, T. P. (1992) Science 255, 325–327  	NO_MATCH
	21. van der Flier, A., and Sonnenberg, A. (2001) Biochim. Biophys. Acta 1538,  99–117  	NO_MATCH
	22. Marzia, M., Neff, L., Baron, R., and Horne, W. C. (2002) J. Bone Miner. Res. 17,  Suppl. 1, 231  	NO_MATCH
	23. Ferguson, S. S. (2001) Pharmacol. Rev. 53, 1–24  	NO_MATCH
	24. Cong, M., Perry, S. J., Hu, L. A., Hanson, P. I., Claing, A., and Lefkowitz, R. J.  (2001) J. Biol. Chem. 276, 45145–45152  	NO_MATCH
	25. Whistler, J. L., Enquist, J., Marley, A., Fong, J., Gladher, F., Tsuruda, P.,  Murray, S. R., and von Zastrow, M. (2002) Science 297, 615–620  	NO_MATCH
	26. Cao, T., Deacon, H., Reczek, D., Bretscher, A., and von Zastrow, M. (1999)  Nature 401, 286–290  	NO_MATCH
	27. Shiraha, H., Glading, A., Chou, J., Jia, Z., and Wells, A. (2002) Mol. Cell. Biol.  22, 2716–2727  	NO_MATCH
	28. Chen, M., and Stracher, A. (1989) J. Biol. Chem. 264, 14282–14289  	NO_MATCH
	29. Li, M., Bermak, J. C., Wang, Z. W., and Zhou, Q. Y. (2000) Mol. Pharmacol. 57,  446–452  	NO_MATCH
	30. Lin, R., Karpa, K., Kabbani, N., Goldman-Rakic, P., and Levenson, R. (2001)  Proc. Natl. Acad. Sci. U. S. A. 98, 5258–5263  	NO_MATCH
	31. Awata, H., Huang, C., Handlogten, M. E., and Miller, R. T. (2001) J. Biol.  Chem. 276, 34871–34879  	NO_MATCH
	32. Hjalm, G., MacLeod, R. J., Kifor, O., Chattopadhyay, N., and Brown, E. M.  (2001) J. Biol. Chem. 276, 34880–34887  	NO_MATCH
	33. Gorlin, J. B., Yamin, R., Egan, S., Stewart, M., Stossel, T. P., Kwiatkowski,  D. J., and Hartwig, J. H. (1990) J. Cell Biol. 111, 1089–1105  	NO_MATCH
	34. Shyu, J. F., Inoue, D., Baron, R., and Horne, W. C. (1996) J. Biol. Chem. 271,  31127–31134  	NO_MATCH
JCI0317193.pdf
11196499.pdf
	1. Shuval HI. Control of waterborne disease is still on the public  health agenda. Israel Journal of Medical Sciences, 1988,  24: 637–639.  	3215754
	2. Halperin R. Regulations for water quality in Israel and  internationally [in Hebrew]. Health in the Field, 1999, 7: 3–6.  	NO_MATCH
	3. Tulchinsky TH et al. Waterborne enteric disease outbreaks  in Israel. In: Melnick JL, ed. Enteric viruses in water. Basel, Karger,  1984: 61–69 (Monographs in Virology, 15).  	NO_MATCH
	4. Tulchinsky TH et al. Waterborne enteric disease outbreaks  in Israel, 1976–1985. Israel Journal of Medical Sciences, 1988,  24: 644–651.  	NO_MATCH
	5. Tulchinsky TH et al. Microbiological drinking water quality  in Israel: standards, monitoring and treatment. Israel Journal  of Medical Sciences, 1988, 24: 652–659.  	3215757
	6. Tulchinsky TH et al. Water quality, waterborne disease and  enteric disease in Israel, 1976–92. Israel Journal of Medical  Sciences, 1993, 29: 783–790.  	NO_MATCH
	7. Egoz N et al. An outbreak of typhoid fever due to contamination  of the municipal water supply in northern Israel. Israel Journal  of Medical Sciences, 1988, 24: 640–643.  	3215755
	8. Egoz N et al. An outbreak of Shigella sonnei infection due  to contamination of a municipal water supply in Northern Israel.  Journal of Infection, 1991, 22: 87–93.  	2002237
	9. McCarthy N et al. Epidemiological explanation of an outbreak  of gastroenteritis in Sweden in the absence of detailed micro biological information. European Journal of Epidemiology, 1998,  14: 711–718.	9849833
	10. Payment P et al. Randomized trial to evaluate the risk  of gastrointestinal disease due to consumption of drinking water  meeting current microbiological standards. American Journal  of Public Health, 1991, 81: 703–708.  	2029037
	11. Fattal B. Infectious disease morbidity in kibbutzim [in Hebrew].  Harefuah, 1998, 115: 111–115.  	NO_MATCH
	12. Israel Center for Disease Control. Health status in Israel  1999. Jerusalem, Ministry of Health, 1999.  	NO_MATCH
	13. World Health Organization. Guidelines for drinking-water  quality. Vols I, II. Geneva, World Health Organization, 1998.  	NO_MATCH
	14. Centers for Disease Control and Prevention. Update:  cholera — Western hemisphere, 1992. Morbidity and Mortality  Weekly Report, 1993, 42: 89–91.  	NO_MATCH
	15. Blake PA. Epidemiology of cholera in the Americas. Gastro enterological Clinics of North America, 1993, 22: 639–660.  	7691740
	16. Craun GP. Waterborne disease outbreaks in the United States  of America: causes and prevention. World Health Statistics  Quarterly, 1992, 45: 192–199.  	1462654
	17. Levy DA et al. Surveillance of waterborne-disease outbreaks —  United States, 1995–96. Morbidity and Mortality Weekly Report,  1998, 47 (RR 5) 1–34.  	NO_MATCH
	18. Furtado C et al. Outbreaks of waterborne infectious disease  in England and Wales, 1992–95. Epidemiology and Infection,  1998, 121: 109–119.  	NO_MATCH
	19. Mackenzie WR et al. A massive outbreak in Milwaukee  of cryptosporidium infection transmitted through the public water  supply. New England Journal of Medicine, 1994, 331: 161–167.  	7818640
	20. Centers for Disease Control and Prevention. Assessing  the public health threat associated with waterborne crypto sporidiosis: report of a workshop. Morbidity and Mortality Weekly  Report, 1995, 44 (RR 6): 1–19.  	NO_MATCH
	21. Morris RD, Naumra EN, Griffiths JK. Did Milwaukee  experience waterborne cryptosporidiosis before the large  documented outbreak in 1993? Epidemiology, 1998, 9: 264–270. 	NO_MATCH
	22. Atherton F, Newman CP, Casemore DP. An outbreak  of waterborne cryptosporidiosis associated with a public water  supply in the UK. Epidemiology and Infection, 1995, 115:  123–131.  	7641825
	23. Berkelman RL. Emerging infectious diseases in the United  States. Journal of Infectious Diseases, 1994, 170: 272–277.  	8035009
	24. Hurst CJ. Presence of enteric viruses in freshwater and their  removal by the conventional drinking-water treatment process.  Bulletin of the World Health Organization, 1991, 69: 113–119.  	1647273
	25. Naik SR et al. A large waterborne viral hepatitis E epidemic  in Kanpur, India. Bulletin of the World Health Organization,  1992, 70: 597–604.  	1464145
	26. Goldstein ST et al. Cryptosporidiosis: an outbreak associated  with drinking water despite state-of-the-art water treatment.  Annals of Internal Medicine, 1996; 124: 459–468.  	8602703
	27. Rose JB, Gerba CP, Jakubowski W. Survey of potable water  supplies for cryptosporidium and giardia. Environmental Science  and Technology, 1991, 25: 1393–1400.  	NO_MATCH
	28. Centers for Disease Control and Prevention. Assessment  of inadequately filtered public drinking water — Washington, DC,  December 1993. Morbidity and Mortality Weekly Report, 1994,  43: 661–669.  	NO_MATCH
	29. Johnson CH, Rice EW, Reasoner DJ. Inactivation of  Helicobacter pylori by chlorination. Applied Environmental  Microbiology, 1997, 63: 4969–4970.  	9406419
	30. Goodman KJ, Correa P. The transmission of Helicobacter  pylori: a critical review of the evidence. International Journal  of Epidemiology, 1995, 24: 875–887.  	8557443
	31. Esrey SA et al. Effects of improved water supply on ascariasis,  diarrhoea, dracunculiasis, hookworm infection, schistosomiasis,  and trachoma. Bulletin of the World Health Organization, 1991,  69: 609–621.  	1835675
	32. Centers for Disease Control and Prevention. Achievements  in public health, 1900–1999: control of infectious diseases.  Morbidity and Mortality Weekly Report, 1999, 48: 621–629.  	NO_MATCH
11196487.pdf
	1. Celli A. The history of malaria on the Roman Campagna from  ancient times. London, John Bale, Sons Danielsson, 1933.  	NO_MATCH
	2. Watson RB. Location and mosquito proofing of dwellings. In:  Boyd MF, ed. Malariology. Philadelphia, WB Saunders Co., 1949:  1184–1202.  	NO_MATCH
	3. Ross R. On some peculiar pigmented cells found in two  mosquitoes fed on malarial blood. British Medical Journal, 1897,  2: 1786–1788.  	9293695
	4. Grassi B. [Study on malaria by a zoologist]. Rendiconti della  Reale Accademia dei Lincei, Rome, 1900 (in Italian)  	NO_MATCH
	5. Brown AWA et al. Malaria eradication and control from a global  standpoint. Journal of Medical Entomology, 1976, 13: 1–25.  	781250
	6. Roberts DR et al. Use of remote sensing and geographic  information systems to target malaria control measures in Belize,  Central America. Available at http:// scope.educ.washington.  edu/research/malaria/ddt_ban/roberts/1999-12/(Scope Malaria  Research and Policy Forum, commentary article).  	NO_MATCH
	7. Boyd MF, ed. Malariology. Philadelphia, WB Saunders Co.,  1949: 379–525.  	NO_MATCH
	8. Bentley CA. Malaria in Bengal. Calcutta, Bengal Secretariat Book  Depot, 1916.  	NO_MATCH
	9. Thompson R et al. The Matola project: a temporal and spatial  study of malaria transmission and disease in a suburban area of Maputo, Mozambique. American Journal of Tropical Medicine  and Hygiene, 1997, 57: 550–559.  	9392594
	10. Lindsay SW et al. A malaria control trial using insecticide-treated  bed nets and targeted chemoprophylaxis in a rural area of  the Gambia, West Africa. 3. Entomological characteristics of  the study area. Transactions of the Royal Society of Tropical  Medicine and Hygiene, 1993, 87 (suppl 2): 19–23.  	8212105
	11. Hehir P. Malaria in India. Bombay, Oxford University Press, 1927.  	NO_MATCH
	12. Lindsay SW et al. Ability of Anopheles gambiae mosquitoes  to transmit malaria during the dry and wet seasons in an area  of irrigated rice cultivation in the Gambia. Journal of Tropical Medicine and Hygiene, 1991, 94: 313–324. 	1942209
	13. Rejmankova E et al. Characterisation and detection of  Anopheles vestitipennis and Anopheles punctimacula (Diptera:  Culicidae) larval habitats in Belize with field survey and SPOT  satellite imagery. Journal of Vector Ecology, 1998, 23 (1): 74–88.  	9673933
	14. Rejmankova E et al. Environmental and regional determinants  of Anopheles larval distribution in northern Belize. Environmental  Entomology, 1993, 22: 978–992.  	NO_MATCH
	15. Watson M. General considerations in control and eradication.  In: Boyd MF, ed. Malariology. Philadelphia, WB Saunders Co.  1949: 1161–1166.  	NO_MATCH
	16. Manguin S et al. Characterisation of Anopheles darlingi  (Diptera: Culicidae) larval habitats in Belize, Central America.  Journal of Medical Entomology, 1996, 33: 205–211.  	8742522
	17. Correa RR. [Natural infection with plasmodium malaria from  (K.) cruzii D.K., 1908]. Folia Clinica et Biologia, 1943, 15: 23  (in Portuguese).  	NO_MATCH
	18. Carnevale P et al. [Malaria control in Burkina Faso by means  of pyrethroid-impregnated mosquito nets]. Bulletin de la Socie´te´  de Pathologie exotique, 1988, 81: 832–846 (in French).  	NO_MATCH
	19. Quinones ML et al. Permethrin-treated bed nets do not have  a ‘‘mass-killing effect’’ on village populations of Anopheles  gambiae s.l. in the Gambia. Transactions of the Royal Society  of Tropical Medicine and Hygiene, 1998, 92: 373–378.  	9850383
	20. Charlwood JD, Alecrim WA. Capture-recapture studies  with the South American malaria vector Anopheles darlingi,  Root. Annals of Tropical Medicine and Parasitology, 1989,  83: 569–576.  	2619371
	21. Charlwood JD, Bryan JH. A mark-recapture experiment with  the filariasis vector Anopheles punculatus in Papua New Guinea.  Annals of Tropical Medicine and Parasitology, 1987, 81:  429–436.  	3328568
	22. Trape J-F et al. Vector density gradients and the epidemiology  of urban malaria in Dakar, Senegal. American Journal of  Tropical Medicine and Hygiene, 1992, 47: 181–189.  	1354414
	23. Charlwood JD et al. Cordon sanitaire or laissez faire:  differential dispersal of young and old females of the malaria  vector Anopheles funestus Giles (Diptera: Culicidae) in southern  Mozambique. African Entomology, 1998, 6: 1–6.  	NO_MATCH
	24. Takken W et al. Dispersal and survival of Anopheles funestus  and A. gambiae sl (Diptera: Culicidae) during the rainy season  on southeast Tanzania. Bulletin of Entomological Research, 1998,  88: 561–566.  	NO_MATCH
	25. Smith T et al. Mapping densities of malaria vectors within  a single village. Acta Tropica, 1995, 59: 1–18.  	7785522
	26. Ribeiro JMC et al. Temporal and spatial distribution of  anopheline mosquitoes in an Ethiopian village: implications  for malaria control strategies. Bulletin of the World Health  Organization, 1996, 74: 299–305.  	8789928
	27. Lindsay SW et al. Exposure of Gambian children to Anopheles  gambiae malaria vectors in an irrigated rice production area.  Medical and Veterinary Entomology, 1995, 9: 50–58.  	7696688
	28. Ross R. The prevention of malaria. London, John Murray, 1911.  	NO_MATCH
	29. Gamage-Mendis AC et al. The clustering of malaria infections  within an endemic population: risk of malaria associated with the type of housing construction. American Journal of Tropical  Medicine and Hygiene, 1991, 45: 77–85.  	1867350
	30. Gunawardena DM et al. Malaria risk factors in an endemic  region of Sri Lanka and the impact and cost implications of  risk-factor based interventions. American Journal of Tropical  Medicine and Hygiene, 1998, 58: 533–542.  	9598437
	31. Ghebreyesus TA et al. Incidence of malaria among children  living near dams in northern Ethiopia: community based incidence  survey. British Medical Journal, 1999, 319: 663–666.  	10480820
	32. Thomas CJ, Lindsay SW. Local-scale variation in malaria  amongst rural Gambian children estimated by satellite remote  sensing. Transactions of the Royal Society of Tropical Medicine  and Hygiene, 2000, 94: 159–163.  	10897355
	33. Dobson MJ. Malaria in England: a geographical and historical  perspective. Parassitologia, 1994, 36: 35–60.  	7898959
	34. Hay SI et al. Annual Plasmodium falciparum entomological  inoculation rates (EIR) across Africa: literature survey, internet  access and review. Transactions of the Royal Society of Tropical  Medicine and Hygiene, 2000, 94: 113–127.  	10897348
	35. Ghebreyesus TA et al. Household risk factors for malaria among  children in the Ethiopian highlands. Transactions of the Royal  Society of Tropical Medicine and Hygiene, 2000, 94: 17–21.  	10748890
	36. Lindsay SW, Snow RW. The trouble with eaves: house entry  by vectors of malaria. Transactions of the Royal Society of  Tropical Medicine and Hygiene, 1988, 82: 645–646.  	3256125
	37. Mackinnon M et al. Quantifying genetic and non-genetic  contributions to malarial infection in a Sri Lankan population.  Proceedings of the National Academy of Sciences of the USA  (in press).  	11035799
	38. Woolhouse MEJ et al. Heterogeneities in the transmission  of infectious agents: implications for the design of control  programmes. Proceedings of the National Academy of Sciences  USA, 1997, 94: 338–342.  	8990210
	39. Hasibeder G, Dye C. Population dynamics of mosquito-borne  disease: persistence in a completely heterogeneous environment.  Theoretical Population Biology, 1988, 33: 31–53.  	2897726
	40. Beck L et al. Remote sensing as a landscape epidemiological  tool to identify villages at high risk of malaria transmission.  American Journal of Tropical Medicine and Hygiene, 1994,  51: 271–280.  	7943544
	41. Rejmankova E et al. Predictions of adult Anopheles albimanus  in villages based on distance from remotely sensed larval habitats.  American Journal of Tropical Medicine and Hygiene, 1995,  53: 482–488.	7485706
	42. Roberts DR et al. Predictions of malaria vector distributions  in Belize using multispectral satellite data. American Journal  of Tropical Medicine and Hygiene, 1996, 54: 304–308.  	8600771
	43. Fullerton HR. Screening and mosquito proofing as elements  in malaria control. American Journal of Public Health, 1931,  21: 382–389.  	NO_MATCH
	44. Farid MA. Simple measures for interrupting man-vector contact.  In: Wernsdorfer WH, McGregor I, eds. Malaria: principles and  practice of malariology. Edinburgh, Churchill Livingstone, 1988:  1251–1262.  	NO_MATCH
	45. Macdonald G. The epidemiology and control of malaria. London,  New York, Toronto, Oxford University Press, 1957.  	NO_MATCH
	46. Roberts DR et al. A probability model of vector behaviour:  effects of DDT repellency, irritancy, and toxicity in malaria control.  Journal of Vector Ecology, 2000, 25: 48–61.  	10925797
	47. Beier JC et al. Entomological inoculation rates and Plasmodium  falciparum malaria prevalence in Africa. American Journal  of Tropical Medicine and Hygiene, 1999, 61: 109–113.  	10432066
	48. Alles H et al. Malaria mortality rates in south Asia and in Africa:  implications for malaria control. Parasitology Today, 1998,  14: 369–375.  	NO_MATCH
	49. Malaria and its control in Viet Nam. Hanoi, Ministry of Health,  1996 (unpublished report of a joint European Union and WHO  meeting on malaria control).  	NO_MATCH
	50. Handunetti SM et al. Features of recrudescent chloroquine resistant Plasmodium falciparum infections confer a survival  advantage on parasites and have implications for disease  control. Transaction of the Royal Society of Tropical Medicine  and Hygiene, 1996, 90: 563–567.  	8944275
11196482.pdf
Nucleic Acids Symp Ser-2004-Maruyama-3-4.pdf
tacca00001-0446.pdf
	1. Rowinsky, E. K. and R.C. Donehower. 1995. Paclitaxel (taxol). N. Engl. J. Med. 332:  1004-1014.  	7885406
	2. Weiss, R.B., R. C. Donehower, P. H. Wiernik, T. Ohnuma, R. J. Gralla, D. L. Trump,  J. R. Baker, D. A. an Echo, D. D. von Hoff, and B. Leyland-Jones. 1990. Hypersen sitivity reactions from taxol. J. Clin. Oncol. 8:1263-1268.  	1972736
	3. Sharma, A., E. Mayhew, L. Bolcsak, C. Cavanaugh, P. Harmon, A. Janoff, A., and  R. J. Bernacki. 1997. Activity of paclitaxel liposome formulations against human  ovarian tumor xenografts. Int. J. Cancer 71:103-107.  	9096672
	4. Cabanes, A., K. E. Briggs, P. C., Cokhale, J. A. Treat, and A. Rahman. 1998. Com parative in vivo studies with paclitaxel and liposome-encapsulated paclitaxel. Int. J.  Oncol. 12:1035-1040.  	9538125
	5. Koshkina, N. V., J. C. Waldrep, L. Roberts, E. Golunski, S. Melton, and V. Knight.  2001. Paclitaxel liposome aerosol treatment induces inhibition of pulmonary metas tases in murine renal carcinoma model. Clin. Cancer Res. 7:3258-3262.  	11595722
	6. Ross, H. J., A. L. Canada, and L. M. Slater. 1997. Cyclosporin A enhances paclitaxel  toxicity against leukemia and respiratory epithelial cancers. Clin. Cancer. Res. 3:57 62.  	NO_MATCH
	7. Sood, A.K., J. I. Sorosky, R. C. Squatrito, J. S. Skilling, B. Anderson, and R. E.  Buller. 1999. Cyclosporin A reverses chemoresistance in patients with gynecologic  CYCLOSPORIN IMPROVES ANTICANCER EFFECT OF PACLITAXEL 403 malignancies. Neoplasia 1:118-122. 	10933045
	8. Sonnichsen, D.S., Q. Liu, E. G. Schuetz, J.D. Schuetz, A. Pappo, and M. V. Relling.  1995. Variability in human cytochrome P450 paclitaxel metabolism. J. Pharmacol.  Exp. Ther. 275:566-575.  	7473140
	9. Fujitaka, K., T. Oguri, T. Isobe, Y. Fujiwara, and N. Kohno, N. 2001. Induction of  cytochrome P450 3A4 by docetaxel in peripheral mononuclear cells and its expres sion in lung cancer. Cancer Chemother. Pharmacol. 48:42-46.  	11488523
	10. Gilbert, B.E., C. Knight., F.G. Alvarez, J. C. Waldrep, J. R. Rodarte, V. Knight, and  W.L. Eschenbacher. 1997. Tolerance of volunteers to cyclosporin A-dilauroyl phosphatidylcholine liposome aerosol. Am. J. Respir. Crit. Care Med. 156:1789 1793.  	9412556
	11. Younes, E., G. P. Haas, B. Dezso, E. Ali, R. L. Maughan, M. A. Kukuruga, E.  Montecillo, J. E. Pontes, and G. G. Hillman. 1995. Local tumor irradiation augments  the response to IL-2 therapy in a murine renal adenocarcinoma. Cell Immunol.  165:243-251.  	7553889
	12. Koshkina, N.V., V. Knight, B. E. Gilbert, E. Golunski, L. Roberts, and J. C. Waldrep.  2001. Improved respiratory delivery of the anticancer drugs, camptothecin and pac litaxel with 5% C02-enriched air: pharmacokinetic studies. Cancer Chemother.  Pharmacol., 47:451-456.  	11391862
	13. Koshkina, N.V., E.S. Kleinerman, J.D. Waldrep, S.F. Jia, L.L. Worth, B.E. Gilbert,  and V. Knight. 2000. 9-Nitrocamptothecin liposome aerosol treatment of melanoma  and osteosarcoma lung metastases in mice. Clin. Cancer Res. 6: 2876-2880.  	10914737
	14. Knight, V., N. V. Koshkina, J. C. Waldrep, B. C. Giovanella, and B. E. Gilbert. 1999.  Anticancer effect of 9-nitrocamptothecin liposome aerosol on human cancer xeno grafts in nude mice. Cancer Chemother. Pharmacol. 44:1771-86.  	10453718
	15. Fairchild, G.A 1972. Measurement of respiratory volume for virus retention studies  in mice. Appl. Microbiol. 24: 812-818  	4344961
	16. Phalen, R. 1972. Inhalation studies: foundations and techniques. CRC Press, Boca  Raton. p.22  	NO_MATCH
	17. Schieff, P.B. and S. B. Horwitz. 1980. Taxol stabilizes microtubules in mouse fibro blast cells. Proc. Natl. Acad. Sci. USA 77:1561-1565.  	6103535
	18. Sakai, H., S. Yoneda, T. Tamura, Y. Nishiwaki, A. Yokoyama, K. Watanabe, and N.  Saijo. 2001. A phase II study of paclitaxel plus cisplatin for advanced non-small-cell  lung cancer in Japanese patients. Cancer Chemother. Pharmacol. 48:499-503.  	11800032
	19. Choy, H. and R. MacRae. 2001. The current state of paclitaxel and radiation in the  combined-modality therapy of non-small cell lung cancer. Semin. Oncol. 28(Suppl  14):17-22.  	11605179
	20. Meerum-Terwogt, J.M., M. M. Malingre, J. H. Beijnen, W. W. ten Bokkel Huinink,  H. Rosing, F. J. Koopman, 0. van Tellingen, M. Swart, and J. H. Schellens. 1999.  Coadministration of oral cyclosporin A enables oral therapy with paclitaxel. Clin.  Cancer Res. 5:3379-3384.  	10589748
	21. Sikic, B.I., G. A. Fisher, B. L. Lum, J. Halsey, L. Beketic-Oreskovic, and G. Chen.  1997. Modulation and prevention of multidrug resistance by inhibitors of P-glycop rotein. Cancer Chemother. Pharmacol. 40 (Suppl): S13-19.  	9272128
	22. Germann, U.A. 2000. Detection of recombinant P-glycoprotein in multidrug resis tant cultured cells. Mol. Biotechnol. 14:131-145.  	10872505
	23. Gottesman, M.M. and L. Pastan. 1993. Biochemistry of multidrug resistance medi ated by the multidrug transporter. Annu. Rev. Biochem. 62: 385-427.  	8102521
	24. Wandel, C., R. B. Kim, S. Kajiji, F. P. Guengrich, G. R. Wilkinson, and A. J. J. Wood.  1999. P-glycoprotein and cytochrome P450 3A inhibition: dissociation of inhibitory  potencies. Cancer Res. 59:3944-3948.  	10463589
	25. Cresteil, T., B. Monsarrat, P. Alvinerie, J. M. Treluyer, I. Vieira, and M. Wright.  1994. Taxol metabolism by human liver microsomes: identification of cytochrome  P450 isoenzymes involved in its biotransformation. Cancer Res. 54:386-392.  	7903909
	26. Sugawara, I., S. Akiyama, R. J. Scheper, and S. Itoyama. 1997. Lung resistance  protein (LRP) -expression in human normal tissues in comparison with that of  MDR1 and MRP. Cancer Lett. 112:23-31.  	9029166
	27. Yokoyama, H., T. Ishida, K. Sugio, T. Inoue, and K. Sugimachi, K. 1999. Immuno histochemical evidence that P-glycoprotein in non-small cell lung cancers is associ ated with shorter survival. Surg. Today 29:1141-7.  	10552331
	28. Gilbert, B.E., M. Black, J. C. Waldrep, J. Bennick, C. Montgomery, and V. Knight.  1997. Cyclosporin A liposome aerosol: Lack of toxicity in rats. Inhalation Toxicology  9:717-730.  	NO_MATCH
	29. Koshkina, N. V., B. E. Gilbert, J. C. Waldrep, A Seryshev and V. Knight. 1999.  Distribution of camptothecin after delivery as a liposome aerosol or following intra muscular administration in mice. Cancer Chemoth Pharmacol 44:187-192.  	10453719
tacca00001-0343.pdf
	1. Darwin C. On the Origin of Species by Means of Natural Selection, or the Preser vation of Favoured Races in the Struggle for Life. The Easton Press, Norwalk, Conn,  1993, page 63  	NO_MATCH
	2. Pollack RE. [Book Review] On the origin of species by means of natural selection, or  the preservation offavoured races in the struggle for life. N Engl J Med 337:137-138,  1997  	NO_MATCH
	3. Korber B, Muldoon M, Theiler J, Gao F, Gupta R, Lapedes A, Hahn BH, Wolinsky S,  300  DOUGLAS D. RICHMAN ET AL  Bhattacharya T. Timing the ancestor of the HIV-1 pandemic strains. Science  288:1789-1796, 2000  	10846155
	4. Piot P, Bartos M, Ghys PD, Walker N, Schwartlander B. The global impact of  HIV/AIDS. Nature 410:968-973, 2001  	11309626
	5. Drake JW. Rates of spontaneous mutation among RNA viruses. Proc Natl Acad Sci  USA 90:4171-4175, 1993  	8387212
	6. Mansky LM and Temin HM. Lower in vivo mutation rate of human immunodefi ciency virus type 1 than that predicted from the fidelity of purified reverse tran scriptase. J Virol 69:5087-5094, 1995  	7541846
	7. Perelson AS, Neumann AU, Markowitz M, Leonard JM, Ho DD. HIV-1 dynamics in  vivo: virion clearance rate, infected cell lifetime, and viral generation time. Science  271:1582-1586, 1996  	8599114
	8. Fischl MA, Richman DD, Grieco MH, Gottlieb MS, Volberding PA, Laskin OL,  Leedom JM, Groopman JE, Mildvan D, Schooley RT, Jackson GG, Durack DT, King  D, AZT Collaborative Working Group. The efficacy of azidothymidine (AZT) in the  treatment ofpatients with AIDS and AIDS-related complex. A double-blind, placebo controlled trial. N Engl J Med 317:185-191, 1987  	3299089
	9. Richman DD, Fischl MA, Grieco MH, Gottlieb MS, Volberding PA, Laskin OL,  Leedom JM, Groopman JE, Mildvan D, Hirsch MS, Jackson GG, Durack DT,  Nusinoff-Lehrman S, AZT Collaborative Working Group. The toxicity of azidothy midine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A  double-blind, placebo-controlled trial. N Engl J Med 317:192-197, 1987  	3299090
	10. Larder BA, Darby G, Richman DD. HIV with reduced sensitivity to zidovudine (AZT)  isolated during prolonged therapy. Science 243:1731-1734, 1989  	2467383
	11. Larder BA and Kemp SD. Multiple mutations in HIV-1 reverse transcriptase confer  high-level resistance to zidovudine (AZT). Science 246:1155-1158, 1989  	2479983
	12. Richman DD. The implications of drug resistance for strategies of combination  antiviral chemotherapy. Antiviral Res 29:31-33, 1996  	8721540
	13. Richman DD, Grimes JM, Lagakos SW. Effect of stage of disease and drug dose on  zidovudine susceptibilities of isolates of human immunodeficiency virus. J AIDS  3:743-746, 1990  	2114476
	14. Gulick RM, Mellors JW, Havlir D, Eron JJ, Gonzalez C, McMahon D, Richman DD,  Valentine FT, Jonas L, Deutsch P, Meibohm A, Holder D, Schleif WA, Condra JH,  Emini EA, Chodakewitz JA. Treatment with indinavir, zidovudine, and lamivudine  in adults with human immunodeficiency virus infection and prior antiretroviral  therapy. N Engl J Med 337:734-739, 1997  	9287228
	15. Gunthard HF, Wong JK, Ignacio CC, Guatelli JC, Riggs NL, Havlir DV, Richman  DD. Human immunodeficiency virus replication and genotypic resistance in blood  and lymph nodes after a year of potent antiretroviral therapy. J Virol 72:2422-2428,  1998  	9499103
	16. Hirsch MS, Conway B, D'Aquila RT, Johnson VA, Brun-Vezinet F, Clotet B, Demeter  LM, Hammer SM, Jacobsen DM, Kuritzkes DR, Loveday C, Mellors JW, Vella S,  Richman DD. Antiretroviral drug resistance testing in adults with HIV infection.  JAMA 279:1984-1991, 1998  	NO_MATCH
	17. Hirsch MS, Brun-Vezinet F, D'Aquila RT, Hammer SM, Johnson VA, Kuritzkes DR,  Loveday C, Mellors JW, Clotet B, Conway B, Demeter LM, Vella S, Jacobsen DM,  Richman DD. Antiretroviral drug resistance testing in adult HIV-1 infection. JAMA  283:2417-2426, 2000  	NO_MATCH
	18. Hirsch MS, Brun-Vezinet F, Clotet B, Conway B, Kuritzkes DR, D'Aquila RT, Deme ter LM, Hammer SM, Johnson VA, Loveday C, Mellors JW, Jacobsen DM, Richman  DD. Antiretroviral drug resistance testing in adults infected with human immuno deficiency virus type 1: 2003 recommendations of an International AIDS Society USA panel. Clin Infect Dis 37:113-128, 2003  	12830416
	19. Little SJ, Holte S, Routy JP, Daar ES, Markowitz M, Collier AC, Koup RA, Mellors  JW, Connick E, Whitcomb JM, Hellmann NS, Richman DD. Antiretroviral-drug  resistance among patients recently infected with HIV. N Engl J Med 347:385-394,  2002  	12167680
	20. Korber BTM, Kunstman KJ, Patterson BK, Furtado M, McEvilly MM, Levy R,  Wolinsky SM. Genetic differences between blood- and brain-derived viral sequences  from human immunodeficiency virus type 1-infected patients: evidence of conserved  elements in the V3 region ofthe envelope protein ofbrain-derived sequences. J Virol  68:7467-7481, 1994  	7933130
	21. Haggerty S and Stevenson M. Predominance of distinct viral genotypes in brain and  lymph node compartments of HIV-1-infected individuals. Viral Immunology 4:123 131, 1991  	1684709
	22. Pang S, Vinters HV, Akashi T, O'Brien WA, Chen ISY. HIV-1 env sequence variation  in brain tissue of patients with AIDS-related neurologic disease. JAIDS 4:1082 1092, 1991  	1684385
	23. Epstein LG, Kuiken C, Blumberg BM, Hartman S, Sharer LR, Clement M, Goudsmit  J. HIV-1 V3 domain variation in brain and spleen of children with AIDS: Tissue specific evolution within host-determined quasispecies. Virology 180:583-590, 1991  	1989385
	24. Power C, McArthur JC, Johnson RT, Griffin DE, Glass JD, Perryman S, Chesebro B.  Demented and nondemented patients with AIDS differ in brain-derived human  immunodeficiency virus type 1 envelope sequences. J Virol 68:4643-4649, 1994  	8207838
	25. Edwards TG, Hoffman TL, Baribaud F, Wyss S, LaBranche CC, Romano J, Adkinson  J, Sharron M, Hoxie JA, Doms RW. Relationships between CD4 independence,  neutralization sensitivity, and exposure of a CD4-induced epitope in a human im munodeficiency virus type 1 envelope protein. J Virol 75:5230-5239, 2001  	11333905
	26. Puffer BA, Pohlmann S, Edinger AL, Carlin D, Sanchez MD, Reitter J, Watry DD,  Fox HS, Desrosiers RC, Doms RW. CD4 independence of simian immunodeficiency  virus Envs is associated with macrophage tropism, neutralization sensitivity, and  attenuated pathogenicity. J Virol 76:2595-2605, 2002  	11861825
	27. Gorry PR, Taylor J, Holm GH, Mehle A, Morgan T, Cayabyab M, Farzan M, Wang  H, Bell JE, Kunstman K, Moore JP, Wolinsky SM, Gabuzda D. Increased CCR5  affinity and reduced CCR5/CD4 dependence of a neurovirulent primary human  immunodeficiency virus type 1 isolate. J Virol 76:6277-6292, 2002  	12021361
	28. Edinger AL, Mankowski JL, Doranz BJ, Margulies BJ, Lee B, Rucker J, Sharron M,  Hoffman TL, Berson JF, Zink MC, Hirsch VM, Clements JE, Doms RW. CD4 independent, CCR5-dependent infection of brain capillary endothelial cells by a  neurovirulent simian immunodeficiency virus strain. Proc Natl Acad Sci U S A  94:14742-14747, 1997  	9405683
	29. Reddy YS, Kashuba A, Gerber J, Miller V. Roundtable report: importance of anti retroviral drug concentrations in sanctuary sites and viral reservoirs. AIDS Res  Hum Retroviruses 19:167-176, 2003  	12689408
	30. Wong JK, Ignacio CC, Torriani F, Havlir D, Fitch NJS, Richman DD. In vivo com partmentalization of HIV: evidence from the examination of pol sequences from  autopsy tissues. J Virol 70:2059-2071, 1997  	NO_MATCH
	31. Venturi G, Catucci M, Romano L, Corsi P, Leoncini F, Valensin PE, Zazzi M.  Antiretroviral resistance mutations in human immunodeficiency virus type 1 re verse transcriptase and protease from paired cerebrospinal fluid and plasma  samples. J Infect Dis 181:740-745, 2000  	10669367
	32. Cunningham PH, Smith DG, Satchell C, Cooper DA, Brew B. Evidence for independent development of resistance to HIV-1 reverse transcriptase inhibitors in the  cerebrospinal fluid. AIDS 14:1949-1954, 2000  	10997399
	33. Srinivasakumar N, Chazal N, Helga-Maria C, Prasad S, Hammarskjold M-L, Re kosh D. The effect of viral regulatory protein expression on gene delivery by human  immunodeficiency virus type 1 vectors produced in stable packaging cell lines. J  Virol 71(8):5841-5848, 1997  	9223473
	34. Dezzutti CS, Guenthner PC, Cummins JE, Jr., Cabrera T, Marshall JH, Dillberger  A, Lal RB. Cervical and prostate primary epithelial cells are not productively in fected but sequester human immunodeficiency virus type 1. J Infect Dis 183:1204 1213, 2001  	11262202
	35. Eyre RC, Zheng G, Kiessling AA. Multiple drug resistance mutations in human  immunodeficiency virus in semen but not blood of a man on antiretroviral therapy.  Urology 55:5912000  	10754183
	36. Gupta P, Leroux C, Patterson BK, Kingsley L, Rinaldo C, Ding M, Chen Y, Kulka K,  Buchanan W, McKeon B, Montelaro R. Human immunodeficiency virus type 1 shed ding pattern in semen correlates with the compartmentalization of viral quasispe cies between blood and semen. J Infect Dis 182:79-87, 2000  	10882584
	37. Kiessling AA, Fitzgerald LM, Zhang D, Chhay H, Brettler D, Eyre RC, Steinberg J,  McGowan K, Byrn RA. Human immunodeficiency virus in semen arises from a  genetically distinct virus reservoir. AIDS Res Hum Retroviruses 14 Suppl 1:S33 S411998  	9581882
	38. Krieger JN, Nirapathpongporn A, Chaiyaporn M, Peterson G, Nikolaeva I, Akridge  R, Ross SO, Coombs RW. Vasectomy and human immunodeficiency virus type 1 in  semen. J Urol 159:820-825, 1998  	9474159
	39. Xu C, Politch JA, Tucker L, Mayer KH, Seage GR, III, Anderson DJ. Factors asso ciated with increased levels ofhuman immunodeficiency virus type 1 DNA in semen.  J Infect Dis 176:941-947, 1997  	9333152
	40. Coombs RW, Reichelderfer PS, Landay AL. Recent observations on HIV type-1  infection in the genital tract of men and women. AIDS 17:455-480, 2003  	12598766
	41. Poss M, Rodrigo AG, Gosink JJ, Learn GH, de Vange PD, Martin HL, Jr., Bwayo J,  Kreiss JK, Overbaugh J. Evolution of envelope sequences from the genital tract and  peripheral blood of women infected with clade A human immunodeficiency virus  type 1. J Virol 72:8240-8251, 1998  	9733867
	42. Geijtenbeek TB, Kwon DS, Torensma R, van Vliet SJ, van Duijnhoven GC, Middel  J, Cornelissen IL, Nottet HS, KewalRamani VN, Littman DR, Figdor CG, van Kooyk  Y. DC-SIGN, a dendritic cell-specific HIV-1-binding protein that enhances transin fection of T cells. Cell 100:587-597, 2000  	10721995
	43. Pillai S, Good B, Richman D, Corbeil J. A new perspective on V3 phenotype predic tion. AIDS Res Hum Retroviruses 19:145-149, 2003  	12643277
	44. Paranjpe S, Craigo J, Patterson B, Ding M, Barroso P, Harrison L, Montelaro R,  Gupta P. Subcompartmentalization ofHIV-1 quasispecies between seminal cells and  seminal plasma indicates their origin in distinct genital tissues. AIDS Res Hum  Retroviruses 18:1271-1280, 2002  	12487815
	45. Larsen RA, Bozzette S, McCutchan JA, Chiu J, Leal MA, Richman DD, The Cali fornia Collaborative Treatment Group. Persistent cryptococcus neoformans infection  of the prostate after successful treatment of meningitis. Ann Intern Med 111:125 128, 1989  	NO_MATCH
	46. Smith DM, Kingery JD, Ignacio CC, Havlir DV, Richman DD, Little SJ. The prostate  as a reservoir for HIV-1, The 10th Conference on Retroviruses and Opportunistic  Infections Boston, MA:February 10-14 (2003) (Abstract)  	15238781
	47. Parren PW and Burton DR. The antiviral activity of antibodies in vitro and in vivo.  Adv Immunol 77:195-262, 2001  	11293117
	48. Burton DR. A vaccine for HIV type 1: The antibody perspective. Proc Natl Acad Sci  U S A 94:10018-10023, 1997  	9294155
	49. Richman DD, Wrin T, Little SJ, Petropoulos CJ. Rapid evolution of the neutralizing  antibody response to HIV type 1 infection. Proc Natl Acad Sci U S A 100:4144- 4149,  2003  	12644702
	50. Petropoulos CJ, Parkin NT, Limoli KL, Lie YS, Wrin T, Huang W, Tian H, Smith D,  Winslow GA, Capon DJ, Whitcomb JM. A novel phenotypic drug susceptibility assay  for human immunodeficiency virus type 1. Antimicrob Agents Chemother 44:920 928, 2000  	10722492
	51. Francis T, Jr. Influenza: the newe acquayantance. Ann Intern Med 39:203-221, 1953  	13080880
	52. Fazekas de St Groth S and Webster RG. Disquisitions of Original Antigenic Sin. I.  Evidence in man. J Exp Med 124:331-345, 1966  	5922742
	53. Moutouh L, Corbeil J, Richman DD. Recombination leads to the rapid emergence of  HIV-1 dually resistant mutants under selective drug pressure. Proc Natl Acad Sci  USA 93:6106-6111, 1996  	8650227
	54. Palumbi SR. Humans as the world's greatest evolutionary force. Science 293:1786 1790, 2001	11546863
tacca00001-0242.pdf
	1. McKusick VA. Mendelian Inheritance in Man, 6th edition. Baltimore, Johns Hopkins  University Press, 1983, pp. 506-507.  	NO_MATCH
	2. Kjeldsen AD, Vase P, Green A. Hereditary hemorrhagic telangiectasia in a popula tion-based study of prevalence and mortality in Danish patients. J Int Med 1999;  245:31-39.  	10095814
	3. Massar OS, Friedman CM, White RI. The natural history of epistaxis in hereditary  hemorrhagic telangiectasia. Laryngoscope 1991; 101:977-980.  	1886446
	4. Dines DE, Arms RA, Bernatz PE, et al. Pulmonary arteriovenous fistulas. Mayo Clin  Proc 1974; 49:460-465.  	4834927
	5. Burke CM, Safai C, Nelson DP et al. Pulmonary arteriovenous malformations: A  critical update. Am Rev Resp Dis 1986; 134:334-339.  	3527008
	6. Gossage JR, Kanj G. Pulmonary arteriovenous malformations: A state of the art  review. Am J Resp Crit Care Med 1998; 158:643-661.  	9700146
	7. White RJ, Lynch-Nahm A, Terry P et al. Pulmonary arteriovenous malformations:  Techniques and long-term outcome of embolotherapy. Radiology 1988; 169:663-669.  	3186989
	8. Roman G, Fisher M, Perl DP et al. Neurological manifestations of hereditary hem orrhagic telangiectasia (Rendu-Osler-Weber disease). Report oftwo cases and review  of the literature. Ann Neurol 1978; 4:130-144.  	707984
	9. Press OW, Ramsey PG. Central nervous system infections associated with heredi tary hemorrhagic telangiectasia. Am J Med 1984; 77:86-92.  	6377893
	10. Dyer NH. Cerebral abscess in hereditary hemorrhagic telangiectasia: Report of two  cases in a family. J Neurol Neurosurg Psychiatr 1967; 30:563-567.  	5583577
	11. Garcia-Tsao G, Korzenik JR, Young L et al. Liver disease in patients with hereditary  hemorrhagic telangiectasia. N Engl J Med 2000; 343:931-936.  	11006369
	12. Shovlin CL, Guttmacher AE, Buscarini E et al. Diagnostic criteria in hereditary  hemorrhagic telangiectasia (Rendu-Osler-Weber Syndrome). Am J Med Genetics  2000; 91:66-67.  	10751092
	13. Barzilai B, Waggoner A, Spessert C et al. Two-dimensional contrast echocardiogra phy in the detection and follow-up of congenital pulmonary arteriovenous malfor mations. Am J Cardiol 1991; 68:1507-1510.  	1746435
	14. Shub C, Tajik A, Seward J et al. Detecting intrapulmonary right-to-left shunt with  contrast echocardiography. Mayo Clin Proc 1976; 51:81-84.  	NO_MATCH
	15. Hernandez A, Strauss A, McKnight J et al. Diagnosis of pulmonary arteriovenous  fistula by echocardiography. J Pediatr 1978; 51:81-84.  	671164
	16. Taylor BG, Cockerill EM, Manfredi F et al. Therapeutic embolization of the pulmo nary artery in pulmonary arteriovenous fistula. Amer J Med 1978; 69:360-365.  	629281
	17. Terry PB, Barth KH, Kaufman SL et al. Balloon embolization for treatment of  pulmonary arteriovenous fistulas. N Engl J Med 1980; 302:1189-1190.d  	7366659
	18. Goodenberger D, Barzilai B, Picus D. Incidence and timing of pleuritic chest pain  after therapeutic pulmonary embolization. Chest 1993:103:159S.  	NO_MATCH
	19. Fulbright RK, Chaloupka JCJ, Putman CM et al. MR of hereditary hemorrhagic  telangiectasia: Prevalence and spectrum of cerebrovascular malformations. Am J  Neuroradiol 1998; 19:477-484.  	9541302
	20. Willense RG, Mager JJ, Westermann CJJ et al. Bleeding risk of cerebral vascular  malformations in hereditary hemorrhagic telangiectasia. J Neurosurg 2000; 92:779 784.  	10794291
	21. Ondra SL. Troupp H. George ED et al. The natural history of symptomatic arterio venous malformations of the brain: a 24-year follow-up assessment. J Neurosurg  1990; 73:387-391.  	2384776
	22. Whiting JH, Korzenik JR, Miller FJ et al. Fatal outcome after emobolotherapy for  hepatic arteriovenous malformations of the liver in two patients with hereditary  hemorrhagic telangiectasia. J Vasc Intervent Radiol 2000; 11:855-858.  	10928521
	23. Goodman J, Fallah M, Goodenberger DM, et al. Liver Transplantation for Heredi tary Hemorrhagic Telangiectasia. Poster at the 2003 American Hepato-Pancreato Biliary Congress, Miami, Florida, February 27-March 2, 2003.  	NO_MATCH
	24. Longo A, Ceriati M, Gallitelli G et al. Orthotopic liver transplantation and heredi tary hemorrhagic telangiectasia: a long-term followup study on 2 patients. 5th HHT  Scientific Conference, Bonaire, Dutch Antilles, April 2003.  	NO_MATCH
	25. Miller F, Tietze C, Markewitz B et al. Characteristics and outcome in HHT patients  referred for liver transplantation. 5th HHT Scientific Conference, Bonaire, Dutch  Antilles, April 2003.  	NO_MATCH
	26. Pfitzmann R, Heise M, Langvehr JM et al. Liver transplantation for treatment of  intrahepatic Osler's disease: First experiences. Transplantation 2001; 72:237-241.  	11477345
index.pdf
3659.full.pdf
	Ali, N. & Siddiqui, A. (1995). Interaction of polypyrimidine tract binding protein with the 59 noncoding region of the hepatitis C  virus RNA genome and its functional requirement in internal  initiation of translation. J Virol 69, 6367–6375.  	7666538
	Basset, S. E., Thomas, D. L., Brasky, K. M. & Lanford, R. E. (1999). Viral persistence, antibody to E1 and E2, and hypervariable region 1  sequence stability in hepatitis C virus-inoculated chimpanzees. J Virol  73, 1118–1126.  	NO_MATCH
	Baumert, T. F., Ito, S., Wong, D. & Liang, J. (1998). Hepatitis C virus  structural proteins assemble into viruslike particles in insect cells.  J Virol 72, 3827–3836.  	9557666
	Bender, M. A., Palmer, T. D., Gelinas, R. E. & Miller, A. D. (1987).  Evidence that the packaging signal of Moloney murine leukemia  virus extends into the gag gene. J Virol 61, 1639–1646.  	3502707
	Bertolini, L., Iacovacci, S., Ponzetto, A., Gorini, G., Battaglia, M. &  Carloni, G. (1993). The human bone-marrow-derived B-cell line CE,  susceptible to hepatitis C virus infection. Res Virol 144, 281–285.  	8210709
	Brown, E. A., Zhang, H., Ping, L.-H. & Lemon, S. M. (1992).  Secondary structure of the 59 nontranslated regions of the hepatitis C  virus and pestivirus genomic RNAs. Nucleic Acids Res 20, 5041–5045.  	1329037
	Chaabihi, H., Ogliastro, M. H., Martin, M., Giraud, C., Devauchelle, G.  & Ce´rutti, M. (1993). Competition between baculovirus polyhedrin  and p10 gene expression during infection of insect cells. J Virol 67,  2664–2671.  	8474166
	Chiba, J., Ohba, H., Matsuura, Y., Watanabe, Y., Katayama, T.,  Kikushi, S., Saito, I. & Miyamura, T. (1991). Serodiagnosis of  hepatitis C virus (HCV) infection with an HCV core protein  molecularly expressed by a recombinant baculovirus. Proc Natl Acad  Sci U S A 88, 4641–4645.  	1905012
	Chien, D. Y., Choo, Q. L., Tabrizi, A. & 16 other authors (1992).  Diagnosis of hepatitis C virus (HCV) infection using an immuno dominant chimeric polyprotein to capture circulating antibody:  reevaluation of the role of HCV in liver disease. Proc Natl Acad Sci  U S A 89, 10011–10015.  	1279666
	Choo, Q. L., Kuo, G., Weiner, A. J., Overby, L. R., Bradley, D. W.  & Houghton, M. (1989). Isolation of a cDNA clone derived from  a blood-borne non-A non-B viral hepatitis genome. Science 244,  359–362.  	2523562
	Croizier, G., Coizier, L., Quiot, J. M. & Lereclus, D. (1988). Recom bination of Autographa californica and Rachiplusia ou nuclear poly hedrosis viruses in Galleria mellonella L. J Gen Virol 69, 177–185.  	NO_MATCH
	Croizier, L., Jousset, F.-X., Veyrunes, J.-C., Lopez-Ferber, M.,  Bergoin, M. & Croizier, G. (2000). Protein requirements for assembly  of virus-like particles of Junonia coenia densovirus in insect cells.  J Gen Virol 81, 1605–1613.  	10811945
	Deleersnyder, V., Pillez, A., Wychowski, C., Blight, K., Xu, J.,  	NO_MATCH
	Hahn, S., Rice, C. M. & Dubuisson, J. (1997). Formation of  native hepatitis C virus glycoprotein complexes. J Virol 71, 697–704.  	8985401
	Feinstone, S. M., Kapikiana, A. Z., Purcell, R. H. & Holland, P. V.  (1975). Transfusion associated hepatitis not due to hepatitis A or B.  N Engl J Med 292, 767–770.  	NO_MATCH
	Felgner, P. L. & Ringold, G. M. (1989). Cationic liposome-mediated  transfection. Nature 337, 387–388.  	2463491
	Fukushi, S., Kurihara, C., Ishiyama, N., Hoshino, F. B., Oya, A. &  Katayama, K. (1997). The sequence element of the internal ribosome  entry site and a 25-kilodalton cellular protein contribute to efficient  internal initiation of translation of hepatitis C virus RNA. J Virol 71,  1662–1666.  	8995696
	Gaymard, F., Ce´rutti, M., Horeau, C., Lemaillet, G., Urbach, S.,  Ravallec, M., Devauchelle, G., Sentenac, H. & Thibaud, J. B. (1996).  The baculovirus/insect cell system as an alternative to Xenopus  oocytes. First characterization of the AKT1 K+ channel from  Arabidopsis thaliana. J Biol Chem 271, 22863–22870.  	8798465
	Grakoui, A., Wyshowski, C., Lin, C., Feinstone, S. M. & Rice, C. M.  (1993). Expression and identification of hepatitis C virus polyprotein  cleavage products. J Virol 67, 1385–1395.  	7679746
	Hirowatari, Y., Hijikata, M., Tanji, Y., Nyunoya, H., Mizushima, H.,  Kimura, K., Tanaka, T., Kato, N. & Shimotohno, H. (1993). Two  proteinase activities in HCV polypeptide expressed in insect cells  using baculovirus vector. Arch Virol 133, 349–356.  	8257294
	Honda, M., Brown, E. A. & Lemon, S. M. (1996). Stability of a stem loop involving the initiator AUG controls the efficiency of internal  initiation of translation on hepatitis C virus RNA. RNA 2, 955–968.  	8849773
	Hsu, H. H., Donets, M., Greenberg, H. B. & Feinstone, S. M. (1993).  Characterisation of hepatitis C virus structural proteins with a  recombinant baculovirus expression system. Hepatology 17, 763–771.  	8387945
	Hu¨ssy, P., Langen, H., Mous, J. & Jacobsen, H. (1996a). Hepatitis C  virus core protein: carboxy-terminal boundaries of two processed  species suggest cleavage by a signal peptide peptidase. Virology 224,  93–104.  	8862403
	Hu¨ssy, P., Schmid, G., Mous, J. & Jacobsen, H. (1996b). Purification  and in vitro-phospholabeling of secretory envelope proteins E1 and  E2 of hepatitis C virus expressed in insect cells. Virus Res 45, 45–57.  	8896240
	Hu¨ssy, P., Faust, H., Wagner, J. C., Schmid, G., Mous, J. &  Jacobse, H. (1997). Evaluation of hepatitis C virus envelope  proteins expressed in E. coli and insect cells for use as tools for  antibody screening. J Hepatol 26, 1179–1186.  	9210602
	Hwang, S. B., Park, K. J., Kim, Y.-S., Sung, Y. C. & Lai, M. C. (1997).  Hepatitis C virus NS5B protein is a membrane-associated phospho protein with a predominantly perinuclear localisation. Virology 227,  439–446.  	9018143
	Iacovacci, S., Manzin, A., Barca, S. & 9 other authors (1997).  Molecular characterisation and dynamics of hepatitis C virus replica tion in human fetal hepatocytes infected in vitro. Hepatology 26,  1328–1337.  	9362380
	Inchauspe´, G., Zebedee, S., Lee, D.-H., Sugitani, M., Nasoff, M. &  Prince, A. M. (1991). Genomic structure of the human prototype  strain H of hepatitis C virus: comparison with American and Japanese isolates. Proc Natl Acad Sci U S A 88, 10292–10296.	1658800
	Inoue, Y., Suzuki, R., Matsuura, Y., Harada, S., Chiba, J.,Watanabe, Y., Saito, I. & Miyamura, T. (1992).Expression of the aminoterminal half of the NS1 region of the hepatitis C virus genome and detection of an antibody to the expressed protein in patients with liver disease. J Gen Virol 73, 2151–2154.	1379627
	Ito, T., Mukaigawa, J., Zuo, J., Hirabayashi, Y., Mitamura, K. & Yasui, K. (1996). Cultivation of hepatitis C virus in primary hepatocyte culture from patients with chronic hepatitis C results in release of high titre infectious virus. J Gen Virol 77, 1043–1054.	8609470
	Kaito, M., Watanabe, S., Tsukiyama, K. K. & 7 other authors (1994). Hepatitis C virus particle detected by immunoelectron microscopic study. J Gen Virol 75, 1755–1760.	7517432
	Kato, N., Nakazawa, T., Mizutani, T. & Shimotohno, K. (1995). Susceptibility of human T-lymphotropic virus type I infected cell line MT-2 to hepatitis C virus infection. Biochem Biophys Res Commun 206, 863–869	NO_MATCH
	Kato, N., Ikeda, M., Mizutani, T., Sugiyama, K., Noguchi, M., Hirohashi, S. & Shimotohno, K. (1996). Replication of hepatitis C virus in cultured non-neoplastic human hepatocytes. J Cancer Res 87, 787–792.	8797883
	Khromykh, A. A., Varnavsky, A. N. & Westaway, E. G. (1998). Encapsidation of the ﬂavivirus Kunjin replicon RNA by using a complementation system providing Kunjin virus structural proteins in trans. J Virol 72, 5967–5977.	9621059
	Laemmli, U. K. (1970). Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227, 680–685.	5432063
	Lanford, R. E., Notvall, L., Chavez, D., White, R., Frenzel, G., Simonsen, C. & Kim, J. (1993). Analysis of hepatitis C virus capsid, E, and E2/NS1 proteins expressed in insect cells. Virology 197, 225–235.	8212557
	Le, S., Sonenberg, N. & Maizel, J. V. (1995). Unusual folding regions and ribosome landing pad within hepatitis C virus and pestivirus RNAs. Gene 154, 137–143.	7890155
	Matsumoto, M., Hwang, S. B., Jeng, K.-S., Zhu, N. & Lai, M. M. C. (1996). Homotypic interaction and multimerization of hepatitis C virus core protein. Virology 218, 43–51.	8615040
	Matsuura, Y., Harada, S., Suzuki, R., Watanabe, Y., Inoue, Y., Saito, I. & Miyamura, T. (1992). Expression of processed envelope protein of hepatitis C virus in mammalian and insect cells. J Virol 66, 1425–1431.	1310756
	Matsuura, Y., Suzuki, T., Suzuki, R., Sato, M., Aizaki, H., Saito, I. & Miyamura, T. (1994). Processing of E1 and E2 glycoproteins of hepatitis C virus expressed in mammalian and insect cells. Virology 205, 141–150.	7975209
	Miyamoto, H., Okamoto, H., Sato, K., Tanaka, T. & Mishiro, S. (1992). Extraordinarily low density of hepatitis C virus estimated by sucrose density gradient centrifugation and the polymerase chain reaction. J Gen Virol 73, 715–718.	1312126
	Nakajima, N., Hijikata, M., Yoshikura, H. & Shimizu, Y. K. (1996). Characterization of long-term cultures of hepatitis C virus. J Virol 70, 3325–3329.	NO_MATCH
	Nishihara, T., Nozaki, C., Nakatake, H. & 7 other authors (1993). Secretion and puriﬁcation of hepatitis C virus NS1 glycoprotein produced by recombinant baculovirus infected insect cells. Gene 129, 207–214.	7686870
	Overton, H., McMillan, D., Gillespie, F. & Mills, J. (1995). Recombinant baculovirus-expressed NS3 proteinase of hepatitis C virus shows activity in cell-based and in vitro assays. J Gen Virol 76, 3009–3019.	8847506
	Reggio, H. & Boller, K. (1989). Immunocytochemistry and ultracryotomy. In Immunocytochemistry, Practical Methods, pp. 37–46. Paris: SFME.	NO_MATCH
	Reynolds, J. E., Kaminski, A., Kettinen, H. J., Grace, K., Clarke, B. E., Caroll, A. R., Rowlands, D. J. & Jackson, R. J. (1995). Unique features of internal initiation of hepatitis C virus RNA translation. EMBO J 14, 6010–6020.	8846793
	Rice, C. M. (1996). Flaviviridae: the viruses and their replication. In Fields Virology, 3rd edn, vol. 1, pp. 931–959. Edited by B. N. Fields, D. M. Knipe & P. M. Howley. Philadelphia: Lippincott Raven. 	NO_MATCH
	Rijnbrand, R. C. & Lemon, S. M. (2000). Internal ribosome entry site-mediated translation in hepatitis C virus replication. Curr Top Microbiol Immunol 242, 85–116. Santolini, E., Migliaccio, G. & La Monica, N. (1994). Biosynthesis and biochemical properties of the hepatitis C virus core protein. J Virol 68, 3631–3641.	10592657
	Shimizu, Y. K. & Yoshikura, H. (1994). Multicycle infection of hepatitis C virus in cell culture and inhibition by alpha and beta interferons. J Virol 68, 8406–8408. Shimizu, Y. K., Purcell, R. H. & Yoshikura, H. (1993). Correlation between the infectivity of hepatitis C virus in vivo and its infectivity in vitro. Proc Natl Acad Sci U S A 90, 6037–6041.	7966635
	Shimoike, T., Mimori, S., Tani, H., Matsuura, Y. & Miyamura, T. (1999). Interaction of hepatitis C virus core protein with viral sense RNA and suppression of its translation. J Virol 73, 9718–9725.	10559281
	Simmonds, P., Holmes, E. C., Cha, T. A. & 7 other authors (1993). Classiﬁcation of hepatitis C virus into six major genotypes and a series of subtypes by phylogenetic analysis of the NS-5 region. J Gen Virol 74, 2391–2399.	8245854
	Smith, D. B., Mellor, J., Jarvis, L. M., Davidson, F., Kolberg, J., Urdea, M., Yap, P., Simmonds, P. & The International HCV Collaborative Study Group (1995). Variation of the hepatitis C virus 59 non-coding region: implications for secondary structure, virus detection and typing. J Gen Virol 76, 1749–1761.	9049380
	Summers, M. D. & Smith, G. E. (1987). A manual of methods for baculovirus vectors insect cell culture procedure. Texas Agric Exp Stat Bull 1555, 1–56.	NO_MATCH
	Suzuki, T., Sato, M., Chieda, S., Shoji, I., Harada, T., Yamakawa, Y., Watanabe, S., Matsuura, Y. & Miyamura, T. (1995). In vivo and in vitro trans-cleavage activity of hepatitis C virus serine proteinase expressed by recombinant baculoviruses. J Gen Virol 76, 3021–3029.	8847507
	Tagawa, N., Kato, N., Yokosura, I., Ishikawa, T., Ohto, M. & Omata, M. (1995). Infection of human hepatocyte cell lines with hepatitis C virus in vitro. J Gastroenterol Hepatol 10, 523–527.	8963027
	Tsukiyama-Kohara, K., Lizuka, N., Kohara, M. & Nomoto, A. (1992). Internal ribosome entry site within hepatitis C virus RNA. J Virol 66, 1476–1483.	1310759
	Vaughn, J. L., Goodwin, R. H., Tompkins, G. L. & McCawley, P. (1977). The establishment of two cell lines from the insect Spodoptera frugiperda (Lepidoptera: Noctuidae). In Vitro Cell Dev Biol 13, 213–217.	68913
	Wang, C., Sarnow, P. & Siddiqui, A. (1993). Translation of human hepatitis C virus RNA in cultured cells is mediated by an internal ribosome-binding mechanism. J Virol 67, 3338–3344.	8388503
	Wang, C., Le, S. Y., Ali, N. & Siddiqui, A. (1995). An RNA pseudoknot is an essential structural element of the internal ribosome entry site located within the hepatitis C virus 54 noncoding region. RNA 1, 526–537.	7489514
	Wang, Y. H., Trowbridge, R. & Gowans, E. J. (1997). Expression and interaction of the hepatitis C virus structural proteins and the 59 untranslated region in baculovirus infected cells. Arch Virol 142, 2211–2223.	9672587
	Yen, J.-H., Chang, S. C., Hu, C.-R., Chu, S.-C., Lin, S.-S., Hsieh, Y.-S.& Chang, M.-F. (1995). Cellular proteins speciﬁcally bind to the 59noncoding region of hepatitis C virus RNA. Virology 208, 723–732.	7747444